

- 16 Produced by the National Clinical Guidelines Centre for Acute
- 17 and Chronic Conditions

1 Contents

2	Appendix A - Scope	
3	APPENDIX B – DECLARATIONS OF INTEREST	11
4	Appendix C – Search Strategies	25
5	APPENDIX D – EVIDENCE TABLES	
6	APPENDIX E – FOREST PLOTS	527
7	APPENDIX F - COST-EFFECTIVENESS ANALYSIS	674
8	Appendix G - Recommendations for research	709
9	Appendix H – IPSS score sheet	
10	BIBLIOGRAPHY	
11		

Appendix A - Scope

2	NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
3	
4	SCOPE
5	

6 1 Guideline title

7 The management of lower urinary tract symptoms in men

8 1.1 Short title

9 Lower urinary tract symptoms in men

10

1 2 Background

2 a) The National Institute for Health and Clinical Excellence ('NICE' or 'the Institute') 3 has commissioned the National Collaborating Centre for Acute Care to develop a 4 clinical guideline on the management of lower urinary tract symptoms (LUTS) in 5 men for use in the NHS in England and Wales. This follows referral of the topic 6 by the Department of Health (see appendix). The guideline will provide 7 recommendations for good practice that are based on the best available 8 evidence of clinical and cost effectiveness. 9 b) The Institute's clinical guidelines support the implementation of National Service 10 Frameworks (NSFs) in those aspects of care for which a Framework has been 11 published. The statements in each NSF reflect the evidence that was used at the 12 time the Framework was prepared. The clinical guidelines and technology 13 appraisals published by the Institute after an NSF has been issued will have the 14 effect of updating the Framework. 15 c) NICE clinical guidelines support the role of healthcare professionals in providing 16 care in partnership with patients, taking account of their individual needs and 17 preferences, and ensuring that patients (and their carers and families, where 18 appropriate) can make informed decisions about their care and treatment.

3

4

5

6

7

8

9

10

11

12

13

14

25

26

27

28

29

30

31

32

33

1 3 Clinical need for the guideline

 a) Lower urinary tract symptoms (LUTS) are a collection of symptoms related to problems with the voiding, storage and post-micturition of urine. They generally arise as a result of abnormalities or inadequate functioning of the prostate, urethra, bladder or sphincters. The pathophysiology of LUTS are diverse. In men, benign prostate enlargement, which is secondary to benign prostatic hyperplasia and causes bladder outlet obstruction, is frequently considered to be the major cause of LUTS. However, many other conditions can cause LUTS, including detrusor muscle weakness or overactivity, prostatitis, urinary tract infection, malignancy and neurological disease. In acknowledgement of the non-specific nature of many male LUTS, this clinical guideline will advise on the effective evidence-based management of male LUTS in general, with a specific focus on LUTS associated with benign prostatic disease (presumed benign prostatic hyperplasia).

- 15 b) LUTS in men are best categorised into voiding, storage or post-micturition 16 symptoms to help define the source of the problem. Voiding symptoms (previously 17 known as obstructive symptoms) include weak or intermittent urinary stream, 18 straining, hesitancy, terminal dribbling and incomplete emptying. Storage 19 symptoms (previously known as irritative symptoms, and currently often 20 considered as a symptom complex known as 'overactive bladder') include 21 urgency, frequency, urgency incontinence and nocturia. The major post-micturition 22 symptom is dribbling, which is common and bothersome. Although LUTS do not 23 usually cause severe illness, they can considerably reduce patients' quality of life, 24 and may point to serious pathology of the urogenital tract.
 - c) LUTS are a major burden for the ageing male population. Approximately 30% of men aged 50 and older have moderate to severe LUTS. This is a very large group potentially requiring treatment. Age is an important risk factor for LUTS and the prevalence of LUTS increases as men get older. Other risk factors include hormonal status (presence of androgens), increased size of the prostate gland and bladder decompensation. Ethnicity may also be a risk factor: men of black origin seem to be more likely to need surgery for prostate enlargement than men of white origin. Men of Asian origin seem to be less likely than men of white origin to need surgery.
- 34d) Because prevalence increases with age, the figure above will continue to rise with35increasing life expectancy and the resulting growth of the elderly population. This36will place increasing demands on health service resources in the coming years.37The past 25 years have seen an increase in the use of pharmacotherapy for38LUTS, with a considerable decline in surgical rates. Nevertheless, in England, for39the year 2003–2004, there were almost 30,000 endoscopic resections of the

male bladder outlet, accounting for more than 138,000 bed days. Although transurethral resection of the prostate is often effective in reducing symptoms in men, it is associated with considerable morbidity and a significant overall annual cost. In addition, a significant proportion of men (25–30%) do not benefit from prostatectomy and have poor post-surgical outcome with no improvement of symptoms. Some failures can be attributed to poor surgical technique, whereas others may be due to incorrect diagnosis of the cause of LUTS. Therefore, to minimise the number of unnecessary operations, predicting the outcome of transurethral resection of the prostate is important.

- 10 e) The British Association of Urological Surgeons primary care guidelines (2004) 11 include recommendations on management and referral to secondary care. There 12 are no specific recommendations on urodynamic studies. The European 13 Association of Urology guidelines (2004) recommend the routine use of 14 uroflowmetry before prostatectomy, and that pressure-flow studies should be 15 used in certain circumstances (but not routinely). According to expert opinion, most 16 UK clinicians carry out uroflowmetry and, in appropriate patients in secondary 17 care, pressure-flow studies are done before surgical intervention in units with 18 access to the equipment. However, experts agree that there is wide variation in 19 clinical practice in the UK. This is due to individual clinicians' belief in the value of 20 urodynamic studies, and also due to staffing issues and access to the technology. 21 There are many national and international guidelines concerned with the 22 management of men with LUTS; however, these vary in quality.
- 23 This NICE clinical guideline will address the variations in practice to allow f) 24 equitable and appropriate treatment for all affected men. There may be cost 25 savings in defining the appropriate use of suitable investigational modalities and 26 existing pharmacotherapy, and by potentially preventing unnecessary surgical 27 treatment and the costs of failed prostatectomy. However, costs incurred would 28 include the cost of equipment, carrying out the tests and associated staff time. 29 Uncertainty over the effectiveness of urodynamic studies makes it impossible to 30 estimate resource impact.

31

1

2

3

4

5

6

7

8

1 4 The guideline

2 3 4 5 7	a)	The guideline development process is described in detail in two publications that are available from the NICE website (see 'Further information'). 'The guideline development process: an overview for stakeholders, the public and the NHS' describes how organisations can become involved in the development of a guideline. 'The guidelines manual' provides advice on the technical aspects of guideline development.
8 9 10	b)	This document is the scope. It defines exactly what this guideline will (and will not) examine, and what the guideline developers will consider. The scope is based on the referral from the Department of Health (see appendix).
11 12	c)	The areas that will be addressed by the guideline are described in the following sections.
13	4.1 Popu	lation
14	4.1.1	Groups that will be covered
15	a)	Adult men (18 years or older) with a clinical working diagnosis of LUTS.
16	b)	Men who have a higher prevalence of LUTS or may be at higher risk including:
17		• older men
18		• men who are of black origin.
19	4.1.2	Groups that will not be covered
20	c	a) Women.
21	k	b) Men younger than 18 years.
22	4.2 Healt	hcare setting
23		Primary, secondary and tertiary care settings.
24	4.3 Clinio	al management
25 26	a)	The clinical and cost effectiveness, and possibly morbidity, of intervention in the management of LUTS.

7 of 754

1	b)	Initial diagnostic assessments of LUTS, including:
2		 digital rectal examination (DRE)
3		 symptom scores assessments
4		prostate-specific antigen
5		 urinary flow rate
6		 post-void residual
7		 appropriate use of pressure/flow urodynamics
8		• cystoscopy.
9	c)	Monitoring of chronic LUTS.
10	d)	Non-pharmacological interventions:
11		 active observation ('watchful waiting')
12		 devices (such as catheters, pads and clamps)
13 14		 lifestyle and behavioural changes (such as diet, bladder retraining and pelvic floor exercises).
15	e)	Pharmacological interventions as first- and/or second-line treatment:
16		• 5-alpha reductase inhibitors
17		alpha blockers
18		anticholinergics
19 20		 other pharmacotherapeutic agents (such as phytotherapy and phosphodiesterase inhibitors)
21		• combination therapy.
22 23 24 25 26	f)	Note that guideline recommendations will normally fall within licensed indications; exceptionally, and only if clearly supported by evidence, use outside a licensed indication may be recommended. The guideline will assume that prescribers will use a drug's summary of product characteristics to inform their decisions for individual patients.
27	g)	Surgical interventions or minimally invasive alternatives:
28		transurethral electrovaporisation of the prostate
29		 transurethral radiofrequency needle ablation of the prostate

1 2			 all forms of laser therapy directed at the prostate, including enucleation and vaporisation
3 4			 transurethral resection of the prostate, including newer forms of therapy such as bipolar excision
5			transurethral incision of the prostate
6			open prostatectomy.
7		h)	Combinations of the above interventions.
8 9		i)	Condition-specific information, support and communication needs of patients, carers and families with LUTS.
10		i)	General advice on the appropriate evaluation and management of LUTS in men.
11 12 13		k)	The Guideline Development Group will consider making recommendations on the principal complementary and alternative interventions or approaches to care relevant to male LUTS. This will include phytotherapy.
14 15 16 17 18 19 20		I)	The Guideline Development Group will take reasonable steps to identify ineffective interventions and approaches to care. If robust and credible recommendations for re-positioning the intervention for optimal use, or changing the approach to care to make more efficient use of resources can be made, they will be clearly stated. If the resources released are substantial, consideration will be given to listing such recommendations in the 'Key priorities for implementation' section of the guideline.
21	4.4	Statu	5

- 22 4.4.1 Scope
- 23 This is the final version of the scope.
- 24 The NICE has published the following related guidance:
- Urinary incontinence: the management of urinary incontinence in women. NICE
 clinical guideline 40 (2006)
- Referral guidelines for suspected cancer. NICE clinical guideline 27 (2005)
- Potassium-titanyl-phosphate (KTP) laser vaporisation of the prostate for benign
 prostatic obstruction. NICE interventional procedure guidance 120 (2005)
- Holmium laser prostatectomy. NICE interventional procedure guidance 17 (2003)
- Transurethral radiofrequency needle ablation of the prostate. NICE interventional
 procedure guidance 15 (2003)
- Transurethral electrovaporisation of the prostate. NICE interventional procedure guidance 14 (2003).

1 NICE is in the process of producing the following related guidance:

Prostate cancer: diagnosis and treatment. NICE clinical guideline (publication expected February 2008).

4 4.4.2 Guideline

5

The development of the guideline recommendations will begin on 12 December 2007.

6 5 Further information

Information on the guideline development process is provided in:
'The guideline development process: an overview for stakeholders, the public and the NHS'
'The guidelines manual'.
These booklets are available as PDF files from the NICE website (www.nice.org.uk/guidelinesmanual). Information on the progress of the guideline will

13 also be available from the website.

14 6 Referrals from the Department of Health

15	The Department of Health asked the Institute:
16	'To prepare a clinical guideline on the management of benign prostatic hyperplasia.'
17 18 19	'To prepare a guideline on the assessment, investigation, management and onward referral of men with lower urinary tract symptoms (including male incontinence) within primary care.'

1 Appendix B – Declarations of interest

2 **1 Declarations of interests**

3 1.1 Introduction

4 All members of the GDG and all members of the NCGC-ACC staff were required to 5 make formal declarations of interest at the outset, and these were updated at every 6 subsequent meeting throughout the development process.

7 **1.2 Declarations of interests of the GDG members**

8 1.2.1 Chris Chapple (Chair)

GDG meeting	Declaration of Interests
First GDG meeting (12 th December 2007)	CC declared a personal pecuniary interest, his attendance in National and International conferences for BAUS, EAU and AUA. He declared a personal pecuniary interest in private practice. He declared that he knew of no personal family interest. He declared his non-personal pecuniary interest, consultancy and research honoraria up to 6 months age from Allergan, AMS, Astellas, Novartis, Pfizer and UCB – this was put into the department to provide funding for a researcher. He declared a personal non-pecuniary interest as principal investigator and author on pharmaceutical sponsored papers. He is a member of the committee of the BAUS section of female and functional urology and the Adjunct Secretary General of EAU- responsible for their educational activities. He has written books on the subject of BPH/LUTS. He is editor in chief of the Neurourology and Urodynamics journal (official journal of ICS and SUFU).
Second GDG Meeting (13 th December 2007)	No change
Third GDG Meeting (17 th March 2008)	No change
Fourth GDG Meeting (30 th April 2008)	CC declared a personal pecuniary interest, his attendance in National and International conferences for ICS.
Fifth GDG Meeting (6 th June 2008)	No change
Sixth GDG Meeting (14 th July 2008)	No change
Seventh GDG Meeting (8 th September 2008)	No change
Eighth GDG Meeting (15 th October 2008)	No change
Ninth GDG Meeting (27 th November 2008)	No change
Tenth GDG Meeting (16 th January 2009)	No change
Eleventh GDG Meeting (23 rd February 2009)	CC declared a non-personal pecuniary interest as a consultant for Astellas, Pfizer, Allergen, Xention, Ono, Recordati and Ranbaxy. He declared a personal non-

GDG meeting	Declaration of Interests
	pecuinary interest that any concerns over his views should be expressed at any stage. He declared that he knew of no personal pecuniary interest or personal family interest, above those decared at the previous meeting.
Twelfth GDG Meeting (25 th March 2009)	No change
Thirteenth GDG Meeting (1st May 2009)	No change
Fourteenth GDG Meeting (8 th June 2009)	No change
Fifteenth GDG Meeting (29 th June 2009)	CC declared a personal non-pecuniary interest; he spoke as invited speaker at Astellas symposium at the British Association of Urological Surgeons meeting. He was a speaker at a symposium provided by the European Association of Urology on behalf of Astellas. He was a speaker at a symposium organised by Allergan at the American urology Association meeting. He declared that he had no personal pecuniary interesst, personal family interest or non-personal pecuniary interest above those previously declared.
Actions	None required.

3

1.2.2 Angela Billington

GDG meeting	Declaration of Interests
First GDG meeting (12 th December 2007)	She did not attend this meeting.
Second GDG Meeting (13 th December 2007)	AB declared a personal pecuniary interest, Pfizer education support committee. AB did not declare a personal family interest. AB did not declare a non-personal pecuniary interest. She did not declare a personal non-pecuniary interest.
Third GDG Meeting (17 th March 2008)	She did not attend this meeting.
Fourth GDG Meeting (30th April 2008)	AB declared a personal pecuniary interest, attended conferences for Pfizer, Coloplast, Rochester Medical and Bard. Faculty for Pfizer sense of leadership conference and CARE program for nurses. She did not declare a personal family interest, non-personal pecuniary interests or personal non-pecuniary interest.
Fifth GDG Meeting (6 th June 2008)	She did not attend this meeting.
Sixth GDG Meeting (14 th July 2008)	AB declared a personal pecuniary interest; she is involved in an educational package for Pfizer and educational symposium for Coloplast. Articles for nursing press on catheters. She had dinner courtesy of Pfizer at the ICI meeting. She did not declare a personal family interest, non-personal pecuniary interest or personal non-pecuniary interest.
Seventh GDG Meeting (8 th September 2008)	No change
Eighth GDG Meeting (15 th October 2008)	She did not attend this meeting
Ninth GDG Meeting (27 th November 2008)	No change

GDG meeting	Declaration of Interests
Tenth GDG Meeting (16 th January 2009)	No change
Eleventh GDG Meeting (23 rd February 2009)	No change
Twelfth GDG Meeting (25 th March 2009)	She did not attend this meeting
Thirteenth GDG Meeting (1 st May 2009)	No change
Fourteenth GDG Meeting (8 th June 2009)	No change
Fifteenth GDG Meeting (29 th June 2009)	No change
Actions	During both the 14^{th} GDG on the 8 June 2009 and the 15^{th} GDG on the 29 June 2009, The Chair noted that AB had personal pecuniary interests and required AB to be present in an observatory role during the discussion of the pharmacologic recommendations.

2 1.2.3 Paul Joachim

GDG meeting	Declaration of Interests
First GDG meeting (12 th December 2007)	PJ did not declare a personal pecuniary interest or personal family interest. He declared a non-personal pecuniary interest, trustee of Incontact, a charity that benefits from grants from the industry. He declared a personal non-pecuniary interest, trustee of Incontact (as above) Chair of the patient advisory board. He declared that he has had personal and family experience of symptoms.
Second GDG Meeting (13 th December 2007)	No change
Third GDG Meeting (17 th March 2008)	No change
Fourth GDG Meeting (30 th April 2008)	No change
Fifth GDG Meeting (6 th June 2008)	No change
Sixth GDG Meeting (14 th July 2008)	No change
Seventh GDG Meeting (8th September 2008)	No change
Eighth GDG Meeting (15 th October 2008)	No change
Ninth GDG Meeting (27 th November 2008)	No change
Tenth GDG Meeting (16 th January 2009)	No change

GDG meeting	Declaration of Interests
Eleventh GDG Meeting (23 rd February 2009)	No change
Twelfth GDG Meeting (25 th March 2009)	No change
Thirteenth GDG Meeting (1st May 2009)	No change
Fourteenth GDG Meeting (8 th June 2009)	PJ declared that his interests have not changed, but he informed the group that 'Incontact' had changed its name to 'The Bladder and Bowel Foundation' in September 2008.
Fifteenth GDG Meeting (29 th June 2009)	No change
Actions	None required

2 1.2.4 Malcolm Lucas

GDG meeting	Declaration of Interests
First GDG meeting (12 th December 2007)	He did not attend this meeting
Second GDG Meeting (13 th December 2007)	He did not attend this meeting
Third GDG Meeting (17th March 2008)	ML declared a personal pecuniary interest; I have received lecture fees from Pfizer, UCB Pharma and Astellas within the last 12 months and sponsorship to attend national and international meetings also from Pfizer, Gynecare and AMS. I am not involved in private practice and I am not now accepting invitations to serve on advisory boards. Any current income from lecturing will be payable to a research fund which pays expenses for research fellow and nurses. He did not declare a personal family interest. He declared a non-personal pecuniary interest, I am Principle local investigator for trials with Astellas, Plethora and Bioxell and Lead investigator for trials with Astra. All income goes to Clinical Research Unit, Swansea NHS Trust. He declared a personal non-pecuniary interest, current chairman of Section of Female and Reconstructive Urology, BAUS.
Fourth GDG Meeting (30 th April 2008)	No change
Fifth GDG Meeting (6 th June 2008)	No change
Sixth GDG Meeting (14 th July 2008)	No change
Seventh GDG Meeting (8 th September 2008)	No change
Eighth GDG Meeting (15 th October 2008)	He did not attend this meeting
Ninth GDG Meeting (27 th November 2008)	No change
Tenth GDG Meeting (16 th January 2009)	No change

GDG meeting	Declaration of Interests
Eleventh GDG Meeting (23 rd February 2009)	No change
Twelfth GDG Meeting (25 th March 2009)	ML declared a non-personal pecuniary interest of departmental research fund receiving income from the UK Continence Society Conference April 2009. The primary source of income in this conference derives from healthcare companies (pharmaceutical and device manufactures). He declared that he knew of no personal pecuniary interest, personal non-pecuniary interest or personal family interest, above those declared at the previous meeting.
Thirteenth GDG Meeting (1 st May 2009)	ML declared a non-perosnal pecuianry interest of the clinical research unit receiving research income from Astra tech, Pfizer and astellas. He decared that he knew of no personal pecuniary interest, personal onon-pecuinary interest or personal family interest, above those decalred at the previous meeting.
Fourteenth GDG Meeting (8 th June 2009)	No change
Fifteenth GDG Meeting (29 th June 2009)	He did not attend this meeting.
Actions	None required

2 **1.2.5** Roy Latham

GDG meeting	Declaration of Interests
First GDG meeting (12 th December 2007)	RL declared a personal pecuniary interest, he acted as a Lay Member on an Invited Service Review carried out by the Royal College of Physicians (July 07). He received a fee for this. He did not declare a personal family interest or non- personal pecuniary interest. He declared a personal non-pecuniary interest, he is personally affected by BPH/LUTS as a patient and as the relative/friend of affected people.
Second GDG Meeting (13 th December 2007)	No change
Third GDG Meeting (17 th March 2008)	No change
Fourth GDG Meeting (30 th April 2008)	No change
Fifth GDG Meeting (6 th June 2008)	No change
Sixth GDG Meeting (14 th July 2008)	No change
Seventh GDG Meeting (8 th September 2008)	No change
Eighth GDG Meeting (15 th October 2008)	No change
Ninth GDG Meeting (27 th November 2008)	No change
Tenth GDG Meeting (16 th January 2009)	He did not attend this meeting

GDG meeting	Declaration of Interests
Eleventh GDG Meeting (23 rd February 2009)	He did not attend this meeting
Twelfth GDG Meeting (25 th March 2009)	No change
Thirteenth GDG Meeting (1st May 2009)	No change
Fourteenth GDG Meeting (8 th June 2009)	No change
Fifteenth GDG Meeting (29 th June 2009)	No change
Actions	None required

2 1.2.6 Thomas Ladds

GDG meeting	Declaration of Interests
First GDG meeting (12 th December 2007)	He did not attend meeting
Second GDG Meeting (13 th December 2007)	He did not attend meeting
Third GDG Meeting (17th March 2008)	TL declared a personal pecuniary interest, regular attendance at national and international conferences. BAUS, BAUN, EAU and AUA. Advisory board member for Bard UK Ltd – January 2008. He did not declare a personal family interest or non-personal pecuniary interest. He declared a personal non-pecuniary interest, member and current president of British Association of Urological Nurses (BAUN). Ex officio member BAUS Council Editorial Board member of International Journal of Urological Nursing and Urology News.
Fourth GDG Meeting (30 th April 2008)	TL declared a personal pecuniary interest, sponsorship to attend EAU from Bayer. Lecture fee from Astra Zenecu Marhcin in 2008.
Fifth GDG Meeting (6 th June 2008)	He did not attend this meeting
Sixth GDG Meeting (14 th July 2008)	TL declared that he knew of no personal pecuniary interest, personal family interest or personal non-pecuniary interest. He declared a non-personal pecuniary interest, lecture fees for Astrazeneca and Coloplast Ltd, which were paid to departmental charitable research fund.
Seventh GDG Meeting (8th September 2008)	No change
Eighth GDG Meeting (15 th October 2008)	No change
Ninth GDG Meeting (27th November 2008)	He did not attend this meeting
Tenth GDG Meeting (16 th January 2009)	TL declared a personal pecuniary interest, that he has notified his NHS employer, Central Manchester University Hospitals NHS Foundation Trust that he wished to terminate his contract with them on 27 th March 2009. He is in the process of setting up a limited company, TL Consulting Ltd, of which he will be the director and sole

GDG meeting	Declaration of Interests
	shareholder; he will be employed there from April 1 2009. TL Consulting Ltd. has entered into a contract with ProstaLund Operations AB of Sweden to supply services, including advising them on clinical issues and potential business activities in the UK and overseas. This contract will be operational from April 1 2009. ProstaLunc AB currently develops, manufacture and supply equipment, consumables and software in the field of microwave thermotherapy for BPH. TL Consulting may also negotiate and enter into contracts with other suppliers in urology pharmaceutical and medical technical sectors in the future. He declared that he knew of no non-personal pecuniary interest, personal non-pecuniary interest or personal family interest, above those declared at the previous meeting.
Eleventh GDG Meeting (23 rd February 2009)	TL withdrew from the GDG due to new interests declared in the $10^{\mbox{\tiny th}}$ GDG meeting.
Actions	None required

2 **1.2.7** James N'Dow

GDG meeting	Declaration of Interests
First GDG meeting (12 th December 2007)	JN declared a personal pecuniary interest, principle investigator (PI) on a clinical trial with payment per patient going to the urology department. Involved in private practice. He is a member of BAUS Academic Section. He did not declare a personal family interest. He declared a non-personal pecuniary interest, PI of commissioned research with University of Aberdeen by CYTOSYSTEMS on evaluation of a urinary diagnostic marker for bladder cancer. He declared a personal non-pecuniary interest; he led HTA commissioned research on systematic review of surgical treatments of BPH (in press).
Second GDG Meeting (13 th December 2007)	No change
Third GDG Meeting (17 th March 2008)	No change
Fourth GDG Meeting (30 th April 2008)	JN declared a non-personal pecuniary interest, principle investigator (PI) on a clinical trial with payment per patient going to the urology department.
Fifth GDG Meeting (6 th June 2008)	He did not attend this meeting
Sixth GDG Meeting (14 th July 2008)	He did not attend this meeting
Seventh GDG Meeting (8th September 2008)	No change
Eighth GDG Meeting (15 th October 2008)	He did not attend this meeting
Ninth GDG Meeting (27 th November 2008)	No change
Tenth GDG Meeting (16 th January 2009)	No change
Eleventh GDG Meeting (23 rd February 2009)	No change

GDG meeting	Declaration of Interests
Twelfth GDG Meeting (25 th March 2009)	He did not attend this meeting
Thirteenth GDG Meeting (1 st May 2009)	No change
Fourteenth GDG Meeting (8 th June 2009)	No change
Fifteenth GDG Meeting (29 th June 2009)	No change
Actions	None required

2 1.2.8 Jon Rees

GDG meeting	Declaration of Interests
First GDG meeting (12 th December 2007)	JR declared a personal pecuniary interest, involved in private urological practice. He declared that he knew of no personal family interest, non-personal pecuniary interest or personal non-pecuniary interest.
Second GDG Meeting (13 th December 2007)	No change
Third GDG Meeting (17 th March 2008)	No change
Fourth GDG Meeting (30 th April 2008)	No change
Fifth GDG Meeting (6 th June 2008)	No change
Sixth GDG Meeting (14 th July 2008)	No change
Seventh GDG Meeting (8 th September 2008)	No change
Eighth GDG Meeting (15 th October 2008)	He did not attend this meeting
Ninth GDG Meeting (27 th November 2008)	No change
Tenth GDG Meeting (16 th January 2009)	He did not attend this meeting
Eleventh GDG Meeting (23 rd February 2009)	No change
Twelfth GDG Meeting (25 th March 2009)	He did not attend this meeting
Thirteenth GDG Meeting (1 st May 2009)	No change

GDG meeting	Declaration of Interests
Fourteenth GDG Meeting (8 th June 2009)	No change
Fifteenth GDG Meeting (29 th June 2009)	No change
Actions	None required

2 1.2.9 Mark Speakman

GDG meeting	Declaration of Interests
First GDG meeting (12 th December 2007)	MS declared a personal pecuniary interest, he is involved in giving lectures for drug companies at national and international meetings in last 12 months (Asteltas, GSK, Boehringer Ingelheim, Pfizer). No new consulting work and new projects declined for duration of guideline. Involved in private practice. He did not declare a personal family interest. He declared a non-personal pecuniary interest, investigator in BPH trials (Astellas, Bayer, GSK, Pfizer, MSD, Allergan). None in last 12 months (sponsorship). Previous research sponsorship from Yamanouchi and MSD in last 5 years. He declared a personal non-pecuniary interest, his clear opinion - author of BAUS BPH Guideline 2004. Author of a number of peer-reviewed LUTS/BPH papers.
Second GDG Meeting (13 th December 2007)	No change
Third GDG Meeting (17 th March 2008)	No change
Fourth GDG Meeting (30 th April 2008)	MS declared a personal non-pecuniary interest, he is a member of the editorial board for European Urology.
Fifth GDG Meeting (6 th June 2008)	No change
Sixth GDG Meeting (14 th July 2008)	MS declared a personal pecuniary interest, single lecture (debate) on anticholinergics for Astellas. He declared that he knew of no personal family interest, non-personal pecuniary interest or personal non-pecuniary interest, above those declared at the previous meeting.
Seventh GDG Meeting (8th September 2008)	No change
Eighth GDG Meeting (15 th October 2008)	No change
Ninth GDG Meeting (27 th November 2008)	No change
Tenth GDG Meeting (16 th January 2009)	He did not attend this meeting
Eleventh GDG Meeting (23 rd February 2009)	No change
Twelfth GDG Meeting (25th March 2009)	MS declared a non-personal pecuniary interest of future research studies planned with Allergan and GSK. He declared a personal non-pecuniary interest as national investigator for new LUTS/BPH Registry for the European Association of Urology. He declared that he knew of no personal pecuniary interest or personal family

GDG meeting	Declaration of Interests
	interest, above those declared at the previous meeting.
Thirteenth GDG Meeting (1 st May 2009)	He did not attend this meeting.
Fourteenth GDG Meeting (8 th June 2009)	No change
Fifteenth GDG Meeting (29 th June 2009)	MS declared a non-personal pecuniary interest, new supported research studies with Allergan, Astellas and GSK. He declared participation in EAU LUTS/BPH database. He declared that he knew of no personal pecuniary interest, personal family interest or personal non-pecuniary interest, above those declared at the previous meeting.
Actions	None required

2 **1.2.10** Julian Spinks

GDG meeting	Declaration of Interests
First GDG meeting (12 th December 2007)	JS declared a personal pecuniary interest, he is a member of advisory boards on LUTS and received honoraria from Boehringer Ingeliheim (March 07). He has attended advisory boards on Restless legs syndrome organised by RLS UK with payment from Boehringer Ingelheim. He has been paid for attendance at a focus group on faecal incontinence by Continence UK (Nov 07). He has been paid to speak and chair meetings by Astellas, BMS and ALK. He is a paid member of the editorial boards of Continence UK. He has received payment for attending focus meetings on child growth hormone. He did not declare a personal family interest of non-personal pecuniary interest. He declared a personal non-pecuniary interest, member of the strategy board of Incontact, Chairman of the local division of the BMA and board member of RLS UK.
Second GDG Meeting (13 th December 2007)	No change
Third GDG Meeting (17 th March 2008)	No change
Fourth GDG Meeting (30 th April 2008)	JS declared a personal pecuniary interest, I have received sponsorship to attend the EAU congress in Milan from Pfizer. I have received speaker fees to speak at a conference from Pfizer on GPs and OAB. He is a member of advisory boards on LUTS and received honoraria from Boehringer Ingeliheim (March 07). He has attended advisory boards on Restless legs syndrome organised by RLS UK with payment from Boehringer Ingelheim. He has been paid for attendance at a focus group on faecal incontinence by Continence UK (Nov 07). He has been paid to speak and chair meetings by Astellas, BMS and ALK. He is a paid member of the editorial boards of Continence UK. He has received payment of attending focus meetings on child growth hormone. He did not declare a personal family interest of non-personal pecuniary interest. He declared a personal non-pecuniary interest, member of the strategy board of Incontact, Chairman of the local division of the BMA and board member of RLS UK.
Fifth GDG Meeting (6 th June 2008)	No change
Sixth GDG Meeting (14 th July 2008)	No change
Seventh GDG Meeting (8 th September 2008)	No change

GDG meeting	Declaration of Interests
obo meening	
Eighth GDG Meeting (15 th October 2008)	No change
Ninth GDG Meeting (27 th November 2008)	No change
Tenth GDG Meeting (16 th January 2009)	JS declared a personal non-pecuniary interest, he attended a planning meeting for the "Sense of Leadership" organised by Pfizer. He declared that he knew of no personal pecuniary interest, personal family interest or non-personal pecuniary interest, above those declared at the previous meeting.
Eleventh GDG Meeting (23 rd February 2009)	No change
Twelfth GDG Meeting (25 th March 2009)	No change
Thirteenth GDG Meeting (1 st May 2009)	JS declared that he had no current personal pecuniary interests. He declared that he knew of no non-personal family interest, personal non-pecuniary interest or personal family interest, above those declared at the previous meeting.
Fourteenth GDG Meeting (8 th June 2009)	No change
Fifteenth GDG Meeting (29 th June 2009)	No change
Actions	During the 12 th GDG on the 25 th March 2009, JS was only present as an observer for the presentations on medical interventions and did not participate in discussion due to previously declared interest.

2 1.2.11 William Turner

GDG meeting	Declaration of Interests
First GDG meeting (12 th December 2007)	WT declared a personal pecuniary interest, private practice in urology. He did not declare a personal family interest. He declared a non-personal pecuniary interest, he is the principal local investigator in clinical trials with Allergan (not yet opened), Dianippo Sumuto, Yamanouchi (now Astellas), Schwarz Pharma. He is the principal local investigator in clinical trial with Novartis 2005-6. He declared a personal non-pecuniary interest, executive committee member section of female and reconstructive urology, British Association of Urological Surgeons. Author of papers, chapters and books on urology. Member of NICE Topic Selection Panel and Technology Appraisal Committee.
Second GDG Meeting (13 th December 2007)	No change
Third GDG Meeting (17 th March 2008)	No change
Fourth GDG Meeting (30 th April 2008)	No change
Fifth GDG Meeting (6 th June 2008)	No change

GDG meeting	Declaration of Interests
Sixth GDG Meeting (14 th July 2008)	No change
Seventh GDG Meeting (8th September 2008)	No change
Eighth GDG Meeting (15 th October 2008)	No change
Ninth GDG Meeting (27 th November 2008)	No change
Tenth GDG Meeting (16 th January 2009)	No change
Eleventh GDG Meeting (23 rd February 2009)	No change
Twelfth GDG Meeting (25th March 2009)	No change
Thirteenth GDG Meeting (1st May 2009)	No change
Fourteenth GDG Meeting (8 th June 2009)	No change
Fifteenth GDG Meeting (29 th June 2009)	He declared a non-personal pecuniary interest; he stated that his participation in the clinical trial with Allergan never materialised. He declared that he knew of no personal pecuniary interest, personal family interest or personal non-pecuniary interest above those declared at the previous meeting.
Actions	None required.

2 **1.2.12** Adrian Wagg

GDG meeting	Declaration of Interests
First GDG meeting (12 th December 2007)	He did not attend this meeting
Second GDG Meeting (13 th December 2007)	AW declared a personal pecuniary interest, Astellas pharmaceutical – consultant. Pfizer – occasional consultant. He did not declare a personal family interest. He declared a non-personal pecuniary interest, fees for lectures/writing to research healthcare commission – research fund for Pfizer, Astellas, UCB. He declared a personal non-pecuniary interest, Chairman of trustees of the Continence Foundation and Vice Chairman trustees of Incontact. Researcher for Astellas. Plethora, Boehringer Ingelheim –Lilly. Associate Director CEEU, Royal College of Physicians. He is the National leader for audit of the Continence care.
Third GDG Meeting (17 th March 2008)	He declared a non-personal pecuniary interest, he declared a Pfizer research study, Europenan CI and UK PI.
Fourth GDG Meeting (30th April 2008)	AW declared a personal pecuniary interest, Astellas pharmaceutical – consultant. Pfizer – occasional consultant. Pfizer pharmaceutical advisory board. Sense of leadership course for Pfizer. SCA conference. Lecture fees from Astellas and telephone symposium on LUTS on geriatric medicine. He did not declare a personal family interest. He declared a non-personal pecuniary interest, fees for lectures/writing to research healthcare commission – research fund for Pfizer,

GDG meeting	Declaration of Interests
	Astellas, and UCB. Pfizer research study, European C.I. and UK principal investigator. BUPA grant for research £13K. Sponsorship to EAU by Astellas. He declared a personal non-pecuniary interest, Vice-chairman of the Continence Foundation and Incontact (merged). Researcher for Astellas. Plethora, Boehringer Ingelheim –Lilly. Associate Director CEEU, Royal College of Physicians. He is the National leader for audit of the Continence care. Papers for Pharma funded studies.
Fifth GDG Meeting (6 th June 2008)	AW declared a personal pecuniary interest, since last declaration, speaker for Pfizer at launch meeting for Fesoterodine. Astellas pharmaceutical – consultant. Pfizer – occasional consultant. Pfizer pharmaceutical advisory board. Sense of leadership course for Pfizer. SCA conference. Lecture fees from Astellas and telephone symposium on LUTS on geriatric medicine. He did not declare a personal family interest. He declared a non-personal pecuniary interest, fees for lectures/writing to research healthcare commission – research fund for Pfizer, Astellas, and UCB. Pfizer research study, European C.I. and UK principal investigator. BUPA grant for research £13K. Sponsorship to EAU by Astellas. He declared a personal non-pecuniary interest, Vice-chairman of the Continence Foundation and Incontact (merged). Researcher for Astellas. Plethora, Boehringer Ingelheim –Lilly. Associate Director CEEU, Royal College of Physicians. He is the National leader for audit of the Continence care. Papers for Pharma funded studies.
Sixth GDG Meeting (14 th July 2008)	AW declared a non-personal pecuniary interest, Chairman of Bladder Master class for Astellas Pharma. He declared a personal non-pecuniary interest; he had dinner courtesy of Pfizer at the ICI meeting in Paris and BAUS. He declared that he knew of no personal pecuniary interest or personal family interest, above those declared at the previous meeting.
Seventh GDG Meeting (8th September 2008)	No change
Eighth GDG Meeting (15 th October 2008)	No change
Ninth GDG Meeting (27 th November 2008)	No change
Tenth GDG Meeting (16 th January 2009)	AW declared a non personal pecuniary interest, donation to fellows research fund from Astellas. He declared that he knew of no personal pecuniary interest, personal family interest or personal non-pecuniary interest, above those declared at the previous meeting.
Eleventh GDG Meeting (23 rd February 2009)	He did not attend this meeting
Twelfth GDG Meeting (25 th March 2009)	He did not attend this meeting
Thirteenth GDG Meeting (1st May 2009)	No change
Fourteenth GDG Meeting (8 th June 2009)	AW declared a personal pecuniary interest and had received fees for a talk from Glaxo, he did not declare a personal family interest. He declared a non-personal pecuniary interest for research from Pfizer. He declared a personal non-pecuniary interest that a donation from Astellas for filming.
Fifteenth GDG Meeting (29 th June 2009)	AW declared a non-personal pecuniary interest, Pfizer talk at BAUS – payment into the department. He declared that he had no personal pecuniary interest, personal family interest or personal non-pecuniary interest above those previously declared.
Actions	During both the 14 th GDG on the 8 June 2009 and the 15 th GDG on the 29 June 2009, The Chair noted that AW had personal pecuniary interests and required AW

GDG meeting	Declaration of Interests
	to be present in an observatory role during the discussion of the pharmacologic recommendations.

2 **1.3 Personal pecuniary interests**

ML, MS and CC personal pecuniary interests that were deemed significant conflicts of
 interest had expired before medical intervention recommendations were discussed in the
 10th GDG meeting on the 16th January 2009. Further details of the GDG meetings can
 be found in the minutes on the <u>NICE website</u>.

7

Appendix C – Search Strategies

2 **Overview of Search Strategies**

3 Search Strategies

4 Searches were constructed by using the following groups of terms. These groups 5 are expanded in full in Section 1.2 below.

All searches were run in Medline, Embase and Cochrane Library. Additionally
Cinahl and PsychINFO were searched where this was deemed appropriate.
Economic searches were conducted in Medline, Embase, NHS EED and the HTA
(Health Technology Reports) database from the Cochrane Library. Additionally
in HEED (Health Economic Evaluations Database).

11 12 Medications search 13 14 **BPH/LUTS** terms 15 AND 16 **Medication terms** 17 AND 18 RCT filter or systematic review filter 19 NOT 20 Animal/publication filter 21 22 Surgery search 23 24 **BPH/LUTS** terms 25 AND 26 Surgery terms 27 AND 28 RCT filter or systematic review filter 29 NOT 30 Animal/publication filter 31 32 Laser search 33 34 **BPH/LUTS** terms 35 AND 36 Laser terms 37 AND 38 RCT filter or systematic review filter 39 NOT 40 Animal/publication filter 41 42 Conservative treatment search 43 44 **BPH/LUTS** terms

1	AND
2	Conservative treatment terms
3	AND
4	RCT filter or systematic review filter
5	NOT
5 6 7	Animal/publication filter
8	Diservasia as such
9	<u>Diagnosis search</u>
10	BPH/LUTS terms
11	AND
12	Diagnosis terms
13	NOT
14	Animal/publication filter
15	
16	Monitoring search
17	
18	BPH/LUTS terms
19	AND
20	Monitoring terms
21	NOT
22	Animal/publication filter
23	
24 25	Economic searches (Medline and Embase)
25 26	BPH/LUTS terms
27	AND
28	Economic filter
29	NOT
30	Animal/publication filter
31	
32	Economic searches (NHS EED and HEED)
33	
34	BPH/LUTS terms
35	
36	Patient education search
37	
38	BPH/LUTS terms
39 40	AND Destingt a desetion to man
40 41	Patient education terms NOT
42	Animal/publication filter
43	Animar/ publication timer
44	Patient views search
45	
46	BPH/LUTS terms
47	AND
48	Patient view terms
49	
50	

1 Search terms

2 Animal/publication filter

Animal/publication filter - OVID Embase

3	1	Case-Study/ or Abstract-Report/ or Letter/ or (case adj report).tw. or ((exp Animal/ or Nonhuman/ or exp Animal-Experiment/) not exp Human/)
		Animal/publication filter - OVID Medline
4	1	(Case-Reports NOT Randomized-Controlled-Trial OR Letter OR Historical-Article OR Review-Of-Reported-Cases).PT. OR (exp Animals/ NOT Humans/)

5 Benign Prostatic Hyperplasia (BPH) / Lower Urinary Tract Infection (LUTS) Terms

BPH/LUTS terms – Cochrane Library

- 1 MeSH descriptor Prostatic Hyperplasia, this term only
- 2 (Benign prostat* disease or prostatism or benign prostat* hyperplasia or benign prostat* enlargement or prostat* hypertrophy or prostat* obstruct* or enlarged prostate):ti,ab
- 3 (Lower urinary tract symptom* or urinary symptom* or LUTS or irritable bladder syndrome):ti,ab
- 4 MeSH descriptor Urinary Retention, this term only
- 5 (Bladder obstruct* or incomplete bladder emptying or impaired bladder emptying or storage symptom* or (retention adj5 (chronic or urinary or acute)) or residual urine):ti,ab
- 6 MeSH descriptor Urinary Bladder, Overactive, this term only
- 7 MeSH descriptor Urinary Incontinence, this term only
- 8 MeSH descriptor Enuresis explode all trees
- 9 ((micturition or urin* or bladder or voiding) near (disorder or dysfunction or symptom* or urgency or incontinen*)):ti,ab
- 10 (post micturition dribble or enuresis or nocturia or pollakisuria or weak bladder or overactive bladder or bedwetting):ti,ab
- 11 (haematuria or hematuria):ti,ab
- 12 male or man or men
- 13 ((#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11) AND #12)
- 14 #1 OR #2 OR #13

6

1

BPH/LUTS terms - OVID Embase

- Prostate Hypertrophy/
- 2 (Benign prostat\$ disease or prostatism or benign prostat\$ hyperplasia or benign prostat\$ enlargement or prostat\$ hypertrophy or prostat\$ obstruct\$ or enlarged prostate).tw.
- 3 (Lower urinary tract symptom\$ or urinary symptom\$ or LUTS or irritable bladder syndrome).tw.
- 4 exp Micturition Disorder/
- 5 (Bladder obstruct\$ or incomplete bladder emptying or impaired bladder emptying or storage symptom\$ or (retention adj5 (chronic or urinary or acute)) or residual urine).tw.
- 6 Urinary Frequency/
- 7 ((micturition or urin\$ or bladder or voiding) adj2 (disorder or dysfunction or symptom\$ or urgency or incontinen\$)).tw.
- 8 (post micturition dribble or enuresis or nocturia or pollakisuria or weak bladder or overactive bladder or bedwetting).tw.

- 9 (haematuria or hematuria).tw.
- 10 (male or man or men).mp.
- 11 ((or/3-9) and 10)
- 12 1 or 2 or 11

BPH/LUTS terms - OVID Medline

- 1 prostatic hyperplasia/
- 2 (Benign prostat\$ disease or prostatism or benign prostat\$ hyperplasia or benign prostat\$ enlargement or prostat\$ hypertrophy or prostat\$ enlargement or enlarged prostate).tw.
- 3 (Lower urinary tract symptom\$ or urinary symptom\$ or LUTS or irritable bladder syndrome).tw.
- 4 urinary retention/
- 5 (Bladder obstruct\$ or incomplete bladder emptying or impaired bladder emptying or storage symptom\$ or (retention adj5 (chronic or urinary or acute)) or residual urine).tw.
- 6 urinary bladder, overactive/ or urinary incontinence/ or exp enuresis/
- 7 ((micturition or urin\$ or bladder or voiding) adj2 (disorder or dysfunction or symptom\$ or urgency or incontinen\$)).tw.
- 8 (post micturition dribble or enuresis or nocturia or pollakisuria or weak bladder or overactive bladder or bedwetting).tw.
- 9 (haematuria or hematuria).tw.
- 10 (male or man or men).mp.
- 11 ((or/3-9) and 10)
- 12 1 or 2 or 11

2

3 Conservative

Conservative terms – Cochrane Library

- 1 (conservative next (management or treatment* or therap*))
- 2 MeSH descriptor Pelvic Floor, this term only
- 3 MeSH descriptor Exercise Therapy, this term only
- 4 ((Pelvic floor or pelvic muscle) next (exercise or training))
- 5 MeSH descriptor Behavior Therapy, this term only
- 6 (bladder next (training or education or exercise*))
- 7 Post void milking or post-void milking
- 8 MeSH descriptor Drinking Behavior, this term only
- 9 MeSH descriptor Drinking, this term only
- 10 MeSH descriptor Beverages, this term only
- 11 (Fluid* or water) near (consumption or intake)
- 12 MeSH descriptor Caffeine, this term only
- 13 MeSH descriptor Sweetening Agents, this term only
- 14 MeSH descriptor Carbonated Beverages, this term only
- 15 alcohol* or caffeine or tea or coffee or artifical sweetener* or carbonated drink* or fizzy drink* or beverage*
- 16 MeSH descriptor Catheterization, this term only
- 17 MeSH descriptor Catheters, Indwelling, this term only
- 18 MeSH descriptor Absorbent Pads, this term only
- 19 MeSH descriptor Incontinence Pads, this term only
- 20 Catheter*
- 21 Sheath* or penile clamp*

- 22 (Absorbent or incontinence or continence or protective or bed) near (pad* or pants or product*)
- 23 (bed or seat or chair) near (protection or pad* or sheet*)
- 24 MeSH descriptor Biofeedback (Psychology), this term only
- 25 (biofeedback or bio feedback or bio-feedback)
- 26 MeSH descriptor Electric Stimulation, this term only
- 27 Electric stimulation
- 28 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
- 1

Conservative terms - OVID Embase

- (conservative adj (management or treatment\$ or therap\$)).tw.
- 2 Pelvic floor muscle training/
- 3 ((Pelvic floor or pelvic muscle) adj (exercise or training)).tw.
- 4 Bladder training/
- 5 (bladder adj (training or education or exercise\$)).tw.
- 6 (Post void milking or post-void milking).tw.
- 7 Fluid intake/ or exp beverage/ or drinking behavior/
- 8 ((Fluid\$ or water) adj (consumption or intake)).tw.
- 9 Alcohol consumption/ or caffeine/ or sweetening agent/ or carbonated beverage/
- 10 (alcohol\$ or caffeine or tea or coffee or artifical sweetener\$ or carbonated drink\$ or fizzy drink\$ or beverage\$).tw.
- 11 Catheter/
- 12 Catheter\$.tw.
- 13 (Sheath\$ or penile clamp\$).tw.
- 14 ((Absorbent or incontinence or continence or protective or bed) adj (pad\$ or pants or product\$)).tw.
- 15 ((bed or seat or chair) adj2 (protection or pad\$ or sheet\$)).tw.
- 16 Feedback system/
- 17 (Biofeedback or bio feedback or bio-feedback).tw.
- 18 Electrostimulation/
- 19 Electrical stimulation.tw
- 20 or/1-19

2

Conservative terms - OVID Medline

- 1 (conservative adj (management or treatment\$ or therap\$)).tw.
- 2 Pelvic floor/ or exercise therapy/
- 3 ((Pelvic floor or pelvic muscle) adj (exercise or training)).tw.
- 4 behavior therapy/
- 5 (bladder adj (training or education or exercise\$)).tw.
- 6 (Post void milking or post-void milking).tw.
- 7 Drinking behavior/ or Drinking/ or Beverages/
- 8 ((Fluid\$ or water) adj (consumption or intake)).tw.
- 9 Caffeine/ or sweetening agents/ or carbonated beverages/
- 10 (alcohol\$ or caffeine or tea or coffee or artifical sweetener\$ or carbonated drink\$ or fizzy drink\$ or beverage\$).tw.
- 11 Catheterization/ or catheters, indwelling/ or absorbent pads/ or incontinence pads/
- 12 Catheter\$.tw.
- 13 (Sheath\$ or penile clamp\$).tw.

- 14 ((Absorbent or incontinence or continence or protective or bed) adj (pad\$ or pants or product\$)).tw.
- 15 ((bed or seat or chair) adj2 (protection or pad\$ or sheet\$)).tw.
- 16 "Biofeedback (Psychology) /"
- 17 (biofeedback or bio feedback or bio-feedback).tw
- 18 Electric stimulation/
- 19 Electrical stimulation.tw.
- 20 or/1-19
- 1

2 Diagnosis

Diagnosis terms - Central

- 1 (IPSS or I-PSS or (symptom near score))
- 2 ((American Urological Association or AUA*) near (symptom or score or index or questionnaire)).tw.
- 3 MeSH descriptor Urinalysis, this term only
- 4 MeSH descriptor Kidney Function Tests explode all trees
- 5 kidney function test* or renal function test* or serum creatinine or eGFR or urea or serum biochemistry or blood test* or dipstick test* or urine analys* or urinalys*
- 6 MeSH descriptor Digital Rectal Examination, this term only
- 7 rectal exam*
- 8 MeSH descriptor Prostate-Specific Antigen, this term only
- 9 (prostate specific antigen or PSA) and (test* or assess*)
- 10 MeSH descriptor Urodynamics, this term only
- 11 urinary flow rate* or urodynamics or pressure flow studies or post void residual measurement* or uroflowmetry
- 12 (Frequency volume chart* or ((bladder or volume or void* or urine or urinary or incontinence) adj (diar* or record*)))
- 13 MeSH descriptor Cystoscopy, this term only
- 14 Cystoscopy or cystometry or cystourethroscopy or videocystogram or cystometrogram
- 15 MeSH descriptor Ultrasonography, this term only
- 16 ultrasound or non-invasive test*
- 17 pad test*
- 18 MeSH descriptor X-Rays, this term only
- 19 abdominal x-ray*
- 20 KUB
- 21 MeSH descriptor Urography, this term only
- 22 IVU or IVP
- 23 (intravenous or intra-venous) near (urogram* or pyelogram* or urography)
- 24 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
- 3

Diagnosis terms - OVID Embase

- 1 international prostate symptom score/
- 2 (IPSS or I-PSS or (symptom adj3 score)).tw.
- 3 ((American Urological Association or \$AUA\$) adj3 (symptom or score or index or questionnaire)).tw.
- 4 urinalysis/ or kidney function test/
- 5 (kidney function test\$ or renal function test\$ or serum creatinine or eGFR or urea or serum biochemistry or blood test\$ or dipstick test\$ or urine analys\$ or urinalys\$).tw.
 6 digital rectal examination/

7	rectal exam\$.tw.
8	Prostate Specific Antigen/
9	((prostate specific antigen or PSA) and (test\$ or assess\$)).tw.
10	urodynamics/
11	(urinary flow rate\$ or urodynamics or pressure flow studies or post void residual measurement\$ or uroflowmetry).tw.
12	(Frequency volume chart\$ or ((bladder or volume or void\$ or urine or urinary or incontinence) adj (diar\$ or record\$))).tw.
13	cystoscopy/ or urethrocystometry/
14	(Cystoscopy or cystometry or cystourethroscopy or videocystogram or cystometrogram).tw.
15	(ultrasound or ultrasonography or non-invasive test\$).tw.
16	pad test\$.tw.
17	X Ray/
18	abdominal x-ray\$.tw.
19	KUB.tw.
20	Intravenous Urography/ or Intravenous Pyelography/
21	(IVU or IVP).tw.
22	((intravenous or intra-venous) adj (urogram\$ or pyelogram\$ or urography)).tw.
23	or/1-22

Diagnosis terms - OVID Medline

- 1 (IPSS or I-PSS or (symptom adj3 score)).tw.
- 2 ((American Urological Association or \$AUA\$) adj3 (symptom or score or index or questionnaire)).tw.
- 3 urinalysis/ or exp kidney function tests/
- 4 (kidney function test\$ or renal function test\$ or serum creatinine or eGFR or urea or serum biochemistry or blood test\$ or dipstick test\$ or urine analys\$ or urinalys\$).tw.
 5 digital rectal examination/
- 6 rectal exam\$.tw.
- 7 prostate specific antigen/
- 8 ((prostate specific antigen or PSA) and (test\$ or assess\$)).tw.
- 9 urodynamics/
- 10 (urinary flow rate\$ or urodynamics or pressure flow studies or post void residual measurement\$ or uroflowmetry).tw.
- 11 (Frequency volume chart\$ or ((bladder or volume or void\$ or urine or urinary or incontinence) adj (diar\$ or record\$))).tw.
- 12 cystoscopy/
- 13 (Cystoscopy or cystometry or cystourethroscopy or videocystogram or cystometrogram).tw.
- 14 ultrasonography/
- 15 (ultrasound or non-invasive test\$).tw.
- 16 pad test\$.tw.
- 17 X-Rays/
- 18 abdominal x-ray\$.tw.
- 19 KUB.tw.
- 20 Urography/
- 21 (IVU or IVP).tw.
- 22 ((intravenous or intra-venous) adj (urogram\$ or pyelogram\$ or urography)).tw.
- 23 or/1-22

2

1 Economic

Economic	
	Economic filter - OVID Embase
1	exp economic aspect/
2	cost\$.tw.
3	(price\$ or pricing\$).tw.
4	(fee or fees).tw.
5	(financial or finance or finances or financed).tw.
6	(value adj2 (money or monetary)).tw.
7	resourc\$ allocat\$.tw.
8	expenditure\$.tw.
9	(fund or funds or fundings or funded).tw.
10	(ration or rations or rationing or rationings or rationed).tw.
11	(saving or savings).tw.
12	or/1-11
13	Quality of Life/
14	quality of life.tw.
15	life quality.tw.
16	quality adjusted life.tw.
17	(qaly\$ or qald\$ or qale\$ or qtime\$).tw.
18	disability adjusted life.tw.
19	daly\$.tw.
20	(sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six or short form thirtysix or short form thirty six).tw.
21	(sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.
22	(sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw.
23	(sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short form sixteen).tw.
24	(sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty).tw.
25	(euroqol or euro qol or eq5d or eq 5d).tw.
26	(hql or hqol or h qol or hrqol or hr qol).tw.
27	(hye or hyes).tw.
28	health\$ equivalent\$ year\$.tw.
29	(hui or hui1 or hui2 or hui3).tw.
30	health utilit\$.tw.
31	disutilit\$.tw.
32	rosser.tw.
33	(quality of wellbeing or quality of well being).tw.
34	qwb.tw.
35	willingness to pay.tw.
36 27	standard gamble\$.tw. time trade off.tw.
37	time trade off.tw.
38 39	
39 40	tto.tw. factor analy\$.tw.
40 41	preference based.tw.
41	(state adj2 valu\$).tw.
42	Life Expectancy/
44	life expectancy/
45	((duration or length or period of time or lasting or last or lasted) adj4 symptom\$).tw.

- 46 or/13-46
- 47 exp model/
- 48 exp Mathematical Model/
- 49 markov\$.tw.
- 50 Monte Carlo Method/
- 51 monte carlo.tw.
- 52 exp Decision Theory/
- 53 (decision\$ adj2 (tree\$ or anlay\$ or model\$)).tw.
- 54 model\$.tw.
- 55 or/47-55
- 56 12 or 46 or 55
- 1

Economic filter - OVID Medline

- exp "Costs and Cost Analysis"/
- 2 Economics/
- 3 Economics, Nursing/ or Economics, Medical/ or Economics, Hospital/ or Economics, Pharmaceutical/
- 4 exp "Fees and Charges"/
- 5 exp Budgets/
- 6 budget\$.tw.
- 7 cost\$.ti.
- 8 (cost\$ adj2 (effective\$ or utilit\$ or benefit\$ or minimi\$)).ab.
- 9 (economic\$ or pharmacoeconomic\$ or pharmaco-economic\$).ti.
- 10 (price\$ or pricing\$).tw.
- 11 (financial or finance or finances or financed).tw.
- 12 (fee or fees).tw.
- 13 (value adj2 (money or monetary)).tw.
- 14 Value of Life/
- 15 quality adjusted life.tw.
- 16 (qaly\$ or qald\$ or qale\$ or qtime\$).tw.
- 17 disability adjusted life.tw.
- 18 daly\$.tw.
- 19 Health Status Indicators/
- 20 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six or short form thirtysix or short form thirty six).tw.
- 21 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).tw.
- 22 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).tw.
- 23 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short form sixteen).tw.
- 24 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty).tw.
- 25 (eurogol or euro gol or eq5d or eq 5d).tw.
- 26 (hql or hqol or h qol or hrqol or hr qol).tw.
- 27 (hye or hyes).tw.
- 28 (hui or hui1 or hui2 or hui3).tw.
- 29 utilit\$.tw.
- 30 disutilit\$.tw.
- 31 rosser.tw.
- 32 quality of wellbeing.tw.
- 33 qwb.tw.
- 34 willingness to pay.tw.

35	standard gamble\$.tw.
36	time trade off.tw.
37	time tradeoff.tw.
38	tto.tw.
39	exp models, economic/
40	models, theoretical/ or models, organizational/
41	economic model\$.tw.
42	markov chains/
43	markov\$.tw.
44	Monte Carlo Method/
45	monte carlo.tw.
46	exp Decision Theory/
47	(decision\$ adj2 (tree\$ or anlay\$ or model\$)).tw.
48	or/1-47

2 Laser

	Laser terms - Central
1	MeSH descriptor Prostatic Hyperplasia, this term only with qualifier: SU
2	MeSH descriptor Prostatic Hyperplasia, this term only
3	MeSH descriptor Urinary Bladder Neck Obstruction, this term only
4	benign prostat* near (hyperplas* or hypertroph* or obstruct* or enlarge* or disease)
5	bph or bpo or bpe
6	(bladder neck or bladder outlet or bladder outflow) near obstruct st
7	#2 or #3 or #4 or #5 or #6
8	MeSH descriptor Prostatectomy explode all trees
9	MeSH descriptor Transurethral Resection of Prostate, this term only
10 11	Transurethral near (resect* or electroresect* or incision* or diatherm* or vapori* or electrovapori* or evapori* or ablat* or thermo* or inject* or coagulat*) MeSH descriptor Electrosurgery explode all trees
12	MeSH descriptor Laser Therapy, this term only
13	MeSH descriptor Laser Coagulation, this term only
14	laser near (resect* or ablat* or coagulat* or incision* or vaporis*)
15	laser near (enucleat* or prostatect*)
16	laser near (holmium or yag or nd or ktp or green light)
17	photoselectiv* near vapori*
18	needle near ablat*
19	microwave near thermo*
20	coretherm or prostatron or targis or thermatrx or prolieve
21	ethanol near inject*
22	(water or cooled) near thermotherapy
23	MeSH descriptor Ultrasound, High-Intensity Focused, Transrectal, this term only
24	high intensity near ultrasound
25	MeSH descriptor Stents, this term only
26	prostat* near (stent* or spiral*)
27	turp or tvap or tevap or tvp or tuevap
28	tuip or vlap or holrp or holep or tuna or tumt
29	ilc or tulip or hifu
30	#11 or #12 or #13 or #14 or #16 or #17 or #18 or #19 or #21 or #22 or #23 or #24 or #25 or #29

31	#7 AND #30
32	#1 or #8 or #9 or #10 or #15 or #20 or #26 or #27 or #28 or #31
	Laser terms - OVID Embase
1	Prostate hypertrophy/su
2	Prostate hypertrophy/
3	bladder obstruction/
4	(benign prostat\$ adj1 (hyperplas\$ or hypertroph\$ or obstruct\$ or enlarge\$ or disease)).tw.
5	(bph or bpo or bpe).tw.
6	((bladder neck or bladder outlet or bladder outflow) adj1 obstruct\$).tw.
7	or/2-6
8	exp prostate surgery/
9	(Transurethral adj3 (resect\$ or electroresect\$ or incision\$ or diatherm\$ or vapori\$ or electrovapori\$ or evapori\$ or ablat\$ or thermo\$ or inject\$ or coagulat\$)).tw.
10	exp laser/
11	laser prostatectomy/
12	laser surgery/
13	Laser Coagulation/
14	(laser adj3 (resect\$ or ablat\$ or coagulat\$ or incision\$ or vapori\$)).tw.
15	(laser adj3 (enucleat\$ or prostatect\$)).tw.
16	(laser adj3 (holmium or yag or ktp or nd or green light)).tw.
17	(photoselectiv\$ adj1 vapori\$).tw.
18	(needle adj3 ablat\$).tw.
19	(microwave adj3 thermo\$).tw.
20	(coretherm or prostatron or targis or thermatrx or prolieve).tw.
21	(ethanol adj3 inject\$).tw.
22	Laser thermotherapy/
23	((water or cooled) adj3 thermotherapy).tw.
24	high intensity focused ultrasound/
25	(high intensity adj3 ultrasound).tw.
26	stents/
27	(prostat\$ adj3 (stent\$ or spiral\$)).tw.
28	(turp or tuvp or tevap or tvp or tuevap).tw.
29	(tuip or vlap or holrp or holep or tuna or tumt).tw.
30	(ilc or tulip or hifu).tw.
31	or/10-14,16-19,21-26,30
32	7 and 31
33	or/1,8-9,15,20,27-29,32
34	prostate cancer/ or bladder cancer/
35	(cancer\$ or carcinoma\$ or neoplasm\$).tw.
36	34 or 35
37	36 not 7
38	33 not 37

1

Laser terms - OVID Medline

- 1 Prostatic hyperplasia/su
- 2 Prostatic hyperplasia/

2	
3	Bladder neck obstruction/
4	(benign prostat\$ adj1 (hyperplas\$ or hypertroph\$ or obstruct\$ or enlarge\$ or disease)).tw.
5	(bph or bpo or bpe).tw.
6	((bladder neck or bladder outlet or bladder outflow) adj1 obstruct\$).tw.
7	or/2-6
8	exp prostatectomy/
9	Transurethral resection of prostate/
10	(Transurethral adj3 (resect\$ or electroresect\$ or incision\$ or diatherm\$ or vapori\$ or electrovapori\$ or evapori\$ or ablat\$ or thermo\$ or inject\$ or coagulat\$)).tw.
11	exp electrosurgery/
12	laser therapy/
13	laser coagulation/
14	(laser adj3 (resect\$ or ablat\$ or coagulat\$ or incision\$ or vaporis\$)).tw.
15	(laser adj3 (enucleat\$ or prostatect\$)).tw.
16	(laser adj3 (holmium or yag or nd or ktp or green light)).tw.
17	(photoselectiv\$ adj1 vapori\$).tw.
18	(needle adj3 ablat\$).tw.
19	(microwave adj3 thermo\$).tw.
20	(coretherm or prostatron or targis or thermatrx or prolieve).tw.
21	(ethanol adj3 inject\$).tw.
22	((water or cooled) adj3 thermotherapy).tw.
23	ultrasound, high-intensity focused, transrectal/
24	(high intensity adj3 ultrasound).tw.
25	stents/
26	(prostat\$ adj3 (stent\$ or spiral\$)).tw.
27	(turp or tvap or tevap or tvp or tuevap).tw.
28	(tuip or vlap or holrp or holep or tuna or tumt).tw.
29	(ilc or tulip or hifu).tw.
30	or/11-14,16-19,21-25,29
31	7 and 30
32	or/1,8-10,15,20,26-28,31
33	prostatic neoplasms/ or bladder neoplasms/
34	(cancer\$ or carcinoma\$ or neoplasm\$).tw.
35	33 or 34
36	35 not 7
37	32 not 36

2 Medications

Medication terms - Central

- 1 MeSH descriptor Adrenergic alpha-Antagonists, this term only
- 2 (Alpha near (blocker or blocking agent or antagonist)):ti,ab
- 3 MeSH descriptor Doxazosin, this term only
- 4 MeSH descriptor Indoramin, this term only
- 5 MeSH descriptor Prazosin, this term only
- 6 (Doxazosin or Tamsulosin or Alfusozin or Terazosin or Indoramin or Prazosin or Cardura or Stronazon or Flomaxtra or Flomax or Xaltral or Hytrin or Doralese or Hypovase):ti,ab
- 7 (5-Alpha reductase inhibitor* or Alpha V reductase inhibitor*):ti,ab

- 8 MeSH descriptor Finasteride, this term only 9 (Finasteride or Dutasteride or Avodart or Proscar):ti,ab 10 MeSH descriptor Cholinergic Antagonists, this term only 11 (Anticholinergic* or cholinergic antagonist* or antimuscarininc*):ti,ab 12 (Oxybutynin or Tolterodine or Darifenacin or Propiverine or Solifenacin or Trospium or Cystrin or Ditropan or Lyrinel or Detrusitol or Emselex or Detrunorm or Vesicare or Regurin):ti,ab 13 MeSH descriptor Cyclic Nucleotide Phosphodiesterases, Type 5, this term only 14 (Phosphodiesterase 5 inhibitor* or Phosphodiesterase V inhibitor*):ti,ab 15 (PDE5 or sildenafil or viagra or vardenafil or levitra or tadalafil or cialis):ti,ab
- 16 MeSH descriptor Phytotherapy, this term only
- 17 MeSH descriptor Plant Extracts, this term only
- 18 MeSH descriptor Plants, Medicinal, this term only
- 19 (Phytotherapy or plant extract*):ti,ab
- 20 MeSH descriptor Serenoa, this term only
- 21 MeSH descriptor Sterols, this term only
- 22 MeSH descriptor Sitosterols, this term only

23 (Saw palmetto or serenoa or sabal or s repens or sitosterol* or b-sitosterol* or sitosteryl* or phytosterol*):ti,ab

- 24 MeSH descriptor Secale cereale, this term only
- 25 (pollen or secale cereale or rye or cernitin or cernilton):ti,ab
- 26 MeSH descriptor Cucurbita, this term only
- 27 (pumpkin seed\$ or cucurbita or pepita):ti,ab
- 28 MeSH descriptor Urtica dioica, this term only
- 29 (nettle or urtica):ti,ab
- 30 MeSH descriptor Pygeum, this term only
- 31 (pygeum africanum or prunus or tadenan or docosonal or pigenil):ti,ab
- 32 (cranberry AND (juice or extract)):ti,ab
- 33 MeSH descriptor Diuretics, this term only
- 34 Diuretic*:ti,ab
- 35 MeSH descriptor Furosemide, this term only
- 36 MeSH descriptor Bumetanide, this term only
- 37 (Frusemide or furosemide or bumetanide or burinex):ti,ab
- 38 (Desmopressin or DDAVP or desmotabs or desmomelt or desmospray or octim):ti,ab
- 39 MeSH descriptor Anti-Inflammatory Agents, Non-Steroidal, this term only
- 40 (Aceclofenac or acemetacin or azapropazone or celecoxib or dexibuprofen or dexketoprofen or diclofenac or etodolac or etoricoxib or fenbufen or fenobufen or flurbiprofen or ibuprofen or indometacin or ketoprofen or mefenamic acid or meloxicam or nabumetone or naproxen or piroxicam or sulindac or tenoxicam or tiaprofenic acid or aspirin):ti,ab
- 41 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #'40
- 1

Medication terms - OVID Embase

- 1 Alpha Adrenergic Receptor Blocking Agent/
- 2 (Alpha adj3 (blocker or blocking agent or antagonist)).ti,ab.
- 3 Doxazosin/ or Tamsulosin/ or Alfuzosin/ or Terazosin/ or Indoramin/ or Prazosin/
- 4 (Doxazosin or Tamsulosin or Alfusozin or Terazosin or Indoramin or Prazosin or Cardura or Stronazon or Flomaxtra or Flomax or Xaltral or Hytrin or Doralese or Hypovase).ti,ab.

5	Steroid 5alpha Reductase Inhibitor/
6	(5-Alpha reductase inhibitor\$ or Alpha V reductase inhibitor\$).ti,ab.
7	Dutasteride/ or Finasteride/
8	(Finasteride or Dutasteride or Avodart or Proscar).ti,ab.
9	(Anticholinergic\$ or cholinergic antagonist\$ or antimuscarininc\$).ti,ab.
10	Oxybutynin/ or Tolterodine/ or Darifenacin/ or Propiverine/ or Solifenacin/ or Trospium/
11	(Oxybutynin or Tolterodine or Darifenacin or Propiverine or Solifenacin or Trospium or Cystrin or Ditropan or Lyrinel or Detrusitol or Emselex or Detrunorm or Vesicare or Regurin).ti,ab.
12	Phosphodiesterase V Inhibitor/
13	(Phosphodiesterase 5 inhibitor\$ or Phosphodiesterase V inhibitor\$).ti,ab.
14	Sildenafil/ or Vardenafil/ or Tadalafil/
15	(PDE5 or sildenafil or viagra or vardenafil or levitra or tadalafil or cialis).ti,ab.
16	Phytotherapy/ or Plant extract/ or Medicinal plant/
17	(Phytotherapy or plant extract\$).ti,ab.
18	Sabal/ or Sterol/ or Sitosterol derivative/
19	(Saw palmetto or serenoa or sabal or s repens or sitosterol\$ or b-sitosterol\$ or sitosterol\$).ti,ab.
20	Rye/ or Grass pollen extract/
21	(pollen or secale cereale or rye or cernitin or cernilton).ti,ab.
22	(pumpkin seed\$ or cucurbita or pepita).ti,ab.
23	Urtica extract/
24	(nettle or urtica).ti,ab.
25	Pygeum Africanum extract/
26	(pygeum africanum or prunus or tadenan or docosonal or pigenil).ti,ab.
27	Cranberry extract/ or Cranberry juice/
28	(cranberry adj1 (juice or extract)).ti,ab.
29	Diuretic Agent/
30	Diuretic\$.ti,ab.
31	Furosemide/ or Bumetanide/
32	(Frusemide or furosemide or bumetanide or burinex).ti,ab.
33	Desmopressin Acetate/ Or Desmopressin/
34	(Desmopressin or DDAVP or desmotabs or desmomelt or desmospray or octim).ti,ab.
35	Nonsteroid Antiinflammatory Agent/
36	(Non steroidal anti inflammator\$3 or NSAID\$).ti,ab.
37	Aceclofenac/ or acemetacin/ or azapropazone/ or celecoxib/ or dexibuprofen/ or dexketoprofen/ or diclofenac/ or etodolac/ or etoricoxib/ or fenbufen/ or fenobufen/ or flurbiprofen/ or ibuprofen/ or indometacin/ or ketoprofen/ or mefenamic acid/ or meloxicam/ or nabumetone/ or naproxen/ or piroxicam/ or sulindac/ or tenoxicam/ or tiaprofenic acid/ or aspirin/
38	(Aceclofenac or acemetacin or azapropazone or celecoxib or dexibuprofen or dexketoprofen or diclofenac or etodolac or etoricoxib or fenbufen or fenobufen or flurbiprofen or ibuprofen or indometacin or ketoprofen or mefenamic acid or meloxicam or nabumetone or naproxen or piroxicam or sulindac or tenoxicam or tiaprofenic acid or aspirin).ti,ab.
39	or/1-38
	Medication terms - OVID Medline

Medication terms - OVID Medline

- 1 Adrenergic alpha-Antagonists/
- 2 (Alpha adj3 (blocker or blocking agent or antagonist)).ti,ab.
- 3 Doxazosin/ or Indoramin/ or Prazosin/

- 4 (Doxazosin or Tamsulosin or Alfusozin or Terazosin or Indoramin or Prazosin or Cardura or Stronazon or Flomaxtra or Flomax or Xaltral or Hytrin or Doralese or Hypovase).ti,ab. 5 (5-Alpha reductase inhibitor\$ or Alpha V reductase inhibitor\$).ti,ab. 6 Finasteride/ 7 (Finasteride or Dutasteride or Avodart or Proscar).ti,ab. 8 Cholinergic Antagonists/ 9 (Anticholinergic\$ or cholinergic antagonist\$ or antimuscarininc\$).ti,ab. 10 (Oxybutynin or Tolterodine or Darifenacin or Propiverine or Solifenacin or Trospium or Cystrin or Ditropan or Lyrinel or Detrusitol or Emselex or Detrunorm or Vesicare or Regurin).ti,ab. 11 Cyclic Nucleotide Phosphodiesterases, Type 5/ 12 (Phosphodiesterase 5 inhibitor\$ or Phosphodiesterase V inhibitor\$).ti,ab. 13 (PDE5 or sildenafil or viagra or vardenafil or levitra or tadalafil or cialis).ti,ab. 14 Phytotherapy/ or Plant extracts/ or Plants, medicinal/ or serenoa/ 15 (Phytotherapy or plant extract\$).ti,ab. 16 Serenoa/ or Sterols/ or Sitosterols/ 17 (Saw palmetto or serenoa or sabal or s repens or sitosterol\$ or b-sitosterol\$ or sitosteryl\$ or phytosterol\$).ti,ab. 18 Secale Cereale/ 19 (pollen or secale cereale or rye or cernitin or cernilton).ti,ab. 20 Cucurbita/ 21 (pumpkin seed\$ or cucurbita or pepita).ti,ab. 22 Urtica dioica/ 23 (nettle or urtica).ti,ab. 24 Pygeum/ 25 (pygeum africanum or prunus or tadenan or docosonal or pigenil).ti,ab. 26 (cranberry adj1 (juice or extract)).ti,ab. 27 Diuretics/ 28 Diuretic\$.ti,ab. 29 Furosemide / or Bumetanide / 30 (Frusemide or furosemide or bumetanide or burinex).ti,ab. 31 (Desmopressin or DDAVP or desmotabs or desmomelt or desmospray or octim).ti,ab. 32 Anti-Inflammatory Agents, Non-Steroidal/ 33 (Non steroidal anti inflammator\$3 or NSAID\$).ti,ab. 34 (Aceclofenac or acemetacin or azapropazone or celecoxib or dexibuprofen or dexketoprofen or diclofenac or etodolac or etoricoxib or fenbufen or fenobufen or flurbiprofen or ibuprofen or indometacin or ketoprofen or mefenamic acid or meloxicam or nabumetone or naproxen or piroxicam or sulindac or tenoxicam or tiaprofenic acid or aspirin).ti,ab. 35 or/1-34
- 1

2 Monitoring

Monitoring terms – Cochrane Library

- 1 (review* near (interval* or visit* or inspect* or examin* or attend* or check-up* or recall*))
- 2 (routine* near (interval* or visit* or inspect* or examin* or attend* or check-up* or recall*))
- 3 (periodic* near (interval* or visit* or inspect* or examin* or attend* or check-up* or recall*))
- 4 (regular near (visit* or inspect* or examin* or attend* or check-up*))
- 5 recall* near interval*

	6	visit* near clinic*
	7	#1 or #2 or #3 or #4 or #5 or #6
1		
		Monitoring terms – OVID Embase and Medline
	1	(review\$ adj (interval\$ or visit\$ or inspect\$ or examin\$ or attend\$ or check-up\$ or recall\$)).tw.
	2	(routine\$ adj (interval\$ or visit\$ or inspect\$ or examin\$ or attend\$ or check-up\$ or recall\$)).tw.
	3	(periodic\$ adj (interval\$ or visit\$ or inspect\$ or examin\$ or attend\$ or check-up\$ or recall\$)).tw.
	4	(regular adj (visit\$ or inspect\$ or examin\$ or attend\$ or check-up\$)).tw.
	5	(recall\$ adj interval\$).tw.
	6	(visit\$ adj5 clinic\$).tw.
	7	or/1-6
2		
3	Patien	t education
		Patient education - OVID Embase
	1	Patient/ or Hospital patient/ or Outpatient/
	2	Caregiver/ or exp Family/ or exp Parent/

- 3 (patients or carer\$ or famil\$).tw.
- 4 or/1-3
- 5 Information Service/ or Information center/ or Publication/ or Book/ or Counseling/ or Directive counseling/
- 6 4 or 5
- 7 ((patient or patients) adj3 (education or educate or educating or information or literature or leaflet\$ or booklet\$ or pamphlet\$)).ti,ab.
- 8 Patient information/ or Patient education/
- 9 or/6-8
- 4

Patient education OVID Medline

- 1 Patients/ or Inpatients/ or Outpatients/
- 2 Caregivers/ or exp Family/ or exp Parents/ or exp Legal-Guardians/
- 3 (patients or carer\$ or famil\$).tw.
- 4 or/1-3
- 5 Popular-Works-Publication-Type/ or exp Information-Services/ or Publications/ or Books/ or Pamphlets/ or Counseling/ or Directive-Counseling/
- 6 4 or 5
- 7 ((patient or patients) adj3 (education or educate or educating or information or literature or leaflet\$ or booklet\$ or pamphlet\$)).ti,ab.
 8 Patient-Education/ or Patient-Education-Handout-Publication-Type/
- 9 or/6-8

5

6 Patient views

Patient views - OVID Embase

- 1 Consumer attitude/ or patient satisfaction/ or patient compliance/ or patient right/ or health survey/ or questionnaire/ or interview/
- 2 (patient\$ adj3 (view\$ or opinion\$ or awareness or tolerance or perception or persistenc\$ or attitude\$ or compliance or satisfaction or concern\$ or belief\$ or feeling\$ or position or idea\$ or preference\$ or choice\$)).tw.

3 (Discomfort or comfort or inconvenience or bother\$4 or trouble or fear\$ or anxiety or anxious or embarrass\$4).tw.

or/1-3

1

4

1

Patient views - OVID Medline

- exp Consumer-Satisfaction/ or Personal-Satisfaction/ or exp Patient-Acceptance-Of-Health-Care/ or exp Consumer-Participation/ or exp Patient-Rights/ or Health Care Surveys/ or Questionnaires/ or Interview/ or Focus groups/
- 2 (patient\$ adj3 (view\$ or opinion\$ or awareness or tolerance or perception or persistenc\$ or attitude\$ or compliance or satisfaction or concern\$ or belief\$ or feeling\$ or position or idea\$ or preference\$ or choice\$)).tw.
- 3 (Discomfort or comfort or inconvenience or bother\$4 or trouble or fear\$ or anxiety or anxious or embarrass\$4).tw.

4 or/1-3

2

3 RCT filter

1

RCT filter Embase

- Clinical-Trial/ or Randomized-Controlled-Trial/ or Randomization/ or Single-Blind-Procedure/ or Double-Blind-Procedure/ or Crossover-Procedure/ or Prospective-Study/ or Placebo/
- 2 ((((((((clinical or control or controlled) adj (study or trial)) or (single or double or triple)) adj (blind\$3 or mask\$3)) or randomised or randomized or random\$) adj (assign\$ or allocat\$ or group or grouped or patients or study or trial or distribut\$)) or crossover) adj (design or study or trial)) or placebo or placebos).ti,ab.
 3 1 or 2

4

RCT filter Medline

- 1 Randomized-Controlled-Trials/ or Random-Allocation/ or Double-Blind-Method/ or Single-Blind-Method/ or exp Clinical-Trials as topic/ or Cross-Over-Studies/ or Prospective-Studies/ or Placebos/
- 2 (Randomized-Controlled-Trial or Clinical-Trial or Controlled-Clinical-Trial).pt.
- 3 ((((((((clinical or control or controlled) adj (study or trial)) or (single or double or triple)) adj (blind\$3 or mask\$3)) or randomised or randomized or random\$) adj (assign\$ or allocat\$ or group or grouped or patients or study or trial or distribut\$)) or crossover) adj (design or study or trial)) or placebo or placebos).ti,ab.
 4 or/1-3

5

6 Surgery

Surgery terms – Cochrane Library

- 1 MeSH descriptor Surgery, this term only
- 2 MeSH descriptor Urologic Surgical Procedures, this term only
- 3 MeSH descriptor Botulinum Toxins, this term only
- 4 botulinum or botox
- 5 Cystoplasty or bladder neck incision
- 6 Neuromodulation
- 7 Sacral nerve stimulation
- 8 Myectomy
- 9 MeSH descriptor Suburethral Slings, this term only
- 10 sling

- 11 injectable
- 12 MeSH descriptor Urinary Diversion, this term only
- 13 (Continent or incontinent) and diversion
- 14 MeSH descriptor Urinary Sphincter, Artificial, this term only
- 15 Artificial sphincter
- 16 Compression device
- 17 MeSH descriptor Catheterization, this term only
- 18 Suprapubic catheter*
- 19 Sphincterotomy
 - #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19

20

Surgery terms - OVID Embase

1	Urologic Surgery/ or Male Genital System Surgery/ or Surgery/ or Bladder
2	Surgery/ or Prostate Surgery/ Botulinum Toxin/
3	(botulinum or botox).tw.

- 4 Bladder Reconstruction/
- 5 (Bladder neck incision or cystoplasty).tw.
- 6 Neuromodulation/
- 7 neuromodulation.tw.
- 8 sacral nerve stimulation/
- 9 Sacral nerve stimulation.tw.
- 10 muscle resection/
- 11 Myectomy.tw.
- 12 sling.tw.
- 13 injectable.tw.
- 14 Urinary Diversion/
- 15 ((Continent or incontinent) and diversion).tw.
- 16 Bladder Sphincter Prosthesis/
- 17 Artificial sphincter.tw.
- 18 Compression device.tw.
- 19 Ureter Catheterization/ or Catheterization/
- 20 Suprapubic Catheter/
- 21 Suprapubic catheter\$.tw.
- 22 Sphincterotomy/
- 23 Sphincterotomy.tw.
- 24 or/1-23

2

Surgery terms - OVID Medline

- 1 Surgery/
- 2 Urologic Surgical Procedures/
- 3 Botulinum Toxins/
- 4 (botulinum or botox).tw.
- 5 (Cystoplasty or bladder neck incision).tw.
- 6 Neuromodulation.tw.
- 7 Sacral nerve stimulation.tw.
- 8 Myectomy.tw.

- 9 Suburethral Slings/
- 10 sling.tw.
- 11 injectable.tw.
- 12 Urinary Diversion/
- 13 ((Continent or incontinent) and diversion).tw.
- 14 Urinary Sphincter, Artificial/
- 15 Artificial sphincter.tw.
- 16 Compression device.tw.
- 17 Catheterization/
- 18 Suprapubic catheter\$.tw.
- 19 Sphincterotomy.tw.
- 20 or/1-19
- 1

2 Systematic review filter

Systematic review filter - OVID Medline

- meta-analysis/
- 2 (metaanalys\$ or meta-analys\$ or meta analys\$).tw.
- 3 exp "review literature"/
- 4 (systematic\$ adj3 (review\$ or overview\$)).tw.
- 5 (selection criteria or data extraction).ab. and review.pt.
- 6 (cochrane or embase or psychit or psychit or psychinfo or psycinfo or cinahl or cinhal or science citation index or bids or cancerlit).ab.
- 7 (reference list\$ or bibliograph\$ or hand search\$ or hand-search\$ or manual search\$ or relevant journals).ab.

8 or/1-7

Systematic review filter - OVID Embase

- 1 meta analysis/
- 2 (metaanalys\$ or meta-analys\$ or meta analys\$).tw.
- 3 systematic review/
- 4 (systematic\$ adj3 (review\$ or overview\$)).tw.
- 5 (selection criteria or data extraction).ab. and Review.pt.
- 6 (cochrane or embase or psychit or psychinfo or psycinfo or cinahl or cinhal or science citation index or bids or cancerlit).ab.
- 7 (reference list\$ or bibliograph\$ or hand search\$ or manual search\$ or relevant journals).ab.

8 or/1-7

4

Appendix D – Evidence Tables

2	Evidence Table 1 Diagnostic accuracy for urinalysis	48
2 3	Evidence Table 2: How does PSA predict symptom progression (in terms of symptom score)?	
4 5	Evidence Table 3 Diagnosistic accuracy of uroflowmetry	62
5	Evidence Table 4 Diagnostic accuracty of post void residual	66
6	Evidence Table 5 Pelvic floor exercises (with or without electrical stimulation or biofeedback)	67
7	Evidence Table 6 Post void milking vs. no intervention or other conservative intervention	
8	Evidence Table 7 Product vs. no product or other conservative intervention	
9	Evidence Table 8 Catheters vs. no catheters	
10	Evidence Table 9 Alpha-blockers vs. placebo	
11	Evidence Table 10 Alpha blocker vs. 5-alpha reductase inhibitors	
12	Evidence Table 11 Alpha-blockers vs. anticholinergics	
13	Evidence Table 12 Alpha-blockers vs. phosphodiesterase-5 inhibitors	
14	Evidence Table 13 5-alpha reductase inhibitors vs. placebo	
15	Evidence Table 14 Anticholinergics vs. placebo	
16	Evidence Table 15 Phosphodiesterase-5 inhibitors vs. placebo	
17	Evidence Table 16 Diuretics vs. placebo	
18	Evidence Table 17 Desmospressin vs. placebo	
19	Evidence Table 18 Non steroidal anti-inflammatory drugs (NSAIDS) vs. placebo	
20	Evidence Table 19 Combination therapy: 5-Alpha reductase inhibitor added to alpha-blocker	
21	Evidence Table 20 Combination therapy: Anticholinergic added to alpha-blocker	
22	Evidence Table 21 Combination therapy: phosphodiesterase-5-inhibitor added to alpha-blocker	
23	Evidence Table 22 Holmium laser enucleation (or resection) of the prostate HoLEP (HoLRP) vs. transureth	
24	resection of the prostate	
25	Evidence Table 23 Thulium laser resection vs. transurethral resection of the prostate	
26	Evidence Table 24 Holmium laser eneucleation of the prostate (HoLEP) vs. transurethral incision of the p	
27	(HoBNI)	
28	Evidence Table 25 Holmium laser enucleation of the prostate (HoLEP) vs. open prostatectomy (OP)	
29	Evidence Table 26Laser coagulation vs. transurethral resection of the prostate (TURP)	
30	Evidence Table 27 Laser vapourisation vs. transurethral resection of the prostate (TURP)	
31	Evidence Table 28: Laser vs. open prostatectomy	
32	Evidence Table 29 Laser vs. transurethral microwave thermotherapy (TUMT)	
33	Evidence Table 30 Laser vs. transurethral vapourisation of the prostate (TUVP)	
34	Evidence Table 31 Laser coagulation vs. laser vapourisation	
35	Evidence Table 32 Holmium laser resection of the prostate (HoLRP) vs. laser coagulation	
36	Evidence Table 33 Holmium laser enucleation of the prostate (HoLEP) vs. laser vapourisation	
37	Evidence Table 34 Transurethral microwave thermotherapy (TUMT) vs. no treatment	
38	Evidence Table 35 Transurethral microwave thermotherapy (TUMT) vs. transurethral resection of the pro	
39	(TURP)	
40	Evidence Table 36 Transurethral vapourisation of the prostate (TUVP) vs. transurethral resection of the	
41	(TURP)	
42	Evidence Table 37 Bipolar transurethral vapourisation of the prostate (TUVP) vs. transurethral resection	
43	prostate (TURP)	
44	Evidence Table 38 Transurethral needle ablation (TUNA) vs. transurethral resection of the prostate (TUR	(P) 393
45	Evidence Table 39 Transurethral incision of the prostate (TUIP) vs. transurethral resection of the prostate	(TURP)
43 44 45 46 47		
47	Evidence Table 40 Botulinium toxin vs. placebo	
48	Evidence Table 41 Transurethral vaporesection of the prostate (TUVRP) vs. transurethral resection of the	e prostate
49	(TURP)	
48 49 50	Evidence Table 42 Bipolar TUVRP vs. transurethral resection of the prostate (TURP)	
-		

1	Evidence Table 43 Transurethral ethanol ablation of the prostate (TEAP) vs. transurethral resection of the pro	state
2	(TURP)	440
3	Evidence Table 44 Transurethral resection of the prostate (TURP) vs. watchful waiting	441
4	Evidence Table 45 Bipolar transurethral resection of the prostate (TURP) vs. TURP	445
5	Evidence Table 46 Conservative vs. surgery	466
6	Evidence Table 47: What is the effectiveness of alpha-blockers in treating men after acute urinary retentions	.472
7	Evidence Table 48 Phytotherapy vs. placebo	478
8	Evidence Table 49 Phytotherapy combinations vs. placebo	487
9	Evidence Table 50 Phytotherapy vs. Alpha-blockers	491
10	Evidence Table 51 Phytotherapy vs. 5-Alpha Reductase inhibitors	
11	Evidence Table 52 Provision of information	501
12	Evidence Table 53 Economic evidence	507
13		

Lower urinary tract symptoms (LUTS) - full guideline appendices DRAFT (August 2009)

45 of 754

1 Abbreviations

5-ARI	5-Alpha-Reductase Inhibitors
AB	Alpha-Blockers
AUA	American Urological Association
AUASS	American Urological Association Symptom Score
AUR	Acure Urinary Retention
BOO	Bladder outlet obstruction
BPE	Benign prostatic enlargement
BPH	Benign prostatic hyperlasia
вро	Benign prostatic obstruction
CI 95%	95% Confidence interval
DRE	Digital rectal examination
ED	Erectile dysfunction
GP	General Practitioner
U. HIFU	High Intensity Focused Ultrasound
HoLAP	Holmium Laser Ablation of the Prostate
HoLEP	Holmium Laser Enucleation of the prostate
HoLRP	Holmium Laser Resection of the Prostate
ICER	Incremental Cost-Effectiveness Ratio
ICS	International Continence Society
ILC	Interstitial Laser Coagulation
Int	Intervention
IPSS	International prostate symptom score
IQR	Interquartile range
ІТТ	Intention to treat analysis
КТР	Potassium-Titanyl-Phosphate
LOS	Length Of Stay
LUTS	Lower urinary tract symptoms
M/F	Male/female
Ν	Total number of patients randomised
NA	Not Applicable
NR	Not reported
OAB	Overactive bladder
PFMT	Pelvic floor muscle training
PMD	Post micturition dribble
PPP	Purchasing Power Parities
PSA	Prostate specific antigen
Ρνμ	Post-void milking
PVP	Photoselective vaporisation of the prostate
PVR	Post voidal residual
QALY	Quality-Adjusted Life Years
Qmax	Maximum urinary flow rate
QoL	Quality of life
RBC	Red blood cells
RCT	Randomised controlled trial
RR	Relative risk

SA	Sensitivity Analysis
SD	Standard Deviation
SE	Standard Error
Sig	Statistically significant at 5%
ΤΕΑΡ	Transurethral ethanol ablation of the prostate
TUIP	Transurethral incision of the prostate
TUMT	Transurethral microwave thermotherapy
TUNA	Transurethral needle ablation
TURP	Transurethral resection of the prostate
TUVP	Transurethral vaporisation of the prostate
TUVRP	Transurethral vaporisation resection of the prostate
τνρ	Transurethral electroVaporisation of the Prostate
тwос	Trial Without Catheter
UI	Urinary incontinence
UTI	Urinary Tract Infection
Vs	Versus
ww	Watchful Waiting

1	Evidence Table	1 Diagnostic	accuracy for	urinalysis
---	----------------	--------------	--------------	------------

Study details	Patients	Diagnostic tools	Measure of Disorders	Results	Comments
Ezz et al., 1996 ⁷⁴	Patient group: Consecutive men at one	Assessment tool under investigation: Urinalysis by dipstick readings from	Bladder tumours	Grade 1: 1/516 (0.2%) Grade 2, 3 & 4: 2/234 (0.9%)	Funding: NR.
Study design:	outpatient department	clean mid-stream specimen, If revealed		Grade 2: 2/207	Limitations:
Cross sectional	(Department of Urology,	erythrocytes urine sediment microscopy		Grade 3: 0/15	Cystoscopy performed
study	Nijmegen, The	was completed.		Grade 4: 0/12	on second visit after
	Netherlands) with BPE	•	Sensitivity	,	initial tests.
Evidence level:	and LUTS, either irritative	Sediment grading completed by	Specificity	68.9%	
Level-2 study (II)	or obstructive.	number of red blood cells (RBC):		0.9%	Additional
, , , ,		Grade 1 = 0 RBC	NPV	99.8%	tests:
Duration of		Grade 2 = 1-5 RBC	Prevalence	3/750 (0.4%)	Correlation of grades
follow-up: NR.	Exclusion criteria:	Grade 3 = 6-10 RBC	Positive LR	2.15	of RBC to age,
Tests carried out	Patients excluded from	Grade $4 = 10 + RBC$	Negative LR	0.48	prostate volume, IPSS,
over 2 visits.	further assessment for		Pre-test Odds (CI 95%)	0.004(0-0.01)	residual urine and
	BPH once a prostate	Results:	Post-Test Odds +ve result	0.01	outlet obstruction.
	carcinoma suspected.	Grade 1: 516 (68.8%)	Post-Test Odds -ve result	0.01	Papillary lesion and
		Grade 2: 207 (27.2%)	Urinary tract infection by	Grade 1:7/516 (1.4%)	dilatation were
		Grade 3: 15 (2%)	urine culture	Grade 2, 3 & 4: 10/234 (4.3%)	reported. One renal
	All patients	Grade 4:12 (1.6%)		Grade 2: 9/207	tumour was reported.
	N: 750			Grade 3: 0/15	
	Av Age (range): 64	Gold standard:		Grade 4: 1/12	Notes:
	years (40-85)	Cystoscopy and histology.	Sensitivity		All patients with
	Drop outs: 0		Specificity		positive dipstick
		Additional tests:		4.3%	readings were found
		All patients underwent: History, IPSS,		98.6%	to have red cells on
		physical examination with Digital		17/750 (2.3%)	microscopy.
		rectal examination, biochemistry (PSA	Positive LR		
		and serum creatinine), urine culture and	Negative LR		Sensitivity and
		cytology, trans rectal ultrasonography,	Pre-test Odds (CI 95%)		specificity values
		plain abdominal X-ray, renal	Post-Test Odds +ve result		calculated by NCGC
		ultrasound, flexible cystoscopy, flow,	Post-Test Odds -ve result		using no RBC found
		post void residual (PVR) and			(negative) compared
		urodynamic investigations.	Urinary calculi (Stones) by		to any RBC (positive).
		abdominal X-ray	Grade 2, 3 & 4: 14/234 (6.0%)		
				Grade 2: 12/207	All values calculated to
				Grade 3: 1/15	1d.p.
			6	Grade 4: 1/12	
			Sensitivity		
			Specificity	08.0%	

Study details	Patients	Diagnostic tools	Measure of Disorders	Results	Comments
				6.0%	
				93.2%	
				49/750 (6.5%)	
			Positive LR		
			Negative LR		
			Pre-test Odds (CI 95%)		
			Post-Test Odds +ve result Post-Test Odds -ve result		
			Cyst by renal ultrasound	Grade 1: 39/516 (7.6%)	
				Grade 2, 3, & 4: 22/234 (9.4%)	
				Grade 2: 11/207	
				Grade 3: 10/15	
			a	Grade 4: 1/12	
			Sensitivity		
			Specificity		
				9.4%	
				92.4%	
			Prevalence Positive LR	61/750 (8.1%)	
			Negative LR		
			Pre-test Odds (Cl 95%)		
			Pre-rest Odds (CI 95%) Post-Test Odds +ve result		
			Post-Test Odds -ve result		
			rusi-resi Ouus -ve result	0.10	

Study details	Patients	Outcome measures & Analysis	Effect size	Comments
Carter et al., 2005 ⁴¹	Patient group: cohort of men from the Baltimore Longitudinal Study of Aging (BLSA).	Change in IPSS over time with PSA	No correlation – analysis not shown	Funding: National Institute on Aging Intramural Research
Study design: Longitudinal Cohort	Interventions: Not applicable	Mixed effect Poisson model (because of repeated measures between subjects) used		Program and gift from GSK. Limitations: No results for regression analysis of IPSS score and PSA
	Inclusion criteria:	to test whether there		
Duration of	• < 70 years	was a significant		Additional outcomes:
follow-up: Long-term from 1959	Exclusion criteria:Medical or surgical treatment of BPH	relationship between PSA percentile grouping and symptom score with time		 Symptom score distribution by percentile against PSA percentile grouped by age Correlation plot of medical history symptom
	 Development of prostate cancer 			score with IPSS.
	<u>All patients</u> N: 704			 Plot of symptom score vs. age for each PSA percentile
	Drop outs:			Notes:
	<u>Group 1 (age <50)</u>			Baseline PSA was divided into percentiles: <25 th
	N: 370			25 th - 50 th
	Age (median + range): 37.4 (22.5 – 49.9)			>75 th
	25 th percentile PSA (ng/mL): 0.3 50 th percentile PSA (ng/mL): 0.5 75 th percentile PSA (ng/mL): 0.8			Patients also divided into age groups at the time of 1 st PSA measurement
	Median symptom evaluation (range): 6 (1-18)			PSA measurements at visits started in 1991 otherwise measured retrospectively from
	<u>Group 2 (age 50 - 69.9)</u>			serum samples
	N: 334			
	Age (median + range): 59.3 (50.1 – 69.9)			Medical history questionnaire used from 1959 -
	25 th percentile PSA (ng/mL): 0.5			1991 and IPSS also used from 1991 – 2000.
	50 th percentile PSA (ng/mL): 0.9			Questions relating to lower urinary tract score
	75th percentile PSA (ng/mL): 2.0 Median symptom evaluation (range): 10.5 (0-28)			from medical history were used to devise score - 13

1 E	vidence Table 2: How do	es PSA predict symptom	n progression (in terms of s	symptom score)?
-----	-------------------------	------------------------	------------------------------	-----------------

Study details	Patients	Outcomes			Analysis conducted	Results	Comments
Laguna et al. 2002 ¹³⁸	Patient group: Consecutive patients treated with		Pre- treatment	Change at 12 months	Linear regression:	Spearman r: -0.004 "linear regression	Funding: not stated
	transurethral thermotherapy	Age (years):	66.3 (44.8- 89.7)	-	Change in IPSS vs. pretreatment	coefficient": -0.04 P value: 0.58	Limitations:
Study design: Cohort	Setting: Secondary care, Netherlands	PSA (ng/Ml):	5.3 (0.1- 45)	-	PSA		 Patients received surgical treatment (TUMT)
Duration of	n of transurethral thermotherapy	19.1 (3-35)	9.4(0-32)	Linear regression:	Spearman r: -0.135 "linear regression	- "Retreated patients", analysed as having	
follow-up: Minimum of 1	Inclusion criteria:	QoL (IPSS)	3.9(0-6)	1.9(0-5)	Change in QoL vs. pretreatment	coefficient": -0.04 P value: 0.01	unchanged values at 12 months
year. Evaluated every 3	3 a during and 6 in yearFebruary1992 to June1999, when data were available on pre-treatment determination of 6 PSA, free uroflowmetry, voided and post-void residual urine, ultrasound measurement ofvolume, PV (cm3)178) 18 (11-31)Linear regression: Change in Qmax vs. pretreatmentSpVolume, PV (cm3)178) 18 (11-31)Linear regression: Change in Qmax vs. pretreatmentSpVolume, PV (cm3)19.9)50.3)Change in Qmax vs. pretreatmentPv	Spearman r: 0.105 ,	 Report: "no relevant linea correlation was noted for baseline PSA with change in IPSS, QoL or Qmax." 				
months during year 1 and every 6		Qmax	9.4 (2-		regression:"linear regressionChange in Qmaxcoefficient": 0.105vs. pretreatmentP value: 0.1	coefficient": 0.105	Additional outcomes:
months in year 2 and						 Values for a subgroup of patients, who have similar inclusion criteria for Djavar 	
thereafter	prostate volume, and IPSS scores.	Post-void vol (ml)	86(0-755)		Mann Whitney test:	Box and whisker plots shown, reported as "no	 inclusion criteria for Djava 2004 was reported.
	 Exclusion criteria: Previously treated with transurethral thermotherapy, medical therapy or manipulation of the lower urinary tract interfering with baseline PSA. 	All values reported were mean (r unless otherwise specified		ean (range),	Baseline PSA vs. these outcomes at I year - IPSS>7 vs. les	association"	Notes: - Seems to address the question of" does baseline PSA predict TUMT surgery outcomes"?
	 Neurogenic or systemic disorder that may have impaired bladder function. 				 Qmax >12 vs. less QoL 1 or 2 (or 1 or 0) 		 Retrospective study, on "prospectively collected data".
	All patients N: 404 M/F: 404/0						
	Age (mean, range): 66.3 (44.8- 89.7) Drop outs: 16/404, 388 analysed						

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
details McConnell et al., 2003 ¹⁶⁶ MTOPS research group NCT00021814 Setting: multi- centre, 17 centres USA Study design: RCT double blinded (4 arms) Evidence level: 1+ Duration of follow-up: Mean follow up 4.5 years Study also reported in Bautista et al., 2003 ²²	 Patient group: Men with BPH Inclusion criteria: ≥ 50 years Qmax between 4 - 15 mL/sec; and voided volume ≥ 125 ml. AUA-7 Symptom Score 8 - 30. Voluntarily signed the informed consent agreement prior to the performance of any study procedures. Exclusion criteria: Serum PSA > 10 ng/ml. Supine blood pressure < 90/70 mmHg. Orthostatic hypotension. Any prior medical or surgical intervention for BPH. Received any prior experimental intervention (either medical or surgical) for prostate disease or enrolled in any other study protocol. All patients N: 3047 out of 4391 screened Mean age: 62.6 ± 7.3 Group 1 (Doxazosin) N: 756 Age Mean (± SD): 62.7 ± 7.2	Group 1: Doxazosin 10 mg (+ placebo) Single daily dose at bedtime. Dose doubled at 1 week intervals starting at 1 mg/day for the 1 st week until final dose of 8 mg/day. Men who could not tolerate 8mg were given 4 mg. Those who could not tolerate 4 or 8 mg were discontinued. Group 2: Finasteride 5mg (+ placebo) Single daily dose at bedtime Group 3: Terazosin 10 mg + finasteride 5 mg Single daily dose at bedtime Group 4: placebo for terazosin and placebo for finasteride	Cumulative incidence of clinical progression defined as first occurrence of increase of ≥ 4 points AUA-7 score over baseline at 4 years log rank test Cumulative incidence of clinical progression defined as incidence of acute urinary retention at 4 years log rank test Mean change in AUA ± SD at 4 years Mean change in Qmax ±	Grp 1: 55/756 Grp 2: 65/768 Grp 3: 36/786 Grp 4: 97/737 P value: grp 1 v grp 4 <0.001, P value: grp 2 v grp 4 <0.001 No significant differences between grps 1, 2 or 3 Grp 1: 9/756 Grp 2: 6/768 Grp 3: 4/786 Grp 4: 18/737 P value: grp 1 v grp 4 =0.23 P value: grp 2 v grp 4 =0.009 P value: grp 3 v grp 4 <0.001 Grp 1: 6.6 \pm 5.8** Grp 2: 5.6 \pm 5.0** Grp 3: 7.4 \pm 5.7* Grp 4: 4.9 \pm 4.1* P value: grp 1 v grp 4 <0.001 P value: grp 2 v grp 4 <0.001 P value: grp 2 v grp 4 <0.001 P value: grp 2 v grp 4 <0.001 P value: grp 1 v grp 4 <0.001 P value: grp 1 v grp 4 <0.001 P value: grp 1 v grp 3 <0.001 P value: grp 1 v grp 3 <0.001 P value: grp 1 v grp 3 <0.001 P value: grp 1 v grp 2 =0.001* Grp 1: 4.0 \pm NR	 Funding: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health, National Centre for Minority Health & Health Disparities, Merck and Pfizer. Limitations: Standard deviations were not reported fo mean changes from baseline for secondary outcomes Number of patients discontinuing in the placebo group were not reported. Additional outcomes: Median changes from baseline for symptom score, Qmax and serum PSA at 1 year and 4 years.
	Age Mean (± SD): 62.7 ± 7.2 White race (%): 82.5 AUA-7 (± SD): 17.0 ± 5.8 Qmax (± SD), mL/s:10.3 ± 2.5 Prostate volume (± SD), mL: 36.9 ± 21.6 PVR (± SD), mL: 69.2 ± 88.2	Single daily dose at bedtime Examination methods: Vital signs, AUA	SD at 4 years	Grp 2: 3.2 ± NR Grp 3: 5.1 ± NR Grp 4: NR P values were only available for median change from baseline	Urn method of randomisation and stratified according to centre. Merck and Pfizer supplied active drugs and placebo

Study details	Patients	Interventions	Outcome measures		Effec	t size		Comments
	PSA serum(± SD), ng/mL: 2.4 ± 2.1 Dropouts: 204/756 (27%)	symptom score, Qmax, compliance, adverse events measured	Reason for withdrawal * Total Adverse Events		Grp 2 37 18			designed to look and taste like Doxazosin and Finasteride.
	<u>Group 2 (Finasteride)</u> N: 768 Age Mean (± SD): 62.67 ± 7.3	events measured every 3 months. DRE, Serum PSA and urinalysis performed	Lost to follow up Treatment failure Other	3 12	4 9 6			Allocation concealment preserved by coded medications distributed by
	White race (%): 83.7 AUA-7 (± SD): 17.6 ± 5.9 Qmax (± SD), mL/s:10.5 ± 2.5	annually. Prostate volume assessed by TRUS at baseline and 5 year follow up.	Adverse events\$ Total no. of person-year Erectile Dysfunction Libido decrease	3.56	Grp 2 3600 4.53 2.36	Grp3 3832 5.11 2.51	Grp4 3489 3.32 1.40	drug company. Eligible patients entered 2 week single blind placebo
	Prostate volume (± SD), mL: 36.9 ± 20.6 PVR (± SD), mL: 66.2 ± 80.0 PSA serum(± SD), ng/mL: 2.4 ± 2.1 Dropouts: 174/768 (24%)		Ejaculation disorder Postural hypotension Asthenia	1.10 4.03 2.29	1.78 2.56	3.05 4.33	0.83	run-in. Patients discontinued were followed for primary and
	Group 3: (Doxazosin + finasteride 5 mg) N: 786 Age Mean (± SD): 62.7 ± 7.1		Dizziness Peripheral oedema Dyspnea Allergic reaction	2.06 4.41 2.29	1.56 2.33	4.20 5.35		* P values between comparisons were used
	White race (%): 80.8 AUA-7 (± SD): 16.8 ± 5.8 Qmax (± SD), mL/s:10.6 ± 2.5 Prostate volume (± SD), mL: 36.4 ± 19.2		Somnolence \$ 10 most frequently reported adverse expressed as rate per 100	0.88 0.66 0.93 0.57	0.72 0.56			along with mean differences to estimate standard deviations for
	PVR (± SD), mL: 67.5 ± 81.1 PSA serum(± SD), ng/mL: 2.3 ± 1.9 Dropouts: 141/786 (18%)		person-year of follow up.	0.85 0.46 0.82 0.37	0.58 0.39			groups. Where possible exact p values were used. As numbers of patients as each follow up point not
	<u>Group 4: (placebo for Doxazosin and placebo for Finasteride)</u> N: 737							clear the ITT numbers were used. Methods were following Cochrane Handbook.
	Age Mean (± SD): 62.5 ± 7.5 White race (%): 82.4 AUA-7 (± SD): 16.8 ± 5.9 Qmax (± SD), mL/s:10.5 ± 2.6							**Where >1 possible standard deviations were calculated for a group the mean was used
	Prostate volume (± SD), mL: 35.2 ± 18.8 PVR (± SD), mL: 69.6 ± 82.1 PSA serum(± SD), ng/mL: 2.3 ± 2.0 Dropouts: /737 NR							

Study details	Patients	Interventions	Analysis conducted	Results	Comments
details O'Leary et al., 2003 ¹⁹⁷	Patient group: Men with LUTS, caused by BPHSetting: 2 studies in USA, 1 international study Inclusion criteria: 	Interventions Group 1: dutasteride 0.5mg once daily Group 2: placebo Duration:2 years	Analysis conducted Logistic regression model: (to identify predictors for patients most likely to be bothered at the end of the study. "Bother" was defined as a score of 3 on BII. Variables included were treatment group, baseline prostate volume, AUA-SI, BII item-3 (bother), Qmax, serum dihydrotestosterone, testosterone, PSA, age, weight.	Results Only reported that P value <0.001, with baseline BII item- 3(bother) score of 3 and AUASI≥20 as \predictors.	Funding: NR Limitations: This study looked into predictors of Bll score after treatment by dutasteride. May provide information to answer the question of "which groups of patients are likely to remain bothered by their LUTS symptoms despite treatment with dutasteride?" Additional outcomes: Mean change of Bll from baseline in placebo vs. dutasteride treated groups over 2 years Notes: There is a chart of mean change of Bll from baseline value for dutasteride vs. placebo groups. May provide information about time
	Group 2: 17.1±6.1 BII score: Group 1: 1.05±2.74 Group 2: 3.98±2.76 Prostate volume, PV (cm3) Group 1: 54.9±23.9				
	Group 2: 54.0±21.9 Qmax (ml/s): Group 1: 10.1±3.5 Group 2: 10.4±3.6				

Lower urinary tract symptoms (LUTS) – full guideline appendices DRAFT (August 2009)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Roehrborn et al., 2006 ²¹⁹	3 - - - - - - - - - -		Number (%) progressed to AUR	Group1: 16 (2.1%) Group 2: 14 (1.8%) P=0.82	Funding: Sanofi-Aventis Limitations: Method of
Study design: RCT	Inclusion criteria: ≥55 years with a ≥6 month history of LUTS related to	daily Group 2: Placebo	Number (%) men with BPH- related surgery	Group1: 38 (5.1%) Group 2: 49 (6.5%) P=0.18	randomisation and allocation concealment unclear.
Setting: multi- centre in US, Europe, Australia, Middle-east		of ≥13, a Qmax of 5- voided volume of VR of ≥350mL, a ≥30g estimated by DRE, vel of 1.4-10ng/mL. teria: previous f AUR or prostatic comitant urological gnosed or suspected cinoma; previous x-ray le pelvic region; history ypotension or syncope; use of medications that voiding pattern; and vant biochemical s.	Number (%) patients with symptom progression of ≥ 4points	RR: 22 (-18 to 48)% Group 1: 88 (11.7%) Group 2: 127 (16.8%) P=0.0013 RR with alfuzosin: 30 (10-46)%	Additional outcomes: Haematological or biochemical measurement s-
and South Africa. Evidence level:			Number (%) of men having any LUTS/BPH progression event (AUR and/or surgery and/or IPSS deterioration of ≥4 points)	Group1: 122 (16.3%) Group 2: 167 (22.1%)	reported that there were no significant changes. Notes:
1+	diseases; diagnosed or suspected prostate carcinoma; previous x-ray		Mean (SD) decrease from baseline in IPSS	Group1: -5.9 (6.9) Group 2: -4.7 (6.9)	Baseline variables analysed as predictors of IPSS worsening, AUR or BPH related surgery.
Duration of follow-up: 2 years	therapy of the pelvic region; history of postural hypotension or syncope; concomitant use of medications that my alter the voiding pattern; and		Mean (SD) decrease from baseline in bother score	Group1: -1.3 (1.5) Group 2: -0.9 (1.6) P<0.001	
	My difer the volding pattern; and clinically relevant biochemical abnormalities. All patients N: 1522 Group 1 N: 759 (ITT analysis N: 749)		Mean (SD) decrease from baseline in Qmax, mL/s at 12 months	Group1: 2.0 (3.8) Group 2: 1.3 (3.6) P=0.001	
			Median change in serum PSA levels	Group 1: -0.6% Group 2: 3.6%; P=0.07	
			Treatment emergent adverse events	Group 1: 400 (53.1%) Group 2: 390 (51.2%)	
Mean (±SD) Age: 66.4 (6.7) Dropouts : 230 (Lack of efficacy or disease progression 75; adverse events 71; patients request=39; poor compliance with protocol=8, lost to follow-up=6; other 31)		Discontinuation after TEAE	Group 1: 69 (9.2%) Group 2: 58 (7.6%)	1	
	events 71; patients request=39; poor compliance with protocol=8,		Adverse events	Dizziness Group 1: 45 (6.0%) Group 2: 35 (4.6%) Headache	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
uciuns	Group 2 N: 763 (ITT analysis N: 757) Mean (±SD) Age: 66.5 (7.0) Dropouts: 283 (Lack of efficacy or disease progression=111; adverse events=62; patients request=58; poor compliance with protocol=13, lost to follow-up=12; other=27)			Group 1: 25 (3.3%) Group 2: 17 (2.2%) Hypotension Group 1: 9 (1.2%) Group 2: 4 (0.5%) Syncope Group 1: 5 (0.7%) Group 2: 2 (0.3%) Malaise Group 1: 1 (0.1%) Group 2: 0 Ejaculatory dysfunction Group 1: 15 (2.0%) Group 2: 14 (1.8%) Ejaculatory disorders Group 1: 3 (0.4%) Group 2: 0 Asthenia/fatigue Group 1: 16 (2.1%)	
			Mean (SD) changes in SBP/DBP, mmHg	Group 2: 8 (1.1%) Somnolence Group 1: 0 Group 2: 3 (0.4%) Supine Group 1: -3.2 (15.6)/-2.9 (10.1) Group 2: -0.1 (15.3)/-0.8 (9.3) Standing Group 1: -3.8 (15.5)/ -2.8 (10.3) Group 2: -0.2 (15.5)/-0.5 (10.0)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Number (%) symptom worsening (IPSS worse ≥4 points) by baseline PSA	Group 1: PSA<2.3: 22/248 (8.9%) PSA 2.3-3.9: 33/261 (12.6%) PSA >3.9: 32/228 (14.8%) P=NS Group 2: PSA<2.3: 36/242 (14.9%) PSA 2.3-3.9: 49/237 (20.7%); PSA >3.9: 39/264 (14.0%) P=NS	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Roehrborn et al., 1999 ²²⁰ Study design: RCT Evidence	Patient group: men with clinical BPH diagnosed on the basis of moderate to severe symptoms.Setting: 95 centres (Finasteride Long-Term Efficacy & Safety Study Group)	5mg 1/day Group 2 Placebo	Mean Change in Quasi-AUA Symptom Score (± SE) v baseline PSA at 4 years Within tertile group and between treatment group analysis of variance performed	1st Tertile Group 1: -3.2 ± 0.4 Group 2: -2.4 ± 0.3 Group1 v Group 2 p=0.128 Not sig. (ANOVA)	Funding: Merck & Co., Inc. Limitations: No adjustment mentioned and no regression analysis
evel: 1+ Duration of ollow-up: 4 years A years A years Inclusion criteria: Moderate to severe symptoms Peak flow rate <15 mL/s with voided volume ≥ 150 mL Enlarged prostate by digital rectal examination Serum PSA 4 -9.9 ng/mL with negative biopsy Exclusion criteria:	Assessment: 1 month single blind placebo run in after which randomisation and baseline measurements performed Quasi AUA symptom score (1-34), adverse events, urinary flow were assessed every 4	to compare effect of baseline PSA and prostate volume on symptom changes over time	2 nd Tertile Group 1: -3.4 ± 0.3 Group 2: -0.4 ± 0.4 Group 1 v Group 2 p<0.001 (ANOVA) 3 rd Tertile Group 1: -3.4 ± 0.3 Group 2: -0.2 ± 0.4 P Group 1 v Group 2 p<0.001 (ANOVA)	 Additional outcomes: Mean Change in Quasi-AUA Symptom Score (± SE) v baseline prostate volume tertile at 4 years Mean Change in Quasi-AUA Symptom Score (± SE) v PSA tertile 	
	 Current therapy of α-blocking agents or anti-androgens History of chronic prostatitis Recurrent urinary tract infections Surgery for prostate or bladder cancer Serum PSA >10ng/mL <u>All patients</u> N: 3040 Drop outs: 1157 	month. PSA was measured at baseline and every 4 months in year 1 and every 8 months thereafter. Physical examinations and routine haematological and serum chemistry tests parformed yearly.	Mean Change in Quasi-AUA Symptom Score (± SE) over time (years 1-4) for each PSA tertile in placebo patients (group 2)	1 st tertile had a significantly better long- term symptom improvement than those in other tertiles p < 0.001 There was no significant difference between long term symptom improvement between 2 nd and 3 rd tertiles p=0.65	 over time Mean Change in Quasi-AUA Symptom Score (2 SE) v prostate volume tertile over time Mean Change in Qmax (± SE) v PS tertile over time
	Group 1 N: 1524 Age (mean ± SD): 64 ± 7 Quasi-AUA: 15 ± 6 Serum PSA (ng/mL): 2.8 ± 2.1 (n=1512)* 1st tertile PSA (ng/mL): 0.83 ± 0.3 (n= 472) 2nd tertile PSA (ng/mL): 2.21 ± 0.6 (n= 536)	performed yearly. MRI to determine prostate volume performed at baseline and yearly in a subset of 10% of patients	Mean Change in Quasi-AUA Symptom Score (± SE) over time (years 1-4) for each PSA tertile group 1 v group 2	1 st tertile Not sig. 2 nd tertile (p=0.004) 3 rd tertile (p=0.001)	 Mean Change in Qmax (± SE) v prostate volume tertile over time Notes: Baseline PSA was divided into 3 tertiles:

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	3rd tertile PSA (ng/mL): 5.39 ± 1.7 (n= 504) Qmax (mL/s): 11 ± 4 Prostate Volume (mL): 54 ± 25 (n=157) Drop outs: 524 Group 2 N: 1516 Age (mean \pm SD): 64 ± 6 Quasi-AUA: 15 ± 6 Serum PSA (ng/mL): 2.8 ± 2.1 (n=1498)* 1st tertile PSA (ng/mL): 0.86 ± 0.3 (n= 511) 2nd tertile PSA (ng/mL): 2.24 ± 0.6 (n= 514) 3rd tertile PSA (ng/mL): 5.36 ± 1.7 (n= 473) Qmax (mL/s): 11 ± 4 Prostate Volume (mL): 55 ± 26 (n=155) Drop outs: 633				First (0.2 - 1.3) Second (1.4 - 3.2) Third (3.3 - 12.0) Quasi AUA symptom score: Had all components of the AUA score but the score differed from AUA per question: 0-5 for six questions and 0- 4 for one question. Total 0-34 *Patients numbers quoted for baseline characteristics were different in Roehborn 1999 paper from original study report McDonnell et al 1998 (NEJM).

Study details	Patients	Outcomes		Analysis conducted	Results	Comments
Tubaro et al., 2004 ²⁵⁷	Patient group: Men with LUTS, ambulatory	Age (range) (years):	66.3 (44.8- 89.7)	Multiple logistic regressions:	Odds ratio (95%Cl) BSA<2: 1.0	Funding: not stated
Study design: Cross sectional, observational	-	PSA (ng/ml): IPSS: - Voiding - Storage Prostate	2.23±2.36 13.4 ±6.1 7.6±4.4 5.8±2.9 34.5±18.8	IPSS >7 vs. PSA (ng/ml), IPSS<7 is the reference	PSA≤2: 1.0 PSA>2-4: 1.62(1.2-2.2) PSA>4-10: 2.64 (1.5-4.7) PSA >10: 4.28	 Limitations: Cross sectional study Answers the questions of association of PSA vs. IPSS, rather than ability of PSA to
Duration of follow-up: Nil	 Inclusion criteria: Age: 50-80 years Persistent LUTS/BPH and BPE (as estimated by DRE) Minimal voided volume (VV)of 150ml Exclusion criteria: Associated urological diseases, psychiatric or mental illness, previous surgical or minimally invasive treatments of BPH, indwelling catheter, Pharmacological treatments (e.g. tricyclic amtidepressants, anticholinergic and sympathomimetic drugs) 	volume, PV (cm3) Uroflowmetry Qmax (ml/s) Qave (ml/s) Flow time(s) VV(ml) Post void volume, PVR (ml)	13.6±6.6 6.8±3.7 46.3±27.3 265.9±123.4 58.3±72.6		(1.8-10.3) ≤2	Additional outcomes: Logistic regression of IPSS vs. prostate related variables- PVR, PV, Qmax, Abrams-Griffiths number etc Notes: - All values reported were mean ±standard deviation unless otherwise specified

Study details	Patients	Outcomes	Analysis conducted	Results	Comments
	 Current or previous treatment for LUTS/BPH (e.g. alpha adrenoreceptor antagonists, finasteride, plant extracts) <u>All patients</u> N: 866 M/F: 866/0 Age (mean, range):64(50-80) Drop outs: 64/866, 802 analysed, dropouts are due to missing data Mean duration of LUTS: 30.2 months, median 24 months 				

1 Evidence Table 3 Diagnosistic accuracy of uroflowmetry

Study details	Patients	Diagnostic tools	Measure of Disorders	Results	Comments
Ref ID: Oelke et al., 2007 ¹⁹⁹ Study design: Cross-sectional study Evidence level: Level-2 study (II) Duration of follow- up: 1-3 weeks duration between the index test and the gold standard	Patient group: Men with LUTS, clinical BPH and/or prostate volume >25ml Setting: single centre – urologic outpatient clinic - Germany Inclusion criteria: > 40 years with LUTS, clinical BPH and/or prostate volume >25ml Exclusion criteria: Patients with: Prostate cancer Acute urinary retention Neurological disease Previous prostatic or urethral surgery Medication treating BPH α- blockers, α- reductase inhibitors All patients N: 160 Age median (range): 62 (40-89) Drop outs: 0	Assessment tool under investigation: Uroflowmetry – number of voids not specified. Gold standard: Pressure flow studies (PFS) performed using Ellipse (Andromeda) machine with CHESS used to classify obstruction	Specificity Positive predictive value Negative predictive value Prevalence Positive Likelihood Ratio Negative Likelihood Ratio Pre-test Odds (Cl 95%) Post-Test Odds +ve result Post-Test Odds -ve result Post-Test Odds -ve result Qmax threshold < 15 mL/s Sensitivity Specificity Positive predictive value Negative predictive value Prevalence Positive Likelihood Ratio Negative Likelihood Ratio	72% (62/86) 47% 75/160 2.51 0.44 0.88 (Cl95%: 0.81-0.96) 2.22 0.39 99% (74/75) Cl95% 97 - 100 39% (33/85) Cl95% 29 - 49 59% (74/126) 97% (33/34) 47% 75/160 1.61 0.03 0.88 (Cl95%: 0.81-0.96) 1.42	Funding: NR Limitations: Details of Uroflowmetry methods not reported 1-3 week delay between Uroflowmetry as index test and PFS No mention whether the procedures tested were conducted by the same investigator(s) Additional outcomes: This study also reports Detrusor Wall Thickness measured by 7.5 MHz ultrasound, Post Void Residual measured with 3.5 MHz ultrasound. Prostate Volume measured with TRUS Notes: None

Study details	Patients	Diagnostic tools	Measure of Disorders	Results	Comments
Ref ID: Poulsen et al., 1994 ²⁰⁹ Study design: Cross-sectional study Evidence level: Level-2 study (II) Duration of follow- up:	Patient group: Men with symptomatic BPH (94% uncomplicated), 5% also with recurrent urinary tract infection and 1% with previous AUR Setting: single centre Denmark Exclusion criteria: NR	Assessment tool under investigation: Void into Dantec Urodyn 1000 uroflowmeter. Number of voids not reported Gold standard: Pressure flow studies (PFS) performed using Dantec Urodyn 1000	Specificity Positive predictive value Negative predictive value Prevalence Positive Likelihood Ratio Negative Likelihood Ratio	50% (31/62) 65 % (99/153) 1.61 0.55 1.83 (Cl95%: 1.76 -1.91) 2.96	Funding: NR Limitations: Masking of assessors to test results NR Not clear whether tests were independent (implies PFS before entry into study)
NA	All patients N: 188 Age median (range): 68 (32- 90) Drop outs: Free flow missing for 35/188 (19%) and PFS data missing for 5/188 (3%)	CI . C. C.III.	Specificity Positive predictive value Negative predictive value Prevalence Positive Likelihood Ratio Negative Likelihood Ratio	63% (31/62) 65% (99/153) 1.31 0.32 1.83 (Cl95%: 1.76 -1.91) 2.41	Number of voids NR Additional outcomes: DAN-PSS Symptom Score also recorded Notes: None

Study details	Patients	Diagnostic tools	Measure of Disorders	Results	Comments
Ref ID: Reynard et al., 1996 ²¹² Study design: Cross-sectional study Evidence level: Level-2 study (II)	Patient group: Men > 45 years with) LUTS suggestive of benign prostatic obstruction (BPO) Setting: 2 centres UK Exclusion criteria: Patients with:	Assessment tool under investigation: Uroflowmetry 4 voids into Dantec Urodyn 1000 uroflowmeter. Qmax below threshold indicates BOO 3 voids : 17 (10%) 4 voids : 148 (90%)	Specificity Positive predictive value Negative predictive value Prevalence Positive Likelihood Ratio Negative Likelihood Ratio Pre-test Odds (Cl 95%) Post-Test Odds +ve result	53% 61% (95/157) 3.83 0.58 1.53 (Cl95%:1.46 -1.61) 5.88	Funding: NR Limitations: No indication of who carried out the tests-whether by the same people, or whether the investigator or patients were masked to the results of other tests.
Duration of follow- up: NA	 Prostate cancer (DRE + TRUS) Diabetes Lower urinary tract infection Previous prostatic or urethral surgery Medication affecting lower urinary tract All patients N: 165 	Gold standard: Pressure flow studies (PFS) performed using Dantec Menuet or Dantec 5500 multichannel recorder. Patients characterised for BOO using Abrams-Griffiths nomogram as obstructed or	Specificity Positive predictive value Negative predictive value Prevalence Positive Likelihood Ratio Negative Likelihood Ratio	65% (62/95) Cl95% 55 - 75 74% (46/62) Cl95% 79 - 95 79% 58% 61% (95/157) 2.53 0.47 1.53 (Cl95%:1.46 -1.61) 3.88	Results of individual centres not compared, and inter-rater agreement (presumably tests in different tests done by different people) was not addressed Notes: *Qmax taken as highest value on voids 1 & 2. Also reported < 8 mL/s
	Age median (range): 68 (50-84) Drop outs: PFS data missing for 8/165 (5%) patients	equivocal/ unobstructed.	Specificity Positive predictive value Negative predictive value Prevalence Positive Likelihood Ratio Negative Likelihood Ratio	70% 61% (95/157) 1.82 0.38 1.53 (Cl95%:1.46 -1.61) 2.79	Study suggests increasing specificity and decreasing specificity with increasing number of voids

Study details	Patients	Diagnostic tools	Measure of Disorders	Results	Comments
Ref ID: REYNARD1998 (ICS- 'BPH' study) Study design: Cross-sectional study Evidence level: Level-2 study (II) Duration of follow- up: NA	 Patient group: Men with LUTS and benign prostatic enlargement (BPE) Setting: multi-centre 12 centres in Europe, Australia, Canada, Taiwan & Japan Inclusion criteria: > 45 years Symptoms of BOO secondary to BPH Exclusion criteria: Patients with: Prostate cancer Neurological disease Previous prostatic or urethral surgery Medication affecting lower urinary tract All patients N: 1271 Age mean (range): 66.5 (45-88) Drop outs: Uroflowmetry data missing for 81/1271 (6%) PFS data missing for 338/1271 (27%) 	Assessment tool under investigation: Uroflowmetry 3 voids 1 void: 211 (17%) 2 voids: 443 (35%) 3 voids: 537 (42%) Details of technique not reported Gold standard: Pressure flow studies (PFS) performed according to International Continence Society guidelines with diagnosis of BOO using Schafer classification Ratings 0-2 categorised as non- obstructive while 3-6 were obstructed. Definition of Schaefer method: 0 no obstruction, 1 slightly obstructed, 2-6 obstructed with increasing severity	Specificity Positive predictive value Negative predictive value Prevalence Positive Likelihood Ratio Negative Likelihood Ratio Pre-test Odds (Cl 95%) Post-Test Odds +ve result Post-Test Odds -ve result *Qmax threshold < 15 mL/s Sensitivity Specificity Positive predictive value Negative predictive value Prevalence Positive Likelihood Ratio Negative Likelihood Ratio	46% (250/538) 60% 540/897 1.56 0.76 1.51 (Cl95%:1.48 -1.54) 2.36 1.15 81% (440/540) Cl95% 78 - 85 38% (136/357) Cl95% 78 - 85 38% (136/357) Cl95% 33 - 43 67% (440/661) 58% (136/236) 60% 540/897 1.32 0.49 1.51 (Cl95%:1.48 -1.54) 1.99	Funding: International Continence Society (ICS) Limitations: No information provided about the specific protocol followed in carrying out tests, who carried them out, whether they were blinded and also interval between the tests. Notes: *Qmax taken as highest value for each patient from voids

Evidence Table 4 Diagnostic accuracty of post void residual

See Evidence Table 3 Diagnosistic accuracy of uroflowmetry

- for Oelke et al., 2007.¹⁹⁹
- 1 2 3 4 5
- 6

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Bales et al., 2000 ¹⁹ Study design: RCT Evidence level: 1+ Duration of follow-up:	Patient group: Men with stages T1c-T2c prostate cancer who were to undergo radical retropubic prostatectomy by a single surgeon Inclusion criteria: Men with stages T1c-T2c prostate cancer who were to undergo radical retropubic prostatectomy by a single surgeon. None of the men had undergone	Group 1: Biofeedback 45-minute session with a nurse trained in biofeedback techniques 2 to 4 weeks prior to radical prostatectomy. Patients instructed how to perform graded PFMT using biofeedback. Surface electrodes were used to assess muscle strength and contractions of 5 to 10 seconds, and 10 to 15 repetitions were performed. Patients advised to practice these exercises 4/day until their surgery.	Incidence of urinary continence at 6 months post op. Incidence of urinary continence at 3 months post op Proportion of still incontinent at 3 months (ITT analysis)	Group 1: 44/47 (94%) Group 2: 48/50 (96%) p value: 0.60 Group 1: 27/47 Group 2: 31/50 p value: 0.64 Group 1: 23/50 Group 1: 23/50 p value: NR	Funding: NR Limitations: This study is poorly reported: Method of randomisation and allocation concealment not described, there is insufficient information about patients' baseline characteristics, no description of sample size calculation. Assessments methods
6 months atter surgery Outcome assessment was masked	transurethral resection of the prostate or had pre-existing neurologic disease. Exclusion criteria: See above, exclusion criteria not specifically stated. <u>All patients</u> N: 100 Drop outs: 3 <u>Group 1:</u> N: 50 Age (mean): 59.3 Drop outs: 3 <u>Group 2:</u> N: 50 Age (mean): 60.9 Drop outs: 0	Group 2: Control Patients underwent radical prostatectomy without any biofeedback training. These patients received only written and brief verbal instructions on how to perform PFMT to isolate the muscle that starts and stops urine flow and to practice contractions 4/day with 10 to 15 repetitions. Patients were given written instructions and briefly reviewed these instructions with a nurse. All patients: Postoperatively, the urethral catheter was removed approximately 2 weeks following surgery in both groups. Patients in both groups were encouraged to perform pelvic muscle strengthening exercises 4/day after catheter removal. No patient in either group received adjuvant radiation therapy or hormonal therapy within 6 months following surgery.	Proportion of still incontinent at 6 months (ITT analysis)	Group 1: 6/50 Group 2: 2/50 p value: NR	 could be unreliable. Other limitations stated by authors: no effort was made to assess pelvic muscle floor strength prioto to surgery incidence of incontinence in Group 2: was very low patients received only one preoperative biofeedback sessi subtle differences in results mighave been detected if more rigorous measures of incontinence had been used, such as weighte pad testing. No objective measurement of continence was used. Notes: Patients wearing one pad or less per day were considered to be continent. Those using two or mo pads per day were considered

1 Evidence Table 5 Pelvic floor exercises (with or without electrical stimulation or biofeedback)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Burgio et al., 2006 ³⁴	Patient group: Men elected for radical prostatectomy for prostate cancer	Group 1 Single session of preoperative biofeedback	Proportion of patients with severe/continual leakage at 6 months	Group 1: 3/50 (6%) Group 2: 9/47 (19%) p value: 0.04 (Chi squared) not ITT	Funding: National Institute for Diabetes and
Study design: RCT		enhanced behavioural training on pelvic floor muscle control and instructions on daily PMFT. Rectal probe used to provide feedback of rectal pressure. Daily		NCGC Chi-squared calculation p=0.058 using ITT	Digestive Kidney Diseases, National
Evidence level: 1+	urology clinic(USA) Inclusion criteria: Ambulatory and continent		instructions on daily PMFT. Rectal probe used to provide feedback of	Number of patients wearing pads at 6 months	Group 1: 16/50 (32%) Group 2: 24/46 (52%) p value: <0.05 not ITT NCGC Chi-squared calculation p=0.086
Duration of follow-up: 6 months post surgery	monthsHad documented incontinence in	practice 3 x 15 exercises. Also instructed to interrupt stream when voiding. Postoperatively patients were reminded to resume	Mean days ± SD with no leakage at 6 months	using ITT Group 1: 72.6 ±0.39 Group 2: 54.2 ± 0.47 p value: 0.04 not ITT NCGC t-test with equal variance test calculation p<0.00001 using ITT	in the control group with preserved urethral length. P=0.03 favouring continence.
	 a bladder diary Previous prostatectomy Mental impaired status (<20 on the Mini-Mental State Examination) <1 week before scheduled 	exercise regimen Group 2 Brief instructions on how to interrupt stream when voiding and usual care.	Kaplan-Meier survival curve of proportion of still incontinent at < 3 months (data from Hunter et al., 2007 ¹¹⁰)	Group 1: 49/54 Group 2: 51/53 p value: 0.25 (NCGC Chi-squared calculation – not ITT)	not presented as an ITT analysis Notes: Bladder diaries were scored by an
	surgery <u>All patients</u> N: 112 Age (mean ± SD): 60.9 ± 6.9 Drop outs: 0	All patients Instructed on use of bladder diaries and use of pads to record incontinence. Patients sent a weekly bladder diary	Kaplan-Meier survival curve of proportion of still incontinent at 3 - 6 months (data from Hunter et al., 2007 ¹¹⁰)	Group 1: 32/53 Group 2: 40/51 p value: 0.046 (NCGC Chi-squared calculation – not ITT)	individual kept blind to group assignment Those performing intervention were blinded to next grou assignment.
	Group 1 N: 57* Age (mean ± SD): 60.7 ± 6.6 M: 57 Black: 13 Previous TURP: 2	to investigators during follow up. Patients were contacted for follow-up at 6 weeks, 3 and 6 months after surgery.	Kaplan-Meier survival curve of proportion of still incontinent at 6 - 12 months (data from Hunter et al., 2007 ¹¹⁰)	Group 1: 22/51 Group 2: 30/50 p value: 0.09 (NCGC Chi-squared calculation – not ITT)	Randomisation by computer. Kaplan-Meier data extraction by Hunter et al., 2007 ¹¹⁰ et al Cochrane review
	Drop outs: 0 <u>Group 2</u>	They completed patient questionnaire on bladder			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	N: 55* Age (mean ± SD): 61.1 ± 7.2 M: 55 Black: 18 Previous TURP: 1 Drop outs: 0	control, 7-day bladder diary, QoL score, and Incontinence Impact Questionnaire modified for men.			
	* excludes patients with cancelled operations	Continence defined as 3 consecutive weekly bladder diaries returned with no leakage.			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments			
Filocamo et al., 2005 ⁸⁰ Study design:	Patient group: men undergoing retropubic radical prostatectomy for localised prostate cancer Setting: urology clinic, University of	In 1 st treatment session PFMT was taught using verbal and visual feedback. Strength of muscles evaluated by digital anal control. Patients instructed to perform 3x10 sets/day at home for 6 months.	Proportion of patients still incontinent at 1 month (using subjective ICS male questionnaire)	Group 1: 121/150 (81%) Group 2: 138/150 (92%) p value: NR NCGC Chi-squared calculation p=0.004 using ITT analysis signif.	Funding: NR Limitations: • Randomisation			
RCT Evidence level: 1+	Florence, Italy Inclusion criteria: NR Exclusion criteria:		Strength of muscles evaluated by digital anal control. Patients instructed to perform 3x10 sets/day	Strength of muscles evaluated by digital anal control. Patients instructed to perform 3x10 sets/day	evaluated by digital anal control. Patients instructed to perform 3x10 sets/day	Strength of muscles evaluated by digital anal control. Patients instructed to perform 3x10 sets/day wt here for for months	Proportion of patients still incontinent at 3 months (using subjective ICS male questionnaire)	Group 1: 39/150 (26%) Group 2: 105/150 (70%) p value: NR NCGC Chi-squared calculation p<0.00001 using ITT analysis signif.
Duration of follow-up: 12 months	Prior urinary or faecal incontinence Neurogenic dysfunction of lower urinary tract PMFT taught in all positions and patients asked to identify movements causing incontinence Proportion of p still incontinence months (using subjective ICS) questionnaire)	subjective ICS male	Group 1: 6/150 (4%) Group 2: 53/150 (35%) p value: NR NCGC Chi-squared calculation p<0.00001using ITT analysis signif.	 Proportion of patients still incontinent reported as subjective measurement using 				
	 Preoperative history of overactive bladder <u>All patients</u> N: 300 Age (mean ± SD): NR Drop outs: 0 	Preoperative history of overactive bladder asked to practice new exercises at home for 7 days. patients 300 e (mean ± SD): NR PFMT before any activity	asked to practice newresponse of planentscroup 1.exercises at home for 7still incontinent at 12Group 2:days.months (usingp value:At 3rd treatment sessionsubjective ICS maleNCGC Clpatients asked to practisequestionnaire)p=0.000	Group 1: 2/150 (1%) Group 2: 18/150 (12%) p value: NR NCGC Chi-squared calculation p=0.0002 using ITT analysis signif.	ICS questionnaire Additional outcomes: Correlation between patient age and continence at each time interval			
	Group 1 N: 150 Age (mean ± SD): 65 ± 4.79 (51- 75) M: 150 Mean preop PSA (ng/ml): 8.13 Drop outs: 0	incontinence. Group 2 No treatment All patients Asked to complete a bladder diary and			Notes: Study reports numbers of patients continent at time intervals but data are presented as number of patients still incontinent			
Group 2 N: 150 Age (mean ± SD): 4 75) M: 150	N: 150 Age (mean ± SD): 66.8 ± 5.33 (45- 75)	counselled to prevent leakage by increasing frequency of micturation. All patients were assessed at 1,3 ,6 and 12 months.						

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean preop PSA (ng/ml): 8.11 Drop outs: 0	Incontinence was assessed objectively using 1h and 24h pad test – number of pads used daily. Subjective assessment by completion of International Continence Society (ICS) questionnaire. All patients still incontinent at 6 months underwent urodynamic evaluation Continence defined as 1 precautionary pad			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Floratos et al.,	Patient group:	Group 1: Biofeedback	Mean urine loss as	Group 1:	Funding: NR
200282	Patients undergoing radical retropubic	Patients referred to a specialist in physical	assessed by the 1-h pad	Baseline: 39 g	_
	prostatectomy for localised prostate cancer.	therapy and rehabilitation to have 15	test	1 st month: 18 g	Limitations:
Study design:		sessions of electromyographic (EMG)	Patients were evaluated at	2 nd month: 7 g	Randomisation and
RCT	Setting: multi-centre. Greece and	biofeedback (2 channel Totem	1,2, 3 and 6 months of	3 rd month: 4 g	allocation
	Netherlands	Biofeedback, BEAC, Italy) 3/week of 30	treatment using 1-h pad	6 th month: 3 g	concealment is not
Evidence		min duration each. During the initial $2/3$	test. For the best intra- and	_	described. There is
level:	Inclusion criteria: Patients with objectively	sessions, a strong emphasis was placed on	inter-patient estimates in the		insufficient
1+	confirmed urinary incontinence, no significant	the specificity of muscle contraction. During	pad test, a special type of	Group 2:	information about
	perioperative complications (ureteric or	the sessions the exercises were designed	'pocket pad' was used which	Baseline: 31 g	patients' baseline
Duration of	rectal injury, urine leakage from	to increase the power, endurance and	covered only the penis, thus	1 st month: 11 g	characteristics, no
follow-up։ ó	anastomosis, thrombo-embolism), no history	coordination of the pelvic floor muscles. In	reducing the interference	2 nd month: 3 g	description of
months	of preoperative incontinence and pelvic or	parallel, patients practised 50-100	from sweat on the pad	3 rd month: 1 g	sample size
	lower urinary tract operations, no psychiatric		weight gained during the	6 th month: 0 g	calculation.
	history, a recognised ability to participate in		test.	, i i i i i i i i i i i i i i i i i i i	Masking of outcome
	a learning programme, good general	Group 2: Control		P value > 0.05	assessment is not
	condition and willingness to participate in	Patients were taught how to contract their			reported.
	the study.	pelvic muscles without contracting			
		abdominal muscles simultaneously. Patient	Mean no. pads/ day	Group 1:	Additional
	All patients	was placed in the lateral decubitus	Patients were evaluated	Baseline: 3.9	outcomes:
	N : 42	position and the instructor inserted index	subjectively with a	1 st month: 3.4	No additional
	Age (mean ± SD):	finger into patient's rectum to check for	questionnaire (to determine	2^{nd} month: 1.2	outcomes reported
	Drop outs:	simultaneous contraction whilst palpating	the number and extent of	3 rd month: 0.8	
		the abdominal muscles. Verbal feedback	incontinence episodes,	6 th month: 0.4	Notes:
	Group 1:	used to instruct the patient how to correctly	number of pads used per	0 1101111. 0.4	All patients:
	N: 28	and selectively contract the anal sphincter	day, and any LUTS).	Group 2:	During the study,
	Age (mean ± SD): 63.1 +/- 4	while. Patients received an informative		Baseline: 3.6	patients with
	Drop outs:	leaflet with these instructions. Home		1 st month: 1.8	irritative symptoms
	Received Oxybutynin: n=3	practise comprised 80-100 exercises		2 nd month: 0.9	and a negative
		daily, divided in four sessions of 20-25		3 rd month: 0.4	urine culture
	Group 2:	exercises each. The duration of each		6 th month: 0.2	received empirical
	N : 14	constriction was 3-5 s with submaximal		P value > 0.05	anticholinergic
	Age (mean ± SD): 65.8 +/- 4.3	strength (70%) and relaxation period of			medication
	Drop outs:	6-10 s between the exercises. Initially	Number of men still	Group 1: 4/28	(oxybutynin).
	Received Oxybutynin: n=2	patients practised these exercises while	incontinent at 3-6 months	Group 2: 0/14	
		supine but later when sitting and standing.	(data from Hunter et al.,		Continence defined
		After the first month patients were	2007110)		as <1 g loss /

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
		encouraged to practise the exercises during normal daily activities, including movements that provoked incontinence.			1 hour pad test or < 2 pads per day

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Franke at al., 2000 ⁸⁵ Study design: RCT	Patient group: Incontinent men after radical prostatectomy Setting: Urology department, Vanderbuilt Medical Centre,	Group 1 45 minute biofeedback behavioural therapy session 6, 7, 9, 11 and 16 weeks postoperatively. Perineal	Number still incontinent at 3 months	Group 1: 6/13 (46%) Group 2: 3/10 (30%) P value: NR NCGC Chi-squared calculation p=0.23 using ITT analysis Not sig.	Funding: NR Limitations: • Randomisation
Evidence level: 1+ Duration of	Tennessee, USA Inclusion criteria: 2 weeks post prostatectomy	patch electromyography biofeedback was performed using abdominal electromyography leads to ensure proper isolation.	Number still incontinent at 6 months	Group 1: 1/7 (14%) Group 2: 1/8 (12%) P value: NR NCGC Chi-squared calculation p=1.00 using ITT analysis Not sig.	 method not described Masking of outcome assessment not
follow-up: 24 weeks (6 months)	 Exclusion criteria: Previous TURP Neurological condition affecting the urinary tract. Men with residual urine greater than 50ml or urinary tract infection were excluded at 6 week visit. 	Patients instructed to continue pelvic floor muscle exercises at home (20 contractions 3 times a day). A timed voiding	Mean incontinence (gm/24hours) using pad tests	At 6 weeks Group 1: 162 Group 2: 152, p value: 0.91(Cl95%: 193- 214) At 3 months: Group 1: 58 Group 2: 93, p value: 0.67(Cl95%: 199-128)	mentioned • Not an ITT analysis Additional outcomes: Improvement in pelvic muscle work using electromyography training effect (only
	<u>All patients</u> N: 30 Drop outs: 5 withdrew after	Group 2 No instruction and asked to return voiding diary and 48		At 6 months: Group 1: 8 Group 2: 62, p value: 0.41(Cl95%: 200-90)	assessed in intervention group).
	randomisation <u>Group 1</u> N: 15 Age (mean): 62.3 Dropouts: At 3 months= 2, 6 months= 8	hour pad test at the routine follow-up visits. All patients: Urinalysis and post void residual urine volume tests at 6 week visit. Completed	Mean incontinent episodes/day (mean voiding diary differences)	At 6 weeks Group 1: 7.2 Group 2: 5.2, p value: 0.48 (-3.7-7.7) At 3 months: Group 1: 1.3 Group 2: 0.8, p value: 0.38 (-0.7-1.6)	Notes: Study reports number of patients continent at time intervals but data are presented as number of patients still incontinent.
	<u>Group 2</u> N: 15 Age (mean): 60.7 Drop outs: 3 months: 5, 6 months: 7	voiding diary and 48 hour pad test at 6, 12 and 24 weeks postoperatively.		At 6 months: Group 1: 0.3 Group 2: 0.1, p value: 0.45 (-0.3-0.6)	Incontinent defined as still using pads in the study.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Manassero et al., 2007 ¹⁵⁶ Study design:	Patient group: men undergoing retropubic radical prostatectomy for localised prostate cancer	Indical edPelvic floor muscle training programme by trained urologists with verbal feedback and measurement of muscle strength using digital anal control. Patients with weak muscles had additional electrical still incom monthsstill incom monthotocolHome practice 3x15 sessions/day increasing to 3x30 sessions in supine, sitting and standing positions. After 1 month patients were encourage to integrate exercise into daily life.Proportion still incom monthsorGroup 2 No treatment.Proportion 	ing retropubic radical Pelvic floor muscle training programme by trained urologists with verbal feedback still incontinent at 1 month Group 2: 39/40 (98%) p value: 0.04 (Fishers exact test) NCGC Chi-squared calculation p		Funding: NR Limitations: High drop out rate
	University of Pisa, Italy Inclusion criteria: Compliance with protocol		Proportion of patients still incontinent at 3 months	Group 1: 29/54 (54%) Group 2: 31/40 (76%) p value: 0.03 (Fishers exact test) signif NCGC Chi-squared calculation p=0.61 using ITT analysis Not sig.	13/53 (28%) in control group and results for control group are not presented as intentior
Duration of follow-up: 12 months Masked outcome	 clinic attendance Objectively confirmed urinary incontinence (>2g urine on 24h pad test) Exclusion criteria: 		Proportion of patients still incontinent at 6 months	Group 1: 18/54 (33%) Group 2: 24/40 (60%) p value: 0.01 (Fishers exact test) signif NCGC Chi-squared calculation p=0.21 using ITT analysis Not sig.	to treat (ITT) analysis Additional outcomes Correlation between VAS score subjective assessment and 24h
assessment and computer generated random numbers	 History of preoperative incontinence Significant perioperative complications Active rectal lesions or 		Proportion of patients still incontinent at 12 months	Group 1: 9/54 (17%) Group 2: 21/40 (53%) p value: 0.0003 (Fishers exact test) signif NCGC Chi-squared calculation p=0.008 using ITT analysis signif.	pad test at each time interval. Multivariate logistic regression to find
	 infections Psychiatric or neurological disorders Inability to contract pelvic floor muscles or weak contraction 		Proportion of patients still incontinent at 12 months (incontinence severity)	Group 1: 1 mild (2-9g), 1 moderate (10- 49g), 7 severe (≥50g) Group 2: 7 mild (2-9g), 10 moderate (10- 49g), 4 severe (≥50g)	variables that predict incontinence at 12 months (adjusting for age, IPSS score, blood loss, baseline QoL, incontinence at
	Detrusor over activity All patients N: 107		Subjective comparison of incontinence at 12 months using VAS score	Group 1: NR Group 2: NR p value: 0.01 (Wilcoxon Rank Sum Tets) signif	week, tumour stage 8 nerve preservation)
	Age (mean): M: 107 Drop outs: 13 <u>Group 1</u> N: 54		Subjective comparison of incontinence at 12 months using Quality of Life (QoL) question from IPSS symptom score.	Group 1: NR Group 2: NR p value: 0.03 (Wilcoxon Rank Sum Tets) signif	None

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Age (mean ± SD): 66.8 ± 6.3 M: 54 Mean urine leakage/day: 247 ± 505g Drop outs: 0 Group 2 N: 53 Age (mean ± SD): 67.9 ± 5.5 (n=40) M: 53 Mean urine leakage/day: 97 ± 138g Drop outs: 13 (social reasons and refusal to complete follow-up) Baseline data only available for 40 patients				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Mathewson- Chapman 1997 ¹⁶¹	Patient group: Men with a radical retropubic prostatectomy (RP) for localised prostate cancer	Group 1 Preoperative education and instruction*	Mean ± SD number of episodes of incontinence at week 2	Group 1: 25.1 ± 39.5 Group 2: 12.5 ± 26.3 p value: 0.17 (t test) Not sig.	Funding: In part by a Geriatric Nurse Fellowship from
Study design: RCT	Setting: University of Florida College of Nursing	Then postoperative Pelvic Muscle Exercise protocol	Mean ± SD number of episodes of incontinence at week 5	Group 1: 13.4 ± 31.1 Group 2: 10.4 ± 26.8 p value: 0.71 (t test) Not sig.	Dept. Veteran Affairs, USA
Evidence level: 1+	 Inclusion criteria: Incontinent on day 15 after surgery after catheter removal 	(PME) practiced 3/week for 36 sessions starting at week 3. 15 repetitions performed at home,	Mean ± SD number of episodes of incontinence at week 9	Group 1: 1.5 ± 3.2 Group 2: 5.6 ± 26.3 p value: 0.34 (t test) Not sig.	 The results from the intervention arm are potentially
Duration of follow-up:	 Able to regularly attend hospital appointments 	increasing by 10 every 4 weeks to a maximum of 35	Mean ± SD number of episodes of incontinence at week 12	Group 1: 0.84 ± 1.99 Group 2: 1.00 ± 0.27 p value: 0.68 (t test) Not sig.	confounded by the preoperative instruction on pelvic
3 months	<u>All patients</u> N: 53	Biofeedback using an anal probe (PRS 8900 Incare). Evaluations were done at	Mean ± SD number of pads used at week 2	Group 1: 3.88 ± 3.15 Group 2: 3.84 ± 3.3 p value: 0.95 (t test) Not sig.	floor muscle contraction given to both groups
	Age (mean): 62 (range 47-75) M: 53 Drop outs: 2 (unaccounted for in	any other times requested by the patient. Group 2 Preoperative education and instruction*	Mean ± SD number of pads used at week 5	Group 1: 2.35 ± 2.97 Group 2: 2.84 ± 3.1 p value: 0.56 (t test) Not sig.	No allocation concealmentNo blinding
	report) <u>Group 1</u> N: 27		Mean ± SD number of pads used at week 9	Group 1: 1.1 ± 2.1 Group 2: 2.04 ± 2.7 p value: 0.2 (t test) Not sig.	 Not an ITT analysis – report says 53 randomised but only
	Age (mean): NR M: 27 Drop outs: NR		Mean ± SD number of pads used at week 12	Group 1: 0.6 ± 1.6 Group 2: 1.8 ± 2.7 p value: 0.07 (t test) Not sig.	51 in patient groups. Drop outs not explained.
	Group 2 Examination methods:	Mean ± SD time to continence - no pad needed (days)	Group 1: 51 ± 28.9 Group 2: 56 ± 30.47 p value: 0.59 (t test) Not sig.	Notes: *Both groups were taught preoperatively how to	
	Age (mean): NR M: 24 Drop outs: NR	pads used, number of episodes of incontinence /day over a 3 day period	Mean amount of urine (ounces ± SD) lost in 24h at week 5	Group 1: 4.3 ± 8.9 ($4.3 \text{ oz} = 121g$) Group 2: 4.5 ± 7.7 ($4.5 \text{ oz} = 128g$) p value: 0.95 (t test) Not sig.	contract perineal muscle prior to lifting, standing, coughing or sneezing and
	and frequency of episodes of urine loss. 24h pad test measured	Mean amount of urine (ounces ± SD) lost in 24h at week 12	Group 1: 0.0 ± 80.0 Group 2: 0.5 ± 1.7 (1.7 oz = 48g) p value: 0.22 (t test) Not sig.	also to limit tea, coffee, chocolate and alcohol uptake.	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
		amount of urine lost. Volume of urine lost (ounces), number of pads used, number of episodes of urine loss, number of episodes of incontinence and length of time urine loss was experienced were all evaluated at weeks 2, 5, 9 and 12.	Proportion of still incontinent at 0 – 3 months (60-79 days) Data from Hunter et al., 2007 ¹¹⁰	Group 1: 8/27 Group 2: 10/24 p value: NR	Included study in SR by Hunter et al., 2007 ¹¹⁰ .

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Moore et al., 1999 ¹⁷⁸ Study design:	Patient group: Patients who had undergone radical retropubic prostatectomy	Group 1 (PFMT) Pre and postoperative verbal + written instructions about PFMT by nurses in	Mean (median) [SD, range] urinary loss (g) in 24 h at baseline*	Group 1 (PFMT): n=18: 565.6 (513.9) [403.3, 21.5-1538.6] Group 2 (PFMT+ ES) n= 19: 452.5 (492.1) [385.1, 5.3-1344.8]	Funding: Oncology Nurses' Society, Canadian Nurses' Foundation,
RCT	Setting:	preadmission clinic and follow- up visits to urologist.		Group 3(Control) n=21: 385.9 (395.5) [256.9, 6.3-921.5]	Caritas Health, Alberta Physiotherapy
Evidence level:	University-affiliated hospitals in Edmonton, Canada	Also Intensive physiotherapy 30 min 2/week for 12 weeks.		Total n=58: 463.5 (419.8) [352.2, 5.3- 1538.6] p value: Not sig	Association, Edna Mintor Foundation, and the
1+ Duration of	Inclusion criteria: • >= 4 weeks after radical	Initial contractions were of 5- 10 s + a 10-20 s rest, with 12-20 repetitions. For	Mean (median) [SD, range] urinary loss (g)	Group 1 (PFMT): n=18: 86.9 (32.50) [123.0, 2.2-385.9]	University of Alberta, Edmonton, Canada.
follow-up: 24 weeks Computer generated	 >- 4 weeks after radical prostatectomy (RP) (>2 g of urine loss on pad test) Neurologically normal Within 2 h drive of study 	endurance exercises the 'hold' time was 20-30 s + equal rest time, with 8-10 repetitions. Speed was achieved by sets of quick repetitive contractions	in 24 h at 3 months*	Group 2 (PFMT+ ES) n= 19: 155.5 (87.5) [168.1,1.0-509.3] Group 3 (Control) n=21: 103.8 (23.8) [176.3, 1.0-702.4] Total n=58: 115.5 (27.2) [158.7, 1.0- 702.4] p value: Not sig	 Limitations: Masking of outcome assessment was not reported The results from the
randomisation sequence and allocation concealment	 centre Able to speak and read English Willing to comply with protocol No current treatment Not seeking other treatment 		Mean (median) [SD, range] urinary loss (g) in 24 h at 4 months*	Group 1 (PFMT): n=18: 73.5 (10.35) [131.4, 1.0-494.6] Group 2 (PFMT+ ES) n= 19: 202.2 (85.7) [242.23, 1.0-753.4] Group 3 (Control) n=21: 67.3 (11.5) [137.4, 2.0-530.3] Total n=58: 114.2 (14.1) [185.6, 1.0- 595.7] p value: Not sig	intervention arm are potentially confounded by the preoperative instruction on pelvic floor muscle contraction given to all groups
	 Exclusion criteria: Demand pacemaker Previous pelvic muscle stimulation Active rectal lesions or infections Known detrusor instability 	Pre and postoperative verbal + written instructions about PFMT by nurses in preadmission clinic and follow- up visits to urologist Also patients met with the same physiotherapist 2/week for 30 min. Electrical stimulation (ES) with a surface anal electrode (InCare) was	Mean (median) [SD, range] urinary loss (g) in 24 h at 6 months*	Group 1 (PME): n=18: 69.9 (8.7) [113.5, 1.0-362.8] Group 2 (PME+ ES) n= 19: 98.2 (8.95)[132.1, 1.0-424.2] Group 3 (Control) n=21: 54.1 (6.9) [103.1, 1.0-277.3] Total n=58: 72.5 (7.5) [115.7, 1.0- 424.2] p value: Not sig	Notes: *Data from text for median urinary loss: A one-way repeated- measures ANOVA using a general linear model was computed to test the difference between and within groups, as
	All patients N: 63 Drop outs: 5	alternated with PMFT as for Group 1. Stimulation parameters were 50 Hz, a	QOL Objective QoL measures (IIQ-7 and EORTC QLQ	There were no significant group differences in either IIQ-7 or the QLQ C30	well as the change over time at 12, 16 and 24

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
details	3 because of bladder neck contractures 1 because of rectal pain when he did the exercises 1 because he went on vacation for 4 months and could not continue therapy Age (mean): 67 (range 49-77) Group 1 (PFMT) N: 20 Age (mean): 67.4 Drop outs: 2 Group 2 (PFMT+ ES) N: 22 Age (mean): 65.7 Drop outs: 3 Group 3 (Standard treatment)	biphasic pulse shape with 1-s bursts, a 1 s pulse width and 1 s pulse trains. Group 3(Standard treatment) Pre and postoperative verbal + written instructions about PFMT by nurses in preadmission clinic and follow- up visits to urologist Continence was defined as a loss of <= 2 g of urine; socially acceptable continence was considered as <= 10 g	C-30) Proportion of still incontinent at 0 - 3 months (data from Hunter et al., 2007 ¹¹⁰) Proportion of still incontinent at 3 - 6 months (data from Hunter et al., 2007 ¹¹⁰)	P NR Other data for QoL is reported in text for the whole population and not per group. Group 1: 12/20 Group 2: 11/22 Group 3: 14/21 p value: NR Group 1: 8/20 Group 2: NR Group 3: 7/21 p value: NR	weeks. There were no differences among the groups (F=0.23, P=0.80) at any of the measurements Data for proportion of patients still incontinent was taken from Hunter et al., 2007 ¹¹⁰ Cochrane Review though it is unclear how this data was extracted from the paper.
	N: 21 Age (mean): 66.8 Drop outs: 0				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Parekh et al., 2003 ²⁰¹	Patient group: men scheduled to undergo radical prostatectomy for localised prostate cancer	orPMFT using verbal and visualisation techniques and biofeedback using rectal probe was delivered by a physiotherapist comprising initial evaluation and 2 treatment sessions prior to surgery and then every 3 weeks for 3 months postoperatively. Home exercise programme was followed for 6 months or 	Median time to regain continence	Group 1: 12 weeks Group 2: 16 weeks p value: <0.05 (2 tailed <i>t</i> -test)	Funding: NR Limitations:
Study design: RCT Evidence level:	Setting: Urology clinic, USA Exclusion criteria:		Proportion of patients still incontinent at 3 months	Group 1: 6/19 (32%) Group 2: 12/19 (63%) p value: NR NCGC Chi-squared calculation p=0.051 using ITT analysis Not sig.	assessment not
1+ Duration of follow-up: 12 months	Prior bowel or bladder incontinence <u>All patients</u> N: 38 Age (mean ± SD): NR Drop outs: 0		Proportion of patients still incontinent at 6.5 months	Group 1: 4/19 (21%) Group 2: 7/19 (37%) p value: NR NCGC Chi-squared calculation p=0.28 using ITT analysis Not sig.	mentioned Notes: Study reports numbers of patients continent at
	Group 1 N: 19 Age (mean ± SD): 61.6 M: 19		Proportion of patients still incontinent at 13 months	Group 1: 3/19 (16%) Group 2: 4/19 (21%) p value: NR NCGC Chi-squared calculation p=0.68 using ITT analysis Not sig.	time intervals but data are presented as number of patients still incontinent
	Mean preop PSA (ng/ml): 8.3 Drop outs: 0	All patients Completed urinary incontinence questionnaire	Severe incontinence (>3 pads) at 12 months	Group 1: 2/19 (11%) Group 2: 3/19 (16%) p value: NR	
	Group 2 N: 19 Age (mean ± SD): 55.5 M: 19 Mean preop PSA (ng/ml): 8.1 Drop outs: 0	by telephone or when questioned by medical students at weeks 6, 12, 16, 20, 28 and 52. Incontinence measured by number of pads used daily with continence defined as 0-1 precautionary pad			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Paterson et al., 1997 ²⁰⁵ Study design: RCT Observer masked Evidence level: 1+ Duration of follow-up: 13 weeks	Patient group: Men with post-micturation dribbling (PMD) Setting: Repatriation General Hospital, South Australia Inclusion criteria: Patients with an history of post-micturation dribbling (PMD) Exclusion criteria: No history of surgery on the bladder, prostate or urethra, or had a history of urgency or stress incontinence. All were able to comply with instructions All patients	Group 1 (counselling) Advice on drinking patterns, types of beverages, aperient use, toileting habits, hints to alleviate oedema, dietary advice and relaxation therapy Group 2 (milking) Patients were given insights into the anatomy of the urethra and where the urine pools. They performed the procedure in the clinic to ensure that they did so correctly. An education sheet based on the technique outlined by Millard was issued to this group to reinforce their understanding of the procedure. Group 3 (PFMT) Pelvic muscle exercise: Patients were given simple education on the anatomy and physiology of the act of micturition.	Urinary loss measured by difference in mean pad weight gain Urinary loss was measured at baseline and at 5, 7, and 13 weeks using pad weighing method. Participants were given instruction on how to wear the pads, seal them in plastic bags and how to complete a bladder chart. The weighing and coding of the pads was the responsibility of the research assistant who was unaware of the participant's group	Data is reported in figures. The mean pad weight initially decreased rapidly in the exercise group and less so in the milking group but did not changed dramatically in the counselling group (p values not reported).	 Funding: Cello Paper Pty donated weighing scales. Sancella Pty Ltd supplied the male incontinent pads Limitations: Randomisation method and allocation concealment were not reported. Standard deviations were not available for adjusted improvement in pac weight again. Sample size
	N: 49 Drop outs: 6 Group 1 (counselling) N: 15 Age (mean [SEM]): 69.5 [2.4] Initial pad weight gain (g) (mean [SEM]): 7.56 [1.27] Initial pelvic muscle (mean [SEM]): 2.5 [0.21] Group 2 (milking) N: 15 Age (mean [SEM]): 69.3 [3.1] Initial pad weight gain (g) (mean [SEM]): 10.43 [2.99] Initial pelvic muscle (mean [SEM]):	Time and effort were taken to enable correct identification of the pelvic muscles. Participants were taught to tighten and lift these muscles as if they were controlling flatus or interrupting the flow of urine mid-stream. They were encouraged to do them in front of the mirror to observe penile and scrotal lift and to recognize inappropriate tightening of abdominal and gluteal muscles. The fast-twitch muscle fibres were exercised by a series of 1-second contractions (usually five) and gradually extending the number of repetitions, depending on the individual ability of each participant. The slow-twitch fibres	allocation. Crude and adjusted mean (SEM) improvement in pad	Counselling: n=15 Crude 0.019 (1.04) Adjusted: -1.387 Milking: n=15 Crude 3.97 (2.07) Adjusted: 2.877 p<0.01 compared to counselling Exercise: n=13 Crude 4.28 (2.47) Adjusted: 4.707 p<0.001 compared to	calculation is not reported. Notes: Authors report compliance of participants was excellent, with all patients completing pac wearing and bladder charts, and 99.6% attendance of the required number of clinic visits.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Group 3 (PFMT) N: 14 (1 patient completed 9 of the 13 weeks of the study) Age (mean [SEM]): 70.8 (2.7) Initial pad weight gain (g) (mean	were exercised by repeating the maximum contraction as many times as possible without weakening of the length and strength of the contraction. Participants were instructed to spread exercise sessions throughout the day and to vary the positions from lying to sitting and standing.		counselling Improvement in pad weight gain was strongly influenced by initial pad weight gain, or degree of urine loss at the start of the study. After allowing for the effects of initial pad weight gain, the counselling group showed no improvement, the urethral milking group showed an adjusted mean improvement in urine loss of 2.9 g after 13 weeks, compared with 4.7 in the exercise group.	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Porru et al., 2001 ²⁰⁸ Study design: RCT	Patient group: diagnosis of symptomatic BPH selected to undergo TURP Setting: single centre, university	Pelvic floor muscle training through verbal instructions and feedback on contractions. Patients received verbal and written instructions for home PFMT with a regimen of 3x15 exercises/day	Proportion of patients still incontinent at 4 weeks	Group 1: 1/30 (3%) Group 2: 3/28 (11%) p value: NR NCGC Fishers exact test calculation p=0.34 using ITT analysis Not sig.	Funding: NR Limitations: • Randomisation
Evidence level: 1+	vidence evel: 1+ Exclusion criteria:		Change in AUA symptom score at 30 days	Group 1: from 22 to 9 Group 2: from 24 to 10 p value: reported as Not sig. ANOVA	method not describedMasking of outcome
Duration of follow-up: 1 month	 History of urethral or pelvic surgery Neurogenic bladder 	All patients Pelvic floor muscle strength was measured using digital examination and	Change in ICS-Male Quality of Life score at 30 days	Group 1: from 5.8 to 1.5 Group 2: from 5.5 to 3.2 p value: <0.001 signif. ANOVA	 assessment not mentioned Incontinence was
Blinded outcome assessment for pelvic muscle strength	 Prostate carcinoma <u>All patients</u> N: 58 Age (mean): NR M: 58 Drop outs: 5 	Interstored using digital examination and graded from 0 (none) to 4 (strong) preoperatively and at follow up visits on week 1, 2, 3 and 4. M. Patients began voiding diaries immediately post TURP over 48 hour periods M. The AUA symptom score was administered preoperatively and at 30 days postoperatively. M. ICS male questionnaire was used to assess Quality of Life M. Uroflowmetry was performed pre and 30 days post TURP and pressure flow Pressure flow	Mean muscle contraction strength (grade 0-4) ± SD at 4 weeks	Group 1: 3.8 ± 0.3 Group 2: 2.4 ± 0.2 p value: NR. NCGC calculation using a two-sample t test with unequal variances p <0.00001 signif.	not clearly defined Notes: Urologist measuring pelvic floor muscle strength was masked
	Group 1: N: 30		Mean voiding interval at 4 weeks (± SD)	Group 1: 110 ± 23 Group 2: 118.5 ± 24 p value: reported as Not sig.	to treatment allocation
	Age (mean): 66 (range 53-71) M: 30 Drop outs: 2		Proportion of patients with post micturation dribbling and	Group 1: NR Group 2: NR p value: reported as Not sig.	
	Group 2 N: 28 Age (mean): 67.5 (range 55- 73) M: 28 Drop outs: 3		incontinence episodes at 4 weeks		

Study details	Patients	Interventions	Outcome measures		Eff	ect size		Comments	
Tibaek et al.,	Patient group:	Group 1 (PFMT)	DansPSS-1 total		2 weeks	4 weeks	3 months	Funding:	
2007 ²⁵³	Men with uncomplicated BPO (benign	Pre-TURP pelvic floor	score (values	Group 1:	15(3-61)	11(0-52)	3 (0-24)	Prof Jens C	
5	prostatic obstruction) scheduled for TURP	muscle training	range from 0-	Group 2:	13.5(0-51)	6 (0-37)	4.5(0-51)	Christoffersen's	
Study design: RCT single	(transurethral resection of the prostate).	(digital-anal guided) lasting 4 consecutive	108) Results presented	P value:		0.452	0.754	Memory Fund, Danish	
blinded	Setting: single centre, university hospital,	weeks	as median	i valoe.	0.727	0.432	0.7 0 -	Physiotherapist	
	Denmark	Program consisted of	(range).					Research Fund, SC	
Evidence		:	Leakage in pad		2 weeks	4 weeks	3 months	Hygiene Products	
evel: 1+	Inclusion criteria:	- Individual	test (g/24 hours)	N#	12/26	12/23		A/s. Astra Tech	
Duration of	Fit, ambulatory, uncomplicated BPO scheduled for TURP	information: 1 hour		Group 1:	1(0-188)	12(0-374)	_	Denmark and Coloplast	
follow-up:		session including symptoms, anatomy		Group 2:		4(0-56)	_	colopiusi	
	Exclusion criteria:	and instructions on PFMT - 3 group treatments		P value:		0.755		Limitations:	
TURP	Prostate cancer, previous lower urinary							 Physiotherapi 	
	tract surgery and neurological disease		- 3 group treatments 1 hour of isolated		test	rs were contin	ent and refuse	a to do the	assessing the PFM outcomes
	All patients	PFM contractions.	Dation to such a		2 weeks	4 weeks	3 months	were masked	
	N: 58	strength exercises, endurance exercises repeated 4-8x in used pads per 24hours, n(%)	Group 1:	9/25 (36)	4/26(15)	3/26(12)	However, no		
	Drop outs: 9/58 (before intervention –		not specified) endurance exercises repeated 4-8x in	24hours, n(%)	_	6/21(29)	4/21(19)	5/22(23)	mention on whether
	group nor specified				Relative	0	0	0	urological
	<u>Group 1</u>	the supine, standing and sitting positions		risk:		0	0	nurses who	
	N: 26	and PFM		(95%CI)				measured the	
	Age, median (range): 70(58-77) DAN-PSS-1	contractions before		p value:				subjective and	
	- Symptom score: 15(7-24)	and during rising	Urine		2 weeks	4 weeks	3 months	objective voided	
	- Bother score: 17 (8-28)	from sitting position and walking	output/24hours	Group 1:	1985(1050-	1694(923-	1875(775-	parameters	
	- Total Score: 28 (10-61)	•	(ml)		3415)	3003)	3387)	were blinded.	
	Urine output per 24 h (ml): 1827(1023-	endurance exercises repeated gradually 6 - 10 x in the V		Group 2:	1887(583- 3557)	1903(617- 3803)	1820(367- 2716)	 No mention whether 	
	3187) Maile days (ml) 1 (5(50, 250)			p value:		0.412	0.640	urologists	
	Voided volume (ml): 165(50-350) Frequency (no. of voidings/24hr):		Voidina volumo	p vulue.				performing th	
	12(5-21)		Voiding volume (diary) (ml)		2 weeks	4 weeks	3 months	TURP were	
	Max flow (ml/s): 7(3-15)			Group 1:	165.5(40- 250)	150(30-250)	200(50-300)	blinded	
	Residual urine (ml): 116(0-877)	2/day. Patients		C		150/50 250	155150 210	 Both groups received 	
1st sensation (ml): 64(10-270) received new		Group 2:	127.5(50- 360)	150(50-350)	155(50-360)	received information			

Study details	Patients	Interventions	Outcome measures		Ef	fect size		Comments											
	Max cystometric bladder capacity (ml):	progressive		P value:	0.563	0.599	0.510	about PMFT											
	131(38-406)	programme after	Frequency of		2 weeks	4 weeks	3 months	after TURP.											
	Unstable detrusor; n(%): 22/26(85) Pressure flow AG number (ml/s): 79.5(33-170)	and motivated to continue until at lest 4 weeks after	and motivated to continue until at lest 4 weeks after	and motivated to continue until at lest 4 weeks after	and motivated to continue until at lest	and motivated to continue until at lest 4 weeks after	and motivated to continue until at lest 4 weeks after	and motivated to		and motivated to	and motivated to	and motivated to	and motivated to	voiding, times/24 hours	Group 1:	11.85(7.5- 28.3)	10.3(4.3- 26.3)	10.0(6.0- 1 <i>7</i> .3)	Confounding Additional
	Weight of prostate specimen (g): 22(4- 61)								Group 2:	13.2(5.7- 20.7)	11.3(6.7- 17.3)	10.7(4.3- 19.0)	outcomes: Attendance was						
	Histology; no with prostate cancer: 2	3 7		P value:	0.657	0.499	0.794	100% for 24/26											
	Time from randomisation to TURP (days): 42(18-140)			Maximal Urine		2 weeks	4 weeks	3 months	and 75% for 2/2										
	(ddys): 42(18-140)		Flow (ml/s)	Group 1:	-	-	16.6(4.1-47)	All men had good											
	<u>Group 2</u> N: 23	Group 2 (control) -no preoperative physiotherapy treatment	-no preoperative physiotherapy	 no preoperative physiotherapy 	-no preoperative physiotherapy		Group 2:	-	-	16.8(5.3- 36.5)	initial PFM functio (minimum rating 2								
	Age, median (range): 68(52-79) DAN-PSS-1					physiotherapy			P value:	-	-	0.726	but did not impro						
	- Symptom score: 15(6-22)						Residual urine		2 weeks	4 weeks	3 months	to optimum function post-test.							
	- Bother score: 15(3-28)		(ml)	Group 1:	-	-	22(0-661)												
		Both groups received		Group 2:	-	-	1(0-56)	At 2 weeks, 41 m											
	Urine output per 24 h (ml): 1650 (418-	brief information regarding the		P value:	-	-	0.127	"improved", and "worse". At 3											
	3180) Voided volume (ml): 140 (50-350) Frequency (no. of voidings per 24 hour): 11.7(5-21) Max flow (ml/s): 7(1.5-17) Residual urine (ml): 108(0-875) First sensation (ml): 97(13-238) Max cystometric bladder capacity (ml): 174(42-338) Unstable detrusor; n(%): 19/23(83) Pressure flow AG number (ml/s): 76(22-228) Weight of prostate specimen (g): 24(10-58) Histology; no with prostate cancer: 2 Time from randomisation to TURP (days): 35(5-162)	anatomy and physiology of the bladder and PFM, and were given verbal, instructions about PFMT in the ward 2-3 days after TURP						months, 3 patients still had higher DAN-PSS-1 score than before surge Significant difference (p=0.049) betwe groups on dynam muscle endurance Notes: None.											

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Van Kampen et al., 2000 ²⁶¹ Study design: RCT	Patient group: Men with a radical retropubic prostatectomy (RP) for localised prostate cancer	Group 1 Pelvic floor re-education programme extending for as long as incontinence persisted within time limit of 1 year.	Number of men achieving continence at 3 months	Group 1: 43/48 (not ITT) Group 2: 29/52 p value: 0.001 (Fishers Exact test) NCGC check using ITT analysis p=0.0008 (Chi-squared) signif.	Funding: Grant from Fund of Scientific Research, Flanders, Belgium	
Evidence level: 1+	Setting: Department of Urology, Leuven University Hospital, Belgium Inclusion criteria:	Programme comprised anatomical education pelvic floor and function, active pelvic floor muscle training (PFMT) with biofeedback.	Number of incontinent* patients at 12 months	Group 1: 2/50 Group 2: 9/52 p value: 0.001 (Wald test) NCGC check using ITT analysis p=0.03 (Chi-squared) Not sig.	Limitations: No IPSS change data. No QoL score Notes:	
Duration of follow-up: 12 months	 Incontinent on day 15 after surgery after catheter removal Able to regularly attend 	Strength of pelvic-floor muscles assessed using digital anal control and scored. 7 patients who could not	Duration of incontinence (Kaplan-Meier Survival Analysis)	Group 1: NR Group 2: NR p value: 0.0001 (log rank test)	Patients placed in 6 subgroups according to amount of initial urine loss (>50g, <250g,	
Blinded outcome assessment and allocation concealment	 Able to regularly artend hospital appointments Exclusion criteria: NR 	ttend ttend contract were given electrical stimulation by anal probe. Patients were required to do 90 home exercises/day supine, sitting or standing. Each patient received treatment at weekly	s contract were given electrical stimulation by anal probe. Patients were required to do 90 home exercises/day		Group 1: 15/50 Group 2: 8/52 p value: NR NCGC check using ITT analysis p=0.08 (Chi-squared) Not sig.	>250g) and whether they had had a previou TURP. They were then randomised using permuted blocks by an
	All patients N: 102 Age (mean): 65 range (52-76) M: 102 Drop outs: 4		Number of patients with VAS score=0 completely dry at 6 months	Group 1: 29/50 Group 2: 27/52 p value: NR NCGC check using ITT analysis p=0.5 (Chi-squared) Not sig.	independent person. Sealed envelopes but no statement of opacity All patients treated by	
	<u>Group 1</u> N: 50 Age (mean): 64.4 ± 0.8 M: 50	Attendance of weekly outpatient clinic receiving education on aetiology of UI and placebo electrotherapy that couldn't affect muscle function.	Number of patients with VAS score=0 completely dry at 12 months	Group 1: 26/50 Group 2: 22/52 p value: NR NCGC check using ITT analysis p=0.3 (Chi-squared) Not sig.	All continence assessments done by therapist who was not involved in the study.	
	Drop outs: 2 Previous TURP: 2 (4%) Preoperative micturation (IPSS):	Examination methods: Continence measured by 24h	Proportion of still incontinent at 0 – 3 months	Group 1: 5/48 Group 2: 23/52 p value: NR	interved in the study.	
	<10: 37 (74%) 10-20: 9 (18%)	weighed pad test after catheter removal and everyday until patient was	Proportion of still incontinent at 3 - 6 months	Group 1: 2/48 Group 2: 12/52 p value: NR		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	>20: 4 (8%) Group 2 N: 52 Age (mean): 66.6 ± 0.8 M: 52 Drop outs: 2 Previous TURP: 5 (10%) Preoperative micturation (IPSS): <10: 41 (81%) 10-20: 9 (17%) >20: 2 (2%)	continent. **Continence defined as <2g urine lost per day on 24h and 1 h pad test as well as patients indicating no incontinence in past 3 days Confirmation was by 1h pad test in hospital with additional assessment. Continence was also assessed subjectively by visual analogue scale (0=completely continent, 10=completely incontinent)	Proportion of still incontinent at 6 - 12 months	Group 1: 2/48 Group 2: 9/49 p value: NR	
		Continence assessed preoperatively and at 1, 6, 12 months			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Willie et al.,	Patient group:	Group 1: PFMT:	% patients continent at	Group 1: PFMT:	Funding:
2003273	Men with clinically localized prostate	Patients received verbal and	3 months according to	3 months: 60%	NR
	cancer who were scheduled for	written instructions about	questionnaires to	Group 2: PFMT + ES:	
Study	radical prostatectomy.	postoperative PFMT from a	determine number of	3 months: 65%	Limitations:
design:		physiotherapist. After this	pads daily	Group 3: PMFT + ES +	Method of
RCT	Setting:	introduction each patient	Results available at 3	Biofeedback:	randomisation,
	Department of urology	received intensive physiotherapy	months for	3 months: 53%	allocation
Evidence		for 20 to 30 minutes for 3 days.	questionnaires: n= 120	p= 0.8	concealment and
level: 1 +	Inclusion criteria:	All patients encouraged to	% patients continent at	Group 1: PFMT:	sample size
	Patient willingness to make 2 visits 3	perform the exercises twice	12 months according to	12 months: 88%	calculation not
	and 12 months postoperatively.	daily for 3 months after	questionnaires to	Group 2: PFMT + ES:	described.
Duration of	Patients who underwent previous	discharge.	determine number of	12 months: 81%	
follow-up:	transurethral prostatic resection were		pads daily	Group 3: PMFT + ES +	Additional outcomes
12 months	not excluded from the study.	Group 2: PFMT + Electrical	Results available at 12	Biofeedback:	Compliance to
post.op		Stimulation (ES)	months for	12 months: 88.6%	treatment
	Exclusion criteria:	Patients received PFMT and ES	questionnaires: n= 129	p= 0.50	Measured by asking
	NR	and shown how to use the device	% patients continent at	Group 1: PFMT:	the patients how long
		by a dedicated nurse. ES was	3 months according to	3 months: 64%	they had done the
	All patients	provided with a bioimpulser	20 minute pad test	Group 2: PFMT + ES:	recommended
	N : 139	(Haynl Elektronik, Schonebeck,	Results available at 3	3 months: 78%	treatment.
	Drop outs: see outcomes	Germany) surface anal	months for pad test: n=	Group 3: PMFT + ES +	
		electrode. Therapy time was set	79	Biofeedback:	Notes:
	Group 1: PFMT	for 15 minutes in the device.		3 months: 73%	Subjective continence
	N: 47	After this time the device was		p = 0.5	was defined as no or
	Age (no units reported): 65.9	automatically downloaded to	0/ maticate continent at	Group 1: PFMT:	1 pad used daily.
	Prostate wt (gm): 58.5	ensure that each patient had	% patients continent at 12 months according to	3 months: 76%	Objective continence
	% pathological tumor stage:	same therapy duration.	20 minute pad test	Group 2: PFMT + ES:	<1 g/20 minute pad
	pT1a-2b: 71.7	Stimulation parameters were 27	Results available at 12	3 months: 82%	test
	pT3a-3b: 28.3 pT4: 0	Hz, biphasic pulse shape with 1-	months for pad test: n=	Group 3: PMFT + ES +	
	pite: 0 patients continent at baseline	second bursts, a 5-second pulse	124	Biofeedback:	
	according to questionnaire: 20.5%	width and 2-second pulse trains. Intensity was controlled by each	1 2 7	3 months: 90.5%	
	Patients continent at baseline	patient from 10% to 100%.		p = 0.24	
	according to pad test: 29%				
	according to pad lest: 2970	Group 3: PFMT +ES and	Number of men still	Group 1: PFMT:	
	Dren eutre son outcomos	Biofeedback:	incontinent at 3 months	17/47 (36%)	
	Drop outs: see outcomes	These patients were additionally	(ITT analysis)	Group 2: PFMT + ES:	
		These patients were additionally		10/46 (22%)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Group 2: PFMT + Electrical treated with biofeedback (BFB) Stimulation 15 minutes twice daily for 3		Group 3: PMFT + ES + Biofeedback:		
	StimulationN: 46Age (no units reported): 64.6Prostate wt (gm): 53.7% pathological tumor stage:pT1a-2b: 70.4pT3a-3b: 27.3pT4: 2.3Patients continent at baselineaccording to questionnaire: 22.9%Patients continent at baselineaccording to pad test: 36.4%Drop outs: see outcomesGroup 3: PFMT +ES andBiofeedbackN: 46Age (no units reported): 64.6Prostate wt (gm): 55.4% pathological tumor stage:pT1a-2b: 55.6pT3a-3b: 42.2pT4: 2.2Patients continent at baselineaccording to questionnaire: 20.7%Patients continent at baselineaccording to pad test: 33%	 and the same daily for 3 months using the same device and the same anal probe. Each contraction of the anal sphincter and pelvic flood led to a corresponding signal in the device display to ensure that the patient had control over training. The combined ES and BFB programme consisted of a stimulation time of 5 seconds, and a contracting the relaxing time of 5 and 15 seconds, respectively. All patients: Patients were encouraged to perform the treatment they were randomised to for 3 months. There was regular personal interaction between the patient and a health professional during the 6 weeks of surgery. After that time they had no further support.	Number of men still incontinent at 12 months (ITT analysis)	bioreedbdck: 12/46 (27%) Group 1: PFMT: 11/47 (24%) Group 2: PFMT + ES: 8/46 (18%) Group 3: PMFT + ES + Biofeedback: 5/46 (10%)	
	Drop outs: see outcomes				

1 Evidence Table 6 Post void milking vs. no intervention or other conservative intervention 2

3 See Evidence Table 5 Pelvic floor exercises (with or without electrical stimulation or biofeedback)

for Paterson et al., 1997²⁰⁵

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Fader et al, 2006 ⁷⁶ Study design: Cross over RCT Evidence level: 3+ Duration of follow-up: 4 weeks, 1 week for each design	 Patient group: Men with light urinary incontinence Setting: United Kingdom Inclusion criteria: ≥18 years old usually use an absorbent product for light urinary incontinence or had been accessed by a health care professional to as suitable to use such products All patients N: 74 Age: median 70 years (range 23-92) Dropouts: 6 (did not return any data) Type of incontinence: 50% did not know type 21% stress, 16% urge, 13% mixed Output type: 90% described as "dribbled", 7% as "gush" and 3% as constant flow Time of incontinence: 31(46%) both day and night 37(54%) during the day only 	 Products: All products available for leaf (6 types) and pouch (6 types) design. The best product for pads and pants with inserts were chosen. Products in random order for up to 1 week. Total test time was 14 weeks. Product performance: Rated using product performance questionnaire (developed from earlier study) Wet product weights Measured and recorded using pad leakage diaries. 	 wet, and this can cause skin Fit (71%) – designs which ar Discreteness and ability to schelp product to stay in place down the trouser leg), it can Other issues: Ease of use and p Absorbent products can be a home when wet. Men's toilet cubicles ma sanitary disposal unit. D For washables, need to Washing and drying carembarrassing Pouches fiddly to apply fly, and difficult to reins 	bance without leakage-82%) In allowed the scrotum to stay irritation and discomfort. The flatter preferred tay in place (23%) elastics e. If a product fall off (ie be very embarrassing. be very embarrassing. bractical issues difficult to manage away from y not have the equivalent of Discrete disposal difficult bring home for washing.	 Funding: The products were provided from manufacturers. Limitations: Not a blinded study. Method of qualitative analysis not well described Additional outcomes: Specific product performance measured by product performance questionnaire provided for each brand of leaf or pouches tested. Related outcomes Fader et al 2008 ⁷⁵ reported that men and women have different preferences of products. The suitability of products may depend on time of use (day vs. night) due to the position of the penis and whether when going out or staying at home. For overall acceptability, men preferred pull ups or diapers to pads. Washable diapers were most popular among men for use at night.
	<u>Leaf:</u> 38%		Pouch: 55%		Notes:

Evidence Table 7 Product vs. no product or other conservative intervention

<u>Small disposable pads :</u> 35%	Pantegral: 38%	None
Other methods (including	Small pad: 18%	
pouches or Pantegral): 27%	Leakage performance (10g)	
	96(90-98)%	
Most use 1-2 products during the	88(78-94)%	
day (66%), and during the night	57(43-70)%	
(87%).	93(84-97)%	
	Leakage performance (50g)	
Other characteristics:	87(76-93)%	
76% walked independently,	85(75-91)%	
21% use walking aids routinely,	7(0-56)%	
3% use occasionally.	87(76-93)%	
32% reported penile retraction	*Results from best products in each design category.	
	Leaf products:	
	 Varied in performance within group. Tena Level 2 significantly better (score of 79% in overall opinion) compared to others brands (19-40%) in the same leaf 	
	design group	
	 Leakage performance was generally better for disposables compared to washables (88-96% vs. 59% do not leak when holding 10g of urine) 	
	Pouches:	
	- Least successful design	
	 More homogenous in performance (range of 15-28%). Generally lower score than leafs. 	
	- 74-88% do not leak when holding 10g of urine.	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Jakobsson et al, 2002 ¹¹²	Patient group: sample selected from men with prostate cancer and BPH that were part of larger	Questionnaire – questions on experiences of indwelling catheter installation, wearing and handling and background	Information about wearing a catheter:	Little or less than wanted: Group 1: 23.9% Group 2: 29.9%	Funding: Supported by the medical faculty, Lund University, the Swedish Foundation for Health
Study design: qualitative study	Setting: They were randomly selected from 2	data. Response format was on nominal (no-yes) and ordinal (ranging from 'not at all' to 'much') scale levels.		Satisfaction with information: Group 1: 24.3% Group 2: 52.1%	Care Science sand Allergy Research, the County Council of Kristianstad, and
Evidence level: 3+	urological clinic registers in Sweden.	Assessment of health related quality of life with the QLQ-		Question not applicable: Group 1: 35.1% Group 2: 16.9%	Kristianstad University college.
Duration of follow-up: Questionnaire	Inclusion criteria: Men with experience of indwelling urinary catheter treatment. <u>All patients</u> N: 108 Group 1: n=37 Group 2: n=71	C30 questionnaire – which includes five functional scales (physical, role, emotional, social and cognitive functioning), three symptoms scales (fatigue, pain, and nausea and vomiting) a global health status and additional single items. Response format	Information about handling a catheter	Little or less than wanted: Group 1: 22.6% Group 2: 23.9% Satisfaction: Group 1: 24.3% Group 2: 56.3% Not applicable:	Limitations: - Aim of study to compare results from men with BPH to men with prostate cancer. - QLQ C-30 score is cancer specific. - study only looked at negative views of
	Treatment duration: Group 1: Men with BPH <1 week=48.6 2-4 weeks=18.9 1-2 months=27.0 >3 months=5.4 Group 2: Men with prostate cancer <1 week=11.3	comprised yes-no questions and assessment ranging from 'very bad' to 'excellent' (1-7). All scores linearly transformed to a 0-100 scale. Sense of Coherence Questionnaire, 13 item format used in the study (1-7 score to	Mean (SD) functional scales: higher score better function):	Group 1: 40.5% Group 2: 14.1% Physical: 85.5 (22) / 84.3 (24.1) Role: 83.3 (28) / 83.3 (29) Emotional: 85.4 (19.5) / 86.0 (17.8) Cognitive: 85.1 (15) / 85.2 (18.3) Social: 85.0 (14.6) / 85.2 (18.3) QoL: 69.0 (26) / 72.0 (23.0)	catheters. Additional outcomes: Factor solution of indwelling catheter treatment and mean values. Single items on health related quality of life
	2-4 weeks=54.9 1-2 months=24.0 >3 months=8.5	disagree completely to agree completely).	Feelings of discomfort, tagging, smarting and pain at catheter instalment, resting, moving and problems related to indwelling catheter treatment:	Discomfort: % Rather much / much Instalment: 38 / 5.6% Resting: 32.4 / 1.9% Moving:40.8 / 7.4% Tagging: % Rather much / much Instalment: 25.9 / 0.9% Resting: 19.4 / 2.8% Moving:38.9 / 5.6%	scores. Notes: None

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Smarting: % Rather much / muchInstalment: 25 / 2.8%Resting: 15.7 / 1.9%Moving:23.2 / 1.9%Pain: % Rather much / muchInstalment: 26.9 / 2.8%Resting: 14.8 / 1.9%Moving:20.3 / 2.8%Infections % Rather often / often: 18.5 /7.4%Smeary urethra: 25 / 6.5%Difficulties attaching cathetercomfortably: 30.5 / 1.9%Difficulties changing drainage bagcomfortably: 31.5 / 0.9%Difficulties changing drainage bag: 13.9/ 0.9%Fear of leaking urine: 25.9 / 4.6%Fear of drainage bag rupture: 16.7 /3.7%Difficulties finding comfortableresting/sleeping position: 46.3 / 1.9%	
			Bivariate significant relationship between health related quality of life and sense of coherence	Global quality of life had a moderate correlation to sense of coherence: r=.0.52	
			Multiple logistic regression test:	No association between global quality of life, QOL, and the independent variables under study in any of the groups.	

Study details	Patients	Intervention (Methodology)	Outcomes	Comments
Macaulay et al,	Patient group:	Purpose:	Difference in men vs. women in fitting	Funding:
2004 ^{154,154} Study design:	Men/Women who had moderate/ eavy incontinence. Fully	To evaluate all the reusable products for moderate/heavy incontinence and compare them	 of pads. Men were not always happy with a product they perceived to be 	conducted by Continence Product Evaluation (CPE) Network , funded by MHRA
2 interviews (pre and post tests), and a survey (questionnaire) Evidence level: 3+ Duration of follow- up: Not stated. Up to 8 washes for each product	mobile. Participants recruited from advertisement in a consumer journal (Incontact) Cause of incontinence: Varied, not specified. Setting: UK <u>All participants</u>	with disposable alternatives. Methods: Order of product testing was randomized. Subjects tests products one after another based on randomization order, and repeat the process until each product tested a maximum of 8 times. Sequence of follow up: <u>Pretests interview –</u> to determine attributes of products considered to be important	 designed for women. Fitting of insert pads (for pants with integral pads), shaping of pads did not reflect anatomy. Some reversed the inset pads thereby having their larger end situated to their front. This left the smaller end feeling uncomfortable around the buttocks. Problems with washing A man who had to use a launderette found it difficult. Even 	 Limitations: Selection of participants from specialized consumer journal – not certain how this is representative of men with LUTS. Patients noted to be relatively young. This was a pilot study with small sample size. Feedback from men and women were not reported separately. Method of qualitative analysis not well described
	N: 14 Age (mean): 43.6 , range 28-67 years M/F: 10/4	<u>Testing period:</u> Completion of product performance questionnaire and pad leakage diary. Questionnaire was designed based on the pretest	when washed at home, this could lead to some embarrassment when they are part of the family laundry, in a bucket or on a drying line.	Additional outcomes: More details about the specific performance attributed were reported Notes:
		interview. <u>Post test interview</u> Feedback regarding reusables	 Most important product attributes: Leakage/absorbency, discreteness, comfort and fit. More details about the specific performance attributed were reported. 	A full report on the product performances are detailed in a report to MHRA: MHRA. A pilot study to evaluate reusable absorbent body- word products for adults with moderate/heavy urinary incontinence. Med healthcare Prod Reg Agency. 2003:IN11

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Moore et al., 2004 ¹⁷⁹	Patient group: Men with radical prostatectomy \leq 6 months ago	Group 1: Control- no device	Mean urine loss (grams loss in 4 hour pad	Group 1(No device): 122.8 ± 130.8 Group 2(C-3): 32.3 ± 24.3	Funding: University of Alberta: Internal Allocations Fund and Department of Radiology. One investigator
Study design: Cross over randomised Evidence level: 1+ Duration of follow-up: 4 days, 1 day for each product/control	 Setting: Canada Inclusion/Exclusion criteria: Men with stress incontinence who required continuous incontinence pad protection after radical prostatectomy Normal perineal and penile sensation, intact penile skin, no neurologic disorders that could affect sensation or peripheral circulation, sufficient manual dexterity to manage the penile compression device No overactive bladder No cognitive impairment that could affect their ability to follow instructions or perceive penile discomfort (Mini-Mental State Examination score ≥27), ability to read and speak English All patients N: 12 Mini Mental State Score (Mean29.6±1.2) No other baseline data provided 	Group 2: Timms C- 3 penile compression device Group 3: Cunningham Clamp Group 4: U-Tex Male Adjustable Tension Band All these interventions were randomly carried out on 4 sequential days. Subjects were instructed to standardise their activities, time of day for wearing the devices and the amount of fluid intake.	test)	Group 3(Cunningham): 17.1 ± 21.3 Group 4 (U-Tex): 53.3 ± 65.7 p value: <0.05 for all groups vs. Group 1 Note: The standard deviation sizes were larger than the mean values, indicating that the data was potentially skewed and not normally distributed.	 was supported by the Ministry of Health of the Province of British Columbia. Limitations: Data analysis – Data was potentially not normally distributed, but a parametric test (analysis of variance, Dunnet's procedure for post hoc) was used. Interpretation of results need to be treated with caution since n=12. The duration of intervention was only 4 hours or each product, or the control (1 pad test each). The value for Doppler tests for Cunningham clamp was reported for the loosest setting, but setting for others was not reported. The outcome for patient satisfaction was measured using Male Continence Device Satisfaction Questionnaire, which was adapted from another product testing questionnaire. It is unclear whether this is a fully validated instrument. The criteria for determining "rated positively" were not stated. Additional outcomes: None of the clamps completely eliminated urine loss.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Patient satisfaction (rating device positively, using Male Continence Device Satisfaction Questionnaire)	Group 1(Control): NR Group 2(C-3): 2/12 Group 3(Cunningham): 10/12 Group 4 (U-Tex): 0/12 p value: NR For U-Tex, none reported it "positively" because it was difficult to apply, did not stay on with activity and did not control urine leakage satisfactorily. The patient satisfaction for no control was not reported.	Safety data: Blood flow (Systolic velocity)- measured using Doppler Ultrasound. Right: Group 1(Control): 12.4 \pm 2.8 Group 2(C-3): 12.4 \pm 5.5 Group 3(Cunningham): 9.5 \pm 2.3* Group 4 (U-Tex): 11.9 \pm 4.4 p value: * <0.05 vs. control Left: Group 1(Control): 12.3 \pm 3.0 Group 2(C-3): 11.7 \pm 4.7 Group 3(Cunningham): 7.3 \pm 3.0* Group 4 (U-Tex): 13.8 \pm 7.3 p value: * 0.05 vs. control Resistance Index- measured using Doppler Ultrasound. Right: Group 1(Control): 0.90 \pm 0.10 Group 2(C-3): 0.92 \pm 0.10 Group 2(C-3): 0.92 \pm 0.10 Group 3(Cunningham): 0.92 \pm 0.13 Group 4 (U-Tex): 0.93 \pm 0.08 p value: * 0.05 vs. control) Left: Group 1(Control): 0.87 \pm 0.10 Group 2(C-3): 0.92 \pm 0.11 Group 3(Cunningham): 0.86 \pm 0.29 Group 4 (U-Tex): 0.91 \pm 0.11 p value: * 0.05 vs. control

Study details	Patients	Methodology	Outcomes	Comments
Paterson et al, 2003 ²⁰⁴	Patient group: Participants included people who had incontinence or cared for	Purpose: To understand issues, needs and concerns of people	Overall: Striking similarities in experiences and concerns about selection of consumer products.	Funding: National Continence Management Strategy,
Study design: Qualitative Study Semi structured interviews and focus groups Evidence level: 3+ Duration of follow-up: NR	someone with incontinence, or were part of an advocacy group that had significant numbers of people with incontinence in its membership, from metropolitan, rural and remote Australia. Included people of minority backgrounds and indigenous Australians. Purposive and snowballed sampling. Participant recruitment ceased once no new themes emerged.	with incontinence to inform development of comprehensive Australian consumer guide to continence products. Analysis method: Key issues transcribed from audio tapes. Constant comparison, thematic data analysis was commenced concurrently with data collection enabling the opportunity to follow up an emerging theme. (grounded theory) Transcriptions and notes	 Seeking information: Did not know how to begin to search for information and had problems finding it: Most gathered information themselves, and these are usually not all available in one place. Feeling vulnerable: Most felt discussing about incontinence management and shopping for products very personal and embarrassing. Some reluctant to speak to professionals. Lack of confidence in healthcare professional's knowledge: Although dependent on healthcare professionals for assessment and referral, they had not received much helpful advice on products or directed to sources of advice. The most satisfactory help was from specialist continence nurse advisers. Local doctors knew little about assessment and management and many participants were dissatisfied. There was a pervasive "grin and bear with it" attitude and participants were expected to purchase a supermarket product and learn to live with it. Assessment and management: Participants expressed a need for these to be standardised and coordinated. 	an initiative of the Commonwealth of Australia Department of Health and Aged Care Limitations: Possible selection bias as details of demography, disease disease severity and role of participants not reported. Not clear whether their target group of 'incontinent' patients is for urinary or faecal incontinence or both. Notes:
	Cause of incontinence:	taken during sessions Integrated into common	Finding a suitable product:	Analysis did not use verbatim transcripts.
	Varied widely and included congenital malformations, chronic debilitating diseases, sever spinal cord	themes, shared meanings, similarities and difference. 3 researchers conducted	 <u>Trialed different products</u> to find one which enable them to remain socially continent. <u>Advice for product selection</u>: Most had limited product knowledge in early stages and selected from limited range accessible to them in 	
diseases. <u>All partici</u> N: 82 M Age (mea M/F: NR	<u>All participants</u> N: 82 NR Age (mean): NR	analysis, cross- validated with another. Analysis focused on the similarities in experiences and concerns of consumers across the group.	 shops, hospital suppliers and recommendations of professionals. However, participants in support networks benefited from exchange of information. <u>Key factors influencing selection of continence products</u> were quality, comfort and design balanced against availability and cost. Specific product features of concern including noise, allergy, trouble of keeping on, leakage around the seams 	

Study details	Patients	Methodology	Outcomes	Comments
		Information about product use and disposal required:-Instructions for use and wear-Best methods for care and disposal of products		
			Suggestions for content and format of the consumer guide to products:	
			 Detailed product description More information in general about incontinence (causes, treatments and sources of help) and 	
			 Use simple layman's language throughout guide. Make available a variety of formats and a wide distribution throughout the community 	

Evidence Table 8 Catheters vs. no catheters

See Evidence Table 7 Product vs. no product or other conservative intervention

For Jakobsson et al., 2002¹¹².

23 456789

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Logan et al, 2008 ¹⁴⁸	Patient group: selected from case lists of a continence and urology	In depth interviews from January to June 2006 in the		assment and privacy: out for men and women.	Funding: Gwent Health Care Trust research and
Study design: Qualitative study	service. Patients with experiences of learning clean intermittent self catheterisation (CISC).	guide developed based on the literature and experience and	Men's difficulties were handling the lengthy c	ere expressed by both sexes. related to negotiating the penile anatomy and atheters. Generally men had no problem in	development small grant scheme.
Evidence level: 3+	Patients selected to include maximum variation of	Topics helped guide the interviewer to explore reasons for CISC duration and		One man experienced muscle spasms and urethral ficult insertion and frustration in the first few	Limitations: Mix of views from men and women.
Duration of follow-up: NR	bllow-up: and access to services. teaching aids, information,		The entire sample used 'slippery'. To overcome strategies; another red described complication negotiating the strictur 'Sometimes you (have) ease it in the best way	Additional outcomes: Service interaction was also covered.	
	N: 15 M/F: 8/7 Median age (range): 65 (33-81)			uching the catheter tip for fear of contamination ng concerns about hygiene and the development of	
Frequency times per Reasons f MS, ureth	Duration of use: 6m to >2y Frequency: weekly to four times per day. Reasons for catheterisation: MS, urethral stricture, urine retention.		difficult. Gaining confi were squeamish at the because of psychologi Q: You were going we A: Yes, definitely yes,	andents found CISC emotionally and technically dence was related to pace of skill acquisition. Men thought of inserting a catheter for the first time, cal issues and fear of causing internal damage. tak at the knees were you? and the perspiration I was afraid to blink, I ow, from a man's point of view to think you got push into yourself!	
				felt confident immediately while the majority took accept CISC as part of their lives.	
				rticipants were unfamiliar with CISC, and on eter feared it would involve a permanent 'catheter	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			catheter and I didn't k there was a much simp yourself and that poin Practical demonstratio and a few participant insufficient: 'I would have liked mo	about it – I was just told that I had to start using a now any thing at the pointI didn't know that ler, straight forward version that you could use t I was not at all happy about it'. n was an important component of learning CISC, s felt that their demonstrations had been re than one demonstration or more time spentI and I had to get on with it then.'	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Saint et al, 1999 ²²⁷	Patient group: Consecutive male patients between May and November 1998 who	Face to face interviews with a simple instrument	% of men reporting yes to questions at interview: Question: Is the current urinary		Funding: Supported, in part, by the Department of Veterans Affairs and the Robert Wood
Study design: Qualitative	were using an indwelling or condom urinary catheter.	requiring only yes or no answers for each of the 5	catheter 1. Comfortable?	Group 1: 86%	Johnson Clinical Scholars Program.
study	Setting: Patients housed on the	questions.		Group 2: 58%, p=0.04	Limitations:
Evidence level:	medical, rehabilitation and nursing home units of Puget	Group 1: men	2. Painful?	Group 1: 14% Group 2: 48%, p=0.008	Not population of interest.
3+	Sound VA health Care System.	using a condom catheter	3. Convenient?	Group 1: 86%	Additional outcomes: Nurses views by questionnaire.
Duration of	Inclusion criteria: patients with			Group 2: 75%, p=0.40	
follow-up: NR	a urinary catheter in use for at least 24 hours were eligible to participate.	Group 2: men using an indwelling catheter	4. Restricting your daily activity?	Group 1: 24% Group 2: 61%, p=0.002	Notes: Logistic regression analysis using each 'yes' or 'no' answer
	All patients N: 116 Mean age (SD): 71 (12)		5. Causing you embarrassment?	Group 1: 24% Group 2: 30%, p=0.50	as the dependent variable with patient age, hospital service and current catheter type as independent variables.
	Drop outs: 12 90% response rate.		Logistic regression: Condom catheters compared to indwelling were found to be:		
	Group 1: n = 21 Group 2: n = 83		More comfortable:		
	Location: Hospitalised on an acute care		Less painful:	OR=4.2; 95% Cl: 1.1 to 15.6, p=0.03	
	ward: 72% Other ward (nursing home,		Less restrictive:	OR=0.17; 95% CI: 0.05 to 0.64, p=0.008	
	surgery, neurology, rehabilitation): 28%		Convenience or embarrassment:	OR=0.23; 95% CI: 0.07 to 0.75, p=0.01	
				Catheter type not significantly related.	
			Patients were also asked if they remembered having another type	N=36 Preferred condom: 17 (47%)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			of urinary collection device in the past (alternative catheter or disposable diaper). If yes, we asked whether they preferred current or previous device.	Preferred indwelling: 14 (39%) No preference: 5 (14%)	
			Previous experience of disposable diapers, n=27	Group 1: n=10 preferred current catheter Group 2: n=17; 9 preferred current catheter, four preferred diapers and four had no preference.	
			Men with experience of condom catheter (n=43)	N=7 (16%) offered spontaneously that main drawback was the associated leaking.	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Shaw et al,	Patient group: selected	In depth interviews from	Impact on QoL:		Funding: Gwent Health
2008234	from case lists of a	January to June 2006 in the			Care Trust research and
	continence and urology	UK by two of authors and by a	Positive impacts		development small grant
Same trial as	service. Patients with	continence nurse. Interview	Specific comments from	n men:	scheme.
Logan, et al	experiences of learning	guide developed based on the	There were reports of	relief from symptoms such as recurrent urinary	
(see evidence	clean intermittent self	literature and experience and	tract infections.		
table above)	catheterisation (CISC).	expertise of the research team.	"I would rather do this	than put up with the symptoms of infection."	Limitations:
reporting more		Topics helped guide the			Mix of views from men
outcomes on	Patients selected to include	interviewer to explore reasons	CISC was also deemed	d to be a preferable option compared to	and women.
QOL	maximum variation of	for CISC duration and	other management stre	ategies, such as permanent catheters with leg	
	characteristics likely to	frequency of CISC, experience	bags.		
Study design:	impact on views, attitudes	of being taught, location,		catheter fixed to me permanent, this bag on	Additional outcomes:
Qualitative	and access to services.	teaching aids, information,	the leg or whatever th	ey use".	Same trial as Logan, et
study		ongoing support and follow-			al (see evidence table
	Setting: Continence and	•	Negative impacts		above) reporting more
Evidence level:	urology service in Wales.	areas but allowed interviews	Specific comments from		outcomes on QOL
3+		o pursue themes emerging "if I found a disabled toilet where you can go into the room and			
	All patients N: 15	during the interview.	wash your hands and that"	whatever, and in a normal toilet you can't do	
Duration of	M/F: 8/7				
follow-up:	Median age (range): 65			en I am outFinding water If you go to a	
NR	(33-81) Duration of use: 6m to >2y		public toilet you have	to fill it and then go into the toilet."	
	Frequency: weekly to four		Difficulty experienced	in travelling	
	times per day.			y equipment was a particular problem:	
	Reasons for catheterisation:			t. Where I would much prefer to get on the	
	MS, urethral stricture, urine retention.		train and go over and	come back again, I now drive"	
			Physical impacts		
			Specific comments from	n men:	
				onal bleeding, or ongoing discomfort:	
				wespecially with the withdrawal, insertion	
			and withdrawal. And,	of course, when you empty your bladder for	
			the first time after the	procedure, it's grit your teeth"	
			Carrying out CISC		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
-			Specific comments from men: One man had a common problem of muscle spasm preventing insertion of the catheter. Whilst he had learned how to manage this, he found it an inconvenience as he had to wait before trying to 		
			Type of catheter and sex issues There were sex differences related to type of catheter as male catheters are longer and more unwieldy. This had implications for carrying catheters discreetly. Women easily carried catheters in their handbags, whereas men were less likely to carry a bag and had difficulty carrying catheters in their pockets.		

1	Evidence	Table 9	Alpha-blockers	vs.	placebo
---	----------	---------	----------------	-----	---------

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Andersen et al., 2000 ¹³	Patient group: Men between 50-80 years with evidence of BPH.	Phase 1: 2 week wash out Phase 2: Run-in	Mean (SE) adjusted change from baseline to final visit for total IPSS score (per-protocol analysis)	Group1 (n=310): -8.0±0.3; p<0.01 Group 2 (n=311): -8.4±0.3; p<0.01 Group 3 (n=151): -6.0±0.4	Funding: Pfizer Inc.
Study design: RCT Setting: Multi- centre,	Inclusion criteria : Maximum urinary flow rate ≥ 5 ml/s and ≤ 15 ml/s in a total voided volume of ≥ 150 ml and IPSS score of 12 or more.	period 2-week	IPSS Mean difference ±SEM (95% Cl) in change from baseline at the final visit for Group 1-Group 2 [least squares difference]	0.39±0.39 (-0.38, 1.15)	Method of randomisation and allocation concealment was NR
Scandinavia. Evidence level:	Exclusion criteria: Patients who had undergone prostate surgery, had a prostatic stent, or had undergone microwave thermotherapy were	double blind Group 1: Doxazosin Gastrointestinal	Mean (SE) adjusted change from baseline to final visit for Qmax (per-protocol analysis)	Group1 (n=300): 2.6±0.2 Group 2 (n=303): 2.2±0.2 Group 3 (n=151): 0.8±0.3	Additional outcomes: Mean changes from baseline in
1+ Duration of follow-up:	excluded, as were those who had had balloon dilation within the previous 6 months. Suspected or known malignancy and or	therapeutic system (GITS) 4mg or 8mg once daily with a doxazosin standard	Mean (SD) adjusted change from baseline to final visit for urinary flow (per-protocol analysis)	Group1 (n=300): 1.2±2.4; p<0.04 Group 2 (n=303): 1.1±2.0; p<0.05 Group 3 (n=151): 0.6±2.1	individual symptom IPSS score. Graphical presentation of IPSS
13 weeks	PSA>10ng/ml; any known cause of urinary symptoms or reduced flow rate other than BPH; known acute urinary retention within the year, major residual urine, bladder stones,	f placebo tablet. Initially 4mg dose given for at least 7 weeks. At week 7 the dose was increased to 8mg c, once daily if subjects had not experienced	Mean (SD) adjusted change from baseline to final visit for total quality of life IPSS question (per- protocol analysis) – least squares difference	Group1 (n=310): -1.3±0.1 Group 2 (n=311): -1.4±0.1 Group 3 (n=151): -0.9±0.1 P<0.001	not be combined for meta-analysis.
	large bladder diverticulum. Hepatic, renal, cardiac and gastrointestinal dysfunction or disease; uncontrolled diabetes, hypotension; and known allergy to study drugs. Use of prespecified drugs that mightor he or 		Adverse events	Dizziness 	
	investigational drug or donation of blood 4 weeks prior to or during the study and conditions precluding good compliance were also cause for exclusion. All patients N: 795	Group 2: Doxazosin standard 1 to 8mg once daily Initial dose 1mg that was increased at the end of 1 week to 2mg, at week to		Group 3: 7/156 (4.5%) Asthenia Group 1: 10/317 (3.2%) Group 2: 16/322 5.0%) Group 3: 2/156 (1.3%) Vertigo Group 1: 8/317 (2.5%) Group 2: 24/322 (7.5%)	analysis: Group 1 GITS: 44.2% remained at the 4mg and 55.8% received 8mg at the final visit. Group 2: doxazosin standard group

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	ITT analysis: 784 Per protocol analysis: 780 Mean age : 65.2 years Drop outs: Group 1 N : 317 ITT analysis =311 Mean (±SD) Age: 64.9 Baseline IPSS: 17.7±4.3 Race: White=311 Dropouts:22 (treatment related adverse events=11) Group 2 N : 322 (ITT analysis =318) Mean (±SD) Age: 65.3 Baseline IPSS: 17.8±4.5 Race: White=318 Dropouts:38 (treatment related	4mg and at week 7the dose wasincreased to 8mgonce daily ifrequired to achievethe target increasingurinary flow anddecrease in IPSS.Group 3: Placeboonce dailyReceived double-dummy matchingplaceboStudy medicationstaken once daily atbreakfast, except onstudy visit days,		Flu syndrome Group 1: 4/317 (1.3%) Group 2: 6/322 (1.9%) Group 3: 7/156 (4.5%) Back pain Group 1: 4/317 (1.3%) Group 2: 4/322 (1.2%) Group 3: 4/156 (2.6%) Postural hypotension Group 1: 4/317 (1.3%) Group 2: 7/322 (2.2%) Group 3: 1/156 (0.6%) Nausea Group 1: 3/317 (0.9%) Group 2: 8/322 (2.5%) Group 3: 1/156 (0.6%) Discontinuation - adverse events Group 1: 11 (3.5%) Group 2: 20 (6.2%) Group 3: 1 (0.6%)	14.9% were receiving 2mg;day, 34% were on 4mg/day and 51.1% were receiving 8mg/day. Mean final dose for Group 1: 6.2mg/day Group 2: 5.7mg/day
	adverse events=20; insufficient clinical response=1) <u>Group 3</u>	was administered after study assessments.	Reduction from baseline IPSS of ≥30%	Group 1: 73.5% Group 2: 74.7% Group 3: 53.5%	
	N: 156 (ITT analysis =155) Mean (±SD) Age: 65.4 Baseline IPSS: 18.0±4.3		Increase in maximum urinary flow rate ≥3ml/s	Group1: 38.8% Group 2: 38.7% Group 3: 21.4%	
	Race: White=153; Asian=1; Other=1 Dropouts: 8 (treatment related adverse events=1)		Investigator s assessment of efficacy (intention to treat analysis)	Excellent or good rating Group 1: 193 (62.3%) Group 2:207 (65.5%) Group 3: 57 (37.5%) Poor rating Group 1: 39 (12.6%) Group 2:48 (15.2%) Group 3: 47 (30.9%)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Carbin et al., 1991 ³⁷ Study design: Randomised controlled trial. Setting:	years of age with a knownAlfzosin 2.5mg X 3diagnosis of BPH.If no effect of therapy	Mean urinary flow rate, ml/sec	Baseline Group 1: 8.1 (2.2) Group 2: 8.4 (3.0) 3 weeks Group 1: 9.2 (3.3) Group 2: 8.2 (3.8) 8 weeks Group 1: 8.9 (2.8) Group 2: 8.9 (3.4)	Funding: NR Limitations: Method of randomisation, allocation concealment and blinding were unclear.	
NR Evidence level: 1+ Duration of follow-up: 8 weeks			Timed micturition seconds	P=NS Baseline Group1: 19.6 (13.1) Group 2: 23.9 (15.4) 3 weeks Group1: 14.7 (10.4) Group 2: 22.6 (13.2) 5 weeks Group1: 14.3 (9.8) Group 2: 23.9 (17.8) 8 weeks Group1: 15.8 (11.7) Group 2: 21.8 (10.6) P=0.023	Additional outcomes: Serum concentration, heart rate and blood pressure reported. Notes: Baseline number in each group not reported in methods. The table for adverse events reports that 15 in the intervention group.
			Residual urine	Baseline Group 1: 97.9 (115) Group 2: 92.7 (86) 3 weeks Group 1: 30.9 (32) Group 2: 114 (167) 8 weeks Group 1: 42.8 (51) Group 2: 94.2 (121) P=0.02	
			Frequency number	Baseline Group 1: 8.9 (3) Group 2: 10.7 (3.0)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				3 weeks Group1: 7.1 (2) Group 2: 10.4 (3) 5 weeks Group1: 8.6 (3) Group 2: 9.5 (3) 8 weeks Group1: 7.4 (2) Group 2: 9.4 (3) P=NS	
			Boyarsky score	Baseline Group1: 11.3 (3.0) Group 2: 11.7 (3.7) 3 weeks Group1: 7.3 (3.0) Group 2: 8.9 (2.6) 5 weeks Group1: 6.3 (3.2) Group 2: 7.9 (2.6) 8 weeks Group1: 5.9 (3.6) Group 2: 7.1 (2.2) P=NS	
			% of patients that had the dose increased	Group 1: 27% Group 2: 47%	-
			Patients/physicians correct guess of treatment given	Group 1: 60% / 60% Group 2: 67% / 58%	
			Adverse events	Vertigo Group 1: 3/15 Group 2: 2/15 Headache Group 1: 1/15 Group 2: 1/15 Weakness Group 1: 1/15	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Group 2: 0/15	
				Weight gain	
				Group 1: 1/15	
				Group 2: 0/15	
				Indigestion	
				Group 1: 2/15	
				Group 2: 0/15	
				Diarrhoea	
				Group 1: 1/15	
				Group 2: 2/15	
				Constipation	
				Group 1: 1/15	
				Group 2: 0/15	
				Dry mouth	
				Group 1: 0/15	
				Group 2: 1/15	
				Dry hands	
				Group 1: 1/15	
				Group 2: 0/15	
				Herpes simplex	
				Group 1: 1/15	
				Group 2: 0/15	
				Conjunctivitis	
				Group 1: 1/15	
				Group 2: 0/15	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Chapple et al., 1994 ⁴⁵ Study design: Randomised controlled study	Patient group: Inclusion criteria: Maximum urinary flow rate<15ml/s accompanied by symptoms of bladder outflow obstruction and in whom outflow obstruction at the level of the	Baseline evaluation:Lasting 2 weeks duringwhich patients receivedone doxazosin or placebotablet each morning.Group 1: Alpha-blockerDoxazosin commencedwith daily dose 1mg,increased to 2mg after 2weeks and to maximum of4mg after 4 weeks	Mean (SEM) maximum flow rate, ml/s	Baseline Group 1: 9.1 (0.5) Group 2: 9.1 (0.5) Change Group 1: 2.6 (0.7) Group 2: 1.1 (0.6) P=0.09	Funding: Pfizer provided medications and material support for study. Limitations: Method of
Setting: Multi- centre, UK Evidence level: 1+	prostate was confirmed by means of videocystometrography. Only patients with a functioning detrusor muscle were included (residual urine <200ml). Exclusion criteria: Patients with		Mean (SEM) maximum detrusor voiding pressure, cmH2O	Baseline Group 1: 78.5 (2.7) Group 2: 74.2 (4.6) Change Group 1: -4.6 (3.2) Group 2: 7.9 (3.0) P=0.007	randomisation and allocation concealment unclear. Additional outcomes: Maximum bladder capacity, volume of first
Duration of follow-up: 12 weeks	Exclusion criteria: Patients with other conditions giving rise to urinary symptoms and reduced urine flow rates, such as carcinoma of the prostate. Previous prostatic surgery, serum creatinine>200mmol/l, poorly controlled diabetes, a history of myocardial infarction or a	Mean flow rate, ml/s	Baseline Group 1: 4.4 (0.3) Group 2: 4.3 (0.3) Change Group 1: 1.0 (0.3) Group 2: 0.2 (0.3) P=0.04	 unstable contraction, end filling pressure reported. Modified Boyarsky scale used to report obstructive and irritative symptoms but figures not provided. 	
	cerebrovascular accident within the preceding 6 months.		Number of reported adverse events in number of patients with adverse events	Group 1: 44/25 Group 2: 12/11	Notes: Headache and dizziness reported as most
	N: 135 Group 1		Withdrawn due to adverse events	Group 1: 2 Group 2: 0	frequent side effects but actual figures not reported.
	N: 67 Mean (±SD) Age: 67 (7.3) Race: Caucasian=55, other=12 Dropouts: 7 (drop out during 2 week run-in=2, withdrew due to concomitant or associated illness=3; adverse events=2) Data for efficacy=60 [Evaluable in		% Improvement in symptoms (evaluation in response to questioning at tend of study)	Hesitancy Group 1: 59% Group 2: 26% P=0.003 Nocturia Group 1: 39% Group 2: 19% P=0.017	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	2 of 12 that withdrew; inevaluable in 1 due to protocol violations] Group 2 N: 68 Mean (±SD) Age: 67 (7.5) Race: Caucasian=64, other4 Dropouts: 5 (drop out during 2 week run-in=1, withdrew due to concomitant or associated illness=4) Data for efficacy=62 [inevaluable in 2 due to protocol violations]			Urgency Group 1: 60% Group 2: 38% P=0.041 Impaired urinary stream Group 1: 56% Group 2: 33% P=0.019 Frequency Group 1: 44% Group 2: 27% P=0.062	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Chapple et al., 2005 ⁴⁴ Study design: RCT Setting: Multi national (18 countries), multi-centre	Inclusion criteria: Men aged 45 years or over with voiding and storage symptoms diagnosed as LUTS/BPH with a total IPSS ≥13	Group 1: Tamsulosin: Oral controlled absorption system 0.4mg once daily Group 2: Tamsulosin: Old modified release tamsulosin: 0.4mg once daily	Mean (SD) IPSS at baseline	Baseline: Group 1: 18.5 (4.4) Group 2: 18.5 (4.5) Group 3: 18.6 (4.5) Group 4: 18.3 (4.5) End point: Group 1 (n=355): 10.8 (6.2) Group 2 (n=703): 10.6 (5.9) Group 3 (n=709): 10.6 (5.9) Group 4 (n=351): 12.4 (6.4)	Funding: NR. Limitations: None. Additional outcomes: Blood pressure was reported.
(138 mainly European) Evidence	Exclusion criteria: any other urological procedures or conditions what may cause LUTS ; patients with	Group 3: Tamsulosin: Oral controlled absorption	IPSS reduction at endpoint	Group1 (n=354): -7.7 (5.8); p<0.001 Group 2 (n=700): -8.0 (5.6); p<0.001 Group 3 (n=707): -8.0 (5.9) Group 4 (n=350): -5.8 (5.6)	Notes: Additional information retrieved from the authors.
level: 1+ Duration of follow-up: 12 weeks	hepatic or renal insufficiency, clinically significant cardiovascular or cerebrovascular diseases within 6 of months prior to enrolment, central nervous system conditions or life- State of the system conditions or life-	clinically significant cardiovascular or cerebrovascular diseases within 6 months prior to enrolment, central nervous system conditions or life- threatening diseases. Patients taking or had taken other drugs for LUTS or were hypersensitive to a 1 AR antagonists or their recipients, were taking drugs which could interfere	Mean (SD) change at endpoint IPSS- QOL	Baseline: Group1 (n=354): 3.8 (1.1) Group 2 (n=699): 3.8 (1.1) Group 3 (n=706): 3.8 (1.1) Group 4 (n=350): 3.8 (1.0) Change at endpoint: Group1 (n=354): -1.4 (1.3) Group 2 (n=699): -1.4 (1.3) Group 3 (n=706): -1.4 (1.4) Group 4 (n=350): -1.1 (1.3)	Outcomes reported for group 1 and 2 combined for meta- analysis by NCGC.
			Investigator reported as slightly improved	Group 1: 33.1% Group 2: 33.5% Group 3: 33.0% Group 4: 35.7%	
		Investigator reported as much improved	Group1: 46.5% Group 2: 48.7% Group 3: 48.4% Group 4: 35.7%		
		Treatment-emergent Adverse events attributable to alpha- blocker	Non cardiovascular Group 1: 16 (4.4%) Group 2: 36 (5.1%) Group 3: 57 (7.9%)		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	response=18, lost to follow-up=9, protocol violations=3, adverse events starting during the placebo run in =3, death=3, abnormal laboratory values=1, non-specified reasons=13 <u>Group 1</u> N: 361 Dropouts:18			Group 4: 7 (2.0%) Cardiovascular Group 1: 9 (2.5%) Group 2: 23 (3.2%) Group 3: 28 (3.9%) Group 4: 8 (2.2%) All: Group 1: 25 (6.9%) Group 2: 55 (7.8%) Group 3: 80 (11.1%) Group 4: 13 (3.7%)	
	<u>Group 2</u> N: 710 Dropouts: 25		Number (%) Dizziness	Group1: 5/360 (1.4%) Group 2: 9/709 (1.3%) Group 3: 17/722 (2.4%) Group 4: 5/356 (1.4%)	
	<u>Group 3</u> N: 724 Dropouts: 45 <u>Group 4</u>		Number (%) Retrograde ejaculation	Group1: 6/360 (1.7%) Group 2: 10/709 (1.4%) Group 3: 18/722 (2.5%) Group 4: 1/356 (0.3%)	
	<u>Group 4</u> N: 357 Dropouts: 19		Number (%) of at least one Treatment- emergent adverse events	Group1: 93/360 (26.0%) Group 2: 168/709 (24.0%) Group 3: 192/722 (27.0%) Group 4: 71/356 (20.0%)	
			Number (%) at least one treatment-related adverse events	Group1: 40/360 (11.0%) Group 2: 82/709 (12.0%) Group 3: 103/722 (14.0%) Group 4: 25/356 (7.0%)	
			% Responders (defined as patients who had at least a 25%j improvement in total IPSS vs. baseline)	Group1: 71.2% Group 2: 75.4% Group 3: 73.8% Group 4: 60.9%	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Group 1: 7/360 Group 2: 9/709 Group 3: 12/722 Group 4: 3/356	
			adverse events	Group 1: 14/360 Group 2: 11/709 Group 3: 28/722 Group 4: 6/356	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Christensen et al., 1993 ⁴⁷	from Feb 1988-May 1989 referred to the out patient clinics of the 2	Run-in period One week Group 1: alpha-blocker Doxazosin once daily at	Mean (SEM) maximum urinary flow rate (estimated from graph)	Baseline Group1 (n=52): 7.6 (SD 3.7) Group 2 (n=48): 7.5 (SD 3.5) O weeks Group1 (n=46): 7.4	Funding: NR Limitations: Method of
Study design: Randomised controlled trial	Inclusion criteria: All had moderate or severe symptoms resulting from	bed time. 1mg week 1,2mg week 2-5 and 4mg week 6-9.		Group 2 (n=43): 8.0 5 weeks Group1 (n=47): 9.5 (0.7)	allocation concealment unclear.
Setting: Denmark Evidence Ievel: 1+	infravesical obstruction, an obstructive flow curve pattern as determined by uroflowmetry and were candidates for TURP. Exclusion criteria: previous prostatic/bladder neck surgery,	Group 2: Placebo Once daily at bedtime		Group 2 (n=42): 9.1 (0.8) 9 weeks Group1 (n=46): 9.4 (0.7) Median improvement: 1.5 (range: -9.0, 22.0) Group 2 (n=42): 8.0 (0.5) Median improvement: -0.3 (-7.0 to 7.2)	Additional outcomes: Mean urinary flow rate – reported but actual figures not provided. Changes in blood pressure and weight were reported.
Duration of follow-up: 9 weeks	suspicion of prostatic cancer on DRE, non-prostatic obstruction on the urethra, overflow incontinence, renal dysfunction, positive urine cytology, hematuria, urinary infection,		Median reduction in voiding frequency chart (3 days average 24-hour voiding frequencies)	9 weeks Group 1: 2.3 Group 2: 1.2 P=0.005	Notes: Maximum urinary flow rates were estimated from a graph.
	symptomatic hypotension, previous or present cerebrovascular disease, history of intolerance to doxazosin, prazosin or other quinazolines, current treatment with alpha adrenoceptor blocking agents, severe psychiatric or neurologic disease. <u>All patients</u> N: 100 Drop outs: 9 <u>Group 1</u> N: 52 Mean (±SD) Age: 66.7 (7.9)	or present cerebrovascular disease, history of intolerance to doxazosin, prazosin or other quinazolines, current treatment with alpha adrenoceptor blocking agents, severe psychiatric or neurologic	Median (range) baseline and change in frequency (daytime)	Baseline Group1 (n=52): 8 (3/18) Group 2 (n=48): 7 (3/16) Week 9 Group1 (n=48): -1.5 (-9/3) Group 2 (n=43): 0.3 (-7/7) P=0.001	
			Median (range) baseline and change in nocturia	Baseline Group1 (n=52): 2.5 (0/6) Group 2 (n=48): 2.5 (0/7) Week 9 Group1 (n=48): -1.1 (-4/1) Group 2 (n=43): -1.0 (-4/1) P=0.12	
		Baseline and change in residual urine	Baseline Group1 (n=52): 100 (10/450)	1	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Dropouts: 4 (diabetes=1, withdrew consent=2, urinary tract infection=1) Group 2 N: 48 Mean (±SD) Age: 68.1 (7.4) Dropouts: 5 (S- creatinine>130micromoles/I, withdrawn due to side effects=2, urinary retention=1, lost to follow- up=1).	=2, urinary tract infection=1)		Group 2 (n=48): 85 (10/340) Week 9 Group 1 (n=48): -15.0 (-430/150) Group 2 (n=43): -1.0 (-305/355) P=0.56	
			Median (range) Bladder capacity (ml)	Baseline Group1 (n=52): 288 (134/490) Group 2 (n=48): 271 (124/660) Week 9 Group1 (n=48): 0.0 (-228/197) Group 2 (n=43): 3.0 (-297/159) P=0.34	
			Number of symptoms improved (%) - all symptoms pooled for each group	Baseline: Group 1: 239 Group 2: 270 Week 9: Group 1:159 (67) Group 2: 95 (35) P=0.023	
			Number of obstructive symptoms improved (%) - all symptoms pooled for each group	Baseline: Group 1: 177 Group 2: 196 Week 9: Group 1:112 (63) Group 2: 62 (32) P=0.015	
			Number of irritative symptoms improved (%) - all symptoms pooled for each group	Baseline: Group 1: 62 Group 2: 74 Week 9: Group 1:47 (76) Group 2: 33 (45) P=0.12	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Group 1: 11 patients reported 13 events Group 2: 10 patients reported 11 events P=Not sign Dizziness/vertigo Group 1:5 Group 2: 5 (2 withdrew due to	
				dizziness)	
			Patients subjective overall assessment at 9 weeks	Group 1 Much worse: 0/48 Worse: 1/48 Unchanged: 9/48 Better: 28/48 Much better: 10/48 Group 2 Much worse: 1/43 Worse: 0/43 Unchanged: 23/43 Better: 12/28 Much better: 7/43	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Djavan et al., 2005D ⁶⁴	Patient group: Men aged 45 years or over with voiding and storage symptoms diagnosed as LTUS/BPH.	Group 1: Alpha-blocker Tamsulosin oral controlled absorption system 0.4mg	Mean (SD) IPSS symptom scores	Baseline Group1: 18.2 (4.0) Group 2: 18.1 (3.3)	Funding: NR
Study design:	, , , , , , , , , , , , , , , , , , , ,	once daily		Change at endpoint	Limitations: Method of
RCT	Inclusion criteria : After a 2 week placebo run in, men 45 years or	Group 2: Placebo		Group1: -8.0 (5.2) Group 2: -5.6 (4.7)	randomisation and allocation concealment
Setting:	older, with lower urinary tract			Difference: 2.4; p=0.0099	was unclear.
European	symptoms (IPSS: 13 or above				_
multi-centre (3	suggestive of BPH (maximum flow		Mean change in	Group1: 1.1	Additional outcomes:
countries)	rate 4-12ml/s and 2 or more nocturnal voids per night.		nocturia question on IPSS questionnaire	Group 2: 0.7 Difference: 0.4; p=0.028	Analysis of IPSS by sub- group of voiding and
Evidence					storage symptoms.
level:	Exclusion criteria: any other		Mean IPSS quality of	Group1: 2.0	
1+	urological procedures or conditions,		life question reduction	Group 2: 1.3	Notes:
	which may cause LUTS; hepatic or		at endpoint	OR: 2.4; p=0.0087	None.
Duration of	renal insufficiency, clinically		Adverse events	The state and a second and second according	
follow-up: 8 week	significant cardiovascular or cerebrovascular diseases within six		Adverse events	Treatment-emergent adverse events (TEAE)	
o week	months prior to enrolment, central			Group1 (n=61): 10	
	nervous system conditions or life-			Group 2 (n=56): 8	
	threatening diseases. Alcohol			At least one TEAE	
	consumption of more than 15 units			Group1: 5 (8.2%)	
	per week; post voiding residual			Group 2: 7 (12.5%)	
	volume of >250ml in at least two			Dizziness	
	assessment over the last 3 months.			Group1: 2 (3.3%)	
	Patient taking or had taken other			Group 2: 0	
	drugs for BPH; hypersensitive to			Nasopharingitis	
	alpha-blockers, were taking drugs			Group1:0	
	with could interfere with the			Group 2: 2 (3.4%)	
	pharmacodynamics of tamsulosin or			Orthostatic hypotension	
	were taking or had taken over			Group 1: 0	
	investigational drugs within previous 3 months.			Group 2: 0 Discontinuations due to AE	
	o monins.			Group 1:0	
				Group 2: 0	
	All patients		Mean change in total	Group 1: 81 minutes (60%)	-
	N: 117		hours of undisturbed	Group 2: 60 minutes (40%)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean age: 67 <u>Group 1</u> N: 61		sleep (defined as time between falling asleep and first awakening to void)	Difference: 21 minutes; p=0.198	
	Mean (±SD) Age: 66.8 (8.5) Baseline IPSS: 19.0 (5.1) Dropouts: 1 (discontinued due to non compliance) Group 2 N: 56		Mean decrease in nocturnal voids as measured by means of voiding diary (defined as time between falling asleep and first awakening to void)	Group1: 1.0 Group 2: 0.7 OR: 0.56; p=0.099	
	Mean (±SD) Age: 67.6 (7.6) Baseline IPSS: 18.1 (3.5) Dropouts: 0		Questionnaire to assess level of tiredness or alertness during the day (not validated)	Group 1: 0.49 Group 2: 0.32 OR: 0.672; p=.27	
			Correlation between number of nocturnal void and the hours undisturbed sleep	Spearman's rank coefficient: -0.63	
			Correlation between IPSS nocturia and IPSS QoL domains	Spearman's rank coefficient: 0.64	

Lower urinary tract symptoms (LUTS) – full guideline appendices DRAFT (August 2009) 122 of 754

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Fawzy et al., 1995 ⁷⁸	Patient group: normotensive patients (sitting diastolic blood pressure <90mm.Hg) with BPH.	Placebo run-in: 2 weeks	Mean change in AUA6 symptom score	Group1: -5.7 Group 2: -2.5 P<0.001	Funding: Pfizer Limitations:
Study design: RCT	Inclusion criteria: AUA of 10 or greater , maximum urinary flow rate	Group 1: Alpha-blocker Doxazosin: 8 week dose titration phase the initial	Mean change from baseline in Qmax, ml/s	Group1: 2.9 Group 2: 0.7 P<0.01	Method of randomisation and allocation concealment
Setting: Multi- centre, US. Evidence	of 5-15ml/s in a voided volume of 125-500ml and post void residual volume of 250ml or less on 2 consecutive weeks of the placebo	dose of doxazosin was 1mg, increasing to 2mg, 4mg, or 8mg at 2-week intervals until the optimum	Mean change from baseline in average urinary flow rate, ml/s	Group1: 1.4 Group 2: 0.3 P<0.01	unclear. Frequency of nocturia significantly greater in
level: 1+	run in period. aged 45 years or over	dose was attained. During the final 6-week phase of the study the dose was	Percent improvement in patient assessed	Total symptoms Group 1: 39	placebo arm. Additional outcomes:
Duration of follow-up: 16 week	vw-up: veekretention, sever outflow obstruction, or non BPH conditions that caused obstruction or symptoms. Patients who had serious concurrent disease, history of clinically significantoptimum level.41 patients in the stud dosage was titrated to maximally efficacious	held constant at the optimum level. 41 patients in the study dosage was titrated to a maximally efficacious s	symptoms (AUA)	Group 2: 17 Obstructive symptoms Group 1: 43 Group 20 Irritative symptoms Group 1: 35	Graphical presentation of Qmax by week. Intervention arm significantly improved compared to placebo by 2 weeks.
	cardiovascular, hepatic or renal dysfunction, poorly controlled diabetes, urinary calculi or intolerance/sensitivity to quinazoline derivatives.	and/or tolerated, stable level of doxazosin, 36 reached dose of 8mg, 1	Adverse events	Group 2: 15 Total Group 1: 44% Group 2: 30% Events in patients over 65 years	Boyarsky modified score also reported. Notes: None.
	All patients N: 100 Race: 96% white, 2% Asian, 1% Hispanic and 1% Black. Drop outs: 2 (did not undergo any	Group 2: Placebo		Group 1: 28% Group 2: 37% Discontinuation due to adverse events Group 1: 1 Group 2: 0 Dizziness	
	efficacy measurement). Patient withdrawal: 22 Group 1 N: 50			Group 1: 15/50 Group 2: 2/50 Fatigue Group 1: 6/50 Group 2: 2/50	
	Mean (±SD) Age: 62.1 (7.8) Withdrawals: 11 (adverse events –			Headache Group 1: 6/50	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	related and unrelated=7; other=4) Group 2 N: 48 Mean (±SD) Age: 61.6 (8.7) Withdrawals: 11 (adverse events – related and unrelated=1; patient request=3; protocol violation=4; entry criteria not me=1; other=2)			Group 2: 2/50 Somnolence Group 1: 5/50 Group 2: 2/50 Hypotension Group 1: 4/50 Group 2: 0 Nausea Group 1: 4/50 Group 2: 0	
			Mean sitting blood pressure change, mmHg	Group 1: -5.6/-4.1 Group 2: 0.7/-0.4 P<0.05	_
			Mean standing blood pressure change, mmHg	Group 1: -6.0/-4.5 Group 2: 1.9/-0.4 P<0.05	
			Mean change in daytime micturition frequency from patient daily diary	Group 1: -1.3 Group 2: -0.7 P=0.043	
			Mean change in nocturia frequency from patient daily diary	Group 1: -0.5 Group 2: -0.5 P=0.470	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Gillenwater et al., 1995 ⁹⁰	Patient group: men 45 years or older with BPH and mild to moderate essential hypertension.	Screening: 0-4 week period allowed for the discontinuation and	Mean (SD) Qmax at trough and peak measurements, ml/s	Trough Group1: 2mg (n=39): 10.5 (2.1)	Funding: Gillenwater, Conn, Chrysant and Roy and the Multicenter
Study design:		wash out of excluded		4mg (n=46): 9.8 (2.0)	Study Group have
	Inclusion criteria: maximum urinary flow rte of 5-15ml/s in a voided volume of 150-500ml, post void	medication, including any other antihypertensive agents.	Trough defined as assessment approximately 24 hours	8mg (n=45): 10.7 (2.1) 12mg (n=45): 10.5 (2.2) Group 2 (n=41): 10.3 (2.3)	participated in clinical studies sponsored by Pfizer Central Research
Setting: Multi- centre, USA	residual volume of less than 200ml, daytime micturition frequency of 4 or more, nocturia of more than 2	Placebo- run in phase: 2 weeks.	following the previous morning dose. Peak defined as	Peak Group1:	new York. Limitations:
Evidence level: 1+	times per night and a sitting diastolic blood pressure of 90-114 mm.Hg.	Group 1: Alpha-blocker Doxazosin 2, 4, 8 or	assessment 2 -6 hours following administration of medication	2mg (n=39): 10.1 (2.7) 4mg (n=46): 9.4 (2.9) 8mg (n=45):10.3 (2.6)	Method of randomisation and allocation concealment
Duration of follow-up:	Exclusion criteria: Any other conditions casuing urinary symptoms or decreased flow rate, previous or	12mg once daily in the morning. The initial dose was 1mg, increasing		12mg (n=45): 9.7 (2.4) Group 2 (n=41):10.5 (2.6)	unclear. Method states that compliance assessed by
16 weeks	imminent prostatic surgery, prostate specific antigen level greater than 10ng/ml, acute urinary retention, recent catheterisation for outflow	sequentially at weekly intervals during a 5-week titration phase to the randomised, fixed dose	Patients with ≥3ml/s increase in Qmax	Trough Group 1: 8mg: 37% 2mg: 39% Group 2: 13%	tablet count of returned medication – results not reported.
	obstruction or prostate malignancy were excluded from the study. Insulin-dependent or poorly controlled noninsulin-dependent	level. The dose then remained constant during the 9-week efficacy phase.		Peak Group 1:	Additional outcomes: Obstructive and irritative sub-groups results for Boyarsky
	diabetes, significant hepatic, renal or cardiovascular dysfunction; secondary hypertension, concurrent serious disease or malignancy, or	Group 2: Placebo		8mg: 42% 2mg: 51% Group 2: 17% * 2mg and 4mg Not sig.ly different from placebo group	score. Qmax also reported as adjusted mean change.
	significant psychiatric disorders. Intolerance/sensitivity to quinazoline derivatives, substance abuse, recent blood donation, obesity, antihypertensive drug therapy or any treatment known to affect vesicourethral function, and recent		Mean (adjusted) change in average flow rate (* significantly different from placebo p<0.05, ** p<0.01)	Trough Group1: 2mg: 0.6 4mg: 0.6 8mg: 1.5** 12mg: 1.3* Group 2: 0.2	Notes: Boyasrsky score was reversed so that lower scores indicated improvement, as with other commonly used symptom scores.
	therapy with any other investigational drug or any prior			Peak	Treatment effect testec

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	doxazosin therapy. <u>All patients</u> N: 248 Efficacy analysis Group 1: 175			Group1: 2mg: 0.9 4mg: 1.1 8mg: 1.6** 12mg: 2.1** Group 2: 0.2	for significance after adjusting for the baseline effect. Intervention at 1 week of treatment with 1mg
	Efficacy analysis Group 2: 41 Drop outs: 32 (no efficacy follow-up measurements=7; not meet inclusion criterion for maximum urinary flow rate=25). Group 1 N: 199 Efficacy analysis: 175 2mg: 39 4mg: 46 8mg: 45 12mg: 45 Mean (±SD) Age:		BPH symptom questionnaire (modified Boyarsky) mean change from baseline (adjusted for baseline effect) Key: * significantly different from placebo mean changes, p<0.01; \$significantly different from placebo mean changes, p<0.05	End point analysis of severity Group 1 2mg (n=34): -2.8 4mg(n=38): -5.0* 8mg(n=42): -4.2\$ 1 2mg(n=39): -3.6 Group 2 (n=37): -0.25 End point analysis of bothersomeness Group 1 2mg (n=34): -3.4 4mg (n=38):-5.3\$ 8mg (n=42): -4.7 1 2mg (n=39): -4.9 Group 2 (n=37): -3.0	dose - Qmax +0.8ml/s.
	Dropouts: 69 (adverse events 11%, lack of blood pressure efficacy 7%, and protocol violations 9%) Group 2 N: 49 Efficacy analysis: 41 Mean (±SD) Age: 64.5 (7.7) Dropouts:18 (adverse events 4%, lack of blood pressure efficacy 12%, lack of BPH efficacy 4% and protocol violations 10%)		% of patients with adverse events	Total Group 1 (n=199): 48% Group 2 (n=49): 35% Dizziness Group 1 (n=199): 19% Group 2 (n=49): 4% Headache Group 1 (n=199): 14% Group 2 (n=49): 18% Fatigue Group 1 (n=199): 10% Group 2 (n=49): 0% Hypotension Group 1 (n=199): 2.5% Group 1 (n=199): 2.5% Group 1 (n=199): 11.1% Group 1 (n=199): 11.1% Group 2 (n=49): 4.1%	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Hansen et al., 1994 ¹⁰¹ Study design: RCT	Patient group: Men with BPH enrolled from November 1991 to March 1993. Inclusion criteria: Madsen- lversen symptom score >6;	Run-in phase: All patients entered a four week placebo run-in phase. Single blind.	Median (25% and 75% quartiles) Madsen- Iversen symptom score	Baseline Group 1: 7 (6-8.5) Group 2: 7 (6-9) 12 weeks Group 1: 5 (3.5-7) Group 2: 6 (5-7.5)	Funding: Research grant from Synthelabo International. Limitations:	
Setting: Multi- centre, Denmark and Netherlands Evidence	urinary peak flow rate <10ml/s with a voided volume of at least 100ml. Men with very low urinary flow rates were included.	Group 1: Alpha- blocker Alfuzosin 2.5mg TID Group 2: Placebo Three times a day	Median (25% and 75% quartiles) peak flow rate, ml/s	Baseline Group1: 9 (7-11) Group 2: 9 (7-11) 12 weeks Group1: 11 (7.6-13.5) Group 2: 10 (8-11)	Method of randomisation and allocation concealment was not reported. Additional outcomes:	
level: 1+ Duration of follow-up: 12 weeks	Exclusion criteria: patients whose digital rectal examination suggested presence of prostatic cancer, or patients suffering from other urological diseases such as neurogenic bladder, urethral	eria: patients rectal uggested rostatic cancer, or ing from other rases such as	a digital rectal M ination suggested nce of prostatic cancer, or nts suffering from other gical diseases such as	Median (25% and 75% quartiles) residual urinary volume, ml	Baseline r Group 1: 50 (20-89) s Group 2: 42 (20-100) s 12 weeks i	Blood pressure reported. Small but significant decrease in diastolic blood pressure in alfuzosin group compared to placebo.
	stricture, current urinary tract infection, macroscopic or microscopic hematuria, prostatitis or previous prostatectomy were excluded. Incidence of total urinary retention, history of bladders tones, repeated urinary tract infections, overflow incontinence, azotemia, abnormal acid phosphatise, a history of orthostatic hypotension or know hypersensitivity to alpha-		Adverse events – vasodilatory events	Dizziness Group 1: 3 Group 2: 0 Headache Group 1: 2 Group 2: 2 Postural hypotension Group 1: 1 Group 2: 0 Fatigue Group 1: 1 Group 2: 1 Syncope Group 1: 2 Group 2: 0	Notes: None	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	blockers. All patients: N: 205 Mean age: 45-81 Group 1 N: 104 (91 completed study) Median (±SD) Age: 65 (47- 81) Withdrawals: 5 (lost to follow- up=1; adverse event=1; other=3) Group 2 N: 101 (87 completed study) Median (±SD) Age: 64 (45- 81) Withdrawals: 12 (lack of efficacy=4; lost to follow- up=2; adverse events=1; other=5)		Adverse events – gastro-intestinal disorders	Nausea Group 1: 2 Group 2: 1 Diarrhoea Group 1: 4 Group 2: 1 Vomiting Group 1: 0 Group 2: 0 Pyrosis Group 1: 1 Group 2: 0 Abdominal pain Group 1: 5 Group 2: 0 Obstipation Group 1: 0 Group 2: 1 Flatulence Group 1: 1 Group 2: 0 Haematemesis Group 1: 1	
			Adverse events – urinary tract disorders	Group 2: 0 Cystitis Group 1: 1 Group 2: 0 Urinary tract infection Group 1: 0 Group 2: 0 Hameatura Group 1: 0 Group 2: 0	
			Other adverse events (including pain in arm, lympth disease, pneumonia, hypertension)	Group 1: 2 Group 2: 9	
			Discontinuation due to adverse events	Group 1: 1 Group 2: 1	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Kaplan et al., 2006 ¹¹⁹	Patient group: Men with overactive bladder or other LUTS recruited between Nov 2004 – Feb 2006	Group 1: Tolterodine ER 4mg/day in evening	Number of patients reporting treatment benefit at 12 weeks (ITT	Grp 1: 136/217 Grp 2: 146/215 Grp 3: 172/25	Funding: Pfizer
Study design: RCT NCT0014765 4 Double blind Patients, investigators	 Setting: multi-centre, USA Inclusion criteria: ≥ 40 years IPSS ≥ 12 Self-rated bladder condition of 'some 	Group 2: Tamsulosin 0.4 mg/day in evening Group 3: Tolterodine ER 4mg + Tamsulosin 0.4 mg/day in evening	post hoc figures with imputed data) Pair wise analysis using Fishers 2 sided test	Grp 4: 132/222 Grp 1 v Grp 4 p value 0.49 Grp 1 v Grp 2 p value 0.27 Grp 1 v Grp 3 p value 0.02 Grp 2 v Grp 4 p value 0.07 Grp 2 v Grp 3 p value 0.06 Grp 3 v Grp 4 p value 0.01	Limitations: Outcome measures with standard deviations were not reported. Notes:
and researchers masked to treatment allocation Evidence level: 1+	 moderate problems', 'severe problems' or 'many severe problems' based on the validated Patient Perception of Bladder Condition question. Micturition frequency ≥8/24 hrs and urgency ≥ 3/24 hrs for ≥ 3 months Exclusion criteria: Clinically significant bladder outlet 	Group 4: Placebo in evening Examination methods: A Perception of Treatment Benefit question was posed at weeks 1, 6 and 12. "Have you had any benefit from your	Change in urgency episodes/24h from baseline at 12 weeks (estimated from graph) Analysis of covariance with covariates – treatment, centre, PVR, Qmax and baseline value	Grp 1: -2.9 ± NR Grp 2: -2.4 ± NR Grp 3: -3.3 ± NR Grp 4: -2.5 ± NR Grp 1 v Grp 4 p value Not sig. Grp 2 v Grp 4 p value Not sig. Grp 3 v Grp 4 p value =0.03	Sample size based of projected treatment difference of 15% between Tolterodine ER + Tamsulosin grou compared to placeb for number of patier reporting treatment benefit at week 12.
Duration of follow-up: 3 months	 obstruction defined as PVR ≥200 mL and Qmax < 5 mL/s Serum PSA > 10 ng/mL with risk of prostate cancer History of postural hypotension or syncope Significant hepatic or renal disease Neurological conditions such as MS, spinal cord injury and Parkinson disease Prostate cancer Prostate surgery or other intervention 	treatment? – YES/NO" and if so "How much benefit (little/a lot)?" Bladder diaries for 5 days were assessed prior to each visit at baseline and weeks 1, 6 and 12. IPSS measured at baseline and weeks 1, 6	Change in micturitions/24h from baseline at 12 weeks (estimated from graph) Analysis of covariance with covariates – treatment, centre, PVR, Qmax and baseline value	Grp 1: -1.7 ± NR Grp 2: -1.8 ± NR Grp 3: -2.5 ± NR Grp 4: -1.4 ± NR Grp 1 v Grp 4 p value Not sig. Grp 2 v Grp 4 p value Not sig. Grp 3 v Grp 4 p value <0.001	Randomisation sequence using block method prepared b statistician. Study medication kit were identical in appearance and smell. Missing data impute
	 History of acute urinary retention requiring catheterisation BOO due to diseases other than BPH Any condition for which antimuscarinics are contraindicated Men treated with alpha-blockers with 2 	and 12. PVR and Qmax measured at baseline and at week 12.	Change in micturitions/night from baseline at 12 weeks (estimated from graph) Analysis of covariance with covariates – treatment, centre, PVR,	Grp 1: $-0.36 \pm NR$ Grp 2: $-0.54 \pm NR$ Grp 3: $-0.59 \pm NR$ Grp 4: $-0.39 \pm NR$ Grp 1 v Grp 4 p value Not sig.	for treatment benef question (YES/NO), bladder diary variables, IPSS and IPSS QoL using Last observation carried forward (LOCF)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	weeks or antimuscarinics, phytotherapy or electrical stimulation within 1 month, any investigational drug within 2 months or 5-		Qmax and baseline value	Grp 2 v Grp 4 p value Not sig. Grp 3 v Grp 4 p value=0.02	
	alpha reducatase within 3 months <u>All patients</u> N: 879 Mean age: 62 ± 10 (40-92) White: 83%. <u>Group 1 (Tolterodine ER)</u> N: 217 (baseline data/efficacy analysis for N=210)		Change in IPSS from baseline at 12 weeks (estimated from graph) Analysis of covariance with covariates – smoking status, age, baseline score, duration of OAB, centre	Grp 1: -6.7 ± NR Grp 2: -7.6 ± NR Grp 3: -8.0 ± NR Grp 4: -6.1 ± NR Grp 1 v Grp 4 p value Not sig. Grp 2 v Grp 4 p value <0.01 Grp 3 v Grp 4 p value =0.003	
	Mean (\pm SD) Age: 61.8 \pm 9.6 (range 41-91) Urgency episodes/24h: 7.58 \pm 3.49 Micturitions/24h: 11.79 \pm 2.83 Micturitions/night: 1.97 \pm 1.27 IPSS \pm SD: 19.53 \pm 5.15 IPSS QoL \pm SD: 4.57 \pm 0.94 Qmax \pm SD, mL/s: 13.3 \pm 7.8 PVR \pm SD, mL: 50.5 \pm 55.8 Dropouts: 28/217 (12.9%) 1 patient did not receive study medication		Change in IPSS QoL from baseline at 12 weeks (estimated from graph) Analysis of covariance with covariates – smoking status, age, baseline score, duration of OAB, centre	$ \begin{array}{c} -0.003 \\ \hline \mbox{Grp 1: } -1.4 \pm NR \\ \mbox{Grp 2: } -1.4 \pm NR \\ \mbox{Grp 3: } -1.6 \pm NR \\ \mbox{Grp 4: } -1.2 \pm NR \\ \mbox{Grp 1 v Grp 4 p value Not} \\ \mbox{sig.} \\ \mbox{Grp 2 v Grp 4 p value Not} \\ \mbox{sig} \\ \mbox{Grp 3 v Grp 4 p value} \\ \mbox{= 0.003} \end{array} $	
	$\label{eq:spectral_states} \begin{array}{l} \hline \textbf{Group 2 (Tamsulosin)} \\ \textbf{N: } 215 (baseline data/efficacy analysis for \\ N=209) \\ \hline \textbf{Mean (\pm SD) Age: } 61.7 \pm 10.5 (range 40-90) \\ \hline \textbf{Urgency episodes/24h: } 7.10 \pm 3.83 \\ \hline \textbf{Micturitions/24h: } 12.10 \pm 3.51 \\ \hline \textbf{Micturitions/night: } 1.74 \pm 1.20 \\ \hline \textbf{IPSS \pm SD: } 20.04 \pm 5.02 \\ \hline \textbf{IPSS QoL \pm SD: } 4.57 \pm 0.86 \\ \hline \textbf{Qmax \pm SD, mL/s: } 13.4 \pm 7.6 \\ \hline \end{array}$		Change in Qmax from baseline at 12 weeks Analysis of covariance with covariates – centre, treatment, baseline value	Grp 1: -0.60 ± NR Grp 2: -0.22 ± NR Grp 3: 0.07 ± NR Grp 4: -0.53 ± NR Grp 1 v Grp 4 p value Not sig. Grp 2 v Grp 4 p value Not sig Grp 3 v Grp 4 p value Not sig	
	PVR ± SD, mL: 56.5 ± 55.0 Dropouts: 29/215 (13.5%)		discontinuation	Grp 1Grp 2Grp 3Grp 421621522522057207	

Study details	Patients	Interventions	Outcome measures		Effe	ct size		Comments
	$ \begin{array}{l} \hline \textbf{Group 3 (Tolterodine ER + Tamsulosin)} \\ \textbf{N:} 225 (baseline data/efficacy analysis for N=217) \\ \textbf{Mean (\pm SD) Age: } 61.0 \pm 9.6 (range 40-92) \\ \textbf{Urgency episodes/24h: } 6.72 \pm 3.95 \\ \textbf{Micturitions/night: } 2.07 \pm 1.32 \\ \textbf{IPSS \pm SD: } 20.10 \pm 5.49 \\ \textbf{IPSS QoL \pm SD: } 4.55 \pm 0.93 \\ \textbf{Qmax \pm SD, mL/s: } 12.7 \pm 6.8 \\ \textbf{PVR \pm SD, mL: } 58.8 \pm 53.8 \\ \textbf{Dropouts: } 34/225 (15.1\%) \\ \textbf{Mean (\pm SD) Age: } 62.8 \pm 9.7 (range 40-88) \\ \textbf{Urgency episodes/24h: } 7.33 \pm 3.82 \\ \textbf{Micturitions/night: } 2.02 \pm 1.19 \\ \textbf{IPSS QoL \pm SD: } 4.58 \pm 0.95 \\ \textbf{Qmax \pm SD, mL/s: } 12.2 \pm 6.6 \\ \textbf{PVR \pm SD, mL / 1 \pm 47.7} \\ \textbf{Dropouts: } 34/222 (15.3\%) 2 \text{ patients did not receive study medication} \\ \end{array} $		Adverse event Lack of efficacy Withdrew consent Protocol deviation Lost to follow up Death Other All cause adverse events N Constipation Diarrhoea Dizziness Dry mouth Dyspepsia Ejaculation failure Fatigue Headache Rhinitis Somnolence Urinary retention	9 2 1 1 1 2 16 9 7 3 16 2 0 2 0 2 0 2	0 9 4 0 5 Grp 2 215 2 6 12 15 1 4 3 9 3 5 0	4 2 0 6 0 2 Grp 3 225 8 5 6 47 3 7 2 14 10 4 2	7 5 4 4 0 5 Grp 4 220 5 3 2 5 5 0 6 7 2 2 3	

Study details	Patients	Interventions	Outcome measures		Effec	t size		Comments		
Kirby et al., ¹²⁹ Study design:	Patient group: Symptomatic BPH Inclusion criteria:	Group 1: Doxazosin 4 mg(+ placebo) Initiated on 1 mg/day, titrated to 2 mg at	year Group 2: 10. Group 3: 8.7					Funding: Grant provided by Pfizer Ltd. Finasteride &		
RCT double blinded(4 arms) Setting: 90 European centres	 Aged 50 to 80 years IPSS≥ 12 Qmax of ≥5 mL/s but ≤15 mL/s in a total voided volume of ≥150 mL Enlarged prostate as determined by DRE. 	mg from end of week 6. At the end of week 10, the 4-mg dose was maintained in subjects	At the end of week 10, the 4-mg dose was maintained in subjects	IPSS LS mean change ±SEM at 1 year	Compare Group 1: Group 2: Group 3: Group 4: ##P<0.00	<u>d to baselin</u> -8.3 ± 0.4 [#] -6.6 ± 0.4 -8.5 ± 0.4 [#] -5.7 ± 0.4	## ## ed to place	bo, <0.01	placebo provided by Merck & Co Limitations: Randomisation allocation and concealment methods	
Evidence level: 1+ Duration of follow-up: 1 year(52) weeks) Prostate cancer or a PSA level exceeding 10 ng/mL. If PSA was between 4.1 to 10 ng/mL, need to have ≥2 of the following : negative DRE or transrectal	who met the following two criteria: (a) total IPSS had decreased by 30% or more from baseline, and(b) Qmax had increased by 3 mL/s or more from baseline. For subjects who did not meet these goals, the doxazosin dose was	Qmax, ml/s mean ±sd at 1 year Qmax, ml/s change from baseline at endpoint, LS mean change ±sem	Group 2: Group 3: Group 4: Group 1: Group 2: Group 3: Group 4:	3.8 ± 0.3 # 1.4 ± 0.3 01 compar		bo or	not stated. Additional outcomes: Mean change in sitting and SBP and DBP: Normotensive subjects: Not sig Hypertensive subjects			
	 ultrasound findings(within the past 3 months) or negative biopsy findings(within the past 4 weeks) lower urinary tract symptoms or reduced urinary flow rates resulting from a condition other than BPH large bladder diverticulum, bladder stones, recurrent urinary tract infection, or two or more episodes of AUR requiring catheterization within the year 	increased to 8 mg/day and	increased to 8 mg/day and maintained for the remaining 42 weeks. Doses were reduced to the next lower dose if the SBP/diastolic BP(DBP) fell to less than 90/60 mm Hg or tolerability was limited. Subjects unable to tolerate a 2-	increased to 8 mg/day and maintained for the remaining 42 weeks. Doses were reduced to the next lower dose if the SBP/diastolic BP(DBP) fell to less than 90/60 mm Hg or tolerability was limited. Subjects unable to tolerate a 2-	Reason for withdrawal Total withdrawals Reasons Adverse Events Death** Inadequate response Noncompliance Protocol violation Failed screening guidelines Other therapy indicated Lost to follow-up Other	32(11.6) 0(0.0) 3(1.1) 7(2.5) 5(1.8) 3(1.1) 5(1.8) 4(1.5)		Grp 3 89(31.1) 35(12.2) 1(0.3) 3(1.0) 6(2.1) 6(2.1) 1(0.3) 6(2.1) 5(1.7) 26(9.1)		(sitting DBP≥90mmHg, SBP≥140mmHg): LS mean change (sitting SBP/DBP, mmHg) for doxazosin: -11.8/- 5.7 Doxazosin + finasteride: -9.2/-5.6 (P<0.05, clinically sig)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	 before study entry residual urine volumes greater than 200 ml Active urinary tract infection. Serious diseases History of drug or alcohol abuse History of sensitivity to alpha- adrenergic blocking agents, quinazolines, or finasteride. Hypotension(sitting BP less than 95/60 mm Hg) or orthostatic hypotension(greater than a 20- mm Hg decrease in systolic BP [SBP] when changing from a supine to standing position Concomitant therapy with anticholinergics, cholinergics, other olpha-blockers, calcium channel blockers, antiandrogens, other 5-alpha-reductase inhibitors, and plant extract preparations was prohibited during the study. All patients N: 1095(79.5%) out of 1378 screened Age, mean ±sd, (yr): 64 IPSS mean ± sd: 17.2 Qmax, ml/s mean±sd: 10.5 Mean PSA, ng/ml, mean= 2.6 Prostate volume, g, mean= 36.3 Drop outs: Group 1(Doxazosin) doxazosin were withdrawn. doxazosin 4 doxazosin 4 mg + finasteride 5 mg Mean final dose: 6.1 mg/day Broup 3: Doxazosin 4 mg + finasteride 5 mg Mean Finateride 5 mg Mean PSA, ng/ml, mean= 2.6 Prostate volume, g, mean= 36.3 Drop outs: Group 1(Doxazosin) Concomitant 	withdrawn. Mean final dose: 6.4mg/day 8mg: 63.2% 4mg: 31.2% 2 mg: 4.8% 1 mg: 0.8%	AUR TURP Either AUR or TURP Dizziness	1(0.4) 3(1.1) 0(0) 7(2.6)	For Finasteride: -5.7/- 2.7 Placebo: -4.0/-2.1 Not sig Notes: Analysis of covariance was used for efficacy data,
		Orthostatic r than a 20- systolic BP g from a position by withGroup 2: Finasteride 5mg(+ placebo)Group 3: Doxazosin 4 mg + finasteride 5 mg Mean final dose: 6.1mg/day 8mg: 57.0% 4mg: 35.5% 2 mg:6.0% 1 mg:1.5%of 1378Group 4: placebo for terazosin and placebo for finasteride All subjects advised to take medications at about 8am	Postural hypotension Hypertension	Group 1: 16/275(5.8%)# Group 2: 2/264(0.8%) Group 3: 8/286(2.8%) Group 4: 4/269(1.5%) P<0.01 vs. finasteride and placebo Group 1: 5/275(1.8%)# Group 2: 11/264(4.2%)	which included effects of treatment, centre(pooled by country), and treatment by centre interaction
			Hypotension	Group 3: 4/286(1.4%)# Group 4: 15/269(5.6%) P=0.02 vs. placebo. Group 1: 14/275(5.1%)# Group 2: 2/264(0.8%) Group 3: 8/286(2.8%) Group 4: 4/269(1.5%)	 carried forward algorithm was used for subjects who discontinued early. *No overall baseline differences were found except for Qmax. †P <0.0001 vs. placebo. ‡P _<0.09 vs. finasteride.
			Syncope	Group 4: 4/209(1.3%) P=0.01 vs. finasteride & placebo Group 1: 2/275(0.7%) Group 2: 0/264(0.0%) Group 3: 6/286(2.1%)# Group 4: 1/269(0.4%) P=0.04 vs. finasteride	
		Asthenia	Group 1: 29/275(10.5%) # Group 2: 11/264(4.2%) Group 3: 26/286(9.1%) # Group 4: 11/269(4.1%) P<0.01 vs. finasteride & placebo	 §Estimated by DRE(in increments of 5 g). ** Excludes one post therapy death, which 	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments							
	N: 250 Dropouts: Age, mean ±sd,(yr): 63 ±7 Dropouts: Duration of BPH at baseline,		Somnolence	Group 1: 11/275(4.0%) Group 2: 8/264(3.0%) Group 3: 9/286(3.1%) Group 4: 6/269(2.2%) Not sig	occurred approximately 35 days after discontinuation of doxazosin therapy							
	mean(yr): 1.7 ± 2.9 Prostate Vol by DRE,(g)§: 36 ± 14 IPSS mean ± sd: 17.1 ± 4.2 Qmax(ml/s): 10.4 ± 2.5†‡ PSA serum, mean(ng/ml): 2.5 ± 2.0					Vertigo	Group 1: 8/275(2.9%) Group 2: 6/264(2.3%) Group 3: 8/286(2.8%) Group 4: 3/269(1.1%) Not sig					
	Group 2(Finasteride) N: 239 Dropouts: Age, mean ±sd,(yr): 63 ±7 Duration of BPH at baseline,		Impotence	Group 1: 16/275(5.8%) Group 2: 13/264(4.9%) Group 3: 30/286(10.5%)#‡ Group 4: 9/269(3.3%) P<0.01 vs. finasteride, finasteride and doxazosin								
	mean(yr) = 1.4 ± 2.2 Prostate Vol by DRE,(g)§: 36 ± 14 IPSS mean ± sd: 17.1 ± 4.4 Qmax(ml/s): 10.2 ± 2.5† PSA serum, mean(ng/ml): 2.6 ± 2.1		Decreased libido	Group 1: 10/275(3.6%) Group 2: 9/264(3.4%) Group 3: 6/286(2.1%) Group 4: 5/269(1.9%) Not sig								
	<u>Group 3: Terazosin 10 mg +</u> <u>finasteride 5 mg</u> N: 265 Dropouts:		Ejaculatory abnormality	Group 1: 1/275(0.4%) Group 2: 6/264(2.3%) Group 3: 7/286(2.4%) Group 4: 4/269(1.5%) Not sig								
	Age, mean \pm sd,(yr): 64 \pm 7 Duration of BPH at baseline, mean(yr) = 1.8 \pm 2.9 Prostate Vol by DRE,(g)§: 37 \pm 14 IPSS mean \pm sd 17.3 \pm 4.7		PSA at end point , mean±sd ng/ml	Group 1: 2.8 ± 2.3 Group 2: 1.5 ± 1.0 Group 3: 1.4 ± 1.2 Group 4: 2.9 ± 2.6								
	Qmax (ml/s): 10.4 ± 2.7† PSA serum, mean(ng/ml): 2.7 ± 2.3								ba	PSA change from baseline at endpoint , mean ±sd ng/ml	Group 1: 0.3 ± 1.0 Group 2: 1.2 ± 1.4 Group 3: 1.3 ± 1.6 Group 4: 0.3 ± 1.3	
	Group 4: placebo for terazosin and placebo for finasteride N: 253 Dropouts:								Group 4: 0.3 ± 1.3			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Age Mean(\pm SD): 64 \pm 7 Duration of BPH at baseline, mean(yr) = 1.6 \pm 3.0 Prostate Vol by DRE,(g)§: 36 \pm 15 IPSS mean \pm sd: 17.2 \pm 4.5 Qmax(ml/s): 10.8 \pm 2.5 PSA serum, mean(ng/ml): 2.6 \pm 2.1				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Martorana et al., 1997 ¹⁶⁰ Study design: RCT	Patient group: Men with clinical diagnosis of BPH. Inclusion criteria: Men aged 50-80 years with a clinical diagnosis of BPH confirmed by digital rectal examination and transrectal	 Alfuzosin2.5mg t.i.d. Alfuzosin2.5mg t.i.d. Alfuzosin2.5mg t.i.d. Alfuzosin2.5mg t.i.d. Group 2: Placebo 	Mean (±SEM) Qmax, ml/s	Baseline Group1: 10.55 (0.43) Group 2: 10.4 (0.50) 4 weeks Group1 (n=25): 13.16 (0.80) Group 2 (n=25): 11.75 (0.62) P=NS	Funding: NR Limitations: ITT analysis completed but only the per- protocol analysis
Setting: Multi-centre Evidence level: 1+	examination and transrectal ultrasound examination showing prostate enlargement,; at least a 6 month history of BPH related symptoms with a 9-item Boyarsky score>6 before entry and after placebo run-in; peak flow rate between 5-12ml/s with a voided volume>150ml. Exclusion criteria: concomitant urological diseases, had undergone prostatectomy or were scheduled to have prostatectomy within 6 months had systolic blood pressure<100,,Hg or history off orthostatic hypotension, had either renal or severe hepatic insufficiency, a psychiatric disorder, insulin dependent diabetes mellitus, history of sever heart disease, myocardial infarction or cerebrovascular accident within 6 months, had		Mean (±SEM) flow, ml/s	Baseline Group 1: 5.92 (0.34) Group 2: 6.30 (0.43) 4 weeks Group 1 (n=25): 7.80 (0.70) Group 2 (n=24): 6.90 (0.47) P=NS	reported in the study. This is the patient population that complied with the selection criteria and with the complete urodynamic evaluation
Duration of follow-up: 4 weeks			Mean (±SEM) maximum flow rates, ml/s (from pressure/flow study)	Baseline Group 1: 7.76 (0.44) Group 2: 8.52 (0.57) 4 weeks Group 1 (n=25): 10.01 (0.91) Group 2 (n=26): 10.26 (0.92) P=NS	at baseline and end point. Additional outcomes: Detrusor opening pressure and maximum detrusor pressure reported.
			Mean (±SEM) detrsor pressure at maximum flow, cmH20 (pressure/flow study)	Baseline Group 1: 77.88 (5.61) Group 2: 82.27 (5.91) 4 weeks Group 1 (n=25): 54.36 (4.97) Group 2 (n=26): 76.84 (7.78) P<0.05	Reported that blood pressure and heart rate measurement found no statistically significant changes.
	hypersensitivity to afluzosin, had treatment with other drugs for BPH during the 2 weeks prior to inclusion, or concomitant treatment with other alpha-blockers, calcium antagonists, monoamine oxidase inhibitors or anticholinergic drugs.		Mean (SEM) Boyarsky score	Baseline Group 1: 10.7 (0.7) Group 2: 10.5 (0.5) 4 weeks Group 1 (n=25): 8.0 (0.4) Group 2 (n=26): 8.0 (0.5) P=NS	2 week placebo run-in phase before trial. After double blind study there was an 8 week single blind treatment extension study.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	All patients N: 94 Group 1 N: 47 Evaluable for efficacy analysis: 26 Mean (±SD) Age: 62.5 (1.0) Dropouts: 21 (10 lack of complete urodynamic evaluation; 6 lack of compliance with selection criteria at baseline; 5 lack of compliance with protocol treatment requirements; 1 lack of correspondence between treatment drug and blood detection; 2 lost to follow up; 1 lack of uroflowmetric evaluation. Group 2 N: 47 Evaluable for efficacy analysis: 26 Mean (±SEM) Age: 63.1 (1.1) Dropouts: 21 (9 lack of complete urodynamic evaluation; 8 lack of compliance with selection criteria at baseline; 2 lack of compliance with selection criteria at baseline; 2 lack of compliance with selection, 8 lack of compliance with selection, 2 lost to follow up. Note: 5 patients had two reasons and 1 had three reasons of non evaluability.		Adverse events	Total Group 1: 4/47 (8.5%) Group 2: 1/47 (2.1%) Hypertension Group 1: 1(2.1%) arthralgia Group 1: 1(2.1%) Group 2: 0 Vertigo Group 1: 1(2.1%) Group 2: 0 Pathological fracture Group 1: 1(2.1%) Group 2: 0	

- See Evidence Table 2: How does PSA predict symptom progression (in terms of symptom score)?
- 3 for McConnell et al., 2003¹⁶⁶.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Mohanty et al., 2003 ¹⁷⁶ Study design:	Patient group: male patients between 40-80years having lower urinary tract obstructive symptoms suggestive of BPH were recruited.	Group 1: ALPHA- BLOCKER Tamsulosin 0.4mg daily (sustained capsules)	Mean (SD) IPSS	Baseline Group1: 19.53 (3.2) Group 2: 18.52 (5) 2 weeks	Funding: NR
RCT	Inclusion criteria: IPSS>10,	Group 2: PLACEBO		Group1: 12.67 (4.3) Group 2: 15.3 (4.7)	Additional outcomes: Vital signs reported.
Setting: India Evidence	maximum flow rate 5-13mL/s and average flow rate<6mL/s with post residual urine volume >100mL and	ldentical capsules once daily		4 weeks Group1: 9.8 (4.4) Group 2: 13.8 (4.8)	Notes: Adverse events
level: 1+	PSA<4ng/mL Exclusion criteria: patients with			8 weeks Group1 (n=36): 6.9 (4.4) Group 2 (n=33): 12.7 (4.0)	reported at end point but study included figures for each time
Duration of follow-up: 2 months	renal or hepatic failure, carcinoma prostate, stricture urethra, neurogenic bladder, bladder neck stenosis, previous surgery on prostate	oma	Mean (SD) Qmax, mL/s		interval.
	All patients N: 72 Mean age: 61 years Drop outs: 3 Group 1		Average urinary flow rate, mL/s	Baseline Group 1: 4.5 (1.5) Group 2: 5.3 (1.7) 8 weeks Group 1 (n=36): 7.7 (2.1) Group 2 (n=33): 5.8 (1.7)	
	N: 38 Mean (±SD) Age: 61.3 (8.5) Dropouts:2 Group 2 N: 34		Maximum voided volume, mL	Baseline Group1: 341.7 (137.6) Group 2: 310.3 (105.4) 8 weeks Group1 (n=36): 353.1 (154.3) Group 2 (n=33): 336.9 (149.4)	
	Mean (±SD) Age: 62.7 (13.8) Dropouts:1		Mean (SD) post voided residual volume, mL	Baseline Group1: 100.6 (46) Group 2: 97.6 (46.4) 8 weeks Group1 (n=36): 53.1 (19.2) Group 2 (n=33): 91.8 (40.1)	

A	Dizziness
Adverse events at end	
point	Group 1: 9
	Group 2: 11
	Headache
	Group 1:8
	Group 2: 9
	Fatigue
	Group 1:14
	Group 2: 14
	Postural hypotension
	Group 1: 2
	Group 2: 0
	Syncope
	Group 1: 1
	Group 2: 0
	Somnolence
	Group 1: 1
	Group 2: 1
	Abdominal pain
	Group 1: 2
	Group 2: 1
	Dyspnea
	Group 1: 0
	Group 2: 3
	Retrograde ejaculation
	Group 1: 0
	Group 2: 0
	Constipation
	Group 1:7
	Group 2: 0
	Withdrawn due to adverse events
	Group 1:0
	Group 2: 0

Study details	Patients	Interventions	Outcome measures	Effect size	Comments		
Nordling et al., 2005 ¹⁹⁴	Patient group: Men were recruited between Feb 1998 and August 1999.	Run in period: 28 day single blind, placebo run in period. One placebo	Mean (SD) IPSS	Baseline Group1: 18.0 (5.4) Group 2: 17.4 (5.6)	Funding: NR.		
Study design: RCT	Inclusion criteria: men aged ≥50 years with a clinical diagnosis of	tablet matching Alfuzosin 10mg and one matching Tamsulosin 0.4mg at the		Group3: 17.4 (6.2) Group 4: 17.7 (5.0) Change from baseline	Limitations: Method of randomisation and allocation concealment		
Setting: Multi-centre,	symptomatic BPH and at least a 6 month history of LUTS, with all the	end of the evening meal.		Group 1: -6.5 (5.2); p=0.007 Group 2: -6.0 (5.6); p=0.050	not reported.		
Europe and Israel	following criteria met only a the beginning of the placebo run-in	Group 1: Alpha-blocker Alfuzosin 10mg once daily		Group 3: -6.5 (6.2); p=0.014 Group 4: -4.6 (5.8)	Additional outcomes: Blood pressure changes		
Evidence level:]+	period: an IPSS of \geq 13, nocturia twice or more, a peak flow rate of 5-12ml/s for a voided volume of 150mL or more, and a residual urine volume of 350mL or less. Patients	 (one tablet plus one placebo tamsulosin capsule) Group 2: Alpha-blocker Alfuzosin 1 5mg once daily (one tablet plus one placebo tamsulosin capsule) Group 3: Alpha-blocker Tamsulosin 0.4mg once daily (one capsule plus one placebo alfuzosin tablet) Group 4: Placebo One placebo alfuzosin tablet plus one placebo tamsuosin capsule. At the end of the evening meal 	% of patients with a total IPSS improvement (defined as 3 or more points)	Group 1: 81 Group 2: 69 Group 3: 77 Group 4: 64	were reported. Standard laboratory test results were taken but the study did not report figures but stated		
Duration of follow-up: 12 weeks	were not required to these criteria again at the time of randomisation, simulating real-life practice.		ria Alfuzosin 15mg once daily (one tablet plus one placebo tamsulosin capsule) or state; sive daily (one capsule plus one	Mean (SD) Qmax, mL/s	Baseline Group1: 9.2 Group 2: 8.9	no significant changes.	
	Exclusion criteria: concomitant urological diseases; diagnosed or suspected carcinoma of the prostate; previous prostate surgery; invasive BPH treatments; previous x-ray therapy of the pelvic region; patients previously showing no			Group 3: Alpha-blocker Tamsulosin 0.4mg once daily (one capsule plus one placebo alfuzosin tablet)	Group 3: Alpha-blocker Tamsulosin 0.4mg once daily (one capsule plus one placebo alfuzosin tablet)		Group3: 9.4 Group 4: 9.0 Change from baseline Group1: 1.5 (3.3) ; p=0.22 Group 2: 1.6; (3.8) p=0.09 Group3: 2.4 (4.3); p=0.02 Group 4: 0.9 (3.0)
	improvement with treatment with an alpha-blocker; patients with Parkinson's disease, insulin- dependent diabetes, diagnosed or suspected MS, unstable angina or sever heart failure, history of stroke or myocardial infarction within 5 months of day -28 of day 0, known hypersensitivity to alpha blockers or patients taking concomitant medications that might alter voiding		Number (%) adverse events (AE)	Treatment emergent (TE) AE≥ one Group 1: 58 (38) Group 2: 61 (39) Group 3: 58 (37) Group 4: 52 (34) TEAE ≥ one serious Group 1: 3 (2) Group 2: 7 (4) Group 3: 6 (4) Group 4: 3 (2)			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	patterns.			Group 1: 4 (3)	
				Group 2:13 (8)	
	All patients			Group 3: 6 (4)	
	N: 625			Group 4: 5 (3)	
	Patients in ITT analysis: 611			Discontinuation because of serious	
	Dropouts: 47			vasodilatory TEAE	
				Group 1: 0	
	Group 1			Group 2: 1(1)	
	N: 154			Group 3: 1 (1)	
	Mean (±SD) Age: 65 (51-85)			Group 4: 0	
	Dropouts: 9 (adverse events=4;			Dizziness	
	other=5)			Group 1: 9 (6)	
				Group 2: 11 (7)	
	Group 2			Group 3: 3 (2)	
	N: 159			Group 4: 6 (4)	
	Mean (±SD) Age: 65 (50-84)			Headache	
	Dropouts: 17 (adverse events=14;			Group 1: 3 (2)	
	other=3)			Group 2: 4 (3)	
				Group 3: 7 (4)	
	Group3			Group 4: 5 (3)	
	N: 158			Syncope	
	Mean (±SD) Age: 64 (50-87)			Group 1: 0	
	Dropouts: 9 (adverse events=6,			Group 2: 2 (1)	
	other=3)			Group 3: 1 (1)	
				Group 4: 0	
	Group 4			Hypotension	
	N: 154			Group 1: 0	
	Mean (±SD) Age: 64 (50-82)			Group 2: 1 (1)	
	Dropouts:12 (adverse events=5;			Group 3: 1(1)	
	lack of efficacy=2; other=5)			Group 4: 0	
				Malise	
				Group 1:0	
				Group 2: 1 (1)	
				Group 3: 0	
				Group 4: 0	
				Impotence	
				Group 1: 2 (1)	
				Group 2: 2 (1)	
				Group 3: 7 (4)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Group 4: 0	
				Ejaculation disorder	
				Group 1: 2 (1)	
				Group 2: 0	
				Group 3: 5 (3)	
				Group 4: 0	
				Abnormal semen	
				Group 1:0	
				Group 2: 0	
				Group 3: 1 (1)	
				Group 4: 0	
				Asthenia/ Fatigue	
				Group 1: 4 (3)	
				Group 2: 10 (6)	
				Group 3: 6 (4)	
				Group 4: 3 (2)	
				Somnolence	
				Group 1:0	
				Group 2: 1 (1)	
				Group 3: 0	
				Group 4: 2 (1)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments		
Resnick et al., 2007 ²¹¹ Study design:	Patient group: Men aged≥50 years with LUTS suggestive of BPH, including a history of storage and/or voiding symptoms.	Run-in phase: 28 days patients received one tablet of placebo.	Mean improvement in Qmax, ml/s	24 hours Group1: 1.58 Group 2: 0.71; p<0.021 Day 8	Funding: Sanofi-Aventis		
RCT	Inclusion criteria: IPSS of ≥13	Group 1: Alpha-blocker		Group 1: 1.92 Group 2: 0.39; p<0.001	Adverse events figures reported differently in		
Setting: Multi- centre, US	points and IPSS bother score of ≥ 3 pints; Qmax between 5 and 12ml/s with a voided volume ≥ 150 ml and	Alfuzosin 10mg One tablet taken once daily after the evening		Day 29 Group 1: 1.76 Group 2: 0.36; p<0.001	text and table.		
Evidence level:	post void residual ≤350ml.	meal, at approximately 0700 h or as late as	Mean change in IPSS (acute version of IPSS:	Day 8 Group 1: -3.4	Additional outcomes: BPH impact score		
1+ Duration of	Exclusion criteria: Conditions that affect urinary functioning, such as Parkinson's disease, MS, poorly	possible. Group 2: Placebo	to allow evaluation of symptom relief after	Group 2: -2.7; p=0.071 Day 29	reported. Method of randomisation and		
follow-up: 29 days	controlled diabetes, severe heart failure, stroke recent myocardial	n during retention er salpha tuse of ically n during retention eter, se or slpha tuse of ically	One tablet taken once	,	Group1: -4.5 Group 2: -3.1; p=0.003	allocation concealment	
27 0075	infarction or concomitant lower urinary tract disease. Previous prostatic surgery or radiation therapy, an endoscopic procedure		Mean change in IPSS quality of life score	Day 29 Group 1: -0.7 Group 2: -0.6 P=0.125	Notes: No clinically significant changes in blood		
	within 1 month of screening, spontaneous urinary retention during the preceding 12 months, an		hin 1 month of screening, preceding 12 months, an going episode of urinary retention quiring an indwelling catheter, stural hypotension, syncope or n-responders to previous alpha pocker therapy. Concomitant use of dications. Evidence of clinically evant biochemical abnormalities	Treatment emergent adverse events (with > 1% incidence in either aroun)	Total p > Group 1: 46/185 (24.9%) (f Group 2: 43/185 (23.2%) C	pressure were observed (figures not provided). One serious adverse	
	requiring an indwelling catheter, postural hypotension, syncope or				group	Group 1: 11/185 (5.9%) Group 2: 0 Headache	event (non-insulin dependent diabetes mellitus) in intervention
	blocker therapy. Concomitant use of medications. Evidence of clinically				Group 1: 5/185 (2.7%) Group 2: 2/185 (1.1%)	group. Considered not to be due to treatment.	
	relevant biochemical abnormalities or a PSA>10ng/ml.				Upper respiratory tract infection Group 1: 4/185 (2.2%) Group 2: 2/185 (1.1%)		
	All patients N: 372			Orthostatic hypotension Group 1: 3/185 (1.6%)			
	<u>Group 1</u> N: 186 Mean (±SD) Age : 63.5 (8.4)		Group 2: 4/185 (2.2%) Fatigue Group 1: 2/185 (1.1%)				

Ethnicity:	Group 2: 1/185 (0.5%)
Black/African: 161	Insomnia
American:	Group 1: 2/185 (1.1%)
White/Caucasian: 10	Group 2: 0
Other: 14	Erectile dysfunction
Dropouts: 10	Group 1: 1/185 (0.5%)
	Group 2: 2/185 (1.1%)
Group 2	Cough
N: 186	Group 1:0
Mean (±SD) Age : 64.4 (8.0)	Group 2: 2/185 (1.1%)
Ethnicity:	Dry mouth
Black/African: 166	Group 1:0
American:	Group 2: 2/185 (1.1%)
White/Caucasian: 6	Gastroesophageal reflux disease
Other: 13	Group 1:0
Dropouts: 7	Group 2: 2/185 (1.1%)
	Discontinuation due to adverse events
	Group 1: 3/185 (24.9%)
	Group 2: 1/185

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Roehrborn et al., 2001a ²¹⁸	Patient group: Men with LUTS/BPH recruited between Jan 1998-Aug 1999.	Group 1: Alpha-blocker Alfuzosin 10mg once daily without initial dose	Mean (SD) IPSS	Baseline Group 1: 18.2 (6.3) Group 2: 17.7 (5.7)	Funding: Sanofi- Synthelabo
Study design: RCT	Inclusion criteria: men aged 50 years or older with a history of	titration. Group 2: Alpha-blocker		Group 3: 18.2 (6.4) Change Group1 (n=170): -3.6 (4.8); p=0.001*	Limitations: Method of randomisation or
Setting: Multi- centre, US and Canada.	lower urinary tract symptoms consistent with clinical BPH for 6 months or longer, an IPSS of at least	Alfuzosin 15mg once daily without initial dose titration.	[Note: * adjusted p- value compared to placebo]	Group 2 (n=165): -3.4 (5.7); p=0.004 Group 3 (n=167): -1.6 (5.8)	allocation concealment unclear. Prostate volume in alfuzosin 10mg
Evidence level:	13, a Qmax between 5-12mL/s with a voided volume of 150mL or more, a residual urine volume of	Group 3: Placebo	% of patients showing an improvement in IPSS of 3 or more	Group 1: 56% Group 2: 52% Group 3: 39%	significantly larger than other 2 groups.
1+	350mL or less, and a quality of life of at least 3 points. Patients had to		points Mean (SD) quality of	Baseline	Additional outcomes: IPSS voiding and filling
Duration of follow-up: 3 months	meet inclusion criteria on day 1 of placebo run-in period (4 weeks) and did not need to re-qualify on randomisation.		life	Group 1: 3.8 (1.1] Group 2: 3.7 (1.1) Group 3: 3.7 (1.1) Change Group 1 (n=170): -0.7 (1.1); p=0.002	sub-scores were reported. Reported that there were no significant changes in the hematologic or
	lower urinary tract disease; previous prostate surgery; history of postural			Group 2 (n=165): -0.7 (1.2); p=0.002 Group 3 (n=167): -0.3 (1.1)	biochemical measurement were
	hypotension or syncope; concomitant use of medications that may alter the voiding pattern; and clinically relevant biochemical abnormalities. Serum PSA >10ng/mL were		% of patients showing an improvement in IPSS quality of life question of 2 or more points	Group1: 21%; p=0.004 Group 2: 21%; p=0.003 Group 3: 12%	observed. Blood pressure changes reported (reported that no patient experienced clinically relevant
	excluded and those with an elevated serum PSA 4-10 had to have prostate cancer excluded to the satisfaction for the investigator.		Mean (SD) Qmax, mL	Baseline Group 1: 9.9 (3.9) Group 2: 10.0 (3.2) Group 3: 10.2 (4.0)	changes). Notes: Significant improvement in IPSS for treatment
				Mean change Group1 (n=170): 1.7 (4.2); p=0.0004 Group 2 (n=165): 0.9 (3.6); p=0.12 Group 3 (n=167): 0.2 (3.5) Optimal mean change Group1 (n=170): 1.7; p=0.0004	groups by first post treatment assessment (day 28) and maintained throughout study.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Group 1 N: 177 Mean [range) Age: 64.3 (50-92) Prostate volume: 40.2 Dropouts: 11% (adverse events=8; Group 2 N: 181 Mean [range) Age: 63.9 (50-81) Prostate volume: 38.3 Dropouts: 18% (adverse events=8; insufficient efficacy=2 Group 3 N: 178 Mean [range) Age: 62.7 (49-85) Prostate volume: 36.8 Dropouts: 11% (adverse events=4; insufficient efficacy=2		% of patients showing an improvement in Qmax of 2mL/s or more Number (%) treatment emergent adverse events (≥2%) of the exposed population	Group 2 (n=165): 1.2; p=0.03 Group 3 (n=167): 0.3 Median change Group 1 (n=170): 1.1 (4.2); p=0.0006 Group 2 (n=165): 1.0 (3.6); p=0.0006 Group 3 (n=167): Median optimal change Group 1 (n=170): 1.3 Group 2 (n=165): 1.1 Group 3 (n=167): 0.3 Group 1: 40% Group 2: 41% Group 2: 44% Group 2: 44% Group 3: 26% Total Group 1: 52% Group 3: 43% Dizziness Group 1: 13 (7.4) Group 2: 16 (9.0) Group 3: 5 (2.9) Headache Group 1: 9 (5.1) Group 2: 4 (2.3) Group 3: 4 (2.3) Respiratory tract infection Group 1: 6 (3.4) Group 2: 5 (2.8) Group 3: 4 (2.3) Back pain Group 1: 2 (1.1) Group 2: 6 (3.4) Group 3: 4 (2.3) Rhinitis Group 1: 3 (1.7) Group 2: 4 (2.3) Group 3: 4 (2.3)	Qmax was not normally distributed so median values were also reported. Men over 65 years who received alfuzosin 15mg reported more adverse events potentially related to vasodilation (dizziness, malaise, hypotension) than younger patients (17% v 5%). This was not observed in the 10mg group.

		Fatigue Group 1: 4 (2.3) Group 2: 3 (1.7)	
		Group 2, 3 (1,7)	
		Group 2: 3 (1./)	
		Group 3: 4 (2.3)	
		Inflicted injury	
		Group1: 4 (2.3)	
		Group 2: 3 (1.7)	
		Group 3: 1 (0.6)	
		Impotence	
		Group1: 5 (2.8)	
		Group 2: 2 (1.1)	
		Group 3: 2 (1.1)	
		Somnolence	
		Group1: 4 (2.3)	
		Group 2: 3 (1.7)	
		Group 3: 0	
		Sinusitis	
		Group1: 5 (2.8)	
		Group 2: 1 (0.6)	
		Group 3: 4 (2.3)	
		Constipation	
		Group1: 4 (2.3)	
		Group 2: 1 (0.6)	
		Group 3: 1 (0.6)	
		Pain	
		Group1: 5 (2.8)	
		Group 2: 0	
		Group 3: 1 (1.1)	
		Nausea	
		Group1: 4 (2.3)	
		Group 2: 1 (0.6)	
		Group 3: 1 (0.6)	
		Abdominal pain	
		Group1: 2 (1.1)	
		Group 2: 2 (1.1)	
		Group 3: 4 (2.3)	
		Arthralgia	
		Group 1: 2 (1.1)	
		Group 2: 1 (0.6)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Group 3: 4 (2.3) Dyspepsia Group 1: 3 (1.7) Group 2: 0 Group 3: 4 (2.3) Orthostatic hypotension (decrease in systolic BP of 20mmHg or more when standing) Group 1: 3.4% Group 2:2.3% Group 3: 3.4%	

See Evidence Table 2: How does PSA predict symptom progression (in terms of symptom score)?

³ for Roehborn et al., 2006²¹⁹

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Randomised cross over trial		Alfuzosin 2.5mg three times daily Group 2: Placebo Three times daily an es ers ef;	Peak flow, ml/sec	Baseline Group 1: 9.06 (2.9) Group 2: 9.14 (2.8) 4 weeks Group1(n=68): 13.95 (6.3) Group 2(n=73): 11.69 (5.5)	Funding: NR Limitations: Method of randomisation and allocation concealment
Setting: Multi- centre Evidence level: 1+	Exclusion criteria: men suffering from urogenital diseases other than BPH or from neurological diseases that might influence the parameters measured during the trial were excluded.		Mean flow, ml/sec	Baseline Group 1: 4.72 (1.9) Group 2: 5.00 (1.9) 4 weeks Group 1(n=68): 6.85 (3.4) Group 2(n=73): 6.01 (2.5)	unclear. No washout period between cross over of treatments. Additional outcomes: Results after the cross over period.
Duration of follow-up: 4 weeks	low-up: N: 161		Post voiding volume, ml	Baseline Group 1: 90.65 (82.2) Group 2: 83.86 (67.4) 4 weeks Group 1 (n=61): 50.88 (47.76) Group 2 (n=68): 71.13 (77.0)	Adverse events – not reported as unclear whether in phase 1 before cross over of treatments.
	lack of efficacy=1) <u>Group 1 (alfuzosin-placebo)</u> N: 79 Mean Age: 63.5 <u>Group 2 (placebo-alfuzosin)</u> N: 82 Mean Age: 61.9		Boyarsky symptoms score	Baseline Group 1: 12.33 (2.55) Group 2: 12.42 (2.36) 4 weeks Group 1 (n=61): 50.88 (47.76) Group 2 (n=69): 7.65 (3.58)	Notes: After 4 weeks of treatment each group then had 4 more week on the opposite treatment. There was n wash out period and th effect of the initial treatment could not be distinguished from any new effects. Therefore only the first 4 weeks of this trial are reported limit bias.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
VanKerrebroe ck et al., 2000 ²⁶² Study design: RCT Setting: 48 Urology centres, Europe Evidence level: 1+ Duration of follow-up: 3 months	anKerrebroe Patient group: Men over 50 years anKerrebroe with micturition disorders related to 000262 BPH from April 1997 to July 1998. rudy design: Inclusion criteria: IPSS ≥13 and a CT maximum urinary flow rate betwee 5 and 12ml/s for a voided volume of at least 150ml and a residual urine volume of ≤350ml. entres, prope Exclusion criteria: concomitant urinary tract disease, previous prostatic surgery or other invasive procedures for the treatment of BPH, associated severe visceral disease, history of postural hypotension or syncopes, clinically relevant biological abnormalities,	Run-in period: One moth, placebo controlled period' Group 1: Alpha-blockers Alfuzosin 10mg once daily at the end of the evening meal Group 2: Alpha-blockers Alfuzosin 7.5mg (2.5mg thrice daily) Group 3: Placebo	Mean (SD) IPSS Mean (SD) IPSS quality of life question Mean (SD) Qmax	Baseline Group 1: 17.3 (3.5) Group 2: 16.8 (3.7) Group 3: 17.7 (4.1) 3 months Group 1: 10.4 (4.7) Group 2: 10.5 (6.1) Group 3: 12.8 (6.7) Baseline Group 1: 3.3 (0.9) Group 2: 3.3 (1.0) Group 3: 3.3 (1.0) 3 months Group 1: 2.2 (1.1) Group 3: 2.6 (1.3) Baseline Group 1: 9.4 (1.9) Group 3: 9.2 (2.0) 3 months Group 1: 11.7 (3.9) Group 2: 11.9 (4.3)	Funding: NR Limitations: Qmax was significantly lower in alfuzosin 2.5mg group at baseline. Method of randomisation and allocation concealment unclear. Additional outcomes: IPSS sub-scores for filling and voiding symptoms. Changes in haemodynamic parameters in normotensive and hypertensive patients (no significant differences reported).
	All patients N: 447 Drop outs: 40 (8.9%) Group 1 N: 143 Mean (±SD) Age: 64.9 (7.4) Dropouts: 16 Group 2 N: 150 Mean (±SD) Age: 64.7 (7.5) Dropouts: 14		Adverse events	Group 3: 10.6 (3.3) Vasodilatory events Group 1: 9/143 (6.3%) Group 2: 14/149 (9.4%) Group 3: 4/154(2.6%) Drop outs due to Vasodilatory events (syncope) Group 1: 0 Group 2: 1/149 (0.7%) Group 3: 0 Dizziness Group 1:3/143 (2.1%) Group 2: 7/149 (4.7%)	Notes: NCGC calculated means for Group 1 and 2 for the meta-analysis.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<u>Group 3</u> N: 154 Mean (±SD) Age: 64.2 (7.8) Dropouts: 10			Group 3: 2/154 (1.3%) Headache Group 1: 2/143 (1.4%) Group 2: 3/149 (2%) Group 3: 1/154 (0.6%) Hypotension/postural hypotension Group 1: 1/143 (0.7%) Group 2: 2/149 (1.3%) Group 3: 0/154 Malaise Group 1: 2/143 (1.4%) Group 2: 1/149 (0.7%) Group 3: 0/154 Asthenia/fatigue Group 1: 5/143 (3.5%) Group 3: 4/154 (2.6%) Sexual dysfunction Group 3: 2/154 (1.3%) Acute urinary retention Group 1: 0 Group 2: 0 Group 3: 1/154	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Wilt et al., 2000a ²⁷⁷ Study design:	Patient group: Men with symptomatic benign prostatic hyperplasia.	Group 1: Alpha- blocker Terazosin (hytrin) – non-uroselective	AUA symptoms score (0-35) * extrapolated from graphs	Group1 (n=275): 10.1 (6.35) Group 2 (n=265): 13.2 (6.3) Mean difference: -3.10 [-4.17, -2.03]; 1study P<0.00001	Funding: Minneapolis/VISN- 13 Centre for Chronic Diseases	
Systematic Review – Cochrane. This	Inclusion criteria: treatment duration of at least 4 weeks. Exclusion criteria: NR.	atment alpha-blocker weeks.	Mean change in AUA symptom score (fixed dose studies, 10mg only)	Group1 (n=976): -7.6 (7.17) Group 2 (n=973): -3.7 (7.16) Mean difference: -3.90 [-4.54, -3.26]; 1study P<0.00001	Outcomes Research (CCDOR), USA. Department of Veterans Affairs	
comparison includes 10 randomised controlled trials. Setting:	All patients N: 5151 Mean age: 65 (45-94) Racial characteristics (reported in 6 trials): White: 82%, Asian: 10%,		Mean change in peak flow rate (10mg), mL/s	Flexible dose studies: MD: 1.40 [0.56, 2.24]; n=424; 2 studies Fixed dose: 10mg MD: 1.53 [0.35, 2.70]; n=148; 2 studies Total: MD: 1.44 [0.76, 2.13]; 4 studies; p<0.0001	Health Services Research and Development Program, USA. Limitations: Only 3 of 10 studies	
Europe, Canada and US. Evidence	Black 6%, Other : 2% Discontinuation: 26% (5-42%) Mean symptoms score (7 trials)= 18.8 Drop outs: 23 (lost to follow-up,	pharmacological or surgical therapies)=	pharmacological or	Mean change in Peak flow rate (5mg), mL/s	Flexible dose studies: MD: 1.40 [0.56, 2.24]; n=424; 2 studies Fixed dose: 5mg MD: 0.46 [-0.76, 1.69]; n=153; 2 studies Total: MD: 1.10 [0.41, 1.70] 4 studies n=0.002	described their method of allocation concealment (unclear in remaining 7)
level: 1++ Duration of follow-up: Range 4-52 weeks	reported as erroneously randomised or unaccounted for and not included in outcome analysis) <u>Group 1</u> N: 2438		Mean peak flow rate (up to 10mg), mL/s	MD: 1.10 [0.41, 1.79]; 4 studies; p=0.002 Dose escalation/Flexible dose studies: MD: 1.75 [1.09, 2.41]; n=424; 2 studies Fixed dose: MD: 0.90 [-1.06, 2.86]; n=153; 1 study Total: MD: 1.66 [1.03, 2.29]; 3 studies; p<0.00001	Additional outcomes: Boyarsky symptom score was reported. Notes: Baseline values for	
	Group 2 N: 1821 Group 3 N: 990		Discontinuations, all causes*	Dose escalation/flexible-dose studies RR: 0.86 [0.78, 0.95]; 4 studies Fixed doses: all doses RR: 0.93 [0.55, 1.55]; 3 studies Total: Group 1: 521/1904 (27.4%) Group 2: 555/1621 (34.2%) RR: 0.87 [0.79, 0.95]; p=0.003; 7 studies	symptoms scores, peak urine flow did not differ by treatment group. * NCGC used fixed effect meta-analysis model rather than	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Discontinuations, due to adverse events	Dose escalation/flexible-dose studies RR: 1.51 [1.24, 1.85]; 4 studies Fixed doses: all doses RR: 1.77 [0.58, 5.40]; 2 studies Total: Group 1: 229/1817 (12.6%) Group 2: 140/1607 (8.7%) RR: 1.52 [1.25, 1.86]; p<0.00001	random effect used by Cochrane. Fixed model used as there was no heterogeneity present. Cochrane model detected no significant difference between the
			Dizziness	Group 1: 252/1802 (14.0%) Group 2: 98/1586 (6.2%) RR: 2.40 [1.92, 3.00]; 6 studies; p=<0.00001	interventions.
			Asthenia	Group 1: 153/1736 (8.8%) Group 2: 62/1566 (4.0%) RR: 2.42 [1.78, 3.28]; 5 studies; p=<0.00001	
			Headache	Group 1: 40/749 (5.3%) Group 2: 25/555 (4.5%) RR: 1.24 [0.76, 2.01]; 5 studies; p=0.39	
			Postural hypotension	Group 1: 57/1655 (3.4%) Group 2: 8/1487 (%) RR: 5.52 [2.71, 11.24]; 4 studies; p=<0.00001	
			Impotence/erectile dysfunction	Group 1: 24/386 (6.2 %) Group 2: 15/384 (3.9%) RR: 1.59 [0.85, 2.99]; 2 studies; p=0.15	
			Flu syndrome	RR: 1.22 [0.49, 3.06]; 3 studies; p=0.67	
			Abnormal ejaculation	RR: 1.50 [0.05, 40.91]; 2 studies; p=0.81	
			Rhinitis	RR: 1.34 [0.77, 2.31]; 2 studies; p=0.30	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments														
Wilt et al., 2002 ²⁷⁶ Study design: Systematic	Patient group: Men with symptomatic benign prostatic hyperplasia. Inclusion criteria: treatment	Group 1: Alpha- blockers Tamsulosin Group 2: Placebo	IPSS/AUA final score by dose	Tamsulosin 0.4mg: MD: -2.55[-3.46, -1.63]; p<0.00001; 2 studies Tamsulosin 0.8mg: MD: -3.42 [-4.32, -2.52]; p<0.00001; 2 studies	Funding: internal sources: Minneapolis/VISN- 23 centre for chronic Disease Outcomes														
Review – Cochrane. 14 RCTs identified; 6	duration at least 30 days. Exclusion criteria: NR.	Group 3: Active control	Mean change in IPSS/AUA	Tamsulosin 0.4mg: MD: -2.14[-3.42, -0.87]; p=0.001; 2 studies Tamsulosin 0.8mg: MD: -3.15 [-5.01, -1.28]; p=0.0009; 2 studies	Research, USA. Dept of Veterans Affairs Health Service research and														
included in this comparison. Setting: Europe, Japan	All patients N: 3418 Mean age: 64 (45 to 85) Drop outs: 395 (lost to follow-up,	Medical, phytotherapeutic or surgical therapies.	Qmax	Tamsulosin 0.4mg: MD: 0.91 [0.51, 1.32]; p<0.00001; 5 studies	Development Program, USA. Limitations: Allocation														
and US. Evidence level:	reported as erroneously randomised or unaccounted for and not included in outcome analysis)		Mean change in Qmax	Tamsulosin 0.4mg: MD: 1.02 [0.68, 1.35]; p<0.00001; 4 studies	concealment unclear in all of the studies.														
1++ Duration of	Mean IPSS/AUA: 19.5 (6 studies) Mean discontinuation rate: 12% Racial characteristics from one	•															Discontinuation due to adverse events	RR: 1.08 [0.73, 1.62]; p=0.69; 3 studies	Additional outcomes:
follow-up: Range 4-26	study: White > 99%		Discontinuation – all men	RR: 1.02 [0.80, 1.31]; p=0.85; 3 studies	Boyarsky scores. Mean urine flow. Comparisons by dose														
weeks.	<u>Group 1</u> N: 2486		Serious adverse events	RR: 1.18 [0.57, 2.43]; p=0.65; 3 stuies	for adverse events.														
	Group 2 N: 781 Group 3 N: 851		Adverse events – cardiovascular	RR: 0.78 [0.40, 1.53]; p=0.47; 1 study	Notes: Converted pooled analysis to fixed														
													Adverse events – digestive system	RR: 0.86 [0.65, 1.12]; p=0.27; 2 studies	model rather than random effect model				
			Adverse events – nervous system	RR: 1.55 [1.24, 1.95]; p=0.0002; 3 studies	reported in Cochrane review – expect when there was heterogeneity.														
			Adverse events – urogenital system	RR: 2.67 [0.89, 7.96]; p=0.08; 3 studies															
		Adverse events - drug related	RR: 1.07 [0.71, 1.62]; p=0.75; 2 studies	1															

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Dizziness	Group 1: 176/1473 (11.9%) Group 2: 56/714 (7.8%) RR: 1.53 [1.15, 2.02]; p=0.003; 4 studies	
			Headache	Group 1: 211/1473 (14.3%) Group 2: 104/714 (14.6%) RR: 1.00 [0.81, 1.24]; p=1.00; 4 studies	
			Abnormal ejaculation	Group 1: 148/1375 (10.8%) Group 2: 3/686 (0.4%) RR: 21.13 [7.33, 60.87]; p<0.00001; 3 studies	
			Rhinitis	Group 1: 154/1375 (11.2%) Group 2: 41/686 (6.0%) RR: 1.86 [1.34, 2.57]; p=0.0002; 3 studies	
			Asthenia	Group 1: 89/1473 (6.0%) Group 2: 31/714 (4.3%) RR: 1.38 [0.93, 2.04]; p=0.11; 4 studies	
			AUA bother score	Tamsulosin 0.4mg: MD: -1.60 [-2.44, -0.76]; 0.00018; 1 study Tamsulosin 0.8mg: MD: -2.00 [-2.83, -1.17]; p<0.00001; 1 study	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments				
Debruyne et al., 1998 ⁶¹ ALFIN study	Patient group: Lower urinary tract symptoms related to BPH Inclusion criteria:	All patients received placebo during a 2-week, single blinded run in period	IPSS change, at 6 months (mean ±SD)	Group 1: -6.3±5.8 Group 2: -5.2±5.7 Group 3: -6.1±5.6 P values:	Funding: Synthelabo Recherche, France Limitations:				
Study design: RCT double blinded(3 arms)	 Men 50-75 years IPSS≥7 Qmax of ≥5 mL/s but ≤15 mL/s in a 	Group 1: Alfuzosin SR 5mg twice daily Group 2: finasteride 5mg once daily Group 3: Alfuzosin SR 5mg twice daily + finasteride 5 mg once daily Duration: 6 months	Group 1:	Group 1:	Group 1:	Group 1:		Group 1 vs. 2: 0.01 Group 2 vs. 3: 0.03 Group 1 vs. 3: NR	Method of randomisatio n allocation
Setting: European, multicenter (104 centres). Conducted from Sept 1994 to	 Contax of 25 mL/s but \$15 mL/s mu total voided volume of \$150 mL (no threshold for prostate size was specified, patients with hypertension included) Exclusion criteria: Other concomitant urinary tract 		IPSS improved by >50% at 6 months (% of patients)	Group 1: 43 Group 2: 33 Group 3: 42 P values: Group 1 vs. 2: 0.008 Group 2 vs. 3: 0.009 Group 1 vs. 3: NR	and concealment was not reported No report of placebos being used				
Dec1996 Evidence level: 1+	 Other concomman of hary fract disease (prostate cancer, neurogenic bladder dysfunction, bladder stones, chronic bacterial prostatitis, untreated urinary tract infection) 		Qmax change, at 6 months (mean ±SD), ml/s	Group 1: 1.8±3.8 Group 2: 1.8±4.5 Group 3: 2.3±4.7 P values: Not sig	to mask the different number of pills and				
Duration of follow-up: 6 months	 Previous invasive procedure to treat BPH 		Subgroup analysis in 497/1051 men who had Qmax <10ml/s at baseline (most likely to be obstructed) - Qmax increase >30% compared to baseline, %	Group 1: 51 Group 2: 38 Group 3: 49 P values: Group 1 vs. 2: 0.02 Group 2 vs. 3: 0.06 Group 1 vs. 3: NR	treatment regimens Additional outcomes: Supine blood pressure (systolic				
aminotran aminotran limit of no micromol/ Serum PSA	abnormalities (aspartate aminotransferase and alanine aminotransferase > 2 times the upper limit of normal, blood creatinine ≥160 micromol/I) ■ Serum PSA>20ng/ml		Prostate volume change, at 6 months (mean ±SD), ml	Group 1: -0.2±14.3 Group 2: -4.3±15.0 Group 3: -4.9±12.4 P values: Group 1 vs. 2: <0.001 Group 2 vs. 3: Not sig Group 1 vs. 3: <0.001	and diastolic), change compared to baseline. There were no sig. difference between groups Notes:				
	All patients N: 1051 Dropouts: 133(13%) Age, mean ±sd,(yr): 63.3±6.5		PSA change, at 6 months (mean \pm SD), ng/ml	Group 1: 0.1±2.7 Group 2: -1.7±1.9 Group 3: -1.4±1.7	None.				

1 **Evidence Table 10 Alpha blocker vs. 5-alpha reductase inhibitors**

Study details	Patients	Interventions	Outcome measures		Effect size		Comments
	IPSS mean ± sd: 15.4±5.5 Duration of symptoms, mean ± sd, (yr): 3.4±3.2 Prostate vol ,mean ± SD (ml): 41.2±24.0			Group 2	vs. 2: <0.001 vs. 3: Not sig vs. 3: <0.001		
	PSA serum, mean ± sd:(ng/ml): 4.0 ± 2.08 Qmax mean±sd (ml/sec): 9.9±3.0		Withdrawals Withdrawal due to adverse	Grp 1 N=358	Grp 2 N= 344 54	Grp 3 N=349 39	
	<u>Group 1(Alfuzosin SR)</u> N: 358 Dropouts: 40(11%)		events Lack of efficacy	25	24 2	18 2	
	Age, mean ±sd,(yr): 63.2±6.4 IPSS, mean ± sd: 15.3±5.5 Duration since first LUTS, mean ± sd, (yr): 3.5±3.0 Prostate vol ,mean ± SD (ml):41.4±25.7		Vasodilatory events (%) Vertigo/dizziness Headache Postural		4(1.2) 4(1.2) 3(0.9) 1(0.3)	8(2.3) 5(1.4) 2(0.6) 1(0.3)	
	PSA serum, mean ± sd:(ng/ml): 3.0±2.5 Qmax mean±sd (ml/sec): 9.7±2.8 Group 2 (Finasteride)		hypotension/hypotension Malaise Sexual disorders (%)		23(6.7) 5(1.5) 6(1.7)	26(7.4) # 3(0.9) 7(2.0)	
	N: 344 Dropouts: 39(11%) Age, mean ±sd,(yr): 63.0±6.4 IPSS, mean ± sd: 15.5±5.2 Duration since first LUTS, mean ± sd, (yr): 3.3±3.2		Impotence Ejaculatory failure Decreased libido Others (%) Somnolence Asthenia/fatigue	-(-) 4(1.1) -(-) 2(0.6)	2(0.6) -(-) 1(0.3) 1(0.3)	1(0.3) 2(0.6) 1(0.3) 1(0.3)	
	Prostate vol ,mean ± SD (ml): 40.9±23.5 PSA serum, mean ± sd:(ng/ml): 3.4±2.5 Qmax mean±sd (ml/sec): 9.8±2.6		Myocardial infarction Acute urine retention Asymptomatic orthostatic hypotension during at least one	Grp 1	Grp 2	Grp 3	
	<u>Group 3: Alfuxosin SR + finasteride</u> N: 349 Dropouts: 54(15%) Age, mean ±sd,(yr): 63.7±6.7		visit				

Study details	Patients	Interventions	Outcome measures		Effect siz	e	Comments
	IPSS , mean ± sd: 15.6±5.7			Grp 1	Grp 2	Grp 3	
	Duration since first LUTS , mean \pm sd, (yr):			N=358	N= 344	N=349	
	3.4±3.3		Withdrawals		• •	54(15%)	
	Prostate vol , mean ± SD (ml):41.1±22.6		Adverse events	-	18	24	
	PSA serum , mean \pm sd:(ng/ml): 3.1 \pm 2.7		Lost to follow up		6	6	
	Qmax mean±sd (ml/sec): 10.1±3.5		Lack of efficacy		2	2	
			Other reasons	9	13	22	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Lepor et al., 1996 ¹⁴² Also reported in Lepor 1998 ¹⁴³ and	Patient group: Symptomatic BPH Inclusion criteria:	Group 1: Terazosin 10 mg (+ placebo) (Titrated from 1 mg from days 1 to 3, 2 mg from days 4 to 7,	IPSS/AUASS mean ±SD at 1 year (SD calculated from SEM presented in Lepor1998 ^{143*}	Group 1: 10.2 ± 4.97, n=275 Group 2: 13.0 ±4.84, n=260 Group 3: 9.80 ±5.00, n=278 Group 4 13.2±4.88, n=265	Funding: Veterans Affairs Medical Research Service, Merck and Abbott
Lepor 2000 ¹⁴¹ Study design: RCT double blinded (4 arms)	Mean AUA symptom score ≥8 Mean Qmax ≥4ml/s, ≤15 ml/s, with a minimal	Aean AUA symptom score 5 mg from days 8 to 8 14 and 10 mg from Aean Qmax ≥4ml/s, ≤15 aday 15 to end of nl/s, with a minimal study. Patients oided volume 125ml and allowed to reduce to a mean residual volume 5 mg in the event of after voiding <300ml	IPSS/AUASS mean change (95% CI) at 1 year * [calculated by NCGC team from baseline and 1 year follow up values]	Compared to baseline value Group 1: -6.00 [-6.85, -5.15] Group 2: -3.20 [-4.04, -2.36] Group 3: -6.10 [-3.97, -5.23] Group 4: -2.60 [-3.45, -1.75]	 ADDOTT Limitations: Values for Qmax and AUA/IPSS had to be extrapolated
(Dec 1992 to March 1995)	a mean residual volume after voiding <300ml Exclusion criteria: Taken the following drugs within the specified time periods: experimental		Difference in IPSS/AUA mean change (95% Cl) at 1 year, between groups [calculated by NCGC team]	MD Gp1-2: -2.80 [-3.99, -1.61]** MD Gp1-3: 0.10 [-1.31, 1.11] MD Gp1-4:-3.40 [-4.60, -2.20]** MD Gp2-3: 2.90 [1.70, 4.10]** MD Gp2-4:-0.60 [-1.79, 0.59] MD Gp3-4: -3.50 [-4.71, -2.29]** **p value:<0.001	from graphs, no actual values reported. Additional outcomes: AUA symptoms scores
Evidence level: 1+ Duration of follow-up:	drug < 4 weeks before screening; alpha adrenergic agonist, cholinergic agonist or		Qmax, ml/s mean ±SD at 1 year (SD calculated from SEM presented in Lepor1998 ^{143*}	Group 1: 13.2±4.97, n=275 Group 2: 12.1±4.76, n=252 Group 3: 13.6±1.66, n=277 Group 4: 11.8±4.87, n=264	started to be significantly different between arms containing terazosin vs. finasteride only or
year antagonist, topical beta adrenergic antagonist drug for glaucoma, or any hypertensive drug other than a diuretic or angiotensin converting enzyme inhibitor within 2	terazosin and placebo for finasteride	Qmax, ml/s mean change (95% Cl) at 1 year compared to baseline* [calculated by NCGCAC team from baseline and 1 year follow up values]	Compared to baseline value Group 1: 2.70[2.04, 3.36] Group 2: 1.50[0.85, 2.15] Group 3: 3.20[2.54, 3.86] Group 4: 1.40[0.74, 2.06]	placebo at week 2, reached nadir at week 13 and maintained until week 52. There were no significant differences between	
	 weeks before lead in period; estrogens, androgens or androgen inhibitors within 3 months. Unstable angina, myocardial infarction, transient ischaemic attack, 		Difference in Qmax mean change (95% Cl) at 1 year, between groups* [calculated by NCGC team]	MD Gp1-2: 1.20 [0.28, 2.12]** MD Gp1-3: -0.50 [-1.43, 0.43] MD Gp1-4: 1.30 [0.37, 2.23]** MD Gp2-3: -1.70 [-2.62, -0.78]** MD Gp2-4: 0.10 [-0.82, 1.02] MD Gp3-4: 1.80 [0.87, 2.73]** **p value:<0.001	terazosin only vs. terazosin + finasteride arm through out study period. The Qmax outcomes had a similar trend,
	stroke within past 6		Discontinuation due to adverse	•	expect that statistical

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	 months, insulin dependent diabetes mellitus, orthostatic hypotension Previous BPH, obstruction 		events	Group 2: 15/310 (4.8%) Group 3: 24/309 (7.8%) Group 4: 5/305 (1.6%) P<0.05	significance between terazosin containing arms vs. finasteride only and placebo arms
	or pelvic surgery Prostate carcinoma Urinary tract infections Renal or hepatic 		Discontinuation – all men	Group 1: 49/305 (16%) Group 2: 67/310 (22%) Group 3: 55/309 (18%) Group 4: 51/305 (17%)	started at week 4. (based on graph, no actual values reported)
	impairment <u>All patients</u> N: 1229 (73%) out of 1686 screened Age Mean (±SD): Drop outs: <u>Group 1 (Terazosin)</u> N: 305		Reason for withdrawal * Total withdrawals Reasons Adverse Events Absolute indication for surgery Unrelated medical problem Death Lost to follow up Other	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Notes: Slight differences in values of differences between baseline and 1 year values between Lepor1996 and Lepor1998. Postural hypotension and other adverse events values
	Age Mean (±SD): 65±6 Dropouts:49/305 Prostate volume (cm ³): 37.5±1.1 White race (%): 81		Dizziness	Group 1: 79/305 (26%) Group 2: 26/310 (8%) Group 3:66/309 (21%) Group 4: 22/305 (7%) P<0.001 [†]	reported in Lepor1996 was slightly different from 1998 † P values for overall
	AUASS: 16.2±5.5 Qmax (ml/s):10.5±2.6 PSA serum (ng/ml): 2.2±1.9 <u>Group 2 (Finasteride)</u> N: 310		Postural hypotension (determined by principal investigator, involving light headedness when standing and not measurable change in blood pressure)	Group 1: 23/305 (8%) Group 2: 7/310 (2%) Group 3: 27/309 (9%) Group 4: 3/305 (1%) P<0.001 [†] , Gp 1 +- 2: P=0.004	difference among all 4 groups * Values for Qmax and AUASS was obtained from Lepor1998 ¹⁴³ .
	Age Mean (±SD): 65±7 Dropouts:67 Prostate volume (cm ³): 36.2±1.0 White race (%): 79 AUASS:16.2±5.4		Orthostatic hypotension, at least once during study (A fall of more than 20 mmHg in the systolic blood pressure when patient changed from supine to upright position)	Group 1: 45% Group 2: 26% Group 3: 39% Group 4: 30% (Information was provided in replies and correction section NEJM1997; 336:293)	There are some discrepancies in differences between baseline and 1 year follow up. Values in Lepor 1998 were used.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Qmax (ml/s):10.6±2.5 PSA serum (ng/ml): 2.2±1.8 Group 3: Terazosin 10 mg + finasteride 5 mg		Syncope	Group 1: 3/305 (1%) Group 2: 3/310 (1%) Group 3: 5/309 (2.3%) Group 4: 0/305 (0%) Not sig	
	N: 309 Age Mean (±SD): 65±7 Dropouts:55 Prostate volume (cm ³): 37.2±1.1 White race (%): 80 AUASS:15.9±5.7 Qmax (ml/s):10.4±2.7 PSA serum (ng/ml): 2.3±2.0 Group 4: placebo for terazosin and placebo for terazosin and placebo for finasteride N: 305 Age Mean (±SD): 65±7 Dropouts:51 Prostate volume (cm ³): 38.4±1.3 White race (%): 79 AUASS:15.8±5.5 Qmax (ml/s):10.4±2.6 PSA serum (ng/ml): 2.4±2.1		Asthenia	Group 1: 42/305 (14%) Group 2: 23/310 (7%) Group 3: 43/309 (14%) Group 4: 21/305 (7%) P<0.002 [†] , Gp 1 +- 2: P= 0.01	
		5.7 10.4 ± 2.7 y/ml : 2.3 ±2.0 <u>ebo for</u> <u>placebo for</u> SD): 65 ± 7 me (cm ³): y: 79 5.5 10.4 ± 2.6	Headache	Group 1: 18/305 (6%) Group 2: 19/310 (6%) Group 3: 16/309 (5%) Group 4: 10/305 (3%) Not sig	
			Decreased libido	Group 1: 8/305 (3%) Group 2: 14/310 (5%) Group 3: 15/309 (5%) Group 4: 4/305 (1%) P=0.05 [†] , Grp 1 vs. 2: Not sig	
			Ejaculatory abnormality	Group 1: 1/305 (0.3%) Group 2: 6/310 (2%) Group 3: 21/309 (7%) Group 4: 4 /305 (1%) P<0.001†, Grp 1 vs. 2: Not sig	
			Rhinitis	Group 1: 20/305 (7%) Group 2: 8/310 (3%) Group 3: 24/309 (8%) Group 4: 14/305 (5%) P=0.02 ⁺ Grp 1 vs. 2: Not sig	
			Sinusitis	Group 1: 6/305 (2%) Group 2: 4/310 (1%) Group 3: 7/309 (2%) Group 4: 4/305 (1%) Grp 1 vs. 2: 0.02	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			BPH impact index (BII) mean ±SD at 1 year (SD calculated from SEM presented in Lepor1998 ^{143*}	Group 1: 2.4±1.66 n=276 Group 2: 3.0±1.61 n=259 Group 3: 2.0±1.67 n=279 Group 4: 3.0±1.63 n=265	
			BPH impact index (BII) mean change (95% CI) at 1 year * [calculated by NCGC team from baseline and 1 year follow up values]	<u>Compared to baseline value</u> Group 1: -1.2±2.4 Group 2: -0.5±2.4 Group 3: -1.7±2.4 Group 4: -0.5±2.4	
			BPH impact index (BII) mean change ±SD(95% CI) at 1 year, between groups [calculated by NCGC team]	MD Gp1-2: -0.7±3.4(-1.0,-0.4)** MD Gp1-3: 0.5±3.4 (0.2,0.8)** MD Gp1-4: -0.5±3.4 (-1.0,-0.4)** MD Gp2-3: 1.2±3.4 (0.9,1.5)** MD Gp2-4: 0.0±3.4 (-0.3,0.3) MD Gp3-4: -1.2±3.0 (-1.5,-0.9)** **P<0.001	
			Prostate volume, ml, ±SD at 1 year (SD calculated from SEM presented in Lepor1998 ^{143*}	Group 1: 38.0±21.5 n=271 Group 2: 30.1±20.8, n=252 Group 3: 30.2±21.7, n=275 Group 4: 38.9±25.2, n=258	
			Prostate volume, ml, mean change (95% Cl) at 1 year * [calculated by NCGC team from baseline and 1 year follow up values]	Compared to baseline value Group 1: 0.5±21.57 Group 2: -6.1±20.80 Group 3: -7.0±21.72 Group 4: 0.5±25.20	
			Difference in prostate volume mean change (95% Cl) at 1 year, between groups [calculated by NCGC team]	Change in AUA between groups, at 1 year MD Gp1-2: 6.6(3.0, 10.2) ** MD Gp3-1: -7.5(-11.1,-3.9) ** MD Gp1-4: 0(-4.0, 4.0) MD Gp3-2: -0.9(-4.5, 2.7)** MD Gp2-4: -6.6(-10.6, -2.6) ** MD Gp3-4: -7.5(-11.5,-3.5) **	

See Evidence Table 9 Alpha-blockers vs. placebo
for Kirby et al., 2003¹²⁹
See Evidence Table 2: How does PSA predict symptom progression (in terms of symptom score)?
for McConnell et al., 2003¹⁶⁶
.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Rigatti et al, 2003 ²¹⁶	Patient group: Lower urinary tract symptoms related to benign prostatic hyperplasia	During the 2-week, single-blind, placebo run-in period,	IPSS change from baseline at 26 weeks (mean ±SD)	Group 1: -6.3 ±5.5 (-32.0%) Group 2: -5.7 ±5.7 (-37.3%) P value: 0.080	Funding: Boehringer Ingelheim Italy
MICTUS study Study design: RCT double	Inclusion criteria: men between 50 and 80 y with ta	patients took one capsule of tamsulosin-matching placebo and one	IPSS improved by ≥50% at 26 weeks compared to baseline (% of patients)	Group 1: 42.5% Group 2: 35.6% P value: Not sig	SpA Limitations:
blinded	 I-PSS ≥13 Qmax between 4 and 15 ml/s Total Symptom Problem Index (SPI) score 	tablet of finasteride- matching placebo once daily.	I-PSS-Qol change from baseline at 26 weeks, (mean±sd)	Group 1: -1.1±1.2 (-31.2%) Group 2: -1.0±1.2 (-25.8%) P value: 0.163	randomisation allocation and concealment was
Italian, multicenter (50 centres)	 ≥7. Post-void residual volume (PVR: evaluated by ultrasonography) 	Group 1: Tamsulosin One capsule of tamsulosin 0.4 mg + bo	Qmax change from baseline at 26 weeks, (mean±sd) ,ml/s	Group 1: 2.4±5.9 (30.7%) Group 2: 1.9±5.1 (21.7%) P value: 0.271	not reported Notes: None.
Evidence level: 1+	<400 ml PSA level <3 or 3–10 ng/ml (provided that prostate cancer was ruled out by the investigator according)		Voided volume, change from baseline at 26 weeks, (mean±sd), ml	Group 1: 21.3±152.4 (29.9%) Group 2: 5.2±141.0 (16.4%) P value: 0.043	none.
Duration of follow-up:	to the usual procedure in the centre).	placebo once daily	Number of patients treated	Grp 1 Grp 2 N=196 N= 204	
	 Exclusion criteria: Known history or a diagnosis of urological disturbances, cardiovascular diseases, neurological diseases, hepatic or renal insufficiency 	Group 2: Finasteride One tablet of finasteride 5 mg + one capsule of	Any AE Serious AE Discontinued due to AE Adverse events reported in more than 3% patients)		
	 Clinically significant abnormalities in haematological and biochemical tests Took an alpha-1-adrenoreceptor antagonist (A-1-ARA) or phytotherapy in the 6 weeks prior to the study or 	tamsulosin-matching placebo once daily. Patients were assessed at visit 1	Influenza-like symptoms Influenza-like symptoms Impotence Abdominal pain Ejaculation disorder	6 (3.1) 7 (3.4) 6 (3.1) 5 (2.5)	
	 finasteride in the 6 months prior to the study. Required concomitant medications influencing pharmacodynamic or pharmacokinetic properties of tamsulosin, in particular A-1-ARA, mixed alpha- beta-antagonists, alpha- 	(screening visit) and 2 weeks later (randomisation/base line visit) during the placebo run-in period. Treatment period:	Study withdrawals Adverse events Lost to follow up Lack of efficacy Non compliance to protocol Withdrawal of consent	13(6.6) 9(4.4) 4(2.0%) 8(3.9%) 4(2.0%) 1(0.5%)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	agonists and anticholinergics.	26 weeks + 26	Other reasons	7(3.6%) 5(2.5%)	
	All patients N: 403 randomised from 441 enrolled Dropouts: see study withdrawals Age, mean ±sd,(yr): 63±7.1 Prostate vol ,mean ± SD (ml): 39±18.9 Group 1(Tamsulosin)	weeks	Symptom Problem Index (SPI) ITT population	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	
	N: 199			n=202 P value: 0.055	
	Dropouts: 34(17%) at week 26, 63 (31%) at week 52 IPSS, mean ± sd: 16.3±5.1 IPSS-QoL, mean ± sd: 3.2 (1.0) *Prostate vol < 50 ml): 68% Qmax mean±sd (ml/sec):10.8±3.7 Voided volume, mean±sd, ml 239.5 (118.4)		Symptom Problem Index (SPI)): Per protocol population	Baseline Group 1: 13.6 \pm 4.4, n=130 Group 2: 14.1 \pm 4.2, n=152 Change at week-26 Group 1: -5.5 \pm 5.0 (-39.6%) Group 2: -4.5 \pm 4.9 (-31.5%) P value: 0.032	
	<u>Group 2(Finasteride)</u> N: 204		% Symptom Problem Index (SPI) responders (50% improvement from baseline)	<u>% Patients at week-26</u> Group 1: 43.5%, n=193 Group 2: 35.1%, n=202	
	Dropouts: 24(11.8%) at 26 weeks, 45 (22%) at 52 weeks IPSS, mean ± sd: 16.9±5.0 IPSS-QoL, mean ± sd: 3.1 (1.1) *Prostate vol < 50 ml): 75% Qmax mean±sd (ml/sec): 10.8±3.4 Voided volume, mean±sd,ml:226.5 ±93.1 * Not statistically significant, calculated by NCGC team using Fisher's exact test		Symptom Problem Index (SPI) -storage	$\begin{array}{r} \underline{Baseline} \\ \hline \textbf{Group 1: } 6.1 \pm 2.4 \\ \hline \textbf{Group 2: } 6.2 \pm 2.2 \\ \underline{Change \ at \ week-26} \\ \hline \textbf{Group 1: } -2.3 \pm 2.5 \ (-34.3\%), \\ n=193 \\ \hline \textbf{Group 2: } -1.9 \pm 2.7 \ (-22.0\%), \\ n=202 \\ \hline \textbf{P value: } 0.09 \end{array}$	
	INCOC team using Fisher's exact fest		Symptom Problem Index (SPI) -voiding	Baseline Group 1: 7.5 ± 3.0, n=193 Group 2: 7.8 ± 2.7, n=202 Change at week-26 Group 1: -3.0 ± 3.2(-35.0%) Group 2: -2.6 ± 3.1(-27.3%) P value: 0.069	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Roehborn et al., 2008 ²²⁵ for the 2 year results	Patient group: Clinical diagnosis of BPH, prostate size ≥30cc	All patients received placebo run in the 4 weeks run in period.	IPSS, at 24 months (mean ±SD) SE	Group 1: 11.9±6.8, SE 0.17 Group 2: 11.4±6.4, SE 0.16 Group 3: 10.1±6.4, SE 0.16	Funding: GSK
Study design: RCT double blinded(3 arms) Setting: International, multicenter (446 investigators in	 Inclusion criteria: Men 50 years or older Clinical diagnosis of BPH by medical history and physical examination, including digital rectal examination IPSS≥ 12 Qmax of ≥5 mL/s but ≤15 mL/s in a total voided volume of ≥125 mL 	Group 1: Tamsulosin 0.4mg (+ placebo dutasteride) Group 2: dutasteride 0.5mg(+ placebo	IPSS, change from baseline at 24 months (mean ±SD) SE	Compared to baseline value Group 1: -4.3 \pm 6.0, SE 0.15 Group 2: - 4.9 \pm 6.0, SE 0.15 Group 3: - 6.2 \pm 6.0, SE 0.15 P value: < 0.001 for Grp 3 vs. Grp1 and Grp 2, P=0.0113 for Grp 1 vs. Grp 2	Limitations: Only interim results available. Final 4-year results will be published at a later date (Autumn2009)
35 countries) Evidence level: 1+	 5 countries) Prostate volume≥ 30 cc on TRUS Total serum PSA ≥1.5 ng/ml Exclusion criteria: Total serum PSA > 10.0 ng/ml A history or evidence of prostate cancer Previous surgery to treat BPH History of AUR within 3 months before study entry. Postvoid volume >250mL (suprapubic ultrasound) Use of phytotherapy for BPH within 2 weeks of screening visit or / and predicted need for phytotherapy Use of any alpha adreneronter 	c All administered	IPSS, adjusted** mean difference between groups at 24 months	Group 3 vs. Group 1: -1.8 Group 3 vs. Group 2: -1.3	Additional outcomes: % of responders defined as 25% or greater, 2points of more
Duration of follow-up: This is the results from the 2-year interim results			IPSS-QoL, change from baseline at 24 months (mean ±SD) SE	Compared to baseline value Group 1: -1.1 Group 2: -1.1 Group 3: -1.4 P value: < 0.001 for Grp 3 vs. Grp1 and Grp 2	improvement in IPSS 30% or greater improvement in Qmax Qmax improved
208 weeks treatment + 16 weeks additional safety follow up(224 total)			Patients who improved by more than 3 points on the IPSS at 24 months compared to baseline (%)	Group 1: 62 Group 2: 65 Group 3: 72 P value: < 0.001 for Grp 3 vs. Grp1 and Grp 2	significantly greater from baseline for combination vs. monotherapies from month-6.
	 blockers within 2 weeks of screening visit and/or predicted need to any alpha blocker other than tamsulosin during study History of postural hypotension, dizziness, vertigo or any other signs and symptoms or orthostasis, which in 		Qmax, ml/s adjusted** mean change from baseline ±sd at 24 months	Group 1: 0.9 ± 4.8 , SE 0.12 Group 2: 1.9 ± 4.8 , SE 0.12 Group 3: 2.4 ± 4.8 , SE 0.12 P value: ≤ 0.003 for Grp 3 vs. Grp 1 and Grp 2, P<0.001 for Grp 1 vs. Grp 2	IPSS score improvement from baseline of combination vs. dutasteride was significant from month 3, vs. tamsulosin was
	the opinion of the investigators, could		Prostate volume change from baseline at 24	Group 1: $0.0\% \pm 33.4$ SE 0.84% Group 2: $-28.0\% \pm 24.3$ SE	significant from month 9.

Study details	Patients	Interventions	Outcome measures		Effect siz	e	Comments
	be be exacerbated by tamsulosin and putting the subject at risk <u>All patients</u> N: 4,844		months, mean %	SE0.62%	-26.9% ± : 0.001 for		IPSS-QOL improvement was significant from months 3 and 12 respectively.
	Dropouts: Age, mean \pm sd,(yr): 66.1 \pm 7.01 No. white ethnicity (%): 4,259 (88) IPSS mean \pm sd: 16.4 \pm 6.16 Duration since first LUTS mean \pm sd, (yr): 5.4 \pm 4.84 Prostate vol (cc): Mean \pm SD total: 55.0 \pm 23.58 Median total: 48.9 Mean \pm SD transition zone* 29.5 \pm 21.97 PSA serum, mean \pm sd:(ng/ml): 4.0 \pm 2.08 Qmax mean \pm sd (ml/sec): 10.7 \pm 3.62 Post-void residual vol, mean \pm sd, (ml): 67.7 \pm 64.87 No. sexually active (%): 3,529 (73) No. previous α-blocker use (%):		PSA change from baseline at 24 months , mean %	Group 1: Group 2: Group 3:	-55.0%		Notes: "investigator blinding
			Any Serious Drug related † Leading to study withdrawal Drug related, leading to study withdrawal		193(12) 386(24) 161(10 81(5) 2<0.001 fo treatments	3 5)) 145(9)	to the treatment was maintained by an independent, unblended reviewer who doubled the PSA values in subjects receiving dutatsteride or combination therapy with the value randomly stated as the doubled value, or 0.1 units higher or lower. Methods published in Siami et al ²⁴⁰ .
	2,444 (50) No. previous 5-ARI use (%): 531 (11)		Adverse events occurring in	Grp 1 N=1611	Grp 2 N= 1623	Grp 3 N=1610	The study recruitment was completed in
	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$		>1% patients Erectile dysfunction Retrograde ejaculation Ejaculation failure Loss of libido Semen volume decreased Altered (decreased) libido Dizziness Breast enlargement Nipple pain Breast tenderness	61(3.8) 18(1.1) 13(0.8) 14(0.9) 13(0.8) 27(1.7) 27(1.7) 13(0.8) 5(0.3)	97(6.0) 10(0.6) 8(0.5) 21(1.3) 5(0.3) 45(2.8) 11(0.7) 29(1.8) 10(0.6) 16(1.0)	$119(7.4) \\ 68(4.2) \\ 39(2.4) \\ 27(1.7) \\ 29(1.8) \\ 55(3.4) \\ 26(1.6) \\ 23(1.4) \\ 19(1.2) \\ 16(1.0) \\ 1000$	2005. The standard deviation values in the results were calculated by the NCGC team from the SE values reported. * In a subset of 656 men. The baseline values

Study details	Patients	Interventions	Outcome measures	Ef	fect size	Comments
	Mean \pm SD transition zone*: 30.5 \pm 24.47		Other adverse events			were taken 4 weeks
	PSA serum, mean \pm sd:(ng/ml): 4.0 \pm 2.08		Breast neoplasm			after screening, when
	Qmax mean ± sd (ml/sec): 10.7 ± 3.66		Floppy iris syndrome	0(0) 0(0	0(0)	all men received
	Post-void residual vol , mean \pm sd, (ml):					placebo treatment
	67.7 ± 65.14					
	No. sexually active (%): 1,164 (72)					** General linear
	No. previous α-blocker use (%): 819 (51)					model adjusted for
	No. previous 5-ARI use (%): 172 (11)					treatment, investigative
	Group 2(Finasteride)					site cluster, and baseline IPSS
	N: 1,623					busenne il 55
	Dropouts:					
	Age, mean \pm sd,(yr): 66.0 \pm 6.99					
	No. white ethnicity (%): 1,433 (88)					
	IPSS , mean \pm sd: 16.4 \pm 6.03					
	Duration since first LUTS mean \pm sd, (yr):					
	5.3 ± 4.69					
	Prostate vol (cc):					
	Mean \pm SD total: 54.6 \pm 23.02					
	Median total: 48.4					
	Mean \pm SD transition zone*: 30.3 \pm 21.02					
	PSA serum , mean \pm sd:(ng/ml): 3.9 \pm 2.06					
	Qmax mean \pm sd (ml/sec): 10.6 \pm 3.57					
	Post-void residual vol, mean ± sd, (ml): 67.4 ± 63.49					
	No. sexually active (%): 1,189 (73)					
	No. previous α-blocker use (%): 820 (51)					
	No. previous 5-ARI use (%): 188 (12)					
	<u>Group 3: Tamsulosin + finasteride</u>					
	N: 1,610					
	Dropouts:					
	Age , mean \pm sd,(yr): 66.0 \pm 7.05					
	No. white ethnicity (%): 1,421 (88)					
	IPSS , mean \pm sd: 16.6 \pm 6.35					
	Duration since first LUTS mean \pm sd, (yr):					
	5.4 ± 5.07					
	Prostate vol (cc):					

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean \pm SD total: 54.7 \pm 23.51 Median total: 48.9 Mean \pm SD transition zone*: 27.7 \pm 20.20 PSA serum , mean \pm sd:(ng/ml): 4.0 \pm 2.05 Qmax mean \pm sd (ml/sec): 10.9 \pm 3.62 Post-void residual vol , mean \pm sd, (ml): 68.1 \pm 66.01 No. sexually active (%): 1,176 (73) No. previous α -blocker use (%): 805 (50) No. previous 5-ARI use (%): 171 (11)				

1	Evidence Table 11 Alpha-blockers vs. anticholinergics
2	

- 3 See Evidence Table 9 Alpha-blockers vs. placebo
- 4 for Kaplan et al., 2006 ¹¹⁹

Evidence Table 12 Alpha-blockers vs. phosphodiesterase-5 inhibitors

1	
2	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Kaplan et al., 2007 ¹¹⁷ Study design:	Patient group: consecutive men with moderate to severe untreated LUTS and erectile dysfunction Inclusion criteria:	citrate 25 mg one daily at night Group 2: Alfuzosin 10mg once daily after the same meal Group 3: Sildenafil citrate 25 mg/day + Alfuzosin 10 mg/day Examination methods: Patients assessed at baseline and 12 weeks. IPSS taken and frequency and nocturia quantified with bladder diary. Qmax and PVR also assessed. Q3 frequency of penetration and Q4 frequency of maintained erection were analysed separately.	IPSS ± SD at 12 weeks P value calculated by NCGC as <i>t</i> -test with equal variances	Grp 1: 14.9 ± 4.2 Grp 2: 14.6 ± 3.7 Grp 3: 13.5 ± 4.2 P value grp 1 v grp 2 = 0.81	Funding: NR Limitations:
RCT open label Setting: single- centre, Department of Urology, Weill Cornell Medical	LUTS and self reported erectile 10mg of dysfunction (not specific cut off the sam points) Group Exclusion criteria: Group citrate Alfuzos All patients Group		IPSS change (%) from baseline at 12 weeks (p change from baseline t-test) Change (mean ±sd) calculated by NCGC from the difference in baseline and follow up values. % values as reported	Grp 1: -2.40 ±4.25 (11.8%) p=0.03 Grp 2: -2.30 ±3.91(15.6%) p=0.01 Grp 3: -2.70 ±3.96 (24.1%) p=0.002	 This was an open label study with no randomisation allocation and concealment methods reported. The outcomes are mainly subjective outcomes, and this
College, NY, USA Evidence level: 1+ Duration of follow-up:	N: 62 Mean age: 63.4 ± 7.6 Drop outs: 7 (11%) due to adverse events <u>Group 1 (Sildenafil)</u> N: 21 Mean (\pm SD) Age: 64 ± 5.9 Duration of LUTS, mths: 14.3 ± 2.4 Duration of ED, mths: 25.6 ± 5.4 Frequency: 9.3 ± 2.6		Qmax mean± SD P value calculated by NCGC as <i>t</i> -test with equal variances	$\begin{array}{r} \underline{at \ 12 \ weeks} \\ \textbf{Grp 1: } 10.3 \pm 2.4 \\ \textbf{Grp 2: } 10.5 \pm 2.3 \\ \textbf{Grp 3: } 11.5 \pm 2.9 \\ \underline{Change \ from \ baseline} \\ \textbf{Grp 1: } 0.3 \pm 3.1 \\ \textbf{Grp 2: } 1.1 \pm 2.3 \\ \textbf{Grp 3: } 2.0 \pm 2.6 \end{array}$	makes it particularly at risk of biases. Additional outcomes: % change from baseline for Qmax, PVR, frequency and nocturia
3 months	Nocturia: 2.9 ± 0.6 IPSS, mean \pm SD: 17.3 ± 4.3 IPSS moderate (8-19): 43% IPSS severe (>20): 57%		Frequency ± SD at 12 weeks P value calculated by NCGC as <i>t</i> -test with equal variances	Grp 1: 7.8 ± 1.7 Grp 2: 6.4 ± 2.1 Grp 3: 6.1 ± 2.2 P value grp 1 v grp 2 = 0.02	IIEF Q3 % change from baseline and IIEF Q5 % change from baseline
	IIEF-EF domain, mean ± SD: 14.3 ± 5.2 IIEF Q3, mean ± SD: 2.1 ± 1.1 IIEF Q5, mean ± SD: 2.3 ± 1.3 Qmax, mean ± SD, mL/s: 9.7 ± 3.7 PVR, mean ± SD, mL: 46 ± 14.3 Dropouts: 2 (10%) <u>Group 2 (Alfuzosin)</u>		Nocturia ± SD at 12 weeks P value calculated by NCGC as <i>t</i> -test with equal variances	at 12 weeks Grp 1: 2.1 ± 0.9 Grp 2: 1.8 ± 0.9 Grp 3: 1.8 ± 1.1 Change from baseline Grp 1:-0.8±0.8 Grp 2:-1.3±1.0 Grp 3:-1.1±1.0	Notes: **Erectile Dysfunction assessed using the Erectile Function domain score of the 15-question IIEF, ie, ie Q1-5 and Q15 (Maximum score 30).
	N: 20		IIEF erectile function domain**	Grp 1: 21.4 ± 5.7	1

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean (± SD) Age: 62.6 ± 8.2 Duration of LUTS, mths, mean ± SD: 12.4 ± 2.3		± SD at 12 weeks P value calculated by NCGC as <i>t</i> -test with equal variances	Grp 2: 20.3 ± 5.2 Grp 3: 25.7 ± 4.9 P value grp 1 v grp 2 = 0.52	This is different from IIEF-5, which consists of question Q2, Q4, Q5,
	Duration of ED, mths, mean ± SD: 22.5 ± 4.9 Frequency, mean ± SD: 8.9 ± 2.5 Nocturia, mean ± SD: 3.1 ± 1.1		IIEF erectile function domain** % change from baseline at 12 weeks (p change from baseline t-test)	Grp 1: 49.79%, p=0.01 Grp 2: 16.7%, p=0.11 Grp 3: 58.6%, p=0.002	Q7 and Q15 of the IIEF (maximum score 25).
	IPSS, mean \pm SD: 16.9 \pm 4.1 IPSS moderate (8-19): 45% IPSS severe (>20): 55% IIEF-EF, mean \pm SD: 17.4 \pm 4.9 IIEF Q3, mean \pm SD: 2.3 \pm 1.3 IIEF Q5, mean \pm SD: 2.4 \pm 1.2 Qmax, mean \pm SD, mL/s: 9.4 \pm 2.2 PVR, mean \pm SD, mL: 54 \pm 17.8 Dropouts: 2 (10%)		Adverse Events N Withdrawals due to adverse events Dizziness Flushing Dyspepsia Gastric upset	2 2 3 0 2 1 1 0 0 1 0 0	*Q3 - frequency of penetration and Q4 - frequency of maintained erection from the IIEF were analysed separately. % of IIEF change from baseline had been
	Group 3 (Sildenafil + Alfuzosin) N: 21 Mean (± SD) Age: 63 ± 6.9 Duration of LUTS, mths mean±SD: 13.9±2.7 Duration of ED, mths, mean±SD:				updated to correct publication error in original article.
	$\begin{array}{l} 26.9 \pm 5.4 \\ \hline \text{Frequency, mean} \pm \text{SD: } 9.1 \pm 2.2 \\ \hline \text{Nocturia, mean} \pm \text{SD: } 2.89 \pm 0.9 \\ \hline \text{IPSS}, \text{mean} \pm \text{SD: } 16.2 \pm 3.7 \\ \hline \text{IPSS} \text{ moderate (8-19): } 48\% \\ \hline \text{IPSS severe (>20): } 52\% \\ \hline \text{IIEF-EF mean} \pm \text{SD: } 16.2 \pm 3.7 \\ \hline \text{IIEF Q3, mean} \pm \text{SD: } 2.1 \pm 1.1 \\ \hline \text{IIEF Q5, mean} \pm \text{SD: } 2.3 \pm 1.3 \\ \hline \text{Qmax, mean} \pm \text{SD, mL/s: } 9.5 \pm 2.3 \\ \hline \end{array}$				
	PVR , mean ± SD, mL: 53 ± 19.8 Dropouts: 3 (14%)				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
-	Patient group: Men meeting objective evidence of obstruction after pressure flow studies Inclusion criteria: > 55 years Ambulatory Enlarged prostate by DRE Presence of LUTS Exclusion criteria: PSA > 10 ng/mL Need for immediate surgery	Interventions Group 1: Finasteride 5 mg 1/day Group 2: Placebo 1/day Examination methods: Uroflowmetry performed at 4, 8, 12 months with voided volume of ≥ 150 mL. Prostate volume measured at baseline and month 12. IPSS assessed at 4, 8, 12 months	Outcome measures Mean change in IPSS ± SD from baseline at 1 year Mean change in Qmax ± SD from baseline at 1 year Withdrawals due to adverse events	Effect size Grp 1: -4.8 \pm 6.4* (n=69) Grp 2: -3.3 \pm 6.4* (n=37) P value: NS Grp 1: 1.1 \pm 2.5 (n=69) Grp 2: -0.1 \pm 1.5 (n=37) P value: 0.02 Grp 1 Grp 2 3 3	Comments Funding: NR Limitations: Randomisation & allocation concealment method not reported. Unclear whether examiners or investigators are masked. Primary outcomes are not changed in symptom score or adverse events
Duration of follow-up: 1 year	 PVR ≥300 mL Urethral strictures Chronic Bacterial prostatitis Neurogenic bladder Previous prostate or testicular surgery Prostate cancer or suspect Neurogenic bladder Acute UTI Use of drugs with anti-androgenic properties or alpha-blockers or plant extracts History of drug or alcohol abuse Evidence of renal or hepatic impairment 				Additional outcomes: Detrusor pressure Free maximum flow rate Notes: Study was designed to detect differences in urodynamic parameters rather than symptom score. Randomisation was on a 2:1 basis
	 History of recurrent renal or prostatic calculi <u>All patients</u> N: 121 (out of 201 screened) Mean age: Drop outs: 15/121 (12.4%) Group 1 (Finasteride 5mg/dayl) 				* Standard deviation for change from baseline calculated using reported mean difference and confidence intervals for the between group comparison following methods from Cochrane Handbook

1 Evidence Table 13 5-alpha reductase inhibitors vs. placebo

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	N: 81 Mean (\pm SD) Age: 68.1 \pm 6.1 IPSS \pm SD: 19.4 \pm 6.3 Qmax \pm SD, mL/s: 6.7 \pm 2.4 Prostate volume \pm SD, mL: 45.4 \pm 21.9 Number obstructed: 61 Number equivocal: 19 Dropouts: 12/81 (14.8%) Group 2 (Placebo 1/day) N: 40 Mean (\pm SD) Age: 67.4 \pm 7.2 IPSS \pm SD: 17.4 \pm 6.8 Qmax \pm SD, mL/s: 7.0 \pm 2.0 Prostate volume \pm SD, mL: 44.8 \pm 20.2 Number obstructed: 33 Number equivocal: 7 Dropouts: 3/40 (7.5%)				Study reports that analysis of variance was used to compare baseline to follow up with treatment centre and treatment group as variables.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Andersen et al., 1995 ¹² Setting: multi-	Patient group: Men moderate symptoms of BPH Inclusion criteria:	Group 1: Finasteride 5 mg 1/day Group 2: Placebo 1/day	Mean change in total symptom score from baseline at 24 months (Boyarsky scale)	Grp 1: -2.0 ± 6.2 *(n=347) Grp 2: 0.2 ± 7.6 * (n=346) P value: <0.01	Funding: Merck & Co, Inc. Limitations:	
centre, 59 centres in 5 Scandinavian countries	e, 59 es in 5 dinavian → ≤ 80 years • Ambulatory and good physical and mental health → bysical examination → bysical examination	Mean change in obstructive symptom score from baseline at 24 months (Boyarsky scale)	Grp 1: -1.5 ± 4.3 * (n=348) Grp 2: -0.2 ± 4.7 * (n=344) P value: <0.01	 Randomisati n & allocatio concealment method not 		
(Denmark, Finland, Iceland, Norway and Sweden)	 start of placebo run-in) Enlarged prostate by DRE At least 2 symptoms indicting moderate BPH (increased frequency of urination 	performed at baseline and months 12 and 24. Symptoms measured at baseline and months 1.4.	Mean change in Qmax from baseline at 12 months estimated from graph with confidence intervals	Grp 1: 1.2 ± 3.1* (n=308) Grp 2: -0.3 ± 3.6* (n=309) P value: <0.01	whether examiners o	
Study design: RCT double	or difficulty in urination) but not more than 2 severe symptoms • Serum PSA ≤ 10 ng/mL	using modified Boyarsky scale (9 questions max score is 54) and	Mean change in Qmax from baseline at 24 months	Grp 1: $1.5 \pm 3.6^*$ (n=308) Grp 2: $-0.3 \pm 3.1^*$ (n=309) P value: <0.01	 investigator are masked Median changes fro 	
blinded	 PVR ≤ 150 mL Exclusion criteria: 	obstructive symptoms	Mean change in Prostate volume from baseline at 24 months	Grp 1: -19.2 ± 23.1* (n=197) Grp 2: 11.5 ± 47.3 *	baseline reported.	
Evidence level: 1+	 Haematuria associated with UTI, prostatitis or bladder carcinoma Serum creatinine > 150 mmol/L or liver 	force of urinary stream, hesitancy or delay in starting urination,		(n=197) P value : <0.01	Additional outcomes:	
Duration of follow-up:	function tests ≥50% above normal • Urethral strictures	dribbling, interruption of	Median % change in PSA from baseline at 24 months	Grp 1: -52% Grp 2: 6% P value < 0.0001	Change in total symptom score c 12 months	
24 months	months • Chronic Bacterial prostatitis score is 30) F • Previous prostate or testicular surgery • Flow rates measured using • Prostate cancer Dantec Urodyn 1000, PVR • Neurogenic bladder measured using portable • ≥2 catheterisations for AUR in previous ultrasound device at • 2 years baseline and 12 & 24	Reason for withdrawal § N Adverse Events Insufficient response Other (lost to follow up, protocol deviation, uncooperative)	13 22	Notes: Eligible patients entered 1 mont single blind placebo run-in 1 reduce placebo		
	 Significant abnormalities detected in screening examination Untreated UTI Use of drugs with anti-androgenic properties 	baseline and months 12 &	baseline and months 12 & 24. Subset of 416 patients had prostate volume	Adverse events – sexual dysfunction	Grp 1: 67/353 Grp 2: 34/354 P value < 0.01	effect then randomised. Patients who withdrew were included in

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	$\label{eq:spectral_series} \begin{array}{ c c c c } \hline \textbf{All patients} \\ N: 707 \\ \mbox{Mean age: } 65.5 \mbox{(range 46-80)} \\ \mbox{Drop outs: } 130 \mbox{(18.4\%)} \\ \hline \textbf{Group 1 (Finasteride 5mg/dayl)} \\ \mbox{N: } 353 \\ \mbox{Mean (range) Age: NR} \\ \mbox{Total symptom score: } 13.4 \pm NR \mbox{(n=347)} \\ \mbox{Total obstructive score: } 8.8 \pm NR \mbox{(n=348)} \\ \mbox{Qmax \pm SD, mL/s: } 10.2 \pm NR \mbox{(n=308)} \\ \mbox{Prostate volume \pm SD, mL: } 40.6 \pm NR \\ \mbox{(n=197)} \\ \mbox{Dropouts: } 66 \mbox{(18.7\%) see withdrawals§} \\ \hline \mbox{Group 2 (Placebo 1/day)} \\ \mbox{N: } 354 \\ \mbox{Mean (range) Age: NR} \\ \mbox{Total symptom score: } 13.1 \pm NR \mbox{(n=346)} \\ \mbox{Total obstructive score: } 8.6 \pm NR \mbox{(n=344)} \\ \mbox{Qmax \pm SD, mL/s: } 10.5 \pm NR \mbox{(n=309)} \\ \mbox{Prostate volume \pm SD, mL: } 41.7 \pm NR \\ \mbox{(n=197)} \\ \mbox{Dropouts: } 64 \mbox{(18.1\%) see withdrawals§} \\ \hline \end{array}$				analysis using Last observation Carried Forward. Study reports that analysis of variance used to compare outcomes but it unclear what variables were used in the model.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments							
Beisland et al., 1992 ²⁵	Patient group: men with symptomatic urinary obstruction	Group 1: Finasteride 5 mg 1/day	Mean change in Qmax(ml/s) from baseline at 24 weeks	Grp 1: 1.6 ± 1.4* (n=87) Grp 2: 1.1 ± 1.4* (n=81) P value: 0.022(as reported)	Funding: Not stated. Most likely Merck Laboratories, as 4/12 authors							
Setting: multi- centre (8) in Sweden and Norway	 Inclusion criteria: 40-80 years in good physical and mental health with symptoms of urinary 	Group 2: Placebo 1/day Symptoms were	Median % change in PSA from baseline at 12 weeks months	Grp 1: -22.4 Grp 2: No change P value < 0.001	 were from Merck Limitations: Method of randomisation 							
Scandinavian finasteride study group	 obstructions and Qmax <15 ml/s documented by two measurements at screening. Enlarged prostate by DRE 	assessed using a modified Boyarksy scale modified which comprises 9 questions	Median % change in PSA from baseline at 24 weeks months	Grp 1: -32.4 Grp 2: No change P value < 0.001	 and concealment not reported A modified Boyarksy scale was used 							
Study design: RCT double blinded.	 Exclusion criteria: Clinical or laboratory abnormalities 	(max score is 36). Patients were treated as mild if the score was	Mediun % decrease iun prostate volume from baseline at 24 weeks	Grp 1: 22.5 Grp 2: 1.0 P value < 0.001	Additional outcomes: Change of to total symptom score (Boyarsky scale) from							
Patients and investigators.	All patients	<6, moderate (6-13) and severe if scores were >13.	§ Reason for withdrawal** (see notes)	Grp 1 Grp 2	baseline at 12 weeks for finasteride (-2.1) vs. placebo 0.8) was significant							
Evidence level: 1+	N: 182 Mean age: NR Drop outs: 14/182 (7.65)	Obstructive symptoms totalled for the	N Adverse Events No response Other	6 1	(0=0.0046) for 12 weeks. Change for obstructive							
Duration of follow-up: 6 months	Group 1 (Finasteride 5mg/dayl) N: 94 Mean (range) Age: 66.6 (46-80)	following questions: impairment of size and force	Withdrawal due to sexual adverse events	Grp 1 Grp 2 1 1	symptoms scores were -2.0 vs. 0.7 for 24 weeks (p=0.05) using analysis of covariance							
o monins	Total symptom score, mean ± SD: 8.8 ± 6.1 Total obstructive score, mean ± SD: 2.2 ± 4.0	of urinary stream hesitancy or delay in starting	stream hesitancy or	stream hesitancy or	stream hesitancy or	stream hesitancy or	stream hesitancy or	stream hesitancy or	stream hesitancy or	Adverse events N Insomnia and depression Deep vein thrombosis		DHT level changes from baseline were also reported
	Troublesome score, mean ± SD: Qmax ± SD, mL/s: 8.0 ± 3.0 Prostate volume ± SD, cm ³ : 44.2 ±	the flow of urine dribbling after urination	Urinary retention Decreased libido Impotence	1 0 1 0	Notes: *Standard deviations for changes from baseline							
	22.4 Drop outs: 7/94 (7.4%) see withdrawals§	 feeling of incomplete emptying of the bladder 			calculated from reported p values between groups using Cochrane methodology							
	<u>Group 2 (Placebo 1/day)</u>	 interruption of urinary stream 			Analysis of covariance used to compare baseline parameters							

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	N: 88 Drop outs: 3/88 (3.4%) Mean (range) Age: 68.0 (54-79) Total symptom score, mean ±S D: 7.8 ± 4.9 Total obstructive score, mean ± SD: 1.1 ± 3.3 Troublesome score, mean ± SD: 6.8 ± 3.9 Qmax ± SD, mL/s: 7.6 ± 3.1 Prostate volume ± SD, cm ³ 43.8 ± 24.1				and % change from baseline. **6 year follow up reported by Ekman et al.,1998 ⁶⁹ . The number of drop outs reported in this report was 14. Adverse events reported in more detail in BEISLAND1992.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments								
Byrnes et al., 1995 ³⁵	Patient group: Men attending community- based clinics for treatment of BPH	Group 1: Finasteride 5 mg 1/day	Mean change in AUA-7 symptom score from baseline at 3 months	Grp 1: $-3.3 \pm 7.7^*$ (n=1759) Grp 2: $-2.6 \pm 7.8^*$	Funding: Merck & Co, Inc.								
Setting: multicentre, USA	 Inclusion criteria: Clinical diagnosis of BPH based on moderate to severe symptoms with prostate gland enlargement on DRE 	Group 2: Placebo 1/day	Estimated from graph with confidence intervals. Numbers at follow up not clear so total for efficacy analysis used.	(n=583) P value : <0.05	 Limitations: Randomisation & allocation concealment method 								
Study design: RCT double blinded Evidence	 PSA ≤ 10 ng/mL Exclusion criteria: Urethral strictures Previous prostate surgery 	Examination methods: Physical examination including DRE was	methods: Physical examination	methods: Physical examination including DRE was	methods: Physical examination including DRE was	Examination M methods: s Physical 6 examination e including DRE was c	Mean change in AUA-7 symptom score from baseline at 6 months estimated from graph with confidence intervals	Grp 1: -4.1 \pm 7.7* (n=1759) Grp 2: -3.3 \pm 7.8* (n=583) P value: <0.05	 Unclear whether examiners or investigators are masked. 				
level: 1+ Duration of follow-up:	 Pelvic radiotherapy Chronic Bacterial prostatitis Neurogenic bladder Recurrent UTI Use of drugs with anti-androgenic 	performed at baseline and 12 mths. Serum dihydrotestosterone measured at	Mean change in AUA-7 symptom score from baseline at 12 months estimated from graph with confidence intervals	Grp 1: $-4.6 \pm 9.6^*$ (n=1759) Grp 2: $-3.3 \pm 8.6^*$ (n=583) P value: <0.05	 Numbers of patients remaining at each time point not clear for AUA score. Additional outcomes: 								
12 months	 Prostate cancer or suspected 	baseline and mths 6 & 12 AUA-7 Symptom score, BPH Impact Index (BII) used for	Mean change in BPII at 12 months	Grp 1: $-1.2 \pm 4.2^*$ (n=1711) Grp 2: $-0.9 \pm 3.7^*$ (n=575) P value: <0.04 (ANOVA)	BPII + patient satisfaction question at 12 mths, activities of living score a 12 mths, general adjustment question at 12								
	All patients N: 2417 included in safety analysis, 2342 in efficacy analysis Mean age: 65 Drop outs: 465 (19.2%)	HRQoL, Patient satisfaction with urinary condition as extra question (0- 6) and additional	n satisfaction with urinary condition as extra question (0-	satisfaction with urinary condition as extra question (0- 6) and additional	satisfaction with urinary condition as extra question (0- 6) and additional	satisfaction with urinary condition as extra question (0- 6) and additional	satisfaction with urinary condition as extra question (0- 6) and additional	satisfaction with urinary condition as extra question (0- 6) and additional	satisfaction with urinary condition as extra question (0- 6) and additional	satisfaction with urinary condition as extra question (0- 6) and additional	Mean change in patient global assessment at 12 months	Grp 1: $4.9 \pm 2.1.2^*$ (n=1714) Grp 2: $4.7 \pm 1.2^*$ (n=575) P value: 0.0001 (ANOVA)	mths, investigator global assessment at 12 mths Notes: Eligible patients entered
	Group 1 (Finasteride 5mg/dayl) N: 1821 randomised 1759 efficacy	questions from modified BSIA instrument to	% Patients rating themselves "better" at 12 mths	Grp 1: 56.2 % Grp 2: 44.2 % P value: <0.001	1 month single blind placebo run-in. Men with moderate to severe								
	Mean (range) Age: 65 (42-91) White/other: 1226 Black: 285	measure interference with activities and extra quastion about	% Investigators rating patients "better" at 12 mths	Grp 1: 55.3 % Grp 2: 45.8 % P value: <0.001	symptoms after run-in with good compliance were randomised in 3:1								
	Hispanic: 248 AUA symptom score mild (<8): 33 AUA symptom score moderate (8-19):	question about adjustment of activities to cope	Reason for withdrawal § Total withdrawals Adverse Events		ratio. *Standard deviations for								

1001 AUA symptom score unknown: 1 Blit 5.1 C195% 4.9-5.2 Bli + patient satisfaction: 8.8 C195% 8.6- 9.0 Activities of living score: 13.3 C195% 12.8-13.8 Group 2 (Placebo 1/day) N: 596 randomised 583 efficacy Mean (range) Age: 65.1 (45-91) White/other: 397 Black: 95 Hispania: 91 AUA symptom score unknown: 0 Blit 5.0 C195% 4.8-5.3 Bli + patient satisfaction: 8.6 C195% 8.3- 9.0 Activities of living score: 12.8 C195% 8.3- 9.0 Activities of living score: 12.8 C195% 1.2-1.4 Blit 1- patient satisfaction: 8.6 C195% 8.3- 9.0with unary symptom score mild (<8): 13 AUA symptom score unknown: 0 Blit 5.0 C195% 4.8-5.3 Blit + patient satisfaction: 1.3 C195% 1.2-1.4with unary symptom score mild (<8): 1.3 Adjustment question: 1.3 C195% 1.2-1.4with unary symptom score mild (<8): 1.3 Adjustment question: 1.3 C195% 1.2-1.4with unary symptom score mild (<8): 1.3 Adjustment question: 1.3 C195% 1.2-1.4with unary symptom score mild (<8): 1.3 Adjustment question: 1.3 C195% 1.2-1.4with unary symptom score mild (<8): 1.3 Adjustment question: 1.3 C195% 1.2-1.4with unary symptom score mild (<8): 1.3 Adjustment question: 1.3 C195% 1.2-1.4divide a factore of a

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Finasteride Study Group, 1993 ⁸¹	Patient group: Men with BPH and symptoms of BOO Inclusion criteria:	Group 1: Finasteride 5 mg 1/day Group 2: Placebo 1/day	Median change in total symptom score (Boyarsky scale) from baseline at 12 months Estimated from graph	Grp 1: 3.3 Grp 2: 2.0 P value = signif (value NR)	Funding: Merck Limitations:	
Setting: multicentre worldwide	 40-80 years Good physical and mental health Qmax < 15 mL/s (from 2 measurements) 	Group 3: Finasteride 1 mg 1/day	Median change in Qmax from baseline at 12 months Estimated from graph % patients achieving ≥ 3 mL/s	Grp 1: 1.38 Grp 2: 0.42 P value = 0.025 Grp 1: 31.0 %	Randomisation Randomisation n & allocation concealment method not	
Study design: RCT double blinded	 Prostate volume ≥ 30 mL Exclusion criteria: 	Results and baseline characteristics reported for normal dose finasteride arm	flow increase Median % change in prostate	Grp 2: 21.0 % Grp 1: 22.4 %	reported. Unclear whether	
Evidence	Bacterial prostatitisPrevious prostate or testicular	5mg/day only Examination methods:	mination methods: aseline and months 3, 6 & rostate volume measuredmonthsP value < 0.001Median % change in PSA from baseline at 12 monthsGrp 1: 46.0 % Grp 2: 0 (no change)		examiners o investigators are masked	
level:]+	surgery • Prostate cancer • PSA ≥ 40 ng/mL	At baseline and months 3, 6 & 12 prostate volume measured by TRUS and Qmax		Grp 1: 46.0 % Grp 2: 0 (no change) % P value < 0.001	 Median changes from baseline 	
Duration of follow-up: 12 months	 PVR > 350 mL Neurogenic bladder Repeated catheterisations 	measured at by Dantec Urodyn 1000 uroflowmeter, Boyarsky symptom		Grp 1 Grp 2 249 255	 reported. Dropouts no clearly 	
	 Repeated catheterisations Use of drugs with anti-androgenic properties 	questionnaire taken (9 questions). Testosterone, dihydrotestosterone, luteinising hormone measured at baseline and weeks 2, 8, 16, 24 and 9 and 12 months. Thyroxine and thyroid stimulating hormone measured at baseline and months 3 & 6. PSA measured at -2, 12, 24 weeks and 9 & 12 months	questions).	Withdrawals due to adverse events Impotence	12 1 p <0.001	reported Additional
	All patients N: 750 (all treatment arms) Mean age: NR Drop outs: NR		Acute urinary retention		outcomes: % change from baseline for plasma dihydrotestostero	
	Group 1 (Finasteride 5mg/dayl) N: 249 Mean (range) Age: 66 (46-83) Total obstructive score (max 20): 11.2				ne Notes: Eligible patients entered a 2 wee	
	± 3.8 Total symptom score (max 36): 18.6 ± 6.0 Qmax ± SD, mL/s: 9.2 ± 4.0				month single blin placebo run-in to reduce placebo effect then	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Prostate volume ± SD, mL: 47.0 ± 20.8 PSA ± SD, ng/mL: 5.8 ± 6.7 Dropouts: Not clear. 1 patients withdrew due to impotence but others not mentioned Group 2 (Placebo 1/day) N: 255 Mean (range) Age: 66 (46-81) Total obstructive score (max 20): 11.1 ± 3.7 Total symptom score (max 36): 18.2 ± 5.9 Qmax ± SD, mL/s: 8.6 ± 3.4 Prostate volume ± SD, mL: 46.3 ± 23.4 PSA ± SD, ng/mL: 5.7 ± 7.2 Dropouts: NR				randomised. Analysis of variance used to compare outcomes with treatment centre and treatment group and treatment-centre interaction as model parameters

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Gormley et al., 1992 ⁹⁴	Patient group: Men with BPH and symptoms of urinary obstruction	Group 1: Finasteride 5 mg 1/day	Mean symptom score(Boyarsky) at 12 months	Grp 1: 7.5 ± 5.2 (n=257) Grp 2: 8.8 ± 6.1 (n=263) P value: <0.05	Funding: Merck & Co, Inc.
Finasteride study group Setting: multi-	 Inclusion criteria: 40-83 years Enlarged prostate gland enlargement 	Group 2: Placebo 1/day Group 3: Finasteride	Mean obstruction score(Boyarsky) at 12 months	Grp 1: 5.1 ± 3.6 (n=257) Grp 2: 5.9 ± 3.8 (n=263) P value: <0.001	 Limitations: Randomisation n & allocation
centre, 25 centres in USA and 5 in	 on DRE Qmax < 15 mL/s with voided volume of ≥ 150 mL Men with very low urinary flow rates 	1 mg 1/day Results and baseline	Mean Qmax at 12 months	Grp 1: 11.2 ± 4.7 (n=257) Grp 2: 9.8 ± 3.7 (n=263) P value: <0.001	 concealment method not reported. Unclear
Canada Study design: RCT double	Exclusion criteria:	characteristics reported for normal dose finasteride arm 5mg/day only	Mean Prostate volume at 12 months	Grp 1: $47.5 \pm 23.6 \text{ (n}=257)$ Grp 2: $59.8 \pm 39.4 \text{ (n}=263)$ P value: <0.001	whether key examiners or investigators
blinded	 Prostate cancer or suspected PVR > 350 mL Serum PSA > 40 µg/l 	Examination methods:	Reason for withdrawal * Total Adverse Events		are masked. Additional
Evidence level: 1+	 Serum PSA ≥ 40 µg/L UTI Chronic prostatitis Neurogenic bladder 	Men were examined monthly by the same investigator for	Lost to follow up Treatment failure Other	3 4 12 9 9 6	outcomes: Median PSA at follow up, Median change in
Duration of follow-up: 12 months	<u>All patients</u> N: 895 (all study arms) Mean age: 64 Drop outs: 105/895 (11.7%)	symptoms (Boyarsky – 9 questions max score 36), obstructive symptoms (Boyarsky – first 5 questions max score 20), side effects	Adverse events ** N randomised Impotence Libido decrease Ejaculation disorder Breast pain	10 5 14 4 p <0.05 13 5 p <0.05	prostatic volume % at follow up. Mean Qmax + S at follow up as graph.
	Group 1 (Finasteride 5mg/dayl) N: 297 Mean (range) Age: 64 (40-80) White: 286 Black: 6	and compliance. Flow rate measured using Urodyn 1000, PVR using TRUS. Prostate volume	Digestive system Dizziness Headache Asthenia lens opacity	8 6 0 2 2 2 3 3 0 2	Notes: Eligible patients entered 2 week single blind placebo run-in.
	Other: 5 Total Symptom score \pm SD: 10.2 ± 5.5 Obstructive symptom score \pm SD: 7.0 ± 3.6 Qmax \pm SD, mL/s: 9.6 ± 3.7	measured using MRI at baseline, 3, 6 & 12 mths;, ophthalmic examination at 12 mths; serum amino- transferases, urea	lens change Withdrawal due to sexual dysfunction ** Possibly, probably or definitely drug related		ITT analysis with missing data fron last observation carried forward.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Prostate volume, mL: 58.6 ± 30.5 Serum PSA \pm SD, μ g/L: 3.6 ± 4.2 PVR \pm SD, mL: 73 ± 89 Dropouts: 40 (13%) for reasons see* Group 2 (Placebo 1/day) N: 300 Mean (range) Age: 64 (45-82) White: 288 Black: 8 Other: 4 Total Symptom score \pm SD: 9.8 ± 5.3 Obstructive symptom score \pm SD: 6.7 ± 3.5 Qmax \pm SD, mL/s: 9.6 ± 3.5 Prostate volume, mL: 61.0 ± 36.5 Serum PSA \pm SD, μ g/L: 4.1 ± 4.8 PVR \pm SD, mL: 73 ± 91 Dropouts: $37 (12\%)$ for reasons see*	nitrogen, creatinine, Na, K, Ca and glucose measured every 3 mths. Compliance determined by counting number of tablets remaining and serum dihydrotestosterone measurements			Analysis of variance used to compare outcomes with treatment centre and treatment group as model parameters

See Evidence Table 10 Alpha blocker vs. 5-alpha reductase inhibitors

3 for Lepor et al., 1996¹⁴².

Study details	Patients	Interventions	Outcome measures	Effect size	Comments				
Marberger et al., 1998 ¹⁵⁷ PROWESS	Patient group: Men moderate symptoms of BPH Inclusion criteria:	Group 1: Finasteride 5 mg 1/day	Mean change ± SD in total symptom score at 1 year (Boyarsky scale)	Grp 1: -2.9 ± NR Grp 2: -1.9 ± NR P value: ≤0.001 (ANOVA)	Funding: Merck & Co, Inc. manufacturers of finasteride				
study group Setting: multi- centre, 285 worldwide	 50 - 75 years Good general health Enlarged prostate gland enlargement on DRE 	Examination methods: Total and obstructive symptom score on modified	1/day Examination methods: Total and obstructive symptom score on modified	1/day Examination methods: Total and obstructive symptom score on modified	Mean change ± SD in total symptom score at 2 years(Boyarsky scale)	Grp 1: -3.2 ± NR Grp 2: -1.5 ± NR P value: ≤0.001 (ANOVA)	Limitations: Standard deviations for Qmax were not		
Study design: RCT double blinded	 Qmax 5 - 15 mL/s with a voided volume ≥ 150mL (2 measurements) No more than 2 severe symptoms on modified Boyarsky scale 				Total and obstructive symptom	Mean change in Qmax ± SD at 1 year	Grp 1: 1.2 ± NR Grp 2: 0.6 ± NR P value: 0.01 (ANOVA)	reported. Additional outcomes:	
(patients and investigators)	 PSA < 10 ng/mL PVR < 150 mL 	measured at baseline and every 4 months. Prostate	Mean change in Qmax ± SD at 2 year	Grp 1: 1.5 ± NR Grp 2: 0.7 ± NR P value: 0.002 (ANOVA)	Change in obstructive symptom score at				
Evidence level: 1+	 Exclusion criteria: Dysuria, haematuria Previous prostate or bladder 	volume measured at baseline and 1 and 2 years by TRUS.	baseline and 1 and	baseline and 1 and	baseline and 1 and	Dysuria, haematuria Previous prostate or bladder baseline and 1 and 2 years by TRUS.	Mean % change in prostate volume from baseline at 1 year	Grp 1: -13 ± NR Grp 2: +5 ± NR P value: ≤0.01 (ANOVA)	1 and 2 years % change in prostate volume
Duration of follow-up:	 surgery Concurrent use of alpha-blockers or anti-androgens Recurrent UTI 		Mean % change in prostate volume from baseline at year	Grp 1: -15 ± NR Grp 2: +9 ± NR P value: ≤0.001(ANOVA)	Notes: Eligible patients entered 1 month				
2 years	 Chronic prostatitis Bladder cancer Abnormalities on clinical examination Liver function tests >50% above upper limit of normal Allergies 		Adverse Events Lack of improvement Protocol deviation Patient compliance	111 144 50 64 25 14 40 40 70 55	single blind placebo run-in prior to computer generated randomisation. Sample size of 3000 to detect				
	 History of drug or alcohol abuse Prostate cancer or suspected Neurogenic bladder Urinary catheterisation for AUR twice during previous 2 years 		Drug related adverse events (>1%)	Grp 1 Grp 2 1577 1591 63 44 104 74 p <0.05	change in symptom score of 1.4 ± 7 from baseline and change of 1.1 ± mL/s in Qmax				

Study details	Patients	Interventions	Outcome measures	Effect	size	Comments
-	 Patients Poor compliance during placebo run in. Planned fatherhood All patients N: 2902 in efficacy analysis (368 excluded from some centres for poor clinical practice) and 3168 included in safety analysis Mean age: Drop outs: Group 1 (Finasteride 5mg/dayl) N: 1450 Mean (± SD) Age: 63.0 ± 6.3 Total Symptom score (Boyarksy) ± SD: 14.5 ± 7.3 Obstructive score ± SD: 9.3 ± 4.6 Qmax ± SD, mL/s: 11.2 ± 5.9 Prostate volume, mL: 38.7 ± 20.1 Dropouts: 331/1450 (23%) see* 	Interventions	Asthenia/fatigue Rash Headache Withdrawal due to sexual problem	11 24 17 21 33 36 22 16 28 40 48 58 44 29 38 36 72 64 55 61 57 55 27 46 16 13 10 24	size p <0.05 p <0.05 p <0.05	and 11% ± 40 change in prostate volume of power=99% and α 0.05. Data collected for those patients that discontinued ** Mean change and SD from baseline were estimated from graphs for mean change and standard error. Analysis of variance used to compare outcomes but it's not clear what
	N: 1452 Mean (± SD) Age: 63.4 ± 6.1 Total Symptom score (Boyarksy) ± SD: 14.3 ± 7.2 Obstructive score ± SD: 9.1 ± 4.5 Qmax ± SD, mL/s: 10.9 ± 3.6 Prostate volume, mL: 39.2 ± 20.2 Dropouts: 360/1452 (23%) see*					variables have been included in the model

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
McConnell et al., 1998 ¹⁶⁵ Study also reported in	Patient group: Men moderate to severe symptoms of BPH	Group 1: Finasteride 5 mg 1/day	Mean change ± SD in Quasi-AUA score at 1 year**	Grp 1: -2.4 \pm 4.5 (n=1314) Grp 2: -1.6 \pm 4.5	Funding: Merck & Co, Inc.	
Roehrborn et al., 2000{ROEHRBORN2000)	 Inclusion criteria: Enlarged prostate gland enlargement on DRE 	Group 2: Placebo 1/day		(n=1296) P value : NR	manufacturers of finasteride	
PLESS study group Setting: multi-centre, 95 centres in USA	 Qmax < 15 mL/s PVR < 300 mL Exclusion criteria: 	Examination methods: Patients were evaluated every 4 months fpr symptom score, flow	Mean change ± SD in Quasi-AUA score at 2 year**	Grp 1: -2.9 ± 6.4 (n=1153) Grp 2: -1.3 ± 6.2 (n=1101) P value: NR	Limitations: • High discontinuation rate at	
Study design: RCT double blinded	udy design: • Previous prostate or bladder surgery rate (• Concurrent use of alpha-blockers • measu month	 measured every 4 months for 1 year and every 8 months thereafter. Blood components and DRE A performed every year to and biopsy if clinically indicated. Prostate volume was measured in a subset of 10% of patients at 13 sites using MRI. At the beginning of the study symptom score was assessed using a symptom score 	Mean change ± SD in Quasi-AUA score at 3 year**	Grp 1: -3.1 ± 6.1 (n=1047) Grp 2: -1.3 ± 5.8 (n=961) P value: NR	- >30% for both arms though efforts were made	
Evidence level: 1+ Duration of follow-up: 4 years	 Recurrent UTI Chronic prostatitis PSA >10 ng/mL (those with PSA > 4 ng/mL had a TRUS biopsy to rule out prostate cancer) 		components and DRE performed every year and biopsy if clinically	Mean change ± SD in Quasi-AUA score at 4 year**	Grp 1: -3.3 \pm 5.8 (n=965) Grp 2: -1.1 \pm 5.5 (n=853) P value: NR	data (see notes) • Unclear
	All patients N: 3040 randomised but 1 centre		Mean change in Qmax ± SD at 1 year**	Grp 1: 1.3 ± 3.1 (n=928) Grp 2: 0.2 ± 3.0 (n=899) P value: NR	whether key examiners or	
	closed (n=24) so data available for 3016 patients Mean age: Drop outs: 1157/3040 (38%)		At the beginning of the study symptom score	Mean change in Qmax ± SD at 2 year**	Grp 1: 1.8 ± 5.6 (n=786) Grp 2: 0.4 ± 5.4 (n=720) P value: NR	investigato s are masked.
	Group 1 (Finasteride 5mg/dayl) N: 1524		Mean change in Qmax ± SD at 3 year**	Grp 1: 1.8 ± 5.3 (n=691) Grp 2: 0.0 ± 4.9 (n=608) P value: NR	Additional outcomes: % change in	
	White: 94.9 %the AUA but with aBlack: 3%slightly different score	slightly different score.	Mean change in Qmax ± SD at 4 year**	Grp 1: 2.0 ± 4.9 (n=588) Grp 2: 0.2 ± 4.9 (n=496) P value: NR	prostate volume	
	Other: 2.1% Quasi AUA Symptom score ± SD: 15.2 ± 5.6	The AUA symptom score was then adopted and the data from both	Mean change (%) in prostate volume at 1 year	Grp 1: -16 (n=144) Grp 2: +5 (n=136) P value: NR	Eligible patients entered 1 month single	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Qmax ± SD, mL/s: 10.9 ± 3.9 Prostate volume, mL: 54 ± 25 Serum PSA ± SD, μg/L: 2.8 ± 2.1	scores combined as a Quasi AUA 0-34 points (1-5 for 6 questions and	Mean change (%) in prostate volume at 2 year	Grp 1: -18 (n=130) Grp 2: +9 (n=119) P value: NR	blind placebo run-in prior to computer
	Dropouts: 524/1524 (34%) see* <u>Group 2 (Placebo 1/day)</u> N: 1516 Mean (± SD) Age: 63.9 ± 6.6 White: 995.5.9 % Black: 3% Other: 1.5% Quasi AUA Symptom score ± SD: 15.2 ± 5.8 Qmax ± SD, mL/s: 11.1 ± 4.8	1-4 for 1 question)	Mean change (%) in prostate volume at 3 year Mean change (%) in prostate volume at 4 year Reason for withdrawal * Total discontinuations Adverse Events Lack of improvement Worsening of disease	176 166 99 104	generated randomisation stratified according to centre Those discontinuing study were also contacted at 6 months after discontinuing
	Qmax ± SD, mL/s: 11.1 ± 4.8 Prostate volume, mL: 55 ± 26 Serum PSA ± SD, μg/L: 2.8 ± 2.1 Dropouts: 633/1516 (42%) see *		Worsening of disease Need for surgery or medical therapy Loss to follow up Other Spontaneous or precipitated AUR Acute urinary retention defined as spontaneous (no precipitating factors) or precipitated (stroke, UTI, pre surgery etc)	80 172 52 36	discontinuing study and at the 4 year end point. Complete outcome data was collected for 92% in both treatment groups including discontinuations.
			Drug related adverse events (>1%) in year 1 Decreased libido Impotence Ejaculation disorder Breast tenderness Breast enlargement Rash	122 56 p <0.001 12 2 p =0.003 6 2 NR 8 2 p=0.04	** Mean change and SD from baseline were estimated from graphs for mean change and standard error.

See Evidence Table 2: How does PSA predict symptom progression (in terms of symptom score)?

3 For McConnell et al., 2003¹⁶⁶.

Lower urinary tract symptoms (LUTS) – full guideline appendices DRAFT (August 2009)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Nickel et al., 1996 ¹⁸⁹ Setting: multi-	Patient group: Men moderate symptoms of BPH Inclusion criteria:	Group 1: Finasteride 5 mg 1/day Group 2: Placebo 1/day	Mean change in Quasi-IPSS ± SD from baseline at 4 months Number of patients remaining is unclear so use ITT figures	Grp 1: -1.0 ± 4.9* Grp 2: -1.0 ± 5.3* P value: NS	Funding: Merck Frost Canada, inc.
centre, 28 sites in Canada PROSPECT	 ≤ 80 years Ambulatory and in good health Qmax 5 - 15 mL/s (at screening or start of placebo run-in) 	Examination methods: At baseline and 12 and 24 months patients received a	Mean change in Quasi-IPSS ± SD from baseline at 1 year Number of patients remaining is unclear so use ITT figures	Grp 1: -1.5 ± 5.4* Grp 2: -1.0 ± 5.3* P value: <0.05	Limitations: • Quasi IPSS score • Data
study Study design: RCT double	 Enlarged prostate by DRE At least 2 symptoms indicting moderate BPH (increased frequency of urination or difficulty 	physical examination including DRE, urodynamics, serum PSA, liver function tests, and urinalysis.	Mean change in Quasi-IPSS ± SD from baseline at 2 year Number of patients remaining is unclear so use ITT figures	Grp 1: -1.7 ± 6.7* Grp 2: -0.5 ± 6.3* P value: <0.01	estimated from graph. • Unclear how many
blinded. Patients and investigators.	in urination) but not more than 2 severe symptoms • Serum PSA ≤ 10 ng/mL • PVR ≤ 150 mL	Primary outcomes for symptom score and flow rates measured every 4 months. Symptoms assessed using the	Mean change in Qmax ± SD from baseline at 4 months Number of patients remaining is unclear so use ITT figures	Grp 1: 0.7 ± 3.8* Grp 2: 0.65 ± 6.2* P value: NS	patients remaining at each time interval.
Evidence level: 1+ Duration of	 Exclusion criteria: Prostate cancer or suspect Neurogenic bladder 	Boyarksy scale modified by Bolognese et al. which comprises 9 questions (max score is 54) and obstructive symptoms totalled for Q1-5	Mean change in Qmax ± SD from baseline at 1 year Number of patients remaining is unclear so use ITT figures	Grp 1: 0.95 ± 6.0* Grp 2: 0.3 ± 4.2* P value: <0.05	Additional outcomes: Mean change in total symptom
follow-up: 2 years	 ≥2 catheterisations for AUR in previous 2 years Previous prostate or testicular surgery Urethral strictures 	as impairment in size and force of urinary stream, hesitancy or delay in starting urination, dribbling,	Mean change in Qmax ± SD from baseline at 2 years Number of patients remaining is unclear so use ITT figures	Grp 1: 1.25 ± 4.3* Grp 2: 0.25 ± 4.9* P value: <0.01	score and obstructive score from baseline an % change in prostate volume
	 Chronic Bacterial prostatitis Serum creatinine > 150 mmol/L or 	,	Mean change in % prostate volume from baseline at 1 year	Grp 1: -19 Grp 2: +7 P value: ≤0.01	from baseline.
	liver function tests ≥50% above normal • Use of drugs with anti-androgenic	A quasi IPSS score was also developed using the seven items that corresponded from the Boyarsky scale and	Mean change in % prostate volume from baseline at 2 year	Grp 1: -21 Grp 2: +9 P value: ≤0.01	Eligible patients entered 1 month single blind
	 properties Haematuria associated with UTI, prostatitis or bladder carcinoma 	condensing the 2 highest values on the 6 point scale to	Median % change in PSA from baseline at 24 months	Grp 1: -52% Grp 2: 6% P value < 0.0001	placebo run-in t reduce placebo effect then

Study details	Patients	Interventions	Outcome measures	Effec	t size	Comments
	 Any condition that might jeopardise the patient's ability to complete the study <u>All patients</u> N: 613 Mean age: NR 	1.	Reason for withdrawal § N Adverse Events Insufficient response Lost to follow up Protocol violation Other	16 19 5 9 6 3	2	randomised by computer generated sequence. Allocation preserved using sealed opaque
	Drop outs: 141 (23%) <u>Group 1 (Finasteride 5mg/dayl)</u> N: 310		Other adverse events Urinary retention or surgery Non-drug related mortality	19 31	2 p=0.08	envelopes. Analysis was ITT *Standard
	Mean (range) Age: 63 (46-79) Total symptom score: 15.8 ± 7.6 Total obstructive score: 10.2 ± 4.8 Qmax ± SD, mL/s: 11.1 ± 3.7 Prostate volume ± SD, mL: 44.1 ± 23.5 Dropouts: 64/310 (20.6%) see withdrawals§		Adverse events related to sexual function N Decreased libido Impotence Ejaculation disorder			deviations for changes from baseline calculated using confidence intervals and Cochrane methodology
	Group 2 (Placebo 1/day) N: 303 Mean (range) Age: 63.5 (47-80) Total symptom score: 16.6 ± 7.2 Total obstructive score: 10.7 ± 4.5 Qmax ± SD, mL/s: 10.9 ± 3.5 Prostate volume ± SD, mL: 45.8 ± 22.4 Dropouts: 77/303 (25.4%) see withdrawals§			Analysis of variance used to compare outcomes with treatment centre and treatment group as model parameters.		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Polat et al.,1997 ²⁰⁷ Setting: single centre,	Patient group: men with BPH Inclusion criteria: • 50-80 years	Group 1: Finasteride 5 mg 1/day	Mean AUA score ± SD at 3 months	Grp 1: 11.6 ± 5.3* Grp 2: 14.1 ± 5.3* P value: <0.01	Funding: Merck Frost Canada, inc.
Turkey Study design: RCT	 In good health Prostate volume >30 ml Qmax <15 mL/s 	Group 2: Placebo 1/day Examination methods: Prostate volume (TRUS),	Mean AUA score ± SD at 6 months	Grp 1: 10.9 ± 6.4* Grp 2: 13.9 ± 6.4* P value: <0.01	Limitations: • Randomisation method,
Evidence level:	 Exclusion criteria: Prostate cancer or suspect All patients 	AUA symptom score, Qmax, serum PSA, PVR and adverse events were	Mean AUA score ± SD at 12 months	Grp 1: 10.5 ± 9.0* Grp 2: 13.7 ± 9.0* P value: <0.05	allocation concealment and blinding not
Duration of follow- up: 12 months	N: 123 Mean age: NR	recorded at 3, 6, 9 and 12 months	Mean Qmax ± SD at 3 months	Grp 1: 10.5 ± NR Grp 2: 10.3 ± NR P value: NS	 reported. High dropout rate in
	$\label{eq:group_loss} \begin{array}{l} \underline{Group 1} (\underline{Finasteride 5mg/dayl}) \\ \text{N: } 62 \\ \text{Mean (range) Age: } 61 (45-80) \\ \text{AUA symptom score: } 15.1 \pm \text{NR} \\ \text{Qmax } \pm \text{SD, mL/s: } 9.9 \pm \text{NR} \\ \text{Prostate volume } \pm \text{SD, mL: } 39.1 \pm \text{NR} \\ \text{PvR } \pm \text{SD, mL: } 96.2 \pm \text{NR} \\ \text{Serum PSA } \pm \text{SD, ng/mL: } 2.2 \pm \text{NR} \\ \text{Dropouts: } 23/62 (37\%) \\ \hline \\ \underline{Group 2} (\underline{Placebo 1/day}) \\ \text{N: } 61 \\ \text{Mean (range) Age: } 59 (44-80) \\ \text{AUA symptom score: } 15.3 \pm \text{NR} \\ \text{Qmax } \pm \text{SD, mL/s: } 10.1 \pm \text{NR} \\ \text{Prostate volume } \pm \text{SD, mL: } 38.2 \pm \text{NR} \\ \text{PVR } \pm \text{SD, mL: } 100.0 \pm \text{NR} \\ \text{Serum PSA } \pm \text{SD, ng/mL: } 2.32 \pm \text{NR} \\ \text{Dropouts: } 0 \end{array}$		Mean Qmax ± SD at 6 months	Grp 1: 10.6 ± NR Grp 2: 10.4 ± NR P value: NS	 Finasteride arm Reasons for withdrawal not explained.
			Mean Qmax ± SD at 12 months	Grp 1: 13.2 ± 4.6* Grp 2: 10.4 ± 4.6* P value: <0.001	Additional outcomes:
			Mean PSA (ng/dl) at 3 months	Grp 1: 1.6 ± NR Grp 2: 2.3 ± NR P value: ≤0.01	% reduction in PSA Notes: * Standard
			Mean PSA (ng/dl) at 6 months	Grp 1: 1.4 ± NR Grp 2: 2.3 ± NR P value: ≤0.001	deviations for changes from baseline calculated
			Mean PSA (ng/dl) at 12 months	Grp 1: 1.2 ± NR Grp 2: 2.3 ± NR P value: ≤0.001	using p values for intergroup comparison following the Cochrane
			Prostate volume (cm ³) at 3 months	Grp 1: 32.4 ± NR Grp 2: 38.1 ± NR P value: ≤0.01	methodology
			Prostate volume (cm ³) at 6 months	Grp 1: 31.1 ± NR Grp 2: 38.0 ± NR P value: ≤0.01	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Grp 1: 30.0 ± NR Grp 2: 38.0 ± NR P value: ≤0.01	
			Adverse events Impotence	Grp 1 Grp 2 1/62 0/61	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
A priori design for	Patient group: Men with a clinical diagnosis of BPH (according to medical history, DRE and physical examination)	Group 1: Dutasteride 0.5 mg 1/day Group 2: Placebo 1/day	Mean change ± SD in AUA score from baseline at 2 years (ITT analysis)	Grp 1: -4.5 ± 6.6 (n=2167) Grp 2: -2.3 ± 6.8 (n=2158) P value: <0.001	Funding: GSK of dutasteride
pooled analysis of parallel studies ARIA 3001, 3002, 3003 with		Examination methods: AUA score and Qmax were evaluated at	Mean change in Qmax ± SD from baseline at 2 years (ITT analysis)	Grp 1: 2.2 ± 5.2 (n=2167) Grp 2: 0.6 ± 4.7 (n=2158) P value: <0.001	Limitations: Additional outcomes:
identical inclusion/exclusion criteria.	 Prostate volume (TRUS) ≥ 30 mL AUA-7 ≥ 12 Qmax ≤ 15 mL/s on 2 consecutive voids of ≥125 mL 	baseline and months 1, 3, 6 and every 6 months thereafter. Total prostate volume by	Mean change in total prostate volume ± SD from baseline at 2 years (ITT analysis)	Grp 1: -14.6 \pm 13.5 (n=2167) Grp 2: 0.8 \pm 14.3 (n=2158) P value: <0.001	Serum DHT and transition zone volume. BSLA – BPH
Study also reported in O'Leary et al., 2003 ¹⁹⁷ and	 Exclusion criteria: PVR > 250 mL History of prostate cancer 	TRUS was measured at baseline and months 6, 12, 24 and additionally in month 1 for ARIA 3001 and in month 3 for ARIA	Mean change in Serum PSA ± SD from baseline at 2 years (ITT analysis)	Grp 1: -3.1 ± 2.0 (n=2167) Grp 2: 0.5 ± 2.1 (n=2158) P value: <0.001	Specific lifestyle adaptations. (19 questions)
O'Leary et al., 2008 ¹⁹⁸ Setting: multi-	 Previous prostate or bladder surgery Previous AUR within 3 months of screening 	3002. PSA analysis was completed at baseline	Mean change SPI ± SD from baseline at 2 years (ITT analysis)	Grp 1: -2.2 ± 5.8 (n=2167) Grp 2: -0.8 ± 5.8 (n=2158) P value: <0.001	Notes: Eligible patients entered 1 month single blind
centre, 400 sites in 19 countries	 Serum PSA <1.5 ng/mL or >10 ng/mL Concurrent use of alpha- 	and months 1, 3, 6, 12, 18 and 24.	Mean change BSIA ± SD from baseline at 2 years (ITT analysis)	Grp 1: -1.7 ± 5.5 (n=2167) Grp 2: -1.5 ± 6.0 (n=2158) P value: <0.001	placebo run-in prior to randomisation by
Study design: RCT double blind. Patients and investigators	blockers or anti-androgens <u>All patients</u> N: 4325	O'Leary at al., 2008 ¹⁹⁸ reports quality of life measures. Symptom Problem Index	Mean change BPWB ± SD from baseline at 2 years (ITT analysis)	Grp 1: -1.5 ± 3.9 (n=2167) Grp 2: -0.6 ± 4.0 (n=2158) P value: <0.001	computer generated block sequence. Author confirms allocation
	Mean age: NR Drop outs: 1374/4325 (32%)	SPI - 7questions about frequency and urgency with a scale of 0-28	Reason for withdrawal * Total discontinuations Adverse Events	Grp 1 Grp 2 657 717 193 192	concealment was preserved.
1+ Duration of	<u>Group 1 (Dutasteride 0.5mg/day)</u> N: 2167	where 0= no problem and 4=big problem. SPI is similar to AUA.	Lack of improvement		Paper reports that a linear model was used
follow-up:	White: 91% Mean (± SD) Age: 66.5 ± 7.6	BPH-specific interference	Loss to follow up Other/missing	67 52	to compare baseline and

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
details	AUA Symptom score \pm SD: 17.0 \pm 6.0 Qmax \pm SD, mL/s: 10.1 \pm 3.5 Prostate volume, mL: 54.9 \pm 23.9 Serum PSA \pm SD, ng/L: 4.0 \pm 2.1 SPI (QoL): 11.7 \pm 6.1 BSIA (QoL): 8.7 \pm 6.2 BPWB (QoL): 11.0 \pm 4.2 Dropouts: 657/2167 (30%) see* Group 2 (Placebo 1/day) N: 2158 White: 92% Mean (\pm SD) Age: 66.1 \pm 7.4 AUA Symptom score \pm SD: 17.1 \pm 6.1 Qmax \pm SD, mL/s: 10.4 \pm 3.6 Prostate volume, mL: 54.0 \pm 21.9 Serum PSA \pm SD, ng/L: 4.0 \pm 2.1 SPI (QoL): 11.8 \pm 6.1 BSIA (QoL): 8.9 \pm 6.2 BPWB (QoL): 11.0 \pm 4.3 Dropouts: 717/2158 (33%) see *	with activities BSIA – 7 questions about how often urinary problems interfered with everyday activities with a scale of 0- 28 where 0= none of the time and 4=all of the time. BPH-Specific Psychological Well Being (BPWB) – 6 questions about how often urinary condition has affected mental health with a scale of 5-25 where 1=not at all and 5=almost always	Spontaneous or precipitated AUR Acute urinary retention defined as spontaneous (no precipitating factors) or precipitated (stroke, UTI, pre surgery etc) Drug related adverse events over 2 years N Decreased libido Impotence Ejaculation disorder Gynaecomastia	48 17 p <0.001	follow up data for continuous variables with baseline values, treatment, protocol and investigator cluster as model parameters.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Tenover et al.,1997 ²⁵²	Patient group: men seeking treatment for symptomatic BPH from a primary care physician.	Group 1: Finasteride 5 mg 1/day	Adjusted mean change in AUA score* from baseline at 12 months		Funding: Merck & Co., Inc
Setting: multi- centre, 97 centres in the USA recruitment	 Inclusion criteria: ≥ 45 years Moderate to severe AUA 	Group 2: Placebo 1/day Examination methods: Physical examination including DRE was	Adjusted mean change in BII score** from baseline at 12 months	Grp 1: -1.12 Cl95% -1.32 to -0.92 Grp 2: -0.70 Cl95% -1.00 to -0.40 P value: 0.007	Limitations: Randomisation method and allocation concealment
from April 1993 to October 1994.	 Enlarged prostate gland on DRE PSA ≤ 10 ng/mL 	performed at baseline and 12 mths. Serum	Adjusted mean change in general adjustment question** from baseline at 12 months	Grp 1: -0.26 Cl95% -0.35 to -0.17 Grp 2: -0.10 Cl95% -0.23 to 0.03 P value: 0.019	was not clear
Study design: RCT double blind. Patients	 Exclusion criteria: Urethral stricture History of repeated 	dihydrotestosterone measured at baseline and mths 6 & 12 AUA-7 Symptom score,	Adjusted mean change in BSIA score** from baseline at 12 months	Grp 1: -2.65 Cl95% -3.25 to -2.06 Grp 2: -2.21 Cl95% -3.09 to -1.32 P value: 0.343	outcomes: Changes in lipid profiles from baseline
and investigators masked.	 catheterisations Previous pelvic radiotherapy Recurrent urinary retention Previous prostate or bladder 	BPH Impact Index (BII) used for HRQoL, Patient satisfaction with urinary condition as extra	Reason for withdrawal \$ Total discontinuations Adverse Events (all) Lack of improvement	118 36	Notes: Eligible patients entered 1 month
Evidence level: 1+ Duration of	surgeryChronic prostatitisNeurogenic bladder	question (0-6) and additional questions from modified BSIA instrument to measure interference	Protocol violation or patient request Loss to follow up	54 20 73 25	single blind placebo run-in prior to
follow-up: 12 months	 Recurrent UTI Concurrent use of alpha- blockers or anti-androgens Prostate cancer suspects 	with activities and extra question about adjustment of activities to cope with urinary symptoms were	Acute urinary retention	Grp 1: 34/1736 Grp 2: 23/579 P value: 0.644	randomisation in a 3:1 ratio * Mean AUA symptom score
	All patients N: 2315 (2112 in efficacy	taken at baseline and 3 mth intervals. Patient and investigator global assessment of	Drug related adverse events (possibly, probably or definitely drug related) N Randomised	1736 579	was adjusted for treatment, centre and baseline age.
	analysis and baseline characteristics) Mean age: NR Drop outs:	change in urologic status also rated from 1 (much worse) to 7 (much better) every 3 mths.	Withdrawals due to drug related AE Decreased libido Impotence	85 17 p =0.038 128 19 p <0.001 57 5 p =0.001	** Mean BII score, general adjustment question, BSIA,
	<u>Group 1 (Finasteride 5mg/day)</u>	Patients with visual impairment had	Ejaculation disorder Withdrawal due to sexual AE	-	Patient global assessment and

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	N: 1589 Mean (± SD) Age: 63.6 ± 8.7 White/other: 1473 Black: 76 Hispanic: 40 AUA symptom score* ± SD: 19.03 ± NR BII**: 4.76 Cl95% 4.61-4.9 General adjustment question**: 1.29 Cl95% 1.21-1.36 BSIA**: 12.7 Cl95% 12.16-13.24 Dropouts: 288/1736 (16.65) for reasons see§ Group 2 (Placebo 1/day) N: 523 Mean (± SD) Age: 62.7 ± 8.9 White/other: 482 Black: 28 Hispanic: 13 AUA symptom score* ± SD: 18.35 ± NR BII**: 4.67 Cl95% 4.45-4.9 General adjustment question**: 1.21 Cl95% 1.09-1.33 BSIA**: 12.75 Cl95% 11.93- 13.57 Dropouts: 95/579 (16.4%) for reasons see§	questionnaires read to them and Spanish versions provided.			investigator global assessment were adjusted for treatment, centre, baseline AUA and age covariates. A graph was presented in the study with adjusted AUA score at follow up but it was not clear if the mean was with a standard deviation or CI95%

1	Evidence	Table	14	Anticholi	nergics	vs. placebo	0
---	----------	-------	----	-----------	---------	-------------	---

- 3 See Evidence Table 9 Alpha-blockers vs. placebo
- 4 For Kaplan et al.,2006 ¹¹⁹.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments		
McVary et al., 2007b ¹⁷² Study design:	Patient group: Men 45 years and older with a history of LUTS secondary to BPH of 6 months or longer were recruited from 21	Run-in period: Eligible patients entered 4 week single blind run in period with placebo	weeks	Baseline Group1 (n=138): 17.4 Group 2 (n=143): 18.5 6 weeks	Funding: NR Limitations: Randomisation		
Randomised controlled trial	centres in US from November 2004 to July 2005. Patients agreed not to use other BPH	dosed once daily.		Group1 (n=135): 14.5 Group 2 (n=136): 17.0 Change from baseline:	method and allocation concealment unclea		
Setting: US	medications during this study. Inclusion criteria: IPSS of 13 or	PHOSPHODIESTERASE 5 INHIBITORS		Group 1: -2.8 (0.5) Group 2: -1.2 (0.5); p=0.003	Additional		
Evidence level: 1+	greater and a Qmax of 4-15ml/s on a voided volume of 125ml or greater was required.	Tadalafil 5mg once daily for six weeks, followed by dose		Difference between change from baseline: 1.7 (95% Cl: 0.5-2.9); p=0.003	outcomes: Comparisons from before placebo ru		
Duration of follow-up: 12 weeks Exclusion cr without treat during run in excluded. M >10ng/ml, r dutasteride tradical pros- pelvic surger condition aff function; recu- tract instrum- retention or history of ura- to strictures, tumour; detr dyssynergia inflammatior intravesical of prostate can greater; cerr diseases, clir	Exclusion criteria: patients without treatment compliance during run in phase (<70%) were excluded. Men with PSA >10ng/ml, recent finasteride or dutasteride treatment, history of radical prostatectomy or other pelvic surgery; neurological condition affecting bladder function; recent lower urinary tract instrumentation, urinary retention or bladder stones;	escalation to 20mg for remaining 6 weeks. Medication ingested at same time every day. Group 2: PLACEBO	Mean (SE) IPSS at 12 weeks	$\begin{array}{l} \textbf{Baseline} \\ & \text{Group1 (n=138): 17.5} \\ & \text{Group 2 (n=143): 18.3} \\ \textbf{12 weeks} \\ & \text{Group1 (n=136): 13.3} \\ & \text{Group 2 (n=138): 16.1} \\ & \textbf{Change:} \\ & \text{Group 1: -3.8 (0.5)} \\ & \text{Group 2: -1.7 (0.5); p<0.001} \\ & \textbf{Difference between change from} \\ & \textbf{baseline: 2.1 (95\% Cl: 0.9-3.3);} \\ & p<0.001 \\ \end{array}$	to endpoint were reported. BII reported and IF results for obstructi and irritative dome reported separate Voided volume and average urinary fl were also reported Notes: * All reports of erection increased		
	history of urethral obstruction due to strictures, valves, sclerosis or tumour; detrusor-sphincter dyssynergia; urinary tract inflammation or infection; intravesical obstruction secondary				Responders (defined as patients with an IPSS change from baseline or 3 points or greater)	6 weeks: Group 1: 49.3% Group 2: 36.4%; p=0.03 12 weeks: Group 1: 60.9% Group 2: 42.7%; p<0.01	were from 1 study site, reported in response to specifi questioning by the investigator and described as
	to the prostate median lobe; prostate cancer; PVR 200ml or greater; certain cardiovascular diseases, clinically significant renal or hepatic insufficiency;		Mean (SE) IPSS quality of life question at 6 weeks	Baseline Group1 (n=138): 3.6 Group 2 (n=143): 3.8 6 weeks Group1 (n=136): 3.1 Group 2 (n=138): 3.5	secondary to sexua stimulation. Least square mean calculations used fo		

Evidence Table 15 Phosphodiesterase-5 inhibitors vs. placebo

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	recent history of stroke or spinal cord injury; current treatment with nitrates, cancer chemotherapy,			Change from baseline: Group1: -0.5 (0.1) Group 2: -0.2 (0.1); p=0.017	analysis. NCGC calculated SD for meta-analysis from
	All patients N: 281		Mean (SE) IPSS quality of life question at 12 weeks	Baseline Group1 (n=136): 3.6 Group 2 (n=138) : 3.8 12 weeks Group1 (n=136): 2.8 Group 2 (n=138): 3.3 Change from baseline:	Cochrane calculations.
	Group 1 N: 138		0/ of	Group1: -0.7 (0.1) Group 2: -0.3 (0.1); p=0.004	
	Ethnicity/race: Black 10.9%, white 79%, Hispanic 6.5%, other 3.6% Mean (range) Age: 62 (45.1- 82.4) Dropouts: 13 (adverse events=5,		J	Group 1 (n=136): 55.9 Group 2 (n=138): 32.6; p<0.001 12 weeks Group 1 (n=136): 57.4 Group 2 (n=138): 37.7; p<0.001	
	lost to follow up=1, patient decision=2, other =5)		Mean (SE) Qmax, ml/sec at 6 weeks	Baseline Group1 (n=110): 11.7 Group 2 (n=111) : 11.2	
	Group 2 N: 143 Mean (range) Age: 61 (45.0- 82.3) Ethnicity/race: Black 8.4%, white 83.2%, Hispanic 7%, other 1.4% Dropouts: 17 (adverse events=2, lack of efficacy=1, lost to follow up=5, patient decision=6, other=3)			12 weeks Group1 (n=110): 12.2 Group 2 (n=111): 11.8 Change from baseline: Group1: 1.1 (0.6) Group 2: 1.0 (0.6); p=0.46	
			Mean (SE) Qmax, ml/sec at 12 weeks	Baseline Group1 (n=116): 11.8 Group 2 (n=121) : 11.1 12 weeks Group1 (n=116): 12.3 Group 2 (n=121): 12.1 Change from baseline: Group1: 0.5 (0.5) Group 2: 0.9 (0.5); p=0.72	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Mean (SE) PVR, ml at 6 weeks	Baseline Group1 (n=132): 58.0 Group 2 (n=135) : 58.5 12 weeks Group1 (n=132): 57.2 Group 2 (n=136): 53.8 Change from baseline: Group1: 3.6 (7.0) Group 2: 0.1 (6.7); p=0.66	
			Mean (SE) PVR, ml at 12 weeks	Baseline Group1 (n=132): 58.0 Group 2 (n=135) : 58.2 12 weeks Group1 (n=132): 57.9 Group 2 (n=136): 54.2 Change from baseline: Group1: 1.4 (6.5) Group 2: -2.6 (6.2); p=0.69	
			Mean (SE) IPSS change from baseline in men that were sexually active	6 weeks Group 1 (n=80): -3.2±0.7 Group 2 (n=76): -0.7±0.7; p=0.001 12 weeks Group 1 (n=80): -4.4± 0.7 Group 2 (n=76): -1.8± 0.7; p=0.001	
			Mean (SE) IIEF EF domain change from baseline in men that were sexually active	6 weeks Group 1(n=80): 6.0±0.9 Group 2(n=76): 0.6±0.9; p<0.001 12 weeks Group 1(n=80): 7.7± 0.9 Group 2 (n=76): 1.4± 1.0; p<0.001	
			Discontinuation due to treatment emergent adverse events	Group 1: 3.6% Group 2: 1.4%	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Treatment emergent	Erection increased*	
			adverse events with a	Group 1:7 (5.1%)	
			frequency of 2% or	Group 2: 2 (1.4%)	
			greater at 12 weeks	Dyspepsia	
				Group 1: 6 (4.3%)	
				Group 2:0	
				Back pain	
				Group 1: 5 (3.6%)	
				Group 2: 2 (1.4%)	
				Headache	
				Group 1: 4 (2.9%)	
				Group 2: 1 (0.7%)	
				Nasopharyngitis	
				Group 1: 3 (2.2%)	
				Group 2: 0	
				Upper respiratory tract infection	
				Group 1: 3 (2.2%)	
				Group 2: 1 (0.7%)	
				Serious adverse events:	
				Group 1:0	
				Group 2: 1 (0.7%)	
				AUR:	
				Group 1:0	
				Group 2: 0	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments		
McVary et al., 2007c ¹⁷¹ Study design: Randomised controlled	Patient group: men with erectile dysfunction and LUTS/BPH from 41 urology clinics and clinical research centres.	Group 1: Phosphodiesterase 5 inhibitors Sildenafil citrate: 50ma	Mean (SD) IIEF – erectile function domain (1-30; higher scores indicate better	Baseline Group1:13.4 Group 2:13.2 Change from baseline	Funding: Supported by Pfizer, Inc.		
trial.	Inclusion criteria: Men≥45 years,	once daily with each night at bedtime or 30	treatment outcome)	Group1: 9.2 (1.0) Group 2: 1.9 (1.0)	Limitations: Actual figures and SD not		
Setting: USA Evidence level:	had a clinical diagnosis of ED (score≤25 on the erectile function domain of the International Index	minutes to 1hr before sexual activity. After 2 weeks the does		Mean change: 9.17, 95% Cl: 7.25- 11.09 vs. 1.86, 95% Cl: -0.03, 3.74;p<0.0001	provided for IPSS, Qmax and IPSS QoL question.		
1+ Duration of follow-up:	of Erectile Function) and IPSS ≥12.increased to 100mg but could be decreased toExclusion criteria: Men with50mg if the higher dose	increased to 100mg but could be decreased to	increased to 100mg but could be decreased to	Least mean change in IPSS score	Group 1 (n=182): -6.3 (-8.1, -4.6) Group 2 (n=178): -1.9 (-3.7, -0.2) P<0.001	Additional outcomes: BPHII score, SEAR	
12 weeks	confirmed or suspected prostate malignancy, serum prostate- specific antigen >10ng/ml, previous invasive intervention for	was not tolerated. Group 2: Placebo	Least mean change in Qmax, ml	Group 1: 0.31 (-1.6, 2.2) Group 2: 0.16 (-1.7, 2.1) P=0.8	questionnaire (self- esteem and relationship questionnaire)		
	bladder/pelvic rations or surgery. IP Those with PSA between 4-	<i>γ</i> .			Least mean change in IPSS quality of life score	Group 1: -0.97 (-1.32, -0.62) Group 2: -0.29 (-0.64, 0.05) P<0.001	Notes: 8 week open label
	10ng/ml required two additional forms of documentation to confirm the absence of clinically evident malignancy. Men with acute			LS mean (SE) EDITS score (end of treatment satisfaction score; 0-100)	Group 1: 71.2±3.2 Group 2: 41.7±3.2; p<0.0001	extension study after this 12 week study. Least square means	
	urinary tract disease or cystoscopy with in 4 weeks of the trial, calculi in the urinary tract or acute urinary retention within 6 months		Number (%) of patients reporting adverse events	Group 1: 100/189 (53%) Group 2: 78/180 (43%)	calculations used for analysis. NCGC calculated SD for meta-analysis from		
of the trial, recurrent urinary tract infections or catheterisation for outflow obstruction in the year		Number (%) of treatment related adverse events	Group 1: 86/189 (%) Group 2: 25/180 (%)	Cochrane calculations.			
	before the trial, or other known or suspected causes of urinary		Headache	Group 1: 21/189 (11%) Group 2: 6/180 (3%)			
	symptoms other than BPH, hypotension, hypertension orthostatic hypotension or		Flushing	Group 1: 9/189 (5%) Group 2: 1/180 (1%)			
	significant cardiovascular disease. Men were excluded if used		Dyspepsia	Group 1: 12/189 (6%) Group 2: 2/180 (1%)			

Lower urinary tract symptoms (LUTS) – full guideline appendices DRAFT (August 2009)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	nitrates, had hepatic or renal dysfunction, poorly controlled		Rhinitis	Group 1: 8/189 (4%) Group 2: 3/180 (2%)	
	diabetes or a history of retinitis pigmentosa. Use of		Discontinuations due to adverse events	Group1: 9/189 (5%) Group 2: 2/180 (1%)	
	antimuscarinics, 5-alpha-reductase inhibitors within 6 months or alpha blockers within 4 weeks during		Serious adverse events	Group1: 2/189 (1%) Group 2: 3/180 (2%)	
	study. PDE5 inhibitor or any other treatment for ED must have terminated therapy 4 weeks or more before the study.		Discontinuations due to serious adverse events	Group1: 1/189 (1%) Group 2: 0	
	All patients N: 370 Mean age: 60 (9) Drop outs: 1 not treated/withdrew				
	Group 1 N: 187 Mean (±SD) ED: 5.7 (4.6) years Ethnicity/race: White: 84%; Black: 10% Discontinuations:21				
	Group 2 N: 179 Mean (±SD) ED: 5.6 (5.1) years Ethnicity/race: white: 80%; black: 13% Discontinuations: 25				

-	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments		
Roehrborn et al., 2008b ²²³ Study design:	Patient group: Men with a history of LUTS secondary to BPH of 6 months longer. Inclusion criteria:	Group 1: PDE5I Tadalafil 2.5mg once daily Group2: PDE5I	Least squares mean (SE) IPSS change from baseline	Group1 (n=208): -3.88 (0.50) Group 2 (n=212): -4.87 (0.49) Group 3 (n=216): -5.17 (0.49) Group 4 (n=208): -5.21 (0.50) Group 5 (n=210): -2.27 (0.49)	Funding: Eli Lilly and Co. Limitations: method of		
RCT Setting: 92 centres in 10 countries	 At least 45 years old IPSS of 13 or greater Qmax of 4-15ml/s from pre- void bladder volume between 150-550ml with a voided volume of 125ml or greater. 	Tadalafil 5 mg once daily Group 3: PDE51	Least squares mean (SE) IPSS quality of life change from baseline	$\begin{array}{l} P{<}0.001 (tad v placebo) \\ \hline \\ Group1 (n=208): -0.74 (0.11) \\ Group 2 (n=212): -0.86 (0.11) \\ Group 3 (n=216): -0.92 (0.10) \\ Group 4 (n=208): -0.88 (0.11) \\ Group 5 (n=210): -0.49 (0.11) \end{array}$	randomisation and allocation concealment unclear. Additional outcomes: BPH-II score		
Evidence level: 1+ Duration of	Exclusion criteria: • PSA > 10ng/ml • PVR volume was 300ml or	Group 4: PDE51 Tadalafil 20 mg once daily Group 5: Placebo once	Least squares mean (SE) Qmax change from baseline	P<0.01 (tad v placebo) Group1 (n=208): 1.41 (0.39) Group 2 (n=212): 1.64 (0.39) Group 3 (n=216): 1.58 (0.38) Group 4 (n=208): 1.96 (0.39)	Notes: None.		
follow-up: 12 weeks	 greater at screening visit 1 Patients reporting use of other BPH or ED treatments underwent a 4 week treatment free screening/ washout period. 	daily	% Yes LUTS GAQ end	Group 5 (n=210): 1.24 (0.40) P=Not sig. (tad v placebo) Group1 (n=208): 61.9 Group 2 (n=212): 69.2	-		
	 Penile or pelvic surgery, radiotherapy, lower urinary tract malignancy, trauma or recent instrumentation, urinary retention or bladder stones, History of urethral obstruction 		(GAC question: Has the treatment you have been taking since your last visit improved your urinary symptoms)	Group 3 (n=216): 73.0 Group 4 (n=208): 74.2 Group 5 (n=210): 54.8 P<0.05 (tad v placebo)			
	 Neurological condition Detrusor sphincter dyssynergia, intravesical obstruction secondary to the prostate median lobe, Urinary tract inflammation or 				Lease squares mean (SE) sexually active ED IIEF-EF change from baseline (55% of patients)	Group1 (n=208): 5.59 (1.01) Group 2 (n=212): 6.97 (1.01) Group 3 (n=216): 7.98 (1.0) Group 4 (n=208): 8.34 (1.01) Group 5 (n=210): 2.20 (1.03) P<0.001 (tad v placebo)	
	 Prostate cancer. Renal or hepatic insufficiency, 		Treatment emergent adverse events	Headache Group1: 5/209 Group 2: 6/212 Group 3: 11/216			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Cardiovascular conditions,			Group 4: 7/209	
	history of stroke or spinal cord			Group 5: 6/211	
	injury, cancer chemotherapy,			Dyspepsia	
	uncontrolled diabetes			Group1: 2/209	
				Group 2: 10/212	
	All patients			Group 3: 6/216	
	N: 1058			Group 4: 10/209	
				Group 5: 0/211	
	Group 1			Back Pain	
	N: 209			Group1: 3/209	
	Mean Age: 62.03			Group 2: 2/212	
	Ethnicity/race: White 88.46%,			Group 3: 10/216	
	Hispanic 9.62%, black 1.44%, other			Group 4: 12/209	
	0.48%			Group 5: 1/211	
	Mean % ED history: 64.9%			Myalgia	
	Dropouts: 27			Group1: 3/209	
				Group 2: 3/212	
	Group 2			Group 3: 6/216	
	N: 212			Group 4: 6/209	
	Mean Age: 61.95			Group 5: 0/211	
	Ethnicity/race: White 84.43%,			Nasopharyngitis	
	Hispanic 11.79%, black 3.30%,			Group1: 7/209	
	other 0.47%			Group 2: 4/212	
	Mean % ED history: 67.92%			Group 3: 2/216	
	Dropouts: 30			Group 4: 5/209	
				Group 5: 2/211	
	Group 3			Diarrhoea	
	N: 216			Group1: 2/209	
	Mean Age: 62.22			Group 2: 6/212	
	Ethnicity/race: White 86.11%,			Group 3: 1/216	
	Hispanic 11.11%, black 2.31%,			Group 4: 5/209	
	other 0.46%			Group 5: 3/211	
	Mean % ED history: 69.44%			Gastroesophageal reflux disease	
	Dropouts: 41			Group1:2/209	
				Group 2: 2/212	
	Group 4			Group 3: 6/216	
	N: 209			Group 4: 3/209	
	Mean Age: 62.55			Group 5: 0/211	
				Extremity pain	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Ethnicity/race: White 84.21%, Hispanic 11.96%, black 2.39%, other 1.44% Mean % ED history: 69.38% Dropouts: 47 Group 5 N: 212 Mean Age: 61.75 Ethnicity/race: White 84.83%, Hispanic 13.74%, black 1.42%, other 0% Mean % ED history: 67.30% Dropouts: 27			Group 1: 3/209 Group 2: 5/212 Group 3: 2/216 Group 4: 3/209 Group 5: 0/211 Influenza Group 1: 4/209 Group 2: 4/212 Group 3: 1/216 Group 4: 2/209 Group 5: 1/211 Bronchitis Group 1: 3/209 Group 2: 1/212 Group 3: 5/216 Group 4: 0/209 Group 5: 1/211 Muscle spasms Group 1: 2/209 Group 2: 0/212 Group 3: 2/216 Group 4: 5/209 Group 5: 0/211 Urinary retention Group 1: 0/209 Group 2: 0/212 Group 3: 0/216 Group 4: 0/209 Group 5: 1/211	
			Discontinuation due to adverse events	Group 1: 4/209 Group 2: 12/212 Group 3: 11/216 Group 4: 14/209 Group 5: 5/211	

1

Study details	Patients	Interventions	Outcome measures	Effect size	Comments			
Stief et al.,2008 ²⁴⁶	Patient group: Men with BPH/LUTS from 16 centres in Germany from October 2005-June 2006.	Group 1: Phosphodiesterase 5 (PDE5) inhibitors	Mean IPSS symptom score*	Baseline Group1: 16.8 Group 2: 16.8	Funding: This study was sponsored by Bayer Healthcare AG,			
Study design: Randomised control trial. Setting: multi-centre,	Inclusion criteria: Men aged 45-64 years with a history of BPH/LUTS for at least 6 months before commencing the study and an IPSS \geq 12 at screening. Patients completed a 4 week run-in	10mg Vardenafil twice daily Group 2: Placebo Matched placebo	10mg Vardenafil twice daily Group 2: Placebo	10mg Vardenafil twice daily Group 2: Placebo Matched placebo	10mg Vardenafil twice daily Group 2: Placebo Matched placebo		8 weeks Group1 (n=105): 11.0 Group 2 (n=110): 13.2 Between group difference in change from baseline: 2.3 (0.90-3.64), p=0.0013	Leverkusen, Germany. Bayer healthcare AG involved in the design and conduct of the study; management, analysis and interpretation of the
Germany Evidence level:	phase during which no study medications was administered.	(12-h dosing interval).	Mean Qmax, ml/s*	Baseline Group1: 15.9 Group 2: 15.9	data; and preparation, review and approval of the manuscript.			
1+ Duration of follow-up: 8 weeks.	vardenafil, spinal cord injury, prostatitis, history of prostate or bladder cancer, bladder o r urethra stricture, urinary retention (PVR≥100ml), pelvic trauma or surgery, history of any malignancies, and	4		8 weeks Group1 (n=105): 17.5 Group 2 (n=110): 16.9 Between group difference in change from baseline: -0.6 (-2.62-1.43), p=0.5614	Limitations: No SD values provided for further analysis. [NCC emailed author for this information]			
	life expectancy of less than 3 yr. concomitant use of nitrates or NO donors, androgens or anti-androgens, anticoagulants, cytochrome P-50 3A4 inhibitors, any treatment for ED or alpha1-adrenocoetpro antagonists were		Intern Erect Erect		Mear	Mean PVR volume	Baseline Group 1: 28.0 Group 2: 26.9 8 weeks Group 1 (n=105): 27.0	Additional outcomes: IPSS also reported by irritative and obstructive sub score.
	prohibited. Alpha blockers – if withdrawn at screening, subjects would fail o be eligible for study drug treatment, precious or current use of 5-				Group 2 (n=110): 28.8 Between group difference in change from baseline: 1.8 (-7.39 to 10.99); p=0.6994	Notes: Serious adverse events reported included myocardial infarction,		
	alpha reductase inhibitors. <u>All patients:</u> N: 222				International Index of Erectile Function – Erectile function (IIEF- EF) score	Baseline Group1: 15.9 Group 2: 15.9 8 weeks	chest pain, and cardiac rehabilitation therapy (one patient) and hypertensive crisis in the	
	Group 1 N: 109 Mean (±SD) Age: 56.5 (5.4) years Ethnicity: White 100%			Group1 (n=105): 23.4 Group 2 (n=110): 17.4 Between group difference in change from baseline: -6.0 (-7.77 to 4.16), p=0.0001	intervention group. The placebo group comprised of haematochezia, a meniscus injury and knee			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Dropouts: 4 (1=not received medication, 3=did not provide efficacy data)		Total Urolife Qulatiy of life-9 score	-9.3 (95% Cl: -12.79, -5.71) P<0.0001	surgery. None were considered related to
	Premature discontinuation=13 ITT population=105 Group 2 N: 113 Mean (±SD) Age: 55.4 (5.7) years Ethnicity: White 98.2%; Black 0.9%; Asian 0.9%. Dropouts: 3 (3=did not provide efficacy data) Premature discontinuation=14 ITT population=110		Number (%) of adverse events (treatment-emergent adverse events affecting at least 2% of patients)	Any event: Group 1 (n=108): 32 (29.6%) Group 2 (n=113):18 (15.9%) Headache: Group 1:14 (13.0%) Group 2: 2 (1.8%) Dyspepsia: Group 1: 8 (7.4%) Group 2: 0 Flushing: Group 1: 7 (6.5%) Group 2: 1 (0.9%) Diarrhoea: Group 1: 5 (4.6%) Group 2: 1 (0.9%) Gastrointestinal reflux disease: Group 1: 3 (2.8%) Group 2: 0 Back pain: Group 1: 3 (2.8%) Group 2: 0 Serious adverse events Group 1: 2 Group 2: 3	study medication. * Least square means analysis reported for outcomes. NCGC calculated estimated SD for mean change in IPSS/Qmax from Cochrane handbook formula.

1	Evidence	Table	16	Diuretics	vs.	placebo
---	----------	-------	----	------------------	-----	---------

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Reynard et al., 1998a ²¹³	Patient group: elderly men presenting with lower urinary tract symptoms and completed 7day	Two week placebo period. In second week a frequency volume chart	Reduction in night time frequency	Group 1: -0.5 Group 2: 0 P=0.014	Funding: NR. Limitations:	
Study design: Randomised controlled trial	years, with nocturnal polyuria	IPSS symptom score. Group 1: Diuretic Frusemide 40mg Afternoon dose taken ó hours before their usual bedtime. Group 2: Placebo		Increase in daytime frequency	Group1: +1.9 Group 2: -0.1 P<0.001	Method of randomisation, allocation concealment not reported.
Setting: Hospital, UK Evidence level: 1+	(defined as night time diuresis defined as the production of >33% of the 24-h urine volume between midnight and 8am). Exclusion criteria: serum creatinine		Correlation for % night time voided volume at entry to the study against change in night-time voiding	Spearman's correlation coefficient: 0.25 P=0.3	Actual figures not reported. Additional outcomes: No significant correlation between the	
Duration of follow-up: 4 weeks.	>150umol.L, previous lower urinary tract surgery, symptomatic heart failure, taking medication active on the lower urinary tract including		frequency Increase in daytime voided volume, mL	Group 1: +365 Group 2: -31 P=0.002	% night time voided volume and changes in night time frequency, night time voided	
	those taking any diuretic, concomitant neurological disease which could potentially affect lower urinary tract function, and clinical		Night time voided volume, mL	Group 1: -120 Group 2: +9 P=0.065	volume or % voided volume. Figures not reported. Notes: Day time defined as 08.00 and 23.59h and night time as between 00.00 and 07.59h.	
	evidence of prostate cancer or diabetes mellitus.		Reduction in night-time voiding frequency of one or more	Group 1: 7/19 Group 2: 1/20 P=0.02		
	All patients N: 49 Number obstructed: 19/41		Night time voiding frequency was reduced 2 or more	4/19 0/20		
	Drop outs: 6 (withdrew) <u>Group 1</u> N: 21 Mean (±SD) Age: 70		Correlation between % night time voided volume at entry and reduction in night time voided volume	Spearman's correlation coefficient: 0.03 P=0.9		
	Dropouts: 3 (evening frequency). <u>Group 2</u> N: 22		Total urine output (24h), mL	Group 1: 1663 Group 2: 1780 P=0.2		
	Mean (±SD) Age: 69		% change of night time voided volume	Group 1: -18% Group 2: 0%		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Dropouts: 3=(lack of efficacy or evening frequency)		Correlation between % night time voided volume and change in % night time voided volume Change in IPSS Patients reported that intervention 'helped'	P=0.001 Spearmans correlation coefficient = 0.43, p=0.08 Group 1: +1 Group 2: 0 P=0.9 Group 1: 14/21 Group 2: 5/22 P<0.001	

1	Evidence	Table	17	Desmospressin vs.	placebo
---	----------	-------	----	-------------------	---------

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Cannon et al., 1999 ³⁶ Study design: RCT-cross over trial	Patient group: Men with nocturia Inclusion criteria:	Group 1: Desmopressin 20 microgram nasal spray, administered	24-h volume , (ml) mean, se: (measured using FV-chart*)	Baseline: 1646.6 se107.6 Group 1: 1567.4 se 96.7 Group 2: 1713.5 se 119.4 P value (paired t-test): Not sig	Funding: Ferring Pharmaceuticals Limitations:
Setting: UK Evidence level: 1+	 Men >50 years Nocturnal polyuria confirmed after 48 hours of inpatient 	just before going to bed each evening Group 2: Placebo	Nocturnal frequency mean, se: (measured using FV-chart*)	Baseline: 3.0 se 0.3 Group 1: 2.7 se 0.33 Group 2: 3.1 se 0.3 P value (paired t-test): Not sig	 Cross over study Small sample size Method of randomisation allocation and concealment
Duration of follow-up: Two-2 week periods	monitoring or a 1- week FV chart, which showed in excess of a third of their 24- hour urine volume	nasal spray, administered just before going to bed each evening	Nocturnal volume (ml)mean, se: (measured using FV-chart*)	Baseline: 749.6 se 67.5 Group 1: 633.9 se 60.8 Group 2: 809.1 se 78.7 P value (paired t-test): <0.01	was not described. Additional outcomes: Adverse events: For 20 microgram of desmopressin: dry
	being produced overnight Exclusion criteria:		Nocturnal percentage (%) (measured using FV-chart*)	Baseline: 45.7 se 3.1 Group 1: 40.5 se 3.1 Group 2: 46.9 se 3.3 P value (paired t-test): <0.05	throat plus cough (1), increased sputum (1), and fluid retention plus hyponatraemia (1). For placebo: headache (1), flu like
	 Nocturnal enuresis or incontinence Significant cardiovascular, renal 		24-h volume , (ml) mean, se: (24 hour urine collection**)	Baseline: 1487.2 se110.5 Group 1: 1419 se 121.20 Group 2: 1400.6 se 88.5 P value (paired t-test):	illness (1). Another 2 patients had fluid retention symptoms while receiving the 40microgram
	or hepatic disease, diabetes, UTI or concomitant medication active on		Nocturnal volume (ml)mean, se: (24 hour urine collection**)	Baseline: 718.3 se 79.1 Group 1: 562.0 se 73.5 Group 2: 726.7 se74 P value (paired t-test): <0.01	dose. Notes: This is a cross over study. Patient
	the lower urinary tract <u>All patients</u> N: 20		Nocturnal percentage (%) (24 hour urine collection**)	Baseline: 47.3 se 3.5 Group 1: 39.2 se 3.5 Group 2: 50.6 se 3.5 P value (paired t-test): <0.001	had 1 week run in with placebo, and then allocated to desmopressin 20 microgram or placebo for 2 weeks, before crossing over for another 2 weeks. *FV chart resulted were collected at the second week. ** The 24 hour urine collection was done on the last day of the treatment period.
	Mean age, mean (range): 70.5(52-80) years Drop outs: 2		Hyponatremia and hyposmolaemia (withdrawn early from study, sodium 127mmol/L, hypoosmolaemia 263mosmol/kg)	Group 1: 1/20 Group 2: 0/20	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Falahatkar et al., 2008 77	Patient group: BPH patients with refractory nocturia Inclusion criteria:	Group 1: COX II selective NSAID (celecoxib) 100mg capsule at 9PM Group 2: Placebo	IPSS	At 1 month Group 1: 15.5±4.2 Group 2: 18.0±3.9 P values:	Funding: NR Limitations: • Randomisation allocation and concealment not reported • Small sample size • Short length of follow up • Additional outcomes: Authors reported that not baseline parameters did not influence level of response
Study design: RCT, double blinded	 BPH with ≥2 voids per night Mean night time voided volume of <30% of the 24 hour volume IPSS≥8 		Qmax , ml/s, mean±sd	At 1 month Group 1: 12.9±2.7 Group 2: 12.3±2.5 P value:	
Setting: Iran,Jan to May 2007 Evidence	 Prostate volume >20cm³ Prescribed alpha-blockers or alpha blockers or finasteride (if prostate volume>30cm³) for 2-3 months but incidence of nocturia remained ≥2 times per night Negative urine culture findings Normal renal function Exclusion criteria: Previous prostate surgery or other invasive procedures for testing of BPH Prostate cancer, or PSA>10ng/mL. Men with PSA 4.1 to 10ng/mL were required to provide ultrasound guided biopsy 		Nocturia frequency	At 1 month Group 1: 2.5±1.9 Group 2: 5.1±1.9 P value:	
level: 1+ Duration of			Nocturia frequency, classified as excellent if decreased ≥2 voids/night or disappeared, improved if decreased by 1 void/night and no change. At 1 month Group 1: 28(70) Excellent improved no change Group 1: 28(70) 5(12.5) Values in brow Group 2: 3(7.5) 6(15) Values in brackets are percentages 31(77.5) Values in brackets are percentages Adverse events – mild gastric discomfort At 1 month Group 1: 4/40 Group 2: 0/40 P value: 0.11 [calculated by NCGC using Fisher's exact test]	At 1 monthAuthors r baseline not influe responseExcellent improved no change Group 1: 28(70)5(12.5) 5(12.5)7(17.5) Group 2: 3(7.5)6(15) Notes: None	
follow-up: 1 month					
	All patients N: 80 Mean age: range 49 to 80years Drop outs: 0				
	<u>Group 1 - Celecoxib</u> N: 40 Mean (±SD) Age: 64.3±7.7 (49- 80) Dropouts: 0				

Evidence Table 18 Non steroidal anti-inflammatory drugs (NSAIDS) vs. placebo

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	IPSS, mean ±sd: 18.2±3.4 Qmax, ml/s, mean±sd: 12.5±2.1 Nocturia frequency, mean±sd: 5.17±2.1 Prostate volume, ml, mean±sd:18.25±4.5 PSA level, ng/ml, mean±sd:2.62±1.16 Group 2 - Placebo N: 40 Mean (±SD) Age: 64.9±7.05 (50- 80) Dropouts:0 IPSS, mean±sd: 18.4±3.1 Qmax, ml/s, mean±sd:12.1±2.1 Nocturia frequency, mean±sd:5.30±2.4 Prostate volume, ml, mean±sd:50.11±5.6 PSA level, ng/ml, mean±sd: 2.68±1.18				

APPENDIX D — EVIDENCE TABLES - (DRAFT FOR CONSULTATION)

1 2	Evidence Table 19 Combination therapy: 5-Alpha reductase inhibitor added to alpha-blocker
3	See Evidence Table 10 Alpha blocker vs. 5-alpha reductase inhibitors
4	for Debruyne et al., 1998 ⁶¹ .
5	See Evidence Table 9 Alpha-blockers vs. placebo
6	Kirby et al., 2003 ¹²⁹ .
7	See Evidence Table 10 Alpha blocker vs. 5-alpha reductase inhibitors
8	for Lepor et al., 1996 ¹⁴³ .
9	See Evidence Table 2: How does PSA predict symptom progression (in terms of symptom score)?
10	for McConnell et al., 2003 ¹⁶⁶ .
11	See Evidence Table 10 Alpha blocker vs. 5-alpha reductase inhibitors
12	for Roehborn et al., 2008 ²²⁵
13	

1 2	Evidence Table 20 Combination therapy: Anticholinergic added to alpha-blocker
3	See Evidence Table 10 Alpha blocker vs. 5-alpha reductase inhibitors
4	for Debruyne et al., 1998 ⁶¹ .
5	See Evidence Table 10 Alpha blocker vs. 5-alpha reductase inhibitors
6	for Roehborn et al., 2008 ²²⁵
7	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Macdiarmid	Patient group:	Group 1:	IPSS, mean±sd at various time	At week 4 Change	Funding:
et al.,	Men with LUTS who remained	Oxybutynin ER +	points and change from	Group 1: 15.9±6.7 -4.4±5.6	Ortho Urology, US
2008 ¹⁵⁵	symptomatic despite 4 weeks of	0.4 mg	baseline	Group 2: 16.6±5.8 -3.8±5.5	(oxybutynin manufacturer)
	alpha blocker therapy	tamsulosin		P value: 0.24	
Study design:		Oxybutynin ER	P values provided in paper	<u>At Week 8 Change</u>	Limitations:
RCT, double	Inclusion criteria:	dose was	based on ANCOVA using	Group 1: 14.5±7.3 -5.7±6.3	 Randomisation
blinded	■ Age ≥ 45 years	10mg/day, the	baseline values as the	Group 2: 16.0±6.7 -4.4±6.0	allocation and
, multicentre	 Diagnosed with LUTS, had 	recommended	covariates	P value: 0.03	concealment not
March2004 to	urgency and frequency, with or	starting dose		<u>At week 12 Change</u>	described
June2005	without urge incontinence			Group 1: 13.3±7.4 -6.9±6.5	 The criteria for
Setting:	 Qmax of 4ml/s with voided 			Group 2: 15.2±6.9 -5.2±6.2	excluding about $\frac{1}{2}$ of
Double	volumes of 125mL and post void	Group 2: 0.4mg		P value: 0.006	the screened
blinded RCT	residual volume of ≤ 150 mL on at	Tamsulosin +	IPSS-QoL (maximum 6 points) at	Week 4 Change	population from
	least 2 occasions	placebo	various at various time points	Group 1: 3.2±1.3 -0.9±1.4	randomisation not
Evidence	After receiving ≥ 4 weeks of 0.4mg		and change from baseline	Group 2: 3.5±1.3 -0.5±1.3	provided
level:	tamsulosin, they should still have:		Ĵ,	P value: 0.006	 Characteristics at
1+	■ IPSS ≥13 and IPSS storage		P values provided in paper	Week 8 Change	screening visit not
	component (Question 2, 4 and 7)		based on ANCOVA using	Group 1: 3.0±1.5 -1.2±1.5	provided
Duration of	≥8.	Note:	baseline values as the	Group 2: 3.4±1.4 -0.6±1.3	 This study only
follow-up:		All patients	covariates	P value: <.001	randomised patients
12 weeks post	Exclusion criteria:	received 4 weeks		Week 12 Change	who remained
randomisation.	risiony of ormany refermion,	of 0.4mg		Group 1: 2.8±1.5 -1.3±1.5	symptomatic despite
All patients	bladder or prostate cancer	tamsulosin before		Group 2: 3.2±1.5 -0.8±1.4	\geq 4 weeks of treatment
received 4	■ PSA ≥4 ng/ml	randomisation		P value:0.001	with alpha blocker
weeks of	 Angle closure glaucoma 		IPSS-Storage (maximum 15	At week 4 Change	and should only be
tamsulosin	 Surgical or procedural treatment 		points), mean \pm sd at various	Group 1: 7.7±2.9 -2.6±2.7	generalised to this
between screening and	of the prostate		time points and change from	Group 2: 8.2±2.6 -1.9±2.6	group of patients (this
randomisation			baseline	P value: 0.008	is likely to augment the
randomisation	Amendments in protocol in			<u>At Week 8 Change</u>	difference seen
	<u>July2004</u>		P values provided in paper	Group 1 : 7.0±3.2 -3.3±3.0	between the two
	Inclusion criteria		based on ANCOVA using	Group 2: 7.9±3.0 -2.1±2.8	intervention groups)
	 Qmax of 8 ml/s with voided 		baseline values as the	P value: <.001	Additional outcomes:
	volumes of 125mL and post void		covariates	<u>At week 12 Change</u>	
	residual volume of ≤ 150 mL on at			Group 1 : 6.5±3.2 -3.7±3.0	SPI (symptom problem index) values were also
	least 2 occasions			Group 2: 7.6±3.1 -2.4±2.9	reported
	Discontinuation criteria:			P value : <.001	reported

Study details	Patients Interventions		Outcome measures	Effect size	9	Comments
	 Qmax decreased to 5mL/s or less Post void residual volume >300mL All patients 		Qmax (ml/s), mean±sd P value and change values calculated by NCGC	<u>At 12 weeks</u> Group 1:15.5±8.4 Group 2:14.7±8.4 P value: NS	<u>Change</u> -0.2±7.8 0.1±7.6	Notes: There were 6/209 vs. 1/209 patients with PVR
	N: 420 randomised out of 818 screened Mean age: 62.9±9.1		Post void residual volume (ml), mean±sd	<u>At 12 weeks</u> Group 1:69.7±75.3 Group 2:53.7±52.9	<u>Change</u> 18.2±77.3 7.8±47.5	>300ml (all withdrawn from study) in group 1 vs. group 2 respectively. There were 14/209 vs. 13/209
	Drop outs: 2 (took <1 dose of medications)		P value and change values calculated by NCGC	P value: NS		patients with Qmax<5 ml/s (8/209 vs. 12/209 at
	<u>Group 1</u> - Oxybutynin ER + 0.4 mg tamsulosin		Any adverse events		NS	endpoint) respectively.
	N: 209 Age, mean ±sd: 62.6±9.0		Serious adverse events AEs leading to withdrawal Dry mouth	21(10) 20(9.6)		The number patients discontinued as per protocol did not tally with
	Dropouts: Years since LUTS diagnosis, years, mean±sd:5.0±5.7		Infections and infestations Renal and urinary AEs	18(8.6)22(10.3)10(4.8)10(4.8)	NS	the number of patients who had PVR>300ml
	IPSS , mean±sd:20.2±5.0 IPSS-QoL , mean±sd:4.1±1.1		AUR (with or without Foley catheter) Nervous system disorders		NS NS	
	Qmax, ml/s, mean±sd:15.7±7.1 Post void residual volume, ml, mean±sd: 50.7±42.9		Constipation Reasons for study	1(0.5) 4(1.9)	NS P value	-
	Group 2 N: 209 Age, mean ±sd: 63.3±9.2		discontinuation Adverse events Lack of efficacy Patient choice Others (include PVR> 300ml	4/209 6/209 5/209 0/209	2 NS NS NS NS	
	Dropouts: Years since LUTS diagnosis, years, mean±sd:5.0±4.7 IPSS, mean±sd:20.5±4.9		and Qmax <5ml/s)	, , ,	145	
	IPSS-QoL, mean±sd:4.0±1.0 Qmax, ml/s, mean±sd:14.6±6.6 Post void residual volume, ml, mean±sd: 45.8±41.4					

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Bechara et al., 2008 ²⁴	Patient group: LUTS and erectile dysfunction Inclusion criteria:	Group 1: Tamsulosin0.4mg/day+ tadalafil 20mg/day	IPSS change from baseline at end of 6 week treatment, mean ±SD	Grp 1: -9.2±5.08 Grp 2: -6.7±3.87 *P value: <0.05	Funding: NR
Study design: double blinded, cross over study	 > 50 years Clinical diagnosis of LUTS by medical history and physical examination At least 6 months of LUTS; IPSS≥12, Total PSA ≤4.0ng/ml Qmax > 5ml/s with minimum voided 	For 6 weeks, at about the same time each day Group 2: Tamsulosin 0.4mg/day +placebo	IPSS-QOL at end of 6 week treatment, mean ±SD Qmax, ml/s, mean± SD	Grp 1: 1.6, no SD Grp 2: 2.3, no SD *P value: <0.05 Grp 1: 12.6, no sd Grp 2: 11.7, no sd *P value: >0.05	 Limitations: This is a cross-over RCT. Therewas no washout period to provide verification that patients had returned to their baseline level.
Setting: single-centre in Argentina	volume of >125ml	For 6 weeks, at about the same time each day The capsules were	IIEF-EF mean± SD	Grp 1: 23.2, no sd Grp 2: 16.9, no sd *P value:<0.001	 The sample size is small Additional outcomes: IIEF-EF, GAQ (Global Assessment)
Evidence level: 1+ Duration of follow-up: Week 12	 History or evidence of prostate cancer Previous prostate surgery or other invasive procedure to treat BPH Post void residual volume >250ml History of AUR ≤3 months of screening visit Use of alpha reductase inhibitors or phytotherapy ≤ 6 months; alpha blockers or PDE5-l ≤2 weeks Cardiovascular comorbidities and uncontrolled diabetes 	identical and prepared by a third party (pharmacist) in numbered containers Cross over design: The patients were randomised to treatment Group 1 or Group 3 at Visit 1 (week 0). At week 6, end point measures were collected and	Adverse Events Headache Hypotension Dizziness Dyspepsia Diarrhoea Ejaculation disorder Altered vision Withdrawals due to adverse events	2 1 0 1 3 1 0 1 0 1 0 1 Grp 1 Grp 2	Quality) and a visual analogue scale (no mention of validations) Notes: *P values were as reported in paper. Authors reported using Tukey Cramer test with multiple comparisons **IIEF-EF>25 points was reported as 28/30(93.3%) at baseline in Table 1. These numbers did not
	 Comorbidities which may interfere with urinary flow or symptoms. <u>All patients</u> N: 30 out of 40 patients screened Drop outs: 3 (2 adverse events, 1 personal reasons) Age, mean (range): 63.7(51-78) Sexually active: 28/30 (93.3%) IPSS, mean (range): 19.4 (12-34) IPSS-QoL, mean (range): 4.1 (0-6) Qmax, ml/s, mean (range): 9.6 (4 to 14) **IIEF-EF mean(range):17(1-29) 	were collected and patients switched over to the other treatment group. At week 12, end points were measured again.	Headache Rashes	/ /	tally with mean IIEF (sexual function domain) of 15 points at baseline (Table3) and number of men with ED who completed study (19/27). Erectile Function domain of the 15- question IIEF (Q1-5 and Q15, maximum score 30) was used. This is different from IIEF-5, which consists of Q2, Q4, Q5, Q7 and Q15 of the IIEF (maximum score 25)

1 Evidence Table 21 Combination therapy: phosphodiesterase-5-inhibitor added to alpha-blocker

1 See Evidence Table 12 Alpha-blockers vs. phosphodiesterase-5 inhibitors

2 for Kaplan et al., 2007¹¹⁷

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Liguori et al., 2009 ¹⁴⁶	Patient group: Men with LUTS and previously untreated erectile dysfunction	Group 1: Tadalafil 20 mg every other day	IPSS Note: The change from	<u>Baseline:</u> Grp 1: 13.8±5.6 Grp 2: 15.7±4.8	Funding: Reported no conflicts of interest
Study design: RCT open label, Setting: Multicentre (5) in Italy from Feb to Dec2007	 Inclusion criteria: Men aged 50 to 75 years with previously untreated ED and a history of LUTS secondary to BPH for 6 months or longer IPSS>8 Exclusion criteria: 	Group 2: Alfuzosin 10 mg/day Group 3: tadalafil 20 mg every other day + alfuzosin 10 mg/day	baseline values were calculated by NCGC	Grp 3:15.3 \pm 4.5 <u>At 12 weeks</u> Grp 1: 12.5 \pm 5.6 Grp 2: 10.6 \pm 3.6 Grp 3: 9.0 \pm 4.0 <u>Change from baseline</u> Grp 1: -1.3 \pm 5.6 Grp 2: -5.2 \pm 4.2 Grn 2: -6.2 \pm 4.2	 Limitations: This was an open labe study with no randomisation allocation and concealment methods reported. The
Evidence level: 1+	 Contraindications to the study drugs Using medications to control bladder symptoms or had ever taken alpha blockers, PDE5-I, or 5 alpha reductase inhibitors. Bladder tumours, urethral strictures, 		IPSS % change from baseline at 12 weeks The P values reported were for 12 weeks compared to baseline	Grp 3: -6.3±4.3 Grp 1: -8.4, p=NS Grp 2: -27.2, p=0.003 Grp 3: -41.6, p<0.001	outcomes are mainly subjective outcomes, and this makes it particularly at risk of biases.
Duration of follow-up: 12 weeks	 neurogenic bladder dysfunction History of prostatits, prostate cancer; prostate surgery, radiotherapy PSA level>20 ng/ml Acute urinary retention or indwelling catheter Infection on urinalysis <u>All patients</u> N: 66 		IPSS-QoL	Baseline: Grp 1: 3.5 ± 1.1 Grp 2: 3.4 ± 0.9 Grp 3: 3.2 ± 1 At 12 weeks Grp 1: 2.5 ± 1.2 Grp 2: 2.1 ± 0.9 Grp 3: 1.6 ± 0.8 Change from baseline	Additional outcomes: Changes in IPSS (obstructive), IPSS (irritative) IIEF-EF, and IIEF Q15 were also reported Notes: **Erectile Dysfunction assessed using the
	N: 60 Mean age: 61 years (range 50 to 75) Drop outs: 8/66 (Baseline data excluded patients who dropped out of study) Group 1 (Tadalafil)		Qmax, ml/s mean ±sd	Grp 1: 1±1.2 Grp 2: 1.3±0.9 Grp 3: 1.6±0.9 Baseline: Grp 1: 13.1±4.3 Grp 2: 12.3±5.4	Erectile Function domain score of the 15-question IIEF, ie , ie Q1-5 and Q15 (Maximum score 30).

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	N: 21 Dropouts:2 /21 Mean (± SD) Age: 60.8±8 IPSS mean± SD:13.8±5.6 IIEF-EF, mean±sd: 14.1 IIEF Q15 mean± SD: 2.5 Qmax mean± SD, mL/s:13.1 Group 2 (Alfuzosin) N: 22 Dropouts: 4/22 Mean (± SD) Age: 61.3±6.8 IPSS mean± SD:15.7±4.8 IIEF-EF, mean±sd:14.2 IIEF Q15 mean± SD: 2.8 Qmax mean± SD, mL/s:12.3 Group 3 (Tadalafil + Alfuzosin) N: 23 Dropouts: 2/23 Mean (± SD) Age: 63±6.9		Nocturia (as recorded in voiding diary)	Grp 3: 11.9 ± 2.7 <u>At 12 weeks</u> Grp 1: 14.3 ± 5.2 Grp 2: 14.0 ± 3.7 Grp 3: 15.0 ± 4.0 <u>Change from baseline</u> Grp 1: 1.2 ± 4.8 Grp 2: 1.7 ± 4.6 Grp 3: 3.1 ± 3.4 <u>Baseline:</u> Grp 1: 1.7 ± 1 Grp 2: 1.9 ± 0.9 Grp 3: 1.9 ± 0.9 <u>At 12 weeks</u> Grp 1: 1.1 ± 1.1 Grp 2: 1.0 ± 0.7 Grp 3: 1.1 ± 0.9 <u>Change from baseline</u> Grp 1: -0.6 ± 1.1 Grp 2: -0.9 ± 0.8 Grp 3: -0.8 ± 0.9	This is different from IIEF- 5, which consists of question Q2, Q4, Q5, Q7 and Q15 of the IIEF (maximum score 25).
	IPSS mean± SD:15.3±4.5 IIEF-EF, mean ±SD: 14.6		Withdrawals due to AE	Grp 1 Grp 2 Grp 3 1/21 3/22 2/23	-
	lIEF Q15 mean± SD: 2.4 Qmax mean± SD, mL/s:11.9		The reason for withdrawals were	Group 1: back pain, head aches Group 2 :dizziness, constipations Group 3: myalgia, dizziness, sensation of heaviness	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Ahyai et al.,	Patient group: Patients with lower	Group 1: HoLEP	Mean (SD) AUA	Baseline:	Funding: Financial
2007 ⁹	urinary tract symptoms due to BPH.	40-50 Hz, 80-100₩		Group1 (n=100): 22.1 (3.8)	interest and/or other
		used. Saline used as		Group 2 (n=100): 21.4 (5.2); p=0.56	relationship with
Study design:	Inclusion criteria: AUA of 12 or	irrigation fluid and		6 months:	Lumenis, Inc and Karl
RCT	more, Qmax of 12ml/s or less, PVR	electrolyte-free solution		Group1 (n=94): 2.2 (1.6)	Storz, Inc.
	volume > 50ml, Schafer grade of II	for electrocautery loop		Group 2 (n=89): 3.7 (3.4); p=0.006	
Setting:	or more in pressure flow studies, and	tissue fragmentation.		12 months:	Limitations:
Urology	a total prostate volume <100cc in	Postoperative bladder		Group1(n=89): 1.7 (1.8)	Allocation concealment
department,	transrectal ultrasound.	irrigation used as		Group 2(n=86): 3.9 (3.9); p<0.001	and blinding unclear.
Berlin		necessary until haematuria		18 months:	
	Exclusion criteria: previous prostate	had settled sufficiently to		Group1 (n=82): 1.3 (1.5)	
Evidence	or uerthral surgery and voiding	remove catheter.		Group 2 (n=78): 4.0 (3.8); p<0.0001	Notes:
level:	disorders not related to benign	Median postoperative		24 months:	Linked to Kuntz 2004 ¹³²
1+	prostatic hyperplasia. Prostate	catheterisation=1 day		Group1 (n=80): 1.7 (1.7)	– follow up for 24
	carcinoma excluded by biopsy.	Median Hospital stay=2		Group 2 (n=75): 3.9 (3.7); p<0.0001	months.
Duration of		days		36 months:	
follow-up:	All patients			Group1 (n=75): 2.7 (3.2)	
36 months	N: 200			Group 2 (n=69): 3.3 (3.0); p=0.17	
		Group 2: TURP	Mean (SD) Qmax, ml/s	Baseline:	1
	Group 1	standard tungsten wire		Group1: 4.9 (3.8)	
	N: 100	loop with a cutting current		Group 2: 5.9 (3.9); p=0.08	
	Mean Age: 68.0	of 160 W and		6 months:	
	Dropouts: 25 (prostate cancer=3,	coagulating current of 80		Group1: 25.1 (6.9)	
	stricture=4, refused follow-up=6,	W. Postoperative bladder		Group 2: 25.1 (9.4); p=0.72	
	bladder neck contracture=3, moved	irrigation used as		12 months:	
	away=3, polymorbidity=2,	necessary until haematuria		Group1: 27.9 (9.9)	
	death=3, BPH recurrence=1)	had settled sufficiently to		Group 2: 27.7 (12.2); p=0.76	
		remove catheter.		18 months:	
	<u>Group 2</u>	Median postoperative		Group1: 27.5 (9.2)	
	N: 100	catheterisation=2 day		Group 2: 28.2 (11.2); p=0.89	
	Mean Age: 68.7	Median Hospital stay=3		24 months:	
	Dropouts: 31 (prostate cancer=10,	days		Group1: 28.0 (9.0)	
	stricture=3, refused follow-up=4,			Group 2: 29.1 (10.9); p=0.82	
	bladder neck contracture=3, moved			36 months:	
	away=1, polymorbidity=5,			Group1: 29.0 (11.0)	
	death=3, transition cell carcinoma=2)			Group 2: 27.5 (9.9); p=0.41	

Evidence Table 22 Holmium laser enucleation (or resection) of the prostate HoLEP (HoLRP) vs. transurethral resection of the prostate

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Mean (SD) PVR, ml	Baseline: Group 1: 237 (163) Group 2: 216 (177); $p=0.08$ 6 months: Group 1: 4.8 (12.5) Group 2: 16.7 (16.9); $p=0.03$ 12 months: Group 1: 5.3 (15.3) Group 2: 26.6 (60.4); $p<0.001$ 18 months: Group 1: 1.6 (11.5) Group 1: 5.6 (19.9) Group 2: 19.9 (29.6); $p<0.0001$ 36 months: Group 1: 8.4 (16.0) Group 2: 20.2 (33.0); $p<0.012$	
			Peri-operative complications	Blood transfusion Group 1: 0 Group 2: 2 (2%) Recatheterisation Group 1: 0 Group 2: 5 (5%) Mortality Group 1: 0 Group 2: 0	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Complications at 36 months	Urethral stricture Group 1: 4 (4.1%) Group 2: 3 (3.3%) Bladder neck contracture Group 1: 3 (3.1%) Group 2: 3 (3.3%) BPH recurrence: Group 1: 1 (1.0%) Group 2: 0 Reoperation: Group 1: 7.2% Group 2: 6.6%	
			Urinary incontinence at 12 months	Preoperatively: Group 1: 27/89 Group 2: 33/86 Post operatively: Group 1: 5/89 Group 2: 5/86	
			Stress incontinence developed after surgery	Group 1: 1 Group 2: 1	
			Potency following preoperative erectile dysfunction (insufficient for sexual intercourse)	Group 1: 2/43 Group 2: 0/41	
			Resolved erectile dysfunction postoperatively	Group 1: 1 Group 2: 1	
			Decreased potency at 12 months compared to preoperative level	Group 1:10/89 (11.2%) Group 2: 9/86 (10.5%)	

- 1	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments				
Gupta et al., 2006 ⁹⁷	Patient Group: Patients with BPH who were candidates for TURP were selected from July 2002 to	Group 1: HoLEP Power settings were 80- 100W.	Mean (SD) IPSS:	Baseline: Group 1: 23.4 (4.5) Group 2: 23.3 (3.9)	Funding: NR				
Study design: RCT	December 2003. Inclusion criteria: glands of >40g	Operative duration: 75.4 minutes		Group 3: 24.9 (3.9) 6 months: Group1: 5.2 (0.31)	Limitations: No mention of drop outs in the study.				
Setting: India	Exclusion criteria: patients with a previous history of prostatic and	Group 2: TURP 80W cutting and 50W coagulation used.		Group 2: 6.1 (0.42) Group 3: 5.9(0.25) 12 months:	Additional outcomes:				
Evidence level: 1+	urethral surgery, neurovesical dysfunction and carcinoma of the prostate were excluded from the	Operative duration: 64.1 minutes		Group 1: 5.2 (0.17) Group 2: 5.6 (0.32) Group 3: 5.4 (0.28)	Irrigation, haemoglobin decrease, serum sodium decrease.				
Duration of follow-up:	study.	Group 3: TUVRP 180W cutting and 80W coagulation used.	Mean (SD) Qmax	Baseline: Group1: 5.15 (4.4) Group 2: 4.5(3.9)	Notes: None.				
12 months.	<u>All patients</u> N: 150	Operative duration: 55.9 minutes		Group 3: 4.65 (3.6) 6 months: Group 1: 23.1(1.2)					
	<u>Group 1</u> N: 50 Mean (±SD) Age: 65.88 (10.1)			Group 2:20.7 (1.32) Group 3: 22.5 (0.95) 12 months:					
	Dropouts: NR <u>Group 2</u>							Group 1: 25.1 (1.06) Group 2: 23.7 (1.58) Group 3: 23.6(0.96)	
N: 50 Mean (±SD) Age: 65.67 (7.5) Dropouts: NR <u>Group 3</u> N: 50 Mean (±SD) Age: 67.68 (9.8) Dropouts: NR	Mean (±SD) Age: 65.67 (7.5)		Mean (SD) PVR, mL	Baseline: Group 1: 112.0(155.9) Group 2: 84.0(129.7)					
			Group 3: 103 (174.1) 6 months: Group1: <20						
				Group 2: <20 Group 3: <20 12 months: Group1: <20					
				Group 2: <20 Group 3: <20					

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Mean (SD) blood loss, mL	Group 1: 40.6 (37.3) Group 2: 140.5 (60.7) Group 3: 68.6 (42.7)	
			Mean (SD) catheter duration, hours	Group 1: 28.6 (20.5) Group 2: 45.7 (12.7) Group 3: 36.2 (8.3)	
			Mean (SD) nursing contact time, minutes	Group 1: 28.1 (8.4) Group 2: 48.3 (9.2) Group 3: 37.2 (6.7)	
			Number (%) complications	Re-catheterisation: Group 1: 2 (4) Group 2 3 (6) Group 3: 3 (6) Fever: Group 1: 1 (2) Group 2: 1 (2) Group 3: 2 (4) Hyponatraemia: Group 2: 1 (2) Group 3: 1 (2) Blood transfusion: Group 1: 0 Group 2: 1 (2) Group 3: 1 (2) Blood transfusion: Group 2: 1 (2) Group 3: 0 Capsular perforation: Group 1: 1 (2) Group 2: 0 Group 3: 0 Bladder mucsal injury: Group 1: 2 (4) Group 2: 0 Group 3: 0	
				Death (pneumonia): Group 1: 0 Group 2: 0 Group 3: 1 (2)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Transient dysuria: Group 1: 5 (10) Group 2: 1 (2) Group 3: 9 (18) Stricture: Group 1: 1 (2) Group 3: 1 (2) Incontinence: Group 1: 1 (2) Group 3: 1 (2) Incontinence: Group 2: 2 (4) Group 3: 1 (2) Incontinence: Group 2: 1 (2) Group 3: 0	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Mavuduru RM 2009 ¹⁶³	Patient group: Patients who underwent surgery for BPH.	Group 1: Transurethral resection of the prostate (TURP).	Mean ±SD symptom score- IPSS	Baseline: Group1: 21.4±3.7 Group 2: 22.53±4.79	Funding: NR Limitations:	
Study design: RCT	Inclusion criteria:	TURP was performed by standard technique using a 26-Fr continuous flow		3 months: Group 1: 2.86±1.72 Group 2: 2.26±1.57	Small study size and duration of follow up is less than 1 year.	
Evidence level: 1+	Exclusion criteria: Patients with a history of previous prostatic or urethral surgery, and documented cases of prostate	resectoscope (Karl Storz) with a cutting current of 100-120 D and coagulating current of 50-		p value: 0.329 9 months: Group 1: 3.57±1.03 Group 2: 4.32±1.25	Additional outcomes: Intraoperative data including weight of	
Setting: Chandigarh,	carcinoma.	60 W. The intraoperative irrigation fluid used	Mean ± SD PVR	p value: 0.37 Baseline:	gland resected and volume of irrigation	
India Duration of	N: 30 TURP ch by Ellich	prostate (HoLEP)	JRP TURP chips were removed by Ellick's evacuator. JRP Group 2: Holmium laser enucleation of the	volume (ml)	Group1:103 ±27 Group 2: 91±30 3 months:	fluid.
follow-up: 9 months	Group 1: TURP N: 15 Age (mean): 66.46±5.79 Drop outs: 0				Group 1: 13.66±14.0 Group 2: 13±8.61 p value: 0.87 9 months:	
	Group 2: HoLEP N: 15	550nm end-firing flexible quartz, and a continuous		Group1: 35.66±15.0 Group 2: 43±10.61 p value: 0.97		
Age (mean): 69.86±9.6 Drop outs: 0	-	Drop outs: 0 consisting of a 27-Fr outer sheath, an inner rotating sheath with a self- designed working element. HoLEP was performed by standard technique as described by Gilling et al. The machine used was Versapulse Holmium Laser, with a frequency if 35-40 Hz	Mean ± SD Uroflowmetry	Baseline: Group 1:6.9 ±2.5 Group 2: 5.79±2.7 3 months: Group 1: 27.8±6.5 Group 2: 28.6±6.2 p value: 0.721 9 months: Group 1: 27.8±6.5		
			Operative time	Group 2: 28.6±6.2 p value: 0.64 Group1: 43±9.36	_	
	and a power setting of 2 joules. The irrigant used	(minutes)	Group 1: 43±9.36 Group 2: 53±9.84 p value: <0.01			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
		was normal saline.	Duration of catheterization (hours)	Group1: 78.20±17.84 Group 2: 46.42±14.25 p value: <0.001	
			Adverse events	Transient dysuria Group 1: 3/15 (40%) Group 2: 1/15 (6.66%) Recatheterization Group 1: 1/15 (6.66%) Group 2: 1/15 (6.66%) Bleeding Group 1: 2/14 (13.33%) Group 2: nil Incontinence Group 1: nil Group 2: 2/15 (13.33%)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Montorsi et al., 2004 ¹⁷⁷	Patient group: consecutive patients with symptomatic obstructive BPH from January to October 2002.	Group 1: HoLEP Tissue morcellation of the prostatic lobes into	Mean (SD) IPSS	Baseline: Group 1: 21.6±6.7 Group 2: 21.9±7.2	Funding: NR Limitations:
Study design: RCT	Inclusion criteria: Age<75 years, peak urinary glow rate <15ml/s, post void residual urine <100cc,	fragments that were retrieved form the bladder cavity. Energy		6 months: Group 1: 3.9±2.9 Group 2: 2.9±2.6	Number of drop outs not reported. Prostate size
Setting: 2 centre study (Milan and	medical therapy failure, transrectal ultrasound adenoma volume <100gm and urodynamic	delivered by a 360u fibre. Enucleation performed at		12 months: Group 1: 4.1±2.3 Group 2: 3.9±3.6;p=0.58	significantly different at baseline.
Bergamo) Evidence	obstruction. Exclusion criteria: Neurogenic bladder, diagnosis of prostate	2.0J and 35Hz. Total operative time:	Mean (SD) QoL question	Baseline: Group 1: 4.6±1.11 Group 2: 4.7±1.0	Additional outcomes: Average flow reported. Orgasmic function,
level:]+	cancer and any previous prostatic, bladder neck or urethral surgery.	74±19.5 minutes. Catheterisation time 31±13 hours		6 months: Group 1: 1±0.8 Group 2: 0.6±0.2	sexual desire, intercourse satisfaction.
Duration of follow-up: 12 months	All patients N: 100	Hospital stay 59±19.9 hours		12 months: Group 1: 1.4±0.9 Group 2: 0.8±1.28;p=0.31	Notes: Linked with Rigatti 2006 ²¹⁵
	Group 1 N: 52 Mean Age: 65.14 Mean TRUS volume (gm): 70.3 Dropouts: NR	Group 2: TURP Using a standard tungsten wire loop with a cutting current of 80W and a coagulation g current of	Mean (SD) maximum flow (ml/s)	Baseline: Group 1: 8.2±3.2 Group 2: 7.8±3.6 6 months: Group 1: 23.1±8.6	
N: Me Me	Group 2 N: 48 Mean Age: 64.5 Mean TRUS volume (gm): 56.2	160W. Following procedure catheter inserted into bladder and irrigation started.		Group 2: 26.5±15.5 12 months: Group 1: 25.1±7.2 Group 2: 24.7±10;p=0.25	
	Dropouts: NR Total operative time: 57±15 minutes. Catheterisation time 57.78±17.5 hours Hospital stay 85.8±18.9	Mean detrusor pressure at max flow (cmH20)	Baseline: Group 1: 77.3 Group 2: 81.8 12 months Group 1:36.2 Group 2: 38.5 ; p=0.85		
		hours	Mean Schafer grade	Baseline: Group 1: 3.4 Group 2: 3.5	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				12 months Group 1: 0.9 Group 2: 1.2; p=0.55	
			Mean (SD) Erectile function (International Index of Erectile Function IIEF-15)	Preoperatively: Group 1: 22.3±3.6 Group 2: 21.4±3.1 6 months: Group 1: 23.5±3.6 Group 2: 23.4±3.5 12 months: Group 1: 23.8±3.9 Group 2: 24.1±3.7	
			Number (%) of early Adverse events	Bladder mucosal injury Group 1: 10 (18.2%) Group 2: 0 Re-intervention for bleeding Group 1: 1 (1.7%) Group 2: 1 (2.2%) Transurethral resection syndrome Group 1: 0 Group 2: 1 (2.2%) Early acute urinary retention Group 1: 3 (5.3%) Group 2: 1 (2.2%) Dysuria (burning) Group 1: 33 (58.9%) Group 2: 13 (29.5%) Transitory urge incontinence Group 1: 25 (44%) Group 2: 17 (38.6%)	
			Adverse events at 6 & 12 month follow up (%)	Urethral stricture: Group 1: 1 (1.7%) Group 2: 4 (7.4%) Stress incontinence: Group 1: 1 (1.7%) Group 2: 1 (2.2%)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Westenberg	Patient group: Candidates for	Group 1	AUA score	Baseline:	Funding: Financial
et al., 2004 ²⁷²	surgery for LUTS and obstruction	Holmium laser resection		Group1 (n=61): 21.9±6.2	interest and/or other
	due to BPH at Tauranga Hospital	(HoLRP). Maximum		Group 2 (n=59): 23.0±5.9	relationship with
Study design:	from April 1996 to August 1997.	average power of 80W		3 months:	Lumenis, Inc.
RCT	Inclusion criteria: Age 80 years or	was used. General or		Group1 (n=61): 5.6±5.1	
	younger, AUA score ≥8, peak	spinal anaesthesia		Group 2 (n=59): 5.7±5.2	
Evidence	urinary flow rate ≤ 15 ml/s,	required in all cases.		6 months:	Limitations:
level:	transerectal ultrasound volume of	Postoperative bladder		Group1 (n=61): 3.8±3.8	Allocation concealment
1+	the prostate <100ml, post void	irrigation was only used if		Group 2 (n=59): 5.0±4.5	and blinding unclear.
	residual volume <400ml and	deemed necessary by the		12 months:	
Setting:	Schafer grade ≥2.	surgeon. Catheter		Group1 (n=53): 4.2±6.0	Additional outcomes:
Tauranga	Exclusion criteria: Catheterised	removed the morning		Group 2 (n=49): 4.3±4.1	Detrusor pressure at 6
Hospital, New	patients and those who had	after surgery.		18 months:	months.
Zealand.	undergone previous urethral or	Mean catheter time:		Group1: 2.9±5.3	
	prostatic surgery. All patients had a	26.2±11.71.		Group 2: 4.5±5.3	
Duration of	digital rectal examination and SPA			24 months:	Notes:
follow-up:	before enrolment to excluded men	Group 2		Group1 (n=45): 3.4±4.9	Linked to Gilling
48 months	with carcinoma of the prostate.	TURP using a cutting		Group 2 (n=41): 3.7±4.9	1999 ⁹³ , Gilling 2000 ⁹
		current of 160W and a		48 months:	and Fraundorfer 2001
	All patients	coagulating current of		Group1 n=43): 5.2±5.9	
	N: 120	80W. General or spinal		Group 2 (n=30): 6.6±5.0; P=0.32	
		anaesthesia was used.	Quality of Life score:	Baseline:	_
	Group 1	Bladder irrigation was		Group1 (n=61): 4.5 ± 1.1	
	N: 61	used and catheter		Group 2 (n=59): 4.7 ± 1.1	
	Mean (±SD) Age: 66.9±6.5	removed before patient		3 months:	
	Dropouts at 48m: 18 (2 died	discharged from hospital.		Group1 (n=61): 1.4 ± 1.5	
	cardiovascular disease, 5 required	Mean catheter time:		Group 2 (n=59): 1.6±1.4	
	reoperation, 6 intercurrent illness, 5	47.5±17.37.		6 months:	
	lost to follow up).			Group1 (n=61): 1.1±1.3	
				Group 2 (n=59): 1.5 ± 1.4	
	Group 2			12 months:	
	N: 59			Group1 (n=53): 0.88±1.4	
	Mean (±SD) Age: 66.8±7.4			Group 2 (n=49): 1.6 ± 1.5	
	Dropouts at 48m: 29 (7 died –			18 months:	
	cardiovascular or malignant disease,			Group1 (n=61): 0.72±1.1	
	8 required reoperation, 4			Group 2 (n=59): 1.3 ± 1.1	
	intercurrent diseases, 10 lost to			24 months:	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	follow up).			Group1 (n=45): 0.98±1.3 Group 2 (n=41): 1.0±1.3 48 months: Group1 n=43): 1.1±1.1 Group 2 (n=30): 1.4±1.4; P=0.37	
			Qmax (ml/s)	Baseline: Group1 (n=61): 8.9 ± 3.0 Group 2 (n=59): 9.1 ± 3.2 3 months: Group1 (n=61): 22.8 ± 10.0 Group 2 (n=59): 20.2 ± 9.5 6 months: Group1 (n=61): 23.9 ± 8.7 Group 2 (n=59): 22.4 ± 9.0 12 months: Group1 (n=53): 25.2 ± 11.9 Group 2 (n=49): 20.4 ± 8.5 18 months: Group1: 25.1 ± 9.3 Group 2: 19.2 ± 9.3 24 months: Group1 (n=45): 25.0 ± 11.1 Group 2 (n=41): 20.9 ± 11.1 48 months: Group1 n=43): 22.3 ± 14.2 Group 2 (n=30): 18.5 ± 8.2 ; P=023	
			TRUS volume (cc)	Baseline: Group1: 44.3±19.0 (11-92) Group 2: 44.6±20.7 (11.5-95) 6 months: Group1: 29.3 (11-61) Group 2: 27.3 (10-75)	
			Post void residual (ml)	Baseline: Group1: 87.8±88.4 (0-346) Group 2: 84.7±81.7 (0-373) 6 months: Group1: 26.7 (0-245) Group 2: 34.3 (0-295)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			<u>Adverse events:</u> Perioperative blood transfusions:	Group1: 0/61 Group 2: 4/59	
			Recatheterised	Group1: 5/61 Group 2: 8/59	
			Reoperations	Group1: 5/61 Group 2: 8/59	
			Urinary tract infections	Group1: 3/61 Group 2: 5/59	
			Strictures	Group1: 6/61 Group 2: 6/59	
			Deep vein thrombosis	Group1: 0/61 Group 2: 1/59	
			Incontinence	Group 1: 1/61 Group 2: 2/59	
			Deaths (due to cardiovascular or malignant disease)	12 months: Group 1: 1/61 Group 2: 1/59 48 months: Group 1: 2/61 Group 2: 7/59	
			% UI (preoperatively/48 months follow up)	Group 1: 50%/20% Group 2: 47%/17%	
			Patients with decreased erection quality at 48m	Group 1: 8% Group 2: 17%	
			% of men potent	Baseline: Group 1: 50% Group 2: 70% 48 months Group 1: 53% Group 2: 60%	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Group 1: 24/25 (96.0%) Group 2: 32/37 (86.5%)	

1	
I	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
-	Patients Patient group: Men at urology service at Hospital between June 1997 and December 2000 and considered for surgical treatment for bladder outlet obstruction secondary to BPH. Inclusion criteria: TRUS volume of 40-200g, Qmax of 15ml/s or less, AUA symptom score of 8 or greater, PVR of less than 400ml and urodynamic Schaffer grade 2 or greater. Exclusion criteria: prostatic carcinoma, catheterised patients and those with a history of previous urethral or prostatic surgery. All patients N: 61 Group 1 N: 31 Mean (±SD) Age: 71.7 (1.1) Dropouts: 9 (one died preoperatively)	Group 1: HoLEP Maximum power 100W and a Versacut morcellator was used. Post operative Foley catheter irrigation was performed if deemed necessary; most patients were treated with a Foley catheter, which was normally removed the day after surgery. Mean catheter time: 17.7 hrs Mean hospital time: 27.6 hrs Group 2: TURP Tungsten cutting wire at 160W cutting and 80 W coagulating current. Irrigating Foley catheter inserted and bladder irrigation was used as necessary until haematuria had settled	Mean (SD) AUA symptom score Mean (SD) QoL	Effect size Baseline (n=60) Group 1: 26 ± 6.02 Group 2: 23.7 ± 6.57 3 months (n=56) Group 1 (n=28) 4.8 ± 4.23 Group 2 (n=29): 3.4 ± 4.85 6 months (n=54) Group 1 (n=26): 6.0 ± 5.10 Group 2 (n=29): 4.8 ± 3.77 12 months (n=52) Group 1 (n=25): 4.3 ± 3.5 Group 2 (n=27): 5.0 ± 4.68 24 months (n=48) Group 1 (n=22): 6.1 ± 4.69 Group 2 (n=26): 5.2 ± 4.08 Baseline: Group 1: 4.8 ± 1.1 Group 2: 4.7 ± 1.1 3 months: Group 1: 1.8 ± 2.12 Group 2: 1.9 ± 3.23 6 months Group 1: 1.6 ± 1.53 Group 1: 1.5 ± 2.5 Group 1: 1.5 ± 2.5 Group 1: 1.5 ± 2.5 Group 2: 1.4 ± 1.56 24 months	CommentsFunding: Supported by Pub Charity, Inc. Financial interest and/or other relationship with Lumenis, Inc, Tel Aviv, Israel.Limitations: Reported Tan 2003 results but these differ to some of the figures quoted in Wilson 2006. Used same results as HTA report.Additional outcomes: PSA before and after in selected patients. PVR at 6 months.Notes: Linked to Tan 2003251 Calculated SD from SE figures given in study.
	Group 2 N: 30 Mean (±SD) Age: 70.3 (1.0) Dropouts: 4	sufficiently to remove the catheter. Mean catheter time: 44.9 hrs	Mean (SE) Qmax, ml/s	Group 1: 1.25±0.94 Group 2: 1.25±1.02 Baseline: Group 1: 8.4±0.5 Group 2: 8.3±0.4 3 months: Group 1: 24.2±1.7 Group 2: 18.9±1.9 6 months	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Group1: 26.4±1.8 Group 2: 20.8±2.3 12 months Group1: 21.8±2.1 Group 2: 18.4±2.8 24 months Group1: 21.0±2.0 Group 2: 19.3±2.2	
			PdetQmax (cmH20)	Preoperative Group 1: 73.2±4.4 Group 2: 85.8±5.4 6 months Group 1: 20.8±2.8 Group 2: 40.7±2.7 P<0.001	
			Schaffer grade	Preoperative Group 1: 3.5±0.2 Group 2: 3.7±0.2 6 months Group 1: 0.2±0.09 Group 2: 1.2±0.2 P<0.001	
			TRUS volume (cc)	Preoperative Group 1: 77.8±5.6 Group 2: 70.0±5.0 6 months Group 1: 28.4±1.8 Group 2: 46.6±4.4 P<0.001	
			Onset of erectile dysfunction at 24 months	Group 1: 2 Group 2: 2	
			Retrograde ejaculation	Group 1: 12/16 Group 2: 8/13	
			Preoperative incontinence	Group1: 15/31 (48%) Group 2: 11/30 (38%)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Patients that regained continence post operatively	Group1: 6/15 Group 2: 8/11	-
			Adverse events at 24 months	Blood transfusion Group 1: 0 Group 2: 1 Re-catheterisation Group 1: 5 Group 2: 4 Re-operation Group 1: 0 Group 2: 2 Urinary tract infections Group 1: 0 Group 2: 2 Strictures Group 1: 1 Group 2: 3 Deaths (cardiovascular causes) Group 1: 0 Group 2: 1	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Xia et al., 2008 ²⁸⁰	Patient group: consecutive BPH patients from November 2004 to December 2005.	Group 1: Thulium laser resection of prostate – tangerine technique.	Mean ±SD symptom score- IPSS	Baseline: Group1: 21.9±6.7 Group 2: 20.8±5.8	Funding: NR
Study design: RCT Evidence level:	Inclusion criteria: age < 85yr, maximum urinary flow rate <15ml/s, post void residual urine	Epidural anaesthesia was achieved. An average power of 50-W thulium lasers operated in		6 months: Group 1: 4.0±2.4 Group 2: 3.8±2.8 12 months:	Limitations: Allocation concealmen and method of randomisation unclear
1+	volume <150ml, medical therapy failure, transrectal ultrasound	continuous wave mode was used. Energy		Group1: 3.5±2.9 Group 2: 3.9±2.7	Additional outcomes
Setting: China	adenoma volume <100g and urodynamic obstruction.	delivered via 550um end- firing fibres. Saline irrigation used. Procedure	Mean \pm SD quality of life	Baseline: Group1: 4.7±0.9 Group 2: 4.5±1.1	Haemoglobin, serum sodium decrease, resected weight.
Duration of follow-up: 12 months	Exclusion criteria: neurogenic bladder, diagnosis of prostate cancer and any pervious prostatic, bladder-neck or urethral surgery, and the presence of an indwelling catheter.	similar to peeling a tangerine. Group 2: TURP Standard tungsten wire loop with a cutting power of 160W and a		6 months: Group 1: 1.1±1.1 Group 2: 0.9±1.0 12 months: Group 1: 1.0±0.9 Group 2: 0.9±0.8	Notes: None.
	All patients N: 100 Group 1 N: 52 Age (mean): 68.9±7.7 TRUS volume (ml): 59.2±17.7 Drop outs: 0		Mean ± SD Qmax (ml/s)	Baseline: Group 1: 8.0±2.8 Group 2: 8.3±3.0 6 months: Group 1: 24.5±9.2 Group 2: 23.3±10.5 12 months: Group 1: 23.7±6.0 Group 2: 24.1±6.4	
	Group 2 N: 48 Age (mean): 69.3±7.3 TRUS volume (ml): 55.1±16.3 Drop outs: 0	Following both procedures, triple lumen catheter inserted into the bladder. Patients kept in hospital 3 days following catheter removal. 500mg levofloxacin used 1 hour before operation	Mean ± SD PVR volume (ml)	Baseline: Group 1:93.1 ±32.1 Group 2: 85.0±36.7 6 months: Group 1: 7.1±6.6 Group 2: 6.7±6.3 12 months: Group 1: 5.2±4.8 Group 2: 6.1±5.6	

1	Evidence Table 23 Thulium	laser resection vs. t	ransurethral resection	of the prostate
---	----------------------------------	-----------------------	------------------------	-----------------

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
		and in the postoperative days (once a day).	Catheterisation time (hours)	Group1: 45.7±25.8 Group 2: 87.4±33.8 p value: <0.0001	
			Hospital stay (hours)	Group1: 115.1±25.5 Group 2: 161.1±33.8 p value: <0.0001	
			Operative time (minutes)	Group1: 46.3±16.2 Group 2: 50.4±20.7 P=0.28	
			Adverse events	Blood transfusion Group 1: 0 Group 2: 2 (4.2%) TUR Group 1: 0 Group 2: 1 (2.1%) Urinary tract infection Group 1: 2 (3.9%) Group 2: 4 (8.3%) Recatheterisation Group 2: 0 Transitory urge incontinence Group 1: 12 (23.1%) Group 2: 15 (31.3%) Retrograde ejaculation Group 1: 18/33 (55%) Group 1: 18/33 (55%) Group 1: 1 (1.9%) Group 2: 3 (6.3%) Stress incontinence Group 1:0 Group 2: 1 (2.1%)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			IIEF-5 scores	Preoperative: Group 1: 19.3±6.1 Group 2:20.0±5.2 6 months Group 1: 20.4±6.0 Group 2: 21.7±4.8 12 months: Group 1: 21.0±5.8 Group 2: 21.4±5.3 P=0.67	
			Mean ± SD PdetQmax(cmH2O)	Preoperative: Group 1: 85.9±29.3 Group 2:83.4±33.3 12 months: Group 1: 38.1±17.5 Group 2: 38.9±17.3 P=0.80	
			Schafer grade	Preoperative: Group 1: 3.8±1.1 Group 2: 3.6±1.2 12 months: Group 1: 0.71±0.67 Group 2: 0.79±0.77 P=0.58	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Aho et al., 2005 ⁸	Patient group:	Group 1: HoLEP	IPSS symptom score, mean	At 1 months	Funding:
	Men with bladder outflow	Performed under general	±SD, (range)	Group 1: 8.7±5.8 (0-21)	Supported by Pub Charity
Study design:	obstruction (BOO) and small	anaesthesia by 1 of 2		Group 2: 6.2±6.8 (0-30)	Inc
RCT	prostate (<40g)	surgeons. (technique		Relative risk:	
		described in another		95% CI:	Limitations:
Evidence level:	Setting:	paper)		At 3 months	 Number of patients
1+	Urology department, New			Group 1: 6.8±5.5 (1-21)	with urinary
	Zealand, between July 1998	Energy used (kJ), mean		Group 2: 6.2±6.7 (0-22)	incontinence was
Duration of	to May 2001	<u>(range):</u> 74.2 (56-104)*		Relative risk:	significantly different
follow-up:		Operative time, mins,		95% CI:	pre-operatively.
12 months	Inclusion Criteria:	<u>mean, SD (range):</u>		<u>At 6 months</u>	 Reporting of adverse
	 Qmax less than 15 ml/s 	29.7±6.1(18-43) *		Group 1: 7.9±6.6 (0-26)	event – definitions an
	■ AUA symptom score ≤8	As outpatient procedure:		Group 2: 9.1±8.4 (1-28)	follow-up period
	 Prostate volume (measured 	15/19		Relative risk:	 There was imbalance
	by TRUS) ≤40cc	(the above values are for		95% CI:	in the number of
	■ PVR<400ml	19 patients- 1 died		At 12 months	incontinence cases at
	Schafer grade ≥2	preoperatively)		Group 1: 8.9±8.5 (1-31)	baseline.: 2/20 vs.
	-			Group 2: 6.1±5.6 (1-16)	11/20
	Exclusion Criteria:			Relative risk:	 Retrograde ejaculation
	 Known prostate cancer, or 	Group 2: Ho BNI		95% CI:	outcome was based a
	suspected prostate cancer	Performed under general		p value: NS at anytime point	the number of patient
	(increased PSA and/or	anaesthesia by 1 in 3	IPSS QoL score mean ±SD,	At 1 months	who were able to
	suspicious of DRE	surgeons. Incisions made at	(range)	Group 1: 2.2±1.6 (0-6)	comment (sexually
	underwent TRUS biopsy)	the 5 and 7 o' clock		Group 2: 1.4±1.6 (0-6)	active?). The number
	 Catheterised patients 	positions from just distal to		Relative risk:	patients who were
	 History of urethral surgery 	each urethral orifice to		95% CI:	able to comment was
	 On anticoagulants or had 	either side of the		At 3 months	not reported.
	coagulation defects	verumontanum down to the		Group 1: 1.8±1.4 (0-6)	
	, i i i i i i i i i i i i i i i i i i i	depth of the surgical		Group 2: 1.8±1.5 (0-6)	Additional outcomes:
		capsule. No tissue was		Relative risk:	Death – 1 in HoLEP (pre-
		excised.		95% CI:	operative), 1 in BNI at 6 th
		Energy used (kJ), mean		At 6 months	month (cardiac)
	All patients	<u>(range):</u> 13.3 (5-26)*		Group 1: 2.0±1.4 (0-5)	
	N: 40	Operative time, mins,		Group 2: 2.1±1.5 (0-5)	Notes:
	Drop outs:	mean, SD (range):		Relative risk:	Sample size calculation we
		7.0±3.3(2-17) *		95% CI:	provided. As sample size
		As outpatient procedure:		At 12 months	40 would be required to

1 Evidence Table 24 Holmium laser eneucleation of the prostate (HoLEP) vs. transurethral incision of the prostate (HoBNI)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Group 1 - HoLEP N: 20 Age (mean): 65.1 ± 11.5 (range not provided) Drop outs at $0/1/3/6/12$ months: $0/1/2/3/4$, 1 patient died pre-operatively IPSS symptom: $25.2\pm5.9(15-34)$ IPSS QoL: 5.2 ± 0.8 (4-6) Qmax: $8.3\pm3.0(4-14)$ PdetQmax H ₂ O: 72.0 $\pm29.1(45-145)$ Schafer Grade: $3.2\pm1.3(2-6)$ Prostate Volume, PV: $30.3\pm6.6(14-39)$ Urinary incontinence: $2/20^{\#}$ Erectile dysfunction: $10/20$ Group 2 - HoBNI N: 20 Age (mean): 64.9 ± 10.1 (44- 79) Drop outs at $0/1/3/6/12$ months: $0/0/2/3/8$ IPSS symptom: $24.2\pm5.1(14-35)$ IPSS QoL: 5.0 ± 1.0 (3-6) Qmax: $9.7\pm1.3(8-12)$ PdetQmax H ₂ O: $71.0\pm30.2(40-128)$ Schafer Grade: $3.2\pm1.3(2-6)$ Prostate Volume, PV:	 14/20 Both groups Maximal lasing power: 100 W (2J at 50 Hz) Versacut[™] morcellator Catheters: Two way catheters unless post- operative bladder irrigation was necessary. Catheters removed at the hospital or in the community the morning following surgery. Discharged from hospital: the afternoon or evening following surgery *P value<0.001 	Qmax , mean ±SD, (range) PdetQmax (cm H₂0), mean ±SD, (range)	Group 1: $1.7\pm0.9 (0-5)$ Group 2: $1.5\pm0.9 (0-3$ Relative risk: 95% Cl: p value: NS at anytime point At 1 months Group 1: $19.9\pm6.9(9-40)$ Group 2: $18.7\pm8.0(9-40)$ Relative risk: 95% Cl: At 3 months Group 1: $20.7\pm7.6 (7-36)$ Group 2: $18.5\pm9.2 (10-36)$ Relative risk: 95% Cl: At 6 months Group 1: $20.2\pm8.0 (5-33)$ Group 2: $17.4\pm7.3 (3-31)$ Relative risk: 95% Cl: At 12 months Group 1: $21.6\pm7.7 (10-38)$ Group 2: $17.4\pm4.6 (12-24)$ Relative risk: 95% Cl: At 6 months Group 1: $29.1\pm11.1 (15-50)$ Group 1: $29.1\pm11.1 (15-50)$ Group 2: $43.2\pm25.4 (2-100)$ Relative risk: 95% Cl: p value:<<0.01	detect HoLEP is superior (Qmax change of 12ml/s compared to 8ml/s in BNI), at a power of 80% and p of 0.05

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	30.5±5.9(18-39) Urinary incontinence: 11/20# Erectile dysfunction: 9/20 #P value =0.006, calculated		Urodynamic obstruction, Schafer grade, mean ±SD, (range)	At 6 months Group1: 0.5 ±0.7(0-5) Group 2: 1.6±1.4 0-5 Relative risk: p value:<0.01	
	by NCGC team using Fisher's exact test		Urodynamically obstructed No definition. 4 patients in HoBNI group subsequently had HoLEP. See "Reoperation"	At 6 months Group1: 0/19 Group 2: 5/20 (25%) Relative risk: 95% CI: p value: NR	
			Prostate Volume , (g) mean ±SD, (range). Measured using TRUS	At 6 months Group1: 22.2 ±7.1(11-35) Group 2: 31.5±8.0(21-49) Relative risk: p value:<0.05	
			Catheter duration , mean ± SD (range), hours	Group1: 22.9±6.9(12-48) Group 2: 23.2±1.9(17-25) Relative risk: 95% CI: p value: NS	
			Post-op complications (early): Recatheterisation	Group1: 0/19 Group 2: 2/20 Relative risk: p value: NR	
			Post-op complication: Reoperation: Patients had HoLEP between 6-16 months because of persistent LUTS	Group1: 0/19 (within 1 year) Group 2: 4/20 Relative risk: p value:	
			Post-op complications: Submeatal Strictures	Group1: 1 (dilated) Group 2: 1 (meatomy) Relative risk: p value: NS	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Note: Patients in Group 2 (BNI)	At 12 months Group1: 4/16 (44%) - Group 2: 0/13 (0%) Relative risk: p value:<0.01 None of the patients required pads	
			Erectile function: (No change /Worsened/ Improved)	At 12 months Group1: 11/2/3 Group 2: 10/1/2 Relative risk: p value: NS	
			Post-op complications: Retrograde ejaculation in sexually, % (in patients who are able to "comment" on it, number of patients not stated	Group1: 100% Group 2: 80% Relative risk: p value: reported as <0.01	
			Hospital time: mean ± SD (range), hours	Group1: 12.3±7.0 (7-28) Group 2: 13.7±8.5 (7-28) Relative risk: 95% CI: p value: NS	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Kuntz et al.,	Patient group: Candidates for	Group 1: HoLEP	Mean +/- SD	Preoperatively:	Funding:
2008133	surgical therapy of lower urinary	HoLEP was carried out	AUA symptom	Group 1: 22.1 +/- 3.3 (n=60)	Prof. Kuntz is a
	symptoms and obstruction due to	at 80 or 100 W with a	score:	Group 2: 21.0 +/- 3.6 (n=60);	consultant for the
Study design: RCT	a prostate larger than 100 gm.	high-powered Ho:YAG		3 months	companies Lumenis and
, .		laser (2.0 J; 40-50 Hz).		Group 1: 3.3 +/- 27 (n=54)	Karl Storz.
Setting:	Inclusion criteria:	It involved retrograde		Group 2: 3.6 +/- 27 (n=50)	
Department of	$AUA>=8$, (Q_{max}) of $<=12 \text{ ml/s}$,	enucleation of the		6months	Limitations:
Urology- Germany	post void residual urine volume	median and lateral		Group 1: 2.4 +/- 1.9 (n=54)	Allocation concealment
<i>,</i>	>= 50 ml, Schafer grade $>= 2$.	lobes from the apex		Group 2: 2.8 +/- 3.9 (n=50)	and blinding unclear.
Evidence level: 1+		toward the bladder.		1-year:	-
	Exclusion criteria:	When the trial started,		Group 1: 2.3 +/- 2.0 (n=56)	Notes:
Duration of	Previous prostate or urethral	a mechanical tissue		Group 2: 2.3 +/- 1.7 (n=49); P value: 0.94	Linked with Kuntz
follow-up:	surgery and non-BPH-related	morcellator was not yet		2-year:	2002 ¹³¹ and
5 years	voiding disorders. Preoperatively,	commercially available.		Group 1: 2.3 +/- 2.2 (n=53)	Kuntz2004 ¹³²
	prostate carcinoma was screened	Therefore in the first 50		Group 2: 2.4 +/- 1.6 (n=46); P value: 0.89	
	for and excluded by prostate	of the 60 HoLEP		3 year.	
	biopsy if indicated. There was no	patients, fragmentation		Group 1: 3.0 +/- 3.1 (n=48)	
	upper limit for prostate size.	of the lobes was		Group 2: 2.8 +/- 1.6 (n=40); P value: 0.82	
		performed by		4-year:	
	All patients	traditional		Group 1: 3.0 +/- 3.1(n=45)	
	N: 120	electrocautery loop		Group 2: 2.8 +/- 1.9 (n=36); P value: 0.68	
	Drop outs: 46	resection whilst the		5-year:	
	-	devascularised lobes		Group 1: 3.0 +/- 3.2 (n=42)	
	Group 1:	were still connected to		Group 2: 3.0 +/- 1.7 (n=32); P value: 0.98	
	N: 60	the surgical capsule by	Mean +/- SD peak	Preoperatively:	
	Mean ±SD (range) Age: 69.2 +/-	a narrow pedicle. In the	flow (ml/s)	Group 1: 3.8 +/- 3.6 (n=60)	
	8.4 (56-89)	last 10 of the 60 HoLEP		Group 2: 3.6 ± -3.8 (n=60); P value: 0.60	
	Schaffer grade: 4.3 +/- 1.12 (3-	patients, the lobes were		3 months:	
	6)	enucleated in their		Group 1: 27.6+/- 7.0 (n=54)	
	Postvoid residual volume (ml):	entirety, pushed into the		Group 2: 27.3 +/- 6.2 (n=50); P value: 0.66	
	280 +/- 273 (50-1,000)	bladder, and		1-year:	
	Peak urinary flow rate (ml/s): 3.8	fragmented with the use		Group 1: 27.4+/- 9.7 (n=56)	
	+/- 3.6 (0-10)	of a mechanical tissue		Group 2: 28.3 +/- 7.5 (n=49); P value: 0.86	
	Dropouts: 18 (died=3,	morcellator.		2-year :	
	intercurrent illness=3, moving=6,			Group 1: 26.7+/- 8.3 (n=53)	
	prostate cancer=3,	Group 2: Open		Group 2: $27.4 + - 6.8 (n=46)$; P value: 0.65	
	reoperations=3)	prostatectomy (OP)		3-year:	

Evidence Table 25 Holmium laser enucleation of the prostate (HoLEP) vs. open prostatectomy (OP)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Group 2: N: 60 Mean ±SD (range) Age: 71.2 +/- 8.3 (54-89) Schaffer grade: 4.3 +/- 0.79 (3- 6) Postvoid residual volume (ml): 292 +/- 191 (50-1,000) Peak urinary flow rate (ml/s): 3.6 +/- 3.8 (0-12) Dropouts: 28 (died=8, intercurrent illness=3, moving=7, prostate cancer=6, reoperation=4)	Open prostatectomy was performed by a suprapubic transvesical approach via midline incision. The bladder catheter was routinely removed on the seventh postoperative day.	Mean +/- SD Residual volume (ml)	Group 1: 27.0+/- 9.8 (n=48) Group 2: 25.3 +/- 6.9 (n=40); P value: 0.32 4-year: Group 1: 27.7 +/- 9.6 (n=45) Group 2: 25.0 +/- 8.3 (n=36); P value: 0.20 5-year: Group 1: 24.3 +/- 10.1 (n=42) Group 2: 24.4 +/- 7.4 (n=32); P value: 0.97 Preoperatively: Group 1: 280+/- 273 (n=60) Group 2: 292 +/- 191 (n=60); P value: 0.43 1-year: Group 1: 5.8 +/- 16.7 (n=56) Group 2: 6.4 +/- 12.3 (n=49); P value: 0.83 2-year: Group 1: 1.7 +/- 6.5 (n=53) Group 2: 2.4 +/- 6.8; P value: 0.61 3-year: Group 1: 6.1 +/- 12.1 (n=48) Group 2: 4.4 +/- 10.5 (n=40); P value: 0.50 4-year: Group 1: 8.6 +/- 13.5 (n=45) Group 2: 6.5 +/- 12.1 (n=36); P value: 0.48 5-year: Group 1: 10.6 +/- 24.4 Group 2: 5.3 +/- 11.2 (n=32); P value: 0.25	
			Mortality (follow up 60 months)	Group 1: n=3 Group 2: n= 8	
			Mortality (3 months postoperatively)	Group 1: n=0 Group 2: n= 2	
			Complications (6 months postoperatively):	Blood transfusion Group 1: 0 Group 2: 8 (13.3%); P value: 0.003 Reoperation for secondary coagulation of bleeding arteries (18) Group 1: 3	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Group 2: 3; P value: NR <u>Reoperation for secondary apical resections</u> Group 1: 2 Group 2: 0; P value: NR	
			Re-interventions (60months)	Bladder neck contracture- holium laser incision: Group 1: 1 (1.7%) Group 2: 3 (5.0); P value: 0.60 <u>Visual urethrotomy (from stricture):</u> Group 1: 2 (3.3%) Group 2: 1 (1.7); P value: 0.61	
			Mean +/- SD Post- op stay (hrs.)	Group 1: 69.6 +/- 36.4 (24-192) Group 2: 251.0 +/- 45.5 (216-552) P value: <0.0001	
			Recatheterisation	Group 1: 3 (5%) Group 2: 3 (5%)	
			Incontinence	Group 1: 5/60 Group 2: 6/60	
			Erectile dysfunction	Group 1: 5/54 Group 2: 5/50	
			Retrograde ejaculation (in sexually active patients; 58%)	Group 1: 70% Group 2: 79%	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Naspro et al.,	Patient group: Consecutive patients	Group 1: HoLEP	Mean (SD) IPSS	Baseline:	Funding:
2006184	from March 2003 to December	The surgical technique		Group 1: 20.11 +/- 5.84	NR
	2004 who suffered from BPH-	included enucleation of		Group 2: 21.60 +/- 3.24; p value: 0.27	
Study design:	related obstructed voiding	the prostatic lobes with		1-month:	Limitations:
RCT	symptoms with prostate volume >70	subsequent tissue		Group 1: 6.9 +/- 4.2	Allocation
	g, as determined by transrectal	morcellation into the		Group 2:: 4.7 +/- 2.1; p value: 0.20	concealment and
Setting: Italy	ultrasound and who had not	fragments, which were		3-month:	blinding unclear.
0 /	responded to pharmacologic	retrieved from the		Group 1: 3.9 +/- 2.9	
Evidence	therapy.	bladder cavity.		Group 2:: 2.9 +/- 2.6; p value: 0.46	Notes:
evel: 1+	. ,	7		12-month:	None.
	Inclusion criteria:	Total mean operative		Group 1: 8.45 +/- 5.87	
Duration of	Postvoiding residue <150 ml, peak	time: 72.09 +/- 21.22		Group 2:: 8.40 +/- 6.0; p value: 0.98	
follow-up:	urinary flow rate <15 ml/s, and	,		24-month:	
24-months	urodynamic obstruction (Schafer	Group 2: OP		Group 1 (n=35): 7.9 +/- 6.2	
	grade >2).	Standard transvesicle		Group 2: (n= 30): 8.1 +/- 7.1; p value: 0.44	
	5 · · _/.	approach.	•	Baseline:	-
	Exclusion criteria:		Qmax		
	Neurogenic bladder, history of	Total mean operative		Group 1: 7.83 +/- 3.42	
	adenocarcinoma of the prostate, or	time: 58.31 +/- 11.95		Group 2:: 8.32 +/- 2.37; p value: 0.64	
	any previous prostatic, bladder-			1-month:	
	neck, or urethral surgery.			Group 1: 26.6 +/- 8.7	
				Group 2:: 24.3 +/- 6.8; p value: 0.53	
	All patients			3-month:	
	N: 80			Group 1: 22.2 +/- 8.6	
	Drop outs: 15			Group 2:: 25.5+/- 10.5; p value: 0.57	
				12-month:	
	Group 1:			Group 1: 22.32 +/- 3.8	
	N: 41			Group 2:: 24.21+/- 6.49; p value: 0.27	
	Mean (±SD) Age: 66.26 (+/- 6.55)			24-month:	
	Total serum PSA ng/ml mean (±SD):			Group 1 (n=35): 19.19+/- 6.3	
	6.33 +/- 3.45			Group 2: (n= 30): 20.11+/- 8.8; p value: 0.91	
	Incidental adenocarcinoma: 2		QOL question	Baseline:	
	(4.8%)			Group 1: 4.07 +/- 0.93	
	Dropouts: 6			Group 2: 4.44 +/- 0.96; p value: 0.17	
				1-month:	
	Group 2:			Group 1: 1.4 +/- 1.4	
	N: 39			Group 2: 1.3 +/- 0.7; p value: 0.76	
	IN: 37			3-month:	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean (±SD) Age: 67.27 (+/- 6.72) Total serum PSA ng/ml mean (±SD): 6.99 +/- 4.28 Incidental adenocarcinoma: 3 (7.6%) Dropouts: 9			Group 1: 1 +/- 0.8 Group 2: 0.6 +/- 0.2; p value : 0.18 12-month : Group 1: 1.7 +/- 0.94 Group 2: 1.77 +/- 0.83; p value : 0.85 24-month : Group 1 (n=35): 1.5 +/- 0.87 Group 2 (n= 30): 1.66 +/- 0.76; p value : 0.76	
			Mean detrusor pressure at maximum flow rate (P _{detqmax})cm H ₂ O	Baseline: Group 1: 80.6 (44-130) Group 2:: 83.1 (41-147); p value: 0.94 12-month: Group 1: 30.6 (22-80) Group 2:: 34.8 (18-88); p value: 0.66	
			Schafer grade (LinPURR):	Baseline: Group 1: 3.8 (2-6) Group 2:: 3.1 (2-6); p value: 0.33; 12-month: Group 1: 0.7 (0-4) Group 2:: 0.8 (0-4); p value: 0.18	
			Perioperative morbidity (surgery to 3months)	Bladder mucosal injury: Group 1: 3 (7.3%) Group 2:: 0 (2-6); p value: < 0.001 Transitory urge incontinence: Group 1: 14 (34.1%) Group 2:: 17 (38.6%); p value: 0.2 Dysuria (burning): Group 1: 28 (68.2%) Group 2:: 16 (41.0%); p value: <0.001 Stress incontinence: Group 1: 1 (2.4%) Group 2: 1 (2.5%); p value: 0.9 Reintervention for bleeding:	
				Group 1: 1(2.4%) Group 2:: 0; p value: 0.9 Early acute urinary retention:	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Group 1: 5 (12.1%) Group 2:: 2 (5.1%) ; p value: 0.11	
			Complications 12- month follow-up:	Urge incontinence: Group 1: 2 (5.4%) Group 2: 3 (8.5%); p value: 0.03 Dysuria (burning): Group 1: 4 (10.8%) Group 2: 3 (8.5%); p value: 0.02 Bladder-neck/urethral strictures: Group 1: 2 (5.4%) Group 2: 2 (5.7%); p value: 0.3 Overall reintervention: Group 1: 2 (5.4%) Group 2: 2 (5.7%); p value: 0.55 Prostate cancer: Group 1: 4 (10.8%) Group 2: 4 (11.4%); p value: 0.4 24-month follow-up: Prostate cancer: Group 1: 0 Group 2: 0; p value: Dysuria (burning): Group 1: 1 (2.8%) Group 2: 1 (3.3%); p value: 0.02 Bladder-neck/urethral strictures: Group 1: 1 (2.8%)	
			Mean +/- SD IIEF domains	Group 2: 1 (3.3%); p value: 0.3 baseline: Group 1:20.3+/-6.6 Group 2: 21.1 +/- 5.3; p value: 0.5 3 months: Group 1: 21.4 +/- 2.6 Group 2: 20.6 +/- 5.5; p value: 0.67	
				6 months: Group 1: 22.8 +/- 2.1	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Group 2: 24.6 +/- 4.0; p value: 0.55	
				12 months:	
				Group 1: 25.2 +/- 4.2	
				Group 2: 23.5 +/- 1.8; p value: 0.31 24 months:	
				Group 1: 22.3 +/- 4.0	
				Group 2: 21.9 +/- 5.6; p value: 0.21	
				Autologous blood transfusion:	
				Group 1: 2 (4%)	
				Group 2: 5 (12.8%)	
				p value: < 0.001	
				Homologous blood transfusion:	
				Group 1:0	
				Group 2: 2 (5.1%)	
				p value: < 0.007	
				Catheterisation time:	
				Group 1: 1.5 +/- 1.07	
				Group 2: 4.1 +/- 0.5	
				p value: < 0.0001	
				<u>Hospital stay, d</u> :	
				Group 1: 2.7 +/- 1.1	
				Group 2: 5.43 +/- 1.05	
				p value: < 0.0001	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Anson1995 ¹⁵	Patient group: Patients with BPH	Group 1- Laser coagulation	All cause mortality	<u>"immediate post-operative</u> period"	Funding: Bard Europe Division
McAllister2000 ¹⁶⁴	Setting: From March 1992, UK	(ELAP) Procedure:		Group 1: 0/76 Group 2: 0/75	Limitations:
Study design: RCT, open label,	Inclusion criteria:	Nd:YAG, using Urolase fibre.		p value: NS Week 52 (1 year)	Open label studyRandomisation concealment
(multi-centre)	 Age>50 yers old American Society of Americal science (ASA) 	Energy was applied at 60W for 6S at the		Group 1: 1/76 Group 2: 1/75 p value: NS	 method not described Only 44% of patients
Setting: United Kingdom	Anaesthesiologist (ASA) Grade 1 to 3 Prostatic urethral length	2, 5, 7, and 10 o clock positions, modified according	AUA-6 symptom score, mean (95% CI):	Week 4 Group 1: 13.5(95%Cl: 12.0 to	available at 5-year follow up, and no sd was provided
Evidence level: 1+	 >24mm Urinary flow rates consistent 	to prostate length and presence of		Group 1: 13.3(75%CI: 12.010 15.0) Group 2: 8.7 (95%CI: 7.6 to	Additional outcomes:
Duration of follow-	with outlet obstruction Exclusion criteria:	median lobe. Room temperature		9.8) p value: NS	 Pulmonary embolism – 1 patient in TURP group had F
up: Up to 5 years	 ASA Grade >3 Known history or suspicion of prostate cancer 	sterile water was used for irrigation		Week 12 Group 1: 8.7 (95%Cl:7.3 to 10.1)	 after operation Deep vein thrombosis: 1 patient in laser group vs. 2
	 Renal impairment Life expectancy <6 months On modication such as 	Power: 60W		Group 2: 6.4 (95%Cl:5.2 to 7.6) p value: NS	patients in TURP group had DVT
	 On medication such as anticoagulants 	Group 2 –TURP Procedure: Standard electroresection, by		Week 26 Group 1: 7.9 (95%Cl: 6.4 to 9.4)	Notes: 5 year data not used in meta- analysis due to small number of
	All patients N: 151, out of 166 candidates	experienced urologists		Group 2: 5.9 (95%Cl: 4.6 to 7.2)	available data compared to original sample size
	Age, mean, (range) (years): 68.1(52-84)			p value: NS <u>Week 52</u> Group 1: 7.7 (95%Cl: 6.3 to	McAllister2000 reported the 5 year follow up period
	Drop outs 1 year review : 137/151 5-year review: 42/151			9.1) Group 2: 5.1 (95%Cl: 3.8 to	
	(109 patients were traced from 151 at the 5-year review)			6.4) p value: <0.05	
	Group 1-Laser coagulation N: 76			<u>5 years</u> Group 1: 6.3, n=28 Group 2: 6.5, n=39	
	IN: /0			p value: NS	

1 Evidence Table 26Laser coagulation vs. transurethral resection of the prostate (TURP)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Drop outs: At 1-year review: 9/76 (11.8%) At 5-year review: 19/76 (25%) Age: mean (95% Cl): 67.9 (66.3-69.5) Drop outs: Not stated AUA-6 symptom score, mean (95% Cl): 18.1(17.1-19.1) Qmax, mean (95% Cl): 9.6(8.8-10.4) Post void residual volume: mean (95% Cl): 113(91-135) Sexually active: 27/76 (36%) Group 2 - TURP N: 75 Drop outs: At 1-year review:		Qmax, mean (95% Cl):	Week 12 Group 1: 15.9 (95%Cl: 13.6 to 18.2) Group 2: 21.3 (95%Cl: 19.0 to 23.6) p value: <0.05	
	5/75(6.7%) At 5-year review: 24/75(32%) Age: mean (95% Cl): 68.3(66.5- 70.1) AUA-6 symptom score, mean (95% Cl): 18.2(17.1-19.3) Qmax, mean (95% Cl): 10.0 (9.1- 10.9) Post void residual volume: mean (95% Cl): 121(93-148) Sexually active:24/75 (32%)		Post void residual volume: mean (95% Cl):	Week 12 Group 1: 70.3 (95%Cl: 51.1 to 89.3) Group 2: 21.3 (95%Cl: 43.9 to 80.3) p value: NS Week 26 Group 1: 90.1 (95%Cl: 61.6 to 118.0) Group 2: 19.9 (95%Cl: 17.4 to 22.4) p value: <0.05	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				61.3) p value: <0.05 <u>5 years</u> Group 1: 76, n=24 Group 2: 55, n=35 p value: NS	
			Post-operative complications: Blood transfusion: (Mean of 2.7 units blood)	Group 1: 0/76 Group 2: 3/75 p value: NS	
			Post-operative complications: Retrograde ejaculation (among patients who were sexually active preoperatively)	<u>Up to week 52 (1 year)</u> Group 1: 9/27 (33%) Group 2: 15/24 (63%) p value: NS	
			Post-operative complications: Clot retention	Up to week 52 (1 year) Group 1: 1/76 Group 2: 5/75 p value: NS	
			Post-operative complications: urinary tract infection (positive culture). 22/28 of patients in the ELAP group received prophylaxis	Up to week 4 Group 1: 18/76 Group 2: 5/75 RR: 3.55 (95% Cl: 1.47 to 8.97) p value: <0.01 Up to week 52 (1 year) Group 1: 28/76 Group 2: 7/75 RR: 3.95 (95% Cl: 1.92 to 8.48) p value: <0.01	
			Post-operative complications: Dysuria	Up to week 52 (1 year) Group 1: 25/76 Group 2: 6/75 RR: 4.11 (95% Cl: 1.88 to	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				9.42) p value: <0.01	
			Post-operative complications: epididymorchitis	Up to week 52 (1 year) Group 1: 2/76 Group 2: 1/75 p value: NS	
			Post-operative complications: Reoperation- by week 52, 2 had bladder neck incision, 3 had TURP	Up to week 52 (1 year) Group 1: 5/76 Group 2: 0/75 p value:: <u>5 years</u> Group 1: 18/47 (38%) Group 2: 8/51 (16%) p value: <0.006	
			Hospitalisation days, mean (95% Cl)	Group 1: 2.7(95%Cl: 2.2 to 3.2) Group 2: 4.3 (95%Cl: 3.3 to 5.3) p value:NS	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Chacko et al., 2001 ⁴³ CLASP study- acute	Patient group: men with acute painful, urinary retention	Group 1- Laser coagulation Procedure: Nd:YAG/	All cause mortality Not treatment related	Group1: 2/74 Group 2: 4/74 p value: NS	Funding: Laser machines provided by Bard Diagnostics,
urinary retention Study design: RCT, multicentre, open label Setting: UK	 Setting: 3 centres in UK , open Inclusion criteria: Acute painful, urinary retention. All patients without strong history of LUTS underwent at least one trial without catheter Exclusion criteria: Prostate cancer or previous prostatic surgery; 	Non-contact VLAP, side- firing fibre (Bard Urolase), using standard fixed spot technique Power: 60W ND: YAG for 60s, depends on prostate size. For prostate size	IPSS, mean change from baseline (±SD): Adjusted for centre and baseline symptom score, ANCOVA	Group 1: -10.1 (95%Cl: -12.8, -7.3), n=54 Group 2: -13.5 (95%Cl -15.8, -11.2), n=48 p value: 0.26 Both groups stats sig compared to baseline	 Redmond, Washington. Limitations: Open label study, with main outcomes using patient reported measures. The actual values of
Evidence level: 1+ Duration of follow- up: 7.5 months		with urethral length of >25 mm, additional set of laser was used. If median lobe was present, 60W for 30s was applied for each side of lobe. Energy: 33.93kJ (mean total delivered)	IPSS-QoL, mean(±SD): Adjusted for centre and baseline symptom score, ANCOVA	Group 1: -3.10 (95%Cl -3.65, -2.55), n=49 Group 2: -3.42 (95%Cl -3.89, -2.95), n=45 Adjusted difference: : 0.26 (0.81- 0.30)- page 169 P value: 0.37 Both groups stats sig compared to baseline	 The actual values of data and standard deviations were not
	associated with recent operation, constipation or drugs which could cause acute urinary dysfunction, Neurogenic bladder	Suprapublic catheter,	Post-op complications: Transurethral resection syndrome	Group 1: 0/74 Group 2: 2/74 P value: NS	 meta-analysis Additional outcomes: Myocardial infarctic during hospital stay
	 All patients Number of eligible patients: 155 N randomised: 148 Mean age: Drop outs: 		Post-op complications: Blood transfusion (units and criteria not stated)	Group 1: 0/74 Group 2: 4/74 P value: NS	 Composite outcomes categories, and categorical outcome for IPSS and Qmax
		Impatients Group 2 – TURP 55 Procedure: Standard I randomised: 148 electroresection Aean age: Catheter protocol:	Post-op complications: Heavy bleeding (criteria not stated)	Group 1: 2/74 Group 2: 3/74 P value: NS	Notes: Sample size calculation was
			Post-op complications: Septicaemia	Group 1: 3/74 Group 2: 4/74 P value: NS	 performed. In the laser group, 7/74 patients were converted to the
		depends on success	Post-op	Group 1: 0/74	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Group 1-Laser coagulation N: 74	voiding after urine is clear.	complications: Incontinence	Group 2: 3/74 P value: NS	standard surgery in theatre, and 3
	Dropouts: Of Received as allocated: 57/74 Al Age, mean (±SD): 74.2 ± 7.9 an IPSS, mean (±SD): 20.3 ± 9.3 an	Other: All patients received antibiotic prophylaxis and anti-inflammatory suppository.	Post-op complications: Reoperation (surgery due to "unacceptable symptoms" or retention after 8 weeks)	Group 1: 7/74 Group 2: 1/74 P value: NS	 refused treatment. In the TURP group, 5 refused or deferred treatment. A total of 1073 patients were
			Post-op complications: Urinary retention (>8 weeks)	Group 1: 1/74 Group 2: 0/74 P value: NS	 considered for inclusion of the 3 linked CLASP trial, and 570 were entered. 318
	Received as allocated: 68/74 Age, mean (±SD): 72.7±7.3 IPSS, mean (±SD): 19.4±7.6 IPSS-QoL, median(IQR): 5 (4- 6) Ethnicity (% white): 97.3		LOS, geometric mean, days	Group 1: 3.4 (95% Cl 2.8 to 4.0) Group 2: 5.8 (95% Cl 5.2 to 6.5) Relative risk: 1.73 95% Cl: 1.40-2.14 P value: <0.0001	(29.5%) were not eligible because of ≥1 exclusion criteri The rest did not en for various reasons There were 240 patients in the uncomplicated LUT trial, 148 in the act urinary retention tr and 82 in the chron retention trial.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Cowles et al., 1995 ⁴⁹ Study design: RCT, open label, multicentre Setting: United states Evidence level: 1+ Duration of follow- up: 12 months	, 1995 ⁴⁹ Patient group: Bladder outlet obstruction due to BPH Group 1- coagulati ibel, BPH Procedure witticentre, United States in August 1991 to June 1992 Nd; YAG is Inclusion criteria: Bladder outlet obstruction due to Bladder outlet obstruction due to Bladder outlet obstruction due to BPH, not in urinary retention o'clock poi 60s each, & 12 o'clock poi coclock poi follow- follow- Exclusion criteria: Physical status exceeding category III of the American Society of Anaesthesiologists For patier	verumontanum and bladder neck >4 cm,	AUA-6 symptom score Post void residual volume, ml Qmax, ml/s	At 12 months, compared to baseline Group 1: -9.0 ±8.9, range -27 to 8 Group 2: -13.3 ±7.5, range - 29 to 7 p value: <0.04 At 12 months, compared to baseline Group 1: -55.4±124.3, range - 425 to 220 Group 2: 138.8±162.3 range - 728 to 130 p value: <0.01 At 12 months, compared to baseline Group 1: 5 3±6 9	Funding: partially funded by CS Bard Limitations: The baseline AUA-6 was significantly lower for laser coagulation group. Statistical adjustment with ANCOVA reported Not stated which QoL instrument was used Impotence outcome- not certain if these are newly acquired cases Time point/period of
	 prostate Bladder neck to verumontanum length less than 2.4cm Life expectancy of < 6 months < 50 years Clinically significant illness Medication (hormonal therapy, alpha blockers, 	treatment was repeated in 2 transverse planes, one just distal to the bladder and one just proximal to the verumontanum Average number of	Reoperation with VLAP or TURP (by 12months): 2 patients had VLAP: 1 patient had residual bladder neck tissue and later diagnosed with cancer. The other had residual apical lobe. 4 others had TURP.	Group 1: 5.3±6.9 Group 2: 7.0±9.5 p value: 0.27 Group 1: 2/56 Group 2: 0/59 p value: NS	complication measurement not stated Additional outcomes: Number of patients "non-serious" complications such as pain, hesitancy etc % of quality of life
	 finasteride) that would have precluded participation in the study Medical condition (such as recent myocardial infarction, coagulopathy, recent stroke, sepsis) that investigators deemed unsuitable for one or more procedures 	5.5±2.1 Cumulative duration of laser application: 4.2±1.5 minutes Power: 40W Energy: 5760- 11520 J per patient,	Post-op complications: Blood transfusions Urinary retention Urinary tract infection	Group 1: 0/56 (0%) Group 2: 2/59(3.4%) p value: NS Group 1: 17/56 (30.4%) Group 2: 5/59 (8.5%) Relative risk: 3.58(95% Cl: 1.50, 9.00) p value: <0.005 Group 1: 3/56 (5.4%)	 improved, at 12 months compared to baseline for Laser vs. TURP: 43/55 (78.2%) vs. 53/57 (93.0%) Post-op complications: (Bleeding (drop> 2.2g/dl of Hb in 24 hours post-procedure):

Study details	Patients	Interventions	Outcome measures	Effect size	Comments						
	(the protocol had subsequently changed to report patients with urinary retention, but these patients were not part of the cohort reported in this study)	Anaesthesia: Spinal: 36/56 (64.2%)	Strictures (urethral and meatal stenosis): 6 patients in TURP group had urethral strictures. 1 patient in laser and 3 in TURP group had meatal stenosis	Group 2: 1/59 (1.7%) p value: NS Group 1: 1/56 (0%) Group 2: 9/59 (10.2%) RR: 0.12 (95% CI: 0.02, 0.67) p value: 0.02**	1/46 (2.2%) vs. 18/45 (40%). RR= 0.05 (95% Cl: 0.01-0.28), p value: <0.01 for Laser vs. TURP ■ Total number of patients with ≥1 serious						
	All patients N: 115 Group 1-Laser coagulation	(35.7%) Intravenous sedation only: 2(3.6%)	Bladder neck contracture	Group 1: 0/56 (0%) Group 2: 3/59 (5.1%) p value: NS	complication, (impotence, UTI, meatal stenosis, urethral stricture, clot retention,						
	N: 56 Dropouts: Age, mean (±SD): 65.8±6.7	Group 2 –TURP Procedure: Standard prostate	Incontinence	Group 1: 0/56 (0%) Group 2: 2/59 (3.4%) p value: NS	bladder neck contracture, blood transfusions, TUR						
	**AUA – 6 symptom score, mean (±SD): 18.7±6.0 Prostate volume, ml:42.2±19.0 Qmax, ml/s: 8.9±3.6	resection using wire loop electrocautery under direct vision	Impotence (not stated how many were sexually active or whether these are newly acquired cases)	Group 1: 3/56 (5.4%) Group 2: 2/59 (3.4%) p value: NS	syndrome, incontinence, deep vein thrombosis, extravasation of irrigation fluid,						
	Post void residual volume, ml: 162.7±126.6 Previous BPH therapy: 9/56(9.1%)	Anaesthesia: Spinal: 54/59(93.1%) General:	Spinal: 54/59(93.1%)	Spinal:	Spinal: 54/59(93.1%)	Spinal: 54/59(93.1%)	Spinal: 54/59(93.1%)	Spinal: 54/59(93.1%)	Deep vein thrombosis	Group 1: 0/56 (0%) Group 2: 1/59 (1.7%) p value: NS	prostatitis) was 6/56 in laser vs. 21/59 in TURP, RR = 0.30 (95% Cl: 0.13, 0.66),
	9/30(9.1%) <u>Group 2 - TURP</u> N: 59	5/59(8.6%) Intravenous sedation only: 0/59(0%)	Post TURP syndrome	Group 1: 0/56 (0%) Group 2: 2/59 (3.4%) p value: NS	p<0.01.						
	Dropouts: Age, mean (±SD): 67.0±7.8 **AUA- 6 symptom score, mean	For BOTH groups: Discharged when deemed medically fit, minimum of 24 hours hospitalisation	Clot retention	Group 1: 0/56 (0%) Group 2: 3/59 (5.1%) p value: NS	** AUA-6 score was significantly lower in VLAP group. This required						
	(±SD): 20.8±4.8 Prostate volume, ml: 38.6±20.2 Qmax, ml/s: 9.5±5.2		Hospitalisation duration, days	Group 1: 1.8±1.1 Group 2: 3.1±0.9 p value: <0.01 **	adjustment in data analysis using ANCOVA (analysis of covariance)						
	Post void residual volume, ml: 206.7±181.9 Previous BPH therapy: 17/59(28.8%)		Duration of procedure, min	Group 1: 23.4±11.1 Group 2: 45.2±21.5 p value: <0.01 **	**calculated by NCGC team using Fisher's exact test						

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Donovan et al., 2000 ⁶⁵	Patient group: men with uncomplicated LUTS symptoms	Group 1- Laser coagulation Procedure: Nd:YAG/	All cause mortality Not treatment related	Group 1: 5/117 Group 2: 0/117 Group 3: 1/106	Funding: Laser machines provided by Bard
CLASP study- acute urinary retention Study design: RCT, multicentre, open label Setting: UK Evidence	 Setting: 3 centres in UK Inclusion criteria: IPSS score of≥8, with physician and patient agreement that the symptoms require intervention Qmax <15ml.s when voided volume>200ml, <13ml/s when voided volume between 150- 200ml and <10ml/s when voided volume between 100 to 149ml measured on two 	iring fibre (Bard Urolase), using standard fixed spot technique Power: 60W ND: YAG for 60s, depends on prostate size. For prostate size with urethral length of >25 mm, additional set of laser was used. If median lobe was present, 60W for 30s was	IPSS, mean change from baseline (95%Cl): Adjusted for centre and baseline symptom score, ANCOVA	p value: NS for all groups Group 1: -10.8 (95% Cl: -12.5,-9.0), n=96 Group 2: -12.3 (95% Cl: -13.8,-10.7), n=89 Group 3: -1.3 (95% Cl: -2.8,0.2), n=85 Adjusted difference: Group 1 vs. Group 2: -1.7 (95% Cl: - 3.6,0.1) p value: NS Statistically significant for surgical procedures vs. conservative	Diagnostics, Redmond, Washington. Limitations: Open label study, with main outcomes using patient reported measures. However, this paper specified that clinicians measuring outcome
level: 1+ Duration of follow-up: 7.5 months	 applied for each side of lobe. analysis >300ml post void volume urine on ultrasound Exclusion criteria: Prostate cancer or previous prostatic surgery; prostate size > 120ml; applied for each side of lobe. Energy: 28684J Catheter protocol: Suprapubic catheter, removed when clinically appropriate. Other: All patients received antibiotic prophylaxis and 	IPSS-QoL, mean (95%CI): Adjusted for centre and baseline symptom score, ANCOVA	Group 1: -1.9 (95% Cl: -2.3, -1.6), n=93 Group 2: -2.2 (95% Cl: -2.5, -1.8), n=85 Group 3: -0.4 (95% Cl: -0.7, -0.1), n=85 Adjusted difference: Group 1 vs. Group 2: -0.2 (95% Cl: - 0.6,0.2)	were different from surgeons conducting the surgery Additional outcomes: Composite outcomes categories, and categorical outcomes for IPSS	
	 Life expectancy < 6 months; Urinary retention associated with recent operation, constipation or drugs which could cause acute urinary dysfunction, Neurogenic bladder dysfunction; 	anti-inflammatory suppository. Group 2 –TURP Procedure: Standard electroresection Catheter protocol: Suprapubic catheter.	Qmax, mean(95%Cl): Adjusted for centre and baseline symptom score, ANCOVA	p value: NS Group 1: 5.8 (95% Cl: 4.5, 7.2), n=102 Group 2: 9.7 (95% Cl: 7.7, 11.6), n=98 Group 3: 0.2 (95% Cl: -04, 0.8), n=92 Adjusted difference: Group 1 vs. Group 2: Group 1 vs. Group 2: 9 value: <0.05	and Qmax Notes: Sample size calculation performed Please see Chacko2001 for the acute urinary retention population of
	 Serum creatinine >250 μmol/L. 	Group 3 – Conservative management	Post void residual volume, mean(95%Cl): Adjusted for centre and	Group 1: -73.4(95% Cl:-91.3, -55.5), n=100 Group 2: -74.0 (95% Cl:-89.2, -58.8),	CLASP trial and Gujral 2000 for the chronic urinary retention

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	All patients N: 340 Drop outs: <u>Group 1-Laser coagulation</u> N: 117 Dropouts:1/117	Procedure: Men were given general advice and bladder training as deemed clinically appropriate	baseline symptom score, ANCOVA	n=98 Group 3: 2.19 (95% Cl:-23.1, -27.5, n=90 Adjusted difference: Group 1 vs. Group 2: -13.4 (95% Cl: - 32.9, -6.1) p value: NS	population.
	Age, mean (±SD): 67.4±8.1 IPSS, mean (±SD): 19.1±6.6 IPSS-QoL, median(range): 4(2-6)		Post-op complications: Blood transfusion (units and criteria not stated)	Group 1: 1/117 Group 2: 1/117 p value: NS	
	Qmax, mean, (±SD): 10.4±2.9 Post void residual urine, mean, (±SD): 123.7±91.8 Prostate volume, mean, (±SD):		Post-op complications: Perforation	Group 1:0/117 Group 2: 2/117 p value: NS	
	No obstructed (%): 90/117 (78.3) No equivocal and/or unobstructed		Post-op complications: Septicaemia	Group 1: 0/117 Group 2: 2/117 p value: NS	
	(%): 25/117 (21.7) Group 2 - TURP		Post-op complications: Urinary tract infection (symptomatic)	Group 1: 3/117 Group 2: 2/117 p value: NS	
	N: 117 Dropouts:2/117 Age, mean (±SD): 66.4±7.9 IPSS, mean (±SD): 19.2±6.7 IPSS-QoL, median(range): 4(0-6)		Time to catheter removal geometric mean, days	Group 1: 2.2(95%Cl 1.9 to 2.4) Group 2: 3.9(95%Cl 3.7 to 4.2) Relative risk: 1.83 95% Cl: 1.58 to 2.11 P value: <0.0001	
	Qmax, mean, (±SD): 10.3±2.7 Post void residual urine, mean, (±SD): 104.2±69.5 Prostate volume, mean, (±SD): 38.1±19.1 No obstructed (%): 91/117(78.4) No equivocal and/or unobstructed (%): 25/117(21.6)		LOS, geometric mean (95% CI) days	Group 1: 11.8(95%Cl: 10.2 to 13.7) Group 2: 2.4 (95%Cl: 2.1 to 2.9) Relative risk: 4.79 95% Cl: 3.88 to 5.91 p value: <0.0001	
	Group 3 – Conservative management N: 106 Dropouts: 5/106				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Age, mean (±SD): 67.2±7.8 IPSS, mean (±SD): 18.8±6.5 IPSS-QoL, median(range): 4(1-6) Qmax, mean, (±SD): 9.9±2.7 Post void residual urine, mean, (±SD): 119.1±90.4 Prostate volume, mean, (±SD): 36.8±17.2 No obstructed (%): 82/106(77.4) No equivocal and/or unobstructed (%): 24/106(22.6)				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Gujral et al., 2000 ⁹⁶	Patient group: men with chronic urinary retention	Group 1- Laser coagulation Procedure: Nd:YAG/	All cause mortality Not treatment related	Group 1: 0/38 Group 2: 1/44 p value: NS	Funding: Laser machines provided by Bard Diagnostics,
chronic urinary retention	- Setting: y 3 centres in UK Inclusion criteria:	Non-contact VLAP, side- firing fibre (Bard Urolase), using standard fixed spot technique Power: 60W ND: YAG for 60s, depends on prostate size. For prostate size with urethral length of >25 mm, additional set of laser was used. If median lobe was present, 60W for 30s was applied for each side of lobe. Energy: 33.8kJ or 0.94kJ/ml of prostate	IPSS, mean change from baseline (95%CI): Adjusted for centre and baseline symptom score, ANCOVA IPSS-QoL, mean (95%CI): Adjusted for centre and baseline symptom score, ANCOVA Qmax, mean(95%CI): Adjusted for centre and baseline symptom score, ANCOVA	Group 1: -12.2 (95%Cl: -15.7, -8.7), n=29 Group 2: - 14.2, (95% Cl: 17.2,-11.2), n=33 Adjusted difference: -3.6 (95%Cl-7.2 to -0.1) p value: 0.048 Group 1: -2.8(95%Cl: -3.4, -2.1), n=30 Group 2: -3.2(95%Cl: -3.9, -2.6), n=33 Adjusted difference: -0.6(95% Cl:-1.3 to 0.1) p value: NS Group 1: 5.7 (95%Cl: 2.6, 8.8), n=33 Group 2: 9.4 (95%Cl: 6.5, 12.2), n=40 Adjusted difference: 1.1 (95%Cl: -3.0 to 5.3)	Redmond, Washington. Limitations: Open label study, with main outcomes using patient reported measures. However, this paper specified that clinicians measuring outcomes were different from surgeons conducting the surgery Additional outcomes:
follow-up: 7.5 months	 Exclusion criteria: CLASP criteria Prostate cancer or previous prostatic surgery; prostate size > 120ml; Life expectancy < 6 months; dysfunction; Neurogenic bladder Serum creatinine >250 µmol/L. Criteria specific to Chronic urinary retention group Long term medication active on 	tissue Catheter protocol: Suprapubic catheter, removed when clinically appropriate. Other: All patients received antibiotic prophylaxis and anti-inflammatory suppository. Group 2 –TURP	Post void residual volume, mean(95%Cl): Adjusted for centre and baseline symptom score, ANCOVA Post-op complications: Confusion (TUR syndrome) Post-op	p value: NS Group 1: -329 (95%Cl: -377, -281), n=33 Group 2: -464(95%Cl: -553, -374) ,n=40 Adjusted difference: -27.5 (95%Cl: - 68.1 to 13.0) p value: NS Group 1: 0/38 Group 2: 1/44 p value: NS Group 1: 0/38	 Composite outcomes categories, and categorical outcomes for IPSS and Qmax Notes: Sample size calculation performed, to detect 30% differences in binary outcomes and SD of 0.63for continuous outcomes at a power of 80%
	the lower urinary tract <u>All patients</u>	electroresection	complications: Blood transfusion (units and criteria not stated)	Group 2: 3/44 p value: NS	Please see Chacko2001

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	N: 82 Drop outs: 2 Group 1-Laser coagulation N: 38		Post-op complications: Heavy bleeding (4 no termination, 2 cases termination	Group 1: 0/38 Group 2: 6/44 p value: NS	for the acute urinary retention population of CLASP trial and Donovan2000 for the uncomplicated LUTS
	Dropouts:2/38 Received as allocated: 30 Age, mean (±SD): 70.2±6.8		Post-op complications: Perforation	Group 1: 0/38 Group 2: 1/44 p value: NS	symptom population.
	IPSS, mean (±SD): 20.9±6.4 IPSS-QoL, , mean, (±SD): 5.0±2.6 Prostate volume, mean, (±SD):		Post-op complications: Septicaemia	Group 1: 1/38 Group 2: 3/44 p value: NS	
	40.7±19.9 Qmax, mean, (±SD):11.2±5.3 Post void residual urine, mean, (±SD): 438±151		Post-op complications: Urinary tract infection (symptomatic)	Group 1: 1/38 Group 2: 2/44 p value: NS	
	Group 2 - TURP N: 44 Dropouts: 0 Received as allocated: 44 Age, mean (±SD): 70.6±5.8 IPSS, mean (±SD): 19.5±7.2		Post-op complications: Reoperation (performed resection after laser therapy due to "unacceptable levels of symptoms")	Group 1: 3/38 Group 2: 0/44 p value: NS	
	IPSS-QoL, mean, (±SD): 4.5±2.6 Prostate volume, mean, (±SD): 49.7±21.8 Qmax, mean, (±SD): 8.5±3.6 Post void residual urine, mean, (±SD): 545±275		Time to catheter removal geometric mean, days	Group 1: 25.5(95%Cl 20.2 to 28.3) Group 2: 3.0 (95%Cl 2.3 to 3.9) Relative risk: 8.62 95% Cl: 6.04, 12.29 p value: <0.0001	
			LOS, geometric mean (95% Cl) days	Group 1: 2.2(95%Cl 1.7 to 2.8) Group 2: 4.4(95%Cl 3.9 to 4.9) Relative risk: 2.01 95% Cl: 1.54 to 2.61 P value: <0.0001	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
-	Patient group: Bladder outflow obstruction secondary to BPH Setting: six US tertiary care hospitals between Nov 1997 and Feb 1999 Inclusion criteria: AUASI ≥13 Qmax <15ml/s for 2 s with an adequately filled bladder	Group 1- Laser coagulation Performed with the Indigo 830e (830nm) laser system. Procedure: Slightly flexible laser fibre was inserted through the urethra and into the prostate using a standard cystoscope. A 1-cm long diffuser tip radiates heat in all directions at a low power (20W). The heat produces an olive-shaped area of coagulation necrosis about 2 x 2.5 cm or a volume	AUASI score, median:	Effect size At 6 months Group 1: 7.0 Group 2: 6.0 Difference: 1.0 (95% Cl: -3.0 to 3.0) p value: Not sig At 24 months Group 1: 9.0 Group 2: 7.0 Difference: 2.0 (95% Cl: -3.0 to 4.0) p value: Not sig At 6 months Group 1: 14.3 Group 2: 16.6 Difference: -2.3 (95% Cl: -0.4 to -6.5) p value: <0.05	 Funding: Indigo Medical Inc (the laser system manufacturer). First author a paid consultant of the parent company (Ethicon Endo- Surgery) Limitations: Patient reported outcomes methods were not clearly reported. It was unclear which questionnaires were used to evaluate QoL and sexual function. Only point estimates (median) were reported for continuous variables.
	 History of prostate cancer; suspected prostate cancer (based on diaital rectal 	of approximately 4 cm ³ . Power: 20W	volume (ml), mean ± SD (note that the baseline value was significantly different)	Group 1: 42.4 Group 2: 46.0 Difference: -3.6 (95% Cl: -12.6 to 27.3) p value: NS At 24 months	 Only 61% (73/120) of targeted sample size was recruited. Enrolment stopped
	 with biopsy Acute urinary retention Acute or chronic prostatitis cystolithiasis, neurogenic 	Energy: NR Catheter protocol: patients discharged with catheter in		Group 1: 57.7 Group 2: 44.0 Difference: 13.7(95% Cl: -15.2 to 40.3) p value: NS	early because of low patient participation. Additional outcomes:
	bladder, bladder neck contracture, or active urinary tract infection.	place, which was usually removed in	Post-op complications: Blood transfusion	Group 1: 0/37 Group 2: 0/35 p value: NS	 Median prostate volume and PSA

Study details	Patients	Interventions	Outcome measures	Effect size	Comments				
	 Taking terazoxin, doxazosin or tamsulosin within 14 days of enrolment; finasteride or phytotherapy and 	Other:IUsually performedIas an outpatientFprocedure.rAnaesthesia:rgeneral/spinal/topircal: 17/15/5FGroup 2 – TURPFProcedure:Standardradiofrequencymonopolar loopprocedureFCatheter protocol:Generally removedone day post-operatively, beforedischargeFOthers:C	Other: Usually performed as an outpatient procedure. Anaesthesia: general/spinal/topi cal: 17/15/5 Group 2 –TURP Procedure: Standard radiofrequency monopolar loop procedure Catheter protocol: Generally removed one day post- operatively, before discharge Others:	Other: Usually performed as an outpatient procedure. Anaesthesia: general/spinal/topi cal: 17/15/5 Group 2 –TURP Procedure: Standard radiofrequency monopolar loop procedure Catheter protocol: Generally removed one day post- operatively, before discharge	Post-op complications: Development of anaemia (hematocrite less than 30%)	Group 1: 0/37 Group 2: 2/35 p value: NS	level post surgery were reported. • "Problems from		
	anticholinergic within one month of enrolment. <u>All patients</u> N: Age, range, years: 50-81 Drop outs: 1 patient withdrew consent before treatment group assignment <u>Group 1-Laser coagulation</u>				procedure. Anaesthesia: general/spinal/topi cal: 17/15/5 Group 2 –TURP Procedure: Standard radiofrequency monopolar loop procedure Catheter protocol: Generally removed one day post- operatively, before discharge Others:	as an outpatient procedure. Anaesthesia: general/spinal/topi cal: 17/15/5 Group 2 -TURP Procedure: Standard radiofrequency monopolar loop procedure Catheter protocol: Generally removed one day post- operatively, before	Post-op complications: reoperation (2 patients retreated within 6 months, 1 with ILC and 1 with TURP. 4 additional patients receive TURP	Group 1: 2/37 Group 2: 0/35 Id 1 Relative risk: NE nal p value:: NS	Symptom Index" score and "American Urological Association QoL Assessment" score were reported. However, it what unclear which questionnaire were used from the paper. There was
	N: 37 Dropouts: Age, mean (years): 67.6 Ethnicity, white (%): 30/37 (81%) AUASI ,median: 24.0 Qmax, median (ml/s): 9.2						Catheter protocol: Generally removed one day post- operatively, before	Post-op complications: Incontinence (1 case of urge incontinence and another case of stress incontinence requiring pads)	Group 1: 0/37 Group 2: 2/35 Relative risk: 0 (0-1.77) p value:: NS
	PVR ,median (ml): 81 PSA, median (ng/ml): 2.3 Prostate volume, median					LOS, median (range), (days)	Group 1: 7.0 (3 to 145) Group 2: 33.5 (10 to 120) p value: NR	Notes: None.	
	(cm ³):41.5 <u>Group 2 - TURP</u> N: 35 Dropouts: Age, mean: 69.3 Ethnicity, white (%): 29/35(83%) AUASI ,median: 23.0 Qmax, median (ml/s): 9.1 PVR ,median (ml): 87.5 PSA, median (ng/ml): 2.3 Prostate volume, median (cm ³): 40		Sexual function score (Name of questionnaire not provided. Stated that the range was 0-30, higher scores better)	At 6 months Group 1: 19.0 Group 2: 5.0 Difference: 14.0 (95% Cl: 3.0 to 14.0) p value: <0.05 At 24 months Group 1: 19.5 Group 2: 10.0 Difference: 9.5 (95% Cl: -1.0 to 12.0) p value: Not sig					

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Liedberg et al., 2003 ¹⁴⁵ Study design: RCT, open label Setting: Hospital, Sweden Evidence level: 1+ Duration of follow-up: Up to 1 year	Patient group: moderate to severe BPH Setting: Department of urology, hospital in Sweden, Dec 1997 to Feb 2000 Inclusion criteria: IPSS ≥ 12 Qmax ≤15ml/s Exclusion criteria: Indwelling urinary catheter Prostatic carcinoma Clinical suspicion of neurogenic bladder disturbance All patients N: 38 Drop outs: 7/38 (3 due to prostate cancer), one was randomised to ILC but received TURP; 1 did not wish to undergo surgery and 2 could not undergo surgery due to undercurrent illness.	Group 1- Laser coagulation Procedure: Performed with the Indigo 830e (830nm) laser system. Each puncture site was treated for 3 min with a target temperature of 85C. The prostate was punctured under visual control and the target was one puncture for every 4ml of prostate. Power setting not stated. Catheter protocol: suprapubic catheter, removed when PVR <150ml Others: Norfloxacin 400mg twice daily while catheter was in place Group 2 –TURP Procedure: Standard electroresection.	IPSS, median (IQR): Qmax (ml/s), median (IQR): Post void residual volume (ml), median (IQR): Post-op complications: Clot retention (requiring	At 3 months Group 1: 10(4-15), n=20 Group 2: 4(2-7), n=11 p value: NS At 12 months Group 1: 11(6-14), n=19 Group 2: 6(3-10), n=9 p value: NS At 3 months Group 1: 11(8-15), n=19 Group 2: 12(9-18), n=10 p value: NS At 12 months Group 1: 11(6-12), n=18 Group 2: 14(10-19), n=9 p value: NS At 3 months Group 1: 74(38-140), n=19 Group 2: 0(0-53), n=10 p value: NS At 12 months Group 1: 126(25-190), n=19 Group 2: 22(3-62), n=8 p value: NS Group 1: 1/20 Group 2: 0/11	 Funding: Partly finance by FroU- Kronoberg Limitations: Open label study with subjective patient reported outcomes. Study stopped early (targeted N=50) due to prolonged rate of catheterisation and high rate of UTI Large number of exclusions from TURP group resulte in imbalance of sample Additional outcomes: Prostate volume post operation Notes: Age of subjects not 	
N C II C 7 7 7 8	Group 1-Laser coagulation N: 20 Drop outs: Not stated			transurethral clot evacuation under general anaesthesia	p value: NS	Age of subjects not reported
	IPSS, median (IQR): 19(16-24) Qmax, median (IQR): 8(7-10) [n=19] Prostate volume, median (IQR):49(41- 75) Post void residual volume: median	Peri-operative complications: Bleeding (blood loss, median (IQR), (ml))	Group 1: 0(0-50) Group 2: 350(200-514) p value: <0.001			
	(IQR): 96(64-190)	ian	Post-op complications: Catheterisation	Group 1: 24(14-34) Group 2: 2(1-2) p value: <0.001		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Group 2 - TURP N: 11 Dropouts: Not stated IPSS, median (IQR): 17(17-24) Qmax, median (IQR): 8(6-9) [n=10] Prostate volume, median (IQR):47(37- 61) Post void residual volume: median (IQR): 117(67-200)		Post-op complications: urinary tract infections	Group 1: 13/20 Group 2: 1/11 p value: <0.007	
			Post-op complications: urethral stricture	Group 1: 0/20 Group 2: 0/11 p value: NS	
			Post-op complications: bladder neck stenosis	Group 1: 0/20 Group 2: 0/11 p value: NS	
			Post-op complications: Retrograde ejaculation	Group 1: 1/20 Group 2: 3/11 p value: NS (0.084)	
			Hospitalisation, median (IQR), (days):	Group 1: 2.5 (0.25 to 3.8) Group 2: 3 (3 to 4) p value: NR	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Martenson et al., 1999 ¹⁵⁹ Study design: RCT, open label Setting: Netherlands Evidence level: 1+ Duration of follow-up: 2 years	Patient group: BPH patients Setting: Department of Urology, University Hospital Nijmegen, Netherlands Oct 1994 to April 1996 Inclusion criteria: Prostate volume >25 cm ³ age >45 years Duration of symptoms> 3 months IPSS12 Peak uroflow <15ml/s	Group 1- Laser coagulation Procedure: Performed with the Indigo 830 (830nm) laser system. Each individual fibre placement received 1420 J in a standard for 4 min treatment cycle Power: 10 W, decreased to 5 W Catheter protocol: Suprapubic catheters were removed when adequate voiding was demonstrated at scheduled follow up (1, 2 or 4 weeks) Group 2 –TURP Procedure: Standard procedure. 24Fr resectoscope used in combination with glycine irrigation fluid. Catheter protocol: Removed according to individual needs	IPSS, mean±sd IPSS-QoL, mean ±sd	At 3 months (12 weeks) Group 1: 11.8 \pm 6.9 Group 2: 4.7 \pm 4.0 p value: NS At 6 months (26 weeks) Group 1: 10.3 \pm 5.4 Group 2: 3.8 \pm 2.4 p value: NS At 12 months (52 weeks) Group 1: 12.4 \pm 7.7 Group 2: 3.5 \pm 2.9 p value: NS At 24 months (104 weeks) Group 1: 12.0 \pm 4.9 Group 2: 5.0 \pm 4.4 p value: NS At 3 months (12 weeks) Group 1: 2.3 \pm 1.4 Group 2: 0.9 \pm 1.3 p value: NS At 6 months (26 weeks) Group 1: 2.2 \pm 1.4 Group 2: 0.5 \pm 0.7 p value: NS At 12 months (52 weeks) Group 1: 2.2 \pm 1.4 Group 2: 0.5 \pm 0.7 p value: NS At 12 months (52 weeks) Group 1: 2.2 \pm 1.5 Group 2: 0.6 \pm 0.8 p value: NS At 24 months (104 weeks) Group 1: 2.2 \pm 1.5 Group 1: 2.2 \pm 1.5 Group 2: 0.7 \pm 0.9	 Funding: Indigo- the laser manufacturer Limitations: Small sample size, with no power calculation provided Patient age not reported T-tests were used Additional outcomes: The paper also reported the results of another non- randomised phase II study which temperature-sensing laser system Notes: The patients were randomised 2:1 in this study.
	Drop outs: NR <u>Group 1-Laser coagulation</u> N: 30 IPSS, mean ±sd: 21.7±6.1 IPSS-QoL, mean ±sd: 4.1±1.4 Qmax, mean±sd, (ml/s):7.3±3.8		Qmax, mean±sd, (ml/s):	p value: NS At 3 months (12 weeks) Group 1: 12.5±5.4 Group 2: 25.8±9.7 p value: NS At 6 months (26 weeks)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	PVR, mean±sd, (ml):116±146 Normal erectile function: 28/30 Group 2 - TURP N: 14 IPSS, mean ±sd: 21.6±7.7 IPSS-QoL, mean ±sd: 4.0±1.3 Qmax, mean±sd, (ml/s):9.3±3.2 PVR, mean±sd, (ml):88±126 12/14			Group 1: 11.1±4.5 Group 2: 18.2±6.6 p value: NS At 12 months (52 weeks) Group 1: 11.9±5.5 Group 2: 25.7±11.1 p value: NS At 24 months (104 weeks) Group 1: 10.3±4.4 Group 2: 20.1±13.7 p value: NS	
			PVR, mean±sd, (ml):	At 3 months (12 weeks) Group 1: 58±103 Group 2: 12±19 p value: NS At 6 months (26 weeks) Group 1: 60±56 Group 2: 14±27 p value: NS At 12 months (52 weeks) Group 1: 59±77 Group 2: 14±21 p value: NS At 24 months (104 weeks) Group 1: 94±128 Group 2: 63±100 p value: NS	
			Post-op complications: Blood transfusion	Group 1: 0/30 Group 2: 0/14 p value: NS	
			Post-op complications: Clot retention	Group 1: 0/30 Group 2: 0/14 p value: NS	
			Post-op complications: In continence (up to 24 months), definition of incontinence not provided	Group 1: 0/30 Group 2: 0/14 p value: NS	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Post-op complications: urinary tract infections	Group 1: 10/30 Group 2: 4/14 RR: 4.67(95% CI : 0.94 to 27.8) p value: NS	
			Post-op complications: Reoperation (up to 24 months)	Group 1: 6/30 Group 2: 1/14 RR: 2.8(95%Cl: 0.51 to 17.5) p value: NS	
			Post-op complications: Retrograde ejaculation	Group 1: 0/30 Group 2: 3/14 p value: NS (0.084)	
			Length of catheterisation, mean ±sd (days)	Group 1: 27±23 Group 2: 3±1	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Rodrigo Aliaga et al., 1998 ²¹⁷ (data extracted from HTA report) Study design: Setting: Spain Evidence level: 1+ Duration of follow-up: 6 months	 Patient group: patients with BPH Inclusion criteria: prostate size 20-60 g; symptom score; IPSS score ≥ 15 Exclusion criteria: age < 50 years <u>All patients</u> N: 41 Drop outs: <u>Group 1 -TUIP</u> N: 20 Age, years, mean±sd (range): NR Residual volume, mean ± SD (ml): 89 ± 92 	hours postoperatively if no complications	IPSS score, mean ± SD Qmax, ml/s, mean ±sd (range)	$\begin{array}{r} \underline{Baseline} \\ \hline \textbf{Group 1: } 24.2 \pm 7.7 \\ \hline \textbf{Group 2: } 24.4 \pm 10.3 \\ \underline{3 \text{ months}} \\ \hline \textbf{Group 1: } 4.3 \pm 4.5 \\ \hline \textbf{Group 2: } 4.8 \pm 4.8 \\ \underline{6 \text{ months}} \\ \hline \textbf{Group 1: } 5.7 \pm 6.2 \\ \hline \textbf{Group 1: } 5.7 \pm 6.2 \\ \hline \textbf{Group 2: } 3.7 \pm 3.8 \\ \hline \underline{Baseline} \\ \hline \textbf{Group 1: } 8.7 \pm 5.5 \\ \hline \textbf{Group 1: } 8.7 \pm 5.5 \\ \hline \textbf{Group 2: } 8.3 \pm 4.5 \\ \underline{3 \text{ months}} \\ \hline \textbf{Group 1: } 22 \pm 12.2 \\ \hline \textbf{Group 2: } 18.6 \pm 8.5 \\ \underline{6 \text{ months}} \\ \hline \textbf{Group 1: } 20.6 \pm 8.7 \\ \hline \textbf{Group 2: } 20.6 \pm 10.1 \\ \end{array}$	Funding: NR Limitations: No information of randomisation allocation and concealment methods Baseline prognostic factors were reported as not equal in quality assessment (uncertain which factor this referred to) Additional outcomes: Irritative symptoms Quality of life score (WHQ)
	Group 2 -TURP		Blood transfusion	Group 1: 0/20 Group 2: 1/21 P value: Not sig	Length of hospital stay Catheter duration Residual volume
	N: 21 Age, years, mean±sd (range): NR Desideraturaturaturaturaturaturaturaturaturatu		Reoperation	Group 1: 1/20 Group 2: 1/21 P value: Not sig	Notes: None.
	Residual volume, mean ± SD (ml): 146 ± 133		Retrograde ejaculation	Group 1: 14/20 Group 2: 15/21	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Sengor et al., 1996 ²³²	Patient group: Symptomatic bladder outlet obstruction due to BPH referred to urology clinic	Group 1 Under spinal or general anaesthesia Ultraline	AUA score , mean ± SD:	At 3 months Group 1: 8.5±4.2 Group 2: 9.8±3.1	Funding: NR
Study design: RCT, open label Evidence level: 1+	 Setting: urology clinic, single-centre, Istanbul, Turkey Inclusion Criteria: Significant voiding symptoms to request therapy Owner £15 ml/c and Owner £10 	side firing Nd:YAG laser fibre 600µm using SMA- 905 adapter and standard Nd:YAG laser generator at 60W through 21F cystoscope. Bladder was		 p value: NS (P=0.17), calculated by NCGC team using t-tests. Reported as 0.034 At 6 months Group 1:7.8±2.6 Group 2: 9.3±4.2 p value: NS (P=0.1), calculated by 	 Limitations: Outcome assessment was not masked. Randomisation and allocation method not reported. Statistical methods and sample size
Duration of follow-up: 6 months	 Qmax ≤15 ml/s and Qave ≤ 10 ml/s from uroflowmetric volume of ≥ 150 ml Age >50 years Exclusion Criteria: Prostate cancer- Induration or nodularity of prostate on DRE or PSA ≥ 4.0 mg/ml further 	continuously irrigated with saline. No indwelling catheter was used but supra public tubes were clamped 4-5 days after treatment and removed after successful urination. Group 2	Qmax (ml/s), mean ± SD:	NCGC team using t-tests At 3 months Group 1: 18.9±3.1 Group 2: 20.7±2.6 p value: 0.01, calculated by NCGC team using t-tests. Reported as 0.025 At 6 months Group 1: 18.2±2.1 Group 2: 19.8±2.5	calculation not reported Baseline values of post void residual volume significantly different between groups. Additional outcomes:
	examined for cancer. Infections (treated with suitable antibiotics preopreatively) <u>All patients</u> N: 60 Age: 50-85 Drop outs: NR <u>Group 1 - Laser</u> N: 30	TURP in standard manner under spinal anaesthesia using Storz 26F resectoscope with mannitol solution for irrigation. A 3-way Foley catheter was inserted and bladder irrigated with normal saline for 24-48 h.	Post void residual volume (ml), mean ± SD (note that the baseline value was significantly different)	<pre>p value: <0.01, calculated by NCGC team using t-tests, reported as NS At 3 months Group 1: 50.4±30 Group 2: 70±27 p value: NS At 6 months Group 1: 47±19 Group 2: 68±22 p value: NS</pre>	% of mean change was reported for AUA score, Qmax and residual volume but standard deviations were not provided Notes: None.
	Mean age (yrs): 66 (range 50-85) Drop outs: Erectile dysfunction: 7/30 AUA, mean ± SD: 21.8 ± 7.6 Prostate volume (TRUS) ml: 55 (30- 80)	Examination methods: Patients followed at 3 and 6 months using AUA	Post-op complications: Transurethral resection syndrome Post-op complications: Blood transfusion (units	Group 1: 0/30 Group 2: 0/30 p value: NS Group1: 0/30 Group 2: 2/30	•

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	 *PVR mean ± SD: 110 ± 68 Qmax mean ± SD (ml/s): 8.7 ± 2.3 Group 2 - TURP N: 30 Mean age (yrs): 61 (55-70) Drop outs: Erectile dysfunction: 3/30 AUA, mean ± SD: 22.1 ± 2.6 Prostate volume (TRUS) ml: 47 (30- 50) *PVR, mean ± SD: 155 ± 40 Qmax, mean± SD (ml/s): 8.4 ± 2.8 *P =0.003,calculated by t-test by NCGC team 	and PVR measurements	Post-op complications: urethral strictures (6 months follow up)	Group 1: 0/30 Group 2: 0/30 p value: NS	
			Post-op complications: Retrograde ejaculation (6 months follow up)	Group 1: 1/23 (3%) Group 2: 24/27 (80%) Relative risk:: 0.05 (95% Cl: 0.01- 0.19) p value: <0.001	
			Operation time , mean (range), (min):	Group 1: 43 (15-70) Group 2: 56 (45-90) P value : NR	
			LOS, mean (range), days	Group 1: 1.6 (1-3) Group 2: 5.9 (4-7) P value : NR	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Suvakovic et al., 1996 ²⁴⁹ Study design: RCT, open label Evidence	Patient group: Consecutive patients with prostatic symptomsSetting: Urology department, South Cleveland University, UKInclusion Criteria:	Group 1: VLAP – side fire free beam alone 4 spot thermocoagulation at the 10, 2, 4 and 8 o'clock positions. Laser delivered at 60W for 60s.	IPSS symptom score, mean±sd. Values for 12 months follow up reported in paper, but n was not reported	At 3 months Group 1: 16.8±15.0, n=10 Group 2: 9.7±2.6, n=10 Group 3: 8.1±5.4, n=8 Group 4: 12.8±5.9, n=10 P value: NS [#] P value for Group 1 vs. Group 3 was reported to be <0.01 in	Funding: NR Limitations: • Small sample size, n of 10 in each arm • Unclear which statistical test was
level: 1+ Duration of follow-up: 1 year	 Qmax ≤15mL/s for a voided volume of ≥150 mL Age Significant voiding symptoms (AUA score >15) PSA level <2.5 ng/mL Prostate volume <40g (assessed by TRUS, DRE and cystoscopy) Length of the prostatic urethra >4 	Group 2 : CLAP- contact laser alone Nd: YAG laser applied at 40W for vaporising and coagulating the prostate with a minimum depth of penetration. a 16 F two – way catheter was inserted into the bladder and		paper, but this could not be repeated. <u>At 6 months</u> Group 1: 16.2±4.2, n=9 Group 2: 18.7±7.5, n=9 Group 3: 19.4±3.4, n=4 Group 4: 19.0±0.8, n=10 P value: NS [#]	 statistical test was used for data – discrepancies in the stat sig reported for AUA score for 3 months and calculated by NCGC team. Number of participants
	 Exclusion Criteria: Malignancy <u>All patients</u> N: 40 Group 1 - VLAP - side fire free beam 	removed after 24 h. Group 3 : Hybrid – side fire free beam and debridement As in VLAP, plus debridement of coagulated tiisue using a 26F continuous irrigating resectoscope. At the end of	Qmax ml/s, mean±sd Values for 12 months follow up reported in paper, but n was not reported	At <u>3</u> months Group 1: 14.8±5.4, n=10 Group 2: 15.6±13.5, n=10 Group 3: 15.1±7.3, n=8 Group 4: 17.8±3.8, n=10 P value: NS At <u>6</u> months Group 1: 16.2±4.2, n=9 Group 2: 18.7±7.5, n=0	followed up at 12 months not reported. Additional outcomes: Operation duration for each procedure Notes:
	alone N: 10 Age (mean): 67.5(8.7) IPSS: 15.7(5.1) Qmax ml/s: 10.5 (3.7) Residual Vol mL: 47.4(48.1)	the procedure, a 16 F two -way catheter was inserted into the bladder and removed after 24 h Group 4 : TURP		Group 2: 18.7±7.5, n=9 Group 3: 19.4±3.4, n=4 Group 4: 19.0±0.8, n=10 P value: NS [#]	[#] values calculated by NCGC team based on mean and sd reported. It was not possible to calculate using Kruskal Wallis test without the

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Prostate size (by TRUS), g: 23.6(6.4) PSA (ng/ML): 2.3(0.8) Group 2 - CLAP- contact laser alone N: 10 Age (mean): 62.6(5.8) IPSS: 18 (6.0)	Standard resection using a 26 F continuous irrigating resectoscope. A 22 F threeway urethral catheter was inserted into the bladder and irrigation was continued up to 24 h. The	Catheter duration, mean, hours (range or standard deviations not reported)	Group 1: 24, n=10 Group 2: 24, n=10 Group 3: 20, n=10 Group 4: 48, n=10 p value: reported as <0.05 between group 4 and "lasers"	raw data. All patients received preoperative oral antibiotics and controlled for more than 5 days post-operatively.
	Qmax ml/s: 12.2 (3.8) Residual Vol mL: 139.6(103) Prostate size (by TRUS), g: 24(5.8) <u>Group 3 - Hybrid – side fire free</u> beam and debridement N: 10 Age (mean): 64.1(6.9) IPSS: 17(6.0) Qmax ml/s: 11.8(4.1) Residual Vol mL: 68.3(64) Prostate size (by TRUS), g: 27(12.3) <u>Group 4 - CLAP- TURP</u> Standard resection N: 10 Age (mean): 66.1(5.1) IPSS: 18.8 (4.5) Qmax ml/s: 11.1(6.4) Residual Vol mL: 161.8(104) Prostate size (by TRUS), g: 22(5)	catheter was removed after 48 h and the patients discharged home 3-4 days after the procedure.	Length of hospitalisation, (hours)	Group 1: 30,n=10 Group 2: 30, n=10 Group 3: 24, n=10 Group 4: 84, n=10 p value: reported as <0.05 between group 4 and "lasers"	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Bouchier-Hayes et al., 2006 ²⁹ Study design: RCT	Patient group: Patients referred with LUTS to urology outpatient department	y Photoselective vaporisation was performed using 80W KTP using Greenlight laser system and StarPulse quasi-continuous wave laser (Laserscope) emitting green light at 532 nm. A 600 µm laser fibre with 70° lateral	Change IPSS symptom score from baseline at 6 weeks**	Group1: 14.0 ± 9.8 (n=38) Group 2: 12.9 ± 10.6 (n=38) p value: Not Signif. (NCGC calculated p=0.63)	Funding: NR Limitations:	
Evidence level: 1+ Duration of follow-up:	Setting: single centre, Melbourne, Australia Inclusion Criteria:		laser system and StarPulse quasi- continuous wave laserChange in flow rate (Qmax) from baseline at 6 weeks**Group 1: 11 Group 2: 8.5 p value: Not calculated p	Group1: 11.96 ± 8.23 (n=38) Group 2: 8.56 ± 9.08 (n=38) p value: Not Signif. (NCGC calculated p=0.09)	 Baseline values for Qmax and IPSS, QoL bother and BSFQ not reported 	
ó weeks	 Age >50 years Referral by GP Flow rate ≤ 15 mL/s IPSS ≥ 12 		Change in QoL score from baseline at 6 weeks**	Group1: 2.65 ± 2.1 (n=38) Group 2: 2.91 ± 2.04 (n=38) p value: Not Signif.	 **Follow up period not clear for main outcome data or complications. Might 	
	 Gland 15-85 cm³ on TRUS Obstructed Abrams-Griffiths (A-G) continuous flow 	element used through	Change in bother score from baseline at 6 weeks**	Group1: 2.65 ± 2.1 (n=38) Group 2: 1.61 ± 1.22 (n=38) p value: Not Signif.	be 6 weeks as number of patients with data at 6 weeks is 76	
	Able to complete QoL, Bother Score & Baseline Sexual Function Questionnaire (BSFQ) questionnaires	irrigation. Catheters left situ at the discretion of the surgeon. Group 2 TURP in standard manner through 25F resectoscope sheath using ValleyLab diathermy machine	Change in prostate volume from baseline at 6 weeks**	Group1: 125 ± 198 (n=38) Group 2: 86 ± 124.38 (n=38) p value: Not Signif.	 Outcome assessment was not masked. Randomisation method not reported. Allocation concealment not reported 	
	 Able to give informed consent Exclusion Criteria: Neurogenic bladder 		Post-op complications Failure to void: (follow up period 6 weeks**)	Group1: 4/38 Group 2: 3/38 p value: NR		
	 Known or suspected prostate cancer Chronic retention Taking α-blocker or herbal remedy On anticoagulants 		resectoscope sheath using ValleyLab diathermy machine	resectoscope sheath using ValleyLab diathermy machine	Post-op complications Stricture: (follow up period 6 weeks**)	Group1: 0/38 Group 2: 5/38 p value: NR
	On finasteride or dutasteride On finasteride or dutasteride All patients N 05	Post-op complications urine retention: (follow up period 6 weeks**)	Group1: 3/38 Group 2: 1/38 p value: NR	- 2008		

1 Evidence Table 27 Laser vapourisation vs. transurethral resection of the prostate (TURP)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments		
	Drop outs: 19 (25%)* <u>Group 1 - Laser</u> N: 38 Mean age (yrs): 65.2 range (51-81)	by registrars in training or fellows in the department, all of whom had performed <5 laser prostatectomies each and between 35 & 325 TURPs Examination methods: Patients followed at 6 weeks, 3, 6, 12 months by same investigator During follow up Qmax, IPSS, QoL, bother and BSFQ all completed and TRUS, urodynamics and serum PSA measured at 6 months	Post-op complications number of patients with blood transfusion (follow up period 6 weeks**)	Group1: 0/38 Group 2: 1/38 p value: NR			
	Drop outs: NR* IPSS: NR Erectile dysfunction: NR Prostate volume (TRUS) ml: 42.4 range (16.5-82.6) Qmax: NR Operation time: 30.2 mins range (9-70)		prostatectomies each and between 35 & 325 TURPs Examination methods: Patients followed at 6 weeks, 3, 6, 12 months by same investigator	prostatectomies each and between 35 & 325 TURPs Examination	Post-op complications number of patients Peri-operative urinary tract infections (follow up period 6 weeks**)	Group1: 2/38 Group 2: 3/38 p value: NR	
	Mean catheterisation time (days): 0.5 ± 0.4 Mean length of stay (days): 1.1 ± 0.3 Group 2 - TURP			Post-op complications number of patients TUR syndrome (follow up period 6 weeks**)	Group1: 0/38 Group 2: 1/38 p value: NR		
	N: 38 Mean age (yrs): 66.2 range (55-80) Drop outs: NR* IPSS: NR Erectile dysfunction: NR PVR (TRUS) ml: 33.2 range (15.4-67.5) Qmax: NR Operation time: 31.3 mins range (5-70) Mean catheterisation time (days): 1.9 ± 1.3 Mean length of stay (days): 3.4 ± 1.2		Post-op complication: Haemorrhage necessitating readmission: (follow up period 6 weeks**)	Group1: 1/38 Group 2: 3/38 p value: NR			
	*3 patients dropped out after randomisation but groups not defined. Only 76 patients has data at 6 weeks postoperatively						

Study details	Patients	Interventions	Outcome measures	Effect size	Comments		
Carter et al., 1999 ^{39,40} Study design:	Patient group: Patients from urology outpatient department with BPE severe enough to warrant operation	Group 1 Hybrid laser performed using Laserscope 40W	Change IPSS symptom score from baseline at	Group1: Group 2: p value:	Funding: Partially funded by Somerset Health Authority		
RCT Evidence level:	Setting: single centre, UK Inclusion Criteria: (based on British	KTP/60W Nd:YAG generator system abd AddStat laser delivery fibres	Change in flow rate (Qmax) from baseline	Group1: Group 2: p value:	 Limitations: Baseline values for were not reported with standard deviations 		
1+ Duration of follow-up:	Laser Urological Evaluation Society (BLUES) • Qmax ≤ 15 ml/s • Voided volume > 150 ml	producing forward or side beams through a 21 F laser cystoscope (Storz).	Change in QoL score from baseline	Group1: Group 2: p value:.	 Follow up outcomes Qmax and IPSS, QoL scores not reported with standard deviations. Only 		
12 months	 PVR < 300 ml IPSS≥ 12 	30W KTP treatment to create bladder neck incisions and vaporisation then Nd:YAG 60W used to coagulate.	to create bladder neck incisions and vaporisation then Nd:YAG 60W used to coagulate.	to create bladder neck incisions and vaporisation then Nd:YAG 60W used	Change in bother score from baseline at	Group1: Group 2: p value: Not Signif.	as graphs.Outcome assessment was not masked.
	 Exclusion Criteria: History of acute retention Histological diagnosis of prostate 				Nd:YAG 60W used to coagulate.	Change in prostate volume from baseline	Group1: Group 2: p value: Not Signif.
	 adenocarcinoma Prostate volume > 100 ml (TRUS) Neurogenic bladder 	Urethral catheter removed either 1 or 2 days or 1-2 weeks Group 2	Early post-op complications: Failure to void as inpatient following catheter removal (follow up period up to 6 months)	Group1: 26/81 Group 2: 5/96 p value: <0.00001 (calculated by NCGC Fishers exact test)	 were used *Unclear which follow up complications refer to ar how many patients remained. ITT analysis 		
	N: 204TURP in standor manner throug 2 with calculi, 2 with urethral strictures)Group 1 - Laserpostoperative	TURP in standard manner through 24 or 26 Fr resectoscope. Catheters removed postoperatively when	Late post-op complications: urinary tract infection (follow up period > 6 weeks to 1 year)*	Group1: 2/95 Group 2: 6/96 p value: Not signif. (calculated by NCGC Fishers exact test)	used for late complications Notes: None.		
	N: 95 Mean age ± SD (yrs): 67.9 ± 7.8 Drop outs: NR IPSS: 20.3 ± NR Erectile dysfunction: NR	All nationts:	Late post-op complications: urethral stricture (follow up period > 6 weeks to 1 year)*	Group1: 2/95 Group 2: 9/96 p value: 0.06 (calculated by NCGC Fishers exact test)			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean Prostate volume (TRUS) ml ± SD: 41.6 ± 17.3 Mean PSA ng/ml ± SD: 3.8 ± 2.7 Mean Creatinine mmol/l ± SD: 95.3 ± 15.7	a ± 2.7 operation and catheter removal. SD: 95.3 ± Intervention performed by: 1 of 3 consultants, 2 Snr registrars, 1 clinical research fellow or 1 staff-grade	Late post-op complications: acute retention (follow up period > 6 weeks to 1 year)*	Group1: 2/95 Group 2: 0/96 p value: Not signif. (calculated by NCGC Fishers exact test)	
	Qmax: 9.0 ± NR PVR: 109 ± NR Operation time: 37.4 ± 12.1 mins 3.4 ± 1.2 Median catheterisation time (days): NR		Late post-op complications: incontinence (follow up period > 6 weeks to 1 year)*	Group1: 1/95 Group 2: 0/96 p value: Not signif. (calculated by NCGC Fishers exact test)	
	Median length of stay (days): 2 (0-9) Group 2 - TURP N: 96 Mean age \pm SD (yrs): 67.0 \pm 7.5 Drop outs: NR IPSS: 19.8 \pm NR Erectile dysfunction: NR Mean Prostate volume (TRUS) ml \pm SD: 41.7 \pm 19.4 Mean PSA ng/ml \pm SD: 3.2 \pm 2.4 Mean Creatinine mmol/I \pm SD: 99.7 \pm 27 Qmax: 9.5 \pm NR PVR: 135 \pm NR Operation time: 35.7 \pm 10.8 mins Median catheterisation time (days): NR Median length of stay (days): 2 (2-14)	urologist. Examination methods: Patients followed at 6 weeks, 6, 12 months During follow up IPSS, Symptom problem index (SPI), BPH impact Index (BPHII), Short Form 36 (HRQoL) questionnaires completed and uroflometry (Dantec Uroflow 1200), TRUS to find PVR.		Group1: 2/95 Group 2: 1/96 p value: Not signif. (calculated by NCGC Fishers exact test)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Horasanli et al., 2008 ¹⁰⁹ Study design:	Patient group: Patients referred to urology clinic with symptoms of BOO due to BPH	Photoselective valorisation performed using KTP/532 emitting green light at 80W via a 6E side firing	IPSS symptom score at 3 months	Group1: 11.2 ± 7.6 Group 2: 6.1 ± 5.4 p value: 0.01 (calculated by NCGC as t test with unequal variances using ITT analysis)	Funding: NR Limitations:
RCT Evidence level: 1+	Setting: single centre, dept urology, Memorial Hospital, Istanbul, Turkey		Change in IPSS symptom score from baseline at 3 months	Group1: 7.7 ± NR Group 2: 14.1 ± NR p value: NR	 Randoomisatric n method not reported Allocation
1+ Istanbul, Turkey Duration of follow-up: Inclusion Criteria: 6 months Prostate volume 70-100 mL (TRUS) or PVR >150		IIEF-5 at 3 months	Group1: 19.0 ± 3.8 Group 2: 20.0 ± 4.7 p value: Not signif. (calculated by NCGC as t test with equal variances using ITT analysis)	 Allocation concealment no reported Masking of outcome 	
	mL with IPSS score > 7 Exclusion Criteria:	place and bladder irrigated with saline for 24 hours.	Change in IIEF-5 from baseline at 3 months	Group1: 0.9 ± NR Group 2: 0.1 ± NR p value: NR	assessment not reported • Drop out
	 Urethral strictures PVR > 400mL Previous prostatic, bladder or urethral 	 Urethral strictures PVR > 400mL Previous prostatic, TURP in standard manner under general angesthesig 	flow rate (Qmax) at 3 months	Group1: 14.1 ± 8.7 Group 2: 21.3 ± 12.8 p value: 0.006 (calculated by NCGC as t test with unequal variances using ITT analysis)	numbers not clear so ITT analysis used Notes:
	 surgery Prostate malignancy Indwelling catheters 	continuous flow resectoscope. A 20F 3-way Foley catheter was left in	Change in flow rate (Qmax) from baseline at 3 months	Group1: 5.5 ± NR Group 2: 12.1 ± NR p value: NR	* Drop out number not clear so ITT analysis used.
All patients	catheter was left in place and bladder irrigated with saline for 24-48 hours.	IPSS symptom score at 6 months	Group1: 13.1 ± 5.8 Group 2: 6.4 ± 7.9 p value: 0.0001 (calculated by NCGC as t test with equal variances using ITT analysis)	1.	
	Group 1 - LaserAntibiotics before and afterN: 39and after	Change in IPSS symptom score from baseline at 6 months	Group1: 5.8 ± NR Group 2: 13.8 ± NR p value: NR		
	Mean age ± SD (yrs): 69.2 ± 7.1 (range 59-78) IPSS Score: 18.9 ± 5.1 IIEF-5: 19.9 ± 5.1	Intervention performed by: 5 surgeons	IIEF-5 at 6 months	Group1: 19.0 ± 5.2 Group 2: 21.0 ± 6.8 p value: Not signif. (calculated by NCGC as t test with equal variances using ITT analysis)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments						
	Mean Prostate vol (TRUS) ml ± SD: 86.1 ± 8.8 Mean PSA ng/ml ± SD: 5.2	experienced SpR)	Change in IIEF-5 from baseline at 6 months	Group1: 0.9 ± NR Group 2: -0.9 ± NR (IIEF-5 increased) p value: NR							
	± 4.5 Qmax ml/s ± SD : 8.6 ± 5.2 PVR ml ± SD: 183.0 ± 50.1 Operating time (min ± SD): 87 ± 18.3	$ \begin{array}{l} \textbf{ml/s} \pm \textbf{SD}: 8.6 \pm 5.2 \\ \textbf{l} \pm \textbf{SD}: 183.0 \pm 50.1 \\ \textbf{ing time (min \pm \textbf{SD}):} \end{array} \end{array} \begin{array}{l} \textbf{Examination} \\ \textbf{methods:} \\ \textbf{Patients followed at} \\ \textbf{3} \text{ and } 6 \text{ months.} \\ \textbf{All patients works} \end{array} $	methods: Patients followed at 3 and 6 months. All patients were	methods: Patients followed at 3 and 6 months. All patients were	methods: Patients followed at 3 and 6 months. All patients were	methods: Patients followed at 3 and 6 months. All patients were	methods: Patients followed at 3 and 6 months. All patients were	methods: Patients followed at 3 and 6 months. All patients were	flow rate (Qmax) at 6 months	Group1: 14.1 ± 8.7 Group 2: 21.3 ± 12.8 p value: 0.002 (calculated by NCGC as t test with unequal variances using ITT analysis)	
	Mean catheterisation time (days): 1.7 ± 0.8 Mean length of stay (days): 2.0 ± 0.7	preoperatively and at follow ups for IPSS score,	Change in flow rate (Qmax) from baseline at 3 months	Group1: 4.7 ± NR Group 2: 11.5 ± NR p value: NR							
	Drop outs: NR <u>Group 2 - TURP</u> N: 37	Drop outs: NR Group 2 - TURP N: 37 Mean age \pm SD (yrs): 68.3 \pm 6.7 (range 58-76) IPSS Score: 20.2 \pm 6.8 IIEF-5: 20.1 \pm 5.5 Mean Prostate vol (TRUS) ml \pm SD: 88.0 \pm 9.2 Mean PSA ng/ml \pm SD: 4.7 \pm 3.8 Qmax ml/s \pm SD : 9.2 \pm 5.6 PVR ml \pm SD: 176.9 \pm 45.3 Operating time (min \pm SD): 51 \pm 17.2	(yrs): 68.3 ±5)± 6.8561 (TRUS) ml21 ± SD: 4.7	of Erectile Dysfunction (IIEF-5), PSA, Qmax, PVR. In addition, postoperatively, data on length of stay, operating time, catheter removal time, and complications were collected.	of Erectile Dysfunction (IIEF-5), PSA, Qmax, PVR. In addition, postoperatively, data on length of stay, operating time, catheter removal time, and complications were	of Erectile Dysfunction (IIEF-5), PSA, Qmax, PVR. In addition, postoperatively, data on length of stay, operating time, catheter removal time, and complications were	8.3 ± of Erectile Dysfunction (IIEF-5), PSA, Qmax, PVR. In addition, postoperatively, data on length of stay, operating time, catheter removal	of Erectile Dysfunction (IIEF-5), PSA, Qmax, PVR.	Early post-op complications: patients requiring transfusion (follow up period up to 6 months)	Group1: 0/39 * Group 2: 3/37 * p value: Not signif (calculated by NCGC Fishers exact test)	
	6.7 (range 58-76) IPSS Score: 20.2 ± 6.8 IIEF-5: 20.1 ± 5.5							Early post-op complication: urinary retention (follow up period up to 6 months)	Group1: 6/39 * Group 2: 1/37 * p value: Not signif (calculated by NCGC Fishers exact test)		
	± SD: 88.0 ± 9.2 Mean PSA ng/ml ± SD: 4.7 ± 3.8						Early post-op complications: urinary tract infection (follow up period up to 6 months)	Group1: 6/39 * Group 2: 5/37 * p value: Not signif (calculated by NCGC Fishers exact test)			
	PVR ml \pm SD: 176.9 \pm 45.3 Operating time (min \pm SD):		Early post-op complications: urethral stricture (follow up period up to 6 months)	Group1: 2/39 * Group 2: 3/37 * p value: Not signif (calculated by NCGC Fishers exact test)							
	(days): 3.9 ± 1.2 Mean length of stay (days): 4.8 ± 1.2 Drop outs: NR		Early post-op complications: incontinence (follow up period up to 6 months)	Group1: 0/72 ** Group 2: 1/76 ** p value: Not signif. (calculated by NCGC Fishers exact test)							
			Reoperation rate (follow up period up to 6 months)	Group1: 7/39 * Group 2: 0/37 * p value: 0.01 (calculated by NCGC Fishers exact test)							

Study details	Patients	Interventions	Outcome measures	Effect size	Comments		
Keoghane et al., 2000 ^{124,126} &	Patient group: Patients referred to hospital requiring surgery for BPE	Group 1 Vaporisation using MD60 Nd:YAG (Selected Laser	AUA 7 symptom score from baseline at 3 months	Group1: $9.6 \pm 7.5 (n=55)$ Group 2: $6.5 \pm 5.1 (n=62)$ p value: 0.03	Funding: Oxford Regional Health Authority		
Keoghane et al., 1996 ^{122,123,125}	Setting: single centre, UK	Technologies) with 600 μm fibre incorporating sapphire-tipped probe. Irrigation using saline.	Change in AUA 7 symptom score from baseline at 3 months	Group1: 10.1 ± 9.7 (n=47) Group 2: 13.6 ± 6.9 (n=54) p value: NS	Limitations: **Patient numbers for primary and secondary		
Study design: RCT	NR Exclusion Criteria:	Group 2 TURP in standard manner	AUA 7 symptom score from baseline at 12 months	Group1: 8.7 ± 6.5 (n=53) Group 2: 5.8 ± 5.4 (n=60) p value: 0.006	outcomes and complications were unclear so ITT analysis		
Evidence level: 1+	 Previous surgery or instrumentation for BPE Prostate malignancy 	using Storz equipment and irrigation with glycine	Change in AUA 7 symptom score from baseline at 12 months	Group1: 10.9 ± 8.4 (n=44) Group 2: 13.3 ± 7.8 (n=53) p value: not signif. (NCGC t-test)	used. Notes: – Randomisation by random		
Duration of follow-up: 5 years	 Insufficient knowledge of English to answer questionnaire Refusal of consent 	All patients: Oral ciprofloxacin prophylaxis before surgery. After treatment 22F 3-way catheter inserted and continuous irrigation commenced. Catheter removed when clinically indicated Intervention performed by: 5 surgeons (consultant or	Oral ciprofloxacin prophylaxis before	AUA 7 symptom score from baseline at 2 years	Group1: 7.8 ± 6.6 (n=45) Group 2: 5.7 ± 6.0 (n=52) p value: 0.018	number tables and allocation concealment through sealed envelopes	
	Refusal of consent All patients N: 148		After treatment 22F 3-way catheter inserted and	catheter inserted and	Change in AUA 7 symptom score from baseline at 2 years	Group1: 11.7 ± 9.7 (n=35) Group 2: 13.7 ± 7.7 (n=47) p value: not signif. (NCGC t-test)	although opacity was not reported. Patients and investigators were masked to
	Drop outs: *at 5 years 63/148 (43%): 17 (7 laser and 10 TURP) had died., 8 unable to respond to		AUA 7 symptom score from baseline at 3 years	Group1: $8.9 \pm 6.6 (n=37)$ Group 2: $6.5 \pm 6.5 (n=41)$ p value: 0.001	Treatment allocation Change from baseline at		
	and 38 lost to follow up.		Change in AUA 7 symptom score from baseline at 3 years	Group1: 11.0 ± 9.7 (n=37) Group 2: 12.9 ± 7.9 (n=41) p value: not signif. (NCGC t-test)	5 years were reported for AUA score but SDs were not reported.		
	N: 72 experienced SpR) Mean age ± SD (yrs): 69 ± 8 (range 51-95) Examination methods:	Change in flow rate (Qmax) from baseline at 12 months	Group1: 6.2 ± 15.0 (n=32) Group 2: 9.4 ± 12.5 (n=37) p value: not signif. (NCGC t-test)				
	Drop outs: * AUA 7 Score: 19.9 ± 7.7 (n=54) Bother score: 5.8 ± 3.0 (n=59)	weeks, 3, 12, 24, 36 months to 5 years	Change in flow rate (Qmax) from baseline at 24 months	Group1: 5.2 ± 7.0 (n=18) Group 2: 4.9 ± 7.5 (n=26) p value: not signif. (NCGC t-test)			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments			
	Mean SF36 (physical) ±SD: 43.69 ±12.58 (n=51) Mean SF36 (mental) ±SD: 47.07	Patients received cysto- urethroscopy after randomisation to assess	Change in flow rate (Qmax) from baseline at 24 months	Group1: 1.8 ± 6.2 (n=24) Group 2: 2.1 ± 6.9 (n=24) p value: not signif. (NCGC t-test)				
	±11.2 (n=51) Erectile dysfunction (difficulty maintaining erection): 9/38 (24%) Mean Prostate volume ml ± SD:	preoperatively and at 4 weeks. Qmax was a secondary outcome measurement methods not reported.	Erectile Dysfunction (difficulty maintaining erection) at 3 months	Group1: 7/38 Group 2: 12/50 p value: Not signif. (calculated by NCGC Chi squared test)				
	54.2 ± 26.3 (n=44) Qmax: 11.8 ± 4.5 (n=48) PVR: NR		Bother score at 3 months	Group1: 2.9 ± 3.0 (n=54) Group 2: 2.4 ± 3.0 (n=64) p value: Not Signif.				
	(days): 1 (0-9) Median length of stay (days): 3 (1-10) <u>Group 2 - TURP</u>		Early post-op complications: Failure to void as inpatient following catheter removal (follow up period first 3 months)	Group1: 17/72 ** Group 2: 8/76 ** p value: Not signif. (calculated by NCGC Chi squared test)				
	N: 76 Mean age ± SD (yrs): 70 ± 8 (range 47-84) Drop outs: * AUA 7 Score: 19.4 ± 6.5 (n=63) Drift 50 = 2.2 (10)					Early post-op complications: patients requiring transfusion (follow up period first 3 months)	Group1: 0/72 ** Group 2: 13/76 ** p value: 0.0001 (calculated by NCGC Fishers exact test)	
	Bother score: 5.9 ± 2.3 (n=68) Mean SF36 (physical) ±SD: 44.66 ±12.12 (n=57) Mean SF36 (mental) ±SD: 47.75 ±10.47 (n=57)					Late post-op complications: urinary tract infection (follow up period first 3 months)	Group1: 1/72 ** Group 2: 3/76 ** p value: Not signif. (calculated by NCGC Fishers exact test)	
	Erectile dysfunction (difficulty maintaining erection): 20/50 (40%) Mean Prostate volume ml ± SD:		Late post-op complications: urethral stricture ((follow up period first 3 months)	Group1: 0/72 ** Group 2: 3/76 ** p value: Not signif. (calculated by NCGC Fishers exact test)				
	51.9 ± 24.1 (n=48) Qmax: 11.4 ± 5.0 (n=54) PVR: NR Median catheterisation time						Late post-op complications: incontinence (follow up period first 3 months)	Group1: 0/72 ** Group 2: 1/76 ** p value: Not signif. (calculated by NCGC Fishers exact test)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	(days): 2 (1-20) Median length of stay (days): 4 (1-8)		years	Group1: 13/72 Group 2: 11/76 p value: Not signif. (calculated by NCGC Fishers exact test)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Mottet et al., 1999 ¹⁸¹	Patient group: Patients in urology clinics	Group 1 Dual length VersaPulse Select Laser at 60W-	Mean IPSS at 3 months	Group1: 7.7 ± NR (n=22) Group 2: 7.5 ± NR (n=12) p value = NR	Funding: NR	
Study design: RCT Evidence	Setting: multi-centre, Nimes & Paris, France Inclusion Criteria:	through 550µm fibre or	energy in pulsed mode through 550μm fibre or	Mean IPSS at 6 months	Group1: $6.2 \pm NR (n=20)$ Group 2: 7.7 $\pm NR (n=11)$ p value = NR	Limitations: Outcomes were reported without
level:]+	 Qmax <12ml/s age >45 years PVR <250ml 	side-firing fibre in 24F cystoscope. 6 patients also received additional Nd:YAG vaporisation.	Mean IPSS at 12 months	Group1: 5.9 ± NR (n=12) Group 2: 7.5 ± NR (n=7) p value = NR	 standard deviations Outcome assessment was not masked. Randomisation method 	
Duration of follow-up: 12 months	 AUA> 13 PSA < 10ng/ml informed consent 	3 0ng/ml 20 or 24F Foley placed without irrigation and removed the next day.	Mean Qmax at 3 months	Group1: 22.8 ± NR (n=22) Group 2: 18.3 ± NR (n=12) p value = NR	not reported.Allocation concealment not reported	
	Exclusion Criteria:history of prostatic or urethral	Group 2 TURP in standard manner under spinal	Mean Qmax at 6 months	Group1: 17.5 ± NR (n=20) Group 2: 16.6 ± NR (n=11) p value = NR	Additional outcomes: Madsen score at follow up	
	surgery prostate >60g diabetes 	anaesthesia with glycine irrigation followed by postoperative saline	Mean Qmax at 12 months	Group1: 19.3 ± NR (n=12) Group 2: 17.6 ± NR (n=7) p value = NR	Notes: Randomisation on 2:1 mode	
	All patientsremoved.N: 36Age: 66 (range 50-77)Intervention performedDrop outs: 17 (at 12 mths)by same 2 experiencedGroup 1 - LaserSurgeonsN: 23Examination methods:	clear. Catheter was then	clear. Catheter was then removed. Early Post-op complications number of patients with blood	Group1: 0/23 Group 2: 0/13		
		Post-op complications number of patients incontinence at 6 months	Group1: 1/23 Group 2: 0/13			
	Mean age (yrs): 67 Drop outs: 11 without outcome data at 12 months	an age (yrs): 67Patients followed at 1,p outs: 11 without outcome data3, 6, 12 months	Reoperation rate	Group1: 1/23 Group 2: 2/13		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	IPSS: 20 Madsen score: 15 Erectile dysfunction: NR Prostate volume (TRUS) ml: 39 Qmax ml/s: 8 Operation time mins: 75 Mean catheterisation time (days): 1.6 \pm NR Mean length of stay (days): 2.2 \pm NR Group 2 - TURP N: 13 Mean age (yrs): 64 Drop outs: 6 without outcome data at 12 months IPSS: 24 Madsen score: 17 Erectile dysfunction: NR Prostate volume (TRUS) ml: 34 Qmax ml/s: 8 Operation time mins: 40 Mean catheterisation time (days): 3.1 \pm NR Mean length of stay (days): 2.1 \pm NR	During preoperative assessment and follow up DRE, Qmax, IPSS and Madsen score, PSA and TRUS all completed. Patients were also questioned about potency and ejaculation status. Length of stay, catheterisation time, reoperation rate also recorded			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments					
	Patient group: Patients with failed α -blockers	Group 1 Laserscope	AUA symptom score at 3 months	Group 1: 7.0 ± NR (n=48) Group 2: 4.0 ± NR (n=48) p value = 0.01	Funding: In part by					
Shingleton et al., 1999 ²³⁸ &	therapy for voiding symptoms	KTP/Nd:YAG with Laserscope ADD or ADD/stat fibre. 36W	AUA symptom score at 6 months	Group 1: 7.0 ± NR (n=46) Group 2: 4.0 ± NR (n=48) p value = 0.01	Laserscope					
Study design: RCT	Setting: single-centre, Istanbul, Turkey Inclusion Criteria: • peak urine flow rate <15ml/s • age >45 years	was used first for vaporisation then 60W for further vaporisation and coagulation. A catheter was placed for between 1-5 days depending on size of prostate and energy used Group 2 TURP in standard manner using Circon/ACMI continuous flow resectoscope with	was used first for vaporisation then 60W for further vaporisation	was used first for vaporisation then 60W for further vaporisation	vaporisation then 60W for further vaporisation and coagulation. A	AUA symptom score at 12 months	Group 1: $6.0 \pm 6.0 \text{ (n=40)}$ Group 2: $3.8 \pm 4.1 \text{ (n=33)}$ p value = 0.03 (calculated by NCGC using t test with equal variances *	 Reasons for drop out were not reported and there were 		
Evidence level: 1+ Duration of	 failure of medical therapy (α-blockers) able to undergo regional/general anaesthesia 		AUA symptom score at 18 - 24 months	Group 1: 5.9 ± 5.7 (n=23) Group 2: 4.6 ± 4.2 (n=19) p value = 0.19 (calculated by NCGC using t test with equal variances *	more patients of 3 years than 2 years • Outcome					
Duration of follow-up: 3 years	 medical therapy discontinued 1 month before surgery Exclusion Criteria: 		Group 2 TURP in standard manner using Circon/ACMI continuous flow resectoscope with	AUA symptom score at 36 months	Group 1: 9.9 \pm 6.7 (n=29) Group 2: 7.7 \pm 5.6 (n=33) p value = 0.07 (calculated by NCGC using t test with equal variances *	 assessment was not masked. Allocation concealment not 				
	Prostate cancer			flow resectoscope with	flow resectoscope with	flow resectoscope with	flow resectoscope with	flow resectoscope with	flow resectoscope with	Qmax at 3 months
	All patients N: 100 Age: 66 (range 50-77)	mannitol solution. Laser intervention	Qmax at 6 months	Group 1: 15.8 ± 6.9 (n=46) Group 2: 16.3 ± 6.4 (n=48) p value = 0.77	not reported					
	Drop outs: Group 1 - Laser N: 50	performed by one surgeon and TURPs by senior residents under same surgeon. Examination methods:	Qmax at 12 months	Group 1: 14.6 ± 5.9 (n=40) Group 2: 16.2 ± 7.2 (n=33) p value = 0.23 (calculated by NCGC using t test with equal variances *	Additional outcomes: Prostate volume at follow up, serum PS. at follow up					
	Mean age ± SD (yrs): 68.2± 7.9 Ethnicity: 38/50 (76%) white. Mean AUA score ± SD: 22.5 ± 6.0 Erectile dysfunction (full): 22/50 (44%)		Qmax at 18-24 months	Group 1: 14.9 ± 5.4 (n=23) Group 2: 14.3 ± 6.3 (n=19) p value = 0.6 (calculated by NCGC using t test with equal variances*	Other complications including retrograde ejaculation.					
	Prostate volume (TRUS) ml: 32.2 ± 21.4 Mean PSA ng/ml ± SD: 2.7 ± 2.3		Qmax at 36 months	Group 1: 12.3 ± 5.3. (n=29) Group 2: 12.8 ± 5.6 (n=33) p value = 0.64 (calculated by NCGC using t test with equal variances *	Notes: Computer generate randomisation. *ITT analysis used fo					

Study details	Patients	Interventions	Outcome measures	Effect size	Comments			
	Mean Qmax ± SD (ml/s): 8.2± 3.2 Operation time mins: 43 (15-70) Drop outs: Mean catheterisation time (days): NR Mean length of stay (days): NR	measurements at 1, 3, 6, 12, 18, 24, 36, 48, 60 and 72 months	Post-op complications number of patients with urethral stricture (follow up period 12 months)*	Group1: 1/50 Group 2: 1/50 p value: NR	statistical analysis			
	Group 2 - TURP N: 50 Mean age ± SD (yrs): 67.4± 7.3 Ethnicity: 34/50 (68%) white. Mean AUA score ± SD: 21.2 ± 6.1 Erectile dysfunction (full): 21/50		Post-op complications number of patients incontinence (follow up period 12 months)*	Group1: 1/50 Group 2: 1/50 p value: NR				
	(42%) Prostate volume (TRUS) ml: 29.6 ± 15.4 Mean PSA ng/ml ± SD: 3.2 ± 2.2 Mean Qmax ± SD (ml/s): 7.3± 3.7 Operation time mins: 56 (45-90) Drop outs: Mean catheterisation time (days): NR	P cc n w re (f	Post-op complications number of patients with urinary retention (follow up period 12 months)	Group1: 3/50 Group 2: 1/50 p value: NR				
	Mean length of stay (days): NR			-				

Study Details	Patients	Interventions	Outcome measures	Effect size	Comments		
Suvakovic & Hindmarsh,1996 ²⁴⁹ Study design: RCT, open label	Patient group: Consecutive patients with prostatic symptoms Setting:	contact laser alone Nd: YAG laser applied at 40W for vaporising and coagulating the prostate with a	contact laser alone Nd: YAG laser applied at 40W for vaporising and coagulating the prostate with a minimum depth of penetration. a 16 F two –way catheter was	contact laser alone Nd: YAG laser applied at 40W for vaporising	IPSS symptom score, mean ± SD at 3 months	Group 1: 9.7 \pm 2.6, n=10 Group 2: 12.8 \pm 5.9, n=10 p value: 0.15 (calculated by NCGC using t test with unequal variances using ITT analysis)	Funding: NR Limitations: • Small sample size
Evidence level: 1+ Duration of follow-up:	Urology department, South Cleveland University, UK Inclusion Criteria: • Qmax ≤15mL/s for a			IPSS symptom score, mean ± SD at 6 months	Group 1: 8.7 ± 5.4, n=9 Group 2: 8.5 ± 3.0, n=10 p value: 0.91 (calculated by NCGC using t test with unequal variances using ITT analysis)	n of 10 in each arm Unclear which statistical test wa used for data –	
 1 year Age Significant voiding symptoms (AUA score >15) PSA level <2.5 ng/mL Prostate volume <40g (assessed by TRUS, DRE 	Group 2 : TURP Standard resection using a 26 F continuous irrigating resectoscope.	IPSS symptom score, mean ± SD at 12 months *Values for 12 months follow up reported in paper, but n was not reported	Group 1: 8.7 ± 4.9, * Group 2: 7.2 ± 6.1, * p value: 0.55 (calculated by NCGC using t test with equal variances using ITT analysis)	 discrepancies in the stat sig reported for AUA score for 3 month and calculated by NCGC team. Randomisation 			
	 and cystoscopy) Length of the prostatic urethra >4 cm 	urethral catheter was inserted into the bladder and irrigation was continued up to 24 h. The catheter was removed after 48 h and the patients discharged home 3-4 days after the procedure. All patients received preoperative oral antibiotics and controlled for more than 5 days post- operatively	urethral catheter was inserted into the	Qmax mean ± SD at 3 months	Group 1: 15.6 ± 13.5, n=10 Group 2: 17.8 ± 3.8, n=10 p value: NR	method and allocation concealment not reported.	
	Exclusion Criteria:Malignancy		Qmax mean ± SD at 6 months	Group 1: 18.7 ± 7.5, n=9 Group 2: 19.0 ± 0.8, n=10 p value: NR	Masking of outcome assessment not		
	All patients N: 40 Group 1 - CLAP- contact laser alone N: 10		Qmax mean ± SD at 12 months *Values for 12 months follow up reported in paper, but n was not reported	Group 1: 23.5 ± 5.9, * Group 2: 15.2 ± 2.7, * p value: NR	 reported. Number of participants followed up at 12 months not reported. 		
	Age (mean): 62.6(5.8) an IPSS: 18 (6.0) co Qmax ml/s: 12.2 (3.8) the Residual Vol mL: 139.6(103) op Prostate size (by TRUS), g:		Post-op complications: Catheter duration, mean, hours (range or standard deviations NR)	Group 1: 24, n=10 Group 2: 48, n=10 p value: NR	Complications were poorly reported Notes:		
	24(5.8)		Post-op complications	Group 1: 30, n=10	None.		

Study Details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean catheterisation time (days): 1 ± NR Mean length of stay (days): 1.3 ± NR Group 2 - TURP Standard resection N: 10 Age (mean): 66.1(5.1) IPSS: 18.8 (4.5) Qmax ml/s: 11.1(6.4) Residual Vol mL: 161.8(104) Prostate size (by TRUS), g: 22(5) Mean catheterisation time (days): 2 ± NR Mean length of stay (days): 3.5 ± NR	Examination methods: At 3, 6 12 months AUA score, PSA, flow rate, PVR measured and TRUS performed	Length of hospitalisation, (hours)	Group 2 : 84, n=10	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Tuhkanen et al., 2001 ²⁵⁹ Study design: RCT Evidence level: 1+ Duration of follow-up: 24 months	 Patient group: Patients with BPH and BOO that were referred to the outpatient clinic at Kuopio university hospital from January 1995 to November 1997. Setting: Urology department, Finland Inclusion Criteria: Obstructed if min. voiding pressure > 40cm water prostate volume 40-100ml (TRUS) 	Group 1: laser (hybrid) Initial noncontact Nd:YAG coagulation 40W power asset for 90 sec burn times. Followed by a contact Nd:YAG vaporisation to open prostatic urethra. Vaporised at 40W. Urethral catheter was inserted for one day. Postoperatively the suprapulae catheter	Mean (range) symptom score (DanPSS-1) Qmax mL/sec (range)	At 3 months Group1 (n=21): 10.0 (0-49) Group 2 (n=22): 5.6 (0-27) At 6 months Group1 (n=19): 5.5 (0-21) Group 2 (n=21): 4.7 (0-22) At 24 months Group1 (n=17): 7.2 (0-25) Group 2 (n=20): 3.4 (0-21) At 3 months Group1: 13.7 (4.9-27.5) C 2 01 (2.0 (1 0))	Funding: NR Limitations: • Randomisation method, allocation concealment and masking of outcome assessment were not reported
2-1 11011113	 Exclusion Criteria: prostate cancer or surgery urinary retention <u>All patients</u> N: 46 Drop outs: 9 (20%) 	suprapubic catheter removed when the patient could urinate and residual urine was less than 150ml. Spinal anaesthesia. Group 2: TURP 28 F Storz resectoscope		Group 2: 21.0 (3.2-41.9) <u>At 6 months</u> Group1: 14.4 (7.9-20.7) Group 2: 19.6 (4.1-43.2) <u>At 24 months</u> Group1: Group 2: 20.6 (9.5-38.9)	 uses DanPSS-1 score standard deviations not reported Additional outcomes: Average urinary flow
	Broup 1without application of the suprapubic catheter. Spreader and suprapublic catheter. Spreader	Examination methods: Patients reviewed at 3, 6,	Residual urinary volume, ml	At 3 months Group1: 77 (0-162) Group 2: 54 (0-210) <u>At 6 months</u> Group1: 69 (0-160) Group 2: 45 (0-177) <u>At 24 months</u> Group1: 114 (28-202) Group 2: 58 (0-166)	rate reported. Notes: Linked to Tuhkanen 1999a ²⁶⁰
	PVR ml (range): 125 (0-350) Drop outs: 4 (1=died cardiac infarct 5 months post-operatively; 3=underwent TURP -	Qmax, PVR, DRE were recorded at each visit. TRUS was performed for	Reoperation rate (24 months follow-up):	Group1: 3/21 Group 2: 2/25	
	Mean prostate size: 55 (42-83)ml Mean catheterisation time (days): NR	suspicious cancer cases	Retrograde ejaculation at 3 months	Group1: 3/16 Group 2: 12/14	1

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean length of stay (days): 4.0 (2-9) <u>Group 2 -</u> N: 25 Age (mean): 67 (46-77) Mean (range) symptom score (DanPSS-1): 22.8 (5-69) Prostate volume: 55 (40-95) Qmax ml/s (range): 7.2 (3.7-14.8) PVR ml (range): 138 (0-450) Drop outs: 5 (2=prostatic adenocarcinoma at initial operation, 1=internal urethrotomy for distal urethral stricture at 5 months; 1=died unknown causes at 13 months; 1=re-TURP due to overflow incontinence) Mean prostate size: 55 (40-94)ml Mean catheterisation time (days): NR Mean length of stay (days): 3.5 (1-8)		Complications	Transfusion: Group1: 1/21 Group 2: 2/25 Mortality Group1: 1 (myocardial infarction at 5 m) Group 2: 1 (unknown at 13 m) Stricture (internal urethrotomy treatment) Group 1: 0/21 Group 2: 1/25 Incontinence (overflow at 13m) Group 1: 0/21 Group 2: 1/24 Urinary retention (at 17 months and underwent TURP) Group 1: 2/21 Group 2: 0/25	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Tuhkanen et al., 2003 ²⁵⁸	Patient group: LUTS with confirmed BOO recruited from September 1994 – January 1998. Prostate volume less than	Group 1: Contact laser vaporisation Porsatic urethra	Median (range) DanPSS-1 symptom score	At 3 months: mean Group1 (n=25): 6 (7) Group 2 (n=25): 5 (6)	Funding: Financially supported by University of Kuopio.
Study design: RCT	40ml. Setting: Finland	vaporised with an Nd:YAG laser at a power setting 40W.		At 6 months: mean Group1: 6 (9) Group 2: 5 (7)	Limitations:
Evidence level: 1+	Inclusion Criteria:	Urethral catheter inserted for one day.		At 48 months Group1: (n=22): 5 (0-34)	 Randomisation method, allocation
Duration of follow- up:	 minimum volume of ≥120ml 	Spinal anaesthesia. Ciproflaving eve and		Group 2: (n=20): 4 (0-18)	concealment and
4 years	 minimum voiding detrusor pressure>40 cm water 	morning of operation.	Mean (SD) Qmax, mL/s	At 3 months Group1: 15.0 (5.2) Group 2: 19.0 (9)	masking of outcome assessment were
	Exclusion Criteria:			<u>At 6 months</u>	not reported
	 prostate cancer, prostate surgery or history of TUIP or TURP prostate size>40ml 	Group 2: TURP Ciproflaving eve and morning of operation.		Group1: 17.9 (7.1) Group 2: 21.1 (9.7) At 48 months – median (range)	 uses DanPSS-1 score Patient numbers
	urethral structure	Spinal anaesthesia.		Group1: 14.3 (10.1-33.6) Group 2: 16.1 (7.7-39.6)	not clear at 6 months
	 neurogenic bladder dysfunction residual volume>350ml 	Examination methods: Patients reviewed at 3, 6, 12, 24 and 48 mths	PVR, ml	At 3 months – mean (SD) Group1: 44 (39)	 2 patients in TUR group refused
	All patients N: 52	DanPSS-1, urinalysis, serum creatinine, serum		Group 2: 36 (39) At 6 months - mean (SD)	follow-up due to good subjective
	Drop outs: 10	PSA, Qmax, PVR, DRE were recorded at each		Group1: 50 (64) Group 2: 32 (37)	outcomes.
	Group 1	visit.		<u>At 48 months – median (range)</u>	Notes: Median values
	N: 26 Age (mean): 68 (56-82) Median (range) DanPSS-1 symptom	Urodynamics and TRUS were performed at 6 months and 4 years		Group1: 60 (0-380) Group 2: 10 (0-90) P<0.05	reported at baseline and 48 months in
	score: 18 (5-54) Qmax (mean ± SD) ml/s: 9.0 ± 3.8		UTI (epididymitis) ejaculation at 6 mths	Group 1: 0/26 Group 2: 1/26	Tuhkanen 2003. Earlie study (Tuhkanen 1999 reports mean (SD) for
	Mean prostate volume (range) ml: 30 (15-37) Median PVR ml (range): 87 (0-331) Mean catheterisation time (days): NR		Retrograde ejaculation at 6 mths	Group 1: 1/16 (6%) Group 2: 13/16 (81%)	baseline, 3 months an 6 months.
	Mean length of stay (days): 3.4 (2-7) Drop outs: 4 (3 died of BPH-unrelated		Mortality at 4 years	Group 1:3/26 Group 2: 1/26	-

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	causes and one underwent TURP at 2 years postoperatively due to gross haematuria, residual adenoma tissue and bladder stones)		Reoperation rate at 4 years	Group 1:1/26 Group 2: 1/26	
	Group 2 - N: 26 Age (mean): 67 (55-77) Median (range) DanPSS-1 symptom score: 18 (4-46) Qmax (mean ± SD) ml/s: 8.2 ± 3.2 Mean prostate volume (range) ml: 28 (15-38) Median PVR ml (range): 83 (8-350) Mean catheterisation time (days): NR Mean length of stay (days): 2.9 (2-5) Drop outs: 6 (1 died of BPH-unrelated causes, 2 diagnosed with prostatic carcinoma, one patient with bladder neck stenosis and underwent a re-TURP, 2 refused reviews due to good subjective outcomes).				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments				
Van Melick et al., 2003 ²⁶⁵	Patient group: men over 45 years with LTUS associated with BPH that were	vaporisation	Mean (± SD) symptom score (IPSS) at 6 months	Group1 (n=33): 5.9 ± 5.5 Group 2 (n=37): 3.2 ± 2.7	Funding: NR.				
Charles de claras	recruited from their clinic from1996 to 2001	Transurethral catheter post-operation	Mean (± SD) symptom score (IPSS) at 12 months	Group1 (n=37): 3.6 ± 3.4 Group 2 (n=41): 4.1 ± 4.8	Limitations:				
Study design: RCT	Setting: Netherlands	SLT Nd:Yag (MTRL sapphire tip) through Morgenstern scope	Mean (± SD) symptom score (IPSS) at 1-4 years	Group1 (n=10): 9.3 ± 5.2 Group 2 (n=15): 5.8 ± 7.5	 Randomisation method was not described and masking of outcome 				
Evidence level:	Inclusion Criteria: patient with lower urinary tract symptoms suggestive of	irrigated with isotonic salt solution.	Mean (± SD) symptom score (IPSS) at 4-7 years	Group1 (n=17): 8.3 ± 6.4 Group 2 (n=15): 7.3 ± 7.1	assessment was not reported.				
1+ Duration of	BPH; met ISC criteria for BPH, Schafer obstruction score≥ 2, prostate size between 20-65ml.	Pre-procedural antibiotics and transurethral catheter	Mean (SD) Global quality of life score at 6 months	Group1: 0.8 ± 1.0 Group 2: 0.5 ± 0.5	• High attrition rate at 1-7 years and 4-7 years				
follow-up: Up to 7 years	Exclusion Criteria: age ≤45 yrs	postoperatively.	Mean (SD) Global quality of life score at 12 months	Group1: 0.6 ± 0.9 Group 2: 0.6 ± 0.8	Additional outcomes: Frequency during day,				
	All patients N: 95	Group 2: TURP Stabdard 24FR	Mean (SD) Global quality of life score at 1-4 years	Group1: 2.0 ± 1.0 Group 2: 1.1 ± 1.2	frequency during night, symptom problem index and				
	Group 1 N: 45 Age (mean) ± SD: 67 ± 9	resectoscope using glycine for irrigation. Suprapubic catheter if required peri- operatively.	glycine for irrigation. Suprapubic catheter if required peri- operatively.	glycine for irrigation. Suprapubic catheter if required peri-	Mean (SD) Global quality of life score at 4-7 years	Group1:1.4 \pm 1.2 Group 2: 1.3 \pm 1.3	BPH impact index. Uroflowmetry also reported.		
	IPSS (mean) ± SD: 18.9 ± 6.8 Mean prostate size, ml: 37 ± 11				required peri- operatively.	required peri- operatively.	required peri- operatively.	required peri- operatively.	required peri- operatively.
	Mean (SD) Global quality of life score: 3.7 ± 1.6	Pre-procedural antibiotics and transurethral catheter	Qmax mean ± SD at 12 months	Group1: 27 ± 12 Group 2: 23 ± 10	(up to 6 months), Van Melick 2003				
	Mean Qmax \pm SD ml/s: 12 ± 4 Follow-up 1 to 4 years = 15 Follow-up 4 to 7 years=15	postoperatively.	Qmax mean ± SD at 1-4 years	Group1: 19 ± 6 Group 2: 20 ± 5	Follow up time varied individually as all patients				
 ± 0.4 Mean length of stay (days): 3.8 ± 1.3 Mean catheterisation time (days): 2.1 ± 0.9 Drop outs: 8 at one year post-operatively (procedure during surgery changed for medical reasons=3, 	Urodynamic studies vears	Qmax mean ± SD at 4-7 years	Group1: 19 ± 9 Group 2: 17 ± 8	were analysed within a 2 month period. Depending on					
	Mean catheterisation time (days): 2.1 ± 0.9 Drop outs: 8 at one year post- operatively (procedure during surgery	baseline and 1-6 weeks, 3, 6, 12 months	Post-op complications: urethral stricture (within 12 mths)	Group1: 2/45 Group 2: 2/50	the individual follow-up time, patient divided into two groups: those with a follow-up time between 1 and 4 years and those with follow up time between 4 and 7 years.				
	equipment failure resulting in TURP)=2, reoperation –TURP=1, reoperation – due to stricture =2)		Post-op complications: mortality (within 12 mths)	Group 1: 0/45 Group 2: 2/50					

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<u>Group 2</u> N: 50		Post-op complications: transfusion required (within 12 mths)	Group 1: 0/45 Group 2: 1/50	
	Age (mean) ± SD: 66 ± 8 IPSS (mean) ± SD: 16.8 ± 6.0 Mean prostate size, ml ± SD: 37 ±		Post-op complications: urinary retention (within 12 mths)	Group 1: 5/45 Group 2: 0/50	
	11 Mean ± SD Global quality of life score: 3.8 ± 1.5		Reoperation rate (TURP) within 12 mths	Group 1: 1/45 Group 2: 2/50	
	Mean Qmax \pm SD ml/s: 11 \pm 4 Follow-up 1 to 4 years = 10 Follow-up 4 to 7 years=17				
	Mean length of stay (days): 3.9 ± 0.9 Mean catheterisation time (days): 2.8				
	± 3.1 Drop outs: 9 at one year post- operatively (surgery cancelled=1, mortality=2, morbidity=2, emigrated=1, reoperation (TURP) =2, reoperation (stricture)=1)				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments			
Zorn et al., 1999 ²⁸²	Patient group: military beneficiaries with symptomatic BPH – recruited from June 1995 to June 1996	Group 1: Laser vaporisation contact laser	AUA symptom score	At 1 month Group1: 9.6 (n=20) Group 2: 11.0 (n=12)	Funding: NR Limitations:			
Study design: RCT	Setting: Walter Reed Army Medical Centre and Madigan Army Medical Centre, US	vaporisation of the prostate (CLVP)		At 6 months Group1: 9.1 (n=19) Group 2: 8.2 (n=10)	 Randomisation method, allocation concealment and masking of outcome 			
Evidence level: 1+	Inclusion Criteria: • symptomatic BPH	Nd:YAG laser. Power (w): CLVP 50-60. Performed under		At 12 months Group1: 8.4 (n=18) Group 2: 4.7 (n=7)	 assessment were not reported Standard deviations were 			
Duration of follow-up: 12 months	 Qmax<15ml/s Age > 50 	general or regional anaesthesia	Qmax	<u>At 1 month</u> Group1: 19.3 (n=20)	not reported.			
	 AUA score 13 or more PVR>125ml Prostate volume <45a 			Group 2: 21.4 (n=12) At 6 months	Additional outcomes: Results for 5 patients that had CHRP (see notes).			
	 Prostate volume <45g Exclusion Criteria: 	Group 2 : TURP Performed under general or regional		Group1: 20.0 (n=18) Group 2: 23.1 (n=10) <u>At 12 months</u>	Notes:			
	 previous surgical therapy for BPH known prostate, bladder, urethral or 	anaesthesia.	anaesthesia.	anaesthesia.	anaesthesia.		Group1: 20.0 (n=18) Group 2: 26.9 (n=6)	There was another group of patients (n=5) with prostate
	neurological conditions that could affect the bladder		Transfusions	Group 1: 0/21 Group 2: 0/12	volumes >45 mL that underwer coagulation and haemostatic resection of the prostate (CHRP			
	All patients N: 33		Re-catheterisation	Group 1: 3/21 (14.0%) Group 2: 3/12 (25.0%)	2:1 randomisation method			
	<u>Group 1</u> N: 21 Age (mean): 70.6		Urethral strictures	Group 1: 0/21 Group 2: 0/12				
	Drop outs: 3 IPSS: 24.0 Prostate size: 29.9		Reoperations:	Group 1: 0/21 Group 2: 0/12				
	Qmax (mean) ml: 8.7 AUA symptom score (mean): 24.0 Mean length of stay (days): 1.2 ± NR Mean catheterisation time (days): 1.1 ±							
	NR							

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Group 2 - N: 12 Age (mean): 69.0 Drop outs: 5 (1 diagnosed with prostate cancer and had radical prostatectomy so not included in baseline data) IPSS: 24.7 Prostate size: 33.9 Qmax (mean) ml: 9.0 AUA symptom score (mean): 24.7 Mean length of stay (days): 2.5 ± NR Mean catheterisation time (days): 1.7 ± NR				

Evidence Table 28: Laser vs. open prostatectomy

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Skolarikos et al., 2008 ²⁴²	Patient group: Men recruited from March 2005 to April 2006.	Group 1: Laser Photoselective vaporisation PVP) using	Median (25-75 centile) Symptom score, IPSS	Baseline Group1: 20 (15-22.5) Group 2: 21 (16.2-23.7); p=0.399	Funding: NR Limitations:
Study design: Randomised controlled trialInclusion criteria: Age > 50 years, LUTS due to BPH, prostate volume on TRUS >80cc, IPSS>12, medical therapy failure, no alpha blockers during the last month, no 5AR over the last 3 months, post void residual<150ml, peak urinary flow arte<12ml/sec.Evidence level: 1+Exclusion criteria: neurogenic bladder, history of adenocarcinomo of the prostate, urethral stricture, previous prostatic, bladder neck or urethral surgery, no urethral catheter at baseline, history of	high power potassium titanyl phosphate laser (KTP) PVP performed with an 80 watt KTP side-firing laser system. A flexible green light PV ADDStat fiber was used through a modified 23F continuous irrigation 12* Storz cystoscope. Isotonic saline used for irrigation. At end of procedure a 20F triple lumen catheter was inserted into the		1 month Group 1: 12 (12-13.5) Group 2: 12 (10-16); p=0.019 3 months Group 1: 10 (8-12 Group 2: 10 (7-12); p=0.743 6 months Group 1: 9 (7-12) Group 2: 9 (7-12); p=0.224 12 months Group 1: 9 (7-12) Group 2: 8 (7-12); p=0.128 18 months Group 1: 10 (7-12) Group 2: 8.5 (7-12); p=0.063	Patients significantly older at baseline in the laser group. Allocation concealment method unclear. Additional outcomes: 1, 3, 6, 12 month outcomes for prostate size, PSA, post void residual and IIEF scores Notes: 5 laser patients the resectoscope was used	
	bladder cancer, indwelling urethral catheter. All patients N: 125 Drop outs: NR Group 1 N: 65 Median (25-75 centile) Age: 74 (67-80) Group 2 N: 60 Median (25-75centile) Age:67.5 (65-74)	bladder for irrigation to start. Group 2: Open prostatectomy (OP) Transvesical approach used. At end of the procedure a 22F triple lumen catheter inserted into the bladder and irrigation was initiated. A suprapubic catheter was inserted whenever the surgeon thought extra irrigation needed.	Median (25-75 centile) IPSS quality of life question	Baseline Group 1: 3 (2-4) Group 2: 3 (2.25-4) p=0.520 1 month Group 1: 2 (1-2) Group 2: 2 (1-2) p=0.283 3 months Group 1: 1 (1-2) Group 2: 2 (1-2) p=0.995 6 months Group 1: 1 (1-2) Group 2: 1 (0.25-1) p=0.024 12 months Group 1: 1 (1-2) Group 2: 1 (1-1) p=0.035 18 months Group 1: 1 (1-2) Group 2: 1 (1-1) p=0.001	at some Ooint of the operation to achieve hemostatis. When optimal view restored, the KTP laser reused to finish operation.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Median (25-75 centile) Qmax, ml/s	BaselineGroup 1: $8.6 (6.7-10.5)$ Group 2: $8 (5.8-10.2) p=0.283$ 1 monthGroup 1: $13.4 (10.7-15)$ Group 2: $12.5 (10.7-15) p=0552$ 3 monthsGroup 1: $16 (14-18)$ Group 2: $15.1 (12.6-17) p=0.255$ 6 monthsGroup 1: $16 (13.9-18.8)$ Group 2: $15.6 (12.8-17.1) p=0.220$ 12 monthsGroup 1: $16 (13.7-19)$ Group 2: $15.1 (13-17.5) p=0.186$ 18 monthsGroup 1: $16 (13.5-18.9)$ Group 2: $15 (13-17.4) p=0.271$	
			Median (25-75 centile) PVR, ml	Baseline Group 1: 97 (6-124) Group 2: 89 (50-120) 18 months Group 1: 15 (0-33.5) Group 2: 12 (0-25); p=0.281	
			Median (25-75 centile) IIEF-5	Baseline Group 1: 12 (8-16 Group 2: 12 (7-16 18 months Group 1: 12 (7-17) Group 2: 12 (9-17); p=0.987	
			Median (25-75 centile) P-size, ml	Baseline Group 1: 93 (85-100) Group 2: 96 (86.2-100) 18 months Group 1: 55 (45-65) Group 2:10 (5.5-15); p<0.001	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Median (25-75 centile) PSA, ng/dl	Baseline Group 1: 6.2 (3.1-8.44) Group 2: 6.3 (2.9-8.6) 18 months Group 1: 2.4 (1.8-3.6) Group 2: 2 (1.4-2.6); p=0.025	
			Median (25 th -75 th centile) Catheter removal (hours)	Group1: 24 (20-36) Group 2: 120 (96-144); p< 0.001	
			Median (25 th -75 th centile) Hospital stay (hours)	Group1: 48 (24-48) Group 2: 144 (120-144); p< 0.001	
			Median (25 th -75 th centile) Operation time (minutes)	Group1: 80 (70-90) Group 2: 50 (45-60); p< 0.001	
			Number (%) Adverse events	Stress/urge incontinence Group 1: 0 Group 2: 0 Intra-operative TURP-hemotasis Group 1: 5 (7.69) Group 2: 0 Peri-operative blood transfusion Group 1: 0 Group 2: 8 (13.3) Transurethral resection syndrome Group 1: 0 Group 2: NR Urethrogragia Group 1: 1 (1.54) Group 2: 0 Pulmonary infection Group 1: 0 Group 2: 1 (1.67) Prolonged dysuria Group 1: 5 (7.6) Group 2: 7 (11.6) Culture confirmed UTIs	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Group 1:14 (21.5) Group 2: 16 (27) Re-catheterisation Group 1: 7 (10.7) Group 2: 10 (16.67) Re-operation Group 1: 3 (4.62); urethral strictures (2), persistent bladder outlet flow obstruction symptoms (1) Group 2: 3 (5); urethral stricture (1), bladder neck contracture (2) Mortality Group 1: 1 (liver cancer) Group 2: 0	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Norby et al., 2002a ¹⁹² Study design: Randomised controlled trial (RCT) Evidence level: 1+	Patient group: Men ≥ 50 years between May 1996 and November 1999. Inclusion criteria: IPSS ≥ 7, QoL. ≥ 3, obstructed according to ICS nomogram or Qmax <12mL/s; able to understand	Group 1: LASER Interstitial laser coagulation. NdYag: 7- 20W. Median length of stay was 3 days. Median catheter duration was 3 days	Mean (SD) IPSS:	Baseline: Group 1: 21.4 (5.8), n=44 Group 2: 20.5 (5.7), n=46 Group 3: 21.3 (6.6), n=22 6 Months: Group 1: 9.5 (6.6), n=44 Group 2: 9.5 (7.1), n=44 Mean difference: 0.00 [-2.86, 2.86] Group 3: 6.8 (5.7), n=22	Funding: Supported by a grant from Vejle County, Denmark. Limitations: Had to stop early due to financial restrictions and dic not reach target enrolment population.
Setting: Denmark (two centres) Duration of follow-up: 6 months	Exclusion criteria: suspicion of prostate cancer; PVR> 350mL or urinary catheter; prostatic urethra <25 mm long, neurological disease or diabetes with abnormal cystometry; previous prostate operation; ongoing UTI; previous diagnosis of rectal cancer, intake of mediation known to influence voiding; sever peripheral arterial insufficiency;	Transurethral microwave thermotherapy (TUMT). Prostatron 2.0 (n=8) or 2.5 (n=37). Performed as an outpatient procedure (four stayed overnight and 1 patient for 2 nights). Median catheter duration was 7-14 days	Median (IQR) IPSS Quality of life:	Baseline: Group 1: 4 (4-4), n=44 Group 2: 4 (4-4), n=46 Group 3: 4 (4-5), n=22 6 Months: Group 1: 1 (1-2), n=44 Group 2: 2 (1-3), n=44 Group 3: 1 (1-2), n=22	Additional outcomes: - Effect on prostatic volume. - Results also compared to control group that had either TURP or TUIP. - Overall satisfaction scores reported in comparison to control group. Figures not provided.
	All patients N: 118 Mean age: 66		Mean (SD) peak urinary flow (Qmax mL/s):	Baseline: Group 1: 10.2 (4.0), n=44 Group 2: 9.1 (4.2), n=46 Group 3: 9.6 (3.2) , n=22 6 Months: Group 1: 16.2 (8.5), n=43 Group 2: 13.2 (6.9), n=44 Group 3: 20.6 (12.8), n=22	 Subgroup analysis comparing results from TUMT 2.0 v TUMT 2.5. Notes: Reported in Cochrane Systematic Review by Hoffman 2000.
	Drop outs: 8 (6.7%) <u>Group 1</u> N: 48 Mean age (SD): 65 (8) Median catheter duration: 3 days	days and hospital stay 5 days.	Median (IQR) post void residual, mL	Baseline: Group 1: 117 (50-180), n=44 Group 2: 110 (50-210), n=46 Group 3: 75 (17-193), n=22 6 Months: Group 1: 58 (14-118), n=43 Group 2: 48 (24-129)n=44 Group 3: 23 (3-48), n=22	UTI defined as 'symptomatic UTI requiring antibiotic treatment (infections treated both in the outpatient clinical and in primary health care were included)'.

1 <u>Evidence Table 29 Laser vs. transurethral microwave thermotherapy (TUMT)</u>

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Median prostate volume, ml = 44 Dropouts: 4 (diagnosis changed for 3 and 2 declined surgery, of which one		Urinary retention:	Group1: 4/44 (9%) Group 2: 3/46 (7%) Group 3: 1/22 (5%)	* Erectile dysfunction and retrograde ejaculation was only estimated amongst
	reported IPSS at 6m and included in results).		Urinary tract infection:	Group 1: 27/44 (61%) Group 2: 14/46 (30%) Group 3: 3/22 (14%)	those who had answered the relevant questions both at baseline and at the 6
	<u>Group 2</u> N: 46 Mean age (SD): 66 (7)		Transurethral resection syndrome (TUR)	Group 1: 0/44 (0%) Group 2: 0/46 (0%) Group 3: 1/22 (5%)	month follow-up. Each question was scored from 0 to 3. For evaluation of ejaculation, patients scoring
	Median catheter duration: 7-14 days; with longer catheterisation required after higher energy procedures.		Transfusion:	Group 1: 0/44 (0%) Group 2: 0/46 (0%) Group 3: 2/22 (9%)	0, 1 and 2 (i.e. normal amount, slightly reduced and greatly reduced
	Median prostate volume, ml = 43 Drop outs: 2 (one had TURP, other had apoplexy at 4m and only had 3m		Stricture:	Group 1: 1/44 (2%) Group 2: 0/46 (0%) Group 3: 1/22 (5%)	amount of semen) were classified as having antegrade ejaculation.
	follow-up)		Urinary incontinence:	Group 1: 0/44 (0%) Group 2: 0/46 (0%) Group 3: 1/22 (5%)	Patients scoring 3 (i.e. no ejaculation) were classified as having retrograde ejaculation.
	<u>Group 3</u> N: 24 Mean age (SD): 68 (7) Median prostate volume, ml = 44		Development of erectile dysfunction:*	Group 1: 4/18 (29%) Group 2: 2/22 (9%) Group 3: 1/7 (14%)	elacolarion.
	Drop outs: 2 (prostate cancer)		Development of retrograde ejaculation:	Group 1: 9/26 (35%) Group 2: 6/27 (22%) Group 3: 7/14 (50%)	
			Reoperation for BPO	Group1: 0/44 (0%) Group 2: 1/46 (2%) Group 3: 0/22 (0%)	
			Mortality	Group 1: 0/44 (0%) Group 2: 0/46 (0%) Group 3: 0/22 (0%)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Abdelkhalek et al., 20034	Patient group: Symptomatic bladder outlet obstruction due to BPH	Group 1- Laser prostatectomy: combination of	All cause mortality (due to cardiopulmonary disease)	Group 1: 1/90 Group 2: 2/90 P value: NS	Funding: Not stated
Study design: RCT, open label Setting: Egypt Evidence level: 1+ Duration of follow-up: Up to 4 years	sign: coagulation and vaporisation method In Setting: urology and Nephrology Centre, Mansoura University, Egypt. i) Side firing Egypt. (March1995 to March 1997) i) Side firing Inclusion criteria: Qmax ≤10ml/s lateral beam ang Qmax ≤10ml/s of 90° at 40W f P: Prostate volume of 20- 90s at each years Prostate volume of 20- 12 o clock positions. ii) Vaporisation of two features	 vaporisation methods: i) Side firing coagulation of two lateral lobes using fibres with a lateral beam angle of 90° at 40W for 90s at each coagulation spot in the 2, 4, 8, 10 and 12 o clock positions. ii) Vaporisation of the median lobe using contact (sapphire) 	IPSS, mean± SD:	At 1 year Group 1: 13.3±6 Group 2: 5.6±3.5 p value: 0.003 At 2 year Group 1: 12.2±5.6 Group 2: 5.2±3.3 p value: 0.006 At 3 year Group 1: 13.1±5.7 Group 2: 4.8±2.6 p value: 0.002 At 4 year Group 1: 11.9±6.1 Group 2: 3.7±1.3 p value: <0.001	 Open label study with subjective patient reported outcomes. Randomisation and concealment methods not reported Additional outcomes: Prostate and adenoma volume at 1 and 4 years An additional 6 and 2 reoperations were completed for the laser ar TUVP groups respectively after the 4-year follow up
	 Contracted bladder Large vesicle diverticulum Neuropathic bladder All patients N: 180 Age, mean ±SD Drop outs: 40/180 Group 1-Laser prostatectomy N: 90 Dropouts: 28/90 Age, mean (years): 63.3±6.5 IPSS, mean (±SD): 27.9±5.3 IPSS-QoL, mean (±SD): 5±0.8 	median lobe using contact (sapphire) tips at 60W in a	IPSS-QoL mean ± SD:	At 1 year Group 1: 3.4 ± 0.4 Group 2: 1.4 ± 0.5 p value: 0.008 At 2 year Group 1: 3.2 ± 0.5 Group 2: 1.4 ± 0.4 p value: 0.009 At 3 year Group 1: 3.3 ± 0.6 Group 2: 1.4 ± 0.5 p value: 0.009 At 4 year Group 1: 3.1 ± 1.0 Group 2: 1.3 ± 0.5 p value: <0.001	None.

1 <u>Evidence Table 30 Laser vs. transurethral vapourisation of the pr</u>ostate (TUVP)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments				
	Qmax, mean, (±SD): 6.9±2.8 Post void residual urine, mean, (±SD): 120±97.5 Prostate volume, mean (±SD):43.8±13.4 Group 2 - TUVP N: 90 Dropouts: 12/90 Age, mean (years): 62.9±5.9 IPSS, mean (±SD): 26.0±5.8	an antegrade fashion. The median lobe was vaporised first, and continued down the surgical capsule until a wide prostatic cavity was created, followed by careful coagulation.	Qmax (ml/s), mean ± SD:	At baseline Group 1: 6.9±2.8 Group 2: 6.4±2.5 p value: 0.256 At 1 year Group 1: 15.1±6.0 Group 2: 20.8±7.4 p value: 0.029 At 4 year Group 1: 13.6±3.6 Group 2: 21.4±4.1 p value: <0.001					
	IPSS-QoL, mean (±SD): 4.8±0.9 Qmax, mean, (±SD): 6.4±2.5 Post void residual urine, mean, (±SD): 125±97.5 Prostate volume, mean; 47.4±16.1			Post void residual volume (ml), mean ± SD	At 1 year Group 1: 61.3±49.2 Group 2: 22.1±22 p value: <0.001 At 4 years Group 1: 64.6±29.8 Group 2: 25.1±12.8 p value: <0.001				
			Post-op complications: Bleeding at surgery (definition not provided)	Group1: 0/90 Group 2: 1/90 p value: NS					
							Post-op complications: Haematuria	Group 1: 0/90 Group 2: 2/90 p value: NS	
			Post-op complications: Urethral Stricture (urethral stricture, apparent after 6 months)	Up to 1 year Group 1: 0/90 Group 2: 2/90 p value: NS					
			Post-op complications: Bladder neck stenosis	Up to 1 year Group 1: 2/90 Group 2: 2/90					

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Post-op complications: Retrograde ejaculation	p value: NS <u>At 1 year</u> Group 1: 16/90 Group 2: 57/90 p value: <0.001	
			Post-op complications: Impotence (among patients who were potent at baseline)	At 1 year Group 1: 0/49 Group 2: 4/53 p value: 0.04	
			Post –op complications: Reoperation (cumulative) Details of type reoperation provided.	At 1 year Group 1: 10/89 Group 2: 3/889 p value: 0.04 At 2 year Group 1: 18/90 Group 2: 5/90 p value: <0.05 At 3 year Group 1: 27/90 Group 2: 8/90 p value: <0.05 At 4 year Group 1: 35/90 Group 2: 11/90 p value: <0.001	
			Operation time, mean (range), (min):	Group 1: 37.5±15 Group 2: 36.6±16.4 p value: NS	-
			Catheter period (days)mean ±SD	Group 1: 6.8 (0.9) Group 2: 2.3 (0.5) p value: <0.001	
			Length of hospital stay, (days) mean ±SD	Group 1: 1.1±0.5 Group 2: 2.2±0.8 p value: NS	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Shingleton et al., 1998 ²³⁷	Patient group: consecutive patients with benign prostatic hyperplasia	Group 1: VLAP + KTP (contact laser – vaporisation) KTP laser set at 40 watts for	AUA symptom score, mean (range)	Baseline: Group1: 19 (13-27) Group 2: 22.1(8-31)	Funding: NR
Study design: RCT Setting: USA Evidence level: 1+	Inclusion criteria: Consecutive patients (no further information) Exclusion criteria: Not stated All patients	initial vaporisation of all median and lateral lobe tissue. Nd:YAG beam used at 60 watts for 60 sec to create a series of craters in lateral lobes of the prostate.		3 months: Group 1: 5.9 (1-12) Group 2: 5.2 (2-24) 6 months: Group 1: 5.0 (0-10) Group 2: 5.2 (1-19) P value: NS between arms, stat sig compared to baseline	 Limitations: Randomisation allocation and concealment not reported No specific inclusion or exclusion criteria were stated in this paper.
Duration of follow-up: 6 months	N: 31 Randomised (ratio 2:1) Group 1	put in place without accompanying bladder irrigation.	Qmax , mean (range)	Baseline: Group1: 10.7 (0-11.8) Group 2: 7.7 (3.4-13.2) 3 months:	 No statistical methods provided.
	N: 11 Mean (range) Age: 67.5 (60-82) Mean prostate volume (cc): 34.6 (9.2 to 87.7) Erectile function: Full: 3/11 (27%) Partial: 5/11(45%) None: 3/11 (27%)	Group 2: Transurethral Electrovaporisation (TVP) High energy electrical current to vaporise tissue and create a zone of coagulation surrounding vaporised tissue cavity. Catheter protocol Set at initial 275 watts, but		Group 1: 17.6 (6.2-22) Group 2: 17.5 (7.6-24.9) 6 months: Group 1: 16.5 (7.1-24.9) Group 2: 14.3 (7.8-27.1) P value: NS for all P value: NS between arms, stat sig compared to baseline	Additional outcomes: 1 month outcomes % of patients who had improved more than 5 % compared to baseline at 6 th month follow up Notes:
	Dropouts: Not stated Group 2	increased to 300 watts in all patients. The coagulation setting was 40watts for all	Post-op complications: Clot retention	Group 1: 0/11 Group 2: 2/20 p value: NS	QoL was reported to be collected in method section but was not reported.
	N: 20 Mean (range) Age: 66.7 (48-77) Mean prostate volume (cc): 34.6(13.7 to 66.4)	patients. <u>Catheter protocol:</u> After procedure a 22F three	Post-op complications: haematuria (2 patient in laser group had clot retention)	Group 1: 2/11 Group 2: 6/20 p value: NS	Shingleton1998A – reported on the urodynamics outcome of a
	Dropouts: Not stated Erectile function: Full: 4/20 (25%) Partial: 7/20(35%)	way catheter was put in place and standard irrigation with normal saline begun.	Post-op complications: Post operative urinary retention	Group 1: 3/11 Group 2: 1/20 p value: NS	subset of the patients in thi cohort (10 patients in each arm). However, the basis o selecting this subset of
	None: 9/20 (47%)		Stricture (urethral stricture0	Group 1: 1/11 Group 2: 0/20 p value: NS	patients was not provided.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Post-op complications: Development of erectile dysfunction	Group 1: 1/11 Group 2: 2/20 p value: NS	Inclusion/exclusion criteria from Shingleton1998A Inclusion: >45 years, Qmax
			Operation time, mean, (min):	Group 1: 27.5 Group 2: 46 p value: <0.05	<15ml, no history of carcinoma and ability to undergo general anaesthesia.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Patient group: men over 45 years	Group 1: Laser	Mean (SD) symptom	At baseline:	Funding:
al., 2003 ²⁶⁴	with LTUS associated with BPH that	vaporisation	score (IPSS)	Group1: 18.3±8.2	NR.
	were recruited from their clinic	Transurethral catheter		Group 2: 16.6±5.6	
	from1996 to 2001	post-operation		Group 3: 20.3±6.8	Limitations:
Study design:		SLT Nd:Yag		<u>At 6 months</u>	Open label study
RCT	Setting: Netherlands	Pre-procedural antibiotics		Group1 (n=33): 5.9±5.5	
		and transurethral catheter		Group 2 (n=37): 3.2±2.7	Additional outcomes:
Evidence	Inclusion Criteria: patient with	postoperatively.		Group 3: 3.8±2.7	Frequency during day,
level:	lower urinary tract symptoms			<u>At 1 year</u>	frequency during night,
1+	suggestive of BPH; met ISC criteria	Group 2: TURP		Group1 (n=37): 3.6±3.4	symptom problem index
	for BPH, Schafer obstruction score≥	Suprapubic catheter if		Group 2 (n=41): 4.1±4.8	and BPH impact index.
Duration of	2, prostate size between 20-65ml.	required peri-operatively.		Group 3: 4.8±4.9	Uroflowmetry also
follow-up:	Exclusion Criteria: age ≤45 yrs	Pre-procedural antibiotics		<u>At 1-4 years</u>	reported.
Up to 7 years:		and transurethral catheter		Group1 (n=10): 9.3±5.2	
	All patients	postoperatively.		Group 2 (n=15): 5.8±7.5	Notes:
	N: 141			Group 3: 8.4±8.7	Links with Van Melick
	Group 1	Group 3:		At 4-7 years	2002 ²⁶³ , Van Melick
	N: 45	Electrovaporisation		Group1 (n=17): 8.3±6.4	2003 ²⁶⁴ .
	Age (mean): 67±9	Performed with a		Group 2 (n=15): 7.3±7.1	
	Drop outs: 8 at one year post-	Vaportrode element using		Group 3: 7.0±5.6	Follow up time varied
	operatively (procedure during	glycine for irrigation.	Mean (SD) Global	At baseline:	individually as all patients
	surgery changed for medical	Pre-procedural antibiotics	quality of life score:	Group1: 3.6±1.6	were analysed within a 2
	reasons=3, equipment failure	and transurethral catheter	4	Group 2: 3.9±1.6	month period. Depending
	resulting in TURP)=2, reoperation –	postoperatively.		Group 3: 4.3±1.3	on the individual follow-
	TURP=1, reoperation – due to			At 6 months	up time, patient divided
	stricture =2)			Group1: 0.8±1.0	into two groups: those with
	Mean prostate size, ml: 37±11			Group 2: 0.5±0.5	a follow-up time between
	Follow-up 1to 4 years = 15			Group 3: 1.0±0.8	1 and 4 years and those
	Follow-up 4 to 7 years=15			At 1 year	with follow up time
				Group1: 0.6±0.9	between 4 and 7 years.
	Group 2			Group 2: 0.6±0.8	
	N: 50			Group 3: 1.0±0.9	
	Age (mean): 66±8			At 1-4 years	
	Drop outs: 9 at one year post-			Group1: 2.0±1.0	
	operatively (surgery cancelled=1,			Group 2: 1.1±1.2	
	mortality=2, morbidity=2,			Group 3: 1.0±1.2	
	emigrated=1, reoperation (TURP)			At 4-7 years	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	=2, reoperation (stricture)=1) Mean prostate size, ml : 38±9 Follow-up 1to 4 years = 10 Follow-up 4 to 7 years=17			Group1:1.4±1.2 Group 2: 1.3±1.3 Group 3: 1.4±0.8	
	Group 3 N: 46 Age (mean): 64±10 Drop outs: 22 Mean prostate size, ml: 35±12 Follow-up 1to 4 years = 12 Follow-up 4 to 7 years=12		Mean (SD) maximal flow (mL/s)	$\begin{array}{c} \underline{At \ baseline:} \\ \hline \mathbf{Group1:} \ 9\pm3 \\ \hline \mathbf{Group 2:} \ 13\pm4 \\ \hline \mathbf{Group 3:} \ 9\pm3 \\ \underline{At \ 6 \ months} \\ \hline \mathbf{Group1:} \ 25\pm9 \\ \hline \mathbf{Group 2:} \ 26\pm6 \\ \hline \mathbf{Group 3:} \ 24\pm11 \\ \underline{At \ 1 \ year} \\ \hline \mathbf{Group1:} \ 27\pm12 \\ \hline \mathbf{Group 1:} \ 27\pm12 \\ \hline \mathbf{Group 1:} \ 23\pm10 \\ \hline \mathbf{Group 3:} \ 28\pm6 \\ \underline{At \ 1-4 \ years} \\ \hline \mathbf{Group1:} \ 19\pm6 \\ \hline \mathbf{Group 3:} \ 23\pm6 \\ \underline{At \ 4-7 \ years} \\ \hline \mathbf{Group1:} \ 19\pm9 \\ \hline \mathbf{Group 2:} \ 17\pm8 \\ \hline \mathbf{Group 3:} \ 16\pm11 \\ \end{array}$	
			Stricture	Group1: 2/45 Group 2: 2/50 Group 3: 1/46	
			Incontinence Reported in HTA (ncc study)	Group1: 14/45 (8%) Group 2: 4/50 (39%) Group 3: 15%	
			Reoperation by TURP	Group1: 1/45 Group 2: 2/50 Group 3: 2/46	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Blood transfusion	Group1: 0/45 Group 2: 1/50 Group 3: 0/46	
			Urinary retention	Group1: 5/45 Group 2: 0/50 Group 3: 0/46	
			Urinary tract infection (after one week)	Group1: 4/45 (9%) Group 2: 5/50 (10%) Group 3: 5%	
			Mean (SD) operative time, minutes:	Group 1: 58 (11) Group 2: 58 (26) Group 3: 50 (16)	
			Mean (SD) postoperative hospital days	Group 1: 3.8 (1.3) Group 2: 3.9 (0.9) Group 3: 3.4 (0.9)	
			Mortality: *cardiac failure, hepatic failure (HTA reports 3 v 4)	Group 1: 0/45 Group 2: 2/50* Group 3: 0/46	

1 Evidence Table 31 Laser coagulation vs. laser vapor	ourisation
---	------------

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Bryan et al.,	Patient group:	Laser	IPSS symptom score	At 1, 3, 12th months	Funding:
200033	Bladder outlet obstruction,	prostatectomy was	The data was shown in a graph, and	Group1 : No reported	Not stated
	BOO due to benign prostatic	carried out using a	values only reported for 6 th and 24 th	Group 2 : NR	
Study design:	hyperplasia, BPH.	SLT (Surgical Laser	month.	P value: NS	Limitations:
RCT, single		Technologies,		At 6 months	No sample size
centre – open	Setting:	Oaks, Pa, USA)		Group1: 8.3 ± 6.4***	calculation
study	Urology department, UK	neodymium:YAG		Group 2: 12.5** ± 6.4***	provided- small
	hospital	laser system with		p value: 0.05	sample size
Evidence level:		semi-rigid		At 24 months	 38% in CLAP and
1+	Inclusion Criteria:	endoscopic fibre		Group1: 13.5 ± 8.26*	24% in VLAP
	Ambulant male patients with	(SREF15) set a		Group 2: 13.3 ± 7.36*	group did not
Duration of	BOO due to BPH, confirmed	40W		p value: NS	perform
follow-up:	with pressure/flow			Compared to baseline	urodynamics at 6
2 years	urodynamics.	Group 1-CLAP		Group 1: P value= 0.006	months to
		A chiselled probe		Group 2: P value= 0.002	determine
	Exclusion Criteria:	(MD6) with a	Qmax	At 12 months	obstruction
	 Neurological disorders 	distal end		Group1: 16.6 ± 7.37*	
	affecting the urinary	incorporating a 6		Group 2: 17.5 ± 6.50*	Additional outcomes:
	tract	mm sapphire tippe		P value: NS	 Mean operating
	 Previous prostatic or 	d round probe		Compared to baseline	time
	urethral surgery	was used. The		Group 1: P value = 0.006	 Increased irritative
	 Clinical evidence of 	probe was		Group 2: P value= 0.002	symptoms which
	prostatic or vesicle	brought back to		At 24 months	returned to norma
	malignancy	the verumontanum		Group1: 15.5 ± 7.35*	after 1 month (5 ir
	 Acute urinary tract 	and then pushed		Group 2: 15.9 ± 10.15*	VLAP, 4 in CLAP)
	infection	forward to		P value: NS	
	 Prostate gland volume of 	produce furrows.		Compared to baseline	Notes:
	<20mm ³ On medication			Group 1: P value = 0.02	*SD estimated
	known to influence	Mean operating		Group 2: P value = 0.1	following the Cochrane
	voiding function.	time:37.7min		· ·	— handbook method
		SEM1.6	PdetQmax (cm H ₂ 0)	At 6 months	using p values
	All patients			Group1: 54.6	reported for change
	N: 38	Group 2 - VLAP		Group 2: 56.4	from baseline.
	Drop outs: 0	Laser energy		p value: 0.4	** estimated from
		applied using a		Both Sig different compared to	graph shown. Likely
				baseline p<0.005	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments			
	Group 1 - CLAP N: 21 Age (mean): 72.25, SE1.68 Drop outs: 0	side firing free beam probe (SFB 1.0), to the lateral lobes 1 cm distal	Post-op complications (early): Catheter duration, mean (range), days	Group1: 4.5(1-31) Group 2: 13.2 (7-70) p value: NR#	error in the value from text (21.3) ***SD estimated from standard error bars			
	IPSS: 20.9, SE1.6 Erectile dysfunction: 10, SE 21 (47.6%)	PSS: 20.9, SE1.6to the bladderrectile dysfunction: 10, SEto the bladdererctile dysfunction: 10, SEneck at 40W for90 max:10.0, SE 0.6890s each of 4Quadrants,: 2, 4,8, and 10 o' clockInequivocal obstruction,positions.oroven urodynamically:9/219/21Mean operatingi:179ge (mean): 71.88, SE 1.59Mean operatingOrop outs: 0PSS: 21.8, SE 1.5PSS: 21.8, SE 1.59.8OrdetQmax H20: 91.9, SE 9.8rectile dysfunction: 8/17	Post-op complications (early): Required Catheter > 7 days	Group1: 2/21 Group 2: 7/17 Relative risk: NS	from graph because p value for change from baseline was not			
	PdetQmax H20: 79.4, SE 9.48, andUnequivocal obstruction, proven urodynamically:position		8, and 10 o' clock positions.	4 8, and 10 o' clock positions.Mean operating	79.4, SE 9.48, and 10 o' clock positions.pstruction, mically:Mean operating	Post-op complications (early): Bladder irrigation	Group1: 5/21 Group 2: 0/17 Relative risk: 9.00 95% Cl: 0.53-152.1 p value: NS	reported in the results #No SD provided \$ 9 in the CLAP and 4 in the VLAP group were infirm or refused
	Group 2 - VLAP N: 17 Age (mean): 71.88, SE 1.59 Drop outs: 0 IPSS: 21.8, SE 1.5		Post-op complications (early): Blood transfusion	Group1: 1/21 Group 2: 0/17 Relative risk: 2.45 95% Cl: 0.11-56.7 p value: NS	to do urodynamics at 6 months post-op			
	Qmax:10.0, SE 0.8 PdetQmax H ₂ 0: 91.9, SE 9.8 Erectile dysfunction: 8/17 (47.1%)		Post-op complications (early): Peri-operative urinary tract infections	Group1: 1/21 Group 2: 2/17 Relative risk: 0.40 95% Cl: 0.04-4.09 p value: NS	_			
	Unequivocal obstruction, proven urodynamically: 16/17	Post-op complications: Developed erectile dysfunction	Group1: 1/21 Group 2: 1/17 Relative risk: 0.81 95% Cl: 0.05-12.01 p value: NS					
		Post-op complication: Reoperation:	Group1: 1/21 Group 2: 2/17 Relative risk: 0.40 95% Cl: 0.04-4.09 p value: NS					
		Unequivocal obstruction , proven urodynamically, at 6 months \$	Group1: 3/13 Group 2: 6/13 Relative risk: 0.50 95% Cl: 0.16-1.58 p value: NS					

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Narayan et al., 1995 ¹⁸³	Patient group: Moderate to severe obstruction, including 8 patients in chronic retention and had indwelling Foley catheter*	Group 1 CLAP- Evaporation Standard cystourethroscopy was performed before laser ablation.	IPSS symptom score, only mean value reported, no standard deviation provided	At 1 months Group 1: 9.9 Group 2: 9.8 At 3 months	Funding: Not stated Limitations:
Study design: RCT, multi-centre, open study	Setting: US, in two Veteran Affairs medical centres	Laser applied initially at the 5 and 7'o clock position at 60W until circular fibres of the bladder neck visible.		Group 1: 7.0 ± 14.81* Group 2: 8.4 ± 13.18* <u>At 6 months (N=52)</u> Group 1: 5.0 ± 16.73* Group 2: 5.1 ± 16.35*	 No mention of blinding of outcomes assessors. Relatively small
Evidence level: 1+ Duration of follow- up: 12 months	 Inclusion Criteria: Consecutive patients with moderate to severe obstructive symptoms as defined by AUA symptom score≥13 (midway of the 	Next, the median lobe was treated with laser at 45 degrees angle form the lobe form the right to left sides and vice versa. The ablation was completed by laser		At 12 months (N=15) Group 1: $5.3 \pm 16.45^*$ Group 2: $5.2 \pm 16.25^*$ P value: NR, not sig between arms at all time points (All P<0.001 compared to	sample size- not sample size calculation provided. There was a trend (not statistically
	 scale between mild and moderate obstructive symptoms) Qmax <15ml/s, with or without significant post void residual volume 	application at the 6 o'clock position deep enough to visualise the bladder neck muscle fibres and a smooth, bladder neck between 5 and 7 o'clock positions. Prostate evaporation was	Qmax (ml/s), only mean value reported, no standard deviation provided	At 1 months Group 1: 17 Group 2: 12.0 At 3 months Group 1: 19.7 ± Group 2: 16.3 ± 14.00* At 6 months (N=52) N=52)	significant) of older patients, with larger prostate size, higher number in retention, lower Qmax and higher post void residual
	Exclusion Criteria: Prostate cancer	then performed. Fibre help <u>in contact</u> with area treated and dragged at rate of 1 cm/20 to 30s. At		Group 1: $20.0 \pm 13.08^*$ Group 2: $16.4 \pm 9.04^*$ At 12 months (N=15) Group 1: $19.9 \pm 12.98^*$	volume in the evaporation group. Most continuous
	<u>All patients</u> N: 64 Drop outs:	the beginning each furrow dragging was commenced when bubbling was noted signifying evaporation of		Group 2: 16.9 ± 11.46* P value: <0.05 for all time points. (All P<0.05 compared to baseline)	variable outcomes only reported mean values- not standard

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Group 1 – CLAP-evaporation	tissue. Dragging the fibre at	Post void residual	At 1 months	deviation.
	N: 32	this rate resulted in furrow 5-	volume (ml), only mean	Group 1: 49	
	Age (mean, range): 66.0(49-78)	7 mm deep and with a 3-	value reported, no	Group 2: 46	Additional outcomes:
	Prostate volume (mean, range);	4mm rim of coagulated tissue.	standard deviation	At 3 months	Qmax, AUA symptom
	51.7(16-120)		provided	Group 1: 31	score and post void
	N patient in retention: 6/32			Group 2: 20	residual volume for 8
	Median lobe: 5/32	Group 2 VLAP-Coagulation		At 6 months(N=52)	patients in chronic
	Data excluding patients with	(modified visual laser		Group 1: 29	retention analysed and
	chronic urinary retention (n=26):	ablation technique)		Group 2: 24	reported separately.
	AUA symptom score: 22.4(14-	Laser application at 60W for		At 12 months (N=15)	There was no
	35)	60s to 11-19 spots		Group 1: 26	significant difference in
	Qmax: 6.4(0-15)	(depending on prostate size).		Group 2: 28	terms of improvement
	Post void residual volume:	Spots included 5 and 7 o'		P value: NR, not sig between	in AUA symptom score
	276.6(20-960)	clock positions at the bladder		arms at all time points	or Qmax.
		neck, the 6' o clock position		(All P<0.05 compared to	
	<u>Group 2 – VLAP-Coagulation</u>	for the median lobe and the		baseline)	Notes:
	N: 32	5, 7, 11, and 1 o'clock	Catheter duration,	Group 1: 1.9 (1-10)	# Calculated by
	Age (mean, range): 64.1(48-92)	position for each cm length of	Median (range), days	Group 2: 2.1 (1-21)	NCGC team using
	Prostate volume (mean, range);	the prostate. Each spot		p value: NS	Mantel Haenszel test in
	41.4 (20-62)	covered a 1 cm area.			Rev Man version 5.
	N patient in retention: $3/32$		Post-op complications	Group 1: 0/32	Values reported in
	Median lobe: 4/32	Fibre held 2-4 mm away from	(early):	Group 2: 0/32	paper were based on
	Data excluding patients with	tissue to ensure coagulation	Blood transfusion	p value: NS	chi-square test
	chronic urinary retention (n=29):	and not evaporation.	Post-op complications	Group 1: 0/32	(Pearson)
	AUA symptom score: 22.1(15-		(early): Epididymitis	Group 2: 0/32	
	30)			p value: NS	*SDs estimated
	Qmax: 70(0-14)		Peri-operative urinary	Group 1: 2/32	following Cochrane
	Post void residual volume:	Antibiotic prophylaxis:	tract infections (patients	Group 2: 1/32	methods using p values
	210(0-250)	All patients received cefazolin	operated in 2 hospitals,	Relative risk: 2.00	for change from
		1g/ml perioperatively and	all perioperative UTIs in	95% Cl: (0.19-20.97)	baseline
	* Patients who were in chronic	trimethoprim-	hospital which only	p value: NS #	
	retention were assigned "0"	sufamethoxazole double	provide 24-48 of	p vulue: 143 "	
	Qmax and not assigned any AUA	strength twice daily; one	prophylaxis.		
	score. These results were	hospital provide 24-48 hours			-
	analysed separately.	of prophylaxis whereas	Post-op complications:	Group 1: 0/32	
		another provided 10 days	Developed erectile	Group 2: 0/32	
			dysfunction	p value: NS	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Post-op complications: Incontinence	Group 1: 0/32 Group 2: 0/32 p value: NS	
				Group 1: 0/32 Group 1: 5/32 Relative risk: 0.09 95% Cl: 0.01-1.58 p value: NS	
			Post operative retention	Group 1: 2/32 Group 2: 8/32 Relative risk: 0.25 95% Cl: 0.06-0.94 p value: <0.05#	
				Group 1: 10/32 Group 2: 11/32 Relative risk: 0.87 95% Cl: 0.31-2.47 P value: NS	

4

5

See Evidence Table 26Laser coagulation vs. transurethral resection of the prostate (TURP)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Gilling et al., 1998 ⁹¹ Study design: RCT, open study	Patient group:Men with symptomatic benign prostatichyperplasiaSetting:Urology department, New ZealandInclusion Criteria:	Group 1- HoLRP Retrograde approach to the incision of the first and median lobe and then each lateral lobe in turn. This was performed using a 550micrometer bare quartz fibre passed down	IPSS symptom score , mean (range). All not sig between treatment arms.	At 1 month Group1: 8(0-16) Group 2: 11(2-26) p value: Not Sig At 3 months Group1: 4(0-12) Group 2: 8(0-26) p value: Not Sig	Funding: Not stated Limitations: No details of randomisation method and concealment was
Evidence level: 1+ Duration of follow-up: 12 months	 Qmax ≤15ml/s AUA symptom score >8 Urodynamically proven bladder outlet obstruction – defined as Schaefer grade of≥2 and at detrusor pressure at peak flow (PdetQmax) value in the obstructed or equivocal region of 	a continuous-flow resectoscope. Power setting was 60W. <u>Energy (kJ), mean (range):</u> 67 (32-165) <u>Mean lasing time, mean</u> (range)*: 27.2min (13-75)		At 6 months Group1: 5(1-16) Group 2: 7(0-22) p value: Not Sig At 12 months Group1: Group1: 4(0-9) Group 2: 5(1-18) p value: Not Sig	 provided Small sample size- sample size calculation not provided Open study Additional outcomes:
	Abrams-Griffiths nomogram Exclusion Criteria: Age≥85 years Prostate volume (measured by TRUS), >100ml All patients	Resection weight, g, mean (range): Estimated: 21(10-60) Actual : 5 (2-13) Catheter removed at 6 the following morning and discharged once voided successfully.	Dysuria score , mean, (no SD given) Measured using a visual analogue scale (VAS), ranging from 0 (no voiding symptom), 10 (severe dysuria)	First 10 post-operative days Group1: 2 Group 2: 4 p value: <0.05 First 5 days after catheter removal Group1: 2.1 (Day 1- 5) Group 2: 3.7 (Day 6-10) p value: <0.05	 % of men requiring analgesia for dysuria symptoms (64% VLAP, 41% for HoLRP) Mean duration of surgery – stats sig

1 Evidence Table 32 Holmium laser resection of the prostate (HoLRP) vs. laser coagulation

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
details	N: 44Drop outs: 0Group 1 -HoLRPN: 22N: 22Drop outs:All values provided as mean (range)Age : 64 (44-81)IPSS: 24(14-33)Qmax, ml/s: 8(3-15)PVR (TRUS volume), mL: 42(20-72)PVR (TRUS volume), mL: 42(20-72)PdetQmax H ₂ 0: 72(37-117)Shaffer Grade: 4 (2-5)Residual volume: 179 (30-40)Prostate length, cm: 3(2-5)Group 2 - VLAPN: 22Drop outs: 0All values provided as mean (range)All patients discharged the morning after surgery.		Qmax, mL/s, mean (range) Residual volume, mL, mean (range) PdetQmax (cm H20)	At 1 months Group1: 21(10-56) Group 2: 13(4-27) p value: <0.01	None.
	Shaffer Grade: 4 (2-5) Residual volume: 131 (40-227) Prostate length, cm: 3(2-6)	* Stats sig between groups	Catheter duration, mean	Group 2: 21% 95% CI: NR p value: NR Group1: 1.4 (1-8)	
			(range), days	Group 2: 11.6(3-8) 95% Cl: NR	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				p value: <0.0001	
			Post-op complications (early): Recatheterisation	Group1: 2/22 (9%) Group 2: 8/22 (36%) Relative risk: 0.25 95% Cl: 0.06-1.05 p value: NR	
			Post-op complications (early): Blood transfusion	Group1: 0/22 Group 2: 0/22 p value: NS	
			Post-op complications (early): Catheter irrigation (for hematuria)	Group1: 0/22 Group 2: 0/22 p value: NS	
			Post-op complications (early): Peri-operative urinary tract infections	Group1: 0/22 Group 2: 3/22 (13.6%) Relative risk: 0.14 95% CI: 0.01-2.61 p value: NS	
			Post-op complications: Retrograde ejaculation in sexually active patients (Number sexually active not stated)	Group1: 0/NR Group 2: 0/NR p value: NS	_
			Post-op complication: Reoperation: 3 in VLAP group had to be reoperated because of persistent urinary retention. 1 in the HoLRP group – urethral dilatation for submeatal stricture	Group1: 1/22 Group 2: 3/22 Relative risk:0.33 95% Cl: 0.04-2.96 p value: NS	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Elzayat	Patient group: Between March	Group 1: holmium laser	Mean (SD) symptom	Baseline:	Funding:
200970	2005 and April 2007 men with	ablation of the prostate	score (IPSS)	Group1 (n=57): 20 (6.8)	Author Elhilali has
	LUTS secondary to BPH were	(HoLAP)		Group 2 (n=52): 18.4 (6.6)	financial interest and/or
Study design:	recruited at McGill University Health	Performed using an 80 to		1 month:	other relationship with
RCT	centre, Canada.	100 watt holmium laser		Group1(n=54): 8.7 (6.5)	Lumenis and Laserscope
		generator and 550um		Group 2(n=48): 8.9 (5.4)	
Evidence	Inclusion criteria: prostate size 60cc	side firing laser fibre.		3 months:	Limitations:
level:	or smaller, IPSS of 9 or greater,	Laser setting ranged from		Group1(n=44): 8.4 (7)	Reasons for drop out no
1+	Qmax < 15ml/s.	2.0J and 50Hz to 3.2J		Group 2(n=39):5.8 (4.4)	reported.
		and 30Hz.		6 months:	Allocation concealment
Setting:	Exclusion criteria: previously			Group1(n=40):7.8 (5.7)	not reported.
Canada	diagnosed with prostate cancer,	Group 2: photoselective		Group 2(n=39):7.7 (6.9)	
	urethral stricture or nuerogenic	vaporisation (PVP)		12 months:	Additional outcomes:
Duration of	bladder or previous prostate	Performed using the green		Group1(n=44):6.2 (3.9)	IIEF erectile function
follow-up:	surgery.	light laser system with 80		Group 2(n=42):8.2 (6.2); p=0.22	domain score was
12 months		Watt output and side	Mean (SD) quality of	Baseline:	reported. Level of
	All patients	firing laser fibre with a	life from IPSS score	Group1 (n=57): 3.8 (1.5)	haemoglobin and serum
	N: 109	600 um core diameter.		Group 2 (n=52): 3.6 (1.4)	Na. PSA was reported.
				1 month:	
	<u>Group 1</u>	Both procedures:		Group1(n=54): 1.8 (1.6)	Notes:
	N: 57	Patient under general or		Group 2(n=48): 1.9 (1.6)	None.
	Mean age ± SD: 72.7±10.3	regional anaesthesia and		3 months:	
	Drop outs: 13	normal saline was used as		Group1(n=44): 1.5 (1.4)	
		an irrigant. Continuous		Group 2(n=39): 1.2(1.1)	
	Group 2	flow 26Fr resectoscope		6 months:	
	N: 52	with laser fibre stabilising		Group1(n=40):1.6 (1.3)	
	Mean age \pm SD: 71.6 \pm 10.3	bridge at the tip of the		Group 2(n=39):1.2 (1.1)	
	Drop outs: 10	inner sheath was used.		12 months:	
		After each laser		Group1(n=44):1.6 (1.2)	
		procedure a standard		Group 2(n=42):1.5 (1.4); p=0.81	
		22Fr 2-way catheter was	Mean (SD) Qmax	Baseline:	1
		inserted.		Group1 (n=57): 6.7 (3.9)	
				Group 2 $(n=52)$: 6.4 (3.9)	
		Catheter routinely		1 month:	
		removed the next morning		Group1(n=54): 17.1 (7.5)	
		after surgery and when		Group $2(n=48)$: 18.8 (8.5)	
		patient is able to void		3 months:	

Evidence Table 33 Holmium laser enucleation of the prostate (HoLEP) vs. laser vapourisation

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
		adequately he is discharged from the hospital.		$\begin{array}{l} Group1(n=44): 18.4 (6.4)\\ Group2(n=39): 18.7 (9.9)\\ \hline {\bf 6 \ months:}\\ Group1(n=40):17.4 (5.9)\\ Group2(n=39):19.4 (8.5)\\ \hline {\bf 12 \ months:}\\ Group1(n=44): 17.2 (8.4)\\ Group2(n=42): 18.4 (8.4); p=0.66 \end{array}$	
			Mean (SD) PVR	Baseline: Group1 (n=57): 205 (197) Group 2 (n=52): 215 (208) 1 month: Group 1 (n=54): 47.4 (93) Group 2 (n=48): 56.2 (79.5) 3 months: Group 1 (n=44): 57.2 (104) Group 2 (n=39):73.7 (96) 6 months: Group 1 (n=40): 55 (100) Group 2 (n=39):67.5 (90) 12 months: Group 1 (n=44):68.9 (90) Group 2 (n=42):66 (101); p=0.92	
		Mean (SD) laser time, minutes	Group1: 69.8 (31.6) Group 2: 55.5 (21) P=0.008		
			Mean (SD) catheterisation, days	Group1: 2.1 (2.7) Group 2: 1.65 (1.6) P=0.29	
			Mean (SD) hospital stay, days	Group1: 0.87 (0.3) Group 2: 0.96 (0.27) P=0.15	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Number (%)	Intraoperative bleeding	
			complications	Group1:0	
			-	Group 2: 3 (5.7)	
				Blood transfusions	
				Group1:0	
				Group 2: 0	
				Hematuria	
				Group1: 1 (1.7)	
				Group 2: 1 (1.9)	
				Irritative symptoms	
				Group1: 13 (22.8)	
				Group 2: 10 (19.2)	
				Re-catheterisation	
				Group1: 7 (12.2)	
				Group 2: 6 (11.5)	
				Clot retention	
				Group1: 1 (1.7)	
				Group 2: 1 (1.9)	
				Stress incontinence	
				Group 1: 1 (1.7)	
				Group 2: 2 (3.8)	
				Urge incontinence	
				Group1: 4 (7)	
				Group 2: 3 (5.7)	
				Urinary tract infection	
				Group1: 3 (5.3)	
				Group 2: 2 (3.8)	
			Number (%) late	Urethral stricture	
			postoperative	Group1: 1 (1.7)	
			complications	Group 2: 3 (5.7)	
				BNC	
				Group 1: 2 (3.5)	
				Group 2: 4 (7.7)	
				Reoperation	
				Group 1: 2 (3.5)	
				Group 2: 1 (1.9)	
			Mean prostate volume	Group1: 19.8	—

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			(cc) at 6 months	Group 2: 24.4; p=NS	

- 2
- 3

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Abbou et al., 1995 ³ Study design: Randomised controlled trial Setting: France Evidence level: 1+ Duration of follow-up: 12 months	Patient group: Men recruited from 7 urological departments with symptomatic prostatism that had voiding disorders for at least 3 months. Inclusion criteria: Men >50 years, peak flow rate <15 mL/s for a voided volume of ≥ 150 mL; and residual urine <300 mL/s. No suspicion of prostate cancer, prostate weight between 30 and 80g; PSA level < 10 ng/mL for a prostatic weight <60 g or a PSA level <15 ng/mL for a prostatic weight ≥ 60 g; serum creatinine level <160 mol/L; no infection. Exclusion criteria: undergone previous surgery on the prostate or bladder; mental incapacity; any chronic disease potentially hindering follow-up; diabetes; participation in any clinical protocol within at least 3 months; any other urological disease; any medical treatment of voiding disorders within 15 days of inclusion; taken diuretics in the previous 3 months; anticoagulant therapy; allergy to lidocaine or colorectal disease. <u>All patients</u> N: 200 (includes transrectal arms) <u>Group 1</u>	Group 1: Transurethral hyperthermia (TUMT) Three devices used for transurethral treatment (Thermex II, Technorex, Israel; Prostcare, Brucker Spectrospin, France; BSD-50, BSD medical Corp, USA). Prostate temperature was monitored by an integrated microwave generator and controlled each device through a fibre-optic temperature monitor. One session given that lasted between 1-3 hours depending on the device used. Deliver a temperature compatible with hyperthermia treatment (45°C). Group 2: SHAM Single session with the temperature maintained at 37°C.	Number (%) of complications during treatment Number (%) of early post-treatment complications	Urethral bleeding: Group 1: 2 (3) Group 2: 0 Urethral pain Group 1: 1 (1.5) Group 2: 0 Acute retention: Group 1: 1 (1.5) Group 2: 0 Urethral bleeding: Group 1: 18 (27) Group 2: 9 (29) Cystitis Group 1: 12 (18) Group 2: 6 (19) Acute retention: Group 1: 0 Group 2: 0 Urinary tract infection: Group 1: 0 Group 2: 1 (3) Prostatistis Group 1: 1 (1.5) Group 2: 1 (3) Other: Group 1: 4 (6)	Funding: Grant from Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT). Assitance Publique – Hopitau de Paris. Devices were lent b the following companies: Biodan, Brucker, BSD, Direc and Tecnomatrix. Limitations: Unclear if allocation concealment used. All withdrawals included in th analysis as non-responders, except for two patients who excluded for reasons unrelated to treatment. Additional outcomes: Study randomised patients to transrectal hyperthermia and transrectal sham arm but results not reported. Notes:
	N: 66 Mean (±SD) Age: 65 (8) Mean (±SD) prostate weight: 45g (15) Dropouts: 17% (complementary medical or surgical treatment for worsening obstructive		% Objective response rates (PFR)*	Group1 (n=66) : 14 Group 2 (n=29): 17 Group 2 (n=29): 17	* responder defined as patients showing excellent, good or moderate responses according to each of the criteria analysed separately

1 Evidence Table 34 Transurethral microwave thermotherapy (TUMT) vs. no treatment

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	symptoms; one lost to follow-up and 1 withdrew during treatment) Group 2 N: 31 Mean (±SD) Age: 66 (7) Mean (±SD) prostate weight: 44g (11) Dropouts:38% (complementary medical or surgical treatment for worsening obstructive symptoms; one lost to follow-up)		% Subjective response (Madsen score)*	Group1 (n=66): 50 Group 2 (n=29): 17 P<0.05	(Madsen decrease >30%; a PFR>10mL/s with a PFR increase>30%) Non responders were patients who withdrew during treatment (because of complications complementary treatment or refusal to continue) and patients who had a Madsen score decrease <30%, PFR<10mL/s or a PFR>10mL/s but with an increase <30%.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Albala et al., 2002 ¹⁰	Patient group: Male patients between 50-80 years old with a diagnosis of symptomatic BPH to a	Performed in urology offices or clinics.	AUA symptom index (SI)	Baseline: Group1 (n=125): 22.5 Group 2 (n=65): 22.8	Funding: NR Limitations:
Study design: Randomised controlled	sufficient degree that treatment was warranted.	Group 1: TUMT TherMatrx TMx-2000 that directly heats the transition zone to greater		3 months: Group1 (n=124): 12.4 Group 2 (n=NR): 17	Symptom scores only reported fro TUMT arm for 6 and 12 months.
study	Inclusion criteria: AUA symptom index > 13 and a bother score	than 50 degrees C. 60-90W. Toradol, narcotic analgesic and		6 months: Group1 (n=115): 12.1	
Setting: US	>11. Peak flow rates were <12mL/s and the post voiding	lorazepam were given orally 45 minutes before treatment. Prior to		Group 2 : NR 12 months:	Additional outcomes: Bother and quality of
Evidence level:	residual volume was <125mL. Prostate volume between 30-100cc	catheter insertion lidocaine jelly injected into the urethra and		Group1 (n=119): 11.9 Group 2: NR	life scores reported but only for the treatment
1+	without a significant intravesical middle lobe.	allowed to remain in place for 15 minutes. Treatment temperature	AUASI Change (12 months)	Group1: -10.6 (-47.1%) Group 2: NR	arm.
Duration of follow-up: 12 months	All patients N: 200	delivered to peak tissue temperature of 50 to 55°C. After temperature had increased to 50	PFR change, mL/sec (1 2months)	Group1: +5.0 (58.1%) Group 2: NR	Notes: Patients were unblended at 3 months
1 z monins	<u>Group 1</u>	degrees the treatment was continued for 40 minutes under	Number of complications	Recatheterisation Group 1: 20/121 (16.8%)	and sham treated patients offered options
	N: 125 Mean (±SD) Age: 65.2 (7.3) Mean (±SD) volume: 50.5 (18.6) cc Dropouts: NR	computer control. Foley catheter inserted into bladder following treatment and left in place from 2 to 4 days.		Group 2: 0/62 (0%) Dysuria Group 1: 8/121 (6.6%) Group 2: 3/62 (4.8%)	of having active treatment. Results for treatment arm only includes patients
	Number reporting AUA scores indicates that was 6 drop outs at 12 months.	Group 2: SHAM Placement of the microwave		Urgency Group 1: 0/121 (0%) Group 2: 0/62 (0%)	randomised to active treatment and not those that crossed over at 3
	Complications reported for 121 out of 125 randomised patients.	catheter for the treatment period without energy delivery and received the same post treatment		Gross haematuria Group 1: 11/121 (9.1%) Group 2: 0/62 (0%)	months (intention to treat analysis used).
	Group 2 N: 65 Mean (±SD) Age: 64.6 (7.1) Mean (±SD) volume: 47.1 (17.9) cc Dropouts: NR	care as the active treatment patients.		Bladder spasm Group 1: 5/121 (4.1%) Group 2: 0/62 (0%) Urethral stricture Group 1: 0/121 (0%)	
	Complications reported for 62 of 65 patients.			Group 2: 0/62 (0%) Ejaculatory dysfunction pain Group 1: 0/121 (0%)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Group 2: 0/62 (0%) Rectal damage fistula Group 1: 0/121 (0%) Group 2: 0/62 (0%)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Mean (95% CI) urgency	Baseline Group 1: 3.5 (2.8-4.2) Group 2: 2.8 (1.6-3.1) 3 months: Group 1: 1.1 (0.5-1.8) Group 2: 1.6 (0.9-2.5)	
			Retrograde ejaculation (new cases) * number with antegrade ejaculation preoperatively not reported	Group 1: O/NR Group 2: O/NR	
			% correctly guesses which treatment arm they were in	Group 1: 86% Group 2: 50%	
			Successful outcomes (defined as a decrease in symptom scores with greater than a 50% decrease) at 3 months	Group 1: 18/22 Group 2: 2/20	
			Reoperation (at 3 months patients in sham arm offered active treatment)	Group 1: 0/22 Group 2: 16/20	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Blute et al., 1996 ²⁸ Study design: RCT Setting: US	Patient group: patients with symptomatic BPH. Inclusion criteria: peak urine flow rate<10ml/s; residual volume 100- 200ml; Madsen score>8; prostate length 35-50 mm from TRUS.	Outpatient procedure. Antibodies and nonsteroidal anti- inflammatory agent given before therapy. Group 1: TUMT – Prostation (Prostagoft)	Mean (SD) AUA scores	Baseline Group1 (n=64): 19.7 (7.2) Group 2 (n=31): 21.9 (6.3) 6 weeks: Group1 (n=59): 12.8 (6.6) Group 2 (n=28): 17.1 (6.9) 3 months: Group1 (n=64): 11.3 (6.3)	Funding: NR Limitations: Drop outs and reasons not reported. Additional outcomes: PSA levels at baseline
Evidence level: 1+ Duration of follow-up: 12 months	transurethral or rectal surgery; urinary retention; any medications that affect prostate symptoms; antiandrogen therapy; upper UT pathology shown by ultrasound; metallic implants; symptoms suggesting neuropathological bladder; serum creatinine>2mg/dl; bladder stones; uncontrolled dysrhythmias or cardiac pacemaker;	inserted and treatment catheter with Foley balloon located by transabdominal ultrasound and TURS; anaesthesia: gesting neuropathological dder; serum creatinine>2mg/dl; dder stones; uncontrolled rhythmias or cardiac pacemaker; mmetric median lobe argement; patients at high risk n prostatic disease. patients 115	Mean (SD) peak flow rates (mL/s)	Group 2 (n=34): 11.5 (0.3) Group 2 (n=31): 16.3 (7.6) Baseline Group 1 (n=74): 7.2 (1.6) Group 2 (n=34): 7.4 (1.6) 6 weeks: Group 1 (n=72): 10.7 (4.1) Group 2 (n=32): 8.5 (3.7) 3 months: Group 1 (n=74): 11.5 (4.0) Group 2 (n=34):9.4 (3.7)	and at 6 months. Madsen symptom scores reported. Notes: Sham group offered active treatment at 3 months. Reported that no sexual dysfunction following
	enlargement; patients at high risk from prostatic disease. <u>All patients</u> N: 115		Mean (SD) residual urine by catheter, mL	Baseline Group1 (n=71): 140.9 (35.9) Group 2 (n=33): 142.1 (35.5) 3 months: Group1 (n=71): 145.5 (126.1) Group 2 (n=33):147.2 (107.7)	 procedure but no indication of patients that previously had dysfunction.
	Drop outs: NRGroup 2: SHAM No sedation; urethral coolant circulated; NSAIDs given before therapy. Treatment ran for 60 minutes.Group 2 N: 37 Mean (±SD) Age: 66.9 (7.1)Group 2: SHAM No sedation; urethral coolant circulated; NSAIDs given before therapy. Treatment ran for 60 minutes.	Number (%) of improved symptoms assessed by the patient at 3 months	Any positive change Group 1: 60/75 (80%) Group 2: 11/37 (29.7%) No change Group 1:12/75 (16.0%) Group 2: 23/37 (62.2%) Uncertain Group 1: 3/75 (4.0%) Group 2: 3/37 (8.1%)		
		Number (%) of improved symptoms assessed by the	Any positive change Group1: 63/75 (84%) Group 2: 13/37 (35.1%)		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			physician at 3 months	No change Group 1:8/75 (10.7%) Group 2: 23/37 (62.2%) Uncertain Group 1: 4/75 (5.3%) Group 2: 1/37 (2.7%)	
			Number (%) complications at 3 months	Haematuria: Group 1: 54/78 (69.2%) Group 2: 19/37 (51.3%) Urethral bleeding Group 1:16/78 (20.5%) Group 2: 5/37 (13.5%) Urethral discharge Group 1:2/78 (2.6%) Group 2:0 Urinary retention Group 1:20/78 (25.6%) Group 2:0 Other urinary tract Group 1:11/78 (14.1%) Group 2: 4/37 (10.8%) Reproductive (including genital dermatology) Group 1: 8/78 (10.3%) Group 2: 0 Rectal (including proctoscopy findings) Group 1: 4/78 (5.1%) Group 2: 4/37 (10.8%)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Brehmer et al., 1999 ³⁰	Patient group: Men with LUTS dominated by hesitancy, slow	An ECP system (Comair, Sweden) equipped with a 22F catheter with	Qmax, mL/s	Baseline: Group 1: 8.7	Funding: NR
	urination and an enlarged prostate.	a microwave antenna (915MHz),		Group 2: 7.0	Limitations:
Study design:		a fibre-optic system for measuring		Group 3: 7.9	Method of randomisation,
RCT	Inclusion criteria: maximum flow rate of <12mL/s	the temperature in the urethra and, by a rectal probe in the		4 months: Group1: 12.3	allocation concealment unclear.
Setting:	,	rectum. The two-way urethral		Group 2: 9.9	Baseline urodynamic scores
Sweden	Exclusion criteria: indwelling	catheter has a circulation cooling		Group 3: 8.3	similar between groups but
Evidence	catheter, median prostatic lobe, a prostate gland estimated as >50g,	system that reduces the heat delivered to the urethral wall.	Treatment failure	Group1& 2: 5/30 (17%) Group 3: 7/14	A scores were significantly higher in the 30 minute
level: 1+	suspected prostatic malignancy, neurological disease and previous surgery for prostatic disease.	Maximum heating is achieved within 30s and the temperature limit is 46 degrees in the urethral	Reoperation	Group1: 0/14 Group 2: 3/16 Group 3: 7/14	 TUMT group (Group 1). Complications reported as whole rather than by group
Duration of		and 43 in the rectum. If unable to		Before	
follow-up:	<u>All patients</u>	void a urethral catheter inserted	ICS A score (with %		Additional outcomes:
12 months	N: 44	and left in place for 3 days. All	decrease) * See notes for	Group 1: 58	Frequency and timed void
	Mean age (range): 70.4 (53-83) Drop outs: 2	patients received antibiotics for 5 days.	definition of score	Group 2: 49 Group 3:46	before and after treatment % improved in different
	Group 1	Group 1:		4 months: Group1: 44 (25)	variables reported (but actual figures reported in
	N: 14 Dropouts: 1 (withdrew as had	TUMT for 30 minutes		Group 2: 41 (16) Group 3: 44 (4)	full).
	repeated transient ischaemic attacks	Group 2:			Notes:
	and developed early dementia	TUMT for 60 minutes	ICS B score (with % decrease)	Before Group1: 40	ICS score defined as a Questionnaire with 32
	Group 2	Group 3: SHAM	* See notes for	Group 2: 36	questions (A questions abou
	N: 16	Only water at 20° was circulated	definition of score	Group 3: 36	symptoms and B question
	Dropouts: 0	in the treatment catheter and a computer monitor, visible to the		4 months: Group1: 30 (34)	about the bother related to the symptom. Maximum A
	Group 3	patient, showed a simulated heat		Group 2: 30 (17)	and B scores are 124 and
	N : 14	treatment curve, similar to that		Group 3: 31 (14)	92 respectively. High score

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Dropouts: 1 (prostatic carcinoma)	produced during TUMT.	% improvement using quality of life score (from ICS questionnaire last question - with 7 points indicating worst situation possible)	Group 1: 25% Group 2: 4% Group 3: 0%	indicates worse symptoms.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Dewildt et al., 1996 ⁵⁹ Links with Delarosette 1994 ⁵⁶ and Francisca 1997 ⁸⁴ Study design: Randomised controlled trial Setting: 2 centres – London and	Patient group: From June 1991 to December 1992 patients recruited. Inclusion criteria: >45 years; complaining of symptoms of bladder outlet obstruction for >3 months, have a Madsen symptom score of >8 and urinary free-flow rate estimates of <15 mL/s during two voids of >150mL. Exclusion criteria: prostate caner, prostatitis, urethral stricture, intravesical pathology, neurogenic bladder dysfunction UTI, isolated enlargement of the middle lobe, a residual urine volume of \geq 300mL, use of drugs influencing bladder or prostate function, previous transurethral resection of the prostate or transurethral incision, a metallic pelvic implant, disorders of blood flow or coagulation, diabetes, mental incapacity or inability to give informed consent.		Mean (95% CI) of Madsen symptom score Mean (95% CI) of peak flow rate, mL./s	Baseline Group 1: 13.7 (12.7-14.7) Group 2: 12.9 (11.9-13.9) 3 months Group 1: 4.7 (3.6-5.9) Group 2: 10.4 (8.9-11.8) 12 months Group 1: 4.2 (3.0-5.3) Group 2: 8.2 (5.5-11.0) Baseline Group 1: 9.2 (8.4-9.9) Group 2: 9.6 (8.8-10.4) 3 months Group 1: 13.4 [6.16] (11.7-15.3) Group 2: 9.7 [3.30] (11.7-15.3) 12 months Group 1: 13.4 [5.13] (11.6-15.1) Group 2: 10.5 [4.79] (7.9-13.1)	Funding: NR Limitations: Method of randomisation and use of allocation concealment are unclear. Some significant baseline differences between the two centre. London centre had significantly older patients, more obstructive symptoms and greater residual volume. Additional outcomes: Reports results for SHAM group when they have had an active treatment
Nijmegen, Netherlands Evidence level: 1+ Duration of follow-up: 12 months	All patients N: 93 Group 1 N: 47 Mean (±SD) Age: 66.3 (8.1) Dropouts: 2 (had TURP) At 12 months: 14 (TURP=4, Lost to follow-up5, second TUMT=4, death (not related to treatment)=1) Group 2 N: 46		SD) Age: 66.3 (8.1) : 2 (had TURP) nths: 14 (TURP=4, Lost to follow-up5, JMT=4, death (not related to	Mean (95% CI) of post void residual urine, mL	Baseline Group 1: 93.9 (71.8-116.0) Group 2: 84.7 (64-105.1) 3 months Group 1: 34.2 (19.4-46.8) Group 2: 104.1 (74.7-133.4) 12 months Group 1: 49.72 (33-66.3) Group 2: 56.3 (16.9-95.7)
	Mean (\pm SD) Age: 63.9 (6.0) Drop outs: 3 (lost to follow up=2, technical		Mortality	Group1: 1/47 Group 2: 0/46	genuine TUMT was performed on request.
	failure=1) At 12 months: 33 (5 lost to follow up, technical failure=1 and 27 had TUMT at 3 months)		Retention	Group 1: 10/47 Group 2: 1/46	
	· · · · · · · · · · · · · · · · · · ·		Reoperation	Group 1: 8/47 Group 2: 27/46	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
	Patient group: symptomatic BPH patients enrolled between September 1994 and June	Urologix Targis system used. Microwave energy for one hour.	Mean (SD) / [range] symptom score (AUA)	Baseline: Group1 (n=124): 20.8 [19.8-21.9] Group 2 (n=42): 21.3 [19.3-23.3]	Funding: Supported by a grant from Urologix, Inc.	
Study design: RCT	1996 Inclusion criteria: Qmax	Outpatient setting without anaesthesiologist or		3 months: Group1 (n=123): 9.60 (5.94)		
	≤12mL/s with voided volume	anaesthetist. The catheter		Group 2 (n=40): 14.50 (6.77)	Limitations:	
centres in US.	≥12mL/s with voided volume ≥25mL., AUA symptom score ≥9, 3-5cm preprostatic urethral	provides urethral cooling via circumferential cooking compartments and monitors		6 months: Group1 (n=120): 10.50 (7.26) Group 2 (n=35): 14.30 (6.34)	Method of randomisation and whether allocation	
Evidence level:	length as determined by cystocscopy or TURS, No disproportionally enlarged or prominent prostatic median lobe	temperatures. The thermoablation system automatically interrupts microwave power if urethral	Mean (SD) / [range] Qmax	Baseline: Group1 (n=106): 7.8 [7.4-8.2] Group 2 (n=39): 7.8 [7.00-8.6]	concealment used were not reported. One enrolee who had	
follow-up: 6 months.	on cystoscopy, life expectancy ≥1year. Exclusion criteria: UTI within 1 week of study enrolment, gross hematuria, acute urinary	temperatures reach 44.5°C or higher or rectal temperatures over 42.5. Topical ligocaine anaesthesia used for catheterisation. Microwaye		3 months: Group1 (n=102): 11.70 (5.41) Group 2 (n=37): 9.20 (3.72) 6 months: Group1 (n=101): 11.80 (5.89)	been assigned to the sham group was inadvertently made aware of his group assignment and	
	retention, prostate weight>100g, concomitant medications, use of alpha antagonists or antiandrogens, coexisting disease that could mimic obstructive bladder neck syndrome, coexisting illness or specific obstructive symptoms caused by neurogenic bladder; bladder stones, renal failure,	40 degrees. Treatment administered for one hour. Given 3 day prescription of prophylactic oral antibiotics and catheterisation for 36 to 60 hours.	achieve target temperature of 40 degrees. Treatment administered for one hour. Given 3 day prescription of prophylactic oral antibiotics and catheterisation for 36 to 60 hours.	Mean [range] post void residual, mL	Group 2 (n=31): 9.80 (4.00) Baseline: Group 1 (n=105): 99.1 [82.0-116.1] Group 2 (n=39): 103.6 [79.4-127.8] 3 months: Group 1 (n=103): 68.4 [52.9-83.8] Group 2 (n=37): 93.0 [57.6-128.4] 6 months: Group 1 (n=101): 84.5 [67.8-101.2] Group 2 (n=31): 84.4 [58.3-110.6]	consequently this patient's schedule study treatment was cancelled. Prostate volume 17% greater in sham group at baseline. Additional outcomes: PSA levels before and
		Underwent procedures identical to those in active arm but the microwave energy not applied. Coolant temperature was increased in increments from 8 to 20° over the same time period as microwave power	Quality of life score (SD) evaluated by patient responses to the question of how they would feel if their current urinary symptoms were to continue indefinitely	Baseline: Group1 (n=120): 4.2 (95% Cl: 4.0- 4.4) Group 2 (n=35): 4.0 (95% Cl: 3.6- 4.3) 6 months: Group1 (n=120): 2.20 (1.40) Group 2 (n=35): 2.90 (1.20)	after treatment. 6 week results for symptom score and Qmax. Prostate volume reported but only for active group.	
	study, previous prostate surgery	•	Complications	Blood transfusions	Notes:	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	or non medical treatment for BPH, penile implant or artificial urinary sphincter, previous pelvic or rectal surgery, metallic implants in the pelvic area, cardiac pacemaker, desire for future offspring, likely non compliance.	prophylactic oral antibiotics and catheterisation for 36 to 60 hours.		Group1: 0/125 Group 2: 0/44 Urinary retention Group1: 10/125 Group 2: 1/44 Urinary tract infection Group1: 11/125 Group 2: 2/44 Stricture Group1: 3/125	SD for Qmax and symptom scores was calculated in HTA report. After 6 months follow up continued on unblinded basis, with follow up to one year by mail in questionnaire
	All patients N: 169 Mean age: 45-85 years Drop outs:			Group 2: 0/44 Urinary incontinence Group 1: 5/125 Group 2: 0/44 Reoperation Group 1: 2/125 Group 2: 27/44 Ejaculatory disorders:	only. After 6 months evaluation sham group patients could elect to undergo microwave or other treatment for BPH.
	Group 1 N: 125 Mean (range) Age: 66.0 (64.7-67.4) Dropouts: 5 (prostate cancer=2,			Group 1: 5/125 Group 2: 0/44 Mortality: Group 1: 1/125 Group 2: 0/44	
	need for further treatment for BPH=2, died of unrelated causes=1)		Number (%) that correctly identified intervention received	Group1: 100/112 (90%) Group 2: 21/37 (50%)	
	Group 2 N: 44 Mean (range) Age: 65.9 (63.4-68.3) Dropouts: 9 (study procedure cancelled=1, missed prostatitis at screening=1, need for further treatment for BPH=7)		Number of patients experiencing discomfort during the procedure	None or mild: Group 1: 65/125 (52.0%) Group 2: 37/42 (88.1%) Moderate: Group 1: 57/125 (45.6%) Group 2: 5/42 (11.9%) Severe Group 1: 3/125 (2.4%) Group 2: 0/42 (0%)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Nawrocki et al., 1997 ¹⁸⁷ Study design: Randomised controlled trial. Setting: UK	Patient group: men with symptoms associated with bladder outlet obstruction and BPH. Inclusion criteria: symptoms of lower urinary tract dysfunction thought to e due to benign enlargement of the prostate meriting surgical treatment, Qmax<15mL/s and voided volume 150mL or more, Pdet max of 70cmH2O or more. Exclusion criteria: Complications of bladder outlet obstruction (retention, residual urine	Group 1: TUMT Prostasoft v 2.0. 1 hour treatment with microwaves performed with the patient under local anaesthesia and as an out-patient. Group 2: SHAM Simulated TUMT with	Median (range) AUA symptom score: Mean (SD) Qmax, mL/s	Baseline: Group 1: 19 (7-31) Group 2: 17.5 (7-28) Group 3: 18 (10-29) 6 months: Group 1: 9.5 (1-27) Group 2: 9.5 (0-30) Group 3: 17 (4-28) Baseline:	Funding: Research was in part supported by a LORS grant from the South East Thames Regional Research Committee. This work in part contributed to the award of an MS thesis from University of London.
Evidence level: 1+ Duration of follow-up:	volume >350mL, renal failure, recurrent urinary tract infection, bladder calculus, bladder diverticulum); suspicion of malignancy, short prostate, presence of a prominent middle lobe projecting asymmetrically into the bladder, presence of a urethral stricture, previous prostate or pelvic surgery or radiotherapy,	identical procedure as active treatment but treatment device emitted no microwaves during the procedure. The machine noise, treatment duration		Group 1: 8.83 (2.32) Group 2: 9.44 (2.78) Group 3: 8.79(2.66) 6 months: Group 1: 9.94 (3.08) Group 2: 9.49 (2.88) Group 3: 8.47 (1.92)	Limitations: Allocation concealment use was unclear and drop outs not reported. Additional outcomes: Minimum urethral opening
6 months	presence of metal within the lower trunk or	erapy, and graphical computer unk or display were all simulated by placebo software on disk. Heat simulated using a heat	Mean (SD) residual urine volume, mL	Baseline: Group 1: 85.7 (56.6) Group 2: 96.5 (56.3) Group 3: 86.0 (62.7) 6 months: Group 1: 85.8 (51.2) Group 2: 106.3 (84.5) Group 3: 82.7 (52.7)	Nummum oremral opening pressure, maximum detrusor pressure, voided volume, detrusor instability, functional bladder capacity. Notes: Active and sham arms
	Median age: 70 (56-80) years Drop outs: NR (only that urodynamic data incomplete in 4 patients). <u>Group 1</u> N: 38 <u>Group 2</u> N: 40		Mean (SD) prostate volume, mL	Baseline: Group 1: 41.2 (14.6) Group 2: 46.7 (16.8) Group 3: 46.4 (19.9) 6 months: Group 1: 45.6 (17.6) Group 2: 48.9 (19.7) Group 3: 45.2 (17.9)	included in the meta- analysis. 37% judged that they knew which treatment that they had. Of which 59% were correct. Operators judged correctly 68% of
	<u>Group 3</u> N: 42		Urinary retention	Group 1: 4/38 (10.5%) Group 2: 0/40	time.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Patient group: Recruitment dates from September 1991. Inclusion criteria: peak urine flow rate <15ml/s on two occasions; residual volume ≤350ml. Madsen score>8 for 6 months, prostate urethral length 35-50mm. Exclusion criteria: prostate cancer from DRE; heat to prostate or pelvic surgery/radiotherapy; urinary retention; alpha blockers within 4 weeks; antiandrogens within 1 year; anything affecting prostate of bladder; prostatitis or UTI; renal dysfunction; peripheral arterial disease; diabetic neuropathy; UT disease; bladder disease; mental incapacity; dementia, inability to give informed consent; neurological disorders affecting bladder function; disorders of blood flow or coagulation; history or uncontrolled cardiac arrhythmias or cardiac pacemaker; metallic pelvic implant; prominent isolated median lobe; intravesical pathology; renal impairment due to chronic retention; urethral stricture inhibiting catheterisation. All patients N: 43 Group 1 N: 22 Mean (±SD) Age: 68.3 (64.1-72.5) Group 2 N: 21	Group 1: TUMT Catheter protocol – inserted for retention for one week. Group 2: SHAM Catheter protocol – inserted for retention for one week.	Mean (95% CI) Madsen score Mean (95% CI) Qmax, ml/s	Group1: 14.5 (12.9-16.1) Group 2: 14.2 (12.7-15.7) Baseline: Group 1: 8.5 (7.5-9.5) Group 2: 8.6 (7.6-9.6) 3 months: Group 1: (n=21) 13.0 (5.84) Group 2: (n=19) 9.2 (4.45) Group 1: 13.4 (10.7-16.1) Group 2: 13.3 (9.2-17.4) Group 1: 5/22 Group 2: 1/21 Group 1: 5/22 Group 2: 0/21 Group 1: 1/22 Group 1: 1/22 Group 2: 1/21	Funding: Unknown Limitations: HTA appraisal of study reports unclear method of randomisation and no allocation concealment. Patients blinded but assessors were not. Additional outcomes: Voided volume and residual volume reported in the HTA report. Notes: If patient saw no improvement in 3 months after sham or TUMT a second TUMT was performed on request.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Trachtenberg et al., 1998 ²⁵⁵ Linked to Tan 2005 Study design: Randomised controlled trial. Setting: multicentre, US and Canada Evidence level: 1+ Duration of follow-up:	et al., 1998255 itudy design: Randomised ontrolled rial.Inclusion criteria: AUA >13; peak urinary flow rate <12 ml/s and voided volume >125ml. serum PSA <10ng/ml; prostate volume between 25-100ml; bladder neck to verumontanum distance <30mm.Dornier Urowave used which operates at 915MHz. Generator capable of delivering u to 90W of power. Safe threshold set at 50°C in the urethra and 42.5°C the rectum. Outpatient procedure without general anaesthesia.and CanadaAll patients N: 220Outpatient procedure without general anaesthesia.widence evel:Group 1 N: 147Peri-treatment antibioti prophylaxis at the investigators choice.HMean (rang)) Age: 66.2 (54.4- 82.7)Foley catheter was inserted and left indwelling for 2-5 daysDuration of ollow-up: b monthsGroup 2 N: 73 Mean (range) Age: 66.0 (55.1- 78.1) Dropouts: 3Group 2: SHAM	Dornier Urowave used which operates at 915MHz. Generator capable of delivering up to 90W of power. Safety threshold set at 50°C in the urethra and 42.5°C in the rectum. Outpatient procedure without general anaesthesia. Peri-treatment antibiotic prophylaxis at the investigators choice. Following treatment a Foley catheter was inserted and left indwelling for 2-5 days.	Mean (range) AUA symptom score Mean (range) AUA bother score Mean peak flow, ml/s	Baseline: Group1: 23.6 [5.6] (12-35) Group 2: 23.9 [5.6] (13-35) 3 months: Group1: 11.6 Group 2: 16.4 6 months: Group1: 12.6 Group 2: 17.9 Baseline: Group 1: 18.5 (0-28) 6 months: Group 2: 17.9 Baseline: Group 1: 18.5 (0-28) 6 months: Group 2: 12.6 Baseline: Group 1: 7.7 (3.5-11.5) Group 2: 8.1 (4.0-11.9) 3 months: Group1: 11.0 Group 2: 9.7	Funding: NR Limitations: Randomisation method unclear and reason for dropouts not reported. Results report one stricture in the active treatment compared to none in the sham arm. Conversely, the conclusion reports no strictures in the study so have excluded this outcome. Additional outcomes: Prostate volume and PSA baseline scores. Quality of life question (0-6) but only reported figures for baseline
		programmed treatment	Complications	6 months: Group 1: 10.6 Group 2: 9.6 Pain	figures for baseline scores. Notes: At 6 months follow-up
				Group 1: 80% Group 2:56% Occurrences ejaculatory dysfunction Group 1: 30/147 Group 2: 1/73 Irritative voiding: Group 1: 21/147 Group 2: 4/73 haematuria Group 1: 19/147 Group 2: 1/73	patients on sham treatments were offered active treatment.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				UTI	
				Group 1: 11/147	
				Group 2: 2/73	
				Urinary retention:	
				Group 1: 8/147	
				Group 2: 0/73	
				Scrotal abscess	
				Group 1: 6/147	
				Group 2: 1/73	
				Rectal disorder:	
				Group 1: 8/147	
				Group 2: 2/73	
				Pelvic pain:	
				Group 1: 5/147	
				Group 2: 1/73	
				Penile disorder:	
				Group 1: 5/147	
				Group 2: 0/73	
				Urinary incontinence	
				Group 1:0/147	
				Group 2: 0/73	
				Bladder spasm:	
				Group 1: 1/147	
				Group 2: 1/73	
				Split urinary stream:	
				Group 1: 0/147	
				Group 2: 1/73	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Zerbib et al., 1994 ²⁸¹	Patient group: symptomatic BPH patients.	Group 1: TUMT Prostatic hyperthermia	Mean (SD) peak flow, ml/s	Baseline Group 1: 7.6 (3.8)	Funding: NR.
Study design: Randomised controlled study Setting: France Evidence	prostatectomy. All had failed one conservative treatment (e.g. alpha- blockers) and the symptoms were of sufficient severity such that prostatectomy was indicated. Exclusion criteria: anterior rectal wall thickness>10mm or <2mm;	Intraprostative treatment (e.g. alpha- backers) and the symptoms were of ficient severity such that bostatectomy was indicated.Prostathermer. Intraprostatic temperature maintained at $43\pm0.5^{\circ}$ C. I hour session per week for 5 consecutive weeks.M 	Mean (SD) voided volume, ml	Group 2: 10.6 (5.8) 3 Months: Group 1: 9.60 (5.80) Group 2: 10.8 (5.4) Baseline Group 1: 151 (92.0) Group 2: 145 (86.3) 3 Months: Group 1: 154 (90) Group 2: 166 (91.3)	Limitations: Randomisation method and allocation concealment unclear. Baseline peak flow significantly different between arms. Inclusion and exclusion criteria not defined. No complications
level: 1+ Duration of follow-up: 3 months	anterior to posterior thickness of prostate >55mm. Group 2: SH. of All patients by radiofreq p: N: 68 One hour ses Mean age: 69.5±10.44 (53-88) week for 5 ca		Mean (SD) Residual volume, ml	Baseline Group 1: 110 (88.8) Group 2: 84.2 (76.6) 3 Months: Group 1: 67 (101.6) Group 2: 81.2 (66.8)	reported. Additional outcomes: Siroky S.D. and adjusted flow scores. Response rate (objective
<u>Group</u> N: 38	<u>Group 1</u> N: 38 <u>Group 2</u>		Objective score (simplified version of the Siroky nomogram, lower scores indicates a higher degree of urinary obstruction)	Group 2: 24.8 10.3)	criteria) reported. Notes: 3 month result for peak flow for TUMT group not reported in study –
		Subjective score, ranging from 6 (sever disturbance) to 38 (no disturbance)	Baseline Group 1: 16.7 (7.8) Group 2: 19.4 (8.2) 3 Months: Group 1: 23.0 (10.8) Group 2: 23.6 (7.0)	result obtained from HTA report.	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Ahmed et al., 1997 ⁷	Patient group: Patients presenting with symptomatic, uncomplicated BPH.	Group 1: TUMT With urethral cooling in a high energy protocol	Mean (range) [SD] AUA symptom scores:	Baseline: Group1: 18.5 (17.1-20.1) Group 2: 18.4 (16.7-20.1)	Funding: NR Limitations:
Reported in systematic review HTA	Inclusion criteria: residual urine volume ≤300 ml; AUA score ≥ 12; urine flow rate< 15ml/s, prostate volume 25-100ml by TRUS; symptomatic	(Prostratron version 2.5). Temperature 43.5 degrees, power at		6 months: Group 1: 5.3 (3.9-6.4) [3.5] Group 2: 5.2 (3.9-6.5) [3.6]	3 drop outs after randomisation were substituted. One
2008 Study design:	uncomplicated BPH > 1 year; pdet max>70cm H2O; informed consent; obstructed on Abrams- Griffith nomogram; suitable for either treatment.	70W. 60 minute session under	AUA symptom score decreased > 50%	Group 1: 18/30 (60%) Group 2: 30/30 (100%)	emigrated to Australia; one developed severe UTI requiring hospital
RCT	Exclusion criteria: <55years; prostate cancer;	topical anaesthesia with instillagel.	Qmax (mL/s):	Baseline:	admission and one patient could not be
Setting: Single centre, UK	previous prostatic surgery; acute or chronic retention; mental incapacity; severe cardiovascular disease; rectal surgery or disease; pelvic mass	3 required parenteral pethidine. Antibiotics: gentamycin		Group 1: 10.1 (9.2-10.9) Group 2: 9.5 (8.9-10.1) 6 months:	catheterised with the treatment catheter.
Evidence level: 1+	surgery; cardiac pace marker; metallic implants; uncontrolled coagulation disorder; meatal stricture;	(80mg) before		Group1: 9.1 (8.0-10.2) Group 2: 14.6 (13.4-15.8)	Method of randomisation and use
Duration of follow-up: 6 months	upper tract dilation; obstructive uropathy; bladder calculi; bladder diverticuli; recurrent prostatic haematuria; active drugs; previous medication for BPH; prostatic abscess; active UTI; recurrent UTI; prominent middle lobe.	 Ili; recurrent prostatic i; previous medication for active UTI; recurrent UTI; Group 2: TURP No post operative irrigation was used. Urethral catheter was removed 3 or 4 days after surgery. 5 (58-82) 	Pdet max (cmH20):	Baseline: Group 1: 98.5 (70.1-116.9) Group 2: 96.7 (85.5-103.9) 6 months: Group 1: 105.6 (73.7-	of blinding unclear. Additional outcomes: None
			irrigation was used. Urethral catheter was removed 3 or 4 days		117.5) Group 2: 48.8 (44.3-52.7)
	Group 1 N: 30 Mean (range) age: 69.36 (56-88) Mean AUA score (95% CI): 18.5 (17.1-20.1) Dropouts: 0			PVR (mL):	Baseline: Group 1: 94.4 (70.0-112.8) Group 2: 109.1 (88.2- 130.0) 6 months: Group 1: 104.9 (78.9-
	Group 2 N: 30 Magn (range) age: 69 45 (58 82)			130.9) Group 2: 32.5 (22.5-40.5)	
	Mean (range) age: 69.45 (58-82) Mean AUA score (95% CI): 18.4 (16.7-20.1) Dropouts: 0		Prostate volume (mL):	Baseline: Group1: 36.6 (31.8-41.4) Group 2: 46.1 (38.1-54.1) 6 months:	
				Group 1: 34.5 (29.7-39.3) Group 2: 25.4 (19.4-31.4)	

1 Evidence Table 35 Transurethral microwave thermotherapy (TUMT) vs. transurethral resection of the prostate (TURP)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Blood transfusion:	Group 1: 0/30 Group 2: 4/30	
			Urinary tract infection:	Group 1: 1/30 Group 2: 3/30	
			Strictures:	Group 1: 0/30 Group 2: 1/30	
			Retrograde ejaculation (sexually active men only):	Group 1: 4/18 Group 2: 12/19	
			Hematuria:	Group 1: 1/30 Group 2: 0/30	
			Erectile dysfunction:	Group 1: 0/18 Group 2: 4/19	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Delarosette et al., 2003 ⁵⁷ Reported in systematic review HTA 2008 Study design: RCT Setting:	Patient group:From January1996 to March 1997 patientswith LUTS suggestive of BPHwere recruited.Inclusion criteria: $age \ge 45$ years; duration of LUTS ≥ 3 months, prostate volume ≥ 30 mL; urethral length ≥ 25 mm;peak urine flow rate ≤ 15 ml/s;Residual urine volume ≤ 350 ml; and severe co morbidity.	Group 1: TUMT Prostatron device and Prostasoft 2.5 software. Administered under local anaesthesia. Outpatient procedure. Group 2: TURP Under spinal anaesthesia. Mean in-hospital stay of 5.3 days.	Mean (SD) symptom score IPSS	Baseline: Group 1 (n=78): 20 (6.7) Group 2 (n=66): 20 (6.2) 3months: Group 1: (n=57): 10.5 (7.9) Group 2 (n=55): 5.3 (5.2) 1 year: Group 1 (n=58): 8.1 (6.0) Group 2 (n=48): 3.2 (3.0) 2 years: Group 1 (n=46): 9.3 (7.3) Group 2 (n=38): 3.7 (4.9) 3 years:	Funding: NR Limitations: Method of randomisation, allocation concealment and blinding unclear. Additional outcomes: Cost analysis was performed.
Setting: Netherlands Evidence level: 1+ Duration of follow-up: Median 33 months.	Exclusion criteria: acute prostatitis or urinary tract infection; prostate carcinoma;	Mean (SD) IPSS Quality of life question	Group1 (n=35): 11.5 (6.4) Group 2 (n=33): 2.6 (2.2) Baseline: Group1 (n=78): 4 (0.9) Group 2 (n=66): 4(1.1) 1 year: Group1 (n=58): 1.9 (1.3) Group 2 (n=48): 0.6 (0.7) 2 years: Group1 (n=46): 1.9 (1.0) Group 2 (n=38): 0.9 (1.1) 3 years: Group1 (n=35): 2.3 (1.2) Group 2 (n=33): 0.6 (0.8)	Notes: Links with Francisca 1999, Francisca 2000, Floratos 2001.	
	Group 2: 73 Drop outs: 11 (10 refused and 1 died) – 4 from Group 1 and 7 in Group 2. Not included in the ITT analysis as no follow-up data. Group 1		Mean (SD) Maximum urinary flow (Qmax, mL/s)	Baseline: Group 1: 9.2 (3.1) Group 2: 7.8 (2.8) 3 months: Group 1 (n=54): 15.5 (12.1) Group 2 (n=47): 25.0 (7.5) 1 year: Group 1: 14.9 (7.2) Group 2: 23.8 (10.4) 2 years:	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	N: 78 Mean (±SD) Age: 67(±8.3) Mean (±SD) IPSS: 20 (±6.7) Dropouts: 23 (5 lost to follow up and 2 died unrelated			Group1: 13.7 (6.4) Group 2: 22.5 (11.4) 3 years: Group1: 11.7 (5.8) Group 2: 22.8 (11.6)	
	causes, 16 re-treated by TURP=8, laser prostatectomy=1, cystolithotripsy=2, internal optical urethrotomy=1, TUMT=1, alpha blockers=3).		Mean (SD) post void residual (PVR, mL)	Baseline: Group 1: 68 (85) Group 2: 97 (99) I year: Group 1: 55 (69) Group 2: 20 (49)	
	Group 2 N: 66 Mean (±SD) Age: 66 (±8.2) Mean (±SD) IPSS: 20 (±6.3) Dropouts: 21 (11 lost to follow			2 years: Group1: 91 (116) Group 2: 29 (39) 3 years: Group1: 94 (114) Group 2: 35 (56)	
	up and 2 died of unrelated causes, 8 retreated by bladder neck incisions=3, internal optical		Patients with re-treatment:	Group1: 16/78 22.9% (12.5-33.2) Group 2: 8/66 13.2 (4.5-21.9), P=0.215	
	urethrotomy=2, physiotherapy=1,		Kaplan-Meier risk of retreatment (36 months)	Group 1: 22.9 (12.5-33.2)% Group 2: 13.2 (4.5-21.9)%, P=0.215	
	medication=2).		Urinary retention:	Group 1: 2/78 (3%) Group 2: 0/66 (0%)	
			Urinary incontinence:	Group 1: 0/78 (0%) Group 2: 1/66 (2%)	
			Stricture:	Group 1: 1/78 (1%) Group 2: 2/66 (3%)	
			Mortality (unrelated causes)	Group 1: 2/78 (3%) Group 2: 2/66 (3%)	
			Retrograde ejaculation (reported in HTA 2008)	Group 1: 24/36 (67%) Group 2: 5/42 (12%)	
			Erectile dysfunction	Group 1: 7/35 (20%) Group 2: 9/53 (17%)	
			Reoperation	Group 1: 13/78 (17%) Group 2: 5/66 (8%)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Mattiasson et	Patient group: Patients from ten	Group 1: TUMT	Mean (SD) IPSS	Baseline:	Funding: ProstaLund.
al., 2007 ¹⁶²	centres in Scandinavia and the	PLFT technique. Given as		Group1 (n=99): 21.0 (5.4)	Authors (Wagrell,
and Wagrell	United States recruited between	outpatient procedure		Group 2 (=46): 20.4 (5.9)	Schelin, Larson,
et al., 2002 ²⁶⁸	October 1998 and November	requiring sedo-analgesic		3 months:	Mattiasson) are paid
	1999.	with or without local		Group1 (n=85): 8.4 (5.5)	consultants to the
Reported in		anaesthetic. Diazepam,		Group 2 (n=41): 6.7 (4.3)	sponsor of this study.
systematic	Inclusion criteria: symptomatic BPH,	ketorolac, or		6 months:	
review HTA	peak urine flow rate ≤ 13 ml/s; ml;	ketobemidone or		Group1 (n=95): 7.4 (6.2)	
2008	IPSS score ≥13; prostate volume	combinations of these.		Group 2 (n=43): 5.9 (5.0)	Limitations:
	30-100ml.	Mean duration of		12 months:	Method of
		treatment 57 (27-80)		Group1 (n=93): 7.2 (6.2)	randomisation,
Study design:		minutes.		Group 2 (n=43): 7.1 (6.6)	allocation concealment
RCT	All patients	Catheter after treatment:		P=0.603	and blinding not
	N: 154 eligible	14±8 days before		24 months:	reported.
Setting:	Drop outs: 8 withdrawn before	removal.		Group1 (n=77): 7.2 (5.9)	
Sweden,	treatment			Group 2 (n=38): 4.6 (4.4)	Additional outcomes:
Denmark and		Group 2: TURP		36 months:	Detrusor pressure
USA	Group 1	Urethral catheter usually		Group 1 (n=68): 8.2 (6.9)	Qmax at 3 and 6
	N: 100	removed after 3±4 days.		Group 2 (n=35): 5.0 (3.9)	months.
Evidence	Mean (±SD) Age : 67 (8)			48 months:	
level:	Mean (±SD) IPSS: 21 (5.4			Group 1: (n=56): 7.1 (5.4)	Notes:
1+	Dropouts before intervention: 3			Group 2: (n=30):6.4 (6.6)	% of responders at 12
	(screening failures and not treated)			60 months:	months defined as those
	Withdrawn at 12m: 9			Group 1 (n=63): 7.4 (4.8)	with an IPSS of 7 or les
Duration of	Withdrawn at 60m: 38 (adverse			Group 2 (n=34): 6.0 (5.8)	or $> 50\%$ gain
follow-up:	events=5, treatment failure=10,				compared with baseline
60 months	patient request=22, other =1)		Mean (SD) IPSS Quality of	Baseline:	and/or a Qmax of
			life:	Group1 (n=99): 4.3 (1.0)	15mL/s or greater
	Group 2		-	Group 2 (n=46): 4.2 (1.1)	and/or $> 50\%$ gain.
	N: 46			3 months:	
	Mean (±SD) Age : 69 (8)			Group1 (n=84): 1.5 (1.4)	
	Mean (±SD) IPSS : 20.4 (5.9)			Group 2 (n=41): 1.1 (1.6)	Links with Wagrell
	Dropouts before intervention: 5			6 months:	2004 ²⁶⁹
	(screening failures and not treated)			Group1 (n=93): 1.3 (1.4)	
	Withdrawn: 4			Group 2 (n=42): 1.0 (1.5)	
	Withdrawn at 60m: 12 (reasons:			12 months:	
	adverse events=4, treatment			Group1 (n=93): 1.4 (1.3)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
details	failure=2, patient request=5 and other=1)		Urinary flow rate (Qmax mL/s):	Group 2 (n=43): 1.5 (1.7) 24 months: Group 1 (n=77): 1.3 (1.2) Group 2 (n=38): 0.9 (1.3) 36 months: Group 1 (n=68): 1.3 (1.2) Group 2 (n=35): 1.0 (1.4) 48 months: Group 1: (n=56): 1.2 (1.0) Group 2: (n=30): 1.0 (1.3) 60 months: Group 1 (n=63): 1.1 (0.9) Group 2 (n=34): 1.1 (1.2) Baseline: Group 1 (n=79): 7.6 \pm 2.7 Group 2 (n=35): 7.9 \pm 2.7 3 months: Group 1 (n=81): 12.8 \pm 6.1 Group 2 (n=41): 14.6 \pm 9.0 6 months: Group 1 (n=91): 13.5 \pm 6.1 Group 2 (n=43): 13.8 \pm 6.8 12 months: Group 1 (n=77): 12.4 \pm 5.3 Group 2 (n=37): 15.6 \pm 9.6 36 months: Group 1 (n=77): 12.4 \pm 5.3 Group 2 (n=34): 13.5 \pm 7.4 48 months: Group 1 (n=66): 11.9 \pm 4.9 Group 2 (n=30: 14.7 \pm 7.57 60 months: Group 1 (n=61): 11.4 (4.9) Group 2 (n=32): 13.6 (7.8)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Mean (SD) residual urine in mL	Baseline: Group 1 (n=99): 106 ± 77 Group 2 (n=45): 94 ± 82 12 months: Group 1 (n=86): 49 ± 70 Group 2 (n=38): 54 ± 77 24 months: Group 1 (n=75): 56 (63) Group 2 (n=38): 40 (48) 36 months: Group 1 (n=68): 47 (62) Group 2 (n=34): 54 (118) 48 months: Group 1 (n=55): 60 (59) Group 2 (n=29): 55 (53) 60 months: Group 1 (n=63): 70 (90) Group 2 (n=32): 51 (45)	
			Reduction in prostate volume (after 12 months):	Group1 (n=16): 30% Group 2 (n=13): 51%	
			Additional BPH treatment (5 year follow-up)	Group 1: 10/100 (10%) Group 2: 2/46 (4.3%)	
			Mortality (27 days after treatment)	Group 1: 0/100 Group 2: 1/46	
			Complications	Micturition urgency at 12months: Group 1: 37/100 (37%) Group 2: 6/46 (13%)	
				Urinary retention: 0-12 months: Group 1: 19/100 (19%) Group 2: 6/46 (13%) 12-60 months Group 1: 2/80 (2.5%) Group 2: 0/39	
				Urinary tract infection:	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				12 months: Group 1: 18/100 (18%) Group 2: 9/46 (20%) 12-60 months: Group 1: 0/80 Group 2: 1/39 (2.6%)	
				Haematuria: 12 months Group 1: 13/100 (13%) Group 2: 18/46 (39%) 12-60 months Group 1: 5/80 (6.3%) Group 2:0	
				Erectile dysfunction: 12 months: Group 1: 6/100 (6%) Group 2: 5/46 (11%) 12-60 months: Group 1: 6/80 (7.5%) Group 2: 6/39 (15.4%)	
				Transient incontinence 12 months: Group 1: 3/100 (3%) Group 2: 6/46 (13%) 12-60 months: Group 1: 1/80 (1.3%) Group 2: 2/39 (5.1%)	
				TUR: Group 1: 0/100 Group 2: 1/46 Reoperation (up to 60 months): Group 1: 8/100 Group 2: 1/46	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Dahlstrand et al., 1993 ⁵⁴ Reported in systematic review HTA 2008 Study design: RCT Setting: Sweden Evidence level: 1+ Duration of follow-up: 12 months	Inclusion criteria: residual urine volume ≤ 350 ml; Madsen score ≥ 8 ; prostate length 35-50mm from TRUS. Qmax <15 m/s (twice); BPH; anaesthetic risk group 1-3; obstructive symptoms > 3 months. Exclusion criteria: <45 years; suspicion or known prostate cancer or bladder cancer; previous surgery for cancer of prostate or radiotherapy; rectal surgery; prior surgery or heat treatment of BPH; large median lobe; neurogenic bladder disorder; mental incapacity, dementia or inability to give informed consent; neurological disorders that may affect bladder function; peripheral arterial disease; disorder of haemostasis or serum creatinine $>2mg/dl$; uncontrolled cardiac dysrhythmias, or cardiac pacemaker; total hip replacement or other metallic implants; indwelling or condom catheter; post void residual urine >350 ml; urethral stricture; bladder stones; adrenergic blockers antiandrogen medication or other medication that might affect prostate or bladder; bacterial prostatitis or UTI at time of treatment ; prostatic urethral length of >50 mm or <35 mm by transrectal US; anaesthesia risk category 4 or 5.	Group 1: TUMT Prostatron, Power: 60W; Temperature: urethral: 44.5 degrees and rectal 42.5 degrees. If no voiding use indwelling catheter for 3- 5 days. No general anaesthesia but intraurethral topical lidocaine HCl jelly 2% and NSAID. Postoperative oral norfloxacin 400mg twice per day for 5 days. Treatment time 60 minutes. Group 2: TURP performed by urologists were senior registrar or above. Mean operative time: 60.9 minutes. Hospital stay: 5 ±1.9 days	Mean (SD) Madsen symptom score Mean (SD) residual urine volume (ml) Mean (SD) maximum flow rate (ml/s)	Baseline: Group1 (n=39): 11.2 \pm 3.1 Group 2(n=39): 13.3 \pm 4.2 3 months: Group 2(n=37): 2.3 \pm 2.7 Group 2(n=39): 1.6 \pm 2.5 6 months: Group1(n=28): 3.1 \pm 3.0 Group 2(n=23): 0.9 \pm 1.6 12 months: Group1(n=25): 2.7 \pm 2.9 Group 2(n=22): 0.9 \pm 2.2 Baseline: Group1 (n=39): 105 \pm 88 Group 2 (n=40): 116 \pm 97 3 months: Group1(n=37): 55 \pm 51 Group 2(n=39): 31 \pm 25 6 months: Group1(n=28): 68 \pm 69 Group 2(n=24): 17 \pm 10 12 months: Group1 (n=24): 47 \pm 51 Group 2 (n=22): 22 \pm 16 Baseline: Group1 (n=39): 8.0 \pm 2.8 Group 2 (n=40): 7.9 \pm 3.2 3 months: Group1 (n=35): 12.2 \pm 4.9 Group 2 (n=37): 18.7 \pm 6.0 6 months: Group1 (n=32):12.0 \pm 4.5 Group1 (n=24): 12.3 \pm 4.7 Group2 (n=22): 17.7 \pm 6.5	Funding: NR Limitations: Method of randomisation, allocation concealment and blinding not reported. Additional outcomes: Maximum capacity change. Additional follow-up 6- 8 weeks after surgery. Notes: * Catheterisation required but removed within 3-5 days.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	All patients N: 79		Reoperation:	Group1: 4/39 (10.2%) Group 2: 0/40	
	Drop outs: 4 <u>Group 1</u>		Re-catheterisation due to unable to void:	Group1: 8/39* Group 2: 2/40	
	N: 39 Mean Age: 68 Prostate volume: 33ml Mean Madsen ±SD: 11.2± 3.1 Dropouts: 0 Group 2 N: 40 Mean Age:70 Prostate volume: 37ml Mean Madsen ± SD: 13.3± 4.2 Dropouts: 4 (sever hepatitis=1, cancer discovered=2, refusal for		Transient urgency after surgery	Group 1: 7/39 Group 2: 4/40	
			Transient urinary leakage	Group 1: 0/39 Group 2: 1/40 (2.5%)	
			Bleeding and rehospitalisation	Group 1 0/39 Group 2: 3/40	
			Internal urethrotomy due to stricture	Group 1: 0/39 Group 2: 3/40	
	TURP=1).		Urinary tract infections	Group 1: 3/39 Group 2: 0/40	
			Men with retrograde ejaculation following surgery (previously with antegrade ejaculations)	Group 1: 0 Group 2: 4/16	
			% Reduction in prostate size (6m)	Group 1: 0 Group 2: 47	
			Unstable detrusor contractions	Baseline Group 1: 6/21 Group 2: 5/13 After surgery: Group 1: 8/21 Group 2: 2/13	
			Sexually active men	All men who were sexually active before treatment remained so after.	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Dahlstrand et al., 1995 ⁵⁵ Reported in systematic review HTA 2008 Study design: RCT Setting: Sweden Evidence level:	 Inclusion criteria: residual urine volume ≤ 350ml; Madsen score ≥ 8; prostate length 35-50mm from TRUS. Exclusion criteria: prostate cancer or bladder cancer; previous surgery for cancer of prostate; prior treatment for BPH; indwelling catheter, urethral stricture; large median lobe; neurogenic bladder disorder, metallic hip implant. All patients 	Group 1: TUMT Prostatron (Prostasoft 2.0 software) – 60W. Treatment in single session as outpatient. Intra- urethrally applied lidocaine hydrochloride jelly used. Before treatment patients given indomethacin 50mg and norfloxacin 400mg was given; after treatment indomethacin given twice for one day and	Madsen symptom score	Baseline: Group 1 (n=37): 12.1 ± 3.0 Group 2 (n=32): 13.6 ± 3.9 3 months: Group 1 (n=36): 2.9 ± 3.0 Group 2 (n=32): 1.7 ± 2.6 6 months: Group 1 (n=37): 2.6 ± 2.6 Group 2 (n=32): 1.1 ± 1.8 12 months: Group 1 (n=33): 2.2 ± 2.4 Group 2 (n=31): 0.6 ± 1.4 24 months: Group 1 (n=31): 2.3 ± 3.0 Group 2 (n=30): 1.2 ± 1.9	Funding: NR Limitations: Method of randomisation, use of allocation concealment and blinding were not reported. Unsure if same study as Dahlstrand 1993 – HTA attempted to contact authors.
1+ Duration of follow-up: 2 years	N: 72 eligible – 69 randomised Drop outs: 10 Group 1 N: 37 Mean Age: 67.9±9 Mean Madsen ± SD: 12.1± 3	norfloxacin 400mg twice daily for 5 days. Group 2: TURP by senior registrar grade or above. Mean operation	Reduction in symptom score > 50% Maximum flow rate (mL/s)	Group1: 26/31 Group 2: 29/30 Baseline: Group1 (n=37): 8.6±2.5 Group 2 (n=32): 8.6±3.0 3 months: Group1 (n=36): 11.6±4.2	Additional outcomes: Volume at first sensation to void after 6 months. Detrusor contractions and urethral resistance factor.
	Dropouts: 2 (died=1, hernia operation=1) Group 2 N: 32 Mean Age:70±6 Mean Madsen ± SD: 13.6± 3.9 Dropouts: 8 (TURP=2, abroad=1, refused=1, severe pancreatitis=1, neurological disease=1, reoperation with TUMT and then TURP=2)	time=48±17 minutes. Mean hospital stay=3.9±1.3 days.		Group 2 (n=30): 11.0 ± 4.2 Group 2 (n=32): 18.1 ± 7.1 6 months: Group 1 (n=37): 11.8 ± 3.9 Group 2 (n=31): 18.6 ± 5.2 12 months: Group 1 (n=33): 12.6 ± 3.9 Group 2 (n=31): 18.9 ± 6.0 24 months: Group 1 (n=30): 12.3 ± 4.4 Group 2 (n=29): 17.6 ± 5.9	Notes: Reoperation: TUMT group=4: 2 retreated by TURP, 2 by TUMT; the TUMT reoperations had TURP at 1 year due to unsatisfactory improvement. TURP group: reoperation from early
			Residual urine volume (mL)	Baseline: Group1 (n=37): 194±78 Group 2 (n=32): 1104±95 3 months:	complication=3 due to bleeding or to remove clots; 1 retreatment

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Group1 (n=36): 147 ± 45 Group 2 (n=32): 134 ± 32 6 months: Group 1 (n=37): 166 ± 64 Group 2 (n=32): 134 ± 30 12 months: Group1 (n=33): 152 ± 64 Group 2 (n=31): 123 ± 18 24 months: Group1 (n=31): 148 ± 44 Group 2 (n=30): 127 ± 2	after 1 year due to bladder neck sclerosis.
			Prostate volume	Baseline: Group 1: 33.9±11.9 Group 2: 36.8 ±16 2 years: Group 1: 30.3 ±9.6 Group 2: 22.5±10.9	
			Reoperation:	Group1: 4/37 Group 2: 1/32	
			Catheterisation due to failure to void	Group1: 5/37 Group 2: 0/32	
			Transient rectal pain in perineum	Group1: 1/37 Group 2: 0/32	
			Urethral stricture	Group1: 0/37 Group 2: 2/32	
			Meatal stenosis	Group1: 0/37 Group 2: 2/32	
			Urinary tract infection	Group1: 5/37 Group 2: 4/32	
			Mortality (brain tumour)	Group 1: 0/37 Group 2: 1/32	
			Erectile dysfunction	Group 1: 0/37 Group 2: 0/32	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
D'Ancona et	Patient group: Between January	Group 1:	Mean (SD) IPSS score:	Baseline:	Funding: NR
al., 199853	1994 and August 1995 patients	TUMT – Prostatron		Group1 (n=31): 18.3 (6.3)	_
Reported in	recruited.	software version 2.5.		Group 2 (n=21): 16.7 (5.6)	Limitations:
systematic		Total mean energy		3months:	Method of
, review HTA	Inclusion criteria: unequivocal BPH	applied 151.8kJ.		Group1 (n=31): 15.1 (8.2)	randomisation,
2008	candidates for TURP. Qmax 15ml/s;	100mg suppository of		Group 2 (n=21): 5.1 (3.1)	allocation concealment
	residual volume <350ml; Madsen	diclofenac administered		6 months:	and blinding unclear.
Study design:	score ≥ 8 ; prostate length 25-	and 2mg of medazolam		Group1 (n=28): 6.7 (5.5)	Ũ
RCT	50mm, Prostate Volume 30-100ml;	injected. No additional		Group 2 (n=20): 4.0 (2.1)	
	45 years plus.	anaesthesia during		12 months:	Additional outcomes:
Setting:	,	treatment.		Group1 (n=27): 5.0 (2.7)	Madsen score, voided
Netherlands	Exclusion criteria: prostate cancer;	Out patient.		Group 2 (n=17): 3.4 (2.2)	volumes, URA and
	prior prostate surgery; urinary	Prolonged catheterisation:		30 months:	LPURR.
Evidence	retention requiring catheterisation;	12.7 days.		Group1 (n=17): 7.9 (6.3)	
level:	medications prescribed for			Group 2 (n=12): 6.3 (4.8)	Notes:
1+	prostate/bladder treatment;				Links with D'Ancong
•	neurogenic disorders affecting	Group 2:	Qmax (mL/s)	Baseline:	1997 ⁵²
Duration of	bladder function; diabetic	TURP by 2 urologists and		Group1 (n=31): 9.3 (3.9)	
follow-up:	neuropathy; possible microwave	resection performed under		Group 2 (n=21): 9.3 (3.4)	
2.5 years	sensitive implants (pacemaker, hip	spinal anaesthesia.		3months:	
210 /0015	prosthesis); renal impairment or	Mean length of hospital		Group1 (n=31): 15.5 (8.0)	
	obstructed bladder neck due to	stay 4.1. Mean		Group 2 (n=21): 19.6 (11.2)	
	enlarged median lobe of prostate	catheterisation 4.1 days.		6 months:	
	childiged hieddan lobe of prostate			Group1 (n=38): 17.0 (7.5)	
	All patients			Group 2 (n=20): 15.3 (5.9)	
	N: 52			12 months:	
	N. 52			Group1 (n=27): 17.1 (7.8)	
	Group 1			Group 2 (n=17): 19.3 (29.8)	
	N: 31			30 months:	
	Mean Age ± SD: 69.6 ± 8.5			Group1 (n=17): 15.1 (9.6)	
				Group 2 (n=12): 19.1 (8.2)	
	Mean IPSS \pm SD: 18.3 \pm 6.3				
	Dropouts: 14 (6 TURP, 1 died, 5		PVR (mL)	Baseline:	
	refused or lost to follow up, 2			Group1 (n=31): 49.5 (69.9)	
	medication)			Group 2 (n=21): 91.1 (104.7)	
				3months:	
	Group 2			Group1 (n=31): 25.5 (58.1)	
	N: 21			Group 2 (n=21): 10.5 (24.5)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean Age ± SD: 69.3 ± 5.9 Mean IPSS ± SD: 16.7± 5.6 Drop outs: 9 (4 refused or lost to follow up, 1 bladder neck incision, 1 bladder carcinoma, 1 at own request, 2 dementia)			6 months: Group1 (n=28): 30.6 (41.0) Group 2 (n=20): 52.7 (70.7) 12 months: Group1 (n=27): 70.4 (81.3) Group 2 (n=17): 23.6 (29.8) 30 months: Group1 (n=17): 27.4 (49.1) Group 2 (n=12): 9.3 (14.6)	
			Pdet Qmax (cmH20)	Baseline Group 1: 77.7 (40.0) Group 2: 65.4 (24.9) 6 months: Group 1: 54.0 (15.9) Group 2: 38.5 (24.5)	
			Prostate volume (mL)	Baseline Group 1: 43.4 (11.8) Group 2: 44.9 (15.3) 3 months: Group 1: 36.6 (10.0) Group 2: 23.0 (8.8)	
			Reoperation:	Group 1: 2/31 (6.4%) Group 2: 1/21 (4.8%)	
			Blood transfusions	Group 1: 0/31 Group 2: 0/21	
			UTI	Group 1: 5/31 (16%) Group 2: 1/21 (4%)	
			Irritative voiding symptom	Group 1: 9 (29%) Group 2: 4 (19%)	
			Hematuria	Group 1: 0 Group 2: 3 (14%)]
			Mortality	Group 1: 1 Group 2: 0	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments				
al.,199642	Patient group: moderate or severe symptoms of prostatism	Group 1: Transurethral vaporisation of the prostate (TUVP)	Mean change in AUA symptom score from baseline at 3 months	Group 1: -20.89 Group 2: -21.31 p value: NR	Funding: NR				
RCT	Setting: single centre, urology clinic, Ankara Nummune Hospital, Turkey	electrode. cutting mode: 240-300 W & coagulation mode: 40-70 W TUVP continued until capsule was visible	electrode. cutting mode: 240-300 W & coagulation mode: 40-70 W TUVP continued until capsule was visible	electrode. cutting mode: 240-300 W & coagulation mode: 40-70 W TUVP continued until capsule was visible	electrode. cutting mode: 240-300 W & coagulation mode: 40-70 W TUVP continued until capsule was visible	electrode. cutting mode: 240-300 W & coagulation mode: 40-70 W TUVP continued until capsule was visible Mean baselin	from baseline at 3 months	Group 1: 16.37 Group 2: 17.49 p value: NR	Limitations: • Randomisation method and allocation
Evidence level: 1+	Inclusion criteria: • Peak urine flow rate <15 • AUA moderate to severe						visible	visible ba	visible Mean change in P baseline at 3 mon
Duration of follow-up:	Exclusion criteria:Patients who had previously	of the prostate (TURP) Conventional electroresection	Complications: transfusion	Group 1: 0/23 Group 2: 2/23	 assessment not reported Symptom score and Qmax were not reported at 3 months or at baseline 				
3 months after surgery	undergone a prostate operation or who had any abnormality of kidney and liver function, urethral strictures,	All patients: Glycine was used as irrigant.	Complications: re- catheterisation required (retention)	Group 1: 4/23 Group 2: 0/23					
	 neurogenic deficits, bladder stones Those with confirmed or suspected prostate cancer. 	Indwelling catheter placed after surgery and removed when urine was clear.	Complications: urethral or meatal stricture:	Group 1: 1/23 Group 2: 0/23	 Standard deviations not reported for changes from baseline 				
	All patients N: 46 Drop outs: NR	uroflowmetry taken 3 months after			 Not clear whether ITT analysis performed Drop outs not reported 				
	Group 1: N: 23 Age (mean ± SD): 68.4 ± 8.3 Mean prostate size ± SD: 48.4 ± 9.7 ml (TRUS) Operative duration ± SD: 41.6 ± 22.1 min Solution volume used ± SD: 16.0 ± 10.2 ml Catheterisation time (days): 1.4 ± 0.8 days Length of stay (days): NR Drop outs: NR				 Drop outs not reported Additional outcomes: Irritative symptoms after catheter removal more in TUVP group. Notes: None. 				
	Group 2:								

Evidence Table 36 Transurethral vapourisation of the prostate (TUVP) vs. transurethral resection of the prostate (TURP)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	N: 23 Age (mean ± SD): 62.5 ± 10.1 Mean prostate size ± SD: 48.8 ± 15.4 ml (TRUS) Operative duration ± SD: 52.4 ± 20 min Solution volume used ± SD: 19.8 ± 8.6 ml Catheterisation time (days): 1.9 ± 0.8 days Length of stay (days): NR Drop outs: NR				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Ekengren et al., 2000 ⁶⁸	Patient group: men scheduled for surgery for obstruction	Group 1: Transurethral vaporisation of the prostate (TUVP)	Median IPSS score (range) at 12 months	Group 1: 4.5 (0-24) Group 2: 4.0 (0-100) p value: Not	Funding: Supported by the Board of Research and
Study design: RCT Unmasked	Setting: single centre, department of surgery and urology, Söder Hospital, Stockholm, Sweden	(Stortz) m Cutting mode: 240 W	Mean ± SD IPSS at 12 months*	Group 1: 7.0 ± 6.5 ** Group 2: 9.3 ± 19.8 ** p value: NR	Education of Stockholm County Council
Evidence level: 1+	Inclusion criteria: NR		Median Qmax mL/s (range) at 12 months	Group 1: 10 (4-19) Group 2: 11 (0-19) p value: Not sig.	 Limitations: Patients and investigators were unmasked to
Duration of follow-up:	Exclusion criteria: NR	Conventional electroresection All patients:	Mean Qmax ± SD mL/s at 12 months*	Group 1: 10.7 ± 4.1(n=23) Group 2: 11.1 ± 4.4 (n=28) p value: NR	treatment allocation Not clear whether
12 months after surgery	All patients N: 54 Drop outs: 3 died (TUVP)	Operations performed using 26F resectoscope. Ringer's solution with heparin used to	Median QoL score (range) at 12 months	Group 1: 1.5 (0-6) Group 2: 1.0 (0-6) p value: Not sig.	ITT analysis performed **Values for mean
	<u>Group 1:</u> N: 26 Median age (range): 71 (49-82)	replace blood lost measured using a photometer. Irrigating fluid of mannitol & ethanol and fluid absorption	Mean ± SD QoL at 12 months*	Group 1: 1.8 ± 1.6 (n=23) Group 2: 1.8 ± 2.0 (n=28) p value: NR	IPSS given by author were very different to the
	Median IPSS (range): 22 (1-100) Median QoL score (range): 4.5 (2-6)	using ethanol method.	Complications: mortality	Group 1: 2/26 Group 2: 0/28	median reported i the study values a baseline were >3;
	Mean QoL score ± SD: 4.6 ± 1.2* Median PSA (range): 4 (2-23) ng/mL	Preoperative: Baseline prostate volume &	Complications: transfusion	Group 1: 0/26 Group 2: 0/28	Additional outcomes:
	Median PVR (range): 55 (0-3000) mL Median Qmax (range): 4 (0-8) mL/s Mean Qmax ± SD: 3.7 ± 2.4 mL/s*	PVR (TRUS), IPSS, uroflowmetry (Flo-Labll), serum PSA, Quality of Life	Complications: urethral stricture	Group 1: 2/26 Group 2: 0/28	Significantly higher blood loss during the
	Median prostate vol. (range): 50 (25- 90) mL (TRUS)	Score (QoL) score, Postoperative	Complications: urinary retention	Group 1: 0/26 Group 2: 1/28	operation for TURP. Unable to check p
	Median operative duration (range): 30 (15-80) min	prostate volume & PVR (TRUS), IPSS, uroflowmetry	Complications: reoperation rate	Group 1: 2/26 Group 2: 1/28	value. Notes:
	Median blood loss (range): 75 (8- 400) mL (Flo-Labll), serum PSA, Quality of Life Score (QoL) Drop outs: 3 (1 died from myocardial infarction, 1 died (catheter) and 1 with urethral stricture lost to follow up) score			*Requested Mean IPS Qmax, QoL and follor up data from author. Author reports that data were skewed hence presented as	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	$eq:generalized_set_set_set_set_set_set_set_set_set_set$				median and range. Author reported randomisation performed by drawing of sealed envelopes from a box prior to surgery

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Erdagi et al., 1999 ⁷²	Patient group: men with symptomatic BPH	vaporisation of the prostate (TUVP)(ranVaporTrode® rollerball electrode (Storz) at 240W for cutting and 40W for coagulation.Mea (ranGroup 2: Transurethral resection of the prostate (TURP)Mea (ranStandard 0.012 inch loopMea (ran	Mean IPSS score (range) at 3 months	Group 1: 0.9 ± NR (0-4) Group 2: 5.3 ± NR (1-12) p value: Not sig.	Funding: NR
Study design: RCT Unmasked	Setting: single centre, Turkish High Specialisation Hospital, Ankara, Turkey		Mean IPSS score (range) at 6 months	Group 1: 0.6 ± NR (0-3) Group 2: 3.9 ± NR (1-9) p value: 0.92 (Mann Whitney-U)	Limitations: • Mean and standard deviations not
Evidence level: 1+	Inclusion criteria: NR		Mean Qmax mL/s (range) at 3 months	Group 1: 21.0 ± NR Group 2: 17.0 ± NR p value: NR	reported for outcomes at baseline or end
Duration of follow-up:	Exclusion criteria: NR All patients		Mean Qmax mL/s (range) at 6 months	Group 1: 21.4 ± NR Group 2: 17.7 ± NR p value: 0.04 (Mann Whitney-U)	 point. Randomisation method and
6 months after surgery	Drop outs: NR 26F resectoscope under	Operations performed using	Catheterisation time (days)	Group 1: 1.1 ± NR Group 2: 3.4 ± NR p value: <0.001	 allocation concealment not reported Masking of
	Group 1: N: 20 Mean age (range): 64.2 (56-82) Mean IPSS (range): 20.6 (12-27)	solution. Examination methods Preoperative:	Complications: transfusion	Group 1: 0/20 Group 2: 9/20 p value: NR NCC_AC calculate p=0.01 Fishers exact test	patients or outcome assessment not reported
	(n=15*) Mean Qmax ml/s (range): 5.1 (0- 11.27) (n=15*) Mean PVR ml (range): 68 (20-150)	Baseline IPSS Symptom score, PSA, uroflowmetry using Synectics Urodynamics Polygraph System, PVR by	Complications: retrograde ejaculation	Group 1: 2/20 Group 2: 12/20	 Dropouts not reported Small sample size
	Mean prostate weight. (range): 32.5 (20-48) (TRUS)ultrasonography and prostate volume by TRUS.Mean operative duration (range): 61.5 minAssessed at 1, 3 & 6 months postoperativelyMean operative blood loss ml: 117.6 Catheterisation time (days): 1.1Drop outs: NR	ultrasonography and prostate volume by TRUS. Assessed at 1, 3 & 6 months	Complications: UTI	Group 1: 1/20 Group 2: 5/20 p value: NR NCC_AC calculate p=0. 18 Fishers exact test	Notes: Mann Whitney test was used for statistical
		Complications: Urethral Stricture	Group 1: 0/20 Group 2: 1/20 p value: NR NCC_AC calculate p=1.00 Fishers exact test	analysis	
Group 2: N: 20 Mean age (range): 66.1 (58-75) Mean IPSS (range): 21.5 (11-30) (n=15*)					

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean Qmax ml/s (range): 4.6 (0-9.6) (n=15*) Mean PVR ml (range): 123 (0-600) Mean prostate weight. (range): 37 (15-60) (TRUS) Mean operative duration (range): 67.7 min Mean operative blood loss ml: 491 Catheterisation time (days): 3.4 Drop outs: NR *10 patients with chronic retention with indwelling catheter also included did not have baseline IPSS or Qmax data				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Fowler et al., 2005 ⁸³	Patient group: men considering surgery for BPH	Group 1: Transurethral vaporisation of the prostate (TUVP)	Mean change in IPSS Score from baseline ± SD at 2 mths	Group 1: 9.8 ± 7.2 (n=105) Group 2: 11.8 ± 7.7 (n=110) p value NR	Funding: Supported the INAHTA Health Technology
-	Setting: multi-centre, UK Inclusion criteria:	Circon-ACMI 24.5 Fr continuous flow rectoscope with new	Mean change in IPSS Score from baseline ± SD at 6 mths	Group 1: 8.5 ± 7.4 (n=106) Group 2: 6.9 ± 5.5 (n=108) p value NR	Assessment programme
(though patients on regional anaesthetic	 Must have completed pre-treatment evaluation with current criteria for prostate surgery. Able to give written informed consent to 	Circon- ACMI Fluted VaporTrode® electrode for each patient. 180W for cut and 55W for	Mean change in IPSS Score from baseline ± SD at 2 years	Group 1: 8.6 ± 7.2 (n=90) Group 2: 7.5 ± 5.8 (n=77) p value NR	 Baseline data was not available for all outcomes Drop outs reported
may have known which operation they had)	 Able to give written informed consent to randomisation and treatment Exclusion criteria: Previous bladder outlet surgery clinical 	Group 2: Transurethral resection of the prostate	Mean change in IPSS QoL Score from baseline ± SD at 2 mths	Group 1: 2.6 ± 1.82 (n=105) Group 2: 2.3 ± 1.73 (n=109) p value NR	 Drop outs reported for primary outcome rather than those completing study
Evidence level:]+	 Previous bladder other surgery clinical evidence of prostate cancer Physical status >ASA 3 Medications that (in investigators opinion) would preclude entry into trial 	(TURP) Circon-ACMI 24.5 Fr continuous flow rectoscope with new wire	Mean change in IPSS QoL Score from baseline ± SD at 6 mths	Group 1: 2.0 ± 1.63 (n=107) Group 2: 1.6 ± 1.34 (n=108) p value NR	 Investigators were not masked to treatment allocation
Duration of follow-up: 2 years	 Clinically significant acute illness Known disease of central or peripheral nervous system. 	loop for each patient. Cutting mode: 120-140 W. Coagulation mode: 50-60 W	Mean change in IPSS QoL Score from baseline ± SD at 2 years	Group 1: 1.9 ± 1.62 (n=89) Group 2: 1.8 ± 1.34 (n=80) p value NR	Additional outcomes: Change in General Health related EuroQol
	 Prostate cancer. <u>All patients</u> N: 235 45/235 patients in acute retention Drop outs: Number of patients completing study NR 	All patients: Irrigating fluids varied between glycine and	Mean change in Qmax from baseline ± SD at 2 mths	Group 1: 19.12 ± 11.76 (n=108) Group 2: 21.23 ± 10.20 (n=111) p value NR	score from baseline Erectile dysfunction, failed ejaculation, change in ejaculatory
		glycine & ethanol depending on the centre 3-way catheters were	Mean change in Qmax from baseline ± SD at 6 mths	Group 1: 19.60 \pm 11.04 (n=109) Group 2: 22.29 \pm 10.25 (n=109) p value NR	function, change in PVR and prostate volume. Additional procedures
	Group 1: N: 115 Mean age (± SD): 70.2 ± NR Mean IPSS (± SD): 20.7 ± 7.2 (n=107) Mean 22 (n=112)	removed when degree of haematuria was permitted. Preoperative: Baseline blood tests (FBC,	Duration of catheterisation (days)	Group 1: $4.9 \pm 11.6^*$ (Cl95% 2.7-7.1) n=107 Group 2: $3.1 \pm 4.4^*$ (Cl95% 2.3- 3.9) n=116 p value: 0.93	Notes: Randomisation method was computer generated by study
	Mean EuroQoL score: 0.78 ± 0.23 (n=112) Mean IPSS QoL: 4.6 ± 1.7 (n=109) Mean PSA (± SD): 4.7 ± NR ng/mL (n=101)	urea, PSA), Uroflow using Dantec Urodyn 1000 (2	Length of hospital stay (days)	Group 1: $4.4 \pm 3.6^*$ (Cl95% 3.8- 5.1) n=115 Group 2: $4.6 \pm 4.2^*$ (Cl95% 3.9-	organisers and allocation concealment by sequentially

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean PVR (\pm SD): 181 \pm NR mL (n=91) Mean Qmax (SD): 10.1 \pm 4.35 mL/s (n=94) Mean prostate vol. (SD): 54.3 \pm NR mL (TRUS) (n=100) Serum creatinine (mmol/L): 105 \pm NR (n=100) Number of patients with ED: 34/109 Drop outs: 6/115 violated protocol. Number of patients completing study NR Group 2: N: 120 Mean age (\pm SD): 69.7 \pm NR Mean IPSS (\pm SD): 20.7 \pm 6.9 (n=114) Mean EuroQoL score: 0.74 \pm 0.25 (n=116) Mean IPSS QoL: 4.9 \pm 0.98 (n=114) Mean PSA (\pm SD): 4.6 \pm NR ng/mL (n=99) Mean PVR (\pm SD): 171 \pm NR mL (n=94) Mean Qmax (SD): 10.52 \pm 5.04 mL/s (n=97) Mean prostate vol. (SD): 51.1 \pm NR mL	flow rates >150mL if possible), PVR using TRUS 7.5 MHz, Cystometrography and questionnaires: IPSS, EuroQoL, Sexual Function from ICS-BPH questionnaire. Postoperative Assessment at 2 months, 6 months: Blood tests (FBC & urea only) Uroflow using Dantec Urodyn 1000 (2 flow rates >150mL if possible), PVR using TRUS 7.5 MHz, cystometrography and questionnaires: IPSS, EuroQoL, Sexual Function from ICS-BPH	Complications: transfusion Complications: reoperation rate (TUIP) Complications: urethral or meatal stricture. Reported as number of	Effect size 5.4) n=120 p value: 0.47 Group 1: 2/115 Group 2: 9/120 P value: 0.04 (Chi-squared) Group 1: 5/115 Group 2: 17/120 P value: NR Group 1: 64/115 Group 2: 66/120	Comments numbered opaque envelopes. *SD calculated from confidence intervals and sample size according to section 7.7.3.2 of the Cochrane Handbook Number of patients in each group was not reported for length of stay data but states that data collected for all but 3 patients. Use numbers randomised for calculation.
	(TRUS) (n=103) Serum creatinine (mmol/L): 104 ± NR (n=106) Number of patients with ED: 48/110 Drop outs: 6/120 violated protocol Number of patients completing study NR	questionnaire. IPSS Score, ICS-BPH & EuroQoL repeated 2 years as well.			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Gallucci et al., 1998 ⁸⁸	Patient group: men symptomatic men with BPH who were urodynamically obstructed	Group 1: Transurethral vaporisation of the prostate (TUVP)	Mean IPSS score ± SD at 3 months	Group 1: 5.50 ± 4.77 Group 2: 5.52 ± 4.11 p value: Not sig.	Funding: NR
Study design: RCT	Setting: multi-centre, 9 centres, Italy	electrode (Circon ACMI) at 200-250W for cutting.at a at aGroup 2: Transurethral resection of the prostate (TURP)Me at 1Standard diathermic loopMe SDAll patients: Operations performed using 22.5F resectoscope under continuous 5% mannitolMe SD	Mean IPSS score ± SD at 6 months	Group 1: 4.94 ± 4.69 Group 2: 3.77 ± 3.31 p value: Not sig.	Limitations: Randomisation method and
Evidence level: 1+	Inclusion criteria: NR Exclusion criteria:		Mean IPSS score ± SD at 12 months	Group 1: 4.04 ± 4.27 Group 2: 3.52 ± 3.04 p value: Not sig.	allocation concealment not reported
Duration of follow-up: 12 months	 Complete urinary retention Bladder calculi Neurogenic bladder 		Mean Qmax mL/s ± SD at 3 months	Group 1: 18.18 ± 7.7 Group 2: 19.21 ± 8.14 p value: Not sig.	Masking of outcome assessment not reported
	 Prostate weight >70g Bladder cancer Mental illness 		Mean Qmax mL/s ± SD at 6 months	Group 1: 20.13 ± 9.62 Group 2: 20.77 ± 8.5 p value: Not sig.	Additional outcomes: Detrusor and opening
	Prostate cancer or suspect All patients	solution. 3-way catheter inserted. Prophylactic antibiotics were used.	Mean Qmax mL/s ± SD at 12 months	Group 1: 20.31 ± 6.02 Group 2: 20.30 ± 6.35 p value: Not sig.	pressure at 3 months. Transient stress incontinence.
	N: 150 Drop outs: 0	Examination methods Preoperative: Baseline IPSS Symptom score,	Catheterisation time (days)	Group 1: 1.96 ± 1.09 Group 2: 2.71 ± 1.07 p value: <0.0001	Notes: No patients were lost to follow up
	Group 1:PSA, Blood, TRUS,N: 70uroflowmetry (oper	PSA, Blood, TRUS, uroflowmetry (opening pressure, detrusor pressure,	Length of hospital stay (days)	Group 1: 3.9 ± 2.01 Group 2: 4.69 ± 1.97 p value: <0.0001	SD calculated from standard error and and
	Mean IPSS ± SD: 18.84 ± 5.69 Mean Qmax mI/s ± SD: 7.26 ± 3.1 Mean PVR mI ± SD: 84.7 ± 95.3 Mean prostate weight ± SD (g):	catheters).	Complications: incontinence (at 12 mths)	Group 1: 4/70 Group 2: 3/80 p value: NR	sample size according to section 7.7.3.2 of the Cochrane Handbook
	Mean proside weight 1 3D (g):and pressure now and s36.61 ± 12.72months.Drop outs: 0IPSS assessed at 1, 3, 6 & 12months postoperatively	Complications: Urethral Stricture	Group 1: 3/70 Group 2: 3/80 p value: NR	numbers randomised for calculation.	
	<u>Group 2:</u> N: 80 Mean age (range): NR		Complications: transfusion	Group 1: 0/70 Group 2: 0/80 p value: NR	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean IPSS ± SD: 18.19 ± 5.90 Mean Qmax ml/s ± SD: 8.78 ± 10.38 Mean PVR ml ± SD: 64.61 ± 77.37 Mean prostate weight ± SD (g): 36.59 ± 12.25 Drop outs: 0		Complications: transient urinary retention	Group 1: 12/70 Group 2: 3/80 p value: NR	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Hammadeh et al., 2003 ⁹⁹	Patient group: men with bladder outflow obstruction due to BPH		Mean IPSS score ± SD at 1 year	Group 1: 4.4 ± 3.8 (n=51) Group 2: 5.9 ± 5.2 (n=51) p value: 0.3	Funding: NR
linked to Hammadeh et	considering surgery	(TUVP) Circon VaporTrode® roller-	Mean IPSS score ± SD at 2 years	Group 1: 4.3 ± 3.5 (n=47) Group 2: 6.3 ± 4.6 (n=47) p value: 0.02	Limitations:
al., 2000 ¹⁰⁰ & Hammadeh et al., 19980 ⁹⁸	Setting: single-centre, Whipps Cross Hospital, UK	Group 2: Transurethral	Mean IPSS score ± SD at 3 years	Group 1: 4.1 ± 3.3 (n=40) Group 2: 7.1 ± 6.2 (n=40) p value: 0.01	 Dropouts were only partially
Study design:	Inclusion criteria: ● IPSS ≥ 13		Mean IPSS score ± SD at 5 years	Group 1: 5.9 ± 6.3 (n=26) Group 2: 8.6 ± 7.1 (n=27) p value: 0.16	reported.
RCT Investigator	 QoL index ≥ 3 Qmax ≤ 15 mL/s 	(TURP) Standard loop with 145W	Mean Qmax mL/s ± SD at 1 year	Group 1: 22.5 ± 9.0 (n=51) Group 2: 20.8 ± 7.7 (n=51) p value: 0.4	Additional outcomes:
masked Evidence	Exclusion criteria:	cutting & 60W coagulation All patients:	Mean Qmax mL/s ± SD at 2 years	Group 1: 22.4 \pm 7.7 (n=47) Group 2: 21.2 \pm 8.5 (n=47) p value: 0.5.	Notes:
level: 1+	Complete urinary retentionNeurogenic bladder	Operations performed using 27F resectoscope using	Mean Qmax mL/s ± SD at 3 years	Group 1: 22.2 ± 8.5 (n=40) Group 2: 18.0 ± 7.1 (n=40) p value: 0.02	Patients allocated by
Duration of follow-up:	 Previous prostatic or urethral surgery Bladder calculi 	continuous glycine. 3-way catheter inserted. TURP patients were irrigated	Mean Qmax mL/s ± SD at 5 years	Group 1: 21.0 ± 9 (n=26) Group 2: 17.9 ± 13.1 (n=27) p value: 0.17	nurse drawing a sealed opaque envelope prior to surgery.
5 years	 Prostate cancer or suspect Receiving anticoagulant 	postoperatively until bleeding stopped.	Mean IPSS QoL ± SD at 1 year	Group 1: 1.2 ± 1.0 (n=51) Group 2: 1.5 ± 1.0 (n=51) p value: 0.3	
	therapy All patients	Examination methods Preoperative:	Mean IPSS QoL ± SD at 2 years	Group 1: 1.1 ± 1.0 (n=47) Group 2: 1.7 ± 1.1 (n=47) p value: 0.004	
	N: 104 (109 randomised but 5 excluded for medical problems or	Baseline IPSS Symptom score, DRE, urinalysis, PSA, Blood,	Mean IPSS QoL ± SD at 3 years	Group 1: 1.0 ± 0.9 (n=40) Group 2: 1.6 ± 1.4 (n=40) p value: 0.04	
Drop outs: *51 at 5 years: 6 TURP and 3 TUVP died from cardiopulmonary disease, 12 TURP and 16 TUVP lost to follow up.Follow u 6 & 12 postope	Drop outs: *51 at 5 years:	Follow up visits at 6 weeks, 3,	Mean IPSS QoL ± SD at 5 years	Group 1: 1.1 ± 1.2 (n=26) Group 2: 1.7 ± 1.4 (n=27) p value: 0.09	
	6 & 12 months, 2, 3 5 years postoperatively	Catheterisation time (days) hours reported converted to days	Group 1: 0.87 ± 0.29 Group 2: 1.94 ± 0.52 p value: <0.001		
	Remaining 14 patients unaccounted for.		Length of hospital stay (days)	Group 1: 2.2 ± 0.59 Group 2: 3.19 ± 0.76 p value: <0.001	
	Group 1: N: 52		Complications: transfusion (early)	Group 1: 0/52 Group 2: 1/52 p value: 0.3	
	Mean age (± SD): 67.5 ± 6.7 (52-		Complications: urinary	Group 1: 12/52	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	82)		retention (early)	Group 2: 4/52 p value: 0.04	
	Mean IPSS ± SD: 26.5 ± 4.5 IPSS QoL ± SD: 4.9 ± 0.9 Mean Qmax ml/s ± SD: 8.9 ± 3.2 Mean PVR ml ± SD: 131.0 ± 78.5 Mean prostate weight ± SD (g):		Complications: UTI (early)	Group 1: 3/52 Group 2: 2/52 p value: 0.7	
			Complications: TUR (early)	Group 1: 0/52 Group 2: 0/52 p value: 0.7	
	32.0 ± 9.1 Drop outs: *		Complications: urethral stricture (long term)	Group 1: 2/52 Group 2: 2/52 p value: NR	
	Group 2:		Complications: incontinence (long term)	Group 1: 0/52 Group 2: 0/52 p value: NR	
	N: 52 Mean age (± SD): 70.2 ± 7.2 (52- 87)		Complications: Retrograde ejaculation	Group 1: 21/52 Group 2: 28/52 p value: NR	
	Mean IPSS ± SD: 26.6 ± 4.8 IPSS QoL ± SD: 5.0 ± 0.7		Reoperation rate	Group 1: 2/52 Group 2: 2/52 p value: NR	
	Mean Qmax ml/s ± SD: 8.6 ± 3.2 Mean PVR ml ± SD: 101.0 ± 87.93		Mortality at 5 years (cardiopulmonary)	Group 1: 3/52 Group 2: 6/52 p value: NR	
	Mean prostate weight ± SD (g): 27.0 ± 12.2 Drop outs: *				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Kaplan et al., 1998 ¹¹⁸	Patient group: men with moderate to severe LUTS	Group 1: Transurethral vaporisation of the prostate (TUVP)	Mean AUA score ± SD at 3 months	Group 1: 9.2 ± 2.7 (n=32) Group 2: 8.6 ± 2.5 (n=32) p value: Not sig.	Funding: Partial funding: Grant RR-0045 from
RCT Examiner	Setting: single-centre, department of urology, Columbia University, New York, USA	luted roller-ball electrode at Me 40-270W for cutting at 0	Mean AUA score ± SD at 6 months	Group 1: 7.4 ± 2.9 (n=32) Group 2: 7.9 ± 3.1 (n=32) p value: Not sig.	National Institutes of Health Limitations:
masked Evidence Ievel:	Inclusion criteria: • AUA symptom score ≥ 10 • Qmax ≤ 15 mL/s	Group 2: Transurethral resection of the prostate (TURP) Standard loop	Mean AUA score ± SD at 12 months	Group 1: 6.6 ± 2.4 (n=30) Group 2: 6.1 ± 1.9 (n=31) p value: Not sig.	Randomisation method and allocation
1+ Duration of follow-up:	 Prostate volume 15-60g (TRUS) Exclusion criteria: 	All patients: Operations performed using 27F continuous flow	Mean Qmax mL/s ± SD at 3 months	Group 1: 14.8 ± 3.9 (n=32) Group 2: 16.8 ± 3.6 (n=32) p value: 0.03 (NCGC calculate as t-test with equal variance)	concealment not reported
12 months	 < 50 years old Neurogenic bladder Previous prostatic or urethral surgery 	resectoscope. Examination methods Preoperative:	Mean Qmax mL/s ± SD at 6 months	Group 1: 15.6 ± 3.2 (n=32) Group 2: 18.1 ± 4.2 (n=32) p value: 0.01 (NCGC calculate as t-test with equal variance)	not reported Additional
	voiding functionProstate or bladder cancer	Prostate or bladder cancer TRUS, uroflowmetry (Dantec Urodyn). I patients Follow up visits at 1, 3, 6 and 12 months postoperatively op outs: 3 at 1 year 7000 1: 32	Mean Qmax mL/s ± SD at 12 months	Group 1: 16.9 ± 4.1 (n=30) Group 2: 19.6 ± 4.9 (n=31) p value: 0.02 (NCGC calculate as t-test with equal variance).	Notes: Statistical analysis was performed by
	N: 64 Drop outs: 3 at 1 year		Catheterisation time (days) hours reported converted to days	Group 1: 0.54 ± 0.19 Group 2: 2.81 ± 0.57 p value: <0.01	third party who was masked to treatment allocation
	<u>Group 1:</u> N: 32 Mean age (± SD): 68.9 ± 8.7		Length of hospital stay (days)	Group 1: 1.3 ± 0.5 Group 2: 2.6 ± 0.9 p value: <0.03	
	Mean AUA ± SD: 19.4 ± 3.5 Mean Qmax ml/s ± SD: 7.2 ± 2.8 Mean PVR ml ± SD: 77.8 ± 20.3		Complications: transfusion	Group 1: 0/32 Group 2: 1/32 p value: NR	
	Mean prostate volume ± SD: 47.8 ± 22.3 Operative time ± SD: 47.6 ± 17.6 mins Drop outs: 2		Complications: UTI	Group 1: 5/32 Group 2: 4/32 p value: NR	
	•		Complications: TUR	Group 1: 0/32	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<u>Group 2:</u>			Group 2: 1/32 p value: NR	
	N: 32 Mean age (± SD): 72.8 ± 6.9 Mean AUA ± SD: 18.3 ± 4.7 Mean Qmax ml/s ± SD: 8.3 ± 3.6 Mean PVR ml ± SD: 66.9 ± 15.7 Mean prostate volume ± SD: 41.5 ± 19.7 Operative time ± SD: 34.6 ± 11.2 mins Drop outs: 1		Complications: urethral stricture	Group 1: 1/32 Group 2: 1/32 p value: NR	
			Complications: incontinence	Group 1: 0/32 Group 2: 0/32 p value: NR	
			Retrograde ejaculation	Group 1: 17/32 Group 2: 13/32 p value: NR	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments				
Kupeli et al., 1998 ¹³⁴ KUPELI A	Patient group: men with symptomatic BPH	vaporisation of the prostate (TUVP)	Mean AUA score (range) at 6 months	Group 1: 7.9 ± NR (0-12) (n=27) Group 2: 7.3 ± NR (1-12) (n=33) p value: NR	Funding: NR				
1998 (forest plot) Study design:	Setting: single-centre, department of urology, Ankara Hospital, Turkey	Storz spike electrode: cutting 180-250W (mean 220W) and coagulation 40-70W (mean 60W)M (r mGroup 2: Transurethral resection of the prostate (TURP) Standard loopM (r r (r mAll patients: Operations performed using 24F continuous flow resectoscope with 1.5% glycine as an irrigantC C (c	Mean AUA score (range) at 12 months	Group 1: 6.1 ± NR (0-11) (n=26) Group 2: 7.0 ± NR (1-14) (n=30) p value: NR	Limitations: Allocation concealment not				
RCT Evidence	Inclusion criteria: • AUA symptom score ≥ 7 • Qmax ≤ 15 mL/s		Mean Qmax (range) at 6 months	Group 1: 13.8 ± NR (8.2-16.4) (n=27) Group 2: 14.3 ± NR (7.2-17.5) (n=33) p value: NR	 reported Masked outcomassessment was not reported 				
level: 1+ Duration of	Exclusion criteria: ● Prostate volume ≥ 60g		Standard loop All patients: Operations performed using 24F continuous flow resectoscope with 1.5% glycine as an irrigant	Standard loop()All patients:()Operations performed using()24F continuous flow()resectoscope with 1.5%()glycine as an irrigantL	Mean Qmax (range) at 12 months	Group 1: 17.3 ± NR (11.5-23.8) (n=26) Group 2: 19.6 ± NR (9.4-24.5) (n=30) p value: NR	• Standard deviations were missing from		
follow-up: 12 months	 (TRUS) < 50 years old Neurogenic bladder 				Catheterisation time (days)	Group 1: 1.61 ± 0.8 Group 2: 3.83 ± 1.39 p value: <0.0001	primary outcom measures (AUA symptom score		
	 Previous prostatic or urethral surgery On medications know to 				Examination methods	Examination methods	Examination methods	Examination methods	Examination methods
	affect voiding functionProstate or bladder cancer	Preoperative: Baseline AUA symptom score, DRE, urinalysis, PSA, Blood,	Complications: transfusion	Group 1: 0/30 Group 2: 2/36 p value: NR	Notes: Randomisation by flipping a coin				
	All patients N: 66 Drop outs: 6 at 6 months and 10 at 1 year.	TRUS, uroflowmetry. Follow up visits to collect AUA symptom score and Qmax collected at 6 and 12 months	Complications: UTI	Group 1: 4/30 Group 2: 3/36 p value: NR					
	Group 1:postoperativelyN: 30Mean age (range): 65.7 (52-72)Mean AUA (range): 13.7 (7-29)Mean Qmax ml/s (range): 8.3	Complications: urinary retention	Group 1: 1/30 Group 2: 0/36 p value: NR						
		Complications: reoperation rate	Group 1: 1/30 Group 2: 0/36 p value: NR						
	(2.7 -11.8) Mean prostate volume ± SD: 43.57 ± 12.01		Complications: urethral stricture	Group 1: 0/30 Group 2: 0/36 p value: NR					

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
details	Operative time ± SD: 38.61 ± 7.32 mins Drop outs: 3 at 6 months and 4 at 1 year Group 2: N: 36 Mean age (range): 62.4 (56-70) Mean AUA (range): 14.6 (8-32) Mean Qmax ml/s (range): 8.8 (3.0 -12.4) Mean prostate volume ± SD: 41.46 ± 10.7 Operative time ± SD: 41.40 ± 7.95 mins Drop outs: 3 at 6 months and 6 at 1 year		Complications: incontinence	Group 1: 1/30 Group 2: 1/36 p value: NR	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Kupeli et al., 1998 ¹³⁵ KUPELI B		Mean IPSS score at 3 months	Group 1: 4.1 ± 22.25* Group 2: 5.2 ± 23.85* p value: Not sig.	Funding: NR		
1998 (forest plot) Study design: RCT	urology, Ankara Hospital, Turkey Inclusion criteria: • IPSS symptom score ≥ 8	Storz spike electrode	Storz spike electrode: cutting mean 250-	Mean Qmax (± SD) at 3 months	Group 1: 17.7 ± 4.1 Group 2: 19.7 ± 3.2 p value: 0.05 (NCGC calculated using t test with equal variances)	Limitations: • Randomisation method and allocation
Evidence level:	 Qmax < 15 mL/s Exclusion criteria: Neurogenic bladder Previous prostatic surgery 	Group 2: Transurethral resection of the	Catheterisation time (days) hours reported converted to days	Group 1: 2 ± NR Group 2: 4 ± NR p value: <0.05	 concealment not reported Masked outcome assessment was not 	
1+ Duration of follow-up:	Prostate cancer All patients	prostate (TURP) Standard loop (80- 120W)	Length of hospital stay (days)	Group 1: 2.5 ± NR Group 2: 4.5 ± NR p value: <0.05	 reported Standard deviations were missing from 	
3 months (mean 4.2 months)	ow-op: onths an 4.2N: 60 Drop outs: 0All patients: Operations performed	Complications: transfusion	Group 1: 0/30 Group 2: 0/30 p value: NR	primary outcome measure IPSS symptom score		
	<u>Group 1:</u> N: 30 Mean age (± SD): 62.4 ± 3.2 Mean IPSS score: 19.4 ± NR	flow resectoscope Examination methods	Complications: TUR	Group 1: 0/30 Group 2: 0/30 p value: NR	Dropouts were not mentioned. Assume all patients completed study at	
	Mean Qmax ml/s (± SD): 7.9 ± 2.1 Mean prostate size (g) ± SD: 48.9 ± 8.7	Preoperative: Baseline AUA symptom score, DRE, urinalysis, PSA Blood TPUS	Complications: UTI	Group 1: 4/30 Group 2: 3/36 p value: NR	3 months Notes:	
	Operative time ± SD : 47.3 ± NR mins Drop outs: 0	ive time \pm SD: 47.3 \pm NR minsuroflowmetry.uts: 0uroflow up visits to collect AUA symptom2:score and Qmax collected at 6 and 12 months postoperativelyPSS score: 21.6 \pm NR Qmax ml/s (\pm SD): 9.2 \pm 2.6 prostate size (g) \pm SD: 9.1 ive time \pm SD: 41.6 \pm NR mins	Complications: urinary retention	Group 1: 0/30 Group 2: 0/30 p value: NR	*SD for change from baseline estimated using Cochrane methods with p ≈ 0.01	
	Group 2: N: 30 Mean age (± SD): 59.8 ± 2.6		Complications: urethral stricture	Group 1: 0/30 Group 2: 0/30 p value: NR		
	Mean IPSS score: $21.6 \pm NR$ Mean Qmax ml/s (\pm SD): 9.2 ± 2.6 Mean prostate size (g) \pm SD: 51.7 ± 9.1 Operative time \pm SD: $41.6 \pm NR$ mins Drop outs: 0		Complications: retrograde ejaculation	Group 1: 23/30 Group 2: 13/30 p value: NR		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Nathan & Wickham 1996 ¹⁸⁵	Patient group: men requiring TURP	Group 1: Transurethral vaporisation of the prostate (TUVP)	Mean IPSS score at 3 months (follow up interval not clear)	Group 1: 2.86 ± 2.8 Group 2: 3.1 ± 2.3 p value: NR.	Funding: NR
Study design: RCT	Setting: single-centre, department of minimally invasive therapy, Guy's Hospital, UK	VaporTrode® electrode: cutting 200W and 40W Group 2: Transurethral	Mean IPSS QoL score at 3 months (follow up interval not clear)	Group 1: 0.5 ± 7 Group 2: 0.9 ± 0.9 p value: NR	Limitations: Randomisation method and allocation
Evidence level: 1+	Inclusion criteria: NR	resection of the prostate (TURP) Standard loop: cutting 120W	Mean Qmax ± SD mL/s at 3 months (follow up interval not clear)	Group 1: 21.3 ± 5.9 Group 2: 20.6 ± 2.6 p value: NR	concealment not reported Masked outcome
Duration of follow-up: 3 months	 Patients with indwelling catheters 	and coagulation 60W All patients: Operations performed using	Catheterisation time (days) hours reported converted to days	Group 1: 0.58 Group 2: 1.9 p value: NR	assessment was not reportedFollow up interval for
5 monins	 Patients on anticoagulant therapy Neurogenic bladder 	24Ch continuous flow resectoscope. A 3-way catheter was inserted.	Length of hospital stay (days)	Group 1: 1.85 Group 2: 3.45 p value: <0.0001	postoperative measurements not clear
	 Previous prostatic surgery <u>All patients</u> N: 40 	Examination methods Preoperative:	Complications: transfusion	Group 1: 0/20 Group 2: 2/20 p value: NR	There were significant baseline differences in IPSS score and Qmax.
	Drop outs: NR Group 1:	Baseline IPSS symptom score and IPSS QoL, , TRUS, uroflowmetry.	Complications: UTI at 3 months	Group 1: 0/20 Group 2: 0/20 p value: NR	Score and Qmax. Dropouts were not mentioned. Assume all patients
	N: 20 Mean age (range): 65.4 (57-77) Mean IPSS score: 21.9 ± 4.2	Follow up visits at 4, 8, 12 weeks for IPSS and uroflowmetry	Complications: TUR	Group 1: 0/20 Group 2: 0/20 p value: NR	completed study at 3 months
	Mean IPSS QoL ± SD: 4.9 ± 0.7 Mean Qmax mI/s (± SD): 10.2 ± 4.4	an Qmax ml/s (± SD): 10.2 ± R mL (range): 130 (0-300) an prostate size (g) ± SD: 5 ± 28	Complications: incontinence (urgency & frequency) at 3 months	Group 1: 0/30 Group 2: 0/30 p value: NR	Notes: None.
	PVR mL (range): 130 (0-300) Mean prostate size (g) ± SD: 53.5 ± 28 Operative time ± SD: 39.2 ± NR		Complications: reoperation rate	Group 1: 1/20 Group 2: 3/20 p value: NR	
	mins Drop outs: 0				
	Group 2:				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	N: 30 Mean age (range): 69.2 (57-81) Mean IPSS score: 17.0 ± 4.3 Mean IPSS QoL ± SD: 4.9 ± 0.7 Mean Qmax ml/s (± SD): 7.2 ± 3.5 PVR mL (range): 120 (0-380) Mean prostate size (g) ± SD: 53.4 ± 21 Operative time ± SD: 37.4 ± NR mins Drop outs: 0				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments		
Nuhoglu et al., 2005 ¹⁹⁵	Patient group: men with LUTS association with BPH	Group 1: Transurethral vaporisation of the prostate (TUVP)	Mean IPSS score ± SD at 3 months	Group 1: 4.7 ± 3.1 (n=35) Group 2: 4.8 ± 4.2 (n=38) P value: Not sig.	Funding: NR		
Study design: RCT Evidence	Setting: single-centre, Ankara, Turkey Inclusion criteria:	Storz spike loop: cutting 250W and 100W coagulation	Mean IPSS score ± SD at ≥5 years	Group 1: 6.5 ± 3.2 (n=21) Group 2: 6.1 ± 3.5 (n=23) P value: Not sig.	Limitations: Randomisation method and		
level: 1+	 IPSS >15 Qmax < 10 mL/s 	Group 2: Transurethral resection of the prostate (TURP)	Mean Qmax ± SD mL/s at 3 months	Group 1: 17.7 ± 2.3 Group 2: 17.5 ± 3.3 P value: Not sig.	 allocation concealment not reported Masked outcome 		
Duration of follow-up: 5 years	Exclusion criteria:Suspected prostate cancerNeurogenic bladder	Standard loop: All patients: Operations performed using	Mean Qmax ± SD mL/s at ≥5 years	Group 1: 12.9 ± 3.1 Group 2: 13.8 ± 2.9 P value: Not sig.	assessment was not reportedDropouts were not		
	Previous prostatic or urethral surgery	24F continuous flow resectoscope using glycine as irrigant. A 3-way catheter was inserted. Antibiotic	ic or urethral 24F continuous flow resectoscope using glycine as irrigant. A 3-way catheter was inserted. Antibiotic prophylaxis applied to surgeon's discretion	Catheterisation time (days) hours reported converted to days	Group 1: 0.92 ± 0.24 Group 2: 3.15 ± 0.52 p value: <0.001	reported completely Additional outcomes: PVR and average flow at	
	All patients N: 77 Drop outs: 33 at 5 years (5 died, 5 dropped out and 19 could not			prophylaxis applied to	prophylaxis applied to	prophylaxis applied to tra	Complications: transfusion
	be contacted. 4 patients are unaccounted for in the study report)	Examination methods Preoperative: Baseline DRE, IPSS symptom	Complications: urinary retention	Group 1: 1/37 Group 2: 0/40 p value: NR	Notes: None.		
	<u>Group 1:</u> N: 37 Mean age (± SD): 64.5 ± 8.7	 score, urinalysis, PSA, TRUS, uroflowmetry. Follow up visits at 1 & 3 months and >5 years thereafter t ± SD: ± 13.2 	Complications: retrograde ejaculation	Group 1: 5/37 Group 2: 4/40 p value: NR			
	Mean IPSS score: 17.3 ± 6.8 Mean Qmax ml/s (± SD): 6.3 ± 2.1		,	Complications: reoperation rate	Group 1: 1/37 Group 2: 0/40 p value: NR		
	PVR mL (range): 88 ± 20 Mean prostate volume mL ± SD: 39 ± 8.1		Complications: urethral stricture	Group 1: 1/37 Group 2: 0/40 p value: NR			
	Operative time ± SD: 45 ± 13.2 mins Drop outs: 16 at 5 years.						

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean follow up time yrs: 5.7 \pm 0.6				
	Group 2:N: 40Mean age (\pm SD): 65.1 \pm 9.4Mean IPSS score: 17.6 \pm 7.2Mean Qmax ml/s (\pm SD): 5.9 \pm 2.6PVR mL (range): 95 \pm 26Mean prostate volume mL \pm SD:39 \pm 7.7Operative time \pm SD: 42 \pm 9.5minsDrop outs: 17 at 5 yearsMean follow up time yrs: 5.7 \pm 0.9				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Patel et al., 1997 ²⁰³	Patient group: men with symptomatic BOO	Group 1: Transurethral vaporisation of the prostate (TUVP)	Mean IPSS score (range) at 3 months*	Group 1: 3.5 (2-4) Group 2: 3.2 (1-5) P value: NR	Funding: Equipment loaned from Circon ACMI
Study design: RCT	Setting: single-centre, department of urology, UCLA, USA	VaporTrode® grooved bar electrode (Circon ACMI) cutting 130-190W and 40W	Mean Qmax (range) mL/s at 3 months	Group 1: 21.4 (17.2-25.3) Group 2: 22.6 (19.3-25.2) P value: NR	Limitations: Randomisation
Evidence level: 1+	Inclusion criteria: IPSS moderate or severe (n=6) Qmax < 15 ml /s	coagulation Group 2: Transurethral resection of the prostate	Catheterisation time (days)	Group 1: 2 (1-3) Group 2: 2.6 (1-5) p value: NR	method and allocation concealment not reported
Duration of follow-up: 3 months	 Qmax < 15 mL/s Acute urinary retention (n=6) Exclusion criteria: 	(TURP) Standard loop resection. cutting 120-170W and 40W	Length of hospital stay (days)	Group 1: 1.8 (1-2) Group 2: 2.6 (2-4) p value: NR	Masked outcome assessment was not reported
	 UTI Neurogenic bladder <u>All patients</u> N: 12 Drop outs: 	coagulation All patients: Operations performed using 25F continuous flow resectoscope using water as irrigant. Examination methods Preoperative: Baseline IPSS symptom score, urinalysis, TRUS, uroflowmetry. Follow up visits at 3 months			 Dropouts were not reported Small sample size pilot study Adverse events poorly reported
	Group 1: N: 6 Mean age (range): 67 (60-85) Mean IPSS score (range): 29.6 (28-31)* Mean Qmax ml/s (range): 10 (7.3-13.1) Mean prostate volume mL (range): 54 (25-90) TRUS Operative time (range): 64.3 (40-120) mins Median energy used: 1657.5 (1286-2010) kJ Drop outs: NR				Additional outcomes: PVR and average flow of 3 months and ≥ 5 years. Serum electrolytes Notes: Randomised after stratification for prostate volume (TRUS) *IPSS score for patients without retention for baseline but unclear whether IPSS postoperative results
<mark>Group 2:</mark> N: б	<u>Group 2:</u> N: 6				were for all patients

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean age (range): 65.8 (59-71) Mean IPSS score (range): 23.3 (17-29)* Mean Qmax ml/s (range): 7.5 (5.1-11) Mean prostate volume mL (range): 64.6 (31.5-119) TRUS Operative time (range): 66 (27- 95) mins Median energy used: 753 (555- 977) kJ Drop outs: NR				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Shokeir et al., 1997 ²³⁹	Patient group: men symptomatic LUTS	vaporisation of the		Mean AUA-7 score ± SD at 3 months	Group 1: 4.5 ± 1.9 Group 2: 4.8 ± 2.2 P value: Not sig.	Funding: NR
Study design: RCT Evidence	Setting: multi-centre, department of urology, New Jeddah and King Hafd Madina Hospitals, Saudi	Storz grooved roller electrode: cutting mean 240W (200-300) and mean 70W (50-80W)	Mean AUA-7 score ± SD at 6 months	Group 1: 4.6 ± 1.2 Group 2: 4.5 ± 1.3 P value: Not sig.	Limitations: Randomisation method and	
Evidence level: 1+	Arabia Inclusion criteria: • AUA-7 Symptom score >15	Group 2: Transurethral	Mean AUA-7 score ± SD at 12 months	Group 1: 5.2 ± 1.4 Group 2: 4.7 ± 1.5 P value: Not sig.	 allocation concealment not reported Masked outcome 	
Duration of follow-up: 12 months	 Qmax < 12 mL/s Prostate size < 60g measured by TRUS 	resection of the prostate (TURP) Standard loop:	Mean Qmax ± SD mL/s at 3 months	Group 1: 19.4 ± 2.2 Group 2: 19.4 ± 2.1 P value: Not sig.	assessment was not reportedDropouts were not	
Mean 14.4 months (12- 17)	Exclusion criteria: • Neurogenic bladder • Prostate cancer	All patients: Operations performed using 26F continuous flow	Mean Qmax ± SD mL/s at 6 months	Group 1: 19.2 ± 2.0 Group 2: 19.3 ± 2.0 P value: Not sig.	reported Additional outcomes: PVR at each follow up	
	Bladder stonePrevious prostatic surgery	resectoscope using glycine as irrigant. A 3-way catheter was inserted.	Mean Qmax ± SD mL/s at 12 months	Group 1: 20.1 ± 3.2 Group 2: 18.2 ± 3.0 P value: Not sig.	and serum electrolytes Notes:	
	 Prostate size > 60g measured by TRUS Patients with acute urinary retention 	Examination methods Preoperative: Baseline serum electrolytes,	Catheterisation time (days)	Group 1: 1.1 ± 0.4 Group 2: 2.0 ± 0.8 p value: <0.001	None.	
	Patients with indwelling catheter All patients	AUA-7 symptom score, urinalysis, PSA, TRUS, uroflowmetry (Qmax from 3 voids >150mL, Urodyn Dantec).	Length of hospital stay (days)	Group 1: 1.5 ± 0.7 Group 2: 2.5 ± 1.0 p value: <0.001		
	N: 70 Drop outs: NR		Complications: transfusion	Group 1: 0/35 Group 2: 0/35 p value: NR		
	Group 1: N: 35 Mean age (± SD): 68.4 ± 9.5 Mean AUA-7 score: 26.3 ± 5.2		Complications: TUR	Group 1: 0/35 Group 2: 0/35 p value: NR		
	Mean Qmax ml/s (± SD): 7.8 ± 2.1 PVR mL (range): 75.2 ± 21.2 Mean prostate size (g) ± SD:	.1				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
-	44.6 ± 10.1 Operative time ± SD: 52 ± 12.5 mins Mean follow up time mths: 14.3 ± 2.1 Drop outs:. NR Group 2: N: 35 Mean age (± SD): 68.4 ± 9.6 Mean AUA-7 score: 25.1 ± 5.5 Mean Qmax ml/s (± SD): 6.9 ± 1.7 PVR mL (range): 77.1 ± 20.3 Mean prostate volume mL ± SD: 39 ± 7.7 Operative time ± SD: 39.7 ± 8.8				
	mins Mean follow up time mths: 14.5 ± 1.8 Drop outs: NR				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments							
Van Melick et al., 2003 ²⁶⁵	LUTS associated with BPH that were	Group 1: Laser vaporisation	Mean (± SD) symptom score (IPSS) at 6 months	Group 1: 7.2 \pm 6.7 (n=33) Group 2: 5.3 \pm 5.1 (n=37)	Funding: NR							
Links with Van Melick et al., 2002 ²⁶³ (up	recruited from their clinic from1996 to 2001	VaporTrode® (Circon ACMI) power settings	ACMI) power settings	ACMI) power settings	ACMI) power settings	ACMI) power settings	ACMI) power settings		ACMI) power settings	Mean (± SD) symptom score (IPSS) at 12 months	Group 1: 6.7 ± 6.4 (n=34) Group 2: 4.6 ± 4.8 (n=41)	Limitations:
to 6 months) and Van	Setting: single-centre, University Medical Centre Utrect, Netherlands	Group 2: TURP	Mean (± SD) symptom score (IPSS) at 1-4 years*	Group 1: 8.4 ± 8.7 (n=12) Group 2: 5.8 ± 7.5 (n=15)	 Randomisation method was not described and 							
Melick et al., 2003 ²⁶⁴ (up	Inclusion Criteria:	Standard resection. Suprapubic catheter if	Mean (± SD) symptom score (IPSS) at 4-7 years*	Group 1: 7.0 ± 5.6 (n=12) Group 2: 7.3 ± 7.1 (n=15)	masking of outcome assessment was not							
to 12 months) Study design:	 met ISC criteria for BPH Schafer obstruction score≥ 2 	required perioperatively.	Mean (SD) Global quality of life score at 6 months	Group 1: 1.6 ± 1.6 Group 2: 0.9 ± 1.2	 reported. Significant baseline difference in IPSS 							
RCT	 prostate size between 20-65ml. Exclusion Criteria: age ≤45 yrs 	All patients: Standard 24FR		Group 1: 1.4 ± 1.4 Group 2: 0.9 ± 1.2	 aitterence in 1755 score Not all patients were 							
Evidence level: 1+	All patients glycine for irrigation	resectoscope using glycine for irrigation. Pre-procedural antibiotics and transurethral 20F catheter postoperatively.	glycine for irrigation. Pre-procedural antibiotics and	glycine for irrigation. Pre-procedural antibiotics and	glycine for irrigation. Pre-procedural antibiotics and	glycine for irrigation.		Group1: 1.0 ± 1.2 Group 2: 1.1 ± 1.2	evaluated with urodynamics during			
। + Duration of	N: 96						Group 1:1.4 \pm 0.8 Group 2: 1.3 \pm 1.3	the follow up periodNumbers of patients				
follow-up: Up to 7 years	Group 1 N: 46 Age (mean) ± SD: 64 ± 10		Qmax mean ± SD at 3 months	Group 1: 20 ± 10 (n=19) Group 2: 25 ± 11 (n=15)	completing IPSS score not clear at 6 & 12 mths							
	IPSS (mean) ± SD: 20.2 ± 6.6 Mean prostate size, ml: 35 ± 11	Examination methods:	Qmax mean ± SD at 6 months	Group 1: 23 ± 10 (n=33) Group 2: 24 ± 7 (n=37)	Additional outcomes:							
	Mean (SD) Global quality of life score: 4.1 ± 1.4	Urodynamic studies (cystometry and pressure flow) at	Qmax mean ± SD at 12 months	Group1: $28 \pm 6 \text{ (n=34)}$ Group 2: $23 \pm 10 \text{ (n=41)}$	Frequency during day, frequency during night, symptom problem index and BPH impact index. Uroflowmetry also reported.							
	Mean Qmax \pm SD ml/s: 11 \pm 4 Follow-up 1 to 4 years = 12 Follow-up 1 to 7 years = 12	baseline and 1-6 weeks, 3, 6, 12 months	Qmax mean ± SD at 1-4* years	Group1: 23 ± 6 Group 2: 20 ± 5								
		after treatment	Qmax mean ± SD at 4-7* years	Group1: 16 ± 11 Group 2: 17 ± 8								
			Catheterisation time (days)	Group 1: 1.9 ± 0.6 Group 2: 2.1 ± 0.7 p value: NR	 Notes: Follow up time varied individually as all patients were analysed 							
			Length of hospital stay (days)	Group 1: 3.4 ± 0.9 Group 2: 3.9 ± 0.9	within a 2 month period. Depending on the							

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
-	Group 2 N: 50Age (mean) \pm SD: 66 \pm 8 IPSS (mean) \pm SD: 16.8 \pm 6.0 Mean prostate size, ml \pm SD: 37 \pm 		Post-op complications: urethral stricture (within 12 mths) Post-op complications: mortality (within 12 mths) Post-op complications: transfusion required (within 12 mths) Post-op complications: urinary retention (within 12 mths) Reoperation rate (TURP) within 12 mths	p value: NR Group1: 1/46 Group 2: 2/50 Group 1: 0/46 Group 2: 2/50 Group 1: 0/46 Group 2: 1/50 Group 1: 0/46 Group 2: 0/50 Group 1: 2/46 Group 2: 2/50	individual follow-up time, patient divided into two groups: those with a follow-up time between 1 and 4 years and those with follow up time between 4 and 7 years. * follow up = 2.8 yrs for TUVP 1-4 yrs and 5.4 yrs for category 4-7 years. For TURP mean follow up = 2.7 yrs for category 1- 4 yrs and 5.7 yrs for category 4-7 yrs.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments			
Wang et al., 2002 ²⁷⁰	Setting: China vo Inclusion criteria: pr	roup 1: Transurethral aporisation of the rostate (TUVP)	Mean IPSS score (range) at 12 months	Group 1: 4 (4-20) n=109 Group 2: 3 (1-17) n=96 P value: NR	Funding: NR			
Study design: RCT Evidence level: 1+	Exclusion criteria: Pcc • Prostate cancer or suspect Gr • Neurogenic bladder Gr • Urethral stricture (T	Electrode not specified.	Power 240-260W Group 2: Transurethral resection of the prostate	Power 240-260W Group 2: Transurethral resection of the prostate	Power 240-260W Group 2: Transurethral resection of the prostate	Mean IPSS score (range) at 24 months Complications: TUR syndrome	Group 1: 5 (4-23) n=38 Group 2: 4 (2-21) n=43 P value: Not sig. Group 1: 3/97 Group 2: 5/109	Limitations: Randomisation method and allocation concealment not reported
Duration of follow-up: 24 months	N: 206	ower 100-140W xamination methods reoperative:	Complications: mortality	Group 1: 1/97 Group 2: 0/109	 Masked outcome assessment was not reported Unable to obtain 			
	Group 1: Not reported in HTA N: 97 Not reported in HTA Mean age (range): 72 (62-85) Not reported in HTA Mean IPSS score (range): 20 (8-30) Nean Qmax ml/s (range): 7 (2-13) Mean PVR ml (range): 120 (60-400) Mean prostate volume mL (range): NR Operation time (range) mins: 35 (25–70) Drop outs: 1 (death due to cardiovascular event)		Complications: incontinence	Group 1: 5/97 Group 2: 1/109	copy of reference to check figures			
		Complications: strictures	Group 1: 5/97 Group 2: 2/109	Notes: Data taken from HT. report.				
Group 2: N: 109 Mean age (range): 71 (61-84) Mean IPSS score (range): 20 (9-31) Mean Qmax ml/s (range): 7 (3-12) Mean PVR ml (range): 131 (60–380) Operation time (range) mins: 35 (25–70) Mean prostate volume mL (range): NR	N: 109 Mean age (range): 71 (61-84) Mean IPSS score (range): 20 (9-31) Mean Qmax ml/s (range): 7 (3-12) Mean PVR ml (range): 131 (60–380) Operation time (range) mins: 35 (25–70)							

Study details	Patients	Interventions	Outcome measures	Effect size	Comments						
Dunsmuir et al., 20036 ⁶⁷	Patient group: men with LUTS secondary to BPH being considered for surgery	Group 1: Bipolar transurethral resection of the prostate (B-TURP)	Mean ± SD IPSS at 3 months	Group 1: 5.7 ± NR (n=30) Group 2: 8.2 ± NR (n=21) P value: NR	Funding: NR						
Study design: RCT	Setting: single-centre: Department of Urology, Monash Medical Centre, Melbourne, Australia.	Gyrus PlasmaKinetic [™] system. Group 2: Transurethral resection of the prostate	system.	system.	system.	system.	system.	system.	system. months Gro	Group 1: 7.1 ± NR (n=24) Group 2: 5.7 ± NR (n=20) P value: NR	 Limitations: Masking of outcome
Evidence level: 1+	Inclusion criteria: • <80 years Exclusion criteria:		Mean ± SD IPSS at 12 months	Group 1: 5.0 ± NR (n=20) Group 2: 6.4 ± NR (n=20) P value: NR	 assessment was no reported Mean ± SD were not reported for 						
Duration of follow-up: 12 months (mean 9	 Acute urinary retention Anticoagulant therapy Prostate volume >80mL 	All patients: Examination methods	Mean ± SD Qmax at 3 months	Group 1: 18.0 ± NR (n=30) Group 2: 20.0± NR (n=21) P value: NR	IPSS and Qmax. Data were estimated from						
months)	 Prostate cancer or suspect Previous prostate surgery 	Preoperative: Baseline IPSS Symptom score, QoL, Qmax, PVR	Mean ± SD Qmax at 6 months	Group 1: 18.5 ± NR (n=24) Group 2: 17.0 ± NR (n=20) P value: NR	 graph. Intermediate report, not all patients 						
	All patients N: 51 Drop outs: 0	assessed and follow up of IPSS, QoL, PVR and Qmax at 3, 6 12 months	Mean ± SD Qmax at 12 months	Group 1: 17.0 ± NR (n=20) Group 2: 15.0 ± NR (n=20) P value: NR	randomised have received surgery or been followed						
	<u>Group 1:</u> N: 30 Mean age ± SD: 63 ± 7.1		Catheterisation time (days) converted into days	Group 1: 0.8 ± NR Group 2: 0.7 ± NR P value: 0.92	up for 12 mths. Notes: Randomisation by						
	Mean AUA ± SD: 24.0 ± 6.9 Mean Qmax ± SD, mL/s: 9.6 ± 3.0 Mean PVR± SD, mL: 112 ± 13.3 Mean prostate volume ± SD, mL: 36 ± 19		Length of stay (days) reported as time to discharge	Group 1: 1.45 ± NR Group 2: 1.55 ± NR P value: 0.88	drawing tickets from previously sealed box containing equal						
	QoL \pm SD: 12 \pm 3.4 Operative time \pm SD, min: 33 \pm NR Drop outs: 0		Complications: urinary retention (re- catheterisation)	Group 1: 10/30 Group 2: 1/21 P value: NR	numbers of tickets for each type of surgery.						
	Group 2: N: 35 Mean age ± SD: 60 ± 6.5 Mean AUA ± SD: 17.0 ± 6.2 Mean Qmax ± SD, mL/s: 10.4 ± 3.1				QoL score was based on AUA symptom scoring section C with a maximum score of 19						

Evidence Table 37 Bipolar transurethral vapourisation of the prostate (TUVP) vs. transurethral resection of the prostate (TURP)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean PVR± SD, mL: 96 ± 11.4 Mean prostate volume ± SD, mL: 42 ± 21 QoL ± SD: 11 ± 3.2 Operative time ± SD, min: $26 \pm NR$ Drop outs: 0				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Hon et al., 2006 ¹⁰⁸	Patient Group: Men with BOO undergoing surgery	Group 1: Bipolar transurethral resection of the prostate (B-TURP)	Mean ± SD IPSS at 9 months	Group 1: 7.7 ± 6.8 (n=73) Group 2: 6.9 ± 5.8 (n=76) P value: 0.44	Funding: NR	
Study design: RCT Observer masked	Setting: single centre: Shrewsbury & Telford Hospital, UK Inclusion criteria:	system with Plasma V™ bar (320-450kHz) at	system with Plasma V™	Mean ± SD Qmax at 9 months	Group 1: 25.6 ± 15.6 (n=73) Group 2: 23.5 ± 15.2 (n=76) P value: 0.41	Limitations: Reasons for missing data a follow up were
Evidence level:	NR Exclusion criteria:	coagulation. Isotonic saline as irrigant	Mean ± SD QoL at 9 months	Group 1: 1.7 ± 1.5 (n=73) Group 2: 1.5 ± 1.5 (n=76) P value: 0.64	Data presented for	
1+ Duration of follow-up:	 Previous myocardial infarction Prostate cancer or suspect Previous history of prostatic surgery Serum creatinine >200 mmol/L 	Group 2: Transurethral resection of the prostate (TURP) Standard loop and	Length of Stay ± SD, days reported as mean postoperative stay	Group 1: 3.0 ± 0.9 (n=81) Group 2: 3.4 ± 1.1 (n=79) P value: 0.04	mean overall follow up Additional	
months	Prostate volume > 80 mL Main Main Main Main Main Main Main M		Complications: Transfusion	Group 1: 0/81 Group 2: 4/79 P value: 0.02	outcomes: Irrigation volumes. Notes:	
	All patients N: 160	Underwent Otis urethrotomy before prostatectomy and	Complications: urinary retention (re- hospitalisation)	Group 1: 1/81 Group 2: 2/79 P value: NR	Randomisation using sequentially numbered opaque	
	Dropouts: NR Group 1	received continuous irrigation with saline.	Complications: urethral stricture	Group 1: 0/81 Group 2: 1/79 P value: NR	envelopes containing compute generated number	
	N: 81 Mean age ± SD: 66.1 ± 8.5	Examination methods Preoperative:				
	Mean IPSS ± SD: 21.3 ± 6.2 Mean Qmax ± SD, mL/s: 12.0 ± 6.4 Mean PVR± SD, mL: 147 ± 156	Baseline IPSS Symptom score, DRE, urinalysis, PSA, Blood, TRUS, uroflowmetry. Follow up for IPSS, QoL, PVR and Qmax				
	Mean prostate volume ± SD, mL: 38.0 ± 17.5 IPSS QoL ± SD: 4.2 ± 1.1					
	History of urinary retention: 17/81 Catheter in situ: 8/81 9.9%					
	Operative time ± SD, min: 32.6 ± 13.4 Drop outs: 0					

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	$\label{eq:spectral_states} \begin{array}{l} \underline{\text{Group 2}} \\ \textbf{N: 79} \\ \textbf{Mean age \pm SD: } 68.1 \pm 7.5 \\ \textbf{Mean IPSS \pm SD: } 20.6 \pm 7.0 \\ \textbf{Mean Qmax \pm SD, mL/s: } 11.9 \pm 6.0 \\ \textbf{Mean PVR\pm SD, mL: } 182 \pm 180 \\ \textbf{Mean prostate volume \pm SD, mL: } 40.0 \pm 17.1 \\ \textbf{IPSS QoL \pm SD: } 4.3 \pm 1.3 \\ \textbf{History of urinary retention: } 18/79 \\ \textbf{Catheter in situ: } 13/79 \ 16\% \\ \textbf{Operative time \pm SD, min: } 28.5 \pm 15.2 \\ \textbf{Drop outs: } 0 \\ \end{array}$				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments				
Karaman et al., 2005 ¹²⁰ and Kaya et	Patient Group: men with BOO secondary to BPH	resection of the prostate (B- TURP)	Mean ± SD IPSS at 3 months	Group 1: 5.0 ± 3.4 (n=38) Group 2: 9.0 ± 2.9 (n=37) P value: <0.001	Funding: NR				
al., 2007 ¹²¹ Study design: RCT	Setting: single centre: Department of Urology, Haydarparsa Numune Training & Research Hospital, Istanbul, Turkey	management system (160Ω, 320-450kHz, 254-350V) using saline irrigant/ 80-100 V coagulation Group 2: TURP Standard loop through 26F continuous flow resectorscope	management system (160Ω, 320-450kHz, 254-350V) using	management system (160Ω, 320-450kHz, 254-350V) using	management system (160Ω, 320-450kHz, 254-350V) using	management system (160Ω, 320-450kHz, 254-350V) using	Mean ± SD IPSS at 6 months	Group 1: 6.0 ± 2.7 (n=38) Group 2: 10.0 ± 2.6 (n=37) P value: <0.001	Limitations: Randomisation method, allocation concealment and
Evidence level:	Inclusion criteria: • Severe LUTS on IPSS score requiring treatment		Mean ± SD IPSS at 12 months	Group 1: 7.0 ± 8.7 (n=38) Group 2: 12.0 ± 2.6 (n=37) P value: <0.001	masking of outcome assessment were not reported				
1+ Duration of follow-up:	 Qmax < 15 mL/s or obstructive pressure flow study Prostatic volume <60 mL 		Mean ± SD IPSS at 2 years	Group 1: 7.1 \pm 1.5 (n=25) Group 2: 5.2 \pm 1.1 (n=15) P value: <0.05	 Dropouts NR. Unclear whether all patients completed follow up 				
12 months.	onths. Exclusion criteria: All patients 3-way catheter inser	3-way catheter inserted and irrigation continued until urine	Mean ± SD IPSS at 3 years	Group 1: 7.6 ± 1.4 (n=25) Group 2: 5.7 ± 1.2 (n=15) P value: <0.05	Notes: Long term follow up for				
	 Untreated UTI Previous history of prostatic surgery Neurogenic bladder 	was clear. Catheter was before the patient was discharged All operations performed by	Mean ± SD Qmax at 3 months	Group 1: 17.0 ± 2.3 (n=38) Group 2: 18.0 ± 2.0 (n=37) P value: NS	2 and 3 years was available for 25 Group1 patients and 15				
	Urethral stricture	the same surgeons	Mean ± SD Qmax at 6 months	Group 1: 17.0 ± 1.3 (n=38) Group 2: 17.0 ± 3.3 (n=37) P value: NS	group 2 patients reported in Kaya et al., 2007 ¹²¹				
	N: 75 Preoperative:	Preoperative: Baseline IPSS, Qmax and PVR,	Mean ± SD Qmax at 12 months	Group 1: 16.0 ± 1.3 (n=38) Group 2: 15.0 ± 0.7 (n=37) P value: NS					
	Group 1 N: 38 Median Age (range), yrs: 66 (49-80) IPSS ± SD: 21.0 ± 3.8	Postoperative: IPSS and Qmax repeated at follow up of 3, 6 & 12 mths	Mean ± SD Qmax at 2 years	Group 1: 12.5 ± 2.1 (n=25) Group 2: 20.8 ± 2.4 (n=15) P value: <0.05					
	Mean ± SD Qmax, mL/s: 6.0 ± 2.1 Mean prostate volume ± SD, mL: 50.0 ± 2.0		Mean ± SD Qmax at 3 years	Group 1: $14.4 \pm 2.6 (n=25)$ Group 2: $21.8 \pm 3.1 (n=15)$ P value: <0.05					
	Operation time ± SD, min: 40.3 ± 15 Dropouts: NR		Catheterisation time (days) converted into	Group 1: 1.5 ± 0.4 Group 2: 2.8 ± 1.1					

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<u>Group 2</u> N: 37 Median Age (range), yrs: 65 (54-78) IPSS ± SD: 22.0 ± 4.6 Mean ± SD Qmax, mL/s: 6.0 ± 3.1 Mean prostate volume ± SD, mL: 51.1 ± 1.0 Operation time ± SD, min: 55.0 ± 11.0 Dropouts: NR	<mark>Group 2</mark> I: 37 Nedian Age (range), yrs: 65 (54-78)	days	P value: <0.001	
			Length of stay (days) equal to catheterisation time	Group 1: 1.5 ± 0.4 Group 2: 2.8 ± 1.1 P value: <0.001	
			Complications: Transfusion	Group 1: 0/38 Group 2: 2/37 P value: NR	
			Complications: TUR	Group 1: 0/38 Group 2: 0/37 P value: NR	
			Complications: urethral stricture	Group 1: 2/38 Group 2: 2/37 P value: NR	
			Complications: retrograde ejaculation	Group 1: 31/38 (82%) Group 2: 32/37 (86%) P value: NR	
			Complications: erectile dysfunction	Group 1: 13% Group 2: 12% P value: NR	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Patients Patient group: Patients with lower urinary tract symptoms attributable to BPH. Inclusion criteria: Lower urinary tract symptoms due to BPH Age > 40 Qmax<15mL/sec	Group 1: TUNA TEAP system (Vidamed Inc.) Radiofrequency (RF)- powered generator that delivers a dual 465-kHz RF signal. The TEAP procedure was performed with the patient in the lithotomy position under spinal or epidural anaesthesia. The number of treatments for each lateral lobe was determined according the length of the prostatic urethra. The procedure was performed at 1-cm intervals starting 1 cm from the bladder neck to 1 cm proximal to the verumontanum. The RF energy was delivered continuously and slowly increased to achieve a minimum of 50°C on the shields after 4 minutes of treatment. At	Outcome measures IPSS, mean ± SD IPSS-QOL , mean ± SD Q _{mex} , mean ± SD (ml/s)	Effect size Baseline: Group 1: 22.9 ± 3.8 Group 2: 24.1 ± 3.8 p value: 0.41 3 months: Group 1: 9.7 ± 2.8 Group 2: 8.3 ± 2.9 p value: 0.25 18 months: Group 1: 8.5 ± 3.2 Group 2: 8.6 ± 1.8 p value: 0.90 Baseline: Group 1: 4.8 ± 0.75 Group 2: 5.2 ± 0.65 p value: 0.90 Baseline: Group 1: 4.8 ± 0.75 Group 2: 5.2 ± 0.65 p value: 0.11 3 months Group 1: 2.1 ± 0.5 Group 1: 2.1 ± 0.5 group 1: 1.9 ± 0.5 p value: 0.30 18 months: Group 1: 1.8 ± 1.3 Group 2: 1.7 ± 0.5 p value: 0.35 Baseline: Group 1: 9.8 ± 3.6 Group 2: 9.2 ± 3.4 p value: 0.66 3 months: Group 1: 16.7 ± 4.5	Comments Funding: Not reported. Authors from Department of Urology Faith University, School of Medicine, Ankara, Turkey. Limitations: Method of randomisation allocation concealment, I' and sample si calculation wa not reported It was unclear how patients were recruited and screened, and how many of those screened were enrolled Unequal numb of patients in both arms, 270 more patient s the TURP arm
	Dropouts: 0 Age, years, mean (±SD): 60.1± 7.3 IPSS, mean (±SD): 22.9±3.8 IPSS-QoL, mean (±SD): 4.8±0.75	the needles is increased to aprox. 100°C. This		Group 2: 23.1 ± 5.3 p value: 0.002 <u>18 months</u> : Group 1: 17.7 ± 4.2 Group 2: 23.3 ± 4.9	Additional outcomes: I patient in TUNA group h acute urinary

Evidence Table 38 Transurethral needle ablation (TUNA) vs. transurethral resection of the prostate (TURP)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments										
	Qmax , ml/s, mean(±SD):9.8±3.6 Prostate size , g, mean(±SD):46.1±11.2 PVR , ml, mean(±SD):67.4±29.4	 to create lesions. Therefore B the device tip was kept firmly pressed against the prostate, and the RF power was applied for 5.5 minutes for each lesion. Catheter protocol: catheter was left indwelling for 12-24 hours. Discharge: discharged home on the same day. Group 2: TURP Performed under spinal or epidural anaesthesia. Catheter protocol: catheter was left indwelling for 48-72 hours. 	Complications: Blood transfusion , (2 patients in TEAP and all patients in TURP group had transient bleeding- haematuria after operation)	Group 1: 0/26 (7.7%) Group 2: 0/33 (100) P value: Not stat sig	retention requiring recatheterisation, unclear how many in the										
	Group 2-TURP N: 33 Dropouts: 0 Age, years, mean (±SD): 63.3		5.5 minutes for each lesion. Catheter protocol: catheter was left indwelling for 12-24 hours. Discharge: discharged home on the same day. Group 2: TURP Performed under spinal or epidural anaesthesia. Catheter protocol: catheter was left indwelling for 48-72 hours. Discharge: hospitalised for	5.5 minutes for each lesion. Catheter protocol: catheter was left indwelling for 12-24 hours. Discharge: discharged home on the same day. Group 2: TURP Performed under spinal or epidural anaesthesia. Catheter protocol: catheter protocol: catheter was left indwelling for 48-72 hours. Discharge: hospitalised for	5.5 minutes for each lesion. Catheter protocol: catheter was left indwelling for 12-24 hours. Discharge: discharged home on the same day. Group 2: TURP Performed under spinal or epidural anaesthesia. Catheter protocol: catheter was left indwelling for 48-72 hours. Discharge: hospitalised for	5.5 minutes for each lesion. Catheter protocol: catheter was left indwelling for 12-24 hours. Discharge: discharged home on the same day. Group 2: TURP Performed under spinal or epidural anaesthesia. Catheter protocol: catheter protocol: catheter was left indwelling for 48-72 hours. Discharge: hospitalised for	5.5 minutes for each lesion. Catheter protocol: catheter was left indwelling for 12-24 hours. Discharge: discharged home on the same day. Group 2: TURP Performed under spinal or epidural anaesthesia. Catheter protocol: catheter protocol: bischarge: hospitalised for	5.5 minutes for each lesion. Catheter protocol: catheter was left	Complications: Retrograde ejaculation (all patients were sexually active pre-operatively)	<u>18 months follow-up</u> Group 1: 0/26 (0) Group 2: 16/33 (48.5) RR: 0.0 (95% CI: 0.0 to 0.25) P value: <0.01	TURP group Prostate size at <u>18 months</u> : g), mean ± SD: TEAP: 41.9 ± 10.9, TURP: 34.3 ± 10.4, p				
	±5.9 IPSS, mean (±SD): 24.1 ±3.8 IPSS-QoL, mean (±SD): 5.2±0.65 Qmax, ml/s, mean(±SD):9.2±3.4							Complications: Urethral stricture	18 months follow-up Group 1: 0/26 (0) Group 2: 2/33 (6.0) P value: Not stat sig	value: 0.08 ■ Post void residual volume					
	Prostate size, g, mean(±SD):49.1±17.7 PVR, ml, mean(±SD):76.1±50.1							Performed under spinal or epidural anaesthesia. Catheter protocol: catheter was left indwelling for 48-72 hours. Discharge: hospitalised for	Performed under spinal or epidural anaesthesia. Catheter protocol: catheter was left indwelling for 48-72 hours. Discharge: hospitalised for	Performed under spinal or epidural anaesthesia. Catheter protocol: catheter was left indwelling for 48-72 hours. Discharge: hospitalised for	epidural anaesthesia. Catheter protocol:	Performed under spinal or epidural anaesthesia. Catheter protocol:	Complications: Reoperation, 18 months follow- up) n/N (%)	18 months follow-up Group 1: 2/26 (7) Group 2: 0/33 (0) P value: Not stat sig	(mL), mean ± SD <u>3 months</u> : Group 1: 45.3 ± 16.7
	(all parameters not stat sig between two groups)										Complications: Slight stress incontinence: (definition not provided)	18 months follow-up Group 1: 0/26 (0) Group 2: 1/33 (0.3) P value: Not stat sig	Group 2: 32.4± 17.4 p value: 0.07 <u>18 months</u> :		
		All patients received analgesics and antibiotics	Complications: Erectile impairment (deterioration in achieving and maintaining erection)	18 months follow-up Group 1: 0/26 (0) Group 2: 4/33 (12) P value: Not stat sig	Group 1: 46.4 ± 17.5 Group 2: 30.3 ± 18.7										
			Duration of operation , minutes, mean±SD	Group 1: 44.3±7.8 Group 2: 55.9±12.4 P value: 0.06	p value: 0.03 Notes: None.										

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	 Patient group: Men with LUTS secondary to BPH Inclusion criteria: Men 50 years or older who have LUTS secondary to BPH a minimum of three months in duration. I-PSS of greater than 13, a PFR of 12 ml per second or less with a minimum voided volume of at least 125 ml and a prostate size of between 20 and 75 gm, as determined by TRUS. Exclusion criteria: Active urinary tract infection urinary retention or PVR greater than 350 cc abnormal renal function, PSA greater than 10 ng/ml (If serum PSA between 4 to 10 ng/ml, TRUS guided prostate biopsies were performed to exclude prostate cancer), biopsy proven prostate cancer an enlarged median lobe neurogenic bladder and/or sphincter abnormalities previous non-pharmacological prostate treatment 	Group 1: TUNA TEAP device consisted of a hand piece similar to a rigid 18 Fr cytoscope with a 0- degree optical lens, light	Outcome measures IPSS, mean ±SEM Qmax (ml/s), mean±SEM	$\begin{array}{r} \hline \\ \hline $	 Funding: Authors report financial interest and/or other relationship with Glaxo, Merek, Medtronic and Celsion. Funding for trial not reported. Limitations: Randomisation well described but concealment of allocation is not described. Number of withdrawals and drop-outs is described for 1-year follow up but not for the 5-year period. Sample size calculation was mentioned, but assumptions used were not described There were discrepancies in the baseline and follow up values of 3 papers reporting the study. Quality of life scale – it was unclear how this was calculated in Bruskewitz1998 and
	 Prostate gland size < 34 or greater than 64 mm in transverse diameter, Current therapy affecting 			2 year follow up Group 1: 12.5 ± 0.7 (n=40) Group 2: 21.3± 1.4 (n=33) P value: 0.0001 3 year follow up	Hill2004. The mean score was more the maximum of IPSS-QoL Scale. Only Roehborn1999B

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	prostate physiology or other medical conditions that would pose an unacceptable patient risk. All patients N: 121 patients Drop outs: 15 lost to follow-up at 1 year Group 1-TUNA N: 65 Age, years, mean (±SE): 66 ± 1.0 IPSS, mean (±SD): 24±0.8 Dropouts: 6 lost to follow up at 1 year PVR, ml, mean ±SEM : 91.8 ± 10.0 (n=65) Group 2- TURP N: 56 Age, years, mean (±SE): 66 ± 1.0 IPSS, mean ±SD: 24.1± 0.8 Dropouts: 9 lost to follow up at 1 year PVR, ml, mean ±SEM : 81.9 ± 9.3 (n=56)		Qol score, mean ±SEM (Unclear what scales were used)	Group 1: 13.0 ± 1.3 (n=33) Group 2: 19.1 ± 2.0 (n=26) P value: 0.0106 <u>4 year follow up</u> Group 1: 11.7 ± 1.4 (n=18) Group 2: 18.9 ± 2.5 (n=17) P value: 0.0142 <u>5 year follow up</u> Group 1: 11.4 ± 1.2 (n=13) Group 2: 18.6 ± 2.3 (n=15) P value: 0.0143 <u>Baseline</u> Group 1: 11.8 ± 0.5 (n=64) Group 2: 12.6 ± 0.5 (n=56) P value: NR <u>1 year follow up</u> Group 1: 4.3 ± 0.5 (n=55) Group 2: 3.7 ± 0.7 (n=45) P value: 0.4814 <u>2 year follow up</u> Group 1: 6.0 ± 0.7 (n=43) Group 2: 3.7 ± 0.7 (n=43) Group 2: 3.7 ± 0.7 (n=43) Group 2: 4.7 ± 1.0 (n=32) P value: 0.5275 <u>4 year follow up</u> Group 1: 5.2 ± 0.9 (n=22) Group 1: 5.2 ± 0.9 (n=22) Group 1: 3.8 ± 0.7 (n=18) Group 2: 4.7 ± 1.0 (n=21) P value: 0.719	reported used of IPSS- QOL. Additional outcomes: Percent improvement over baseline for AUA, QOL, PFR and PVR (table 3) Procedure related mortality: 0 in both arms PVR, ml, mean \pm SEM: <u>1 year follow up</u> Group 1: 80.3 \pm 11.0 (n=52) Group 2: 47.1 \pm 7.0 (n=43) P value: 0.0173 <u>2 year follow up</u> Group 1: 74.1 \pm 12.6 (n=40) Group 2: 34.6 \pm 5.6 (n=31) <u>3 year follow up</u> Group 1: 78.2 \pm 13.7 (n=32) Group 2: 50.7 \pm 10.4 (n=26) P value: 0.1285 <u>4 year follow up</u> Group 1: 138.2 \pm 45.7 (n=19) Group 2: 39.5 \pm 13.1 (n=17) P value: 0.0564 <u>5 year follow up</u> Group 1: 60.4 \pm 21.8 (n=13)
			QoL - IPSS Scale, mean ±SD (only reported in Roehborn1999B)	<u>Baseline</u> Group 1: 4.6±1.1 Group 2: 4.8±1.1	Group 2: 27.4 ± 7.9 (n=17)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				<u>6 months follow up:</u> TEAP: 2.0 (sd not provided) Group 2: 1.5 P<0.001	P value: 0.1281
			Stricture formation/scar tissue	Five-year follow up Group 1: 1/65(1.5) Group 2: 4/56(7.1)	
			Retrograde ejaculation:	Five-year follow up Group 1: 0/65 Group 2: 23/56 (41.1)	
			Urinary incontinence:	Five-year follow up Group 1: 2/65(3.1) Group 2: 12/56 (21.4)	Notes: Where there were
			Reoperation: (The 9 men in TEAP group received TURP, the TURP patient received TUIP). One additional patient received radical prostatectomy for prostate cancer.	<u>Five-year follow up</u> Group 1: 9/65(13.8) Group 2: 1/56(1.8)	discrepancies, values from Hill2004 were used.
			Erectile dysfunction:	Five-year follow up Group 1: 2/65(3.1) Group 2: 12/56(21.4)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Hindley2001 ¹⁰⁵	Inclusion criteria: ■ Man > 50 years referred to an	Group 1: TUNA	Mortality	There were no deaths during	Funding: NR
Study design: RCT Setting: UK Evidence level: 1+ Duration of follow-up: 2-	 Men > 50 years referred to an integrated prostate-assessment unit for cystometry. Urodynamically confirmed bladder outlet obstruction (BOO) due to BPH, defined as Pdet Q_{max} value within the obstructed area of the Abrams Griffith pressure/flow nomogram. Bothersome LUTS, defined as an IPSS>=13 and an IPSS QOLscore ≥3 Written informed consent. 	A simple disposable 7 F RF needle- electrode was inserted into the lateral lobes of the prostate and, where appropriate, the median lobe of the prostate, using a catheterising endoscope. A standard surgical	IPSS, median (interquartile range)	the 2-year follow-up. <u>Baseline</u> Group 1: 20 (15-23) (n=25) Group 2: 22 (18-15) (n=25) <u>6-months</u> : Group 1: 9 (6-23) (n=20) Group 2: 3 (2-6) (n=22) <u>1 year</u> : Group 1: 6 (4-10) (n=19) Group 2: 3 (2-6) (n=19) <u>2 years</u> : Group 1: 8 (5-13) (n=19)	Limitations:
year Links with MOSTAFID1997 ¹⁸	 Exclusion criteria: History of any illness or surgery that might confound the results of the study, and that produce symptoms which might be confused with those produced by BPH, or that pose additional risk to the patient. Confirmed or suspected malignancy of the prostate by DRE or biopsy. PSA level >4 ng/mL unless T1 carcinoma of the prostate excluded by TRUS-guided biopsy. Previous prostatic surgery or thermotherapy Pharmacological treatment of symptomatic BPH within the last 6 months. 	diathermy generator was used to produce the 10 W of coagulation for 3 min. After treatment, patients were catheterised and allowed home on first-operative day. The catheter was removed and a trial of voiding carried out 7 days after treatment. Group 2: TURP Patients undergoing TURP were operated	QoL score , median (inter- quartile range)	Group 2: 3 (1-5) (n=19) P value: NR for all time points Baseline Group 1: 4 (3-5) (n=25) Group 2: 5 (4-5) (n=25) 6-months: Group 1: 2 (1-3) (n=20) Group 2: 1 (0-2) (n=22) 1 year: Group 1: 1 (1-3) (n=19) Group 2: 1 (0-2) (n=19) 2 years: Group 1: 2 (1-3) (n=19) Group 2: 1 (0-2) (n=19) P value: NR for all time points	cystometry at 6 months were also excluded Additional outcomes Post void residual volume (mL), mean ±SD: <u>6-months</u> : Group 1: 50 (44 (n=20) Group 2: 87 (74)(n=22) <u>1 year</u> : Group 1: 104 (109) (n=19) Group 2: 21
	 Confirmed or suspected bladder cancer. Previous rectal surgery other than haemorrhoidectomy. Previous pelvic irradiation. History of cystolithiasis, haematuria or 	on by an experienced surgeon according to the normal principles of prostatic resection. At	Q _{max} (mL /s), mean ±SD	Baseline Group 1: 8.5 (3.7) (n=25) Group 2: 9.0 (3.6) (n=25) <u>6-months:</u> Group 1: 9.8 (4.0) (n=20) Group 2: 18.4 (7.7) (n=22)	936) (n=19) <u>2 years:</u> Group 1: 89 (81 (n=19) Group 2: 32

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	 bladder pathology, urethral strictures, bladder neck contracture, active urinary tract infection or prostatitis. Previous history of neurogenic disorder including Parkinson's disease, multiple sclerosis, stroke and diabetic neuropathy. Patients wishing to maintain potential fertility. PVR >250 mL (measured by ultrasonography) Compromised renal function with a serum creatinine >180 mg/L or radiological evidence of upper tract dilatation. Unable to provide at least one voided volume of >150 mL. Unable to give informed consent. All patients N: 50 Drop outs: 12 Group 1-TUNA N: 25 Dropouts: 5 Age, years, mean (range): 66 (56-82) IPSS, mean (IQ range): 20 (15-23) Post void residual volume (mL), mean ±SD: 55 (44) PdetQmax(cmH ₂ O), mean ±SD: 92 (12) Group 2-TURP N: 25 Dropouts: 3 Age, years, mean (range): 71 (56-88) IPSS, mean (IQ range): 22 (18-25) Post void residual volume (mL): 74 (53)	the end of the procedure a 22 F three-way urethral catheter was inserted to allow bladder irrigation; after a successful trial of voiding the patient was allowed home. Prophylactic antibiotic cover with 120 mg IV gentamicin was given preoperatively in both groups.	Blood transfusion: (2 units each) Incontinence (all were urge incontinence, with detrusor instability) Urinary retention (post-op) (Failed trial of voiding) Clot retention: Urinary tract infection: Persistent dysuria: Treatment failure: Defined as patient dissatisfaction with treatment or the development of complications from persisting BOO, including evidence of detrusor dysfunction, incomplete bladder emptying, urinary retention, infection or upper tract obstruction.	1 year: Group 1: 9.7 (5.0) (n=19) Group 2: 22 (10.3) (n=19) 2 years: Group 1: 8.6 (3.5) (n=19) Group 2: 18.1 (7.1) (n=19) P value: NR for all time points Group 1: 0/20 Group 2: 3/22 Group 1: 2/20 Group 2: 3/22 Group 1: 1/20 Group 2: 0/22 Group 1: 1/20 Group 2: 0/22 Group 1: 4/20 Group 2: 4/22 Group 1: 4/20 Group 2: 0/22 2-year follow-up: Group 1: 2/25 Group 2: 0/25 One patient was dissatisfied with the outcome at 8 months. Another patient was dissatisfied at 2 years. Both patients were found to have persistent BOO at urodynamic assessment and underwent TURP.	 (42) (n=19) P value: NR PdetQmax(cmH2O), mean ±SD <u>6-months</u>: Group 1: 70 (12) (n=20) Group 2: 44 (11) (n=22) P value: NR <u>2 years</u>: Group 1: 71 (36) (n=12) Group 2: 36 (8) (n=9) P value: NR Notes: The methodology stated in MOSTAFID1997¹⁸⁰. The PdetQmax was the primary outcomes variable in the study design

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	PdetQ _{max} (cmH ₂ O), mean ±SD: 99 (10)				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments		
Kim et al., 2006 ¹²⁸ (data obtained from HTA report) Study design: RCT Setting: Korea,	N: 94/110/89/110 204 randomised, from 223 eligible for TEAP vs. TURP 199 randomised from 212 eligible for	Group 1-TEAP Prostajec device (American Medical Systems, Minnetonka, MN, USA) Group 2 - TUNA VidaMed TUNA system (VidaMed Inc.)4 Group 3 - Laser	IPSS, mean:	Baseline TEAP: 19.5 TUNA: 20.8 Coag; 21.1 TURP: 24.0 <u>3 months</u> TEAP: 9.6 TUNA: 10.8 TURP: 10.6 <u>12 months</u> TEAP: 7.5 TUNA: 11.6	 Funding: Unknown Limitations: Uncertain whether the data reported was mean or median Randomisation allocation, concealment and blinding had been rated as "unclear" Baseline severity of TEAP 		
recruitment from January 1998– December 2002 Evidence level: 1+	Laser coagulation vs. TURP 220 randomised out of 235 eligible for TUNA vs. TURP Drop outs: overall drop out not reported Group 1-TEAP N: 94 Dropouts: Unknown Age , years, mean or median (range) : 66.2 (49–88)	Coagulation: Other: procedure: Indigo 830e laser optic system (Ethicon Endosurgery) Group 4 - TURP	Blood transfusion	TURP: 8.8 TEAP: 0/94 TUNA: 0/100 TURP: 19/101 TEAP vs. TURP RR (95% CI): 0.03(0.00 to 0.45) P value: 0.01 TUNA vs. TURP: RR (95% CI): 0.03(0.00 to 0.42) P value: Sig	vs. TURP patient may diffrer: 1. "medium sized" prostates in TEAP vs. large prostate sizes in TURP 2. Mean IPSS at baseline level was numerically higher in TURP compared to		
Duration of follow-up: 12 months	QoL score, mean: 4.4 Qmax (ml/s), mean or median: 7.2 Residual volume, (ml), mean or median: 126.1 Prostate size, (ml), mean or median: 36.4 <u>Group 2- TUNA</u> N: 110 Dropouts: Unknown Age, years, mean or median(range): 66.4				6.4	Urinary retention	TEAP: 2/94 TUNA: 4/100 TURP: 4/101 <u>TEAP vs. TURP</u> RR (95% CI): 0.54 (0.10 to 2.87) P value: 0.47 <u>TUNA vs. TURP</u> : RR (95% CI): 1.01 (0.26 to 3.93) P value: Not sig
	(48–80) IPSS QoL score, mean: 4.3 Qmax (ml/s), mean or median: 7.0 Residual volume, (ml), mean or median:		Urinary tract infection	TEAP: 5/94 TUNA:10/100 TURP: 7/101 <u>TEAP vs. TURP</u> RR (95% CI): 0.77(0.25 to 2.34)	Recatheterisation, Retrograde ejaculation, Erectile dysfunction Reoperation, IPSS-QoL,		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	257 Prostate size, (ml), mean or median: 40.6 Group 3 - Laser Coagulation			P value: 0.64 <u>TUNA vs. TURP</u> : RR (95% CI): 1.44(0.57 to 3.64) P value: Not sig	Length of hospital stay Qmax, Residual volume , Prostate size
	N: 89 Dropouts: Unknown Age, years, mean or median(range): 68.7 (50–89) IPSS QoL score, mean: 4.7 Qmax (ml/s), mean or median: 8.6 Residual volume, (ml), mean or median: 219 Prostate size, (ml), mean or median: 42.7		Stricture (in the TURP arm, this was recorded as 7 in TEAP vs. TURP and 5 in TUNA vs. TURP- 5 urethral + 2 bladder neck)	TEAP: 0/94 TUNA: 0/100 TURP: 7/101 <u>TEAP vs. TURP</u> RR (95% CI) : 0.07(0.00 to 1.24) P value: 0.07 <u>TUNA vs. TURP</u> : RR (95% CI) : P value:	Notes: Evidence Table produced with data from Evidence Table of the HTA report. Values for complications obtained from Figure 11 of HTA report (page 49).
	<u>Group 4 -TURP</u> N: 110 Dropouts: Unknown, 9/110? Age, years, mean or median(range): 7.4 (60–87)		Retrograde ejaculation	TEAP: NR TUNA:5/100 TURP: 39/101 <u>TUNA vs. TURP</u> : RR (95% CI):0.13(0.05 to 0.32) P value: Not sig	
	QoL score, mean: 4.7 Qmax (ml/s), mean or median:11.9 Residual volume, (ml), mean or median: 187 Prostate size, (ml), mean or median: 44.2	or median:	Urinary incontinence	TEAP: 0/94 TUNA: 4/100 TURP: 4/101 <u>TEAP vs. TURP</u> RR (95% CI) : 0.12(0.01 to 2.19) P value: 0.15 <u>TUNA vs. TURP</u> : RR (95% CI) : 1.01 (0.26 to 3.93) P value: Not sig	
			Reoperation	TEAP: NR TUNA: 0/100 TURP: 0/101 <u>TUNA vs. TURP</u> : RR (95% CI): P value:	
			Duration of operation, minutes, mean (range)	TEAP: NR TUNA: 37(25-60) TURP: 51(20-85)]

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			hospitalisation, days,	TEAP: NR TUNA: 1.3(1-3) TURP: 6.5(6-8)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Dorflinger et al., 1992 ⁶⁶ Study design: RCT	Inclusion criteria: bladder neck to seminal crest < 2 cm Exclusion criteria:	Group 1-TUIP 24Fr resectoscope and Collings knife used. An incision to the depth of the surgical capsule was	Symptom score, Madsen Iversen (range of 1-27), median. Only included data from	At baseline Group 1: 14.5, n=22 Group 2: 16, n=29 p value: Not sig At 3 month follow up	Funding: NR Limitations: Methods of	
Setting: Denmark Evidence level: 1+	 Prostatic cancer previous prostatic or major pelvic surgery; high operative risk or overt neurological or psychiatric disease; 		"successfully treated patients"	Group 1: 2.5, n=22 Group 2: 1, n=29 p value: Not sig At12 months follow up Group 1: 2, n=21 Group 2: 2, n=26 p value: Not sig	randomisation and concealme and whether subjects were blinded to treatment received were	
Duration of follow-up: 12 months	ration of ow-up: months and the discuss, and the discus	Group 2-TURP	Qmax , ml/s, mean± SD:	At baseline Group 1: 10.0, n=22 Group 2: 8.0, n=29 p value: Not sig At 3 month follow up Group 1: 15.2, n=22	 not reported Only median values were reported for most outcomes 	
	Sexually/not sexually active: 44/8 Drop outs: <u>Group 1-TUIP</u> N: 29 Age, years, median: 69	used and prostatic tissue resected in a standard fashion			Group 2: 18.8, n=29 p value: Not sig At12 months follow up Group 1: 14.5, n=21 Group 2: 20.2, n=26 p value: 0.025 (Mann Whitney signed rank test)	Additional outcomes: Median values for Obstructive and Irritative components of Madsen Iverse
	Symptom score, Madsen Iversen (median) : 15 Qmax (ml/s), median:10 Urinary retention:9/29 (31%);		Blood transfusion	Group 1: 0/29 Group 2: 4/31 p value: 0.11	score at baseline 3 months and 6 months follow up Total voided	
	Group 2 -TURP N: 31 Age, years, median: 71 Symptom score, Madsen	Retrograde ejaculation (among patients who were sexually active before and after the operations)	Group 1: 1/19 Group 2: 12/24 Relative risk: 0.11(95% CI: 0.02 to 0.51) p value: 0.002 [RR calculated by NCGC team]	 I/44 patient was made sexually inacti- by the operations 		
	Iversen (median) : 15		Erectile dysfunction	Group 1: 1/19 Group 2: 4/24	 No bladder ne 	

Evidence Table 39 Transurethral incision of the prostate (TUIP) vs. transurethral resection of the prostate (TURP)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Qmax (ml/s), median:8			p value: Not sig	contracture
	Urinary retention:5/31 (16%)		Urethral stricture	Group 1: 0/29 Group 2: 1/31 p value: Not sig	Notes: Appropriate
			Reoperation (data from study abstract)	At12 months follow up Group 1: 8/29 Group 2: 4/31 P value: Not sig	statistical tests were used Preliminary results reported in
			Length of hospitalisation, days, median	Group 1: 3 Group 2: 3 p value: Not sig	Dorflinger1987
			Length of indwelling catheterisation, min, median	Group 1: 2 Group 2: 2 p value: Not sig	
			Length of operation, min, median	Group 1: 15 Group 2: 30 p value: <0.001	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Johnson et al., 1998 ¹¹⁵	Patient group: small to medium BPH	Group 1-TUIP Catheter protocol:	All cause mortality (due to cerebrovascular lesion at 8 weeks)	Group 1: 0/43 Group 2: 1/42 p value: Not sig	Funding: NR
Study design: RCT, open Setting: Sweden. Feb to Sept 1991 Evidence level: 1+ Duration of follow-up: 60 months	 Inclusion criteria: Admitted from the waiting list for surgical treatment of BPH No previous treatment for BPH Estimated prostate weight at DRE 20-40g, or 20-40mL by TRUS Distance from verumontanum to bladder neck < 4.0cm1 Exclusion criteria: 	overnight Others: Perioperative heparin :13 Antibiotics:17 Group 2-TURP Resected in a standard manner from bladder neck to verumontanum out to the prostate capsule Catheter protocol:	Symptom score (Madsen Iversen, total score), mean (95% CI)	At baseline Group 1: 15.4 (6-27), n=43 Group 2: 15.8 (5-28), n=42 At 3 months: Group 1: 3.5(0-21), n=41 Group 2: 3.8(0-16), n=39 At 6 months: Group 1: 4.3(0-21),n=36 Group 2: 3.5(0-18),n=34 At 12 months: Group 1: 3.6(0-15),n=31 Group 2: 2.8(0-11),n=32	 Limitations: Methods of randomisation and concealment and whether subjects were blinded to treatment received were not reported Patients who were reoperated not included in analysis
ou months	 Bladder stone or cancer Cystitis Clinical prostatic cancer Prominent median lobe of the prostate Adequate follow up difficult for geographical, psychological or social reasons 	overnight Others: Perioperative heparin:17 Antibiotics: 14 Resection weight, g, mean (range): 18.8 (8–45)	Qmax , ml/s, mean (95% Cl) estimated from graph	At 24 months: Group 1: 4.5(0-14),n=33 Group 2: 4.7(0-17),n=31 <u>At 60 months:</u> Group 1: 4.5(0-14),n=22 Group 2: 4.7(0-17),n=24 p value: Not sig between groups; Sig compared to baseline <u>At baseline</u> Group 1: 9 (7.5-11),n=34	Additional outcomes: Cystoscopy at 24 and 60 months to investigate healing and incision Post void residual volume, blood loss in volume, number
	All patients N: Age, years, mean (±SD): Drop outs: Group 1 N: 43 Drop outs: 2 (reoperated after failing to void post catheter removal) Age, years, mean (range): 70.2 (52–87)	For both groups: Anti provided to those who had indwelling catheter preoperatively, diabetes mellitus or with positive urine culture	for follow ups:	Group 2: 8.5 (7.5–9.5), n=36 <u>At 3 months:</u> Group 1: 20, n=41 Group 2: 15, n=39 <u>At 60 months:</u> Group 1: 15, n=22 Group 2: 12, n=24 p value: Reported sig difference between groups at 3, 6, 12 and 24 months. Not sig diff between groups at 60 months. All sig better than baseline except at 60 months	of preoperative positive cultures. • 3 patients in TURP group was detected with cancer Notes: None.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
	Madsen Iversen, mean (95% CI):15.4 (6–27) Prostate size, ml, mean (range):		Blood transfusion	Group 1: 0/43 Group 2: 1/42 p value: Not sig		
	26.2(20.0-37.6) Residual volume , ml, mean (range): 139 (0–650) Indwelling catheter: 7/43 Group 2 N: 42 Drop outs: 2 (1lost to follow up at			from TUIP group failed to void after catheter removal. 1 from TURP group had urinary retention 3 weeks post surgery and a bladder neck stricture was incised 3 weeks later	Group 1: 2/43 Group 2: 1/42 p value: Not sig	
	8 weeks, 1 died) Age, years, mean (±SD): 70.8 (56–85) Madsen Iversen, mean (95% CI): 15.8 (5–28) Prostate size, ml, mean (range): 25.4(20.0-39.8) Residual volume ml, mean (range): 109 (0–400)		Reoperation rate (repeated when it was impossible to remove the indwelling catheter or symptoms scores deteriorated, combined with a maximum urinary flow rate of ≥150ml)	Group 1: 10/43 (within 1-38 months) Group 2: 3/42 (within 2-25 months) Relative risk: 3.26 (95% Cl: 1.06 to 10.65) p value: 0.04		
	Indwelling catheter: 8/42		Catheter duration, days, mean (range)	Group 1: 2.8 (1-15) Group 2: 1.4(1-5) P value: Sig		
		Duration of operation, min, mean (range)	Group 1: 15 (5-40) Group 2: 32 (15-60) P value: Sig			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Larsen et al.,	Patient group:	Group 1- TUIP	Symptom score (Madsen	<u>Baseline</u>	Funding:
1987 ¹³⁹	 Men with symptoms of 	Performed using Colling's	lversen, Total score), median	Group 1: 17(9-23), n=19	US Veterans
	prostatism due to BPH	knife at the 6 pm position	(range)	Group 2: 17(9-23), n=18	Administration and
Study design:		extending form the		At 3-month follow up	Danish Medical
RCT, open	Inclusion criteria:	internal urethral orifice to		Group 1: 2(0-19), n=19	Research Council
	 Estimated prostate weight 	the verumontanum down		Group 2: 2(0-12), n=18	grant
Setting:	at cystoscopy to be ≤20g	through the prostate and		At 12-month follow up	
US, Veteran		the capsule.		Group 1: 2(0-19), n=12	Limitations:
Affairs	Exclusion criteria:			Group 2: 2(0-7), n=11	 Methods of
	 Severe neurologic and or 	A 3-way Foley catheter		p value: Not sig between groups; <0.05,	randomisation
Evidence	psychiatric disease	with continuous irrigation		compared to baseline values using Mann	and
level:	 Previous TURP 	was used for bladder		Whitney signed rank test	concealment
1+	 Urethral stricture 	drainage.	Symptom score (Madsen	<u>Baseline</u>	and whether
	 Urinary retention 		lversen, Irritative score),	Group 1: 13(5-16), n=19	subjects were
Duration of	 Clinical suspicion of cancer 	Group 2 – TURP	median (range)	Group 2: 12(4-16)18	blinded to
follow-up:	of the prostate	performed using method		<u>At 3-month follow up</u>	treatment
1 year	 Previous major intrapelvic 	described by Blandy JP 1978.		Group 1: 0(0-15), n=19	received were
	surgical procedures	1970.		Group 2: 1(0-7), n=18	not reported Relevance of
		All patients received		At 12-month follow up	 study –
	<u>All patients</u>	antibiotic prophylaxis		Group 1: 0(0-8), n=12	,
	N: 40			Group 2: 0(0-5), n=11	published in 1987
	Drop outs: 3 (2 lost to follow			p value: Not sig between groups; <0.05,	1707
	up-1 had operation cancelled)			compared to baseline values using Mann	Additional
				Whitney signed rank test	outcomes:
	Group 1 -TUIP		Symptom score (Madsen	<u>Baseline</u>	Voided volume, pos
	N: 19		lversen, Obstructive score),	Group 1: 5(2-8), n=19	void residual volum
	Age, years, median (range):		median (range)	Group 2: 5(2-8), n=18	
	63(51-73)			<u>At 3-month follow up</u>	Notes:
	Estimated prostate weight, g,			Group 1: 1(0-5), n=19	None.
	median(range): 20(10-20)			Group 2: 1(0-6), n=18	
	Duration of symptoms, months,			At 12-month follow up	
	median(range): 24(6-240)			Group 1: 1(0-3), n=12	
	Crown Q. TURR			Group 2: 1(0-6), n=11	
	Group 2 – TURP N: 18			p value: <0.05, compared to baseline	
				values using Mann Whitney signed rank test	
	Age, years, median (range):		Qmax , ml/s, median (range)	Baseline	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	61(43-74) Estimated prostate weight, g, median(range): 20(15-20) Duration of symptoms, months, median(range): 24(0.5-72)			Group 1: 7.4(2.7-27.3), n=15 Group 2: 8.6(1.7-15.5), n=16 At 3-month follow up Group 1: 14.4(2.6-34.6), n=15 Group 2: 18.5(5.3-45.3), n=16 At 12-month follow up Group 1: 16.3(6.4-34.7), n=11 Group 2: 20.6(9.0-41.3), n=11 p value: Not sig between groups; <0.05, compared to baseline values using Mann Whitney signed rank test	
			Urinary tract infections (within 1 month of surgery)	Group 1: 2/19 Group 2: 3/18 P value: Not sig	
			Post operative bleeding (definition not provided)	Group 1: 1/19 Group 2: 2/18 P value: Not sig	
			Recatheterisation (2 cases due to bleeding and clot retention in TURP, and 1 case due to haematuria on 10 th day for TUIP)	Group 1: 1/19 Group 2: 2/18 P value: Not sig	
			Retrograde ejaculation (based on number of patients who were potent and had antegrade ejaculation preoperatively)	Group 1: 2/10 Group 2: 8/10 Relative risk: 0.25 (95% CI: 0.09 to 0.71) p value: 0.02 [calculated by NCGC using Fisher's exact test]	
			Catheterisation , hours median (range)	Group 1: 1(1-2) Group 2: 2(2-7) p value: Not sig between groups; <0.01 (Mann Whitney signed rank test)	
			Hospital stay , days, median (range)	Group 1: 2.5(1-4) Group 2: 4.5(3-10) p value: Not sig between groups; <0.01 (Mann Whitney signed rank test)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments		
Li et al., 1987 ¹⁴⁴	Patient group: Patient with prostatism presented with acute urinary	Group 1-TUIP Bladder neck resection was performed with	Mortality (at operation)	Group 1: 0/29 Group 2: 0/30 p value: Not sig	Funding: NR		
Study design: RCT, open Setting:	retention Inclusion criteria: Acute urinary retention	26F continuous irrigation Wolf resectoscope was used. The prostate was	26F continuous irrigation Wolf resectoscope was	26F continuous irrigation Wolf resectoscope was used. The prostate was	Qmax (ml/s), mean ±se [baseline values not reported]	At 3 months Group 1: 22.8±2.9 Group 2: 18.5±2.7 p value: Not sig	Limitations: Baseline parameters, except age, not reported (patients
Hong Kong Evidence level: 1+ Duration of	 Ambulatory Diagnosis confirmed with urethroscopy with use of local anaesthesia before operation Exclusion criteria: 	resected at the 4 and 8 o'clock positions until the capsule was reached. Homeostasis was secured before the capsule of the prostate was incised. Incisions were made with	Perioperative complications: Blood transfusions determined by anaesthetist based on blood pressure, pulse rate, and general condition or observation on the return of irrigation fluid	Group 1: 2/29 Group 2: 13/30 Relative risk: 95% Cl: p value: 0.004	 were in acute urinary retention). Method of concealment not reported. No symptom scores were collected 		
follow-up: Up to 3 months	 medical diseases such as ischaemic heart disease, stroke, diabetes mellitus. All patients 	the same diathermy loop until extracapsular fat was reached. The incision extended from the verumontanum to the	Perioperative complications: UTI	Group 1: 5/29 Group 2: 13/30 Relative risk: 95% Cl: p value: 0.05	Additional outcomes: Bleeding or extravasation requiring further operation=0		
	N: 59 Group 1 -TUIP	level below the trigone. The prostatic chips, which weighted approximately	Perioperative complications: TUR syndrome	Group 1: 0/29 Group 2: 0/30 p value: Not sig	Notes: All the surgeries were only		
	N: 29 Dropouts: 0 Age, years, mean (±SD): 65±1.4	Group 2-TURP The usual complete resection of the prostatic adenoma to the capsule was performed. A 22F 3- way Foley catheter was used with traction on a	Post operative complications: Acute urinary retention	Group 1: 0/29 Group 2: 0/30 p value: Not sig	performed by 2 "experienced urologists"		
	Prostate size, g, mean(±SD): NR		Recatheterisation (due to secondary haemorrhage)	Group 1: 0/29 Group 2: 2/30 p value: Not sig			
	Group 2 -TURP N: 30 Dropouts: 0		Urinary incontinence (transient, 2 weeks for the TURP group)	Group 1: 1/29 Group 2: 2/30 p value: Not sig			
		irrigation with normal saline in both situations.	Urethral stricture (at bulbous urethra asymptomatic, detected using cystoscopy)	At 3 months Group 1: 0/29 Group 2: 1/30 p value: Not sig			
			Bladder neck stenosis	At 3 months			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			(asymptomatic, detected using cystoscopy)	Group 1: 0/29 Group 2: 1/30 p value: Not sig	
			Length of operation, min, mean±se	Group 1: 19±2.9 Group 2: 36±3.6 p value: 0.0002	
			Length of hospitalisation , days, mean ± se	Group 1: 5.6±0.6 Group 2: 8.0±1.3 p value: Not sig	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Nielsen1988 ¹⁹⁰	Patient group: Consecutive patients with	Group 1-TUIP After cytoscopy, a	All cause mortality (myocardial infarction in TURP and colon	Group 1: 1/24 Group 2: 1/25	Funding: NR
Study design: RCT Setting: Odense University Hospital, Denmark Evidence level: 1+ Duration of	 symptomatic benign BPH Inclusion criteria: patients with symptomatic bladder outlet obstruction cause by prostate hypertrophy Age >60 All patients N: 49 Drop outs: 4 at 12 months (2 deaths, 2 refused to attend 	resectoscope was inserted and a cut was made along the sulcus, using the Stortz diathermy knife, either at 5 or 7 o'clock from the left or right ureteric orifice to the level of the verumontanum, and deepened along its whole length until reaching the fat layer. Group 2-TURP The whole of the prostatic gland resected using a cutting loop.	cancer in TUIP) Qmax , ml/s, mean	p value: Not sig <u>At baseline</u> Group 1: 5(5-10), n=24 Group 2: 5(5-13), n=25 p value: Not sig <u>At 2 month follow up</u> Group 1: 10(7-18), n=24 Group 2: 17(6-32) n=25 p value: <0.02 <u>At12 months follow up</u> Group 1: 9(5-25), n=22 Group 2: 12(5-28), n=23 p value: Not sig	Limitations: No symptom scores were collected Randomisation method reported but concealment method unclear Additional outcomes: Notes: Sample size calculation
follow-up: Up to 1 year	follow up) <u>Group 1-TUIP</u> N: 24 Age, years, median: 69(60-85)		Perioperative complication; Blood transfusion	Group 1: 1/24 Group 2: 20/25 Relative risk: p value: <0.02	provided for this study – assumption that TURP was 30% better (not stated which outcome) that TUIP, at the 90%
	Qmax (ml/s), median; 5(5-10) Prostate weight, g, estimated: <30: 3	Haemostasis was achieved using electrocoagulation.	Septicaemia	Group 1: 1/24 Group 2: 2/25 p value: >0.1	power and Type I error or 0.05.
	30-50:14 >50: 7	Prophylactic antibiotics not used	Acute urinary retention (required reoperation, TURP)	Group 1: 3/24 Group 2: 0/25 p value: Not sig	Authors reported statistical significance based on fisher's exact
	N: 25 Age, years, median: 73(61-83)	25 general ge, years, median: 73(61-83) general max (ml/s), median; 5(5-13) Catheter protocol: A ostate weight, g, estimated: catheter (18 to 22 F) was <30: 7	Clot retention (reoperation required)	Group 1: 1/24 Group 2: 1/25 p value: Not sig	test or Mann Whitney test (appropriate)
Prostate weight, g, estim	Prostate weight, g, estimated: <30: 7		Incontinence	Group 1: 0/24 Group 2: 1/25 p value: Not sig	– Sexual function, eg retrograde ejaculation not reported
	>50: 4	clear.	Successful (incontinence or increased frequency of micturation was not considered not successful results)	At 2 month follow up Group 1: 24/24, n=24 Group 2: 20/25 n=25 p value: Not sig	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				At12 months follow up Group 1: 21/22, n=22 Group 2: 18/23, n=23 p value: Not sig	
			Reoperation rate (At 2 months, 3 patients in the TUIP group had urinary retention group had required TURP. 1 patient from each group had clot retention and had to be operated again)	At 2 month follow up Group 1: 4/24 Group 2: 1/25 At 12 month follow up This was not clearly reported	
			Stricture (4 patients in TURP group had stricture, 2 had internal urethratomy and 2 by dilatation)	At 2 month follow up Group 1: 0/24 Group 2: 4/25	
			Length of catheterisation days, median (range)	Group 1: 1(1-2) Group 2: 1(1-4) p value : >0.1	
			Length of operation, minutes, median (range)	Group 1: 18 (10-35) Group 2: 45(20-80) p value: <0.01	
			Length of hospitalisation, days, median, (range)	Group 1: 3(2-13) Group 2: 3(2-18) p value: >0.1	

See Evidence Table 26Laser coagulation vs. transurethral resection of the prostate (TURP)

4 for Rodrigo et al., 1998²¹⁷

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Riehmann et al., 1995 ²¹⁴ Study design:	Inclusion criteria: patients with bladder outlet obstruction symptoms	Group 1-TUIP Performed using a Coling's knife at the 6 o'clock position from	All cause mortality (one death in the TURP group was due to saddle pulmonary embolism, classified as operative death)	Group 1: 14/61 Group 2: 8/56 p value: Not sig	Funding: Not stated Limitations:
RCT Setting: Jan 1985 to Aug 1990, Madison, Wisconsin, US Evidence level: 1+ Duration of follow-up:	randomised: 117 Drop outs: 5 (1 received	the bladder neck distally to the verumontanum. The incision extended through the posterior prostatic capsule Group 2-TURP The prostate was resected completely and circumferentially to the anatomic capsule from the bladder neck to the verumontanum. Mean weight of tissue resected : 15 g (range from 1 to 37 g) For both groups Procedures were performed by staff members or residents supervised for staff	Madsen Iversen, (range of 1-27), mean±se [Values estimated from graph]	At baseline Group 1: 15.5, n=61 Group 2: 15.5, n=56 p value: Not sig At 3 month follow up Group 1: 6 SE1 n=51 Group 2: 6, SE1 n=52 p value: Not sig At 12 months follow up Group 1: 6 SE 0.5, n=50 Group 2: 5.5 SE 0.5, n=46 p value: Not sig A24 months follow up Group 1: 7 SE 1, n=41 Group 2: 5 SE 1.5, n=40 p value: Not sig At 36 months follow up Group 1: 8 SE 1, n=22 Group 2: 6.5 SE 1.5, n=19 p value: Not sig At 48 months follow up Group 1: 10.5 SE 1, n=17 g value: Not sig At 60 months follow up Group 1: 9.5 SE 1.5, n=15 p value: Not sig At 72 months follow up Group 1: 10 SE 1, n=6 Group 2: 9.5 SE 1.5, n=11 p value: Not sig	 Methods of randomisation and concealment and whether subjects were blinded to treatment received were not reported Results reported graphically-actual values not stated Qmax significantly higher in TURP group preoperatively Additional outcomes: Madsen Iversen symptom score – results reported in graph, no statistical difference between two groups' pre and post operatively. The scores were significantly lower compared to baseline for both procedures. Overall subjective assessment of surgical outcomes Perforation during surgery- 1 case (did not state which arm) Notes: Christensen 1990⁴⁶ reported the preliminary results

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
details	Qmax , ml/s mean: 9 (n = 52) Group 2-TURP N: 56 Drop outs: Age, years, mean (range):64 (42–78) Madsen Iversen score, mean: 15 Qmax , ml/s mean:11 (n = 50)		Qmax , ml/s, mean± SD: [Values estimated from graph]	baselineAt baselineGroup 1: 9, n=52Group 2: 11, n=50p value: Stat sig, p<0.015	
				Group 2: 17 SE 2, n=31 p value: Stat sig, p<0.015 <u>At 72 months follow up</u> Group 1: 13 SE 4, n=4 Group 2: 19 SE 5, n=8 p value: Not sig Not sig compared to baseline for 72 month follow up	
			Reoperation (TURP group – 8 TUIP or resection of bladder neck contracture, 1 further TURP, TUIP group- 12 received TURP, 1 received another TUIP)	Group 1: 13/61 Group 2: 9/56 p value: Not sig	
			Retrograde ejaculation (among patients who were sexually active before an after surgery)	Group 1: 8/23 Group 2: 15/22 Relative risk: 95% Cl: p value: 0.02	
			Duration of operation time, mean, (range)	Group 1: 23 (7 to 95) Group 2: 55 (5 to 135) P value: 0.001	
			Catheter duration, day,	Group 1: 1.4 (1-3)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			mean,(range)	Group 2: 2.5(1-12) P value: 0.001	
				Group 1: 3.0 (1-8) Group 2: 4.3 (2-14) P value: 0.001	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Saporta et al., 1996 ²²⁹	Inclusion criteria: patients with obstructive BPH symptoms	Group 1-TUIP Incision with Collings knife from interureteric ridge	Symptom score, Madsen Iversen (range of 1-27), mean ± se (range)	<u>At baseline</u> Group 1: 14.7±0.96 (7-21) Group 2: 14.3±0.93 (6-22)	Funding: Not stated
Study design: RCT Setting: Not stated (Israel/Turkey) Evidence Ievel:	 prostate weight at DRE ≤ 40g Exclusion criteria: chronic urinary retention urethral stricture, bladder cancer, prostatitis; clinical and suspicion of prostatic cancer; prominent median lobe of prostate neurogenic bladder 	from 6 o'clock to verumontanum as deep as fat layer Catheter protocol: 20Fr Foley for 18–24 hours Group 2-TURP Low pressure continuous flow with trocar	mean ± se (range)	p value: Not sig At 1st year Group 1: 5.29±0.62 (2-13), n=17 Group 2: 4.95±0.74 (1-14), n=20 p value: Not sig At 3rd year Group 1: 7.0±0.64 (3-14), n=17 Group 2: 5.79±0.85 (1-18), n=19 p value: Not sig	Limitations: Baseline slightly different Methods of randomisation and concealment and whether subjects were blinded to
1+ Duration of follow-up: 72 months	All patients N: 40 Age, years, mean (±SD): Drop outs: 4 <u>Group 1</u> N: 20	cystostomy Catheter protocol: 14Fr Foley through trocar cystostomy channel and 20Fr Foley through urethra; irrigated for 18–24 hours; 14Fr Foley removed next day, 20Fr 48 hours after	Global assessment of symptoms (marked/moderate or slight improvement/no improvement or worse, %) Patients who required additional treatment were recorded as no improvement	At 1 st year Group 1: 80/5/15 Group 2: 85/10/5 p value: Not sig At 3 rd year Group 1: 50/30/20 Group 2: 60/35/5 p value: Not sig	 treatment received were not reported Patients who were reoperated not included in analysis
	Drop outs: 3 Age, yea , mean (±SE): 66.85 ± 2.28 Prostate size , g, mean(±SE): 29.55±.0.94(20-37) Sexually active with antegrade ejaculation: 16/20† Group 2 N: 20 Drop outs: 1 at 3 rd year	For both groups: spinal, epidural or general were used	Qmax , ml/s, mean ± se(range)	At baseline Group 1: 7.35 \pm 0.56 (3.7-12) Group 2: 6.5 \pm 0.43(3.2-11.9) p value: Not sig At 1 st year Group 1: 14.58 \pm 1.05(5.3-5.7), n=17 Group 2: 17.29 \pm 1.16(8.2 -7.1), n=20	Additional outcomes: There was a third arm of balloon dilatation. Notes: Appropriate non- parametric tests used
	Age, years, mean (±SE): 71.45 ± 1.15 Prostate size, g, mean(±SE): 30.0±1.51(19-40) Sexually active with antegrade ejaculation: 10/20†			p value: Not sig <u>At 3rd year</u> Group 1: 12.65±1.04(4.1-23.3), n=17 Group 2: 14.36±1.14(5.5-25.5), n=19 p value: Not sig	for this study † Unequal number of patients with retrograde ejaculation at baseline

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				<u>At 3rd year</u> Group 1: 3/16 Group 2: 9/10 RR: 0.21 (0.14-0.49) P value: 0.001 [calculated by NCGC team using Fisher's exact test]	
			For TURP patient- 1 internal urethrotomy in 3 rd year. For TUIP patients, 2 had TURP and 1 had another TUIP at 1	At 1 st year Group 1: 3/20 Group 2: 0/20 P value: NR <u>At 3rd year</u> Group 1: 3/20 Group 2: 1/20 P value: NR	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Pardanani1992 ²⁴⁵ Study design: RCT Setting: India	 Patients with prostate hypertrophy Exclusion criteria: prostatic cancer or suspicion of malignancy prostate size >30g A single incision at the 5 or 7 o clock position extending from below the ureteric orifice up to the verumontanum was made the Coling's knife and deepened up to the perivesicle and periprostatic fat along its 	A single incision at the 5 or 7 o clock position extending from below the ureteric orifice up to the verumontanum was made the Coling's knife and deepened up to the perivesicle and periprostatic fat along its entire length Anaesthesia: general	All cause mortality (myocardial infarction- 1 each in TUIP and TURP, 1 septicaemia in TURP Qmax, ml/s, mean	Group 1: 1/110 Group 2: 2/110 p value: Not sig [#] <u>At baseline</u> Group 1: 7.91, n=110 Group 2: 8.04, n=110 <u>At 3 month follow up</u> Group 1: 19.38, n=110 <u>Group 2: 20.69 n=110</u> <u>At12 months follow up</u> Group 1: 19.45, n=70 Group 2: 20.10, n=67	Funding: NR Limitations: Methods of randomisation and concealment and whether subjects were blinded to treatment received were not reported No symptom scores were collected
Duration of follow-up: 24 months		spinal (24), local (17 cases) Catheter protocol: 24Fr Foley; 24–48hours Group 2-TURP Catheter protocol: 24Fr Foley; ≤ 48hours	Perioperative complication; Blood transfusion (mean number of units transfused per patient was 0.44)	At 24 months follow up Group 1: 18.91, n=70 Group 2: 19.86, n=67 p value: Not sig for all time points Group 1: 0/110 Group 2: 38/110 Relative risk: 0.0(95% CI: 0.00 to 1.00) [#] p value: <0.001 [#]	Additional outcomes: 4/7 of the patients with retention after TUIP had repeat TUIP, and 3 had resection. All 4 TURP patients with urinary retention
		ml/s), mean; 8.04Anaesthesia: generalweight, g, mean: 15.6Anaesthesia (88) andy active: 49/110spinal (20) and epidural	TUR Syndrome	Group 1: 0/110 Group 2: 7/110 RR: 0.00 (95%Cl: 0.00 to 0.53) [#] p value: 0.01 [#] [RR and P value calculated by NCGC team]	 had reoperation. % of patients satisfied (excellent/fair) vs. not satisfied (no change/worse)- determined
		Haemorrhage, 3 intraoperative, requiring open surgery, 2 post- operative haemorrhage	Group 1: 0/110 Group 2: 5/110 p value: Not sig [#]	"subjectively", methods not reported	
				Group 1: 2/110 Group 2: 3/110 p value: Not sig [#]	Notes: # Relative risk (RR) and/or P value

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Acute urinary retention (failure to void upon catheter removal)	Group 1: 7/110 Group 2: 4/110 p value: Not sig [#]	calculated by NCGC team using Fisher's exact test
			Acute renal failure	Group 1: 0/110 Group 2: 1/110 p value: Not sig [#]	
			Retrograde ejaculation (among sexually active patients before and after the operations)	Group 1: 14/60 Group 2: 13/49 p value: Not sig #	
			Erectile dysfunction	Group 1: 0/60 Group 2: 0/49 p value: Not sig [#]	_
			Epididymo-orchitis	Group 1: 5/110 Group 2: 2/110 p value: Not sig [#]	
			Urethral stricture	Group 1: 5/110 Group 2: 3/110 p value: Not sig [#]	
			Incontinence	Group 1: 2/110 Group 2: 4/110 p value: Not sig [#]	
			Length of hospitalisation, days, mean	Group 1: 6.03 Group 2: 7.16 p value: NR	
			Length of indwelling catheterisation, min, mean	Group 1: 2.62 Group 2: 3.01 p value: NR	
			Length of operation, min, mean	Group 1: 20.4(10-40) Group 2:59.2(30-95) p value: NR	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Tkocz and Prajsner 2002 ²⁵⁴ Study design: RCT Setting: Poland Evidence level: 1+ Duration of follow-up: 24 months	Patient group: Men with moderate symptoms of BPH caused by a small prostate Inclusion criteria: prostate size<30g Exclusion criteria: presence of median lobe <u>All patients</u> N: 100 Mean age: 68±6.7(51 to 78) years Drop outs: 0 (no drop outs reported) <u>Group 1</u> N: 50 Dropouts: 0 Age, years, mean (±SD): Not reported separately for each group IPSS, mean (±SD): 17.1±2.2 IPSS-QoL, mean (±SD): 4.6±0.5 Prostate size (incised adenoma), g, mean(±SD): 27±2 Residual volume, mean ± SD	Group 1-TUIP Incisions with a Collins blade, from the urethral orifice to the level of the urethral colliculus, deeply reaching the perivesicle fat. All incisions were performed bilaterally, thus resulting in the full opening of the neck and prostatic urethra. Catheter protocol: Foley 18-French catheter left in the urethra for 24 hours Group 2-TURP Performed using the resectoscope, calibre 24- French. All: subarachnoid anaesthesia with hyperbaric lidocaine	Symptom score, IPSS (range of 1-35), mean±sd IPSS-QoL(range of 1-6) mean±sd Qmax, ml/s, mean± SD:	At baselineGroup 1: 17.1 ± 2.2 Group 2: 17.1 ± 1.9 P value: Not sigAt 24 months:Group 1: 4.1 ± 1.8 Group 2: 5.1 ± 1.9 p value: Not sig between groups;<0.01 compared to baseline	Funding: NR Limitations: Methods of randomisation and concealment not reported Patient diary- no mention of content, validation and duration of method of data collection and analysis Additional outcomes: Urodynamic parameters such as Pdetop, PdetQmax, CysCapF etc
	(ml): 75 ± 22 Pdetmax, cmH2O, mean ± SD: 84 ± 10		Blood transfusion	Group 1: 0/50 Group 2: 1/50 p value: Not sig	 No patient reported to have dropped out from study
	Group 2 N: 50 Dropouts: 0 Age, years, mean (±SD): Not		Retrograde ejaculation	Group 1: 6/50 Group 2: 16/50 Relative risk: 0.38(95% Cl: 0.16 to 0.84 P value: 0.03	_ 5.007

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	reported separately for each group IPSS , mean (±SD): 17.1±1.9 IPSS-QoL , mean (±SD): 4.4±0.3 Prostate size (resected adenoma), g, mean(±SD); 28.2±2 Residual volume , ml, mean ±SD : 68 ±21		Detrusor instability	<u>Baseline:</u> Group 1: 31/50 Group 2: 30/50 <u>At 24 months</u> Group 1: 15/50 Group 2: 11/50 P value: Not sig	
	Pdet _{max,} cmH2O, mean, ±SD : 85 ±8		Weakening of detrusor post operation ("lazy" and incomplete voiding, returned to normal by 24 months)	Post-op (time not provided) Group 1: 4/50 Group 2: 11/50 P value: Not sig At 24 months Group 1: 0/50 Group 2: 0/50	
			Urinary frequency, diurnal (recorded through diary. Diary kept for 7 days after preliminary examination (baseline. No mention of how many days data were collected for follow up)	Baseline; Group 1: 7.8±0.9 Group 2: 7.2±1.2 At 24 months Group 1: 4.9±1.1 Group 2: 5.2±1.0 P value: Not sig between groups; <0.001 compared to baseline	
			Urinary frequency, noctural (recorded through diary. Diary kept for 7 days after preliminary examination (baseline. No mention of how many days data were collected for follow up)	Baseline; Group 1: 2.8±0.9 Group 2: 2.4±0.8 At 24 months Group 1: 1.1±0.5 Group 2: 0.9±0.5 P value: Not sig between groups; <0.001 compared to baseline	

1 Evidence Table 40 Botulinium toxin vs. placebo

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Maria et al., 2003 ¹⁵⁸	Patient group: Men with symptomatic BPH	Group 1 Botulinum toxin Received 200U of	AUA symptom score, mean±sd:	<u>Baseline</u> Group 1: 23.2±4.1 Group 2: 23.3±3.9	Funding: Not stated
Study design: RCT, double blinded Setting: Jan to Dec 2000 Department of Surgery,	 Inclusion criteria: Age 50 to 80 years with symptomatic BPH Moderate to severe symptoms of urinary obstruction as determined by the AUA score Qmax ≤ 15 ml/s with a voided volume of ≥150mL An enlarged prostate gland on digital rectal examination Exclusion criteria: 	botulinum toxin Group 2 – Placebo Received saline solution For both groups: 4 ml of solution injected in to the prostate, divided into 2 injections of equal volume (2 mL)	(No data reported for group 2 after 2 nd month)	<u>1 month</u>	Limitations: Small sample size – no calculation provided Uncertain whether all outcomes/side effects relevant to the patient had been reported (eg pain) Additional outcomes:
University Hospital of Agostino Gemelli, Rome Evidence	 Neurogenic voiding disorders Prostate or bladder cancer or a serum PSA level of 10 ng/ml or more Previously had surgery or treated with botulinum toxin 	into each lobe of the gland. With patient lying on the left side, a 22-gauge spinal needle (0.7 X 90-	Qmax, ml/s, mean±sd (No data reported	P values: Sig * <u>Baseline</u> Group 1: 8.1±2.2 Group 2: 8.8±2.5 <u>1 month</u>	Prostate volume, serum PSA, and residual volume at 1 and 2-months follow up. Also reported the 6 and 12 months follow up results for the botulinum
level: 1+ Duration of follow-up:	All patients N: 30 (out of 42 assessed for eligibility, 8 did not meet inclusion criteria, 4 refused) Drop outs: 0 Group 1	mm Yale spinal needle, Becton Dickinson, Spain) was inserted in the perineum in the anterior midline approximately 1.5 to 2.0 cm from the	for group 2 after 2 nd month)	Group 1: 14.9±2.1 Group 2: 8.8±2.3 2 month Group 1: 15.4±1.7 Group 2: 8.7±2.3 6 month (open label)	toxin group Prostate size reduction at 1 and 2 months were significant for the botulinum toxin arm
2 months for blinded study, 12 months for open label on the active arm	N: 15 Age, years, mean (±SD): 69.4±4.9 Prostate vol ml, mean ± (SD): 52.6±10.6 Residual vol, ml, mean±(SD): 126.3±38.3	anus. The injection sites were visualised using transrectal ultrasonography.		Group 1: 14.6±4.1 <u>12 month (open label)</u> Group 1: 15±2.9 P values: Sig *	Notes: * P values <0.001 for Group 1 compared to baseline, and between
	<u>Group 2</u> N: 15 Age, years, mean (±SD): 68.2±3.9 Prostate volume ml, mean ± (SD): 52.3±10.0 Residual volume, ml, mean±(SD): 118.0±39.7	No sedation or anaesthesia was used during the procedure	Urinary incontinence (at <u>1</u> and 2 months	Group 1: 0/15 Group 2: 0/15	Group 1 and 2 at 1 and 2 months

Study details	Patients	Interventions	Outcome measures	Effect size	Comments									
Gotoh et al., 1999 ⁹⁵	Patient group: men with moderate to severe LUTS	Group 1: Transurethral vaporisation of the prostate (TUVP)	Mean IPSS score ± SD at 3 months	Group 1: 3.7 ± 2.4 (n=23) Group 2: 3.8 ± 2.3 (n=28) p value: Not sig.	Funding: NR									
Study design: RCT	Setting: multi-centre, Department of Urology, Nagoya University School of Medicine, Japan	Bandloop cutting 230–250W S Group 2: Transurethral	Group 2: Transurethral	Group 2: Transurethral	Group 2: Transurethral	Group 2: Transurethral	Group 2: Transurethral	Group 2: Transurethral	Group 2: Transurethral	Group 2: Transurethral	Group 2: Transurethral	Mean Qmax mL/s ± SD at 3 months	Group 1: 23.6 ± 13.9 Group 2: 21.2 ± 9.4 p value: Not sig.	Limitations: • Author confirmed no masking of
Evidence level: 1+	Inclusion criteria: • IPSS ≥10 • Qmax < 15mL/s	resection of the prostate (TURP) Standard loop cutting 120W	Catheterisation time (days)	Group 1: 3.4 ± 1.3 Group 2: 3.3 ± 1.3 p value: Not sig.	 outcome assessment and no allocation concealment 									
Duration of follow-up: 3 months	 Qmax < 15mL/s Prostate volume ≥ 30 ml or higher than normal PSA 	All patients: Same surgeon performed all procedures at each different	Complications: transfusion	Group 1: 0/25 Group 2: 0/28 p value: NR	Significant differences at baseline for Qmax									
	Exclusion criteria: NR	hospital Co	Complications: TUR	Group 1: 0/25 Group 2: 0/28 p value: NR	Additional outcomes: Urinalysis									
	<u>All patients</u> N: 53 Drop outs: 2	Preoperative: Baseline IPSS Symptom score, PSA, Blood, TRUS, uroflowmetry.	Complications: Urethral Stricture	Group 1: 0/25 Group 2: 0/28 p value: NR	Notes: Author reports									
	<u>Group 1:</u> N: 25 Mean age (± SD): 69.7 ± 6.3	Flow rate at months 1 & 6 and pressure flow at 3 months.	Complications: UTI	Group 1: 0/25 Group 2: 0/28 p value: NR	randomisation by drawing envelopes									
	Mean lPSS \pm SD: 19.6 \pm 7.5 Mean lPSS \pm SD: 19.6 \pm 7.5 Mean Qmax ml/s \pm SD: 7.3 \pm 2.8 Mean PVR ml \pm SD: 56.7 \pm 51.4 Mean prostate volume \pm SD (mL): 47.8 \pm 16.4 Operative time \pm SD mins: 60 \pm 28 Resected weight (g): 29.4 \pm 15.1 Drop outs: 2 excluded because cancer found	IPSS assessed at 3 months	Complications: incontinence	Group 1: 0/25 Group 2: 0/28 p value: NR										
	<u>Group 2:</u> N: 28 Mean age (± SD): 66.5 ± 15.7 Mean IPSS ± SD: 18.9 ± 7.3													

1 Evidence Table 41 Transurethral vaporesection of the prostate (TUVRP) vs. transurethral resection of the prostate (TURP)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean Qmax ml/s \pm SD: 9.4 \pm 2.8 Mean PVR ml \pm SD: 41.9 \pm 25.5 Mean prostate volume \pm SD (mL): 44.7 \pm 15.2 Operative time \pm SD mins: 61.1 \pm 29 Resected weight (g): 36.5 \pm 17.6 Drop outs: 0				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments							
Gupta et al., 2006 ⁹⁷	Patient Group : Patients with BPH who were candidates for TURP were selected from July 2002 to December 2003.	Group 1: TUVRP Wing (Wolf) loop: 180W cutting and 80W	Mean (SD) IPSS at 6 months	Group 1: 5.9 ± 0.25 Group 2: 6.1 ± 0.42 P value: NS	Funding: NR							
Study design: RCT	Setting: single centre: All India Institute of Medical Sciences, New Delhi, India	coagulation Group 2: TURP Standard tungsten wire	Mean (SD) IPSS at 12 months	Group 1: 5.4 ± 0.28 Group 2: 5.6 ± 0.32 P value: NS	Limitations: Randomisation method and allocation							
Evidence level: 1+	Inclusion criteria: glands of >40g Exclusion criteria:	loop 80W cutting and 50W coagulation	Mean (SD) Qmax at 6 months	Group 1: 22.5 ± 0.95 Group 2: 20.7 ± 1.32 P value: NS	 concealment were not reported. Outcome 							
Duration of follow-up: 12 months.	 Previous history of prostatic and urethral surgery Neurovesical dysfunction 	All patients 27F continuous-flow resectoscope. 22 F Foley catheter inserted and	Mean (SD) Qmax at 12 months	Group 1: 23.6 ± 0.96 Group 2: 23.7 ± 1.58 P value: NS	assessment was not masked • Drop outs NR so							
	Carcinoma of the prostate irrigation with saline	irrigation with saline. Catheter removed when	Mean (SD) catheter duration, days (converted from hours)	Group 1: 1.51 ± 0.35 Group 2: 1.90 ± 0.53 P value: Significant*	patient numbers at follow up unclear							
	Dropouts: NR	Examination methods	Complications: urinary retention (re-catheterisation)	Group 1: 3/50 Group 2: 3/50	Additional outcomes: Irrigation, haemoglobin							
	Group 1 N: 50	Preoperative: Baseline IPSS Symptom	Baseline IPSS Symptom	Baseline IPSS Symptom	Baseline IPSS Symptom	Baseline IPSS Symptom	Baseline IPSS Symptom		Baseline IPSS Symptom	Complications: TUR Syndrome	Group 1: 1/50 Group 2: 1/50	decrease, serum sodium decrease.
	Mean ± SD Age: 67.68 ± 9.8 IPSS ± SD: 24.9 ± 3.9 Mean SD Qmax: 4.65 ± 3.6	Blood, TRUS, uroflowmetry. Follow up at 1, 3, 6, 12	Complications: Transfusion	Group 1: 0/50 Group 2: 1/50	Notes: HOLEP arm of study not							
	Mean SD PVR, mL: 103 ± 174.1 Mean prostate size ± SD, g: 62.6 ± 14.8	months for complications and IPSS, PVR, Qmax reassessed at 6 & 12	Complications: Mortality (pneumonia)	Group 1: 1/50 Group 2: 0/50	reported. *ANOVA analysis used							
	Resectate ± SD g: 24.8 ± 12.7 Operation duration ±SD min: 55.9 ± 18.1 Patients with catheter: 19/50 Dropouts: NR		Complications: urethral stricture	Group 1: 1/50 Group 2: 2/50	to compare 3 groups							
	Group 2 N: 50 Mean ±SD Age: 65.67 ± 7.5 IPSS ± SD: 23.3 ± 3.9 Mean SD Qmax: 4.5 ± 3.9											

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean SD PVR, mL: 84.0 ± 129.7 Resectate ±SD g: 18.9 ± 12.9 Mean prostate size ± SD, g: 59.8 ± 16.5 Operation duration ±SD min: 64.1 ± 13.1 Patients with catheter: 16/50 Dropouts: NR				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Helke et al., 2001 ¹⁰²	Patient Group: Patients moderate or severe voiding dysfunction and BPE.	Group 1: TUVRP Vaporising loop 1mm: 250W cutting	Mean (SD) IPSS at 12 months	Group 1: 4.66 ± 4.3 (n=79) Group 2: 5.21 ± 5.1 (n=69) P value: NS	Funding: NR
Study design: RCT	Setting: single centre: University Hospital Carl Gustav Carus, Dresden, Germany	Group 2: TURP Standard loop 0.3 mm: 150W	Mean (SD) Qmax at 12 months	Group 1: 22.19 ± 12.3 Group 2: 22.12 ± 10.6 P value: NS	 Limitations: Randomisation method and
Evidence level: 1+	Inclusion criteria: • Enlarged prostate on DRE • At least moderate LUTS	cutting All patients 26F intermittent flow	Complications: incontinence	Group 1: 0/93 Group 2: 0/92	allocation concealment were not reported.
Duration of follow-up:	 IPSS > 10 and/or PVR >60 mL Patients with recent urinary retention 	resectoscope. Irrigation with Purisole 0.96% alcohol.	Complications: Transfusion	Group 1: 6/93 Group 2: 9/92	 Outcome assessment was no masked
12 months.	and indwelling catheters < 6 weeks duration	Antibiotic prophylaxis was given and catheter removed 2-	Complications: urethral stricture	Group 1: 5/93 Group 2: 7/92	Significant difference reporte
	 Exclusion criteria: Previous prostatic surgery Neurogenic bladder disorders Known urethral strictures Prostate cancer Indwelling catheter > 6 weeks duration Severe neurological disease Psychiatric abnormalities Reduced patient compliance All patients N: 185 Dropouts: 37 Group 1 N: 93 Mean ± SD Age: 67.3 ± 7.73 (47-85) IPSS ± SD: 17.29 ± 6.06 Mean SD Qmax: 10.8 ± 4.76 Mean SD PVR, mL: 76.0 ± 60.5 Mean prostate volume ± SD, mL: 48.8 ± 	3 days after surgery. TUVRP performed by 5 urologists with experience of at least 5 TUVRP patients each Examination methods Preoperative: Baseline ASA, New York Heart Association scores, IPSS Symptom score, AUA bother score, urinalysis, PSA, Blood, TRUS, uroflowmetry. Follow up at 3, 6, 12 months for PVR and flow rates at 12 months. Symptom score follow up by postal questionnaire	Complications: reoperation	Group 1: 9/93 Group 2: 5/92	 aitterence reporte between baseline Qmax p = 0.02 Significant difference found between baseline PVR p =0.02 white was not reported as significant. Additional outcomes: IPSS & Bother score were reported graphically at 3, 6 and 1 2mths Notes: None.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
details	21.21 Resectate ± SD g: 21.98 ± 13.47 Operation duration ±SD min: 71.02 ± 27.5 Indwelling catheter: 28/93 Dropouts: 14 (2 patients underwent radical prostatectomy and were excluded, 11 lost to follow up and incomplete outcome data for 1) Group 2 N: 92 Mean ±SD Age: 68.7 ± 8.38 (53-89) IPSS ± SD: 18.29 ± 7.49 Mean SD Qmax: 8.5 ± 5.19 Mean SD PVR, mL: 101.8 ± 84.1 Resectate ±SD g: 18.9 ± 12.9 Mean prostate volume ± SD, mL: 49.9 ± 22.1 Operation duration ±SD min: 65.68 ± 25.8 Indwelling catheter: 32/93 Dropouts: 23 (4 patients underwent radical prostatectomy and were excluded, 14 lost				
	to follow up and incomplete outcome data for 5)				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments			
Kupeli et al., 2001 ¹³⁶	Patient Group: Moderate to severe symptoms of prostatism	Group 1: TUVRP Wing (Wolf) loop: 205- 300W cutting	Mean (SD) IPSS at 6 months	Group 1: 4.0 ± NR Group 2: 5.0 ± NR* P value: NS	Funding: NR			
Study design: RCT	Setting: single centre: Ankara University, Turkey	Group 2: IURP Storz 24F loop: 80-120W cutting Examination methods Preoperative: Baseline IPSS Symptom score, DRE, urinalysis, PSA, Blood, TRUS, uroflowmetry.		Storz 24F loop: 80-120W	Storz 24F loop: 80-120W	Mean (SD) Qmax at 6 months	Group 1: 26.7 ± 3.7 Group 2: 24.6 ± 3.4 P value: NR	 Limitations: Randomisation method and
Evidence level: 1+ Duration of follow-up: 6 months	Inclusion criteria:column• IPSS \geq 8• Qmax < 15 mL/s		Mean (SD) catheter duration, days (converted from hours) Mean (SD) length of stay, days	P value: NR Group 1: $2 \pm NR$ Group 2: $4 \pm NR$ P value: <0.05	 allocation concealment were not reported. Outcome assessment was not masked No mention of drop 			
	History of prostate surgery All patients	Follow up at 6 months	Complications: urinary retention (re- catheterisation)	Group 1: 0/50 Group 2: 0/50	 outs in the study Standard deviations for IPSS 			
	N: 100 Dropouts: NR		Complications: TUR Syndrome	Group 1: 0/50 Group 2: 0/50	 NR Significance difference in 			
	<u>Group 1</u> N: 50		Complications: Transfusion	Group 1: 0/50 Group 2: 0/50	baseline Qmax p=0.007			
	Mean ± SD Age: 61.4 ± 3.2 IPSS ± SD: 19.4 ± NR		Complications: Incontinence	Group 1: 0/50 Group 2: 0/50	Almost all patients had retrograde			
	Mean SD Qmax: 7.9 ± 2.1 Mean prostate size ± SD, g: 57.8 ± 4.1 Resectate ± SD g: NR		Complications: Retrograde ejaculation	Group 1: 26/50 Group 2: 27/50	ejaculation prior to surgery			
	Operation duration \pm SD min: 48.2 \pm NR Previous medical treatment: 32/50 Preoperative retrograde ejaculation: 50/50		Complications: urethral stricture	Group 1: 0/50 Group 2: 0/50	Additional outcomes: Haemocrit and sodium			
	Preoperative erectile dysfunction: 14/50 Dropouts: NR				None.			
	Group 2 N: 50 Mean ±SD Age: 58.9 ± 3.6							

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	IPSS ± SD: 21.6 ± NR Mean SD Qmax: 9.2 ± 2.6 Mean prostate size ± SD, g: 56.7 ± 6.3 Resectate ± SD g: NR Operation duration ±SD min: 42.7 ± NR Previous medical treatment: 31/50 Preoperative retrograde ejaculation: 44/50 Preoperative erectile dysfunction: 19/50 Dropouts: NR				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Liu et al., 2006 ¹⁴⁷	Patient Group: Patients with BOO due to BPH on waiting list for surgery	Wedge resection loop: n 200W cutting and 60W	Mean (SD) IPSS at 3 months	Group 1: 8.2 ± 2.2 (n=42) Group 2: 7.9 ± 1.8 (n=30) P value: 0.53	Funding: NR
Study design: RCT Evidence	Setting: single centre: Taipei City Hospital, Taiwan Inclusion criteria:	coagulation Group 2: TURP Standard wire loop 110W	Mean (SD) IPSS at 2 years	Group 1: 9.0 ± 3.1 Group 2: 8.4 ± 2.6 P value: 0.45	Limitations: Unbalanced baseline numbers Allocation
level: 1+	• IPSS \geq 15 • IPSS QoL \geq 3 • Qmax \leq 12 mL/s	cutting and 60W coagulation.	Mean (SD) IPSS QoL at 3 months	Group 1: 1.7 ± 0.5 (n=36) Group 2: 1.5 ± 0.7 (n=26) P value: 0.57	 Allocation concealment unclear Outcome
Duration of follow-up: 2 years	 Exclusion criteria: PSA ≥ 4 ng/mL 	All patients 27F continuous-flow resectoscope. 22 F Foley catheters inserted.	Mean (SD) IPSS QoL at 2 years	Group 1: 1.6 ± 0.6 Group 2: 1.4 ± 0.7 P value: 0.48	assessment was no maskedNumber of patient
	 Neurogenic bladder Carcinoma of the prostate History of prostate or urethral surgery 	TUVRP performed by 3	Mean (SD) Qmax at 3 months	Group 1: $20.7 \pm 2.8 \text{ (n=29)}$ Group 2: $21.6 \pm 2.0 \text{ (n=21)}$ P value: 0.2	remaining at 2 years was unclea and reasons for incomplete outcor
	Bladder stonesPatients on anticoagulant therapy	at least 10 TUVRP patients each	Mean (SD) Qmax at 2 years	Group 1: 19.6 ± 3.7 Group 2: 21.2 ± 2.7 P value: 0.12	data not given.
	All patients N: 76 Dropouts: NR	Examination methods Preoperative: Baseline IPSS Symptom	Mean (SD) catheter duration, days (converted from hours)	Group 1: 1.06 ± 0.18 Group 2: 1.66 ± 0.38 P value: <0.0001	Notes: Randomisation by drawing envelopes
Group 1 N: 44 Mean ± SD Age: 66.0 ± 6.6	N: 44 Mean ± SD Age: 66.0 ± 6.6	Blood, TRUS, uroflowmetry. Follow up at 3, 6, 12 months	Mean (SD) length of stay, days	Group 1: 1.65 ± 0.2 Group 2: 2.06 ± 0.35 P value: <0.0001	
	IPSS ± SD: 26.8 ± 4.7 IPSS QoL ± SD: 4.1 ± 0.6 Mean SD Qmax: 6.9 ± 2.1 Mean SD PVR, mL: 142 ± 48 Mean prostate volume ± SD, mL: 60.5 ± 10.9	Complications: urinary retention (re- catheterisation)	Group 1: 3/44 Group 2: 4/32		
			Complications: TUR Syndrome Complications:	Group 1: 0/44 Group 2: 2/32 Group 1: 1/44	-
	Resectate ± SD g: 32.2 ± 7.1		Transfusion	Group 2: 2/32	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Operation duration \pm SD min: 49.4 \pm 8.0		Complications: Incontinence	Group 1: 2/44 Group 2: 1/32	
	Dropouts: NR		Complications: Reoperation rate	Group 1: 2/44 Group 2: 3/32	
	<u>Group 2</u> N: 32 Mean ±SD Age: 64.7 ± 6.3		Complications: urethral stricture	Group 1: 3/44 Group 2: 2/32	
	IPSS \pm SD: 25.6 \pm 3.5 IPSS QoL \pm SD: 4.0 \pm 0.7 Mean SD Qmax: 6.9 \pm 1.9		Complications: retrograde ejaculation * answered by those men who were		
	Mean SD PVR, mL: 131 ± 41 Resectate ±SD g: 35.5 ± 4.3		sexually active preoperatively in each		
	Mean prostate volume ± SD, mL: 58.4 ± 8.4 Operation duration ± SD min: 52.9 ±		group		
	6.0 Dropouts: NR				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Netto et al., 1999 ¹⁸⁸ Study design: RCT	Patient group: moderate to severe symptomatic BPH Setting: single-centre, division of urology, Unicamp & Hospital Benefcencia Portuguesa, São Paulo, Brazil	vaporisation of the r prostate (TUVP) r Standard loop: cutting in	Mean IPSS score at mean follow up 17 months (follow up interval not clear for each group)	Group 1: 3.83 ± 4.62 Group 2: 8.68 ± 2.30 p value: <0.00001 (calculated by NCGC as t test with unequal variances) conflicts with study finding p=0.88	Funding: NR Limitations: • Randomisation method and
Evidence level: 1+ Patients with >1 symptomatic and uncomplicated BPH IPSS >12 Qmax < 15 mL/s	Group 2: Transurethral resection of the prostate (TURP) Standard loop: cutting	Mean Qmax ± SD mL/s at mean follow up 17 months (follow up interval not clear for each group)	Group 1: 15.43 ± 3.4 Group 2: 16.16 ± 2.48 p value: 0.28 (calculated by NCGC as t test with equal variances) conflicts with study finding p=0.02	 allocation concealment not reported Masked outcome assessment was not reported 	
mean 17 months (11-23)	 Voided volume ≥150mL PVR <250 mL Prostate volume 25-90 mL Exclusion criteria: 	All patients: Operations performed using 24F continuous flow resectoscope using a 3% mannitol as irrigant. A 22F Foley catheter was	Catheterisation time (days) hours reported converted to days	Group 1: 0.77 ± 0.29 Group 2: 1.68 ± 0.36 p value: <0.00001 (calculated by NCGC as <i>t</i> test with equal variances)	 Follow up interval fo each group not clean only overall mean follow up reported. There were
	 Exposure to α-antagonists, anticholinergics, cholinergics, diuretics, estrogens, androgens, antihypertensive medications or other agents within the 		Length of hospital stay (days)	Group 1: 1.55 ± 0.75 Group 2: 2.63 ± 0.63 p value: <0.0001	 significant baseline differences in IPSS score Dropouts were not reported. P values reported conflicted with
	 Prostate cancer Urethral stricture 		Complications: retrograde ejaculation	Group 1: 26/40 (65%) Group 2: 12/38 (32%) p value: NR	
	 Urinary tract stone disease Neurogenic bladder Hydronephrosis 		Complications: TUR	Group 1: 0/40 Group 2: 0/38 p value: NR	outcome measures.
	 UTI within 3 months prior to surgery Pelvic irradiation Previous prostatic surgery 		Complications: urethral stricture	Group 1: 0/40 Group 2: 0/38 p value: NR	─ None.
	All patients N: 78 Drop outs: NR				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	$eq:spectral_set_set_set_set_set_set_set_set_set_set$				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Talic et al., 2000 ²⁵⁰	Patient Group: Patients with BOO due to BPH on waiting list for surgery	Group 1: TUVRP Wing resection loop: 250W cutting and 80W	Mean (SD) IPSS at 6 months	Group 1: 4.0 ± 3.4 Group 2: 5.6 ± 3.1 P value: 0.03	Funding: NR
Study design: RCT	Setting: single centre: King Khalid University Hospital, Saudi Arabia	Group 2: TURP	Group 2: TURP Mean (SD) Qmax ar o Group 1: 19.0 Broup 2: TURP	Group 1: 19.0 ± 6.5 Group 2: 15.2 ± 10.0 P value: 0.01	 Randomisation method and
Evidence level: 1+	Inclusion criteria: • Men with urinary retention • IPSS > 15 • Qmax < 15 mL/s	Standard wire loop 150W cutting and 50W coagulation.	Mean (SD) catheter duration, days (converted from hours)	Group 1: 0.96 ± 0.43 Group 2: 1.5 ± 0.72 P value: <0.0001	allocation concealment not reported • Outcome
Duration of follow-up: 6 months	Exclusion criteria:	All patients 27F continuous-flow	Complications: TUR Syndrome	Group 1: 0/34 Group 2: 0/34	assessment was not masked
(Mean follow up 9.2 mths	Neurogenic bladderCarcinoma of the prostate	irrigation TUVRP performed by 3 urologists with experience of at least 10 TUVRP patients each Examination methods Preoperative: Baseline IPSS Symptom score, DRE, urinalysis, blood, uroflowmetry. Follow up every 3 months	Complications: Transfusion	Group 1: 0/34 Group 2: 0/34	 Significant baseline differences in Qmax p=0.02 &
for TUVRP and 8.8 mths for TURP)	History of prostate or urethral surgery All patients		Complications: urethral stricture	Group 1: 3/34 Group 2: 4/34	IPSS p<0.0001Dropouts were not
	N: 68 Dropouts: NR				reported Additional outcomes:
	<u>Group 1</u> N: 34 Mean ± SD Age : 70.9 ± 9.3				Haematocrit, haemoglobin, serum sodium
	IPSS ± SD: 24.9 ± 6 Mean SD Qmax: 7.5 ± 3.5 Mean prostate size ± SD, g: 52.4 ± 18.7 Resectate ± SD g: 22.4 ± 10.5				Notes: None.
	Men with urinary retention: $15/34$ Operation duration ± SD min: 42.4 ± 15 Urinary retention: $15/34$ Dropouts: NR				
	Group 2 N: 34 Mean ±SD Age: 70.4 ± 8.8 IPSS ± SD: 20.1 ± 6.8				

Lower urinary tract symptoms (LUTS) – full guideline appendices DRAFT (August 2009)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean SD Qmax: 9.1 ± 6.3 Resectate ±SD g: 20.2 ± 9.5 Men with urinary retention: 18/34 Mean prostate size ± SD, g: 57.2 ± 22.5 Operation duration ± SD min: 35.9 ± 12.8 Urinary retention: 18/34 Dropouts: NR				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Fung et al., 2005 ⁸⁷	Patient group: men on waiting list for surgery for BPH with acute or chronic retention, failure to remove catheter and	Group 1: Bipolar transurethral resection of the prostate (B-TURP)	Mean ± SD IPSS change from baseline at 3 months	Group 1: 8.81 ± NR (n=21) Group 2: 9.63 ± NR (n=30) P value: 0.86	Funding: NR
Study design: RCT Observer and patient	Setting: single-centre: Division of Urology, Pamela Youde Nethersole Eastern Hospital,system through 27F resectoscope at 240W	system through 27F resectoscope at 240W	Mean ± SD change in Qmax from baseline at 3 months	Group 1: 16.57 ± NR (n=21) Group 2: 14.71 ± NR (n=30) P value: 0.96	 Example 1 8 dropouts in Group 1 due to machine failure
masked Evidence	Inclusion criteria: • IPSS >20	60W for coagulation. Group 2: Transurethral	Mean ± SD IPSS QoL change from baseline at 3 months	Group 1: 0.55 ± NR (n=21) Group 2: 1.54 ± NR (n=30) P value: 0.17	 Allocation concealment was not reported
level: 1+	• Qmax <10 mL/s Exclusion criteria:	resection of the prostate (TURP) Standard loop through	Mean ± SD Qmax at 12 months	Group 1: 17.0 ± NR (n=20) Group 2: 15.0 ± NR (n=20) P value: NR	Additional outcome reduction in serum
Duration of follow-up: 3 months	Neurogenic bladderUrethral strictureAnticoagulant therapy	All patients: Surgery performed by a consultant, senior medical officer or senior registrar with experience of	Catheterisation time (days)	Group 1: 1.14 ± NR Group 2: 1.21 ± NR P value: 0.59	sodium and haemoglobin Notes:
	 Bladder stone Prostate cancer or suspect Previous prostate surgery 		Complications: urinary retention (re- catheterisation)	Group 1: 4/21 Group 2: 3/30 P value: NR	Randomisation using computer generated numbers
	<u>All patients</u> N: 60		Complications: urinary retention UTI	Group 1: 4/21 Group 2: 4/30 P value: NR	
	Drop outs: 9 <u>Group 1:</u> N: 29 (n=21) Mean age (range): 72.5 (59-91) Mean IPSS ± SD: 15.82 ± NR Mean IPSS QoL ± SD: 3.55 ± NR Mean PVR± SD, mL: NR Mean prostate volume ± SD, mL: NR Resection time (range), min: 36.6 (12-76) Resected weight (range), g: 18.6 (1-57) Patients with urinary retention: 17 Drop outs: 8 for machine failure	performing TURP. A 22F 3-way catheter was inserted with saline irrigant until effluent was clear. Catheter removed the following morning Examination methods Preoperative: Baseline IPSS Symptom score, QoL, assessed and follow up of IPSS, QoL and Qmax at 3 months	Complications: TUR	Group 1: 0/21 Group 2: 0/30 P value: NR	

1 Evidence Table 42 Bipolar TUVRP vs. transurethral resection of the prostate (TURP)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	<u>Group 2:</u> N: 31 (n=30) Mean age (range): 73 (59-88) Mean IPSS ± SD: 19.36 ± NR Mean IPSS QoL ± SD: 3.64 ± NR Mean PVR± SD, mL: NR Mean prostate volume ± SD, mL: NR Resection time (range), min: 32.9 (12-105) Resected weight (range), g: 25.1 (4-100) Patients with urinary retention: 25 Drop outs: 1 (patient contracted sepsis)				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Kim et al., 2006 ¹²⁸ (data obtained from HTA report)	Patient group: Patients with symptomatic BPE Inclusion criteria: NR Exclusion criteria: NR	Group 1- TEAP Prostajec device (American Medical	IPSS, mean:	Baseline Group 1: 19.5 Group 2: 24.0 3 months Group 1: 9.6 Group 2: 10.6	Funding: Unknown Limitations: Uncertain whether the data reported was mean or
Study design: RCT	<u>All patients</u> N: 204 randomised, from 223 eligible	Systems, Minnetonka, MN, USA)		12 months Group 1: 7.5 Group 2: 8.8	medianRandomisation allocation, concealment and blinding
Setting: Korea, recruitment	Drop outs: Group 1-TEAP N: 94	Group 2- TURP	Blood transfusion	Group 1: 0/94 Group 2: 19/101 RR (95% CI): 0.03(0.00 to 0.45) P value: 0.01	had been rated as "unclear" "medium sized" prostates ir TEAP vs. large prostate
from January 1998– December 2002	Age, years, mean or median (range) : 6.2 (49–88) OL score, mean: 4.4 Qmax (ml/s), mean or median: 7.2		Urinary retention	Group 1: 2/94 Group 2: 4/101 RR (95% CI): 0.54 (0.10 to 2.87) P value: 0.47	sizes in TURP Additional outcomes: (values not reported in HTA reported)
Evidence level: 1+	Residual volume, (ml), mean or median: 126.1 Prostate size, (ml), mean or median: 36.4		Urinary tract infection	Group 1: 5/94 Group 2: 7/101 RR (95% Cl): 0.77(0.25 to 2.34) P value: 0.64	Duration of operation, Recatheterisation, Retrograde ejaculation, Erectile dysfunction Reoperation, Quality of life,
Duration of follow-up: 12 months	ow-up: N: 110		Stricture	Group 1: 0/94 Group 2: 7/101 RR (95% Cl): 0.07(0.00 to 1.24) P value: 0.07	Length of hospital stay Qmax, Residual volume , Prostate size
	(60–87) QoL score, mean: 4.7 Qmax (ml/s), mean or median:11.9 Residual volume, (ml), mean or median: 187 Prostate size, (ml), mean or median: 44.2		Incontinence	Group 1: 0/94 Group 2: 4/101 RR (95% CI): 0.12(0.01 to 2.19) P value: 0.15	Notes: Evidence Table produced with data from Evidence Table of th HTA report. Values for complications obtained from Figure 11 of HT report (page 49).

1 Evidence Table 43 Transurethral ethanol ablation of the prostate (TEAP) vs. transurethral resection of the prostate (TURP)

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
aeraits Wasson et al., 1995 ²⁷¹ & Anon1993 ¹ Study design: RCT Setting: US, July 1986 to 1989. Evidence level: 1+ Duration of follow-up: 3 years (average of	Patient group:Group 1: TURP1Consecutive male veterans referredPerformed by the chief101to urology clinics because of BPHsurgical resident or staff1symptomssurgeon. No description1Inclusion criteria:provided1Score of 10-20 on the Madsengroup 2: Watchful1Iverson symptom score (moderate orsomewhat severe)1Somewhat severe)Group 2: Watchful1Somewhat severe)Waiting1No specific description1History of prostate surgery or radiation treatmentAll patients:1Unable to walkcoffee, alcohol, and other liquids after	All cause mortality (no deaths associated with surgery) Symptom scores, mean (±SD) : Range: 0 to 27, (Madsen Iversen questionnaire) higher values more severe	At 3 year follow up Group1: 13/280 Group 2: 10/276 Relative risk:1.28 (95% CI: 0.57 to 2.87) P value: Not sig At baseline Group 1: 146±3.0 Group 2: 14.6±2.8 p value: Not sig At 3 year follow up Group 1: 4.9±4.0 Group 2: 9.1±4.7 p value: Change from baseline Group 1: -9.6±5.0 Group 2: -5.5±5.2 p value: <0.001	Funding: Cooperative Studies Programme of the Department of Vetera Affairs Medical Research Service Limitations: Randomisation allocation and concealment Additional outcomes: Residual volume Perioperative complications: 5 perforation of	
2,8 years)	 Received diagnosis of prostate or bladder cancer Residual volume > 350 ml Low total score on a scale that rates BPH on a the basis of cystoscopy, the symptom interview and bladder ultrasonography Serious medical conditions that would have made surgery inappropriate for follow-up unlikely (e.g: uncontrolled diabetes, neurogenic bladder, cirrhosis, active alcoholism, 	medications that might make their symptoms worse. Physicians were asked to avoid prescribing medications such as alpha- adrenergic antagonists that might confound the results of the trial. A referral to a urologist was considered if there was an indication of treatment failure or a patient requested such referral. All participants were followed in general	Qmax, mean (±SD) : Perioperative complications:	At baseline Group 1: 11.6±6.4 Group 2: 12.5±7.5 p value: Not sig At 3 year follow up Group 1: 17.8±9.1 Group 2: 12.7±7.6 p value: <0.001 Change from baseline Group 1: 6.3±9.7 Group 2: 0.4±9.2 p value: <0.001 Group 1: 9/280	 capsule, 1 thrombophlebitis. 10 men found to have prostate cancer Factors predicting improvement, and influence of patient reported bother from urinary symptoms on outcomes of surgery and watchful waiting
	 bleeding diathesis, psychosis, and late stage cardiac or respiratory disease) Serum creatinine concentration 		Perioperative complications: Recatheterisation Perioperative complications: transfusion	Group 2: 0/276 p value: <0.05* Group1: 3/280 Group 2: 0/276	(see outcomes measure)

1 Evidence Table 44 Transurethral resection of the prostate (TURP) vs. watchful waiting

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
	 >3.0 mg /dl or had doubled in the previous year All patients A total of 800 patients screened 591 eligible for randomisations 30 did not provide informed consent, and 5 were found to be ineligible. N: 556 Drop outs: 71/556 [41/556 	medical clinic six to eight weeks after randomisation and followed-up twice a year	Perioperative complications: Urinary tract infection Incontinence (new persistent urinary incontinence requiring use of pads, clamps or condom)	p value: Not sig Group1: 2/280 Group 2: 0/276 p value: Not sig At 3 year follow up Group 1: 4/280 Group 2: 4/276 Relative risk: 0.99(95% Cl: 0.25-3.90) P value: Not sig	Notes: Related publication: Anon1993 published the patient reported outcomes aspects Intention to treat analyses used. Data for all men, including those who had	
	withdrew consent, 30 lost to follow up] Age, years, mean (±SD): 66±5 <u>Group 1</u> N: 280 Dropouts: 38/280, [24/280 withdrew consent, 14/280 lost to follow up] Age, years, mean (±SD): 65.6±5.2	30 lost to follow (\pm SD): 66 \pm 5 9, [24/280 14/280 lost to (\pm SD): 65.6 \pm 5.2 .4 n (\pm SD): 65.6 \pm 5.2 .4 n (\pm SD) : inary difficulties: mance: 43.3 \pm 32.7 aily living: being: 72.8 \pm 27.9 s: 75.6 \pm 23.5 ping urine or 6.0 n: 60.7 9.[17/276	Treatment failure (Any of these events: death, repeated or intractable UTI, a residual volume of >350 ml, development of bladder calculus, new urinary incontinence; a symptom score of ≥ 24 at one visit of a symptom score of ≥ 21 at 2 consecutive visits, doubling of baseline serum creatinine concentration)	, e	 dropped out were analysed based on th group assigned. *Calculated by NCG- team using Fisher's exact test *Score on a scale ranging from 0 (greatest impairment) 	
	 White race, %: 91.4 **QoL scores, mean (±SD): Bother from urinary difficulties: 43.8±29.3 Sexual performance: 43.3±32.7 Activities of daily living: 66.5±27.2 General well being: 72.8±27.9 Social activities: 75.6±23.5 			Reoperation/received surgery (in the watchful waiting arm) Reason: 9 bladder neck contracture, 9 urethral strictures, 8 received second TURP (4 due to adenoma). In the watchful waiting group: 20 treatment failure (11 high volume residual urine, 8 urinary symptoms, 5 intractable urinary retention)	At 3 year follow up Group 1: 26/280 Group 2: 65/276 Relative risk: 0.39 (95% CI: 0.26 to 0.60) p value: <0.05	to 100 (least impairment) Average period of follow up; 2.8 years
	Problems with dripping urine or wetting of plans: 46.0 Erective dysfunction: 60.7 Group 2 N=276 Dropouts: 33/276 [17/276 withdrew consent, 16/276 lost to follow up]		QoL scores - Bother from urinary difficulties , mean (±SD) :	At baseline Group 1: 43.8±29.3 Group 2: 46.3±29.3 p value: Not sig At 3 year follow up Group 1: 75.7±23.9 Group 2: 57.6±28.3 p value: Change from baseline		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Age, years, mean (±SD):66.2±5.3 White race, %: 93.1 **QoL scores, mean (±SD) :			Group 1: 29.6±29.4 Group 2: 9.6±29.7 p value: <0.001	
	 Bother from urinary difficulties: 46.3±29.3 Sexual performance: 42.5±30.3 Activities of daily living: 69.0±26.6 General well being: 71.2±28.8 Social activities: 74.2±23.1 Problems with dripping urine or wetting of plans: 44.4 Erective dysfunction: 63.7 	QoL scores - Sexual performance: mean (±SD) :	At baseline Group 1: 43.3±32.7 Group 2: 42.5±30.3 At 3 year follow up Group 1: 36.0±26.0 Group 2: 35.6±25.6 Change from baseline Group 1: -3.0±27.9 Group 2: -3.2±26.6 p values: Not sig		
			QoL scores - Activities of daily living: mean (±SD) :	At baseline Group 1: 66.5±27.2 Group 2: 69.0±26.6 p value: Not sig At 3 year follow up Group 1: 86.4±20.1 Group 2: 75.6±27.1 p value: Change from baseline Group 1: 19.6±26.5 Group 2: 6.4±30.3 p value: <0.001	
			QoL scores - General well being: mean (±SD) :	At baseline Group 1: 72.8±27.9 Group 2: 71.2±28.8 At 3 year follow up Group 1: 76.2±27.8 Group 2: 71.4±31.0 Change from baseline Group 1: 3.0±25.5 Group 2: 0.1±28.3 p values: Not sig	
			QoL scores - Social activities: mean	Group 2: 0.1±28.3	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			(±SD) :	Group 1: 75.6±23.5 Group 2: 74.2±23.1 At 3 year follow up Group 1: 75.5±25.3 Group 2: 73.1±25.5 Change from baseline Group 1: -1.6±24.3 Group 2: -1.7±23.5 p values: Not sig	
			Factors predicting improvement from bother from urinary difficulties at follow up (logistic regression, "improvement" not defined. Factors in model were baseline variables of bother from urinary difficulties, treatment assignment, age, symptom score, residual urinary volume, urinary volume after voiding, bladder trabeculation, Qmax)	2 factors were significant: Treatment assigned: odds ratio 5.7 (95% Cl: 1.9 to 17.3) High bother score (>55) at baseline (for surgery group only, odds ration of 6.6(95% Cl: 3.0 to 14.3) for surgery group, odds ratio of 1.4 (95% Cl: 0.8 to 2.5) for watchful waiting group. In the TURP group, % improved High bother: 134/148 (91%) Less bother: 45/73 (62%) In the watchful waiting group, % receiving surgery	
			Association of symptom severity with QoL aspects (Perception of urinary difficulty(UD), sexual function (SF), Activities of daily living (ADL), general well being (GWB), Social activities(SA))	High bother: 48/155 (31%) Low bother: 16/97(16%) Nocturia: UD, ADL, GWB, Dribbling: UD Urgency: Sig for all Hesistancy: SF Frequency: UD, ADL, GWB, SA	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Patient group: men with LUTS including those with urinary retention from failed medical therapy	Group 1: Bipolar transurethral resection of the prostate (B-TURP)	Mean ± SD IPSS at 3 months	Group 1: 8.0 ± NR (n=35) Group 2: 8.0 ± NR (n=35) P value: NR	Funding: NR
De Sio et al., 2006 ⁵⁸ reported 12 month	Setting: Seconda Università di Napoli, Università magna Graecia, Catanzaro & Università Federico, Naples, Italy.	system	Mean ± SD IPSS at 6 months	Group 1: 5.0 ± NR (n=35) Group 2: 5.5 ± NR (n=35) P value: NR	Limitations: • Allocation concealment no reported.
outcomes. Study design:	Inclusion criteria:	resection of the prostate (TURP) Standard loop	Mean ± SD IPSS at 12 months	Group 1: 3.9 ± 3.32 (n=35) Group 2: 3.8 ± 3.32 (n=35) P value: 0.9	Masking of IPS and Qmax were
RCT Evidence	 AUR if catheter failed after medical therapy and CUR after unresponsiveness to medical therapy 	All patients: 26F resectoscope. Insertion of 22F 3-way	Mean ± SD IPSS at 24 months	Group 1: 4.5 ± 3.84 (n=33) Group 2: 4.8 ± 3.84 (n=34) P value: 0.75	not reported by catheterisation time was masked as
1+ Duration of	 IF 35 > 10 Qmax < 15mL/s Prostate volume > 30 ml or higher than 	Mean ± SD IPSS at 36 months	Group 1: 6.8 ± 5.19 (n=33) Group 2: 6.2 ± 5.19 (n=33) P value: 0.64	 primary outcome. 3 and 6 mont outcomes 	
follow-up: 48 months	normal PSA Exclusion criteria: Prostate cancer or suspect	Examination methods Preoperative: Baseline IPSS Symptom score, QoL, Qmax, PVR, PSA assessed and follow up of IPSS, QoL, PVR and Qmax at 3, 6 12 monthsmonthsMean ± SD I monthsMean ± SD I monthsMean ± SD I months	Mean ± SD IPSS at 48 months	Group 1: 6.9 ± 3.57 (n=32) Group 2: 6.4 ± 3.57 (n=31) P value: 0.58	Additional outcomes: Bladder irrigation time PVR at longer follo up periods.
	 Neurogenic bladder Bladder stone and/or diverticula Urethral stricture 			Group 1: 2.1 ± NR (n=35) Group 2: 1.4 ± NR (n=35) P value: NR	
	 Maximum bladder capacity >500mL Previous prostate surgery Warfarin therapy 		Mean ± SD IPSS QoL at 6 months	Group 1: 1.1 ± NR (n=35) Group 2: 1.0 ± NR (n=35) P value: NR	
All patients N: 70 Drop outs: 7 (refused follow-up=3; moved away=2; death, other causes=2)		Mean ± SD IPSS QoL at 12 months	Group 1: 1.0 ± 2.16 (n=35) Group 2: 0.8 ± 2.16 (n=35) P value: 0.7	Notes: Randomisation sequence was	
	away=2; death, other causes=2)			Mean ± SD IPSS QoL at 24 months	Group 1: 1.1 ± 2.49 (n=33) Group 2: 1.2 ± 2.49 (n=34) P value: 0.87
	<u>Group 1:</u> N: 35 Mean age ± SD: 59.0 ± 5.9 Mean IPSS ± SD: 24.8 ± 4.0		Mean ± SD IPSS QoL at 36 months	Group 1: 1.2 ± 1.27 (n=33) Group 2: 1.3 ± 1.27 (n=33) P value: 0.75	from P values and means reported [from Cochrane

1 Evidence Table 45 Bipolar transurethral resection of the prostate (TURP) vs. TURP

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean Qmax ± SD, mL/s: 7.1 ± 2.0Mean PVR± SD, mL: 80.0 ± 22.5Mean prostate volume ± SD, mL: 51.6 ± 3.9		Mean ± SD IPSS QoL at 48 months	Group 1: 1.3 ± 1.74 (n=32) Group 2: 1.4 ± 1.74 (n=31) P value: 0.82	handbook].
	IPSS QoL \pm SD: 4.2 \pm 1.0 Operative time \pm SD, min: 49 \pm NR Resection time \pm SD, min: 33 \pm NR		Mean ± SD Qmax at 3 months	Group 1: 21.5 ± NR (n=35) Group 2: 20.5 ± NR (n=35) P value: NR	
	Resected weight (g): 20 ± NR Drop outs: 3 Group 2:		Mean ± SD Qmax at 6 months	Group 1: 20.5 ± NR (n=35) Group 2: 20.0 ± NR (n=35) P value: NR	
	N: 35 Mean age \pm SD: 61.0 \pm 5.9 Mean IPSS \pm SD: 24.38 \pm 5.0		Mean ± SD Qmax at 12 months	Group 1: 20.8 ± 7.73 (n=35) Group 2: 22.3 ± 7.73 (n=35) P value: 0.42	
	Mean Qmax ± SD, mL/s: 6.3 ± 3.0 Mean PVR± SD, mL: 75.5 ± 35.5 Mean prostate volume ± SD, mL: 47.5 ± 5.1 IPSS QoL ± SD: 3.9 ± 1.0		Mean ± SD Qmax at 24 months	Group 1: 20.2 ± 14.37 (n=33) Group 2: 22.0 ± 14.37 (n=34) P value: 0.61	
	Operative time \pm SD, min: 53 \pm NR Resection time \pm SD, min: 39 \pm NR Resected weight (g): 24 \pm NR		Mean ± SD Qmax at 36 months	Group 1: 20.5 ± 7.3 (n=33) Group 2: 21.5 ± 7.3 (n=33) P value: 0.58	
	Drop outs: 4		Mean ± SD Qmax at 48 months	Group 1: 19.8 ± 7.15 (n=32) Group 2: 21.2 ± 7.15 (n=31) P value: 0.44	-
			Catheterisation time (days) converted into days	Group 1: 3.0 ± NR Group 2: 4.2 ± NR P value: <0.05	
			Length of stay (days) converted into days reported at time to discharge	Group 1: 3.3 ± NR Group 2: 4.5 ± NR P value: <0.05.	
			Complications: transfusion	Group 1: 1/35 Group 2: 0/35 P value: NS	
			Complications: TUR	Group 1: 0/35 Group 2: 0/35 P value: NS	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
			Complications: urinary retention	Group 1: 0/35 Group 2: 0/35 P value: NS	
			Late complications at 48 months	Stricture Group 1: 1/32 Group 2: 2/31; p=0.6 Bladder neck contracture Group 1: 1/32 Group 2: 1/31; p=0.8 BPH recurrence Group 1: 1/32 Group 2: 1/31; p=0.8 Reoperation Group 1: 2/32 Group 2: 3/31; p=0.15	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments				
Bhansali et al., 2009 ²⁷	that necessitated surgical intervention between May 2004 and December 2005.	transurethral resection of the prostate (B-TURP)3PK superpulse using 26F Gyrus Superpulse PK resectoscope and physiologic saline with 1% ethanol as irrigation fluid. Generator settings wereN	Mean (SD) Qmax at 3 months	Group 1 (n=34): 19.85 (3.939) Group 2 (n=33): 19.23 (5.176) P=0.582	Funding: NR Limitations:				
Study design: RCT	Setting: Institute of Urology in Pune, India Inclusion criteria:		Gyrus Superpulse PK resectoscope and physiologic saline with 1% ethanol as irrigation fluid. Generator settings were	Gyrus Superpulse PK resectoscope and physiologic saline with 1% ethanol as irrigation fluid. Generator settings were	Gyrus Superpulse PK resectoscope and physiologic saline with 1% ethanol as irrigation fluid.	Gyrus Superpulse PK 9 mon	Mean (SD) Qmax at 9 months	Group 1 (n=34): 17.41 (2.840) Group 2 (n=33): 17.76 (3.269) P=0.645	Dropouts not explainedAllocation
Evidence level: 1+	 >45 years Exclusion criteria: 					thanol as irrigation fluid. Group 1 (n=34): 16.6 (2.640) Group 2 (n=33): 15.9 (3.126) D=0.715		concealment method unclear	
Duration of follow-up: 1 year	 AUA <18 Qmax >12 Gland size < 60g 	and coagulation, respectively.	Mean (SD) Blood loss	Group 1 (n=34): 195.97 (50.079) Group 2 (n=33): 361.52 (97.599) P=0.000	Notes: None.				
	 Renal insufficiency, bladder stone Urethral stricture, prostate (TURP) 	Mean (SD) Time catheterised	Group 1 (n=34): 19.05 (3.920) Group 2 (n=33): 39.25 (10.223) P=0.000						
	• Receiving 5AR inhibitors	 Receiving 5AR inhibitors Patients 70 po outs: 3 po outs: 3 po Qmax: 4.367 an age ± SD: NR po Qmax: 4.194 20F resectoscope and an electrosurgical generator with glycine as irrigation fluid. Generator settings were 110 for cutting and 70 for coagulation. All patients: 500mg ciprofloxacin and 80mg gentamicin 1 hour preoperatively. All patients catheterised with 20F triple lumen Foley catheter at end of surgery, and irrigation started. 	Mean (SD) Hospital stay	Group 1 (n=34): 79.21 (14.251) Group 2 (n=33): 81.09 (15.438) P=0.605					
	N: 70 Drop outs: 3		Average tissue resected, g	Group 1: 42.8 Group 2: 45.0					
	<u>Group 1:</u> N: 35		Mean AUASS at baseline	Group 1: 26.3 Group 2: 24.6					
	Preop Qmax: 4.367 Gland size: 82.38 Moan and + SD: NP		Mean AUASS at 3 months	Group 1: 6.5 Group 2: 6.8					
	Group 2:		Mean AUASS at 9 months	Group 1: 8.2 Group 2: 8.0					
	N: 35 Preop Qmax: 4.194		Mean AUASS at 12 months	Group 1: 8.8 Group 2: 9.1					
	Gland size: 82.61 Mean age ± SD: NR	TUR	Group 1: 0% Group 2: 12.2%						
			Strictures	Group 1: 5 Group 2: 4					

Stud deta	-	Patients	Interventions	Outcome measures	Effect size	Comments
				Bladder neck contracture	Group 1: 1 Group 2: 0	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments		
Erturhan et al., 2007 ⁷³	Patient Group: Patients with BPH and moderate to severed LUTS	transurethral resection of the prostate (B-TURP)mGyrus PlasmaKinetic™ system with Plasma Sect electrode (200W, 160Ω, 320-450kHz, 254-350V)M27F continuous flow resectoscope with isotonicM	Mean ± SD IPSS at 1 months	Group 1: 5.0 ± 2.0 (n=120) Group 2: 5.0 ± 2.0 (n=120) P value: NS	Funding: NR		
Study design: RCT Evidence	Setting: single centre: Sahinbey Medical Center, Univerity of Gaziantep, Turkey Inclusion criteria:		system with Plasma Sect electrode (200W, 160Ω, 320-450kHz, 254-350V) 27F continuous flow resectoscope with isotonic	system with Plasma Sect electrode (200W, 160Ω, 320-450kHz, 254-350V) 27F continuous flow	Mean ± SD IPSS at 12 months	Group 1: 4.0 ± 2.0 (n=120) Group 2: 4.0 ± 2.0 (n=120) P value: NS	 Kandomisation Randomisation method and allocation
level: 1+	 IPSS ≥ 18 or PVR > 50 mL Exclusion criteria: 				27F continuous flow resectoscope with isotonic	Mean ± SD Qmax at 1 months	Group 1: 17.4 ± 2.5 (n=120) Group 2: 16.4 ± 3.5 (n=120) P value: <0.001
Duration of follow-up: 12 months.	Prostate cancer or suspectPrevious history of prostatic surgery	Group 2: Transurethral resection of the prostate		P=0.01 calculated by NCGC using t- test with unequal variances	Outcome assessment we		
12 monnis.	 Neurogenic bladder Urethral stricture Standard loop: 120W 	Mean ± SD Qmax at 12 months	Group 1: 19.5 ± 3.5 (n=120) Group 2: 18.5 ± 3.0 (n=120) P value: <0.001	not masked Additional			
	<u>All patients</u> N: 240	ropouts: NR resectoscope with glycine N roup 1	coagulation. 26F		P=0.02 calculated by NCGC using t- test with unequal variances	outcomes: Irrigation volumes	
	Dropouts: NR <u>Group 1</u> N: 120		Mean ± SD QoL at 1 months	Group 1: 2.1 ± 1.0 (n=120) Group 2: 2.1 ± 1.0 (n=120) P value: NS	Notes: None.		
	N: 120 Mean age (range): 68.5 (52-90) Mean IPSS ± SD: 25.0 ± 5.0 Mean Qmax ± SD, mL/s: 10.9 ± 1.2	All patients 22 F Foley catheter inserted and irrigation with saline. Catheter removed	Mean ± SD QoL at 12 months	Group 1: 2.1 ± 1.0 (n=120) Group 2: 2.1 ± 1.0 (n=120) P value: NS			
Mean PVR± SD, mL: 114 ± 19 Mean prostate volume ± SD, mL: 43 ± 9 IPSS QoL ± SD: 2.0 ± 1.0 Examination methods	Mean ± SD catheter duration, days	Group 1: 3.0 ± 1.1 (n=120) Group 2: 4.5 ± 1.1 (n=120) P value: <0.001					
	Group 2 Baseline IPSS Symptom score, DRE, urinalysis, PSA,	Length of Stay ± SD, days reported as time to discharge	Group 1: 3.0 ± 1.2 (n=120) Group 2: 5.0 ± 1.2 (n=120) P value: <0.001				
	N: 120 Mean age (range): 67.4 (68-74) Mean IPSS ± SD: 24.0 ± 6.0	Follow up at 1 and 12 months for IPSS QoL PVR	Complications: Transfusion	Group 1: 1/120 Group 2: 7/120 P value: <0.0001			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean Qmax ± SD, mL/s: 9.29 ± 1.7 Mean PVR± SD, mL: 135 ± 25 Mean prostate volume ± SD, mL: 42 ± 11			Group 1: 2/120 Group 2: 5/120 P value: 0.083	
	IPSS QoL \pm SD: 3.0 \pm 1.0 Operative time \pm SD, min: 57 \pm 24 Drop outs: 0			Group 1: 0/120 Group 2: 2/120 P value: 0.15	
				Group 1: 0/120 Group 2: 5/120 P value: 0.025	
			Complications: Incontinence	Group 1: 0/120 Group 2: 0/120	
			Complications: Mortality	Group 1: 0/120 Group 2: 0/120	
			Complications: urethral & meatal stricture	Group 1: 5/120 Group 2: 4/120	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments		
Ho et al., 2007 ¹⁰⁷	Patient Group : Patients awaiting TURP for failed medical therapy (alpha-blockers or 5-alpha reductase inhibitors), UTI or	Group 1: Bipolar transurethral resection of the prostate (B- TURP)	Mean ± SD IPSS at 3 months	Group 1: 9.0 ± NR (n=48) Group 2: 7.5 ± NR (n=52) P value: NS	Funding: NR		
Study design: RCT	haematuria Setting: single centre: Department of	180 \lambda (suffigure and 100 \lambda (180W cutting and 100W	180W cutting and 100W	Mean ± SD IPSS at 6 months	Group 1: 7.0 ± NR (n=48) Group 2: 7.0 ± NR (n=52) P value: NS	Limitations: Allocation concealment not
Evidence level: 1+	Urology, Singapore General Hospital, Singapore Inclusion criteria:	Group 2: TURP Standard loop: 100W cutting and 50W coagulation with	Mean ± SD IPSS at 12 months	Group 1: $6.0 \pm NR (n=48)$ Group 2: $6.0 \pm NR (n=52)$ P value: NS	 reported Outcome assessment was not masked 		
Duration of follow-up: 12 months.	 >50 years Fit for anaesthesia IPSS > 18 	glycine 5% as irrigant. All patients 26F Olympus continuous flow	Mean ± SD Qmax at 3 months	Group 1: 19.5 ± NR (n=48) Group 2: 16.5 ± NR (n=52) P value: NS	 Mean values are estimated from graph for IPSS and 		
	 Qmax < 15 mL/s Patients with acute urinary retention and failed trial of voiding without catheter also included 	resectoscope. 20F Foley 3-way	Mean ± SD Qmax at 6 months	Group 1: 17.5 ± NR (n=48) Group 2: 18.0 ± NR (n=52) P value: NS	Qmax. P values were not provided for change from baseline so SDs		
	Exclusion criteria: Previous prostatic surgery	or 2 days. All operations performed by 2 senior consultants	Mean ± SD Qmax at 12 months	Group 1: 17.0 ± NR (n=48) Group 2: 17.5 ± NR (n=52) P value: NS	could not be estimated		
	 Neurogenic bladder disorders Bladder stones Renal impairment 	Examination methods Preoperative:	Complications: Transfusion	Group 1: 1/48 Group 2: 1/52 P value: NS	Additional outcomes: Decline in post op serun Na ⁺ and Hb		
	 Hydronephrosis Prostate cancer or suspect Urethral strictures 	Baseline IPSS, QoL, Qmax and PVR, PSA, Na ⁺ , creatinine and Hb.	Complications: TUR	Group 1: 0/48 Group 2: 2/52 P value: <0.05	Notes: Computer randomisation		
	 Orethral strictures <u>All patients</u> N: 100 Dropouts: 0 Group 1 Postoperative: Na⁺, Hb repeated after 6 hours and IPSS and Qmax assessed at 1, 3, 6, 12 months follow up visits 	Na ⁺ , Hb repeated after 6 hours and IPSS and Qmax	Complications: urethral stricture	Group 1: 3/48 Group 2: 1/52 P value: NS			
			Complications: urinary retention (re- catheterisation)	Group 1: 5/48 Group 2: 4/52 P value: NS			
	N: 48 Mean ± SD Age, yrs: 66.6 ± 6.8 IPSS ± SD: 22.6 ± 5.5		Complications: UTI	Group 1: 2/48 Group 2: 2/52 P value: NS			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	PSA ± SD , ng/mL: 2.8 ± 1.0				
	Mean \pm SD Qmax, mL/s: 6.8 \pm 4.8				
	Mean prostate volume ± SD, mL: 56.5 ±				
	17.9				
	Resectate ± SD, g: 29.8 ± 11.2				
	Resection time \pm SD, min: 59 \pm 18				
	Number with AUR: 24/48				
	Number with failed medical therapy:				
	20/48				
	Number with UTI/Haematuria: 4/48				
	Dropouts: 0				
	Group 2				
	N: 52				
	Mean ± SD Age, yrs: 66.5 ± 7.2				
	IPSS \pm SD: 24.6 \pm 6.0				
	PSA \pm SD, ng/mL: 2.2 \pm 0.5				
	Mean ± SD Qmax, mL/s: 6.5 ± 3.2				
	Mean prostate volume ± SD, mL: 54.8 ±				
	19.2				
	Resectate ± SD, g: 30.6 ± 9.8				
	Resection time \pm SD, min: 58 \pm 16				
	Number with AUR: 21/52				
	Number with failed medical therapy:				
	25/52				
	Number with UTI/Haematuria: 6/52				
	Dropouts: 0				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments				
lori et al., 2008 ¹¹¹	Patient Group: Patients scheduled for surgery for obstruction	Group 1: Bipolar transurethral resection of the prostate (B-TURP)	Mean ± SD IPSS at 12 months	Group 1: 7.0 ± 1.7 (n=25) Group 2: 6.7 ± 4.0 (n=26) P value: NR	Funding: NR				
Study design: RCT Observer masked	Setting: single centre: Department of Urology, University of Rome, Italy Inclusion criteria:	system with Plasma Sect electrode (200W, 160Ω, 320-450kHz, 254-350V) 27F continuous flow	system with Plasma Sect electrode (200W, 160Ω, 320-450kHz, 254-350V) 27F continuous flow resectoscope with isotonic m	of Rome, Italy system with Plasma Sect electrode (200W, 160Ω, 320-450kHz, 254-350V) 27F continuous flow resectoscope with isotonic	system with Plasma Sect electrode (200W, 160Ω,	system with Plasma Sect electrode (200W, 160Ω,	Mean ± SD Qmax at 12 months	Group 1: 24.2 ± 5.0 (n=25) Group 2: 23.2 ± 9.0 (n=26) P value: NR	Limitations: None. Additional
Evidence level:	 Obstruction class 2-5 on Schaefer nomogram 				Mean ± SD QoL at 12 months	Group 1: 1.1 ± 1.0 (n=25) Group 2: 1.1 ± 1.0 (n=26) P value: NR	outcomes: Irrigation time, postoperative		
1+ Duration of follow-up:	Exclusion criteria:Neurogenic bladderBladder stones	Group 2: Transurethral resection of the prostate (TURP)	Mean ± SD catheter duration, days (converted from hours)	Group 1: 0.96 ± 0.2 (n=25) Group 2: 1.33 ± 0.2 (n=26) P value: <0.0001	Schaefer obstruction class Notes:				
12 months.	 Urethral stricture Renal insufficiency Current finasteride medical therapy 	Standard loop. 26F continuous flow resectoscope with mannitol	Length of Stay ± SD, days (converted from hours)	Group 1: 2.0 ± 0.04 (n=25) Group 2: 2.1 ± 0.13 (n=26) P value: 0.9	Randomisation by drawing opaque sealed envelopes				
	All patients	as irrigant	Complications: Transfusion	Group 1: 0/25 Group 2: 0/26					
	N: 51 Dropouts: 0 Group 1	inserted and irrigation with	Complications: urinary retention (re- catheterisation)	Group 1: 1/25 Group 2: 0/26					
	N: 25 Mean age (range): 65.0 ± 5.0	saline. Catheter removed when urine clear and patient had passed a	Complications: TUR Syndrome	Group 1: 0/25 Group 2: 0/26					
Mean Qm Mean PVI Mean pro	Mean IPSS ± SD: 21.0 ± 2.0 Mean Qmax ± SD, mL/s: 7.0 ± 1.0 Mean PVR± SD, mL: 99 ± 58 Mean prostate volume ± SD, mL: 49 ± 11 IPSS QoL ± SD: 3.0 ± 1.0	stool. Examination methods Preoperative: Baseline IPSS Symptom							
	Resection time \pm SD, min: 39 \pm 19 Drop outs: 0 <u>Group 2</u>	score, QoL DRE, urinalysis, PSA, Blood, TRUS, uroflowmetry.							
	N: 26 Mean age (range): 63.0 ± 5.0 Mean IPSS ± SD: 20.0 ± 4.0	Follow up at 12 months for IPSS, QoL, PVR and Qmax							

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean Qmax ± SD, mL/s: 8.7 ± 2.0 Mean PVR± SD, mL: 96 ± 97 Mean prostate volume ± SD, mL: 48 ± 91 IPSS QoL ± SD: 3.6 ± 1.0 Resection time ± SD, min: 39 ± 19 Drop outs: 0				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Michielsen et al., 2007 ¹⁷⁵	Patient Group: Men with obstruction due to BPH	Group 1: Bipolar transurethral resection of the prostate (B-TURP)	Mean ± SD catheter duration, days	Group 1: 4.0 ± 3.0 Group 2: 4.5 ± 3.5 P value: 0.2	Funding: NR
Study design: RCT	Setting: single centre: Department of Urology, Virije Universiteit, Brussels, Belgium	Olympus TURIS system with 270W cutting and 75W coagulation	Mean ± SD length of stay, days	Group 1: 4.9 ± NR Group 2: 5.1 ± NR P value: 0.6	Limitations: • Unclear whether sealed envelopes
Evidence level: 1+ Duration of follow-up: 1 month	 Inclusion criteria: IPSS ≥ 13 Qmax < 15 mL/s QoL ≥ 3 Exclusion criteria: Neurogenic bladder Carcinoma of the prostate History of prostate or urethral surgery Bladder stones Patients on anticoagulant therapy All patients N: 238 Dropouts: 0 Group 1 N: 118 Mean ± SD Age: 73.8 ± 8.1 (53-92) IPSS ± SD: NR Mean prostate size ± SD, g: NR Resectate ± SD g: 21.0 ± NR Operation duration ±SD min: 56 ± 25 Dropouts: 0 	coagulation Group 2: TURP Standard loop with 26F resectoscope: 175W cutting and 75W coagulation All patients 22 F Foley catheter inserted and irrigation with saline until bleeding ended. Examination methods Preoperative: Baseline IPSS Symptom score, DRE, urinalysis, PSA, Blood, TRUS, uroflowmetry. Postoperative: Full blood count was performed	Complications: urinary retention (re-catheterisation) Complications: TUR Syndrome Complications: Transfusion Complications: reoperation (transurethral revision)	P value: 0.6 Group 1: 3/118 Group 2: 5/120 Group 1: 0/118 Group 2: 1/120 Group 1: 4/118 Group 2: 1/120 Group 1: 0/118 Group 2: 2/120	 sealed envelopes were opaque. Primary outcome in study is not IPSS or Qmax Follow up very short to capture early complications only Additional outcomes: Haemoglobin, sodium, potassium, chloride. Differences in operative times for staff v trainee Notes: None.
	Group 2 N: 50 Mean ± SD Age: 73.1± 8.6 (52-92)				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	IPSS ± SD: NR Mean SD Qmax: NR Mean prostate size ± SD, g: NR Resectate ± SD g: 21.3 ± NR Operation duration ± SD min: 44 ± 20 Dropouts: 0				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Patient Group: Patients with LUTS Setting: single centre: Ministry of Health	Group 1: Bipolar transurethral resection of the prostate (B-TURP)	Mean ± SD IPSS at 1 months	Group 1: 4.8 ± 3.4 (n=27) Group 2: 4.7 ± 3.1 (n=30) P value: NS	Funding: NR
RCT	Ankara Training & Teaching Hospital, Turkey	system with Plasma Sect electrode (200W, 160Ω, 320-450kHz, 254-350V) Resection performed on PK3 Mec	Mean ± SD IPSS at 12 months	Group 1: 5.4 ± 3.7 (n=24) Group 2: 5.2 ± 3.2 (n=26) P value: NS	Limitations: • Randomisation method and
Evidence level: 1+	Inclusion criteria: • IPSS > 15 • Qmax < 10 mL/s		Mean ± SD Qmax at 1 months	Group 1: 17.6 ± 4.3 (n=27) Group 2: 17.7 ± 2.3 (n=30) P value: NS	 allocation concealment were not reported Outcome
Duration of follow-up: 12 months	up: Group 2: TURP	Mean ± SD Qmax at 12 months	Group 1: 17.1 ± 2.7 (n=24) Group 2: 17.9 ± 3.1 (n=26) P value: NS	assessment was not masked	
•	History of prostate or urethral surgeryBladder stonesPatients on anticoagulant therapy	y All patients All patients All patients received antibiotic prophylaxis. 22 F Foley catheters inserted and Foley catheters inserted and continuous irrigation with saline for 1 postoperative day. Catheters removed when urine clear and discharge after free micturation. Examination methods Preoperative: Baseline IPSS Symptom score, DRE, urinalysis, PSA, Blood, TRUS, uroflowmetry.	Mean ± SD catheter duration, days (converted from hours)	Group 1: 1.96 ± 0.23 (n=27) Group 2: 3.15 ± 0.52 (n=30) P value: 0.009	Additional outcomes: Sodium, Haemocrit, Haemoglobin
	<u>All patients</u>		Complications: Transfusion	Group 1: 1/27 Group 2: 2/30	Notes: None.
	N: 57 Dropouts: 7 (5 patients could not be contacted, 1 died and 1 left study)		Complications: urinary retention (re- catheterisation)	Group 1: 1/27 Group 2: 0/30	
	<u>Group 1</u> N: 27		Complications: TUR Syndrome	Group 1: 0/27 Group 2: 0/30	
	Mean ± SD Age, years: 64.6 ± 8.8 IPSS ± SD: 17.6 ± 6.1		Complications: Incontinence	Group 1: 0/27 Group 2: 0/30	
	Mean SD Qmax: 6.9 ± 2.8 Mean SD PVR, mL: 96 ± 27 Mean prostate volume ± SD, mL: 47 ±		Complications: Reoperation rate	Group 1: 0/27 Group 2: 0/30	
	7.7 Operation duration \pm SD min: 55 \pm 9.7		Complications: urethral stricture	Group 1: 1/27 Group 2: 0/30	
	Number of patients on alpha-blockers: 18/27				
	Dropouts: 3 Group 2	assessed at end of the first year.			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	N: 30 Mean ± SD Age, years: 65.2 ± 9.3 IPSS ± SD: 17.3 ± 5.8 Mean SD Qmax: 7.3 ± 2.1 Mean SD PVR, mL: 88 ± 20 Mean prostate volume ± SD, mL: 49 ± 8.1 Operation duration ± SD min: 52 ± 13.2 Number of patients on alpha-blockers: 21/30 Dropouts: 4				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments			
Patankar et al., 2006 ²⁰²	Patient group: men with LUTS associated with BPH	Group 1: Bipolar transurethral resection of the prostate (B-TURP)	Mean AUA score at 3 weeks	Group 1: 6.11 ± 1.02 Group 2: 7.7 ± 1.86 P value: NS	Funding: NR			
Study design: RCT Double blind (patients and	Setting: single-centre. Institute of urology & BJ Medical College, Pune, India Inclusion criteria:	Gyrus PK Superpulse system: Cutting 150V and 120V coagulation with soline irrigant	Mean Qmax ± SD mL/s at 3 weeks	Group 1: 19.16 ± 1.9 Group 2: 20.67 ± 1.63 P value: NS	Limitations: Short follow up interval			
observer) Evidence	 >45 years AUA score ≥ 18 Qmax < 10 mL/s 	rsGroup 2: Transurethral resection of the prostate (TURP) Standard loop through 24F resectoscope with glycine as irriganteria: cancer brostatic surgeryAll patients: Preoperative antibiotics. One consultant performed all the operations. A 20 3-way catheter was inserted and irrigation continued until returning fluid was clear for a minimum of 6 hours. Post irrigation catheter was removed if urine remained clear.4SD, mL/s: 5.9 ± 1.98 SD, mL: NR e volume \pm SD, mins: $49.99 \pm$ Examination methods Preoperative: Baseline AUA score, urinalysis, PSA, TRUS,	Group 2: Transurethral	Group 2: Transurethral (resection of the prostate	Group 2: Transurethral resection of the prostate	Catheterisation time (days) hours reported converted to days	Group 1: 0.77 ± 0.11 Group 2: 1.77 ± 0.63 P value: <0.05	Notes: Randomisation via drawing opaque
level: 1+	 Prostate volume 35-70 mL Exclusion criteria: 		Complications: transfusion	Group 1: 0/53 Group 2: 1/51 p value: 0.5	envelopes			
Duration of follow-up: 3 weeks	Prostate cancerPrevious prostatic surgery		Complications: UTI	Group 1: 6/53 Group 2: 7/51 p value: 0.74				
	<u>All patients</u> N: 104 Drop outs: 1							
	<u>Group 1:</u> N: 53 Mean age: 64							
	Mean AUA score ± SD: 23.3 ± 4.85 Mean Qmax ± SD, mL/s: 5.9 ± 1.98 Mean PVR ± SD, mL: NR		minimum of 6 hours. Post irrigation catheter was					
	Mean prostate volume± SD, mL: 51.3 ± 12.44 Operative time ± SD, mins: 49.99 ±							
	12.35 Resectate ± SD, g: NR Drop outs: 1							
	<u>Group 2:</u> N: 51 Mean age: 62	uroflowmetry. Uroflowmetry and AUA score repeated 21 days						

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean AUA score ± SD: 23.73 ± 4.6 Mean Qmax ± SD, mL/s: 6.4 ± 1.77 Mean PVR ± SD, mL: NR Mean prostate volume± SD, mL: 52.26 ± 10.71 Operative time ± SD, mins: 49.99 ± 12.35 Resectate ± SD, g: NR Drop outs: 0				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Seckiner et al., 2006 ²³¹	e e e e e e e e e e e e e e e e e e e		Mean ± SD IPSS at 3 months	Group 1: 9.3 ± 3.9 (n=24) Group 2: 10.6 ± 6.3 (n=24) P value: NS	Funding: NR
Study design: RCT Observer masked	Urology, Zonguldak Karaelmas University School of Medicine, Turkey Inclusion criteria:	ey with Plasma Sect electrode (200W, 160Ω, 320-450kHz, 254-350V) set to 160W cutting and 80W. Resection performed through 27F resectoscope with colors of performed	Mean ± SD IPSS at 6 months	Group 1: 7.4 ± 2.2 (n=24) Group 2: 6.0 ± 6.7 (n=23) P value: NS	Limitations: Allocation concealment with opaque sealed
Evidence level:	 IPSS ≥ 8 Qmax < 15 mL/s Prostate volume 30-70g on TRUS 		Mean ± SD IPSS at 12 months	Group 1: 8.7 ± 4.1 (n=23) Group 2: 8.3 ± 2.9 (n=21) P value: NS	envelopes was no used
1+ Duration of follow-up:	Exclusion criteria: Group 2: TURP Mea • < 50 years	Mean ± SD Qmax at 3 months	Group 1: 17.7 ± 9.1 (n=24) Group 2: 18.6 ± 9.1 (n=24) P value: NS	Additional outcomes Bleeding score, serum haemoglobin and sodium Notes: Randomisation using	
12 months		Mean ± SD Qmax at 6 months	Group 1: $23.4 \pm 10.6 (n=24)$ Group 2: $16.2 \pm 12.0 (n=23)$ P value: NS		
		All operations were performed	Mean ± SD Qmax at 12 months	Group 1: 18.8 ± 6.9 (n=23) Group 2: 15.7 ± 6.3 (n=21) P value: NS	random number table
IPSS ± SD: 24.1 ± 5.2 IPSS QoL ± SD: 4.4 ± Mean ± SD Qmax, m Mean PVR ± SD, mL	All patients	more than 12 hours	Mean ± SD IPSS QoL at 3 months	Group 1: 1.8 ± 1.0 (n=24) Group 2: 2.1 ± 1.2 (n=24) P value: NS	
	Dropouts: 4 Group 1	Preoperative: Baseline IPSS Symptom score, QoL, DRE, urinalysis, blood, TRUS, uroflowmetry. IPSS and Qmax were recorded at 1, 3, 6 & 12 months, PVR at 3, 6 & 12 months and TRUS at 6 months.	Mean ± SD IPSS QoL at 6 months	Group 1: 1.6 ± 0.7 (n=24) Group 2: 1.6 ± 1.3 (n=23) P value: NS	-
	Mean ± SD Age: 61.2 ± 9.3 IPSS ± SD: 24.1 ± 5.2		Mean ± SD IPSS QoL at 12 months	Group 1: 1.8 ± 0.8 (n=23) Group 2: 2.0 ± 0.8 (n=21) P value: NS	
	Mean ± SD Qmax, mL/s: 8.5 ± 2.9 Mean PVR ± SD, mL: 88 ± 74 Mean prostate size ± SD, mL: 49.4 ±		3, 6 & 12 months and TRUS at	Mean ± SD catheter duration, days	Group 1: 3.1 ± 0.6 Group 2: 3.1 ± 1.4 P value: 0.98
	18.9 Resectate ± SD, g: 36.6 ± 14.4		Complications: urethral stricture	Group 1: 2/24 Group 2: 1/24	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
details	Operation duration ± SD, min: 52.9 ± 12.8 Dropouts: 1 patient where measurements were not obtained Group 2 N: 24 Mean ± SD Age: 63.9 ± 10.9 IPSS ± SD: 23.2 ± 4.9 IPSS QoL ± SD: 4.7 ± 0.9 Mean ± SD Qmax, mL/s: 8.3 ± 3.1 Mean PVR ± SD, mL: 138 ± 115 Mean prostate size ± SD, mL: 41.4 ± 14.5 Resectate ± SD, g: 31.9 ± 13.2 Operation duration ± SD, min: 52.9 ± 16.3 Dropouts: 3 patients where measurements were not obtained				
	measurements were not obtained				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Singh et al., 2005 ²⁴¹	Patient Group: Patients with symptomatic BPH requiring surgical intervention	Group 1: Bipolar transurethral resection of the prostate (B-TURP)	Mean ± SD IPSS at 3 months	Group 1: 5.3 ± NR Group 2: 6.2 ± NR P value: NR	Funding: NR
Study design: RCT Observer masked	Setting: single centre: Department of Urology, Muljibhai Patel Urological Hospital, Gujarat, India	Tissue Percetion system	Mean ± SD Qmax at 3 months	Group 1: 19.0 ± NR Group 2: 17.8 ± NR P value: NR	Limitations: Allocation concealment with opaque envelopes
Evidence level:	vidence • >50 for cutting and 7 for coagulation with saline as irrigant. mor • Vel: • IPSS > 7 irrigant. mor • Qmax < 12 mL/s	Mean ± SD IPSS QoL at 3 months	Group 1: 1.1± NR Group 2: 1.0 ± NR P value: NR	 Unclear if all the patients completed 	
1+ Duration of follow-up:		Mean ± SD catheter duration, days	Group 1: 2.52 ± 0.5 Group 2: 3.41 ± 0.53 P value: 0.02	study • Standard deviations not	
3 months	Exclusion criteria:Neurogenic bladderRenal insufficiency	All patients All operations were performed by the same surgeon. A 20F 3-way catheter was placed and saline irrigation continued as required.	Mean ± SD length of stay, days	Group 1: 3.02 ± 0.55 Group 2: 3.88 ± 0.58 P value: 0.02	reported for IPSS, Qmax or QoL and could not be estimated because
2.0.0	Urethral stricture		Complications: TUR	Group 1: 0/30 Group 2: 0/30	there were p value for change from
	Current finasteride therapy All patients		Complications: UTI	Group 1: 3/30 Group 2: 4/30	baseline Additional outcomes:
	N: 60 Dropouts: NR		Complications: urethral stricture	Group 1: 2/30 Group 2: 1/30	Haematuria, dysuria, urgency, incontinence
	Group 1 N: 30 Mean ± SD Age: 68.9 ± 7.6 IPSS ± SD: 20.5 ± 4.8 IPSS QoL ± SD: 4.6 ± 0.9 Mean ± SD Qmax, mL/s: 5.8 ± 3.0 Mean PVR ± SD, mL: 124 ± 58 Resectate ± SD, g: 24.0 ± 18.2 Operation duration ± SD, min: 39.3 ± 17.8 Number of patients with retention:				and pain results from questionnaire. Notes: Randomised by drawin envelopes

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	10/30 Dropouts: NR <u>Group 2</u> N: 30 Mean ± SD Age: 67.9 ± 9.8 IPSS ± SD: 21.6 ± 6.3 IPSS QoL ± SD: 4.47 ± 1.0 Mean ± SD Qmax, mL/s: 5.1 ± 2.0 Mean PVR ± SD, mL: 136 ± 52 Resectate ± SD, g: 27.6 ± 13.4 Operation duration ± SD, min: 36.9 ± 14.6 Number of patients with retention: 11/30 Dropouts: NR	up to 4 weeks.			

1 Evidence Table 46 Conservative vs. surgery

2

3 Bladder training vs. TURP

Study details	Patients	Interventions	Outcome measures	Effect size	Comments		
Donovan et al., 2000 ⁶⁵ CLasP study	Patient group: men with uncomplicated LUTS symptoms Setting:	Group 1- Laser coagulation Procedure: Nd:YAG/ Non-contact VLAP, side-	IPSS, mean change from baseline (95%CI): Adjusted for centre	Group 1: -10.8 ± 8.64* (95% Cl: -12.5,- 9.0), n=96 Group 2: -12.3 ± 7.36* (95% Cl: -13.8,- 10.7), n=89	Funding: Laser machines provided by Bard Diagnostics, Redmond,		
Study design: RCT, multicentre, open label	 3 centres in UK Inclusion criteria: IPSS score of≥8, with physician and patient agreement that the symptoms require intervention 	centres in UKfiring fibre (Bard Urolase), using standard fixed spotclusion criteria:IPSS score of≥8, with physician and patient agreement that the symptoms require intervention Qmax <15ml.s when voided volume>200ml, <13ml/s when voided volume between 150- 200ml and <10ml/s when voided volume between 100 to 149ml measured on two occasions, with the higher value between these two used for analysis >300ml post void volume urine on ultrasoundFor prostate size with urethral length of >25 mm, additional set of laser was used. If median lobe was present, 60W for 30s was applied for each side of lobe.clusion criteria: Prostate cancer or previous prostatic surgery; prostate size > 120ml; Life expectancy < 6 months; Urinary retention associated with recent operation, constipation or drugs whichFor grostate size cancel antibiotic prophylaxis and anti-inflammatory suppository.	using standard fixed spot technique Power: 60W ND: YAG for 60s, depends on prostate size.	and baseline symptom score, ANCOVA	Group 3: -1.3 ± 5.29* (95% CI: -2.8,0.2), n=85 p value: Group 2 v Group 3 - NR Statistically significant for surgical procedures vs. conservative	Washington. Limitations: Open label study, with main outcomes	
Evidence level: 1+ Duration of follow-up: 7.5 months	 Qmax <15ml.s when voided volume>200ml, <13ml/s when voided volume between 150-200ml and <10ml/s when voided volume between 100 to 149ml measured on two occasions, with the higher value 		IPSS-QoL, mean (95%CI): Adjusted for centre and baseline symptom score, ANCOVA	Group 1: $-1.9 \pm 1.7^*$ (95% Cl: -2.3 , -1.6), n=93 Group 2: $-2.2 \pm 1.62^*$ (95% Cl: -2.5 , -1.8), n=85 Group 3: $-0.4 \pm 1.39^*$ (95% Cl: -0.7 , -0.1), n=85 p value: Group 2 v Group 3 - NR	 using patient reported measures The clinician following up patients was different to the surgeon although it was not stated 		
	 analysis >300ml post void volume urine on ultrasound Exclusion criteria: Prostate cancer or previous 		Catheter protocol: Suprapubic catheter, removed when clinically appropriate. Other:	urine Energy: 28684J Catheter protocol: Suprapubic catheter, removed when clinically appropriate. Other:	Qmax, mean(95%CI): Adjusted for centre and baseline symptom score, ANCOVA	Group 1: $5.8 \pm 6.87^*$ (95% CI: 4.5, 7.2), n=102 Group 2: 9.7 \pm 9.73* (95% CI: 7.7, 11.6), n=98 Group 3: 0.2 \pm 2.9* (95% CI: -0.4, 0.8), n=92 p value: Group 2 v Group 3 - NR	was not stated whether the clinician was masked to treatment allocation Additional outcomes: Composite outcomes categories, and
	 prostate size > 120ml; Life expectancy < 6 months; Urinary retention associated with recent operation, constipation or drugs which 		Post void residual volume, mean(95%CI): Adjusted for centre and baseline symptom score, ANCOVA	Group 1: -73.4(95% Cl:-91.3, -55.5), n=100 Group 2: -74.0 (95% Cl:-89.2, -58.8), n=98 Group 3: 2.19 (95% Cl:-23.1, -27.5, n=90 p value: Group 2 v Group 3 - NR	categorical outcomes for IPSS and Qmax Notes: Randomisation using computer generated numbers in blocks of 6		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments							
	 dysfunction, Neurogenic bladder dysfunction; Serum creatinine >250 μmol/L. 	Catheter protocol: Suprapubic catheter. Group 3 – Conservative	All cause mortality Not treatment related	Group 1: 5/117 Group 2: 0/117 Group 3: 1/106 p value: NS for all groups	Allocation concealed using consecutive opaque sealed envelopes.							
	<u>All patients</u> N: 340 Drop outs:	management Procedure: Men were given general advice and bladder training as deemed clinically appropriate P 8.1 6.6 : 4(2-6) ± 2.9 mean, \pm : SD: 40.7 17 (78.3) bstructed 7.9 6.7 : 4(0-6) ± 2.7 mean, \pm : SD: 38.1 17(78.4)	Post-op complications: Blood transfusion (units and criteria not stated)	Group 1: 1/117 Group 2: 1/117 p value: NS	Sample size calculation performed Please see Chacko et							
	Group 1-Laser coagulation N: 117 Dropouts:1/117		Post-op complications: Perforation	Group 1: 0/117 Group 2: 2/117 p value: NS	al., 2001 ⁴³ for the acute urinary retention population of CLASP trial and Gujral et al.,							
	Age, mean ± SD: 67.4 ± 8.1 IPSS, mean ± SD: 19.1 ± 6.6 IPSS-QoL, median(range): 4(2-6)		Post-op complications: Septicaemia	Group 1: 0/117 Group 2: 2/117 p value: NS	2000% for the chronic urinary retention population.							
	Qmax, mean, ± SD: 10.4 ± 2.9 Post void residual urine, mean, ± SD: 123.7 ± 91.8 Prostate volume, mean, ± SD: 40.7							com Urine	complications: Urinary tract infection	Urinary tract infection	Group 1: 3/117 Group 2: 2/117 p value: NS	* SD estimated using methods detailed in the Cochrane handbook for change from baseline
	± 21.4 No obstructed (%): 90/117 (78.3) No equivocal and/or unobstructed (%): 25/117 (21.7)		Time to catheter removal geometric mean, days	Group 1: 2.2 (95%Cl 1.9 to 2.4) Group 2: 3.9 (95%Cl 3.7 to 4.2) Relative risk: 1.83 95% Cl: 1.58 to 2.11 P value: <0.0001	with confidence intervals							
	<u>Group 2 - TURP</u> N: 117 Dropouts:2/117 Age, mean ± SD: 66.4 ± 7.9 IPSS, mean ± SD: 19.2 ± 6.7 IPSS-QoL, median(range): 4(0-6)		$\begin{array}{c} 2.2 \pm 6.7 \\ nge): 4(0-6) \\ 10.3 \pm 2.7 \\ \textbf{ine, mean, } \pm \\ an, \pm SD: 38.1 \\ 1/117(78.4) \end{array}$					Group 1: 11.8(95%Cl: 10.2 to 13.7) Group 2: 2.4 (95%Cl: 2.1 to 2.9) Relative risk: 4.79 95% Cl: 3.88 to 5.91 p value: <0.0001				
	Qmax, mean, ± SD: 10.3 ± 2.7 Post void residual urine, mean, ± SD: 104.2 ± 69.5 Prostate volume, mean, ± SD: 38.1 ± 19.1 No obstructed (%): 91/117(78.4) No equivocal and/or unobstructed											

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	(%): 25/117(21.6)				
	$\label{eq:Group 3-Conservative} \\ \hline management \\ N: 106 \\ \hline Dropouts: 5/106 \\ Age, mean \pm SD: 67.2 \pm 7.8 \\ IPSS, mean \pm SD: 18.8 \pm 6.5 \\ IPSS-QoL, median(range): 4(1-6) \\ Qmax, mean, \pm SD: 9.9 \pm 2.7 \\ \hline Post void residual urine, mean, \pm \\ SD: 119.1 \pm 90.4 \\ \hline Prostate volume, mean, \pm SD: 36.8 \pm 17.2 \\ \hline No obstructed (\%): 82/106(77.4) \\ \hline No equivocal and/or unobstructed \\ (\%): 24/106(22.6) \\ \hline \end{array}$				

Catheters vs. TURP

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Ghalayini et al., 2005 ⁸⁹	Patient group: men with chronic urinary retention (CUR)	Group 2 – Clean intermittent self catheterisation (CISC)	IPSS, mean change from baseline at 6 months (95%Cl):	Group 1: -12.25 ± 7.77* (95% Cl: - 15.53,-8.97), n=24 Group 2: -20.29 ± 8.86* (95% Cl: -	Funding: NR
Study design: RCT	Setting: 2 centres in Jordan and UK	Patients were taught how to use a 12 or 14 F		24.85,-15.74), n=17 p value: NR	Limitations: Randomisation
Evidence level: 1+ Duration of follow-up: 6 months	 Inclusion criteria: IPSS >7 CUR defined by PVR > 300mL measured by ultrasonography on 2 occasions Exclusion criteria: Prostate cancer Previous prostatic surgery Uncontrolled renal impairment Life expectancy <6 months Neurogenic bladder dysfunction 	catheter every 6 hours. Group 1 – TURP Procedure: Standard electroresection Examination methods: Prior to start men had cystometry and PFS. Men were reviewed at 3 and 6 months after TURP or start of CISC for IPSS, serum creatinine, urine culture	IPSS QoL, mean change from baseline at 6 months (95%CI):	Group 1: -2.54 ± 1.35* (95% Cl: - 3.11,-1.97), n=24 Group 2: -3.00 ± 1.46* (95% Cl: - 3.75,-2.25), n=17 p value: NR	 method, allocation concealment and masking of outcome assessment were not reported. Complications were listed but not by group Additional outcomes: At 6 months, PVR, voiding, end-filling and end-void pressures
	 Inability to perform clean intermittent self catheterisation. <u>All patients</u> N: 51 Drop outs: 10 	and PFS at 6 months. Men			Notes: * SD estimated using methods detailed in the Cochrane handbook for change from baseline with confidence intervals
	Group 1 – CISC N: 29 (baseline variables for only 24 patients who completed the study) Age, mean (± SD): 69 ± 7.3 IPSS, mean (± SD): 23.2 ± 6.1 IPSS-QoL, mean (± SD): 4.2 ± 1.1 Qmax, mean (± SD), mL/s: 5.5 ± 4.2 PVR, mean (± SD), mL: 963 ± 503				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Dropouts: 5 (3 withdrawn and 2 lost to follow up)				
	Group 2 - TURP N: 22 (baseline variables for only 17 patients who completed the study) Age, mean (± SD): 67 ± 8 IPSS, mean (± SD): 25.8 ± 4.2 IPSS-QoL, mean (± SD): 4.4 ± 0.9 Qmax, mean (± SD), mL/s: 5.2 ± 3.4 PVR, mean (± SD), mL: 954 ± 531 Dropouts: 5 lost to follow up				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Kadow et al., 1988 ¹¹⁶	Patient group: men with prostatism and proven BOO Setting:	Group 2 – Conservative treatment Instruction on bladder training	Q max ± SD at 6 months	Group 1: 11.2 ± 3.42, n=17 Group 2: 19.0 ± 4.08, n=21 p value: NR	Funding: NR
Study design: RCT	single-centre, UK Inclusion criteria:	for 1 month consisting of weekly visits of encouragement to increase			Limitations:
Evidence level:	 Men with prostatism Exclusion criteria: 	interval between day-time voids and reduce fluid intake			Additional outcomes: Voiding patterns, day
1+	 Haematuria 	< 1 litre/day. Advice on timing was given to those with			time frequency, nocturia, Max voided
Duration of follow-up: 6 months	 Prostate cancer Normal peak flow rate and pattern after urodynamics 	nocturia. Frequency/volume charts were analysed at each visit. Those with bladder			volume, average voided volume, maximum intervals
	<u>All patients</u> N: 38 Drop outs: 0	instability after a cystometrogram at the end of training were given Pro- Banthine for urgency			between voids, P det max, PVR after treatment.
	<u>Group 1 – Conservative</u> N: 17 Age, mean (± SD): 64.5 ± NR Qmax, mean (± SD), mL/s: 9.8 ± 2.1	symptoms (10 patients). All patients were encouraged to continue bladder training throughout 6 month period			Notes: Marked cards in identical envelopes were used for
	PVR, mean (± SD), mL/s: 9.8 ± 2.1 PVR, mean (± SD), mL: 115 ± 305 Day-time frequency, mean ± SD: 8.25 ±	Group 1 – TURP Procedure: Standard			randomisation
	11.34 Nocturia, voids ± SD: 1.7 ± 4.6 Dropouts: 0	electroresection with histological conformation of BPH			
	Group 2 - TURP N: 21	Examination methods:			
	Age, mean (± SD): 66.5 ± NR Qmax, mean (± SD), mL/s: 8.5 ± 9.53 PVR, mean (± SD), mL: 86.2 ± 369 Day-time frequency, mean ± SD: 7.76 ±	Prior to start men completed a frequency/volume chart for 7 days then voiding water cystometry.			
	16.59 Nocturia, voids \pm SD: 2.6 \pm 5.6 Dropouts: 0	Reassessment after 6 months			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments					
Lucas et al., 2005 ¹⁵³ Study design:	Patient group: Men with acute urinary retention (AUR) secondary to benign prostatic hyperplasia recruited from March 1997 to December 2000 from	Group 1: Alpha- blocker Tamsulosin hydrochloride 0.4mg	Successful trial without catheter (defined as a flow rate of >5mL/s, >100mL voided volume, and a residual volume of≤200mL)	Group1: 24/71 (34%) Group 2: 17/70 (24%) p value: 0.193	Funding: Sponsored by a grant from Yamanouchi Pharma Ltd.					
Randomised controlled study	an Accident and Emergency department Inclusion criteria : Men with acute urinary retention, who had been	in a modified- release capsule once daily. Medication given after	Secondary analysis: (success defined as any of two free-flow criteria described above)	Group1: 41/71 (58%) Group 2: 28/70 (40%) p value: 0.02	Limitations: None					
Setting: 8 hospitals and one in Ireland.	catheterised in the previous 72 hours. Exclusion criteria : Men with initial catheterisation volumes of >1500mL or <500mL ; evidence of renal or	breakfast or lunch on the first dose, then after each day's breakfast. Duration	Secondary analysis: Success defined as flow rate >5mL/s, voided volume>100mL	Group1: 37/71 (52%) Group 2: 24/70 (34%) p value: 0.019	Notes: Definition of success in treatment of AUR has yet to be universally					
Evidence level: 1+	hepatic dysfunction; previous surgery on the urinary tract; other diseases of the bladder; any malignancy; retention-enhancing medications;	of treatment was decided by each site to be either three or 8 doses, according	Secondary analysis: (defined as a flow rate of $>5mL/s$, $>100mL$ voided volume, and a residual volume of $\le 250mL$)	Group1: 43/71 (61%) Group 2: 29/70 (41%) p value: 0.013	agreed. The initial definition was not significant but the authors conducted					
Duration of follow-up: 3-8 days depending on	allergies; and sever cardiac disease. <u>All patients</u> N: 149	to their normal practice. Group 2: placebo	practice.	practice. Group 2: placebo	practice. Group 2: placebo	practice. Group 2: placebo	practice.	Patients not re-catheterised	Group1: 34/71 (48%) Group 2: 18/70 (26%) p value: 0.011 OR: 2.47, 95% Cl: 1.23-4.97	secondary analysis using revised criteria of success. This was completed before
normal practice of hospital.	Mean age: 69.4 (range: 51-91) years Drop outs: 8 not evaluable and not included in III anglysis		Patients re-catheterised	Group1: 37/71 (52%) Group 2: 52/70 (74%)	breaking randomisatior code.					
iospitai.	bital. included in ITT analysis. Group 1 N: 71 Mean (±SD) Age: NR Dropouts: NR Group 2 N: 70 Mean (±SD) Age: NR Dropouts: NR		Adverse events	Dizziness Group 1: 7/71 (10%) Group 2: 2/70 (3%) Somnolence Group 1: 4/71 (6%) Group 2: 2/70 (3%) Mortality (carcinomatosis; not due to intervention) Group 1: 1/71 (1%) Group 2: 0/70 (0%)	Some patients were catheterised for 3 day and others for 8; to allow for variations in practice across the sites Differences in outcome between the two were not statistically significant.					
			Patients withdrew due to adverse events	Group 1: 7 (9%) Group 2: 1 (1%)						

Evidence Table 47: What is the effectiveness of alpha-blockers in treating men after acute urinary retention?

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
McNeill et al., 1999 ¹⁶⁸	Patient group: patients with a first episode of acute urinary retention related to benign prostatic	Group 1: alpha-blocker Sustained-release alfuzosin, an alpha1-	Number (%) of patients successful: (defined as able to void	Group1: 22/40 (55%) Group 2: 12/41 (29%), P=0.034 Odds Ratio (OR): 2.95 (95% Cl 1.08-	Funding: Financial support for the study was received from
Study design: Randomised controlled trial	obstruction were recruited between September 1996 and March 1998 from 4 centres in Scotland.	twice daily, with no dose titration) for 48 hours. Catheter removed after 24 hour of treatment and final dose was given on the afternoon after	successfully after removal of catheter and not re-catheterised within 24h)	8.21)	Lorex Synthelabo UK & Ireland; authors received financial support from Lorex
Setting: Scotland (4 centres)	Inclusion criteria: 55 years or over; residual volume of 0.5-1.5L on catheterisation.		final dose was given on	Number (%) of patient successful using per- protocol analysis (excluding patient that	Group1: 22/39 (56%) Group 2: 12/41 (29%), P=0.026 Odds Ratio (OR): 3.13 (95% Cl 1.13- 8.76)
Evidence level:	Exclusion criteria: patients unwilling or unable to give informed consent;	Group 2: placebo	withdrew and ailed to complete medication)		Limitations: The mean age was 5
1+ Duration of follow-up:	 disorders; neurological disease; for confirmed or suspected urethral stricture; dipstick detected UTI, acute of or chronic prostatitis. History of unstable angina pectoris, or myocardial infarction, transient 	intervention but with placebo (twice daily for	Mean (SD) age for all patients:	Successful: 68.4 (7.8) Unsuccessful: 72.9 (8.1) P=0.02	years lower in the intervention group (significant difference).
Treatment for 48 hours. Follow-up of successful patients for mean 7.2		Mean (SD) age by success in each group:	Group 1: Successful: 69.1 (8.7) Unsuccessful: 69.6 (7.3), p=0.81 Group 2: Successful: 67.2 (6.1) Unsuccessful: 75.0 (8.1), p=0.005	Following power calculation the authors planned to recruit 100 per arm to detect a 20% difference in outcome with 95%	
months	accident of congestive cardiac failure during the previous 6 months, current or previous orthostatic hypotension. Patient taking	ÿ	Logistic regression analysis of treatment versus outcome adjusted for age	P=0.052 OR: 2.55, 95% CI 0.99-6.58	power. Unable to reach this number before the trial medication expired. The difference
	monoamine oxidase inhibitors, cholinergic or anticholinergic drugs, calcium-channel blockers, or alpha blocking drugs. Other		Logistic regression using per-protocol analysis:	P=0.039 OR: 2.72, 95% CI 1.05-7.08	in outcome between the groups was >20% and power of the study is reflected in statistical
	antihypertensive drugs were not altered whilst the patient was receiving the trail medication.		All reported adverse events	Faint: Group 1: 1/40 Group 2: 0/41	significance of the results.
	Phytotherapy or finasteride use did not exclude patients from study but			Dizziness: Group 1: 1/40 Group 2: 0/41	Additional outcomes: Comparison of variables

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	their use was recorded. Known hypersensitivity to afluzosin or alpha blockers. Patients requiring suprapubic catheterisation where urethral catheterisation was unsuccessful; patients who had a suprapubic catheter as a primary procedure were not excluded. Postoperative retention after major abdominal/pelvic surgery. Large residual volume, clot retention secondary to haematuria of any cause. <u>All patients</u> N: 81 <u>Group 1</u> N: 40 Mean (±SD) Age: 67.7 (13.6) Dropouts: 1 (withdrew following a faint after the first dose of the trial medication) <u>Group 2</u> N: 41 Mean (±SD) Age: 72.7 (8.33) Dropouts: 0			Headache: Group 2: 1/40 Group 2: 0/41 Atrial fibrillation* Group 1: 1/40 Group 2: 0/41	between successful and unsuccessful patients. Non significant results for mean residual volume on catheterisation, mean duration of catheterisation and prostate size. Additional follow-up of 11/34 (32%) successful patients experiencing a further episode of AUR and/or requiring a prostatectomy (mean follow-up of 7.2 months). Notes: Atrial fibrillation 8 hours after last dose, which was later resolved. A subsequent 24-h ECG revealed previously undiagnosed asymptomatic paroxysmal atrial trachycardia, which was treated with sotalol.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
McNeill et al., 2004 ¹⁶⁹	Patient group: patients presenting with a first episode of spontaneous AUR related to BPH between January 2000 and March	All patients: urethral bladder catheterisation was performed. Catheter	Success (defined as patient returned to satisfactory voiding within	Group1: 146/236 (61.9%) Group 2: 58/121 (47.9%) p value: 0.012	Funding: NR.
Study design: Randomised controlled trial.	2002. Inclusion criteria: Minimum age of 51 yrs; urine retention volume 500-1500ml at catheterisation	removed after minimum of two doses of study drug and each patient received one additional tablet the	the first 24 hours following removal of the urethral		Limitations: Breakdown of adverse events not listed.
Setting: 71 centres across Europe and South Africa.	Exclusion criteria: Patients with mental disorders, in a trial within last 3 months, patients with neurogenic bladder dysfunction, isolated bladder neck disease, prostatitis, carcinoma of prostate, history of	day after catheter removal. Group 1: Alpha-blocker 10mg alfuzosin once daily	Number of patients experiencing at least one adverse event	Group1: 20/238 (8.4%) Group 2: 16/122 (13.1%)	Additional outcomes: Logistic regression analysis of successful trial without catheter. Age 65 years plus and
Evidence level: 1+	prostatic and urethral surgery, urethral stricture, bladder stones, clot retention secondary to hematuria; residual volume <500ml or >1500ml, AUR not related to	for three days Group 2: Placebo Once daily for three days.			drained volume 1000ml or greater adversely influenced the successful voiding rate.
Duration of follow-up:	BPH; Parkinson's disease, insulin dependent diabetes, multiple sclerosis, stroke or myocardial infarction within last 6 months,				Backward multiple logistic regression.
Treatment for 3 days.	hepatic abnormalities, unstable or severe heart failure, history of postural hypotension or syncope, hypersensitivity to a-blockers, evolutive neoplastic disease; patients who received sympathomimetics within the previous week, received 5a-reductase				Notes: Randomisation in a 2:1 ratio for intervention: placebo.
	inhibitors within previous 3 months or a- blocker in previous month, received tricyclic antidepressants, anticholinergics, sympathomimetics or first generation antihistamines within previous months, patients receiving disopyramide.				Extension study carried out following patients that had a successful trial without catheter.
	All patients: receiving disopyramide. All patients: N: 363 Drop outs: 3 (results missing) Group 1: N: 238				
	Mean (±SD) Age: 69.3 (8.5) Dropouts: 4 (postural hypotension=2,				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	catheter related infection=1 and treatment unrelated haemorrhoids=1) <u>Group 2: N</u> : 122 Mean (±SD) Age: 69.4 (8.0) Dropouts: 1 (catheter related infection)				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Shah et al., 2002 ²³³ Study design:	Patient group: patients presenting with acute urinary retention at the hospital between March 1998 and December 1999.	Group 1: Alpha-Blocker Alfuzosin SR 5mg twice a day. Catheter removed after a minimum of three	Successful voiding (defined as being able to void with a residual volume of < 200ml)	Group1: 17/34 (50%) Group 2: 16/28 (57%) OR: 0.86 (95% Cl: 0.38, 1.98; p=0.72)	Funding: Lorex Synthelabo Pharma Limitations:
Randomised controlled trial	Exclusion criteria: patients with	doses or 36 hours of admission.	Unsuccessful voiding and re-catheterised	Group 1: 17/34 (50%) Group 2: 12/28 (43%)	Method of randomisation and
Setting: St Lukes Hospital and Bradford Royal infirmary, UK	cardiac disease contra-indicating the use of alpha blockers, receiving medical therapy for bladder outflow obstruction, patients with bladder calculi, prostate cancer, renal impairment, urethral stricture,	Group 2: Placebo Catheter removed after a minimum of three doses or 36 hours of admission.	TURP following successful trial without catheter (open labelled study where all patients on alfuzosin)	Year 1: 13/30 (43%) Year 2: 6/15 (40%)	allocation concealment not reported. Baseline characteristics not addressed except for age.
Evidence level: 1+	urinary infection, neurogenic bladder dysfunction, bladder tumour and clot retention.	All patients: if trial without catheter was unsuccessful a second trial was given 2 weeks later.			Additional outcomes: Additional outcomes for patients that had an unsuccessful trial without catheter and were giver
Duration of follow-up: 2 weeks for	N: 81 Mean age: 68.6 (46-88) years Drop outs: 19 (urethral stricture=1,	During this period patients continued their trial medication. If unsuccessful			alfuzosin. Notes:
primary study and follow up of successful patients at 2	patient request for removal=9, adverse events=1, other reasons including suprapubic catheter, aortic aneurysm and other severe co-	again patients were offered alternative treatment options.			The mean age and range at baseline was lower in the placebo group.
years.	morbidity=8) <u>Group 1</u> N: 34 Mean (±SD) Age: 69.5 (56-88) Dropouts: 0				
<u>Group 2</u> N: 28 Mean (±SD) A Dropouts: 0	N: 28 Mean (±SD) Age: 67.7 (46-84)				

Evidence Table 48 Phytotherapy vs. placebo

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Bent et al., 2006 ²⁶ Study design: Randomised	Patient group: Men who had moderate to severe symptoms of benign prostatic hyperplasia. Recruited from San Francisco Veterans Affairs Medical Center	One month placebo run in period – excluded if rate of adherence was <75%. Group 1: Saw palmetto	Mean (SE) change in AUA symptom index score	Group1 (n=112): -0.68 (0.35) [95% Cl: -0.37 to 0.01] Group 2 (n=113): -0.72 (0.35) [95% Cl: -1.40 to -0.04] Difference=0.04 [-0.93 to1.01]	Funding: Grant from the national institute of diabetes and digestive and kidney diseases and by a grant from the
controlled trial Setting:	and the surrounding area by direct mailings, letters to primary care providers, posters and newspapers		Mean (SE) difference maximum urinary flow rate, ml/min	Group 1: 0.42 (0.34) Group 2: -0.01 (0.34) Difference=-1.22 [-3.90 to 1.47]	National Centre for Complementary and Alternative medicine.
Northern California, US Evidence	and local radio adverts between July 2001 and May 2004. Inclusion criteria: Over 49 years, AUA of 8 or more, peak urinary	day with meals) Carbon dioxide extract in a soft gelatine capsule – manufactured in one batch	Mean (SE) Prostate volume (ml)	Group1: 3.76 (0.98) Group 2: 4.98 (0.96) Difference=0.43 [-0.52 to 1.38]	Limitations: BPH impact score significantly different at
level: 1+	flow rate <15ml/s. Eligible if had stopped taking alpha-blocker at least one month before	manufactured in one batch for product consistency. Group 2: Placebo	Mean (SE) residual volume, ml	Group1: 14.10 (7.24) Group 2: 18.62 (7.14) Difference=-4.51 [-24.44 to 15.42]	baseline.
Duration of follow-up: 1 year	of randomisation or discontinued taking saw palmetto or a 5 alpha- reductase inhibitor 6 months before	Similar appearing placebo in soft brown gelatine capsules. Twice a day with meals.	SF-36 score (scores range from 0-100; higher scores indicate better quality of life)	Mental subscale: Group 1: -0.72 (0.72) Group 2: 0.47 (0.71) Difference=-1.18 [-3.16 to 0.79] Physical subscale: Group 1: 0.10 (0.67) Group 2: -0.51 (0.66) Difference=0.61 [-1.24 to 2.45]	Additional outcomes: Prostate transitional zone volume, BPH impact index score reported. Subgroup analyses of AUASI outcome when stratified by varying baseline levels.
decilitre; PSA >4ng; using medications known to affect urination; severe concomitant disease. <u>All patients</u> N: 225		Sexual function (O'Leary scale) range from 0-4; with higher scores indicating better function	Group1: -0.06 (0.10) Group 2: 0.07 (0.10) Difference=-0.13 [-0.40 to 0.14]	Notes: Most commonly reported nonserious adverse events also	
	N: 223 Group 1 N: 112 Mean (±SD) Age: 62.9 (8.0) Dropouts: 5 Discontinued medication: 5 (outcomes assessments completed)		Serious adverse events	cardiovascular Group1: 2 Group 2: 7 Elective orthopaedic surgery Group1: 3 Group 2: 3	reported – no significance difference between the groups.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Group 2			Gastrointestinal bleeding	
	N: 113			Group1: 2	
	Mean (±SD) Age: 63.0 (7.4)			Group 2: 1	
	Dropouts: 4			Bladder cancer	
	Discontinued medication: 5			Group1:0	
	(outcomes assessment completed)			Group 2: 1	
				Colon cancer:	
				Group1:0	
				Group 2: 1	
				Elective hernia repair	
				Group1:0	
				Group 2: 1	
				Hematoma	
				Group1:0	
				Group 2: 1	
				Melanoma	
				Group1:1	
				Group 2: 0	
				Prostate cancer	
				Group 1: 0	
				Group 2: 1	
				Shortness of breath	
				Group 1: 0	
				Group 2: 1	
				Rhabdomyolysis	
				Group1:0	
				Group 2: 1	
				Total	
				Group 1: 8/112 (n=6)	
				Group 2: 18/113 (n=11)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Setting: Iran Evidence level: 1+ Duration of	 Patient group: men with LUTS due to BPH, 1-3 years in duration presenting to the outpatient urology clinic. Inclusion criteria: no cancer laboratory findings were normal; and patient had no lower urinary tract problem other than BPH. Exclusion criteria: loss to follow-up, surgical intervention for BPH, discontinuation of study medication; alpha blocker, 5-alpha reductase inhibitor or other drug therapy during trial and follow-up, any combination of Urtica dioica with other phototherapeutic agent and 	dioica 120mg three times daily Herbal blend contained a standard preparation of to follow-up, surgical discontinuation of study cker, 5-alpha reductase therapy during trial mbination of Urtica dioica 120mg three times daily Herbal blend contained a standard preparation of 100mg of urtica dioica root extract in 1ml. Ingested three times daily therapy during trial	Mean (SD) IPSS Mean (SD) Qmax (mL/s) Mean (SD) PVR, mL	Baseline Group 1: 19.8 (4.9) Group 2: 19.2 (4.6) 6 months Group 1: 11.8 (4) Group 2: 17.7 (3.1) Baseline Group 1: 10.7 (2.4) Group 2: 10.8 (2.8) 6 months Group 1: 18.9 (4.7) Group 2: 14.2 (3.7) Baseline Group 1: 73 (32.6)	Funding: NR Limitations: Number completed trial was used for analysis. Reasons for drop-outs gives different total number of dropouts but this may have included the extension study. Additional outcomes: Serum PSA and serum
follow-up: 6 months	ufficient follow-up. Group 2: placebo I patients: N: 620 three times daily oup 1 205	Mean (SD) Prostate	Group 2: 74 (29.6) 6 months Group 1: 36 (25.5) Group 2: 71 (24.4) Baseline	testosterone also reported. Notes: After the 6 month randomised trial	
	N: 305 Completed by: 287 Mean (range) Age: 64 (57-71) Dropouts: 36; follow-up=25, surgical intervention =5, medication discontinued=2, other pharmacological treatment=4		volume, cc	Group 1: 40.1 (6.8) Group 2: 40.8 (6.2) 6 months Group 1: 36.3 (4.2) Group 2: 40.6 (5.1)	placebo patients were switched to the active treatment until 18 months.
	Group 2 N: 315 Completed by: 271 Mean (range) Age: 62 (53-73) Dropouts: follow-up=36, surgical intervention =14, medication discontinued=10, other pharmacological treatment=9	n	Patients reporting improved LUTS	Group 1: 232/287 (86%) Group 2: 43/271 (16%) P<0.001	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Shi et al., 2008 ²³⁵ Study design: Randomised	Patient group: men between 49-75 years old with newly diagnosed LTS associated with BPH based on urological symptoms, including nocturia, incomplete emptying, urinary frequency, intermittence,	sed LTS 2 Prostataplex soft gels on daily g g, Group 2: 2 placebo soft gels daily and tal tral trae less A than no and	Mean (SD) IPSS	Baseline Group 1: 16.85 (6.48) Group 2: 14.46 (4.32) 12 weeks: Group 1: 14.83 (6.42) Group 2: 14.13 (4.25)	Funding: NR. Limitations: Significant baseline difference in IPSS scores
Setting: China Evidence	weak urine stream, straining and urgency. Inclusion criteria: digital rectal examination showing an enlarged		Number of patients with an IPSS improvement (defined as decrease of 3 points or greater)	Group 1: 18/46 (39.1%) Group 2: 1/46 (2.2%) P<0.001	(lower in placebo group) Baseline IPSS for control was reported differently in the text as
level: 1+ Duration of follow-up: 12 weeks	evel:prostate but no signs of prostateI +cancer, serum creatinine>160umol/I, bacterial count lessburation ofthan 1000,000/ml, serum PSAfollow-up:4ng/ml or less, IPSS greater than		Mean (SD) Qmax, ml/s	Baseline Group1: 12.40; 95%Cl:11.90-12.89 Group 2: 12.89; 95% Cl: 2.22-13.56 12 weeks: Group1: 14.07 (2.56) Group 2: 11.74 (1.23) P<0.001	 14.46 and 14.27. Additional outcomes: Compliance rates reported as > 95% for both groups at each time point.
			Mean (SD) Relative urinary resistance	Baseline Group 1: 2.97; 95% Cl: 2.60-3.35 Group 2: 2.88; 95%Cl: 2.57-3.19 12 weeks: Group 1: 2.35 (0.83) Group 2: 3.02 (1.18) P=0.002	Notes: Prostataplex, contains mainly saw palmetto.
Exclusion criteria: history of prostate cancer and the use of any drugs, herbs or other non-		Mean (95%CI) Blood urea nitrogen at 12 weeks mg/dl	Group 1: 3.872 (3.426-4.318) Group 2: 3.809 (3.414-4.203) P=0.832		
	prescription preparations for LUTS associated with BPH within 4 weeks of screening, including finasteride,		Mean (95% CI) Prostate size, cm3	Group 1: 45.62 (43.85-47.39) Group 2: 45.90 (44.04-47.76) P=0.826	
anticholinergic drugs. Abnorn	alpha or beta blockers, aluretics, calcium channel blockers and anticholinergic drugs. Abnormal lab parameters, including PSA>4, serum		Mean (95% CI) PSA, ng/ml	Group 1: 1.845 (1.617-2.073) Group 2: 1.694 (1.505-1.882)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	creatinine >160umol/l, urine bacterial count>100,000/ml, BUN more than 8mg/dl, MFR >15ml/s		Mean (95% CI) Creatinine, mg/dl	Group 1: 1.107.80 (100.24-115.36) Group 2: 115.43 (109.13-121.73)	
	and voiding volume <150ml, previous bladder or prostate surgery, micturition problems associated with identified bladder pathology, urethral stricture, recurrent urinary tract infections, known renal or hepatic or cardiac insufficiency, diabetes mellitus, recent myocardial infarction, known alcohol abuse, known sensitivity to the ingredients in the product, significant depression or other psychiatric disease, any other cancer in the last 5 years except skin cancer and being on				
	anticoagulation therapy. <u>All patients</u> N: 94 Mean age: 49-75 Drop outs: 2 <u>Group 1</u> N: 46 Dropouts: 0 <u>Group 2</u> N: 48 Dropouts: 2 lost to follow-up				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Willetts et al., 2003 ²⁷⁴ Study design:	Patient group: men with symptoms of benign prostatic hyperplasia screened between January 1999 and March 2000.	Group 1: Serenoa repens 320mg (2X160mg of CO2 extract)	Mean IPSS	Group1: 12 Group 2: 13 1.74 (-0.54 to 4.03; p=0.131	Funding: Blackmores Ltd.
Randomised	Inclusion criteria: Men with at least three symptoms of prostatism, (increased frequency of urination,	Group 2: Placebo Paraffin oil (2 capsules a day)	Mean (95% CI) [SD] Quality of life score (IPSS question)	Baseline: Group 1: 3.66 (3.35-3.97) Group 2: 4.0 (3.58-4.42)	Limitations: At baseline the men in the placebo arm had significantly higher IPSS
Australia Evidence	nocturia, hesitancy, dribbling and poor stream); Under 80 years, with a maximum urinary flow rate of 5-	a aay		12 weeks: Group 1: 3.17 (2.76-3.58) [1.38] Group 2: 3.31 (2.85-3.77) [1.57] Treatment effect: 0.18 (-0.16 to 0.53);	scores and more had symptoms of incontinence than in the
level: 1+	15mL/s for a voiding volume of 150mL and a normal PSA level (<4ng/mL) within previous 3 months.			p=0.292	intervention arm. Qmax reported for 62
Duration of follow-up: 12 weeks	Exclusion criteria: insulin-dependent diabetes, severe cardiopulmonary		Mean Qmax, mL/s	Baseline (n=62): Group 1: 11.1 (10.3-11.8) Group 2: 11.2 (10.5-11.9)	men who attended initia and final visits and who voided >150mL but
12 weeks	disease or significant CNS disease. Men who had used androgens, 5alpha reductase inhibitors, alpha blocker or herbal preparations in the last 4			12 Weeks (n=62): Group1: 12.6 (11.0-14.2) Group 2: 15.6 (13.2-18.1)	number in each group not provided. Therefore, further analysis can not be conducted.
	weeks. Men with a history of prostate cancer, adenomas, urethral bladder, uretric or renal abnormalities, urogenital surgery ,renal stones,		IIEF scores (reported for 74 sexually active men)	Baseline Group 1: 51.5 (43.9-59.1) Group 2: 49.4 (43.3-55.4) 12 weeks:	Additional outcomes: Multivariate regression analysis.
	strictures or scarring , acute urinary			Group 1:55.11 (48.4-61.8) Group 2: 48.7 (41.9-55.4)	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	retention or allergy to study treatment. <u>All patients</u> N: 100 <u>Group 1</u> N: 50 Mean (SEM) Age: 62.1 (1.2) Dropouts: 4 (discontinued due to acute bladder retention, abdominal pain, high PSA, arthralgia) <u>Group 2</u> N: 50 Mean (SEM) Age: 63.9 (1.3) Dropouts: 3 (atrial fibrillation, dysuria, urinary incontinence)		Serious adverse events leading to withdrawal	Acute urinary retention Group 1: 1 Group 2: 0 Atrial fibrillation Group 1: 0 Group 2: 1 Abdominal pain Group 1: 1 Group 2: 0	Notes: Mean IPSS scores estimated from a graph as exact figures not given.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Wilt et al., 1999 ²⁷⁹	Patient group: Men with mild to moderate symptomatic benign prostatic hyperplasia.	Group 1: Phytotherapy Beta-sitosterols derived from South African star	Mean difference Symptom score (IPSS)	-4.91 (95% Cl: -6.29 to -3.53); 2 studies (n=342)	Funding: Internal support from: Department of Veterans Affairs Health
Reports on four studies.	Inclusion criteria : Treatment duration of at least 30 days.	grass, Hypoxis rooperi or from species of Pinus and Picea.	Mean difference Nocturia; times per evening	-1.00 (95% Cl: -1.75 to -0.25); one study (n=80)	Services Research and Development Program, USA and Minneapolis/VISN-13
Study design: Systematic review –	Exclusion criteria: None reported	Three studies contained non-glucosidic B-sitosterol,	Mean difference Peak urine flow, mL/s	3.91 (95% Cl: 0.91 to 6.90); 4 studies (n=474)	Center for chronic Diseases Outcomes Research, USA.
Cochrane review	All patients N: 519	but dosages ranged form 60mg/day to	Mean difference urine flow	2.60 (95% Cl: 1.30 to 3.90)	Limitations: Allocation concealment and method of randomisation
Setting: Germany (3 studies) and	Mean age: 65.4 (34-85) yrs Mean IPSS score=15.2 points (n=377)	195mg/day. Two studies utilised a preparation that contains at least 70% non- glucosidic B-sitosterol and		-28.62 (95% Cl: -41.42 to -15.83); 4 studies (n=475)	was unclear in 2 of the 4 studies. Different studies used
Evidence level:	Mean peak urine flow=10.2mL/s (n=519) Mean prostate size=49.1 cc (n=262)	one utilised a preparation with a non-glucosidic B- sitosterol concerntartion of 50%. One study utilised a	Mean difference in reduction in prostate size	-6.19 (95% Cl: -15.29 to 2.91); 2studies (n=216)	varying doses and preparations of B- sitosterols.
1++	Drop outs: 41 (7.9%)	preparation that contained 100% B- sitosteryl-B-D-glucoside. The other 3 trials had a quantitiy of the b- sitosterol derivative, B-	% of patients with adverse events	Gastrointestinal: Group 1: 1.6	Additional outcomes: - Boyarsky quality of life
Duration of follow-up: 4-26 weeks	Group 1 Dropouts: 7.8% Group 2			Group 2: 0 Impotence: Group 1: 0.5 Group 2: 0	score in one study. - Physician overall evaluation of efficacy. - Sensitivity analysis of
	was leess than 5% of the daily B-sitosterol. Group 2: placebo	was leess than 5% of the	Mean difference of Boyarsky quality of life scale	-4.50 [-6.05, -2.95]; one study (n=200)	peak and residual volume without study Kadow 1986. Increases significance for intervention.
		Patient overall evaluation of efficacy (rated very good or good)	8.25 [3.22, 21.13]; one study (n=80)	Notes: IPSS symptom scores from C to 35.	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments					
Wilt et al., 2002a ²⁷⁸	Patient group: Men with lower urinary tract	Group 1: Serenoa repens (SR) - alone	Mean difference symptom score (0-19)	-1.41 [-2.52, -0.30]; one study (n=205) P=0.013	Funding: Internal sources of support:					
Study design:	symptoms consistent with benign prostatic	or in combination)	Mean change in IPSS score (score from 0-35)	-2.20 [-4.70, 0.30]; one study (n=79) P=0.084	Management decision and research center- department					
Cochrane systematic review 21 RCTS included but	hyperplasia. Inclusion criteria: Treatment duration of at least 30 days	Group 2: placebo Also compares against other interventions.	Patient reported self rating from improved symptoms (men rating very good to good)	RR=1.76 [1.21, 2.56]; 6 studies (n=659) P=0.0029	 of veterans affairs, USA Minneapolis/VISN-13 Center for Chronic Diseases Outcomes Research, USA. 					
17 included that were compared to	All patients		Physician assessed improvement of symptoms	RR=1.72 [1.11, 2.66]; 3 studies (n=524) P=0.015	Limitations: Studies utilised different doses of serenoa repens but most					
placebo.	N: 3139 (1408 in this comparison)		Mean difference Nocturia (times/evening)	-0.76 [-1.21, -0.31]; 10 studies (n=634) P=0.00084	frequently reported dose was 160mg twice per day.					
Setting: Europe and USA	88) Drop outs: 319 (10%) [0-	p outs: 319 (10%) [0- % range]	Weighted mean difference Qmax, mL/s	1.86 [0.60, 3.12]; 9 studies (n=723) P=0.0038	Additional outcomes: Also reported:					
Evidence level:	18% range]		Mean urine flow, ml/s	2.23 [1.18, 3.27]; 4 studies (n=382) P=0.000028	 SR/urtica vs. finasteride. SR vs. pygeum africanum 					
1++									Residual volume, mL	-22.95 [-42.33, -3.56]; 6 studies (n=450) P=0.020
Duration of follow-up:	follow-up: Mean study duration 13 weeks (4 -48		Prostate size	-2.14 [-10.93, 6.65]; 2 studies (n=243) P=0.63	Notes: Results did not substantially change when restricted analysis to studies that had adequate allocation concealment or were					
duration 13			Study withdrawals	0.72 [0.39, 1.32]; 7 studies (n=595) P=0.29						
weeks range).		IPSS t chang repen		-3.50 [-6.75, -0.25]; one study (n=40) P=0.035	double blinded. Meta-analysis used randoms effect model for all comparisons.					
			Qmax (serenoa repens/sabal urtica)	1.60 [-1.67, 4.87]; one study (n=40) P=0.34						

1 Evidence Table 49 Phytotherapy combinations vs. placebo

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Lopatkin et al., 2005 ¹⁴⁹ Study design: Randomised controlled trial Setting: Multi centre, Evidence	Patient group: Male outpatients≥ 50 years suffering from LUTS caused by BPH. Inclusion criteria: maximum urinary flow rate<15ml/s; change in maximum urinary flow between screening and end of run-in period 3ml/s or less; urinary output>100ml at baseline; IPSS total score 14 or greater; IPSS quality of life 4 or greater. Written informed consent. Exclusion criteria: Inability to give informed consent or to complete self-ratings: previous	Group 1: Phytotherapy combination of sabal/urtica 2 X 1 capsule daily of 160mg sabal fruit extract WS1473 and 120mg urtica root extract WS 1031 per capsule (PRO 160/120). Group 2: Placebo	Mean (SD) total changes IPSS	Baseline Group1 (n=127): 18 (4) Group 2 (n=126): 18 (3) Week 16 Group1 (n=127): -4 (4) Group 2 (n=126): -3 (5) Week 24 Group1 (n=127): -6 (4) Group 2 (n=126): -5 (5) P=0.03	Funding: NR Limitations: Baseline assessments: Initial diagnosis of BPH was systematically longer in patients randomised to intervention. Additional outcomes: Per protocol analysis also
level: 1+ Duration of follow-up: 24 weeks	Evidenceconsent or to complete self-ratings; previous or scheduled surgery involving pelvis or urinary tract; urethral stricture disease or a history of pelvic radiation therapy;Puration of ollow-up:PSA>10ng/ml; large residual urine >350ml; symptomatic urinary tract infection; chronic bacterial prostatitis; patients with diabetes mellitus, diabetic neuropathy or prostate carcinoma; serious general and specific risks;	is or ase or a2X1 capsule day (capsule identical in appearance to intervention).>350ml; chronic iabetesAll patients: Placebo run in phase 2 weeks.	Mean (SD) changes in Qmax, ml/s	Baseline Group 1: 10.4 (2.4) Group 2: 10.5 (2.6) Week 24 Group 1: +1.8 (4.6) Group 2: +1.9 (4.5) P=0.59	completed to assess robustness of results. Sub-analysis of IPSS score by irritative and obstructive components and by individual question. Sub-analysis of moderate and severe baseline IPSS scores and number in mild,
concomitant medication affecting the micturition pattern. <u>All patients:</u> N: 257 <u>Group 1</u> N: 129 Mean (±SD) Age: 68 (7) Dropouts: 4 (informed consent revoked=1; adverse events=3)		Adverse events	Group1: 23/129 (17.8%) Group 2: 24/128 (18.8%)	moderate and severe IPSS category after 24 weeks. Notes: This trial was followed by an open label extension period were all patients received the intervention.	
	Group 2 N: 128 Mean (±SD) Age: 67 (7) Dropouts: 3 (lost to follow-up=1, non- compliance=1; informed consent revoked=1)				2 patients from each group terminated trial early without any data for the primary outcome measure, and were excluded from the analysis.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments		
Melo et al., 2002 ¹⁷⁴ Study design: Randomised controlled trial.	Patient group: Men with urinary symptoms. Inclusion criteria: ≥50 years, urinary symptoms assessed by IPSS with minimal score of 12, quality of life index of at least 3 points, rectal examination consistent with BPH and	PHYTOTHERAPY COMBINATION 25mg Pygeum africanum and 300mg stinging nettle (1 PO bid). Group 2: PLACEBO	Mean (SD) IPSS score Mean (SD) quality of life index	Baseline Group 1: 19.3 (5.2) Group 2: 20.0 (5.9) 6 months Group 1: 14.6 (7.3) Group 2: 15.6 (7.9); P=0.658 Baseline Group 1: 3.81 (0.83)	Funding: NR. Limitations: No dropouts were reported in the study and method of randomisation was unclear.		
Setting: NR Evidence level:	Maximum urinary flow rate between 5 and 15mL/s. Exclusion criteria: NR			Group 2: 3.95 (1.09) 6 months Group 1: 3.33 (1.27) Group 2: 3.73 (1.52)	Additional outcomes: Comparison of ≥30% and 50% drop in IPSS, QoL and increase in		
1+ Duration of follow-up: N: 49 6 months Drop outs: NR	N: 49 Drop outs: NR	Mean (SD) Qmax	Baseline Group 1: 11.4 (3.1) Group 2: 10.2 (2.4); P=0.066 6 months Group 1: 12.5 (6.1) Group 2: 11.4 (3.8); P=0.770	Notes: Baseline Qmax was better in the interventio group but Not sig.ly			
	Group 1 N: 27 Mean (range) Age: 65.3 (52-86) Dropouts: NR Group 2 N: 22 Mean (range) Age: 65 (50-79) Dropouts: NR				Adverse events	Headache Group 1: 1/27 (3.7%) Group 2: 1/22 (4.5%) Chest pain Group 1: 0/27 Group 2: 1/22 (4.5%) Epigastric pain Group 1: 4/27 (14.8%) Group 2: 0/22 Drowsiness Group 1: 1/27 (3.7%) Group 2: 1/22 (4.5%) Vertigo Group 1: 0/27 Group 2: 1/22 (4.5%)	different.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Preuss et al., 2001 ²¹⁰	Patient group: Men with diagnosis of BPH.	Group 1: phytotherapy 2 pills of combined natural products	Mean AUA scores	Baseline Group1 (n=70): 18.9 Group 2 (n=57): 17.7	Funding: Rexall/Sundown, Inc, Boca Raton, FL through	
Setting: 3 sites, US	Inclusion criteria: no evidence of cancer by digital rectal and/or PSA examinations; maximal urinary flow rates were to be between 5-15ml/s for a voided volume in excess of 100ml. Read, speaks and understand English and written	Cernitin 378mg, saw palmetto complex and phytosterol (saw palmetto fruit standardised to 40- 50% free fatty acids and B-sitosterol standardised to 43%) 286g, and		Day 45 Group1 (n=70): 14.6 Group 2 (n=57): 15.0 Day 90 Group1 (n=70): 12.7 Group 2 (n=57): 14.5 ANOVA p=0.014	the National Research Council for Health, Washington DC and Meridian ID.	
Evidence level: 1+	informed consent obtained. Exclusion criteria: Age over 80	Vitamin E 100 IU. Group 2: Control	Mean (SEM) [SD] change in AUA symptom index	Group1 (n=70): -6.171 (0.766) [6.41] Group 2 (n=57): -3.241 (0.774) [5.84] P=0.009	Baseline levels not reported.	
Duration of follow-up: 90 days	years, presence of any tumour, malformation, or infection of the genitourinary tract; sever 0 days concomitant medical condition, severe laboratory abnormalities at baseline; finasteride within the last 4	2 pills of placebo	2 pills of placebo Mean (S maximu ml/min	Mean (SEM) [SD] maximum flow rate,	Baseline Group1 (n=70): 11.2 (0.8) Group 2 (n=57): 12.1 (0.9) Day 90 Group1 (n=70): 11.8 (0.7) [5.86] Group 2 (n=57): 13.1 (1.0) [7.55]	Additional outcomes: AUA scores for each of 7 questions reported. Comparison of PSA changes.
	weeks; patients being treated with antibiotics for genitourinary tract infections. <u>All patients:</u> N: 144 Drop outs: 17		Mean (SEM) Average flow rate, ml/min	Baseline Group1 (n=70): 6.0 (0.4) Group 2 (n=57): 6.1 (0.5) Day 90 Group1 (n=70): 6.0 (0.5) Group 2 (n=57): 6.8 (0.5)	SD calculated by NCC.	
Group 1 N: 75 Mean (±SD) Age: Dropouts:5 (withdrew consent=1, lost to follow-up=1)			Mean (SEM) Bladder volume, ml	Baseline Group1 (n=70): 58.9 (11.4) Group 2 (n=57): 59.6 (12.8) Day 90 Group1 (n=70): 57.5 (12.8) Group 2 (n=57): 40.7 (10.4)		
	Group 2 N: 69 Mean (±SD) Age: Dropouts:12 (adverse events=3, withdrew=5, lost to follow-up=3;		Adverse events	Flatulence: Group 1: 3 Group 2: 0 Lower abdominal rash: Group 1: 0		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	protocol violation=1)			Group 2: 1	
				Dizziness	
				Group 1:0	
				Group 2: 1	
				Headache	
				Group 1: 1	
				Group 2: 1	
				Nausea/GI distress	
				Group 1:0	
				Group 2: 2	
				Urinary tract infection:	
				Group 1: 1	
				Group 2: 0	
				Ear infection:	
				Group 1: 0	
				Group 2: 1	
				Lumbar spine surgery	
				Group 1: 0	
				Group 2: 1	
				Herpes Zoster	
				Group 1: 1	
				Group 2: 0	
				Elevated BP:	
				Group 1:0	
				Group 2: 1	
				Chest pain:	
				Group 1: 0	
				Group 2: 1	
				Right arm laceration	
				Group 1: 1	
				Group 2: 0	

1 Evidence Table 50 Phytotherapy vs. Alpha-blockers

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Debruyne et al., 2002 ⁶⁰	Patient group: men with BPH Setting: multicentre, 98 centres across 9	Group 1: Serenoa repens (saw palmetto), Permixon® 320	IPSS ± SD at 12 mths	Group 1: 10.8 ± 5.5, n=269 Group 2: 11.0 ± 6.0, n=273 p value: 0.99	Funding: Grant from Pierre Fabre Médicament, Castres,
Study design: RCT Patients	European countries. Inclusion criteria: IPSS >10	mg/day Group 2 Tamsulosin 0.4 mg/day	Qmax ± SD at 12 mths	Group 1: 12.7 ± 5.2, n=267 Group 2: 13.0 ± 4.9, n=265 p value: 0.79	France, manufacturer of Permixon®. Authors have served as consultants or speakers
masked to treatment	 IPSS > 10 Qmax between 5-15 mL/sec with a urine volume of ≥ 150 mL and PVR <150mL 	Examination methods: Each patient evaluated at	MSF-4 ± SD at 12 mths	Group 1: 8.8 ± 5.4 , n=267 Group 2: 8.2 ± 5.0 , n=266 p value: 0.69	for, or have received research grants from Pierre Fabre
Evidence level: 1+	 Prostate volume ≥25 mL Serum PSA <4ng/mL Men with serum PSA 4-10 ng/mL 	baseline then at 6, 13, 26, 39 and 52 weeks for IPSS and uroflowmetry. At weeks 26 and 52 TRUS was	Serum PSA ± SD at 12 mths	Group 1: 2.8 ± 2.3, n=266 Group 2: 2.9 ± 2.5, n=268 p value: 0.50	Médicament. Limitations: Randomisation
Duration of follow-up: 12 months	required to have free/total PSA ratio of ≥15% to be enrolled • 50 - 85 years	performed and blood and serum PSA taken at week 52.	Prostate Volume ± SD at 6 mths	Group 1: 47.0 ± 20.9, n=269 Group 2: 48.2 ± 22.7, n=270 p value: 0.27	 method was not clear Allocation
	• 90% compliance after a 4 week placebo run in.	**Patient completed the validated male sexual function (MSF-4)	Incidence of Adverse Events N	Group 1: (%) Group 2: (%) 349 354 1 (0.3) 4 (1.1)	 concealment was not clear Masking of outcome
	 Exclusion criteria: Prostate cancer Known history of bladder disease (cancer, bladder neck surgery, 	 questionnaire of 4 questions (0-5 points each): interest in sex quality of erection 		4 (1.1) 5 (1.4) 6 (1.7) 5 (1.4) 10 (2.9) 6 (1.7)	assessment was not clear.Only the per protocol data was
	 neurogenic) Urethral strictures Pelvic radiotherapy Lower urinary tract infection 	 achieving orgasm achieving ejaculation 	Dizziness Rhinitis Hypotension postural Headache Dry Mouth	4 (1.1) 3 (0.8) 28 (8.0) 37 (10.5) 3 (0.9) 2 (0.64)	available at follow up. Additional outcomes:
	 Chronic bacterial prostatitis Any disease affecting micturation Patients with clinically significant cardiovascular disease, haematuria, 		Reasons for withdrawal* Serious Adverse Events Non-serious adverse	Group 1: n=54 Group 2: n=56 3 8	Notes: Masking of treatments to patients was
	type II diabetes, history of hepatic failure or abnormal liver function tests.		events Acute urinary retention Lack of efficacy Sexual dysfunction	4 3 15 8	achieved by providing tamsulosin in a green coloured size 0 capsule similar to Permixon®

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Patients on concomitant medication		Other events		
	likely to interfere with study		Patient decision		Serious advent events
	medication.		Lost to follow up		defined as fatal, life
	Hypersensitivity to study drugs		Other	3 4	threatening, disabling
	Participation in another trial within previous 3 mths				resulting in hospitalisation or associated with cancer
	All patients				
	N: 704 randomised but only 685 included				
	in ITT analysis				
	Mean age: 65.2 yrs				
	Drop outs: 110 (16.1%)*				
	<u>Group 1</u>				
	N: 340				
	Mean (± SD) Age: 65.6 ± 7.4				
	BMI (± SD): 26.7 ± 3.6				
	IPSS (± SD): 15.5 ± 4.8				
	MSF-4 (± SD): $8.3 \pm 5.3^{**}$				
	Qmax (\pm SD), mL/s: 10.9 \pm 3.9				
	Prostate volume (\pm SD), mL: 48.0 \pm 18.2				
	Serum PSA (± SD), ng/mL: 2.8 ± 2.0 Dropouts: 54*				
	Group 2				
	N: 345				
	Mean (± SD) Age: 64.9 ± 7.6				
	BMI (± SD): 26.7 ± 3.7				
	IPSS (\pm SD): 15.2 \pm 5.2				
	MSF-4 (± SD): $7.7 \pm 5.0^{**}$				
	Qmax (± SD), mL/s: 11.3 ± 4.3				
	Prostate volume (± SD), mL: 47.7 ± 18.6				
	Serum PSA (± SD), ng/mL: 2.8 ± 2.2				
	Dropouts: 56*				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Engelmann U	Patient group:	Group 1: PRO	Median IPSS total	Baseline	Funding:
et al., 2006 ⁷¹	Outpatients suffering from BPH that did not	160/120	score	Group 1: 20	NR
	require surgery.	160mg Sabal fruit		Group 2: 20	
Study design:	Inclusion criteria:	extract and		24 weeks	Limitations:
RCT	A maximum urinary flow rate ≤12ml/s at a	120mg Urtica root		Group 1: 13	Median scores
	urinary volume \geq 150ml was required.	per capsule.		Group 2: 12	reported.
Setting:	Aged 50 years old and above.	Group 2:		60 weeks	Details of adverse
23 private	Initial IPSS score of \geq 13 points and an IPSS	Tamsulosin		Group 1: 10	events not
urological	QoL assessment score ≥3.	Slow-release		Group 2: 9	reported.
practices in	Exclusion criteria:	capsules	Median improvement	Group 1: 2	
Germany.	Patients whose peak urinary flow rate	containing 0.4mg	from baseline in LUTS-	Group 2: 1	Additional
	changed by more than 3ml/s during a 2-week	active ingredient.	associated QoL (single		outcomes:
Evidence	placebo run-in phase were excluded.		item, range 0 [very good]		Subgroup analysis
level:	Patients with a residual urinary volume >	For both drugs	-6 [very bad].		of patients with
1+	150ml, congested urinary tract passages, an	placebo capsules	Adverse events		IPSS baseline
	indication for BPH surgery, urinary tract	were available			score of ≤ 19 and
Duration of	infection, prostate carcinoma, diabetes,	which were	(details not reported)	Group 1:15 patients (21.1%) reported 18	IPSS baseline
follow-up:	neurogenic or bladder dysfunction as well as	indistinguishable			score ≥20
60 weeks	patients previously treated with 5α-reductase	from their		Group 2: 19 patients (27.5%) reported	
	inhibitors.	pharmacologically		23 events.	Erectile function
		active			score – median
	All patients	counterparts in all			score change for
	N: 140	aspects of their			both groups = 0.
	Drop outs: 9/140	outer			
		appearance.			Notes:
	Group 1				Randomization
	N: 71	(After screening			was performed in
	Age \pm SD, years: 65 \pm 8	patients entered a			balanced blocks,
	Time since diagnosis of BPH (years): 3.1±4	single blind			by means of a
	Dropouts: 11	placebo run in			validated EDP
		phase of two			random number
	Group 2	weeks.)			generator
	N: 69				program.
	Age \pm SD, years: 65 \pm 8	Examination			
	Time since diagnosis of BPH (years):	methods:			
	3.61±4.5	Visits scheduled			
	Dropouts: 8	after 8, 16, 24,			

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Exclusions after randomization Revoked informed consent: 2 Adverse event during placebo run-in: 2 Not meeting selection criteria: 5	36, 48 and 60weekk of double blind treatment.			

Study details	Patients	Interventions	Outcome measures	Effect size		Comments				
Hizli & Uygar, 2007 ¹⁰⁶ Study design:	Patient group: men with symptomatic BPH Setting: Department of Urology, Oncology, Education and research, Ankara Hospital,	gy, gy, Serenoa repens (Prostagood®) 320 mg/day Group 2 Tamsulosin 0.4 mg/day Group 3 Serenoa repens (Prostagood®) 320 mg/day + Tamsulosin 0.4 mg/day Examination methods: IPSS, Qol, Qmax by uroflowmetry recorded at baseline and	IPSS ± SD reduction from baseline at 6 mths	Group 1: -6.1 ± 2.7 Group 2: -4.6 ± 3.3 Group 3: -4.9 ± 2.3 p value: 0.16 (Kruskal-Wallis)		Funding: NR Limitations:				
RCT open label Evidence level: 1+	Turkey. Inclusion criteria: • IPSS ≥ 10 • Qmax 5-15 mL/s		Tamsulosin 0.4 mg/day Group 3 Serenca repens (Prostagood®) 320 mg/day +	Tamsulosin 0.4 mg/day Group 3 Serenoa repens (Prostagood®) 320 mg/day +	Tamsulosin 0.4 mg/day	Tamsulosin 0.4 mg/day	Tamsulosin 0.4 mg/day	g/day from baseline at 6 mths Group 2: -2.1 ± 0.8 Group 3: -2.2 ± 1.0 p value: 0.14 (Kruskal-Wallis)		 Randomisation n method not reported Allocation concealment
Duration of follow-up: 6 months	 PVR ≤ 150 mL Prostate volume ≥ 25 mL PSA ≤ 4 ng/mL 				renoa repens rostagood®) 20 mg/day + from baseline at 6 mths 20 mg/day + Group 2: 3.7 ± 2.6 Group 2: 3.7 ± 2.6 Group 3: 4.2 ± 2.5 p value: 0.38 (Kruskal-Wallis)		 not reported Masking of outcome assessment 			
o monnis	 Exclusion criteria: History of bladder disease affecting micturation Urethral stenosis 		Prostate volume ± SD decrease from baseline at 6 mths	Group 1: -0.7 ± 2.2 Group 2: -1.0 ± 2.2 Group 3: -0.8 ± 2.0 p value: 0.61 (Kruskal-Wallis)	: -1.0 ± 2.2 : -0.8 ± 2.0	not reported Open label Small study 				
	 Pelvic radiotherapy Prostate cancer Infections of urinary tract or chronic bacterial prostatitis 		by uroflowmetry recorded at baseline and	by uroflowmetry recorded at baseline and	PSA ± SD decrease from baseline at 6 mths	Group 1: -2.0 ± 0.3 Group 2: -0.1 ± 0.2 Group 3: -3.5 ± 0.2 p value: 0.07 (Kruskal-Wallis)		Additional outcomes: No patients withdrew from the study due to		
	 Clinically significant cardiovascular disease Haematuria Type II diabetes Severe hepatic failure or abnormal liver function tests Known hypersensitivity to study drugs Participation in another trial within previous 3 months <u>All patients</u> N: 60 Age (range): 43-73 years Drop outs: 	months 2, 4, 6	Incidence of Adverse Events N Decreased Libido Ejaculation Disorders Asthenia Fatigue Dizziness Rhinitis Hypotension postural Dry Mouth	- 7 (35) 2 (10) - 2 (10) - 2 (10) - 3 (15)	Group 3: 20 1 (5) 3 (15) 1 (5) - - - 1 (5)	adverse events. Notes: Notes				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Group 1				
	N: 20				
	Age \pm SD, years: 56.8 \pm 7.8				
	IPSS \pm SD: 18.0 \pm 4.9				
	IPSS QoL \pm SD: 4.2 \pm 1.1				
	Qmax \pm SD, mL/s: 9.4 \pm 2.9				
	Prostate volume ± SD, mL: 35.2 ± 10.3				
	PVR ± SD, mL: 67.4 ± 27.7				
	PSA \pm SD, ng/mL: 1.9 \pm 0.9				
	BMI \pm SD, kg/m ² : 26.7 \pm 2.5				
	Dropouts: 0				
	Group 2				
	N: 20				
	Age \pm SD, years: 58.9 \pm 5.7				
	IPSS \pm SD: 16.2 \pm 4.7				
	IPSS QoL \pm SD: 3.5 \pm 1.1				
	Qmax \pm SD , mL/s: 10.5 \pm 2.8				
	Prostate volume ± SD, mL: 38.6 ± 11.6				
	PVR ± SD, mL: 65.5 ± 33.3				
	PSA \pm SD, ng/mL: 2.1 \pm 0.9				
	BMI ± SD, kg/m²: 28.0 ± 3.4				
	Dropouts: 0				
	<u>Group 3</u>				
	N: 20				
	Age \pm SD, years: 60.2 \pm 6.3				
	IPSS \pm SD: 15.6 \pm 3.2				
	IPSS QoL \pm SD: 3.5 \pm 1.1				
	Qmax \pm SD, mL/s: 9.9 \pm 2.4				
	Prostate volume \pm SD, mL: 31.2 ± 4.2				
	PVR ± SD, mL: 63.7 ± 23.7				
	PSA \pm SD, ng/mL: 1.7 \pm 0.7				
	BMI \pm SD, kg/m ² : 27.8 \pm 2.3				
	Dropouts: 0				

Study details	Patients	Interventions	Outcome measures	Effe	ct size	Comments					
Carraro et al., 1996 ³⁸	Patient group: men with BPH and symptoms of BOO	Group 1: Serenoa repens (saw palmetto), Permixon® 160 mg + placebo 2/day	IPSS ± SD at 6 mths	Group 1: 9.9 ± Group 2: 9.5 ± p value: 0.17 (5.5, n=484	Funding: NR					
Study design: RCT Placebo controlled	 Setting: multicentre, 87 centres across 9 European countries. Inclusion criteria: BPH diagnosed by DRE 	morning and evening for 26 weeks. Group 2	morning and evening for 26 weeks. Group 2	morning and evening for 26 weeks. Group 2	morning and evening for 26 weeks.	IPSS QoL score ± SD at 6 mths	0.96) Group 1: 2.25 : Group 2: 2.15 : p value: 0.14 (1 0.24)	± 1.26, n=484	 Limitations: Masking of outcome assessment was not clear. Allocation 		
Evidence level: 1+	 IPSS >6 Qmax between 4-15 mL/sec with a urine volume of ≥ 150 mL and PVR <200mL 	+ placebo 1/day in the morning then 2 x placebo in the evening	Sexual Function Score ± SD at 6 mths	Group 1: 7.9 ± Group 2: 9.3 ± p value: <0.00 1.52, 0.96)	5.7, n=484	concealment by packaging of drug: was not clear. Additional outcomes:					
Duration of follow-up: 6 months	 Prostate volume >25 mL Serum PSA <10 ng/mL for prostates <60ml Serum PSA < 15 ng/mL for prostates 	Examination methods: Each patient was examined prior to baseline and at 6, 13 and 26 weeks by the	Qmax ± SD at 6 mths	Group 1: 13.3 Group 2: 14.0 p value: 0.035 -0.054)	•	% patients with Qmax <10 mL/s or Qmax ≥ 10 mL/s at baseline and at 6 mths against %					
	 > 60mL (measured before or 3 days after DRE & TRUS) > 50 years 2 week washout period after previous alpha-blockers or Pygeum 	same investigator. At each visit Qmax (at 200 mL voided volume), IPSS, IPSS QoL and sexual function score (0-20 points) were	visit Qmax (at 200 mL voided volume), IPSS, IPSS QoL and sexual function	visit Qmax (at 200 mL voided volume), IPSS, IPSS QoL and sexual function	visit Qmax (at 200 mL voided volume), IPSS, IPSS QoL and sexual function	visit Qmax (at 200 mL voided volume), IPSS, IPSS QoL and sexual function	visit Qmax (at 200 mL voided volume), IPSS, IPSS 6 mths	Prostate Volume ± SD at 6 mths	Group 1: 41.5 Group 2: 36.7 p value: <0.00 1.18)		patients with IPSS <18 or IPSS ≥18 at baseline and at 6 mths.
	 Good physical and mental condition 	determined. At weeks 13 & 26 TRUS and PSA were performed.	Serum PSA at 6 mths		± 1.98, n=484	Notes: Computer generated randomisation sequence					
	Exclusion criteria:Prostate cancer	performed.		p value: <0.00 1.45)	01 (Cl 95%: 1.33,	**Sexual function					
	 Known history of bladder disease (cancer, bladder neck surgery, neurogenic) 		Inter current clinical events Hypertension	Group 1: (%) 17 (3.1) 12 (2.2)	Group 2: (%) 12 (2.2) 16 (3.0)	comprised 4 questions in the male sexual function questionnaire MSF-4 (0-					
	 Lower urinary tract infection Any disease affecting micturation Abnormal liver function (twice upper normal limit of serum 		Decreased Libido Abdominal pain Impotence Back pain Diarrhoea	10 (1.8) 8 (1.5) 9 (1.6) 5 (0.9)	15 (2.8) 15 (2.8) 3 (0.6) 6 (1.1) 6 (1.1)	5 points each) on interest in sex, quality o erection, achieving orgasm & ejaculation					
	 aminotransferases and/or bilirubin, creatinine >160 μmol/L Diuretics or drugs with antiandrogen 		Influenza-type symptoms Urinary retention Headache	7 (1.3) 7 (1.3)	3 (0.6) 2 (0.4) 6 (1.1)						

1 Evidence Table 51 Phytotherapy vs. 5-Alpha Reductase inhibitors

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	or alpha receptor properties		Nausea Constipation	2 (0.4) 6 (1.1) 2 (0.4) 6 (1.1)	
	administered over previous 3 months for hypertension, cerebrovascualar		Dysuria		
	insufficiency.		-		
	 Prior treatment with Permixon® or 		Reasons for withdrawal* Side effects		
	Finasteride		Lack of efficacy		
			Patient decision		
	All patients		Lost to follow up	-	
	N: 1098		Mortality (non drug		
	Mean age: 64.5 yrs			1 (heart attack) 1 (fatal MI)	
	Drop outs: 147 (13.4%)		Other		
	Group 1				
	N: 553				
	Mean (range) Age: 64.3 (49-87)				
	BMI (range): 26 (17-38)				
	IPSS (± SD): 15.7 ± 5.8				
	IPSS QoL (\pm SD): 3.63 \pm 1.28				
	MSF-4 (± SD): $8.4 \pm 5.5^{**}$				
	Qmax (± SD), mL/s: 10.6 ± 2.8				
	PVR (± SD) , mL: 52 ± 44				
	Prostate volume (± SD), mL: 43.0 ± 19.6				
	Serum PSA (± SD), ng/mL: 3.26 ± 3.41 Dropouts: 86*				
	Group 2				
	N: 545				
	Mean (range) Age: 64.7 (49-88)				
	BMI (range): 25.9 (18-36)				
	IPSS (± SD): 15.7 ± 5.7				
	IPSS QoL (± SD): 3.66 ± 1.17				
	MSF-4 (± SD): $8.5 \pm 5.5^{**}$				
	Qmax (± SD), mL/s: 10.8 ± 3.1				
	PVR (± SD), mL: 52 ± 44				
	Prostate volume (± SD), mL: 44.0 \pm 20.6				
	Serum PSA (± SD), ng/mL: 3.23 ± 3.34 Dropouts: 61^*				

Study details	Patients	Interventions	Outcome measures	Effect size	Comments			
Sökeland, 2000 ²⁴³	Patient group: men with BPH (Aiken stages I to II)	Combination phytotherapy PRO 160/120 (serenoa repens (saw palmetto) extract 160 mg and Urtica (nettle) extract 120 mg) 2/day + 1 placebo 1/day Group 2	IPSS ± SD at 6 mths	Group 1: 8.2 ± 5.8, n=233 Group 2: 8.0 ± 5.7, n=230 p value: 0.66	Funding: NR			
Study design: RCT Placebo controlled	Setting: multicentre, University of Münster, Germany. Inclusion criteria:		extract 160 mg and Urtica (nettle) extract 120 mg) 2/day + 1 placebo 1/day Group 2	extract 160 mg and Urtica (nettle) extract 120 mg) 2/day + 1 placebo 1/day	extract 160 mg and Urtica (nettle) extract 120 mg) 2/day + 1 placebo 1/day Group 2	IPSS ± SD at 12 mths	Group 1: 6.5 ± 5.8, n=230 Group 2: 6.2 ± 5.2, n=223 p value: 0.54	 Limitations: Safety information was not reported in the 2000 study and
Evidence level:	 NR Exclusion criteria: 					Group 2	Group 2	Group 2
Duration of follow-up: 1 year	 < 50 years BPH III or above (Aiken) PSA > 10 ng/mL 	1/day + 1 placebo 2/dayExamination methods:Qmax, average flow and	Qmax ± SD at 6 mths	Group 1: 14.6 ± 6.2, n=245 Group 2: 15.1 ± 7.1, n=244 p value: 0.34	Review.Neither standard deviations or p			
r yeur	Prostate cancerUse of other prostate medicationsInfections	IPSS measured.	Qmax ± SD at 12 mths	Group 1: 14.6 ± 6.4 , n=233 Group 2: 15.4 ± 6.8 , n=232 p value: 0.19	values Notes: Additional methods			
	Severe concomitant disease requiring therapy		Prostate volume ± SD at 12 mths	Group 1: 42.4 ± NR Group 2: 37.2 ± NR p value: NR	information is available from first publication, Sökeland & Albrecht,			
	All patients N: 516 Age (range): 50 - 88 Drop outs: 27 (5%) 489 available for efficacy analysis Group 1 N: 261 IPSS (± SD): 11.3 ± 6.5 (n=258) Qmax (± SD), mL/s: 12.4 ± 4.5 (n=245) Prostate volume (± SD), mL: 42.7 ± 27.8 (n=215) Dropouts: 16		Number of adverse events (details not reported in Cochrane review or Sökeland, 2000) but the	Group 1 : 74 in 52 patients Group 2 : 96 in 54 patients Note: the abstract for Sökeland & Albrecht, 1997 ²⁴⁴ states that there were less cases of diminished ejaculation volume, erectile dysfunction and headache for those patients on PRO160/120	1997 ²⁴⁴ , translated from German in the Wi et al., 2002 ²⁷⁸ Cochrane Review. Randomisation was computer generated and allocation concealment was reported as being adequate in the Cochrane Review			
	Group 2 N: 255							

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Dropouts: 11 IPSS (\pm SD): 11.8 \pm 6.6 (n=255) Qmax (\pm SD), mL/s: 12.8 \pm 4.0 (n=241) Prostate volume (\pm SD), mL: 44.0 \pm 26.6 (n=216)				

1	Evidence	Table 52	Provision	of information
---	----------	----------	-----------	----------------

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Barry et al., 1997 ²⁰	Patient group: Men with clinical diagnosis of BPH. Setting: Urologic practices of Group	Group 1: Computer and interactive video- based shared decision-making	Treatment selection at 3 months:	Prostatectomy: Group1: 5/104 (4.8%) Group 2: 8/123 (6.5%)	Funding: Grant Nos. HS 06540 and 08397 from the Agency for
Study design: RCT	Health Cooperative of Puget Sound (staff model health maintenance organisation) in Washington; 2	program (SDP) to educate men about their condition and its treatments.		<u>Medication</u> : Group1: 14/104 (13.5%) Group 2: 14/123 (11.4%)	Health Care Policy and Research. The development of the first
Evidence level: 1+	practices were located in Seattle and Tacoma. Exclusion criteria: Evidence of	- short questionnaire before viewing; so a subset of items entered into computer to tailor programme to viewer.		Watchful waiting: Group1: 85/104 (81.7%) Group 2: 101/123 (82.1%) P=0.8	edition of the SDP for BPH was funded by a grant from the John A. Hartford Foundation.
Duration of follow-up: 1 Year	prostate cancer, obstructive nephropathy, post void residual >350mL, recurrent or refractory urinary infection, acute retention, previous prostate surgery, repeated	- 30 minute segment explaining importance of participation in the treatment decision and outlines the choices of watchful waiting, medical or surgical treatment. Estimates of	Men undergone prostatectomy at 1 year:	Group1: 8/104 (7.7%) Group 2: 16/123 (13.0%) p value: 0.28 Absolute diff: 5.3% (Cl: - 2.5%, +13.0%)	Limitations: 2 phases of recruitment (pre-consent randomisation phase
	gross hematuria, clot retention, bladder stones, comorbid conditions, inability to understand English.	outcome probabilities given. - then there is an interactive segment that allows for review of old material and inspection of 30	Mean BPH knowledge score: at 2 weeks	Group1: 11.5 (SEM 0.5) Group 2: 6.7 (SEM 0.4) p value: <0.001	and post consent randomisation phase). Additional outcomes:
	<u>All patients</u> N: 227 <u>Group 1</u>	minutes of new material in optional modules on acute retention, sexual dysfunction, incontinence, new	Mean (SE) satisfaction scores for decision process: 12 months	Group1: 74.77 (1.72) Group 2: 69.26 (1.89) p value*: 0.03	Mean change in autonomy preference scores.
	N: 104 Age (mean): 66.4 (SD: 8.6) AUA score (mean): 16.6 (SD: 6.7)	treatments, BPH and prostate cancer, blood transfusion, symptom response to surgery.	Mean (SE) satisfaction scores for decision made: 12 months	Group1: 75.16 (1.80) Group 2: 71.74 (1.75) p value: 0.21	Notes: * p values from a
	Drop outs: 1 <u>Group 2</u> N: 123	Group 2: Brochure to provide basic information about the prostate gland and disease that can affect it,	Mean (SE) changes of AUA symptom score: 12 months	Group1: -0.88 (0.74) Group 2: -1.45 (0.58) p value: 0.58	repeated measures analysis of covariance over all assessment points, controlling for
	Age (mean): 66.2 (SD: 8.2) AUA score (mean): 15.9 (SD: 7.0) Drop outs: 7	including BPH. No quantitative information about treatment outcomes provided.	Mean (SE) change in BPH impact score: 12 months	Group1: -1.05 (0.25) Group 2: -0.59 (0.25) p value: 0.12	age, practice site, marital status, education, income and
	-		Mean (SE) changes in general health score at 12 months:	Group1: 0.61 (1.58) Group 2: -4.99 (1.44) p value: 0.02	race.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				Group1: 0.15 (1.40) Group 2: -3.74 (1.18) p value: 0.02	
			• • •	Group1: -1.46 (1.85) Group 2: -3.52 (1.71) p value: 0.17	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Brown et al.,	Patient group: men over 40	Group 1: Self management and	Number (%)of men	3-month outcome:	Funding:
200731	with uncomplicated lower	standard care group	with treatment failure:	Group 1: 7/71 (10%)	BUPA Foundation
	urinary tract symptoms who	Small group sessions (5-8 men),		Group 2: 27/65 (42%)	Project Grant. Author
Study design:	were referred for the first	each lasting between 1.5 and 2		Difference (95% CI): 32 (18 to 46)	CTB received a research
RCT	time by their GP (from	hours, which were scheduled one,	of 3 points or more on	p value: <0.001	fellowship from the
	January 2003 and April	two and six weeks after	the international		Royal College of
Evidence	2004).	randomisation. The aim of these	prostate symptom score,	6-month outcome:	Surgeons of England,
level: 1+		sessions was to bring about	use of drugs to control	Group 1: 13/69 (19%)	funded by Cazenove &
	Setting: Outpatient	modification of lifestyle (fluid	lower urinary tract	Group 2: 39/64 (61%)	Co. Author JvdM is
Duration of	departments of 2 urological	management, avoidance of	symptoms, acute urinary	Difference (95% CI): 42 (27 to 57)	funded by a national
follow-up:	centres in London, a teaching	caffeine, and use of alcohol) and	retention, or surgical	p value: <0.001	public health career
12 months	hospital and a district	specific changes in behaviour	intervention) during		scientist award from the
	general hospital.	(bladder training, double	follow-up.	12-month outcome:	Department of Health
		voiding, and urethral milking).		Group 1: 18/59 (31%)	and NHS R&D
	Exclusion criteria: medical	Facilitated by urology nurses		Group 2: 44/56 (79%)	Programme.
	treatment in the previous	trained to enhance self		Difference (95% CI): 48 (32 to 64)	
	three months, recent surgery,	management skills and provided		p value: <0.001	Limitations:
	complications potentially	support by brainstorming and			The study was
	related to their symptoms or	group discussion. This intervention	Mean (SD)	3-month outcome:	underpowered as
	severe comorbidity.	group also received standard	International Prostate	Group 1: (n= 71): 10.7 (5.9)	according to their
		care (as described below).	Symptom Score (IPSS)	Group 2: (n=64): 16.4 (5.8)	calculations 84 men in
			(Score: 0-35; the higher	Difference (95% CI): 5.7 (3.7 to 7.7), p	each group were
	All patients	Group 2: Standard care	the score the worse the	value: <0.001	necessary to have a
	N: 140	Standard care began with	symptoms)		90% chance to detect a
	Drop outs: 25	watchful waiting. Escalation to	37	6-month outcome:	3 point reduction in
		medical treatment and surgery		Group 1 ($n = 67$): 10.4 (6.1)	mean international
		was left to the discretion of the		Group 2 (n=61): 16.9 (6.4)	prostate symptom score
		clinician and patient.		Difference (95% CI): 6.5 (4.3 to 8.7), p	at 5% level of
	Group1:			value: <0.001	significance with SD of
	N : 73	All patients, irrespective of			6.
	Age (mean): 63.3 (11.1)	treatment allocation, received		12-month outcome:	
	Drop outs: 14 at 12M	standard written information		Group 1: (n=53): 10.2 (6.1)	Additional outcomes:
	Mean (SD) duration of	about lower urinary tract		Group 2:(n=51): 15.4 (6.6)	Reasons for treatment
	symptoms (years): 3.9 (4.0)	symptoms.		Difference (95% CI): 5.1 (2.7 to 7.6), p	failure at 3, 6 and 12
	Mean (SD) IPSS: 16.9 (5.1)			value: <0.001	months.
	Mean (SD) AUA-QoL score:				BPH index score.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	4.0 (1.0) <u>Group 2:</u> N: 67 Age (mean): 63.4 (10.4) Drop outs: 11 at 12M Mean (SD) duration of symptoms (years): 4.3 (6.7) Mean (SD) IPSS: 15.9 (6.5) Mean (SD) AUA-QoL score: 3.3 (1.1)		Mean (SD) AUA-QoL score: (lower score the better quality of life)	3-month outcome: Group 1: $(n=71)$: 2.8 (1.2) Group 2: $(n=64)$: 3.4 (1.1) Difference (95% CI): 0.6 (0.2 to 1.0), p value: < 0.001 6-month outcome: Group 1: $(n=67)$: 2.6 (1.3) Group 2: $(n=61)$: 3.3 (1.4) Difference (95% CI): 0.7 (0.2 to 1.2), p value: 0.008 12-month outcome: Group 1: $(n=54)$: 2.6 (1.3) Group 2: $(n=52)$: 3.1 (1.2) Difference (95% CI): 0.5 (0 to 1.0) p value: 0.03	Notes: Compliance with self management programme was high; 68 (93%) patients attended all three sessions. The five patients who did not attend were included in the self management group for analysis. Self management group included more men with university degree and fewer men with no qualification.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Murray et al., 2001 ¹⁸² Study design:	Patient group: Men with benign prostatic hypertrophy	Group 1: Interactive multimedia programme with booklet and printed summary.	Mean (SD) decisional conflict score at three months: Higher scores indicated increased	Group 1: 2.3 (0.4) Group 2: 2.6 (0.5) Mean difference (95% Cl): -0.3 (- 0.5 to -0.1), p <0.01	Funding: NHS national research and development programme, the BUPA Foundation, and the
RCT	Setting: Primary care	Treatment options discussed were surgery,	uncertainty.		King's Fund.
Evidence level: 1+	Inclusion criteria: Men with benign prostatic hypertrophy. No more	balloon dilatation of the prostate, drugs, and watchful waiting.	Mean (SD) decisional conflict score at nine months:	Group 1: 2.23 (0.38) Group 2: 2.55 (0.50) Mean difference (95% Cl): -0.33 (-0.51 to -0.14)	Limitations: The initial aim of the study was to detect a difference in
Duration of follow-up: 9 months	details provided. Exclusion: Men with any clinical suggestion of carcinoma of the prostate or if they had chronic retention of the urine, recent urinary tract infection, a history of acute urinary retention or prostate surgery, severe visual or hearing impairment, or severe learning difficulties or mental illness. <u>All patients</u> N: 112 Drop outs: 10		GPs perceptions of decision making at three months. Values are numbers and (%). Question: Who do you think made the treatment decision?	Mainly or only GP: Group 1 (n=48): 1(2) Group 2 (n=49): 5 (10) % difference (95% Cl): -8 (-17.5 to 1.3) GP and patient together: Group 1: 25 (52) Group 2: 32 (65) % difference (95% Cl): -13 (-32.6 to 6.2) Mainly or only patient: Group 1: 22 (46) Group 2: 12 (25) % difference (95% Cl): 21 (2.8 to 39.9) X ² = 6.458, df=2; p=0.04	anxiety, however, recruitment rate was low and it was not possible to recruit the 210 patients needed from the sample size calculation. Additional outcomes: Cost per patient for a number of item. Only total costs are reported in this table. Authors found no difference between the two groups in the trends over time in the EQ-5D responses nor in the SF-36
	Intervention group N: 57 Age (mean +/- SD): 63.7 +/- 8.4 Drop outs: 3 Mean (SD) American Urological Association score: 15.64 (6.57) Up to secondary education; n (%): 25 (44) Beyond secondary education; n (%): 32 (56) Mean (SD) Spielberg state trait	nurse started the programme, taught the patient how to use it, and then withdrew. <u>Group 2:</u> Normal care from GP practitioner.	Patients' perceptions of decision making at three months. Question: Who do you think made the treatment decision?	Mainly or only GP: Group 1 (n=57): 5(9) Group 2 (n=48): 4 (8) % difference (95% Cl): 1 (-10.3 to 11.2) GP and patient together: Group 1: 34 (60) Group 2: 42 (88) % difference (95% Cl): -28 (-43.7 to 12.0) Mainly or only patient:	scores. Data not provided. Anxiety scores: the Spielberger scores were similar at the final assessment in the two groups (Mann- Whitney U test). No data provided. Resource volumes per patient over nine months of trial.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
	Mean (SD) American Urological Association score: 14.85 (7.10)Association sUp to secondary education; n (%): 28 (51)28 (51)Beyond secondary education; n (%): 27(49)4000000000000000000000000000000000000		Group 1: 18 (32) Group 2: 2 (4) % difference (95% Cl): 28 (14.1 to 40.7) X ² = 13.078, df=2; p=0.001	Notes: Decisional conflict score contains three subscales that elicit uncertainty about choosing between	
			American Urological Association scores	Scores improved in both groups over the study period. Median change in score: Group 1: -1 Group 2: -2 Mann-Whitney U test, p=0.8	alternatives, awareness of modifiable factors contributing to the uncertainty, and perceived effectiveness of decision making process. Higher scores indicated increased uncertainty in each subscale. Subscales combined
	anxiety inventory: 32.01 (10.49)		Total costs in pounds sterling (at 1999 prices) per patient: Mean (SD)	Excluding intervention: Group 1 (n=57): 310.3 (602.0) Group 2 (n=48): 188.8 (300.4) Mean difference (95% Cl): 121.5 (-58.9 to 302.0) including intervention: Group 1: 594.1 (602.0) Group 2: 188.8 (300.4) Mean difference (95% Cl): 405.4	to give a total decisional conflict score.
				Mean difference (95% Cl): 405.4 (224.9 to 585.8) P<0.001	

1 Evidence Tal	ole 53 Economic evide	ence
----------------	-----------------------	------

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Annemans 2005 ¹⁴ UK	Patient group: patients hospitalised for acute urinary	Intervention 1: Alfuzosin 10mg once daily used for 3 days during the initial hospitalization	Successful TWOC*	Int 1: 62% Int 2: NA Int 3: 48% p value: 0.012	Funding: Sanofi-Aventis Limitations:
Economic analysis: cost- effectiveness analysis	retention	followed by TWOC (mean duration 55hours). If TWOC is successful treatment with Alfuzosin for 6 months.	Mean cost per patient over 6 months** 2002 GBP cost of hospitalisation, prostatectomy and TURP, drugs, unsuccessful TWOC (prostatectomy), tests.	Int 1: 2,029 Int 2: 2,378 Int 3: 2,921 p value: NR	Short follow-up. Additional outcomes: After successful TWOC, 17% of patients treated with Alfuzosin for 6 months require
Study design Decision analysis* Time horizon:		Intervention 2: Immediate inpatient prostatectomy	Incremental costs over 6 months (based on 1,000 Monte Carlo simulations)	Int 3 vs. Int 1: 349 (95% CI 64-624) Int 2 vs. Int 1: 892 (95% CI 644-1121) Int 2 vs. Int 3 : 543 (95% CI 228 - 776) p value : Sig	prostatectomy compared to 24% of patients treated with placebo.
6 months Discount rates:			Cost-effectiveness cost per successful TWOC	Int 1 dominates Int 2 and 3	* based on the ALFAUR Study ¹⁷⁰ **based on 2002 Reference
Costs: NA Effects: NA		TWOC is successful.	Sensitivity analysis Monte Carlo simulation	If the proportion of patients having an immediate prostatectomy after a failed TWOC is higher, Alfuzosin is more cost- saving. If surgery after successful TWOC is done in an elective setting, Alfuzosin is more cost saving.	Costs inflated to 2003 (inflator 1.035)

Study details	Patients	Interventions*	Outcome measures	Effect size	Comments				
DiSantostefano 2006 ⁶³ USA Economic analysis: Cost-utility analysis	Patient group: men aged 65 years with moderate to severe LUTS and uncomplicated BPH, with no contraindications to any	Intervention 1: Watchful waiting (WW) Intervention 2: Alpha-blockers (AB)	QALYs – Group A	Intervention 1: 10.68 Intervention 2: 10.76 Intervention 3: 10.71 Intervention 4: 10.69 Intervention 5: 10.63 p value: NR	Funding: National Research Service Award Institutional Training Grant from the Institute of Aging; grant from the				
Study design Decision analysis Time horizon: 20 years	of the drugs. Group A: moderate symptoms (IPSS 8-19)	the drugs.Intervention 3: 5-Alpha reductase inhibitors (5-ARI)roup A: oderate symptoms (SS 8-19)Intervention 4: High-energy transurethral microwave thermotherapy (TUMT)roup B: vere symptoms (IPSS 0-35)Intervention 5: Transurethral resection of the prostate (TURP)	Intervention 3: 5-Alpha reductase inhibitors (5-ARI) Intervention 4:	5-Alpha reductase inhibitors (5-ARI)	5-Alpha reductase inhibitors (5-ARI) Intervention 4: High-energy transurethral	5-Alpha reductase inhibitors (5-ARI) Intervention 4:	QALYs – Group B	Intervention 1: 9.79 Intervention 2: 9.88 Intervention 3: 9.83 Intervention 4: 10.30 Intervention 5: 10.47 p value: NR	Agency for Healthcare Research and Quality. Conflict of Interest: the author is an employee of GlaxoSmithKline.
Discount rates: Costs: 3% Effects: 3% 20-35)	severe symptoms (IPSS		Mean cost per patient** – Group A 2004 USD, cost of GP visits, tests, drugs, surgery, complications (strictures, incontinence)	Intervention 1: \$ 4,419 (£ 2,793) Intervention 2: \$ 6,666 (£ 4,213) Intervention 3: \$ 8,891 (£ 5,619) Intervention 4: \$ 7,982 (£ 5,045) Intervention 5: \$ 8,599 (£ 5,435) p value: NR	Limitations: Partial applicability. The lack of long-term studies and differences between patient populations might have biased the results in				
			Mean cost per patient** – Group B 2004 USD, cost of GP visits, tests, drugs, surgery, complications (strictures, incontinence)	Intervention 1: \$ 4,403 (£ 2,783) Intervention 2: \$ 6,664 (£ 4,212) Intervention 3: \$ 8,888 (£ 5,617) Intervention 4: \$ 7,983 (£ 5,045) Intervention 5: \$ 8,558 (£ 5,409) p value: NR	favour of pharmaceuticals. Notes: * Combination of AB and 5-ARI was an additional intervention compared in the study but it was excluded because its effectiveness was based only on experts opinion. ** GBP calculated by using the 2008 PPP				
			Cost-effectiveness** – incremental cost per QALY	Group A Int 2 vs. Int 1: \$ 28,088 (£17,752) Int 3, 4 and 5 are dominated by Int 2. Int 6 is dominated by Int 5. Group B Int 2 vs. Int 1: \$ 25,122 (£ 15,877) Int 3 is dominated by Int 2. Int 4 vs. Int 2: \$ 3,140 (£ 1,984) Int 5 vs. Int 2: \$ 3,210 (£ 2,029) Int 5 vs. Int 1: \$ 6,110 (£ 3,861) Int 5 vs. Int 4: \$ 3,382 (£ 2,137)					

Study details	Patients	Interventions*	Outcome measures	Effect size	Comments
			Sensitivity analysis One-way sensitivity analysis	If switching between treatments was not permitted, TURP would cost \$30,204 (£ 19,090) more than AB for each QALY gained for moderate symptoms patients. The overall results did not change with the age of the patient. If effectiveness of TUMT is set equal to TURP, TUMT dominates TURP.	
			Probabilistic sensitivity analysis	For a willingness to pay equal to \$50,000 alpha-blockers have about a 70% probability of being cost-effective for patients with moderate symptoms. For the same willingness to pay, TURP had almost a 90% probability of being cost-effective for patients with severe symptoms.	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Fader 2008 ⁷⁵ UK Economic analysis: Cost-effectiveness	Patient group: moderate/heavily incontinent adults (urinary or urinary/faecal) living in the	Intervention 1: Insert Intervention 2: Diaper	Proportion of patients willing to buy a product used during the day if they had to bear the cost	Int 1: 39% Int 2: 50% Int 3: 43% Int 4: 39% Int 5: 38% p value: NR	Funding: commissioned by the Health Technology Assessment Programme. Some of the authors have received research grant money and travel grant money
analysis Study design RCT (cross-over)* Duration of	community All patients N: 85 IPSS: NR Age (mean): 52.8	Intervention 3: Pull-up	Proportion of patients willing to buy a product used during the night if they had to bear the cost	Int 1: 33% Int 2: 52% Int 3: 39% Int 4: 33% Int 5: 53% p value: NR	from SCA AB (absorbent pad manufacturing company) Limitations: The study included women and faecal incontinence as well. Not a
follow-up: One month Discount rates: Costs: NA Effects: NA	M/F: 49/36 Drop outs: 0	Intervention 4: T-shaped Intervention 5: Washables	Mean Visual Analogue Scale score** (day use – night use)	Int 1: 48 – 53 Int 2: 66 – 64 Int 3: 73 – 62 Int 4: 60 – 54 Int 5: 34 – 43 p value: NR	full economic evaluation. Effectiveness was not measured in terms of any of the clinical outcomes included in our Guideline.
			Mean monthly cost per patient (day – night) 2005 GBP, cost of supplying the product, assuming three products per day and one per night are used. Cost of laundering washable products is not included. Cost-effectiveness	Int 1: £44 - £23 Int 2: £47 - £15 Int 3: £79 - £25 Int 4: £75 - £25 Int 5: £9 - £6 p value: NR NA***	*crossover design in which each participant tested all products within their group in random order. Only trial 2a is included and reported. ** scale from 0 – 100 to assess patients' preference for a product.
			Sensitivity analysis	Different types of products within the same category have different costs and performance. The results are very sensitive to these variations.	*** Visual Analogue Scale score is not a clinical outcome of interest and an incremental cost- effectiveness analysis based on this outcome would not be useful.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments						
Fehrling2007 ⁷⁹ Sweden Economic analysis:	Patient group: patients with an overactive bladder with or without incontinence	Treatment: 10 session (twice weekly for 5 weeks) of Maximal Functional	Number of patients with: up to 8 voids per day > 8voids per day - NR	Before treatment: 11 – 44 – 5 After treatment: 11 – 30 – 19 p value: NR	Funding: Swedish Research Council, Sahlgrenska university Hospital, and the Martha						
Cost consequences analysis Study design Within group comparison Duration of follow-	All patients N: 60 IPSS: Age: the majority was 70 or older M/F: 31/29 Drop outs: 0	Electrical Stimulation (MFES) at the highest tolerable amplitude	Number of patients with the following degree of leakage: No leakage - Minor - Moderate - Severe- NR	Before treatment*: 17 – 11 – 16 – 13 – 4 After treatment: 21 – 12 – 10 – 11 – 6 p value: NR	and Gustaf Agrens research Foundation. Limitations: Within group study. The outcomes are not clear- cut. Only the cost of the intervention is considered.						
up: 3 months Discount rates:									Mean cost per patient 2007 Euro, cost of 10 sessions.	Before treatment: NR After treatment: €3,500 (£2,640***) p value:	Mixed male and female population.
Discount rates: Costs: NA Effects: NA			Cost-effectiveness	NR**	Notes: * the total sum is 61 while N=60 **Cost of treatment for each successfully treated patient is reported (€17,000) but success is not defined. *** calculated by using the 2008 PPP for Germany						
			Sensitivity analysis)	NR							

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Fraundorfer2001 ⁸⁶ New Zealand	Patient group: men with urodynamically proved outflow obstruction due to	Group 1 Holmium laser resection (HoLRP)	Qmax (mL/s) ± SD	Group 1: 25.2 ± 11.9 Group 2: 20.4 ± 8.5 p value: <0.05	Funding: partially funded by Coherent Medical
Economic analysis: Cost consequences	alysis: BPH, AUA score of 8 or greater, independent peak urinary flow rate (Qmax) of 15 mL/s or less, and bladder outflow obstruction confirmed by pressure flow urodynamic studies (Schafer grade 2 or more). Group 2 TURP all patients All patients		AUA score	Group 1: 4.2 ± 6.0 Group 2: 4.3 ± 4.1 p value: Not Sig	Group. Clinical study authors have financial interest
Study design RCT ^{* 93}			Mean cost per patient 2001 NZD cost of consumables, hospital	Group 1: 2,012 (£857**) Group 2: 2,663 (£1,134**) p value: NR	and/or other relationship with Lumenis, Inc.
up: 1 year Discount rates:		ients	facility use, operations, clinic visits, capital equipment, and unplanned events.		Limitations: Not a full economic evaluation. Partially applicable.
Costs: NA Effects: NA		Cost-effectiveness	NA	In real practice HoLEP might be less successful as it requires high level	
	Mean (±SD) Age: 66.9±6.5		Sensitivity analysis	NR	of skills and experience.
	<u>Group 2</u> N: 59 Mean (±SD) Age: 66.8±7.4				Additional outcomes: Group 1 had a shorter LOS and lower complication rate.
					Notes: * The two year follow- up study ²⁷² was reviewed for clinical effectiveness **calculated by using the 2008 PPP

Study details	Patients	Interventions	Outcome measures	Effect size	Comments	
Hillman 1996 ¹⁰⁴ USA	Patient group: men 55 years or older with a clinical diagnosis of BPH and at least moderate IPSS.	Group 1: Alpha-blockers (Terazosin). 1 mg daily	Mean change in IPSS \pm SE	Group 1: -7.6 ±0.2 Group 2: -3.7 ±0.2 p value: <0.001	Funding: Abbott Laboratories, Abbott Park, Illinois.	
Economic analysis: Cost	All patients N: 2084	for 3days followed by 2mg daily for the remainder of the first 4 weeks. The medication dose was titrated upward at the investigator's discretion until a satisfactory response was achieved (improvement of 35% or more of IPPS).	2mg daily for the	Mean change in IPSS – Quality of Life ± SE	Group 1: -3.6 ±0.1 Group 2: -1.8 ±0.1 p value: <0.001	Limitations: Partial applicability.
consequences and cost- effectiveness	IPSS: 20.1 Age (mean and range): 65.7 (46 – 94) Drop outs*: 867		Mean cost per patient 1992 USD, cost of visits (home, GP and urologist), inpatient care, medication.	Group 1: \$2,932 (£1,865**) Group 2: \$3,404 (£2,165**) p value: NR	Placebo was used instead of watchful waiting. Short follow up.	
Study design Multicentre RCT ²²⁴	<u>Group 1</u> N: 1053 (1010 in economic analysis) IPSS: 20.1 Age (mean): 65.7		Cost-effectiveness *** incremental cost per IPSS point change	Group 1 dominates Group 2	Notes: *Patients withdrawn because of adverse	
Duration of follow-up: 12 months Discount rates: Costs: NA Effects: NA	Drop outs*: 396 <u>Group 2</u> N: 1031 (983 in economic analysis) IPSS: 20.1 Age (mean): 65.7 Drop outs*: 471		Sensitivity analysis one-way SA	Overall results were not sensitive to outlier costs, costs assigned by patient-reported events, regional vs. satellite patients, costs of patients completing a full year of therapy, costs of improperly randomised patients.	events and lack of efficacy were respectively 168 and 93 in group 1, and 114 and 220 in group 2 (p<0.001). **Calculated by using the 2008 PPP *** calculated by NCGC	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Johansen 2007 ¹¹³ Norway Economic analysis: cost analysis Study design	Patient group: men with BPH	Intervention 1: Alpha-blockers (Tamsulosin) Intervention 2: 5-Alpha-reductase inhibitors (Dutasteride and	Mean cost per patient over 4 years 2006 NOK, cost of drugs, tests, visits to GP, pre-TURP visits to urologist, TURP, surgical follow- up, prostate cancer evaluation following TURP, post-TURP antibiotics, cost of AUR.	Int 1: 16,933 (£1,219**) Int 2***: 13,946 (£ 1,004**) Int 3: 46,109 (£ 3,320**) p value: NR	Funding: NR. One of the authors was an employee of GlaxoSmithKline. Limitations: Risk of AUR and TURP for Tamsulosin was assumed to be equal to the placebo arm of the trials.
decision analysis* Time horizon:		Finasteride)	Cost-effectiveness	NA	Notes:
4 years Discount rates: Costs: 5% Effects: NA		TURP	Sensitivity analysis One-way and multi-way SA	 The overall results were not sensitive to the following changes in one-way, two-way and multi-way SA: Time-horizon increased to lifetime. Decrease or increase costs of TURP and AUR by 10%. Inclusion of indirect costs. Probability of AUR decreased by 10% after TURP/any intervention. Probability of TURP after AUR reduced by 25%. Decrease symptoms improvement by 10%. Change in discount rate (0-8%). 	*improvement rates, risk of AUR and TURP were taken from Phase-III trials ¹ for Dutasteride, assumed to be equal for Finasteride. Risk of AUR and TURP of Tamsulosin was assumed to be equal to the placebo arm of those trials. Improvement rate of Tamsulosin was obtained from Phase-III trials and improvement rate of TURP was based on clinical opinion. ** Calculated by using the 2008 PPP ***cost of Dutasteride. Finasteride was more costly than Dutasteride but less costly than Tamsulosin.

¹ <u>http://www.gsk-clinicalstudyregister.com/files/pdf/883.pdf</u>, <u>http://www.gsk-clinicalstudyregister.com/files/pdf/895.pdf</u>, <u>http://www.gsk-clinicalstudyregister.com/files/pdf/895.pdf</u>, <u>http://www.gsk-clinicalstudyregister.com/files/pdf/8241.pdf</u>

Study details	Patients	Interventions*	Outcome measures	Effect size	Comments
Johnson 1999 ¹¹⁴ UK	Patient group: 60 years old patients with	Intervention 1: Watchful waiting. If ineffective it will be	Patients discontinuing treatment over 5 years	Int 1: 46.0% Int 2: 39.1% Int 3: 42.0%	Funding: Pfizer International
Economic analysis: cost- consequences analysis	uncomplicated moderate to severe benign prostatic hyperplasia	followed by second line (Doxazosin or Finasteride) and if necessary surgery.	Patients with improved symptoms**	p value: NR Int 1: 42% Int 2: 74% Int 3: 67% p value: NR	Limitations: It was not clear how the response-years gained were calculated.
Study design decision analysis Time horizon:		(Doxazosin). If ineffective or have side effects it will be	Improvement in symptom score from baseline**	Int 1: 32% Int 2: 48% Int 3: 31% p value: NR	Notes: * Surgery was excluded from the interventions compared as this was a
5 years Discount rates: Costs: 6%			Response-years gained	Int 1: 0.57 Int 2: 0.81 Int 3: 0.60 p value: NR	mix of TURP and open prostatectomy. ** Obtained from the meta-analysis described
Effects: 6%		Mean cost per patient over 5 years 1999 GBP; cost of GP and urologist consultations, laboratory procedures, examinations, medications, surgical procedures, complications.	Int 1: £791 Int 2: £1427 Int 3: £1720 p value: NR	by the American Agency for Health Care Policy and Research	
		followed by second line (Doxazosin or watchful	Cost-effectiveness	NR	-
		Sensitivity analysis One-way SA	Results not sensitive to cost of surgery, response rates, discontinuation rates, response degree, and time horizon		

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Keoghane2000 ¹²⁴ UK	Patient group: all patients presenting for TURP who had not undergone previous	Group 1 Vaporisation using MD60 Nd:YAG	Mean change in AUA 7 symptom score from baseline at 12 months (±SD)	Group1: 10.9 ± 8.4 (n=44) Group 2: 13.3 ± 7.8 (n=53) p value: not Sig (NCGC-ACC t-test)	Funding: Oxford Regional Health Authority
Economic analysis: cost-effectiveness analysis Study design RCT	surgery. <u>All patients</u> N: 152 (100 for cost analysis) Drop outs: NR	(Selected Laser Technologies) with 600 μm fibre incorporating sapphire-tipped probe. Irrigation using saline. Group 2 TURP in standard manner using Storz equipment and irrigation with glycine	Mean change in AUA 7 symptom score from baseline at 24 months (±SD) Mean change in AUA 7 symptom score from baseline at 36 months (±SD)	Group1: 11.7 ± 9.7 (n=35) Group 2: 13.7 ± 7.7 (n=47) p value: not Sig (NCGC-ACC t-test) Group1: 11.0 ± 9.7 (n=37) Group 2: 12.9 ± 7.9 (n=41) p value: not Sig (NCGC-ACC t-test)	Limitations: Surgeons had limited experience with the laser technique which may have caused the high failure rate with this treatment. Additional outcomes: Duration of catheterisation and complications favour Contact Laser. Reoperation rate was 18% in Group 1 and 9% in Group 2. Inpatient stay was 3.5 days in Group 1 and 3.9 days in
Duration of follow- up: 36 months (costs	Group 1 N: 47 for cost analysis AUA score (SD): 19.9 (7.7)		Change in flow rate (Qmax) from baseline at 3 years	Group 1: 1.8 ± 6.2 (n=24) Group 2: 2.1 ± 6.9 (n=24) p value: Not Sig (NCGC-ACC t-test)	
only 24 months) Discount rates: Costs: NR Effects: NR	only 24 months)Group 2 N: 53 for cost analysis AUA score (SD): 19.4 (6.5)manner using Storz equipment and irrigation with glycine		Mean cost per patient at 2 years 1997 GBP*, cost of operation, hospitalisation, outpatient visits, GP and nurse visits, re- operation, capital costs and overheads.	Group 1: £1,252 Group 2: £971 p value: Sig	
			Cost-effectiveness cost per change in AUA score	TURP is dominant	Group 2. Notes: * In the study prices were
			Sensitivity analysis One way	If inpatient stay in Group 1 is reduced to 1.5 days laser becomes less costly by £50.	up-rated using the NHS hospital and community price index.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Lourenco 2008 ¹⁵² UK	Patient group: Men at the age of 70 years with BPE,	Intervention 1: TUVP	QALYs*	Int 1: 0.3668 Int 2: 0.3625 Int 3: 0.3679	Funding: NHS R&D Health Technology Assessment
Economic analysis: Cost-utility analysis	presence of LUTS with a measure of IPSS>7, no	Intervention 2: TUMT		Int 4: 0.3673 Int 5: 0.3631 Int 6: 0.3684	Programme
Study design Decision analysis	complications and TURP indicated (medical treatment	Intervention 3: HoLEP		Int 7: 0.3684 Int 8: 0.3684 p value: NR	Cost of equipment was included only for some strategies.
Time horizon:either10 yearscontraindicatedfailed).	either contraindicated or failed). Mean start age	either Intervention 4: contraindicated or Failed). Mean start age Intervention 5: 70 years.	Mean cost per patient* 2006 GBP, cost of procedure, short-term complications (acute urinary retention, bladder neck contracture or urethral stricture, blood transfusion, transurethral syndrome, urinary tract infections), long-term complications (incontinence: 95% oxybutinin, 5% artificial sphincter), equipment for KTP, HoLEP and TUMT only.	Int 1: £152 Int 2: £155 Int 3: £160 Int 4: £174 Int 5: £223 Int 6: £166 Int 7: £167 Int 8: £167 p value: NR	Duration and cost of operations were equal in all the strategies. Training costs not included. Some interventions (TURP) are used to identify prostate cancer. Additional diagnostic
		Intervention /:	Cost-effectiveness incremental cost per QALY	Int 3 vs. Int 1: £7,273 Int 6 vs. Int 3: £12,000 Int 2 dominated by Int 1. Int 3 vs. Int 2: £833. Int 4 dominated by Int 3, 6, 7, 8. Int 5 dominated by any interventions. Int 7 and 8 dominated by Int 6**.	tests would be necessary of another strategy is adopted. Additional outcomes: Other sequences of treatments starting with TURP or TUMT were dominated.
			Sensitivity analysis Probabilistic sensitivity analysis	At the threshold of £20,000/QALY, Int 6 has a probability of being cost-effective of about 80%.	When compared to TURP alone, only TUVP, KTP and all the strategies involving a second operation starting with TUMT are
				One way sensitivity analysis	If LOS TURP is 2 days instead of 3 days, Int 8 is cost-effective. Results not sensitive to start age, utility of 'incontinence no remission'

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
				state = utility of 'incontinence remission' state, utility of IPSS<8 is 0.97 instead of 1, risk data from all studies instead of UK studies only, test for obstruction after TUVP.	information was £4,187,062 for TUVP epidemiology and £1,652,886 for HoLEP epidemiology. Notes: * results per patient of Monte Carlo simulation with 10,000 samples where 25,000 new individuals enter the model each year. ** Int 8 vs. 6 ICER=£90,576/QALY when results are calculated per population

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
McDonald 2004 ¹⁶⁷ Canada Economic analysis: Cost-utility analysis	Patient group: men 65 years old with moderate to severe symptoms of BPH and an enlarged prostate as determined	Intervention 1: Watchful waiting (WW)	QALYs gained	Int 1: 8.608 Int 2: 8.787 Int 3: 8.709 Int 4: 8.930 p value: NR	Funding: Merck Frosst Canada Ltd. Limitations:
Study design Decision analysis* Time horizon: 15 years Discount rates:	Study design Decision analysis*by digital rectal examination who choose not to undergo immediate surgical treatment.Intervention 2: Alpha-blockers (Doxazosin)Time horizon: 15 yearstreatment.Intervention 3: 5-alpha-reducatse inhibitors (Finasteride)Discount rates: Costs: 5%5%	Mean cost per patient** 2003 CAD, cost of drugs (including 10% pharmacy mark-up charge and dispensing fee), visits (one full and one partial per year plus two partial for Group 1), hospitalisation, surgery, surgical complications, tests. Cost-effectiveness **	Int 1: \$2,254 (£ 1,181) Int 2: \$4,615 (£ 2,418) Int 3: \$6,167 (£ 3,231) Int 4: \$9,477 (£ 4,966) p value: NR Int 2 vs. Int 1***: \$13,190 (£ 6,912)	Partially applicable. Additional outcomes: Incremental cost per AUR averted and incremental cost per	
Costs: 5% Effects: 5%		Intervention 4:	Intervention 4:	incremental cost per QALY gained	Int 3 dominated by Int 2. Int 4 vs. Int 2: \$34,000 (£ 17,816)
		Combination therapy with Doxazosin and Finasteride.	Sensitivity analysis One way SA.	Considering only patients with PSA>1.3 ng/ml or PSA >3.2 ng/ml the results were similar. Results were not sensitive to discounting, probability of TURP following AUR, cost of TURP, cost of AUR. Combination is no longer cost-effective when AUR rates are obtained from MTOPS instead of PLESS, treatment effect is decreased by 50%, or QALY weights from Baladi1996 ¹⁸ are used. Finasteride is more cost-effective than Doxazosin if it improves IPSS past year 4 by 2 points.	* based mainly on the PLESS ²²⁰ and MTOPS studies ¹⁶⁶ ** GBP calculated by using the 2008 PPP *** calculated by NCGC

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Medicare Services Advisory Committee ¹⁷³ Australia	Patient group: Patients with symptomatic benign prostatic	Intervention 1: TUNA	QALY	Int 1: 12.2869 Int 2: 12.3082 p value: NR	Funding: Report prepared from the National Health and
Economic analysis: cost-utility analysis Study design Decision analysis	hyperplasia.	Intervention 2: TURP	Mean cost per patient 1999 AUD, cost of procedures, cost of side effects, cost of treatment failure (GP visits, surgery, hospitalisation, medical treatment).	Int 1: \$8,296 (£4,165*) Int 2: \$6,910 (£3,469*) p value: NR	Medical Research Council Clinical Trials Centre, University of Sydney for the Medical Services Advisory Committee.
Time horizon: 20 years			Cost-effectiveness cost per QALY gained	TURP dominates TUNA	Limitations: Utilities were obtained from expert opinion and
Discount rates: Costs: 5% Effects: 5%			Sensitivity analysis One-way SA	TUNA is cost-effective when either: probability that TURP fails within 6 months ≥20%; time horizon = 5 years;	from expert opinion and not elicited with recognised methods. Notes:
				annual failure rate of TUNA ≤ 2.4%; probability of having TURP after TUNA fails =100%	* Calculated by using the 2008 PPP

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Murray2001 ¹⁸² UK Economic analysis: cost consequences analysis	Patient group: Men with benign prostatic hypertrophy in 33 general practices in the UK. <u>All patients</u> N: 112 Drop outs: 10	Group 1: Interactive multimedia programme with booklet and printed summary. Treatment options discussed were surgery, balloon dilatation of the prostate, drugs, and watchful waiting. Information comprised probabilities of the risks and benefits of each treatment		Group 1: 2.23 (0.38) Group 2: 2.55 (0.50) p value: sig Group 1: -1 Group 2: -2 p value: 0.8	Funding: NHS national research and development programme, the BUPA Foundation, and the King's Fund. Limitations: Results on EQ-5D scores were not reported. The intervention might be different to the clinical practice with a consequent
Study design RCT Duration of follow-up: 9 months Discount rates: Costs: NA Effects: NA	Group 1 N: 57 Age (mean +/- SD): 63.7 +/- 8.4 Drop outs: 3 Mean (SD) American Urological Association score: 15.64 (6.57)	probabilities of the risks and benefits of each treatment, calculated on the basis of information on age, severity of symptoms, and general health entered by the patient at the beginning of the session. All patients saw the core interactive video disc, lasting about 45 minutes; viewing optional sections for further information took up to 60 min. more. A research nurse	Mean cost per patient 1999 GBP, Cost of equipment and staff time, consultations with GPs, referrals to urologists, other referrals, drugs, tests, diagnostic and surgical procedures.	Group 1: 594 Group 2: 188 p value: <0.001	overestimation of costs. Additional outcomes: No difference in health utility scores (EQ-5D) and anxiety scores (data not provided). Mean decisional conflict score at 3 months (- 0.3). GPs and patients' perception of decision making at 3months was significantly
	Group 2 N: 55* Age (mean +/- SD): 63.9 +/- 8.4		Cost-effectiveness	NR	different between the two groups with higher proportion of GPs and patients perceiving that the treatment decision had been mainly or only by the patients in
Drop outs: 7 Mean (SD) American		Sensitivity analysis	NR	Group 1. Notes: *Only 48 included in the economic analysis	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Nathan 1996 ¹⁸⁵ UK	Patient group: men requiring TURP	Group 1: Transurethral electrovaporisation of	Mean IPSS score at 3 months (follow up interval not clear)	Group 1: 2.86 ± 2.8 Group 2: 3.1 ± 2.3 p value: NR	Funding: NR
Economic analysis: cost consequence	Drop outs: 0	the prostate (TVP)	Mean IPSS QoL score at 3 months (follow up interval not clear)	Group 1: 0.5 ± 7 Group 2: 0.9 ± 0.9 p value: NR	Limitations: Cost components included in the analysis
Study design (e.g. RCT, Decision analysis, etc)	<u>Group 1</u> N: 20 Mean age (range): 65.4 (57-77) Mean IPSS score: 21.9 ± 4.2	TURP	Mean Qmax ± SD mL/s at 3 months (follow up interval not clear)	Group 1: 21.3 ± 5.9 Group 2: 20.6 ± 2.6 p value: NR	were only those that significantly differed between interventions.
Duration of follow- up: 3 months	Mean IPSS QoL ± SD: 4.9 ± 0.7 Mean Qmax ml/s (± SD): 10.2 ± 4.4 Drop outs: 0		Mean cost per patient 1996 GBP, cost of fibres and consumables, transfusions, and hospital stay.	Group 1: £1,730 Group 2: £2,373 p value: NR	Additional outcomes: There were more complications in the TURP group.
Discount rates: Group 2: Costs: Broup 2: Effects: N: 30 Mean age (range): 69.2 Mean IPSS score: 17.0 ± Mean IPSS QoL ± SD: 4.	N: 30		Cost-effectiveness	NR	There was no statistically significant or appreciable difference
	Mean IPSS score: 17.0 ± 4.3 Mean IPSS QoL ± SD: 4.9 ± 0.7 Mean Qmax ml/s (± SD): 7.2 ± 3.5		Sensitivity analysis	NR	in the success rates among the two groups.

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Noble 2002 ¹⁹¹ UK Economic	Patient group: men with uncomplicated lower urinary tract symptoms (no acute or chronic urinary retention)	Laser therapy with a noncontact side firing neodymium:YAG probe Group 2: Standard transurethral prostate resection Group 3: conservative management	Mean difference in IPSS from baseline	Group 1: -10.8 Group 2: -12.3 Group 3: -1.3 p value: NR	Funding: Bard UK provided the laser fibres. South West and
analysis: Cost- consequences analysis	<u>All patients</u> N: 340 Drop outs:		Mean difference in IPSS quality of life from baseline	Group 1: -1.9 Group 2: -2.2 Group 3: -1.3 p value: NR	Northern Regional National Health Service Research and Development
Study design RCT ⁶⁵ Duration of	<u>Group 1</u> N: 117 Dropouts:1/117 Age, mean (±SD): 67.4±8.1		Mean change in QALY from baseline	Group 1: 0.044 Group 2: 0.016 Group 3: - 0.001 p value: NR	Directorates. Limitations: Resource use data were available only for 30%
follow-up: 7.5 months	IPSS, mean (±SD): 19.1±6.6 IPSS-QoL , median(range): 4(2-6)		Mean cost per patient 1998 GBP, cost of resources used in investigations, staff time, equipment,	Group 1: £1,223 of f Group 2: £928 pop Group 3: £45 The	of the patients population. The conclusions of the
Discount rates: Costs: NA Effects: NA	Group 2 N: 117 Dropouts:2/117 Age, mean (±SD): 66.4±7.9 IPSS, mean (±SD): 19.2±6.7 IPSS-QoL, median(range): 4(0-6)		medication, hospital stay, rehospitalisation for catheter-free trial, other rehospitalisation, outpatient visits, GP and nursing visits, consumables (catheter bags, pads and other aids)	p value: NR	study were incorrect. Additional outcomes: Patient costs were higher for noncontact laser.
<u>Group 3</u> N: 106 Dropouts: 5/106 Age, mean (±SD): 67.2±7.8 IPSS, mean (±SD): 18.8±6.5 IPSS-QoL, median(range): 4(1-6)		Cost-effectiveness* cost per QALY gained	Group 1 vs. Group 2: £10,536 Group 1 vs. Group 3: £26,178	Notes: * calculated by NCGC using mean cost and	
	SS , mean (±SD): 18.8±6.5		Sensitivity analysis one-way	Cost of probes, their multiple use, and machinery lifetime were varied with no considerable difference in results.	mean change in health- related quality of life utility

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Norby2002 ¹⁹² Denmark	Patient group: Men ≥ 50 years between May 1996 and November 1999.	Group 1: Interstitial laser coagulation (ILC).	Mean difference in IPSS at 6 months from baseline (±SD)	Group 1: 12.0 ±7.5 Group 2: 11.2 ±9.2 p value: Not sig	Funding: Vejle County, Denmark.
Economic analysis: CEA Study design RCT ¹⁹³ Duration of follow-	<u>All patients*</u> N: 113 <u>Group 1</u> N: 45	Group 2: Transurethral microwave thermotherapy (TUMT).	Mean cost per patient** 1999 DKK, cost of hospitalisation, medications, examinations, follow-up visits, GP visits, nurse visits, and re-operations.	Group 1: 14,398 (£1,152***) Group 2: 10,508 (£841***) p value: NR	Limitations: Small sample size for economic analysis. Short follow-up. Limited applicability. Notes:
up: 6 months Discount rates:	N: 45 IPSS (±SD): 21.4 ±5.8 <u>Group 2</u> N: 46		Cost-effectiveness**** cost per 1-point of reduction in IPSS	Group 1 vs. Group 2: DKK 4,862 (£ 388***) per point	* 22 patients were randomised to a mix of TUIP and TURP and therefore excluded. In the results this group dominates Group 1.
Costs: NA Effects: NA	IPSS (±SD): 20.5 ±5.7		Sensitivity analysis One way	If TUMT catheters were reused once, Group 1 vs. Group 2 ICER = DKK 7,981 (£ 638***) If ITT analysis is applied, Group 1 vs. Group 2 ICER = DKK 4,161 (£ 332***)	**ITT analysis was used for clinical outcomes but not for costs **Data collected in 20 patients only. *** Calculated by using the 2008 PPP ****Incremental analysis done by NCGC

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Salonia 2006 ²²⁸ Italy	Patient group: consecutive patients with symptomatic benign prostatic hyperplasia	Group 1: Open prostatectomy	Operative time (minutes)	Group 1: 57.5 Group 2: 73.4 p value: 0.002	Funding: Scientific Institute San Raffaele Hospital, Milan
Economic analysis: cost analysis	in a large prostate (70 to 220 g) and documented bladder outlet obstruction.	Group 2: HoLEP	Catheterisation time (hours)	Group 1: 106.3 Group 2: 35.3 p value: 0.0001	Limitations: Partial applicability.
Study design RCT	<u>All patients</u> N: 63		Hospital stay (hours)	Group 1: 131.0 Group 2: 64.6 p value: <0.0001	Additional outcomes: The amount of unplanned events was
Discount rates: Costs: NR Effects: NR	ration of follow- : Group 1 N: 29 IPSS: 21.6 scount rates: Age (mean): 68.0 brop outs:		Mean cost per patient 2004 Euro, costs associated with the procedures (operating room time, disposables, blood transfusion) and hospital stay. Medical salaries were not included. Capital cost for HoLEP was 85% of actual capital cost. Holmium fibres were used at least 10 times.	Group 1: 2,869 (£2,079*) Group 2: 2,356 (£1,708*) p value: NR	not significantly different. Notes: *calculated byvusing th 2008 PPP
	Drop outs:		Cost-effectiveness	NR	
			Sensitivity analysis	NR	

Study details	Patients	Interventions	Outcome measures	Effect size	Comments
Stovsky 2006 ²⁴⁷ USA Economic analysis: Cost consequences analysis Study design Decision analysis Time horizon: 2 years Discount rates: Costs: NR Effects: NR	Patient group: patients with lower urinary tract symptoms indicative of BOH requiring procedural management with of the interventions indicated.	Intervention 1: Photoselective vaporisation Intervention 2: TURP Intervention 3: TUNA Intervention 4: TUMT Targis Intervention 5: TUMT Prostatron 2.5	% change from baseline IPSS at 2 years % change from baseline Quality of Life score at 2 years % Qmax at 2 years from baseline % Qmax at 2 years from baseline Mean cost per patient* 2005 USD**, cost of intervention, follow-up care, adverse events***, re-treatment. Cost of pharmacological therapy not	Int 2: 66 Int 3: 44 Int 4: 46 Int 5: 39 p value: NR Int 1: 83 Int 2: 73 Int 3: 61 Int 4: 52 Int 5: 24 p value: NR	Funding: All the authors had financial interest and/or relationship with Laserscope Limitations: Discount rate NR. Partially applicable: cost of inpatient stay in the USA is higher than in the UK, which favours laser. Additional outcomes: Qmax and QoL were also reported. The cost-effectiveness results did not change if those outcomes were used. Notes: * based on the assumption that PVP was performed in a hospital outpatient setting, TUNA and TUMT at a physician office site of service, TURP in a hospital inpatient setting, ILC at a physician office site of service (86%), ambulatory surgery
			included. Cost-effectiveness**** cost per 1-point of %reduction in IPSS	p value: NR Intervention 2 dominates Interventions 3, 4 and 5. Intervention 1 dominates all the other interventions, including 2.	centre (9%) and hospital outpatient setting (5%) ** converted into GBP by using the 2008 PPP ***incontinence, UTI, impotence, dysuria/irritative voiding, bladder
			Sensitivity analysis One way Threshold SA	If ILC performed in a less costly setting, it is still dominated by PVP. When retreatment rate of PVP = 17%, PVP and TURP are cost equivalent.	neck stenoisis/stricture, urinary retention, hematuria **** calculated by NCGC-ACC

Appendix E – Forest Plots

2		
3	.1 FREE UROFLOWMETRY (PEAK URINARY FLOW)	535
4 5	Figure E-1: Sensitivity and specificity of free uroflowmetry (Qmax) in the diagnosis of bladder outle obstruction	
6 7	Figure E-2: Summary receiver operating characteristic (SROC) curve for uroflowmetry Qmax in the diagnosis of bladder outlet obstructions.	2
8	.1 PELVIC FLOOR MUSCLE TRAINING (PFMT)	
9 10	2.1.1 PFMT vs. Control Figure E-3: PFMT vs. Control: Number of post-prostatectomy men who were incontinent	
11	Figure E-5: FFM1 vs. Control: Number of post-prostatectomy men who were incontinent Figure E-4: PFMT vs. Control: Mean urine lost (g) per 24 hours (pad test) in post-prostatectomy me	
12	Figure E-4. FFMT vs. Control: Mean urme lost (g) per 24 hours (pad lest) in post-prostatectomy ma Figure E-5: PFMT vs. Control: Number of post-TURP men who were incontinent	
13	2 BIOFEEDBACK	
14		
15	2.2.1 BIOFEEDBACK + PFMT vs. CONTROL Figure E-6: PFMT + Biofeedback vs. no intervention: Number of men who were incontinent at follo	
16	Figure E-0. I FMI + Diojeeubuck vs. no intervention. Number of men who were incontinent at joino	
17	.3 ELECTRICAL STIMULATION (ES)	540
18	2.3.1 ES + PFMT vs. Control	540
19	<i>ES</i> + FFMT VS. CONTROL <i>Figure E-7: ES</i> + <i>PFMT vs. no intervention: Number of men who were incontinent at follow up</i>	
20	.1 ALPHA-BLOCKERS	
21		
21 22	3.1.1 ALPHA-BLOCKERS VS. PLACEBO	
23	Figure E-8: Alpha-blockers vs. Placebo: Symptom score (random effects analysis) Figure E-10: Alpha-blockers vs. Placebo: Qmax (ml/s) (random effects analysis)	
23 24	Figure E-10: Alpha-blockers vs. Flacebo: Qmax (m/s) (random effects analysis) Figure E-10: Alpha-blockers vs. Placebo: Quality of life – IPSS question (random effects analysis)	
25	Figure E-10: Alpha-blockers vs. Flacebo: Quanty of tige – It 55 question (random effects analysis) Figure E-11: Alpha-blockers vs. Placebo: Adverse events (cardiovascular and neurological) - asther	
26	(fatigue) and headache	
27	Figure E-12: Alpha-blockers vs. Placebo: Adverse events (cardiovascular and neurological) - postu	
28	hypotension and rhinitis	
29	Figure E-13: Alpha-blockers vs. Placebo: Adverse events - erectile dysfunction /impotence	
30	Figure E-14: Alpha-blockers vs. Placebo: Adverse events - dizziness and retrograde ejaculation (rat	ndom
31	effects analysis)	545
32	Figure E-15: Alpha-blockers vs. Placebo: Withdrawal from study due to adverse events	
33	3.1.2 ALPHA-BLOCKERS VS. 5-ALPHA REDUCTASE INHIBITORS (5-ARI)	
34	Figure E-16: Alpha-blockers vs. 5-ARI: Symptom score	
35	Figure E-17: Alpha-blockers vs. 5-ARI: Quality of life (IPSS-question)	
36	Figure E-18: Alpha-blockers vs. 5-ARI: Qmax (ml/s)	
37	Figure E-19: Alpha-blockers vs. 5-ARI: Prostate volume (ml)	
38	Figure E-20 Alpha-blockers vs. 5-ARI: PSA (ng/ml)	
39 40	Figure E-21: Alpha-blockers vs. 5-ARI: Adverse events (cardiovascular or neurological)	
40 41	Figure E-22: Alpha-blockers vs. 5-ARI: Adverse events (sexual or urological) Figure E-23: Alpha-blockers vs. 5-ARI: Adverse events - postural hypotension and ejaculatory	331
42	abnormality (random effects analysis)	552
43	Figure E-24: Alpha-blockers vs. 5-ARI: Ejaculatory abnormality – subgroup analysis of tamsulosin	
44	other alpha-blockers	
45	Figure E-25: Alpha-blockers vs. 5-ARI: Withdrawal from study due to adverse events (random effec	
46	analysis)	
47	3.1.3 Alpha-blockers vs. Anticholinergics	553
48	3.1.4 ALPHA-BLOCKERS VS. PHOSPHODIESTERASE 5-INHIBITORS (PDE5-I)	553

1	3.2	5-ALPHA REDUCTASE INHIBITORS (5-ARI)	. 554
2	3.2.1	5-ARI VS. PLACEBO	554
3		igure E-26: 5-ARI vs. Placebo: Symptom score at 3 months, 6 months 2 years and 4 years or longer	
4		random effects analysis)	
5 6		igure E-27: 5-ARI vs. Placebo: Symptom score at 2 years- subgroup analysis	
6		igure E-28: 5-ARI vs. Placebo: Symptom score at 12 months and 3 years	. 555
7		igure E-29: 5-ARI vs. Placebo: Qmax (ml/s) at 3 months, 6 months, 2 years, 3 years and 4 years or	
8		onger	
9 10		igure E-30: 5-ARI vs. Placebo: Qmax (ml/s) at 12 months (random effects analysis)	
11		igure E-31: 5-ARI vs. Placebo: Prostate volume(ml) at 1 year follow up igure E-32: 5-ARI vs. Placebo: Prostate volume (ml) at 2 years follow up (random effects analysis).	
12		igure E-32: 5-ARI vs. Flacebo: Frostale volume (ml) al 2 years jollow up (random ejjecis analysis). igure E-33: 5-ARI vs. Placebo: PSA (ng/ml) level at 2 year follow up	
13		igure E-33: 5-ARI vs. Placebo: Adverse events (cardiovascular and neurological)	
14		igure E-35: 5-ARI vs. Placebo: Adverse events (exual and urological)	
15		igure E-36: 5-ARI vs. Placebo: Withdrawal from study due to adverse events	
16	3.2.2		
17	3.3		. 560
18	3.3.1		
19		i ANTICHOLINERGICS VS. PLACEBO igure E-37: Anticholinergics vs. Placebo: Adverse events	
20		igure E-37: Anticholinergics vs. Placebo: Withdrawal from study due to adverse events	
21	3.3.2		
22		igure E-39: Anticholinergics vs. Alpha-blockers: Adverse events	
23	3.4	PHOSPHODIESTERASE-5-INHIBITORS (PDE5-I)	
24 25	3.4.1		
26		igure E-40: PDE5-I vs. Placebo: Symptom score igure E-41: PDE5-I vs. Placebo: Quality of life (IPSS question)	
27		igure E-42: PDE5-I vs. Placebo: Quality of tije (II 55 question)	
28		igure E-43: PDE5-I vs. Placebo: Qmax(m/s)	
29	3.4.2		
30	F	igure E-44: PDE5-I vs. Alpha-blockers: Symptom score	
31		igure E-45: PDE5-I vs. Alpha-blockers: Qmax (ml/s)	
32		igure E-46: PDE5-I vs. Alpha-blockers: Voiding frequency	
33		igure E-47: PDE5-I vs. Alpha-blockers: Nocturia	
34	F	igure E-48: PDE5-I vs. Alpha-blockers: Adverse events	565
35	3.5	DIURETICS	. 565
36	3.5.1	DIURETICS VS. PLACEBO	565
37	3.6	Desmopressin	. 565
38	3.6.1	DESMOPRESSIN VS. PLACEBO	565
39		igure E-49: Desmopressin vs. Placebo: Adverse events	
40		NSAIDS	
	3.7		
41	3.7.1		
42 43		igure E-50: NSAIDs vs. Placebo: Symptom score at 1 month	
43 44		igure E-51: NSAIDs vs. Placebo: Qmax (ml/s) at 1 month igure E-52: NSAIDs vs. Placebo: Nocturia frequency at 1month	
45		igure E-52: NSAIDs vs. Placebo: Nociaria frequency at Imonin	
46			
	3.8	COMBINATION THERAPY: ALPHA-BLOCKERS PLUS 5-ALPHA REDUCTASE INHIBITORS(5-ARI)	
47	3.8.1		
48		<i>"igure E-54: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: Symptom score</i>	
49 50		<i>Gigure E-55: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: Qmax (ml/s)</i>	
50		igure E-56: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: Prostate volume(ml) igure E-57: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: PSA (ng/ml)	
01	1	is an e Bor. Combination (hipha bioexers + 5 hid) vs. hipha-bioexers. 101 (hg/hd)	

1 2	Figure E-58: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: Adverse events (cardiovascular or neurological)
3 4	Continued Figure E-58: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: Adverse events (cardiovascular or neurological
5 6	Figure E-59: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: Adverse events (sexual or urological)
0 7	<i>Urological)</i> <i>Figure E-60: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: Withdrawal from study due to</i>
8	adverse events
9	3.8.2 COMBINATION (ALPHA-BLOCKERS + 5-ARI) VS. 5-ARI
10	Figure E-61: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Symptom score
11	Figure E-62: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Qmax(ml/s)
12	Figure E-63: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Prostate volume (ml)
13	Figure E-64: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: PSA (ng/ml)
14	Figure E-65: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Adverse events (Cardiovascular or
15	neurological)
16 17	Continued Figure E-65: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Adverse events (cardiovascular or neurological)
18	Figure E-66: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Adverse events (sexual or urological). 577
19 20	Figure E-67: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Ejaculatory abnormality (random effects analysis)
21	Figure E-68: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Ejaculatory abnormality subgroup
22	analysis
23	Figure E-69: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Withdrawal from study due to adverse
24	events (random effects analysis)
25	3.8.3 COMBINATION (ALPHA-BLOCKERS + 5-ARI) VS. PLACEBO
26	Figure E-70: Combination (Alpha-blockers + 5-ARI) vs. Placebo: Symptom score
27	Figure E-71: Combination (Alpha-blockers + 5-ARI) vs. Placebo: Qmax (ml/s)
28	Figure E-72: Combination (Alpha-blockers + 5-ARI) vs. Placebo: Prostate volume (ml)
29	Figure E-73: Combination (Alpha-blockers + 5-ARI) vs. Placebo: Change in PSA (ng/ml)
30	Figure E-74: Combination (Alpha-blockers + 5-ARI) vs. Placebo: Adverse events (cardiovascular and
31	neurological)
32	Figure E-75: Combination (Alpha-blockers + 5-ARI) vs. Placebo: Adverse events – postural hypotension
33 34	(random effects analysis)
35	
36 37	Figure E-77: Combination (Alpha-blockers + 5-ARI) vs. Placebo: Withdrawal from study due to adverse events (random effects analysis)
38	3.9 COMBINATION THERAPY : ANTI-CHOLINERGIC PLUS ALPHA-BLOCKERS
39	3.9.1 COMBINATION (ANTI-CHOLINERGIC + ALPHA-BLOCKERS) VS. ALPHA-BLOCKERS
40	Figure E-78: Combination (Anti-cholinergic + Alpha-blockers) vs. Alpha-blockers: Adverse events 583
41	3.9.2 ANTI-CHOLINERGIC ADDED ON TO ALPHA-BLOCKERS VS. ALPHA-BLOCKERS
42	Figure E-79: Anti-Ch added on to Alpha-blockers vs. Alpha-blockers: Symptom score at 3 months 583
43	Figure E-80: Anti-Ch added on to Alpha-blockers vs. Alpha-blockers: Quality of life (IPSS question) at 3
44	\sim months
45	Figure E-81: Anti-Ch added on to Alpha-blockers vs. Alpha-blockers: Qmax (ml/s) at 3 months
46	Figure E-82: Anti-Ch added on to Alpha-blockers vs. Alpha-blockers: Adverse events (3-months follow
47	<i>up</i>)
48	3.9.3 COMBINATION (ANTI-CHOLINERGIC + ALPHA-BLOCKERS) VS. ANTICHOLINERGICS
49	Figure E-83: Combination (Anti-cholinergic + Alpha-blockers) vs. Anticholinergics: Adverse events 585
50	3.9.4 COMBINATION (ANTI-CHOLINERGIC + ALPHA-BLOCKERS) VS. PLACEBO
51 52	Figure E-84: Combination (Anti-cholinergic + Alpha-blockers) vs. Placebo: adverse events
52	3.10 COMBINATION (PDE5-I + ALPHA-BLOCKERS)
53	3.10.1 COMBINATION (PDE5-I + ALPHA-BLOCKERS) VS. ALPHA-BLOCKERS
54	Figure E-85: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Symptom score
55 56	Figure E-86: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Quality of life (IPSS question)
56	

1 2	Figure E-87: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Qmax(ml/s) Figure E-88: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Frequency at 3-month	
3	Figure E-89: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Nocturia at 3 months	
4	Figure E-90: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Adverse events	588
5	Continued Figure E-90: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Adverse event	
6	Figure E-91: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Adverse events resulting	
7	withdrawal at 3-month	
8	3.10.2 COMBINATION (PDE5-I + ALPHA-BLOCKERS) VS. PDE5-I	. 590
9 10	Figure E-92: Combination (PDE5-I + Alpha-blockers) vs. PDE5-I: symptom score (random effects	500
11	analysis) Figure E-93: Combination (PDE5-I + Alpha-blockers) vs. PDE5-I: Quality of life (IPSS-QoL) up to 3	
12	month	. 590
13	Figure E-94: Combination (PDE5-I + Alpha-blockers) vs. PDE5-I: Qmax (ml/s) at 3-month	
14	Figure E-95: Combination (PDE5-I + Alpha-blockers) vs. PDE5-I: Frequency at 3-month	
15	Figure E-96: Combination (PDE5-I + Alpha-blockers) vs. PDE5-I: Nocturia at 3-month	
16 17	Figure E-97: Combination (PDE5-I + Alpha-blockers) vs. PDE5-I: Adverse events (only those resulti withdrawals reported)	~
18	Figure E-98: Combination (PDE5-I + Alpha-blockers) vs. PDE5-I: Withdrawal from study due to adv	
19	events	
20	4.1 HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP	592
21	4.1.1 HOLEP VS. TRANSURETHRAL RESECTION OF THE PROSTATE (TURP)	592
22	Figure E-99: HoLEP vs. TURP: Symptom score at 3 months, 36 months and 48 months	
23	Figure E-100: HoLEP vs. TURP: Symptom score at 6, 12 and 24 months (random effects analysis)	
24	Figure E-101: HoLEP vs. TURP: Quality of life (IPSS question) – 3, 24 and 48 months	
25	Figure E-102: HoLEP vs. TURP: Quality of life (IPSS question) – 6 to 12 months (random effects	
26	analysis)	
27	Figure E-103: HoLEP vs. TURP: Qmax(ml/s) at 3 months and longest available follow up	
28	Figure E-104: HoLEP vs. TURP: All cause mortality and complications	
29	Continued Figure E-104: HoLEP vs. TURP: All cause mortality and complications	
30 31	4.1.2 THULIUM LASER RESECTION VS. TURP.	
32	Figure E-105: Thulium laser resection vs. TURP: Symptom score – 6 months postoperatively Figure E-106: Thulium laser resection vs. TURP: Symptom score – 12 months postoperatively	
33	Figure E-100. Thulium laser resection vs. TURP: Qmax(ml/s) – 12 months postoperatively	
34	Figure E-109: Thallum laser resection vs. TURP: Quality of life (IPSS question) – 6 and 12 months	
35	Figure E-109: Thulium laser resection vs. TURP: Complications	598
36	4.1.3 HOLEP vs. TRANSURETHRAL INCISION OF THE PROSTATE (TUIP)	
37	Figure E-110: HoLEP vs. TUIP: Symptom score	
38	Figure E-111: HoLEP vs. TUIP: quality of life (IPSS question)	599
39	Figure E-112: HoLEP vs. TUIP: Qmax(ml/s)	
40	Figure E-113: HoLEP vs. TUIP: All cause mortality and complications	
41	4.1.4 HOLEP VS. OPEN PROSTATECTOMY (OP)	
42	Figure E-114: 1 HoLEP vs. OP: Symptom score	
43 44	Figure E-115: 1 HoLEP vs. OP: quality of life (IPSS question	
44 45	Figure E-116: 1 HoLEP vs. OP: Qmax(ml/s) at 3 months (random effects analysis) and longest avail follow up (fixed effects analysis)	
46	Figure E-117: 1 HoLEP vs. OP: All cause mortality and complications	
47	4.2 LASER TREATMENTS	
48	4.2.1 LASER COAGULATION VS. TURP	. 604
49 50	Figure E-118: 1 Laser Coagulation vs. TURP: Symptom score at 3 and 6 months (random effects	(0.1
50 51	analysis), 12 months and 24 months (change and endpoints)	
51 52	Figure E-119: Laser Coagulation vs. TURP: Quality of life (IPSS question), change and endpoints Figure E-120: Laser Coagulation vs. TURP: Omax (m/s)	
52 53	Figure E-120: Laser Coagulation vs. TURP: Qmax (ml/s) Figure 121: Laser Coagulation vs. TURP: All cause mortality and complications	
53 54	Continued Figure 121 Laser Coagulation vs. TURP: All cause mortality and complications	
55	Figure E-122: Laser Coagulation vs. TURP: Complications – retrograde ejaculation (random effects	007
56	analysis)	608

1	4.2.2 LASER COAGULATION VS. TURP IN AUR PATIENTS	. 608
2	Figure E-123: Laser coagulation vs. TURP in AUR patients: Symptom score change	
3	Figure E-124: Laser coagulation vs. TURP in AUR patients: Quality of life (IPSS question), change	
4	Figure E-125: Laser coagulation vs. TURP in AUR patients: \tilde{C} complications	
5	4.2.3 LASER VAPOURISATION VS. TURP	.610
5 6	Figure E-126: Laser vapourisation vs. TURP: Symptom score at 3 months, 6 months and 1 year (rand	
7	effects analysis)	
8	Figure E-127: Laser vapourisation vs. TURP: Symptom score	
9	Figure E-128: Laser vapourisation vs. TURP: quality of life (IPSS question)	.611
10	Figure E-129: Laser vapourisation vs. TURP: Qmax(ml/s) – 3 months(fixed effect analysis) and longe	
11	available follow up(random effects analysis)	.611
12	Figure E-130: Laser vapourisation vs. TURP: All cause mortality and complications	. 612
13	Continued Figure E-130: Laser Vapourisation vs. TURP : Complications	. 613
14	Figure E-131: Laser vapourisation vs. TURP: Complications – retrograde ejaculation (random effect	5
15	analysis)	
16	4.2.4 LASER (PHOTOSELECTIVE VAPOURISATION) VS. OPEN PROSTATECTOMY(OP)	.614
17	Figure E-132: Laser (photoselective vapourisation) vs. OP: Complications	. 614
18	4.2.5 LASER COAGULATION VS. TUMT (TRANSURETHRAL MICROWAVE THERMOTHERAPY)	
19	Figure E-133: Laser coagulation vs. TUMT –Symptom score at 6 months	. 614
20	Figure E-134: Laser coagulation vs. TUMT – Qmax(ml/s) at 6 months	. 614
21	Figure E-135: Laser coagulation vs. TUMT: Complications	
22	4.2.6 LASER VS. TUVP (TRANSURETHRAL VAPOURISATION OF THE PROSTATE)	.616
23	Figure E-136: Laser vs. TUVP: Symptom score (random effects analysis)	. 616
24	Figure E-137: Laser vs. TUVP – Quality of life (IPSS question)	
25	Figure E-138: Laser vs. TUVP – Qmax(ml/s) at 6 month, 12 month(fixed effect analysis) and longest	
26	available follow up (random effects analysis)	. 618
27	Figure E-139: Laser vs. TUVP – All cause mortality and complications	
28	4.2.7 LASER VS. LASER	
29	Figure E-140: Laser vapourisation vs. laser coagulation: Symptom score at 3 months (random effects analysis)	
30		
31	Figure E-140b: Laser vapourisation vs. laser coagulation: Symptom score at 6, 12 and 24 months (fix	ed
32	effect analysis)	
33	Figure E-141: Laser vapourisation vs. laser coagulation: Qmax (ml/s) at 3 months and longest available	
34	follow up	
35	Figure E-142: Laser vapourisation vs. laser coagulation: Complications	
36	Figure E-143: HoLRP vs. Laser coagulation: Complications	
37	Figure E-144: HoLAP vs. Laser vapourisation: Symptom score	
38	Figure E-145: HoLAP vs. Laser vapourisation: quality of life (IPSS question)	. 623
39	Figure E-146: HoLAP vs. laser vapourisation: Qmax(ml/s) at 3 and longest available follow up(12	(2)
40	months)	
41	Figure E-147: HoLAP vs. laser vapourisation: All cause mortality and complications	
42	4.3 TRANSURETHRAL MICROWAVE THERMOTHERAPY (TUMT)	624
43	4.3.1 TUMT vs. Sham procedure	624
44	Figure E-148: TUMT vs. SHAM: Symptom score at 3 and 6 months	
45	Figure E-148. TOMT vs. SHAM. Symptom score at 5 and 6 months Figure E-149: TUMT vs. SHAM: Qmax(ml/s)and 3 months and at long term follow up	
46	Figure E-149. TOMT vs. SHAM: Qmax(m/s)and 5 months and a tong term jottow up Figure E-150: TUMT vs. SHAM: All cause mortality and complications	
47 47	Figure E-150: TOMT vs. SHAM: An eduse monanty and completations Figure E-151: TUMT vs. SHAM: Complications – reoperatoions (random effects analysis)	
48	4.3.2 TUMT vs. TURP	
49	Figure E-152: TUMT vs. TURP: Symptom score at 3, 12 and 36 months (random effects analysis)	
50	Figure E-152: TUMT vs. TURP: Symptom score at 6, 24, 48 and 60 months postoperatively	
51	Figure E-155: TOMT vs. TURP: Qmax(ml/s) at 3 months and longest available follow up (random effo	
52	analysis)	
52 53	Figure E-155: TUMT vs. TURP: Quality of life (IPSS question) at 3 and 6 months postoperatively	
54	Figure E-155: TUMT vs. TURP: quality of life (IPSS question) at 12 months postoperatively (random	/
55	effects analysis)	. 630
56	Figure E-157: TUMT vs. TURP: quality of life (IPSS question) at 48 and 60 months postoperatively	.630
57	Figure E-158: TUMT vs. TURP: All cause mortality and complications	

1 2	Continued Figure E-158: TUMT vs. TURP: Complications Figure E-159: TUMT vs. TURP: Complications - Incontinence and retrograde ejaculation (random ej	
3	analysis)	•
4	4.3.3 TUMT vs. Laser	
5	4.4 TUVP	. 633
6 7	4.4.1 TUVP vs. TURP. Figure E-160: TUVP vs. TURP: Symptom score at 3, 6 and 12 months and 5 years or more postopera	
8	(fixed effects model)	
9	Figure E-161: TUVP vs. TURP: Symptom score at 2 and 3 years postoperatively (random effects anal	
10		634
11	Figure E-162: TUVP vs. TURP: Quality of life (IPSS question)	634
12 13	Figure E-163: TUVP vs. TURP: Quality of life (IPSS question) – 1 year and 2 year postoperatively	(25
13	(random effects analysis) Figure E-164: TUVP vs. TURP: Qmax(ml/s) at 3 months (fixed effect analysis) and longest available	
15	follow up(random effects analysis)	
16	Figure E-165: TUVP vs. TURP: All cause mortality and complications	
17	Continued Figure E-165: TUVP vs. TURP: All cause mortality and complications	
18	Figure E-166: TUVP vs. TURP: Complications – retrograde ejaculation (random effects analysis)	
19 20	4.4.2 BIPOLAR TUVP vs. TURP.	
20	Figure E-167: Bipolar TUVP vs. TURP: Symptom score Figure E-168: Bipolar TUVP vs. TURP: Qmax(ml/s) at 3 months and longest available follow up	
22	Figure E-169: Bipolar TUVP vs. TURP: All cause mortality and complications	
23	4.4.3 TUVP vs. Laser	
24	4.5 TRANSURETHRAL NEEDLE ABLATION OF THE PROSTATE (TUNA)	. 641
25		
26	4.5.1 TUNA vs. TURP Figure E-170: TUNA vs. TURP: Symptom score	
27	Figure E-171: TUNA vs. TURP: Quality of life (IPSS question)	
28	Figure E-172: TUNA vs. TURP: $\widetilde{Q}max(ml/s)$	
29	Figure E-173: TUNA vs. TURP: All cause mortality and complications	643
30	4.6 TRANSURETHRAL INCISION OF THE PROSTATE (TUIP)	. 644
31	4.6.1 TUIP vs. TURP	644
32	Figure E-174: TUIP vs. TURP: Symptom score	
33	Figure E-175: TUIP vs. TURP: Quality of life (IPSS question)	
34	Figure E-176: TUIP vs. TURP: Qmax (ml/s)	
35 36	Figure E-177: TUIP vs. TURP: All cause mortality and complications	
30 37	<i>Figure E-178: TUIP vs. TURP: Complications – retrograde ejaculation (random effects analysis)</i> 4.6.2 TUIP vs. TURP IN AUR PATIENTS	
38	Figure E-179: TUIP vs. TURP in AUR patients: All cause mortality and complications	
39	4.6.3 TUIP vs. HOLEP	
40	4.7 BOTULINUM TOXIN IN THE PROSTATE	. 648
41		
41	4.7.1 BOTULINUM TOXIN VS. PLACEBO Figure E-180: Botulinum toxin vs. placebo: Symptom score at 1- and 2-month follow up	
43	Figure E-181: Botulinum toxin vs. placebo: Symptom score at 1 and 2 month follow up	
44	Figure E-182: Botulinum toxin vs. placebo: Complications (urinary incontinence) – 2 month follow up	
45	4.8 TRANSURETHRAL VAPOURESECTION OF THE PROSTATE (TUVRP)	. 649
46	4.8.1 TUVRP vs. TURP	
47	Figure E-183: TUVRP vs. TURP: Symptom score at 3 months, 1 year and 2 years follow up	
48	Figure E-184: TUVRP vs. TURP: Symptom score at 6 months follow up (random effects analysis)	
49	Figure E-185: TUVRP vs. TURP: Quality of life (IPSS question)	650
50	Figure E-186: TUVRP vs. TURP: Qmax (ml/s)	
51 52	Figure E-187: TUVRP vs. TURP: All cause mortality and complications Figure E-188: TUVRP vs. TURP: Complications – retrograde ejaculation (random analysis)	
52 53	4.8.2 BIPOLAR TUVRP vs. TURP: Complications – reirograde ejacutation (random analysis)	

1 2 3 4	Figure E-189: Bipolar TUVRP vs. TURP: Symptom score at 3-month follow up Figure E-190: Bipolar TUVRP vs. TURP: Quality of life (IPSS question) at 3-month follow up Figure E-191: Bipolar TUVRP vs. TURP: Qmax(ml/s) at 3-month follow up Figure E-192: Bipolar TUVRP vs. TURP: Complications	. 652 . 652 . 653
5	4.9 TRANSURETHRAL ETHANOL ABLATION OF THE PROSTATE (TEAP)	653
6	4.9.1 TEAP vs. TURP	. 653
7	Figure E-193: TEAP vs. TURP: Complications	
8	4.10 OPEN PROSTATECTOMY (OP)	65/
9	4.10.1 OPEN PROSTATECTOMY VS. HOLEP	
10	4.10.2 OPEN PROSTATECTOMY VS. LASER VAPOURISATION	. 654
11	4.11 TRANSURETHRAL RESECTION OF THE PROSTATE TURP	654
12	4.11.1 TURP vs. WATCHFUL WAITING	654
13	Figure E-194: TURP vs. Watchful waiting: Qmax (ml/s)	
14	Figure E-195: TURP vs. Watchful waiting: All cause mortality and complications	
15	4.11.2 BIPOLAR TURP vs. TURP	
16	Figure E-196: Bipolar TURP vs. TURP: Symptom score	
17	Figure E-197: Bipolar TURP vs. TURP: Quality of life (IPSS question)	
18	Figure E-198: Bipolar TURP vs. TURP: \widetilde{Q} max (ml/s) at 3 months or longest available follow up	
19	Figure E-199: Bipolar TURP vs. TURP: All cause mortality and complications	
20	Continued Figure E-199b: Bipolar TURP vs. TURP: All cause mortality and complications	
21	4.11.3 TURP vs. TUVP	. 660
22	4.11.4 TURP vs. TUNA	. 660
23	4.11.5 TURP vs. Laser	. 661
24	4.11.6 TURP vs. TUMT	.661
25	4.11.7 TURP vs. TUIP	.661
26	4.11.8 TURP vs. HoLEP	
27	4.11.9 TURP vs. TUVP	
28	4.11.10 TURP vs. Bipolar TUVP	
29	4.11.11 TURP vs. TUVRP	
30	4.11.12 TURP vs. Bipolar TUVRP	
31	4.11.13 TURP vs. TEAP	
32	7.1.1 BLADDER TRAINING VS. TURP	
33	Figure E-200: Bladder training vs. TURP: Symptom score change at 6 months follow up	
34	Figure E-201: Bladder training vs. TURP: Symptom score change at 6 months follow up	
35	Figure E-202: Bladder training vs. TURP: Qmax (ml/s) change at 6 months follow up	
36	7.1.2 SELF-CATHETERISATION VS. TURP	. 663
37 38	Figure E-203: Self catheterisation vs. TURP in men with chronic urinary retention: Symptom score	(()
30 39	change at 6 months follow up	
39 40	Figure E-204: Self catheterisation vs. TURP in men with chronic urinary retention: quality of life (IPS and the second se	
40	<i>question) change at 6 months follow up</i>	
42	8.1.1 ACUTE URINARY RETENTION Figure E-205: Alpha-blockers vs. placebo in men with acute urinary retention: Able to void	
42	Figure E-205: Alpha-blockers vs. placebo in men with acute urinary retention: Able to vola Figure E-206: Alpha-blockers vs. placebo in men with acute urinary retention: Re-	. 004
44	catheterisation	665
45	8.2 CHRONIC RETENTION	. 665
46	9.1 PHYTOTHERAPY VS. PLACEBO	666
47	9.1.1 Beta-sitosterol	666
48	Figure E-207: Beta-sitosterol vs. placebo: Symptom score	
49	Figure E-208: Beta-sitosterol vs. placebo: Qmax (ml/s)	
50	9.1.2 SERENOA REPENS	
51	Figure E-209: Serenoa repens vs. placebo: Symptom score	
52	Figure E-210: Serenoa repens vs. placebo: Qmax (ml/s)	
53	Figure E-211: Serenoa repens vs. placebo: \widetilde{Q} uality of life (IPSS question)	

1	9.1.3 URTICA DIOCIA	
2	Figure E-212: Urtica diocia vs. placebo: Symptom score	
3	Figure E-213: Urtica diocia vs. placebo: Qmax (ml/s)	
4	9.1.4 PYGEUM	668
5	Figure E-214: Urtica diocia vs. placebo: Qmax(ml/s)	668
6	9.1.5 CERNILTON	
7	Figure E-215: Cernilton vs. placebo: Qmax (ml/s)	
8	9.1.6 Phytotherapy combinations	
9	Figure E-216: Combination of serenoa repens and uritca diocia vs. placebo: Symptom score	
10	Figure E-217: Combination of serenoa repens and uritca diocia vs. placebo: Qmax (ml/s)	
11	Figure E-218: Combination of pygeum and uritca diocia vs. placebo: Symptom score	
12	Figure E-219: Combination of pygeum and uritca diocia vs. placebo: Qmax (ml/s)	
13	Figure E-220: Combination of pygeum and uritca diocia vs. placebo: Quality of life (IPSS question	
14 15	Figure E-221: Combination of cernitin, serona repens, phytosterol and Vitamin E vs. placebo: Syn score	
16 17	Figure E-222: Combination of cernitin, serona repens, phytosterol and Vitamin E vs. placebo: Qma (ml/s)	ıx 670
10		
18	9.2 Phytothearpy vs. Alpha-blockers	670
19	9.2.1 SERENOA REPENS VS. ALPHA-BLOCKERS	670
20	Figure E-223: Phytotherapy vs. Alpha-blockers: Symptom score	670
21	Figure E-224: Phytotherapy vs. Alpha-blockers: Quality of life (IPSS question)	670
22	Figure E-225: Phytotherapy vs. Alpha-blockers: Qmax (ml/s)	
23	Figure E-226: Phytotherapy vs. Alpha-blockers: Urinary retention	
24	9.3 Phytotherapy vs. 5-ARI	671
25	9.3.1 SERENOA REPENS VS. 5-ARI	671
26	Figure E-227: Serenoa repens vs. 5-alpha-reductase inhibitors: Symptom score	
27	Figure E-228: Serenoa repens vs. 5-alpha-reductase inhibitors: quality of life (IPSS question)	
28	Figure E-229: Serenoa repens vs. 5-alpha-reductase inhibitors: Qmax (ml/s) at longest available for	
29		
30	Figure E-230: Serenoa repens vs. 5-alpha-reductase inhibitors: Urinary retention	
31	9.3.2 SERENOA REPENS AND URTICA DIOCIA VS. 5-ARI	
32	Figure E-231: Serenoa repens and urtica diocia vs. 5-alpha-reductase inhibitors: Symptom score	
33	Figure E-232: Serenoa repens and urtica diocia vs. 5-alpha-reductase inhibitors: Qmax (ml/s) at 3	
34	and 12 months.	
35	10.1 EDUCATIONAL INTERVENTION VS. NO INTERVENTION	673
36	Figure E-233: Interactive video vs. no intervention: Decisional conflict score	673
37	10.2 SELF MANAGEMENT VS. STANDARD CARE	673
38	Figure E-234: Self management vs. standard care: symptom score	673
39	Figure E-235: Self management vs. standard care: Treatment failure	
	r Saro 2 200, 509 management vs. standard cure. Fredment Januaren	

1 1 Diagnostic Tests

- 2 1.1 Free Uroflowmetry (Peak Urinary Flow)
- 3 Figure E-1: Sensitivity and specificity of free uroflowmetry (Qmax) in the diagnosis of
- 4 bladder outlet obstruction

535 of 754



- 1 Figure E-2: Summary receiver operating characteristic (SROC) curve for uroflowmetry
- 2 Qmax in the diagnosis of bladder outlet obstructions

2 Conservative Interventions

2.1 Pelvic Floor Muscle Training (PFMT)

2.1.1 PFMT vs. Control

Figure E-3: PFMT vs. Control: Number of post-prostatectomy men who were incontinent

Figure E-4: PFMT vs. Control: Mean urine lost (g) per 24 hours (pad test) in post-prostatectomy men

Figure E-5: PFMT vs. Control: Number of post-TURP men who were incontinent

2.2 Biofeedback

2.2.1 Biofeedback + PFMT vs. Control

Figure E-6: PFMT + Biofeedback vs. no intervention: Number of men who were incontinent at follow up

EF

2.3 Electrical Stimulation (ES)

2.3.1 ES + PFMT vs. Control

Figure E-7: ES + PFMT vs. no intervention: Number of men who were incontinent at follow up

s:T

3 Pharmacological Interventions

3.1 Alpha-blockers

3.1.1 Alpha-blockers vs. placebo

Figure E-8: Alpha-blockers vs. Placebo: Symptom score (random effects analysis)

	Alpha	a-block	ker	P	acebo	I III		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
1.1.1 total									
CHAPPLE 2005	-7.9	5.67	1054	-5.8	5.6	350	9.8%	-2.10 [-2.78, -1.42]	+
DJAVAN 2005	-8	5.2	60	-5.6	4.7	56	5.8%	-2.40 [-4.20, -0.60]	
KIRBY 2003	8.7	5.8	250	11.8	6.9	253	8.2%	-3.10 [-4.21, -1.99]	
LEPOR 1996	10.1	6.35	275	13.2	6.3	265	8.4%	-3.10 [-4.17, -2.03]	
LEPOR 1998	-8.3	6.3	246	-5.5	6.3	246	8.2%	-2.80 [-3.91, -1.69]	
MCCONNELL 2003	-6.6	5.8	756	-4.9	4.1	737	10.4%	-1.70 [-2.21, -1.19]	+
MOHANTY 2003	6.9	4.4	36	12.7	4	33	5.2%	-5.80 [-7.78, -3.82]	
NARAYAN 1998	-5.1	6.37	244	-3.6	5.67	235	8.3%	-1.50 [-2.58, -0.42]	
ROEHRBORN 1996	-7.6	7.17	976	-3.7	7.16	973	10.0%	-3.90 [-4.54, -3.26]	
ROEHRBORN 2001	-3.6	4.8	170	-1.6	5.8	167	8.1%	-2.00 [-3.14, -0.86]	- - -
ROEHRBORN 2006	-5.9	6.9	749	-4.7	6.9	757	9.8%	-1.20 [-1.90, -0.50]	
VANKERREBROECK 2000	10.45	5.46	293	12.8	6.7	154	7.8%	-2.35 [-3.58, -1.12]	
Subtotal (95% Cl)			5109			4226	100.0%	-2.55 [-3.17, -1.92]	•
Heterogeneity: Tau ² = 0.90; C	¢hi² = 58.	71, df:	= 11 (P	< 0.000)01); l ^a	= 81%			
Test for overall effect: Z = 8.03	3 (P < 0.0	00001)	I.						
									-10 -5 0 5

Favours alpha-blocker Favours placebo

Figure E-9: Alpha-blockers vs. Placebo: Qmax (ml/s) (random effects analysis)

	Alpha	a-block	ker	P	acebo			Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% Cl	IV, Random, 95% Cl
ABRAMS 1997	12.1	3.7	29	10.9	4.3	26	1.9%	1.20 [-0.93, 3.33]	
BRAWER 1993	2.6	3.42	73	1.2	3.44	74	4.9%	1.40 [0.29, 2.51]	→
CHAPPLE 1994	2.6	5.42	60	1.1	4.72	62	2.5%	1.50 [-0.31, 3.31]	+
CHAPPLE 1996	11.8	5.91	364	10.7	4.22	185	6.3%	1.10 [0.24, 1.96]	
CHRISTENSEN 1993	9.4	4.75	46	8	3.24	42	2.8%	1.40 [-0.29, 3.09]	+
ELHILALI 1996	12.7	4.53	68	10.2	2.08	75	4.6%	2.50 [1.32, 3.68]	
GILLENWATER 1995	9.92	2.74	130	10.5	2.6	41	5.9%	-0.58 [-1.50, 0.34]	-+-
KAWABE 1990	14	8.65	48	10.8	7.12	49	1.0%	3.20 [0.04, 6.36]	
KIRBY 2003	14	4.9	250	12.1	4.2	253	6.8%	1.90 [1.10, 2.70]	
LEPOR 1992	2.3	3.75	112	1	3.67	54	4.5%	1.30 [0.10, 2.50]	
LEPOR 1996	13.3	4.73	275	11.9	4.79	264	6.7%	1.40 [0.60, 2.20]	
LEPOR 1998	11.21	3.94	254	10.26	3.57	253	7.8%	0.95 [0.30, 1.60]	
LLOYD 1992	2.48	3.85	41	2.5	4	20	2.0%	-0.02 [-2.13, 2.09]	
MARTORANA 1997	13.16	4	25	11.75	3.1	25	2.2%	1.41 [-0.57, 3.39]	+
MOHANTY 2003	15.7	4.6	36	12.5	2.6	33	2.6%	3.20 [1.46, 4.94]	
NARAYAN 1998	11.47	4.03	244	10.87	3.9	235	7.4%	0.60 [-0.11, 1.31]	+ - -
ROEHRBORN 1996	2.2	5.26	137	0.8	5.62	140	4.1%	1.40 [0.12, 2.68]	
ROEHRBORN 2001	1.7	4.2	170	0.2	3.5	167	6.6%	1.50 [0.68, 2.32]	
ROEHRBORN 2006	2	3.8	749	1.3	3.6	757	9.9%	0.70 [0.33, 1.07]	-
SCHULMAN 1994	13.95	6.3	68	11.69	5.5	73	2.2%	2.26 [0.30, 4.22]	
VANKERREBROECK 2000	11.8	4.11	293	10.6	3.3	154	7.4%	1.20 [0.50, 1.90]	
Total (95% CI)			3472			2982	100.0%	1.23 [0.90, 1.55]	•
Heterogeneity: Tau ² = 0.24; (Chi² = 40.	62. df:	= 20 (P	= 0.004	(); $ ^2 = 2$	51%			
Test for overall effect: Z = 7.4		•							-10 -5 Ó Ś 1
		,							Favours placebo Favours alpha-bloc

-	Alpha	-bloci	кег	Pla	acebo	D		Mean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% C	I IV, Random, 95% Cl
CHAPPLE 2005	-1.4	1.3	1053	-1.1	1.3	350	28.2%	-0.30 [-0.46, -0.14	.] 🗕
LEPOR 1998	-4.8	4.7	242	-3.2	4.7	244	3.3%	-1.60 [-2.44, -0.76	j <u> </u>
ROEHRBORN 2001	-0.7	1.1	170	-0.3	1.1	167	21.0%	-0.40 [-0.63, -0.17	n -
ROEHRBORN 2006	-1.3	1.5	749	-0.9	1.6	757	28.3%	-0.40 [-0.56, -0.24	.] –
VANKERREBROECK 2000	2.2	1.1	193	2.6	1.3	154	19.2%	-0.40 [-0.66, -0.14	.j -
Total (95% CI)			2407			1672	100.0%	-0.41 [-0.57, -0.25	ı ♦
Heterogeneity: Tau² = 0.02; Chi² = 9.29, df = 4 (P = 0.05); l² = 57%									
Test for overall effect: Z = 5.09 (P < 0.00001)									-4 -2 0 2 4 Favours alpha-blocker Favours placebo

Figure E-10: Alpha-blockers vs. Placebo: Quality of life – IPSS question (random effects analysis)

Figure E-11: Alpha-blockers vs. Placebo: Adverse events (cardiovascular and neurological) - asthenia (fatigue) and headache

Figure E-12: Alpha-blockers vs. Placebo: Adverse events (cardiovascular and neurological) - postural hypotension and rhinitis

Figure E-13: Alpha-blockers vs. Placebo: Adverse events - erectile dysfunction /impotence

Figure E-14: Alpha-blockers vs. Placebo: Adverse events - dizziness and retrograde ejaculation (random effects analysis)

	Alpha-blo	Place	bo		Risk Ratio	Risk Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
ABRAMS 1997	1	30	2	28	0.7%	0.47 [0.04, 4.87]	· · · · · · · · · · · · · · · · · · ·
ANDERSEN 2000	31	639	1	156	0.5%	7.57 [1.04, 55.01]	
BRAWER 1993	12	81	7	79	2.4%	1.67 [0.69, 4.03]	I +−−
CHAPPLE 1994	2	67	0	68	0.2%	5.07 [0.25, 103.74]	
CHAPPLE 1996	17	382	8	193	3.5%	1.07 [0.47, 2.44]	
CHAPPLE 2005	25	1069	6	356	3.0%	1.39 [0.57, 3.36]	
DJAVAN 2005	0	61	0	56		Not estimable	
FAWZY 1995	1	50	0	50	0.2%	3.00 [0.13, 71.92]	· · · · · · · · · · · · · · · · · · ·
GILLENWATER 1995	22	199	2	49	1.1%	2.71 [0.66, 11.13]	
HANSEN 1994	1	104	1	101	0.3%	0.97 [0.06, 15.32]	
KAPLAN 2006	7	215	7	220	2.3%	1.02 [0.37, 2.87]	
KIRBY 2003	32	275	30	269	10.1%	1.04 [0.65, 1.67]	+
LEPOR 1992	15	216	3	69	1.5%	1.60 [0.48, 5.35]	· · · · · · · · · · · · · · · · · · ·
LEPOR 1996	18	305	5	305	1.7%	3.60 [1.35, 9.57]	
LEPOR 1998	18	254	22	254	7.3%	0.82 [0.45, 1.49]	
LLOYD 1992	4	66	0	20	0.3%	2.82 [0.16, 50.27]	
MOHANTY 2003	0	38	0	34		Not estimable	
NORDLING 2005	10	312	5	154	2.2%	0.99 [0.34, 2.84]	
RESNICK 2007	3	185	1	185	0.3%	3.00 [0.31, 28.58]	
ROEHRBORN 1996	168	1053	114	1031	38.3%	1.44 [1.16, 1.80]	—
ROEHRBORN 2001	8	176	4	172	1.3%	1.95 [0.60, 6.37]	
ROEHRBORN 2006	69	749	58	757	19.2%	1.20 [0.86, 1.68]	I +
SOLOWAY 1992	12	96	11	103	3.5%	1.17 [0.54, 2.53]	· +-
Total (95% CI)		6622		4709	100.0%	1.37 [1.19, 1.58]	•
Total events	476		287				
Heterogeneity: Chi ² = 1	6.77, df = 2	0 (P = 0	.67); I ^z = 1	0%			
Test for overall effect: Z	•	,					0.002 0.1 i 10 500 Favours alpha-blocker Favours placebo

Figure E-15: Alpha-blockers vs. Placebo: Withdrawal from study due to adverse events

3.1.2 Alpha-blockers vs. 5-Alpha reductase inhibitors (5-ARI)

Figure E-16: Alpha-blockers vs. 5-ARI: Symptom score

Figure E-17: Alpha-blockers vs. 5-ARI: Quality of life (IPSS-question)

547 of 754

Figure E-18: Alpha-blockers vs. 5-ARI: Qmax (ml/s)

<u>E</u>=

Figure E-19: Alpha-blockers vs. 5-ARI: Prostate volume (ml)

Figure E-20 Alpha-blockers vs. 5-ARI: PSA (ng/ml)

ET

Figure E-21: Alpha-blockers vs. 5-ARI: Adverse events (cardiovascular or neurological)

The studies were arranged in the forest plots based on duration of follow up (6 months for Debruyne1998 and Rigatti2003, 1 year for Lepor1996 and Kirby2003, 2 years for Roehrborn2008 and 4 years for McConnell2003)

Lower urinary tract symptoms (LUTS) – full guideline appendices DRAFT (August 2009)

Figure E-22: Alpha-blockers vs. 5-ARI: Adverse events (sexual or urological)

The studies were arranged in the forest plots based on duration of follow up (6 months for Debruyne1998 and Rigatti2003, 1 year for Lepor1996 and Kirby2003, 2 years for Roehrborn2008 and 4 years for McConnell2003)

551 of 754

Figure E-23: Alpha-blockers vs. 5-ARI: Adverse events - postural hypotension and ejaculatory abnormality (random effects analysis)

T

Figure E-24: Alpha-blockers vs. 5-ARI: Ejaculatory abnormality – subgroup analysis of tamsulosin and other alpha-blockers

Figure E-25: Alpha-blockers vs. 5-ARI: Withdrawal from study due to adverse events (random effects analysis)

Eller

The studies were arranged in the forest plots based on duration of follow up (6 months for Debruyne1998 and Rigatti2003, 1 year for Lepor1996 and Kirby2003, 2 years for Roehrborn2008 and 4 years for McConnell2003)

3.1.3 Alpha-blockers vs. Anticholinergics

See section 3.3.2 Anticholinergics vs. Alpha-blockers

3.1.4 Alpha-blockers vs. Phosphodiesterase 5-inhibitors (PDE5-I)

See section 3.4.2 PDE5-I vs. Alpha-blockers

553

3.2.1 5-ARI vs. placebo

Figure E-26: 5-ARI vs. Placebo: Symptom score at 3 months, 6 months 2 years and 4 years or longer (random effects analysis)

Figure E-27: 5-ARI vs. Placebo: Symptom score at 2 years- subgroup analysis

Figure E-28: 5-ARI vs. Placebo: Symptom score at 12 months and 3 years

Fine T

Figure E-29: 5-ARI vs. Placebo: Qmax (ml/s) at 3 months, 6 months, 2 years, 3 years and 4 years or longer

Figure E-30: 5-ARI vs. Placebo: Qmax (ml/s) at 12 months (random effects analysis)

Con **P**

- T

-

Figure E-31: 5-ARI vs. Placebo: Prostate volume(ml) at 1 year follow up

Figure E-32: 5-ARI vs. Placebo: Prostate volume (ml) at 2 years follow up (random effects analysis)

Figure E-33: 5-ARI vs. Placebo: PSA (ng/ml) level at 2 year follow up

Figure E-34: 5-ARI vs. Placebo: Adverse events (cardiovascular and neurological)

T

Figure E-35: 5-ARI vs. Placebo: Adverse events (sexual and urological)

Figure E-36: 5-ARI vs. Placebo: Withdrawal from study due to adverse events

Tim

3.2.2 5-Alpha reductase inhibitors (5-ARI) vs. Alpha-blockers

See section 3.1.2: Alpha-blockers vs. 5-Alpha reductase inhibitors (5-ARI)

3.3 Anticholinergics

3.3.1 Anticholinergics vs. placebo

Figure E-37: Anticholinergics vs. Placebo: Adverse events

Figure E-38: Anticholinergics vs. Placebo: Withdrawal from study due to adverse events

3.3.2 Anticholinergics vs. Alpha-blockers

Figure E-39: Anticholinergics vs. Alpha-blockers: Adverse events

3.4 Phosphodiesterase-5-inhibitors (PDE5-I)

3.4.1 PDE5-I vs. placebo

Figure E-40: PDE5-I vs. Placebo: Symptom score

T

T

Figure E-41: PDE5-I vs. Placebo: Quality of life (IPSS question)

Figure E-42: PDE5-I vs. Placebo: Qmax(ml/s)

Elling T.

Figure E-43: PDE5-I vs. Placebo: Adverse events



----T

 \mathbf{T}_{max}

Figure E-44: PDE5-I vs. Alpha-blockers: Symptom score

Figure E-45: PDE5-I vs. Alpha-blockers: Qmax (ml/s)

Figure E-46: PDE5-I vs. Alpha-blockers: Voiding frequency

Figure E-47: PDE5-I vs. Alpha-blockers: Nocturia

Figure E-48: PDE5-I vs. Alpha-blockers: Adverse events

Ŧ

3.5 Diuretics

3.5.1 Diuretics vs. placebo

Forest plots were not prepared for this comparison. Please see Evidence Table 16 in Appendix D for details.

3.6 Desmopressin

3.6.1 Desmopressin vs. placebo

Forest plots were not prepared for the efficacy outcomes of this cross over trial. Please see Evidence Table 17 in Appendix D for details.

Figure E-49: Desmopressin vs. Placebo: Adverse events

This is a cross over trial and a paired test would be more appropriate. Forest plots prepared for illustration purpose.

3.7 NSAIDS

-

-

3.7.1 NSAIDS vs. placebo

Figure E-50: NSAIDs vs. Placebo: Symptom score at 1 month

Figure E-51: NSAIDs vs. Placebo: Qmax (ml/s) at 1 month

Figure E-52: NSAIDs vs. Placebo: Nocturia frequency at 1 month

Figure E-53: NSAIDs vs. Placebo: Adverse events (1 month follow up)

Only one type of adverse event was reported.

3.8 Combination therapy: Alpha-blockers plus 5-alpha reductase inhibitors(5-ARI)

3.8.1 Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers

Figure E-54: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: Symptom score

Figure E-55: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: Qmax (ml/s)

Figure E-56: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: Prostate volume(ml)

Figure E-57: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: PSA (ng/ml)

Figure E-58: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: Adverse events (cardiovascular or neurological)

The studies were arranged in the forest plots based on duration of follow up (6 months for Debruyne1998, 1 year for Lepor1996 and Kirby2003, 2 years for Roehrborn2008 and 4 years for McConnell2003)

Continued Figure E-58: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: Adverse events (cardiovascular or neurological

The studies were arranged in the forest plots based on duration of follow up (6 months for Debruyne1998, 1 year for Lepor1996 and Kirby2003, 2 years for Roehrborn2008 and 4 years for McConnell2003)

Figure E-59: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: Adverse events (sexual or urological)

The studies were arranged in the forest plots based on duration of follow up (6 months for Debruyne1998, 1 year for Lepor1996 and Kirby2003, 2 years for Roehrborn2008 and 4 years for McConnell2003)

571 of 754

Figure E-60: Combination (Alpha-blockers + 5-ARI) vs. Alpha-blockers: Withdrawal from study due to adverse events

Film

The studies were arranged in the forest plots based on duration of follow up (6 months for Debruyne1998, 1 year for Lepor1996 and Kirby2003, 2 years for Roehrborn2008 and 4 years for McConnell2003)

3.8.2 Combination (Alpha-blockers + 5-ARI) vs. 5-ARI

Figure E-61: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Symptom score

Figure E-62: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Qmax(ml/s)

5..... 27.....

Figure E-63: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Prostate volume (ml)

Figure E-64: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: PSA (ng/ml)

E-T

Figure E-65: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Adverse events (Cardiovascular or neurological)

The studies were arranged in the forest plots based on duration of follow up (6 months for Debruyne1998, 1 year for Lepor1996 and Kirby2003, 2 years for Roehrborn2008 and 4 years for McConnell2003)

575

Continued Figure E-65: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Adverse events (cardiovascular or neurological)

The studies were arranged in the forest plots based on duration of follow up (6 months for Debruyne1998, 1 year for Lepor1996 and Kirby2003, 2 years for Roehrborn2008 and 4 years for McConnell2003)

576 of 754

Figure E-66: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Adverse events (sexual or urological)

The studies were arranged in the forest plots based on duration of follow up (6 months for Debruyne1998, 1 year for Lepor1996 and Kirby2003, 2 years for Roehrborn2008 and 4 years for McConnell2003)

Figure E-67: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Ejaculatory abnormality (random effects analysis)

The T

Figure E-68: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Ejaculatory abnormality subgroup analysis

ET

Figure E-69: Combination (Alpha-blockers + 5-ARI) vs. 5-ARI: Withdrawal from study due to adverse events (random effects analysis)

The studies were arranged in the forest plots based on duration of follow up (6 months for Debruyne1998, 1 year for Lepor1996 and Kirby2003 and 2 years for Roehrborn2008)

Figure E-70: Combination (Alpha-blockers + 5-ARI) vs. Placebo: Symptom score

55....**T**

Teres

Figure E-71: Combination (Alpha-blockers + 5-ARI) vs. Placebo: Qmax (ml/s)

Figure E-72: Combination (Alpha-blockers + 5-ARI) vs. Placebo: Prostate volume (ml)

Figure E-73: Combination (Alpha-blockers + 5-ARI) vs. Placebo: Change in PSA (ng/ml)

T

Figure E-74: Combination (Alpha-blockers + 5-ARI) vs. Placebo: Adverse events (cardiovascular and neurological)

The studies were arranged in the forest plots based on duration of follow up (1 year for Lepor1996 and Kirby2003 and 4 years for McConnell2003)

Figure E-75: Combination (Alpha-blockers + 5-ARI) vs. Placebo: Adverse events – postural hypotension (random effects analysis)

Teres

Figure E-76: Combination (Alpha-blockers + 5-ARI) vs. Placebo: Adverse events (sexual or urological)

E Star

Figure E-77: Combination (Alpha-blockers + 5-ARI) vs. Placebo: Withdrawal from study due to adverse events (random effects analysis)

The studies were arranged in the forest plots based on duration of follow up (1 year for Lepor1996 and Kirby2003 and 4 years for McConnell2003)

3.9 Combination Therapy : Anti-cholinergic plus Alpha-blockers

3.9.1 Combination (Anti-cholinergic + Alpha-blockers) vs. Alphablockers

Figure E-78: Combination (Anti-cholinergic + Alpha-blockers) vs. Alpha-blockers: Adverse events

T

3.9.2 Anti-cholinergic added on to Alpha-blockers vs. Alpha-blockers

Figure E-79: Anti-Ch added on to Alpha-blockers vs. Alpha-blockers: Symptom score at 3 months

Anticholinergic add on				Alpha	block	ers	Mean Difference	Mean Difference					
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	IV, Fixed, 95% Cl	IV, Fixed, 95% Cl					
Macdiarmid2008	-6.9	6.5	209	-5.2	6.2	209	-1.70 [-2.92, -0.48]						
								-4 -2 0 2 4					
								Favours Anti-Ch add on Favours alpha blocker					

Anticholin	Alpha blockers			Mean Difference	Mean Difference							
Mean	SD	Total	Mean	SD	Total	IV, Fixed, 95% Cl		IV, I	Fixed, 9	5% CI		
-1.3	1.5	209	-0.8	1.4	209	-0.50 [-0.78, -0.22]			+			
							-4	-2	<u> </u>		2	
-								, ,	, , , , ,			

Figure E-80: Anti-Ch added on to Alpha-blockers vs. Alpha-blockers: Quality of life (IPSS question)at 3 months

Figure E-81: Anti-Ch added on to Alpha-blockers vs. Alpha-blockers: Qmax (ml/s) at 3 months

	Anti-Ch add on			Alpha blockers			Mean Difference	Mean Difference					
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	IV, Fixed, 95% Cl			IV, Fixed	i, 95% Cl		
Macdiarmid2008	-0.2	7.8	209	0.1	7.6	209	-0.30 [-1.78, 1.18]			. — +			
								-	4	-2	Ó	2	4
								Favo	urs add ar	iti-ch add o	Favours	alpha bloci	kers

Figure E-82: Anti-Ch added on to Alpha-blockers vs. Alpha-blockers: Adverse events (3months follow up)

	Anticholinergic a	add on	Alpha blo	ckers	Risk Ratio	Risk Ratio
Study or Subgroup	Events	Total	Events	Total	M-H, Fixed, 95% Cl	M-H, Fixed, 95% Cl
1.4.1 Dry mouth						
Macdiarmid2008	32	209	10	209	3.20 [1.62, 6.34]	
1.4.2 Infections and i	infestations					
Macdiarmid2008	18	209	22	209	0.82 [0.45, 1.48]	-+-
1.4.3 Renal and urina	ary adverse events	;				
Macdiarmid2008	10	209	10	209	1.00 [0.43, 2.35]	<u> </u>
1.4.4 Constipations						
Macdiarmid2008	1	209	4	209	0.25 [0.03, 2.22]	
1.4.5 Nervous system	n disorders					
Macdiarmid2008	8	209	9	209	0.89 [0.35, 2.26]	
1.4.6 Acute urinary r	etention					
Macdiarmid2008	0	209	0	209	Not estimable	
1.4.7 Adverse events	s leading to withdr	awais				
Macdiarmid2008	21	209	20	209	1.05 [0.59, 1.88]	- + -
						· · · · ·
						0.01 0.1 1 10 10

U.U1 U.1 1 10 100 Favours Anti-Ch add on Favours Alpha blocker

3.9.3 Combination (Anti-cholinergic + Alpha-blockers) vs. Anticholinergics

Figure E-83: Combination (Anti-cholinergic + Alpha-blockers) vs. Anticholinergics: Adverse events

Ī

Figure E-84: Combination (Anti-cholinergic + Alpha-blockers) vs. Placebo: adverse events

3.10 Combination (PDE5-I + Alpha-blockers)

3.10.1 Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers

Figure E-85: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Symptom score

Figure E-86: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Quality of life (IPSS question)

----T

Figure E-87: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Qmax(ml/s)

Figure E-88: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Frequency at 3month

T.....

Figure E-89: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Nocturia at 3 months

587 of 754

Figure E-90: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Adverse events

F

Continued Figure E-90: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Adverse events

Figure E-91: Combination (PDE5-I + Alpha-blockers) vs. Alpha-blockers: Adverse events resulting in withdrawal at 3-month

an an T

Figure E-92: Combination (PDE5-I + Alpha-blockers) vs. PDE5-I: symptom score (random effects analysis)

-----T

-----T

Figure E-93: Combination (PDE5-I + Alpha-blockers) vs. PDE5-I: Quality of life (IPSS-QoL) up to 3-month

Figure E-94: Combination (PDE5-I + Alpha-blockers) vs. PDE5-I: Qmax (ml/s) at 3-month

Figure E-95: Combination (PDE5-I + Alpha-blockers) vs. PDE5-I: Frequency at 3-month

Figure E-96: Combination (PDE5-I + Alpha-blockers) vs. PDE5-I: Nocturia at 3-month

T

Figure E-97: Combination (PDE5-I + Alpha-blockers) vs. PDE5-I: Adverse events (only those resulting in withdrawals reported)

___Ŧ

-

Figure E-98: Combination (PDE5-I + Alpha-blockers) vs. PDE5-I: Withdrawal from study due to adverse events

4 Surgery

T

4.1 Holmium Laser Enucleation of the Prostate (HoLEP

4.1.1 HoLEP vs. Transurethral resection of the prostate (TURP)

Figure E-99: HoLEP vs. TURP: Symptom score at 3 months, 36 months and 48 months

Figure E-100: HoLEP vs. TURP: Symptom score at 6, 12 and 24 months (random effects analysis)

Figure E-101: HoLEP vs. TURP: Quality of life (IPSS question) – 3, 24 and 48 months ET

Figure E-102: HoLEP vs. TURP: Quality of life (IPSS question) – 6 to 12 months (random effects analysis)

and the second s

Figure E-103: HoLEP vs. TURP: Qmax(ml/s) at 3 months and longest available follow up

Figure E-104: HoLEP vs. TURP: All cause mortality and complications

Continued Figure E-104: HoLEP vs. TURP: All cause mortality and complications

Elina Flina Elina

4.1.2 Thulium laser resection vs. TURP

Figure E-105: Thulium laser resection vs. TURP: Symptom score – 6 months postoperatively

Figure E-106: Thulium laser resection vs. TURP: Symptom score – 12 months

Figure E-107: Thulium laser resection vs. TURP: Qmax(ml/s) – 12 months postoperatively

Figure E-108: Thulium laser resection vs. TURP: Quality of life (IPSS question) – 6 and 12 months

E-T

postoperatively

Figure E-109: Thulium laser resection vs. TURP: Complications

4.1.3 HoLEP vs. Transurethral Incision of the Prostate (TUIP)

Figure E-110: HoLEP vs. TUIP: Symptom score

ET

* Only one study using holmium laser for bladder neck incision (HoBNI) was found.

Figure E-111: HoLEP vs. TUIP: quality of life (IPSS question)

T

Figure E-113: HoLEP vs. TUIP: All cause mortality and complications

4.1.4 HOLEP vs. Open prostatectomy (OP)

Figure E-114: 1 HoLEP vs. OP: Symptom score

Figure E-115: 1 HoLEP vs. OP: quality of life (IPSS question

March - March

Figure E-116: 1 HoLEP vs. OP: Qmax(ml/s) at 3 months (random effects analysis) and longest available follow up (fixed effects analysis)

T

T

Figure E-117: 1 HoLEP vs. OP: All cause mortality and complications

4.2 Laser treatments

4.2.1 Laser Coagulation vs. TURP

Figure E-118: 1 Laser Coagulation vs. TURP: Symptom score at 3 and 6 months (random effects analysis), 12 months and 24 months (change and endpoints)

Figure E-119: Laser Coagulation vs. TURP: Quality of life (IPSS question), change and endpoints.

For

Figure E-120: Laser Coagulation vs. TURP: Qmax (ml/s)

Figure 121: Laser Coagulation vs. TURP: All cause mortality and complications

:

Continued Figure 121 Laser Coagulation vs. TURP: All cause mortality and complications E Tion E Tion E Tion E Tion

Figure E-122: Laser Coagulation vs. TURP: Complications – retrograde ejaculation (random effects analysis)

Fine

4.2.2 Laser coagulation vs. TURP in AUR patients

Figure E-123: Laser coagulation vs. TURP in AUR patients: Symptom score change

T

Figure E-124: Laser coagulation vs. TURP in AUR patients: Quality of life (IPSS question), change

----T

Figure E-125: Laser coagulation vs. TURP in AUR patients: Complications

Figure E-126: Laser vapourisation vs. TURP: Symptom score at 3 months, 6 months and 1 year (random effects analysis)

T

Figure E-127: Laser vapourisation vs. TURP: Symptom score

610 of 754

Figure E-128: Laser vapourisation vs. TURP: quality of life (IPSS question)

E

Figure E-129: Laser vapourisation vs. TURP: Qmax(ml/s) - 3 months(fixed effect analysis) and longest available follow up(random effects analysis)

e de la comp

Hillion F

611 of 754

Figure E-130: Laser vapourisation vs. TURP: All cause mortality and complications

Continued Figure E-130: Laser Vapourisation vs. TURP : Complications

Figure E-131: Laser vapourisation vs. TURP: Complications – retrograde ejaculation (random effects analysis)

4.2.4 Laser (photoselective vapourisation) vs. Open prostatectomy(OP)

Figure E-132: Laser (photoselective vapourisation) vs. OP: Complications

4.2.5 Laser coagulation vs. TUMT (Transurethral Microwave Thermotherapy)

Figure E-133: Laser coagulation vs. TUMT -Symptom score at 6 months

Figure E-134: Laser coagulation vs. TUMT – Qmax(ml/s) at 6 months

Figure E-135: Laser coagulation vs. TUMT: Complications

<u>L</u>T

4.2.6 Laser vs. TUVP (Transurethral Vapourisation of the Prostate)

Figure E-136: Laser vs. TUVP: Symptom score (random effects analysis)

Figure E-137: Laser vs. TUVP – Quality of life (IPSS question)


617 of 754

Figure E-138: Laser vs. TUVP – Qmax(ml/s) at 6 month, 12 month(fixed effect analysis) and longest available follow up (random effects analysis)

Ŧ

T

No 3 month data was available for this comparison.



4.2.7.1 Laser vapourisation vs. Laser coagulation

Figure E-140: Laser vapourisation vs. laser coagulation: Symptom score at 3 months (random effects analysis)

-----T

Figure E-140b: Laser vapourisation vs. laser coagulation: Symptom score at 6, 12 and 24 months (fixed effect analysis)

I

Figure E-141: Laser vapourisation vs. laser coagulation: Qmax (ml/s) at 3 months and longest available follow up

E-T

Figure E-142: Laser vapourisation vs. laser coagulation: Complications

4.2.7.2 Holmium laser resection of the prostate(HoLRP) vs. Laser coagulation

Figure E-143: HoLRP vs. Laser coagulation: Complications

----T

4.2.7.3 Holmium Laser Ablation of the Prostate(HoLAP) vs. Laser Vapourisation

Figure E-144: HoLAP vs. Laser vapourisation: Symptom score

Only one study was using photoselective laser vapourisation (PVP) method was found

Figure E-145: HoLAP vs. Laser vapourisation: quality of life (IPSS question)

Figure E-146: HoLAP vs. laser vapourisation: Qmax(ml/s) at 3 and longest available follow up(12 months)

T

Figure E-147: HoLAP vs. laser vapourisation: All cause mortality and complications

I

4.3 Transurethral Microwave Thermotherapy (TUMT)

4.3.1 TUMT vs. Sham procedure

Figure E-148: TUMT vs. SHAM: Symptom score at 3 and 6 months

Figure E-149: TUMT vs. SHAM: Qmax(ml/s)and 3 months and at long term follow up

Circa C

Figure E-150: TUMT vs. SHAM: All cause mortality and complications

Figure E-151: TUMT vs. SHAM: Complications – reoperatoions (random effects analysis)

En₹

4.3.2 TUMT vs. TURP

Figure E-152: TUMT vs. TURP: Symptom score at 3, 12 and 36 months (random effects analysis)

Tana

William T

Tanta

Figure E-153: TUMT vs. TURP: Symptom score at 6, 24, 48 and 60 months postoperatively

William .

Turn

____T

Figure E-154: TUMT vs. TURP: Qmax(ml/s) at 3 months and longest available follow up (random effects analysis)

Figure E-155: TUMT vs. TURP: Quality of life (IPSS question) at 3 and 6 months postoperatively

Figure E-156: TUMT vs. TURP: quality of life (IPSS question) at 12 months postoperatively (random effects analysis)

Figure E-157: TUMT vs. TURP: quality of life (IPSS question) at 48 and 60 months postoperatively

T.

Terrat

The state

Tanta

Figure E-158: TUMT vs. TURP: All cause mortality and complications

Continued Figure E-158: TUMT vs. TURP: Complications

ES ----References References

Figure E-159: TUMT vs. TURP: Complications - Incontinence and retrograde ejaculation (random effects analysis)

ET

632 of 754

4.3.3 TUMT vs. Laser

See section 4.2.5 Laser coagulation vs. TUMT (Transurethral Microwave Thermotherapy)

4.4 TUVP

4.4.1 TUVP vs. TURP

Figure E-160: TUVP vs. TURP: Symptom score at 3, 6 and 12 months and 5 years or more postoperatively (fixed effects model)

Cian Cian Cian Figure E-161: TUVP vs. TURP: Symptom score at 2 and 3 years postoperatively (random effects analysis)

States -

Figure E-162: TUVP vs. TURP: Quality of life (IPSS question)

Figure E-163: TUVP vs. TURP: Quality of life (IPSS question) – 1 year and 2 year postoperatively (random effects analysis)

T

Figure E-164: TUVP vs. TURP: Qmax(ml/s) at 3 months (fixed effect analysis) and longest available follow up(random effects analysis)

-----**T**

Figure E-165: TUVP vs. TURP: All cause mortality and complications

636 of 754

Continued Figure E-165: TUVP vs. TURP: All cause mortality and complications

Figure E-166: TUVP vs. TURP: Complications – retrograde ejaculation (random effects analysis)

 T_{ext}

4.4.2 Bipolar TUVP vs. TURP

Figure E-167: Bipolar TUVP vs. TURP: Symptom score

Т

Figure E-169: Bipolar TUVP vs. TURP: All cause mortality and complications

4.4.3 TUVP vs. Laser

See section 4.2.6 Laser vs. TUVP (Transurethral Vapourisation of the Prostate)

4.5 Transurethral Needle Ablation of the Prostate (TUNA)

4.5.1 TUNA vs. TURP

Figure E-170: TUNA vs. TURP: Symptom score

Figure E-171: TUNA vs. TURP: Quality of life (IPSS question)

Figure E-172: TUNA vs. TURP: Qmax(ml/s)

All and a

Figure E-173: TUNA vs. TURP: All cause mortality and complications

4.6 Transurethral Incision of the Prostate (TUIP)

4.6.1 TUIP vs. TURP

Figure E-174: TUIP vs. TURP: Symptom score

T

Figure E-175: TUIP vs. TURP: Quality of life (IPSS question)

Figure E-176: TUIP vs. TURP: Qmax (ml/s)

EDC=T

Figure E-177: TUIP vs. TURP: All cause mortality and complications

Figure E-178: TUIP vs. TURP: Complications – retrograde ejaculation (random effects analysis)

<u>ToT</u>

4.6.2 TUIP vs. TURP in AUR patients

Figure E-179: TUIP vs. TURP in AUR patients: All cause mortality and complications

4.6.3 TUIP vs. HOLEP

See 4.1.3HoLEP vs. Transurethral Incision of the Prostate (TUIP)

4.7 Botulinum toxin in the prostate

4.7.1 Botulinum toxin vs. placebo

Figure E-180: Botulinum toxin vs. placebo: Symptom score at 1- and 2-month follow up

____T

-

Figure E-181: Botulinum toxin vs. placebo: Qmax (ml/s) at-2 month follow up

Figure E-182: Botulinum toxin vs. placebo: Complications (urinary incontinence) – 2 month follow up

4.8 Transurethral Vapouresection of the Prostate (TUVRP)

4.8.1 TUVRP vs. TURP

Figure E-183: TUVRP vs. TURP: Symptom score at 3 months, 1 year and 2 years follow up

Figure E-184: TUVRP vs. TURP: Symptom score at 6 months follow up (random effects analysis)

 $\mathbf{T}_{max}\mathbf{T}$

Figure E-185: TUVRP vs. TURP: Quality of life (IPSS question)

1000 - 10000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1000 - 1

Figure E-186: TUVRP vs. TURP: Qmax (ml/s)

T

Figure E-187: TUVRP vs. TURP: All cause mortality and complications

Figure E-188: TUVRP vs. TURP: Complications – retrograde ejaculation (random analysis)

Film

-

4.8.2 Bipolar TUVRP vs. TURP

Figure E-189: Bipolar TUVRP vs. TURP: Symptom score at 3-month follow up

Figure E-190: Bipolar TUVRP vs. TURP: Quality of life (IPSS question) at 3-month follow up

Figure E-191: Bipolar TUVRP vs. TURP: Qmax(ml/s) at 3-month follow up

652 of 754

Figure E-192: Bipolar TUVRP vs. TURP: Complications

E.T

4.9 Transurethral Ethanol Ablation of the Prostate (TEAP)

4.9.1 TEAP vs. TURP

Figure E-193: TEAP vs. TURP: Complications

4.10 Open Prostatectomy (OP)

4.10.1 Open prostatectomy vs. HOLEP

See section 4.1.4 on HOLEP vs. Open prostatectomy (OP)

4.10.2 Open prostatectomy vs. laser vapourisation

See section 4.2.4 on Laser (photoselective vapourisation) vs. Open prostatectomy(OP)

4.11 Transurethral Resection of the Prostate TURP

4.11.1 TURP vs. Watchful Waiting

Figure E-194: TURP vs. Watchful waiting: Qmax (ml/s)

Figure E-195: TURP vs. Watchful waiting: All cause mortality and complications

Figure E-196: Bipolar TURP vs. TURP: Symptom score

Figure E-197: Bipolar TURP vs. TURP: Quality of life (IPSS question)

Figure E-198: Bipolar TURP vs. TURP: Qmax (ml/s) at 3 months or longest available follow up

Ŧ

658 of 754

Figure E-199: Bipolar TURP vs. TURP: All cause mortality and complications

Continued Figure E-199b: Bipolar TURP vs. TURP: All cause mortality and complications

4.11.3 TURP vs. TUVP

See section 4.4.1 TUVP vs. TURP

4.11.4 TURP vs. TUNA

See section 4.5.1TUNA vs. TURP

4.11.5 TURP vs. Laser

See sections 4.2.1 Laser Coagulation vs. TURP, 4.2.2 Laser coagulation vs. TURP in AUR patients, 4.2.3 Laser Vapourisation vs. TURP

4.11.6 TURP vs. TUMT

See section 4.3.2 TUMT vs. TURP

4.11.7 TURP vs. TUIP

See section 4.6.1 TUIP vs. TURP

4.11.8 TURP vs. HoLEP

See section 4.1.1 HoLEP vs. TURP

4.11.9 **TURP vs. TUVP**

See section 4.4.1 TUVP vs. TURP

4.11.10 TURP vs. Bipolar TUVP

See section 4.4.2 Bipolar TUVP vs. TURP

4.11.11 TURP vs. TUVRP

See section 4.8.1 TUVRP vs. TURP

4.11.12 TURP vs. Bipolar TUVRP

See section 4.8.2 Bipolar TUVRP vs. TURP

4.11.13 TURP vs. TEAP

See section 4.9.1 TEAP vs. TURP

5 Surgical vs. Medical Interventions

There are no forest plots for this section

6 Medical vs. Conservative Interventions

No results found – no forest plots

663 of 754

7 Surgical vs. Conservative Interventions

7.1.1 Bladder training vs. TURP

Figure E-200: Bladder training vs. TURP: Symptom score change at 6 months follow up

Figure E-201: Bladder training vs. TURP: Symptom score change at 6 months follow up

Figure E-202: Bladder training vs. TURP: Qmax (ml/s) change at 6 months follow up

7.1.2 Self-catheterisation vs. TURP

Figure E-203: Self catheterisation vs. TURP in men with chronic urinary retention: Symptom score change at 6 months follow up

Figure E-204: Self catheterisation vs. TURP in men with chronic urinary retention: quality of life (IPSS question) change at 6 months follow up

8 Urinary retention

8.1.1 Acute urinary retention

Figure E-205: Alpha-blockers vs. placebo in men with acute urinary retention: Able to void

Figure E-206: Alpha-blockers vs. placebo in men with acute urinary retention: Re-catheterisation

Elin **T**

8.2 Chronic retention

See forest plots in section surgery vs. conservative and conservative

9 Alternative and complementary therapies

29.1 Phytotherapy vs. placebo

3 9.1.1 Beta-sitosterol

4 Figure E-207: Beta-sitosterol vs. placebo: Symptom score

5 6 - व

7 Figure E-208: Beta-sitosterol vs. placebo: Qmax (ml/s)

9.1.2 Serenoa repens

- 2 Figure E-209: Serenoa repens vs. placebo: Symptom score
 - ---**T**

3

1

4 Figure E-210: Serenoa repens vs. placebo: Qmax (ml/s)

Eiler **X**

5

6 Figure E-211: Serenoa repens vs. placebo: Quality of life (IPSS question)

7

- 8 9.1.3 Urtica diocia
- 9 Figure E-212: Urtica diocia vs. placebo: Symptom score

10

667 of 754

1	Figure E-213: Urtica diocia vs. placebo: Qmax (ml/s)
2 3	
4	9.1.4 Pygeum
5	Figure E-214: Urtica diocia vs. placebo: Qmax(ml/s)
5	
6	
0	
7	9.1.5 Cernilton
8	Figure E-215: Cernilton vs. placebo: Qmax (ml/s)
9	
10	9.1.6 Phytotherapy combinations
11 12	Figure E-216: Combination of serenoa repens and uritca diocia vs. placebo: Symptom score

1 Figure E-217: Combination of serenoa repens and uritca diocia vs. placebo: Qmax (ml/s)

2

T

3 Figure E-218: Combination of pygeum and uritca diocia vs. placebo: Symptom score

6 Figure E-219: Combination of pygeum and uritca diocia vs. placebo: Qmax (ml/s)

7

4 5

8 Figure E-220: Combination of pygeum and uritca diocia vs. placebo: Quality of life (IPSS
 9 question)

- 11 Figure E-221: Combination of cernitin, serona repens, phytosterol and Vitamin E vs.
- 12 placebo: Symptom score
- 13

- 1 Figure E-222: Combination of cernitin, serona repens, phytosterol and Vitamin E vs.
- 2 placebo: Qmax (ml/s)
- 3

49.2 Phytothearpy vs. Alpha-blockers

- 5 9.2.1 Serenoa repens vs. Alpha-blockers
- 6 Figure E-223: Phytotherapy vs. Alpha-blockers: Symptom score

T=3

7

8 Figure E-224: Phytotherapy vs. Alpha-blockers: Quality of life (IPSS question)

9

10 Figure E-225: Phytotherapy vs. Alpha-blockers: Qmax (ml/s)

1	Figure E-226: Phytotherapy vs. Alpha-blockers: Urinary retention
2	
3 9.3	Phytotherapy vs. 5-ARI
4	9.3.1 Serenoa repens vs. 5-ARI
5	Figure E-227: Serenoa repens vs. 5-alpha-reductase inhibitors: Symptom score
6	
7 8	Figure E-228: Serenoa repens vs. 5-alpha-reductase inhibitors: quality of life (IPSS question)
0	

- 9
- Figure E-229: Serenoa repens vs. 5-alpha-reductase inhibitors: Qmax (ml/s) at longest
 available follow up

1	Figure E-230: Sereno	a repens vs. 5-alpha-reductase inhibitors: Urinary retention
	I	
2		
3	9.3.2	Serenoa repens and urtica diocia vs. 5-ARI
4 5	Figure E-231: Sereno score	a repens and urtica diocia vs. 5-alpha-reductase inhibitors: Symptom

```
6
7
```

8 Figure E-232: Serenoa repens and urtica diocia vs. 5-alpha-reductase inhibitors: Qmax
 9 (ml/s) at 3 months and 12 months

1 **10 Provision of information**

210.1 Educational intervention vs. no intervention

3 Figure E-233: Interactive video vs. no intervention: Decisional conflict score

4

T

510.2 Self management vs. standard care

6 Figure E-234: Self management vs. standard care: symptom score

7

8 Figure E-235: Self management vs. standard care: Treatment failure

Appendix F - Cost-effectiveness analysis

2

3 10.1 Introduction

4 Two original cost-effectiveness analyses were carried out to answer the clinical 5 questions on transurethral resection of the prostate (TURP) vs. laser (Chapter 8), 6 and the clinical question on Alpha-blockers (AB) alone or in combination with 5-7 Alpha Reductase-Inhibitors (5-ARI) (Chapter 6). Throughout the guideline we 8 refer to these two analyses respectively as 'NCGC Surgery Model' and 'NCGC 9 Combination model'.

10 10.2 Methods

A review of the literature was conducted followed by economic modelling of the
 cost-effectiveness of the listed interventions in England and Wales. The literature
 search and review methods can be found in Chapter 2.

Our aim in constructing the models was to determine the most cost-effective
strategy in men considering respectively surgery and medical treatment. Those
would be mainly men with moderate to severe lower urinary tract symptoms
(LUTS).

18 We found a number of economic evaluations in the published literature 19 (Chapters 6 and 8), among which a Health Technology Assessment (HTA) model 20 of good quality¹⁵⁰. However the Guideline Decisional Group (GDG) felt that 21 they needed an original model with slightly different assumptions and data in 22 order to make a recommendation with confidence.

- 23 The following general principles were adhered to:
- The GDG was consulted during the construction and interpretation of the
 model.
- When published data was not available we used expert opinion to
 populate the model.
- Model assumptions were reported fully and transparently.
- The results were subject to sensitivity analysis and limitations were discussed.
- We followed the methods of the NICE reference case¹⁸⁶. Therefore costs
 were calculated from a health services perspective. Health gain was
 measured in terms of quality-adjusted life-years (QALYs) gained. Both
 future costs and QALYs were discounted at 3.5%.
- The model employed a cost-effectiveness threshold of £20,000 per
 QALY gained.
- The model was peer-reviewed by another health economist at the NCGC.

1 **10.2.1 Software**

- 2 The cost-effectiveness analyses were conducted using TreeAge Pro 2008.
- 3

4 10.3 NCGC Surgery model

5 10.3.1 General method

6 We based the model on two of the main outcomes considered in our systematic 7 review of the clinical evidence (Chapter 2.4): mean IPSS change from baseline 8 and adverse events. We chose IPSS change because it better expresses the 9 change in quality of life as felt by the patient compared to other clinical 10 measures such as Qmax. Consequently, it was easier to find data linking utility 11 values to levels of symptoms.

- Since LUTS are a lifelong condition, we built a Markov model with a life time
 horizon and we changed this in a sensitivity analysis. The cycle length is three
 months, as this was deemed the minimum clinically meaningful time interval to
 detect differences in patients undergoing surgery.
- All the probabilities, costs and health utilities were converted in order to reflectthe three-month values.
- 18The treatments compared in our analysis are TURP and Holmium Laser19Enucleation of Prostate (HoLEP). TURP is the current standard practice and HoLEP20was one of the alternative treatments that were significantly effective as21compared to TURP. Transurethral electrovaporisation of prostate (TUVP) was22another effective treatment as compared to TURP but the available economic23evidence was considered sufficient to prove it cost-effective.
- Patients in the studies included in our clinical review had a moderate-to-severe
 level of symptoms. Therefore patients in our model were defined as men with
 moderate-to-severe LUTS who are suitable for either TURP of HoLEP.
- Both arms of the model have the same structure (Figure 237): after the
 intervention, the patient can either have a significant remission of symptoms
 (success) or no remission/minor remission (failure).
- Short-term complications identified in the clinical review (see Appendix E) were assumed to be resolved within 3 months (the cycle length) and could occur with a probability independent from the success. Incontinence is the only long-term adverse event and in some cases it requires an artificial urinary sphincter (AUS). If the man still has storage LUTS together with incontinence, he will not undergo further de-obstructive surgery, therefore he will remain in this health state throughout the model.
- Men who initially had a successful outcome can have deterioration in symptoms
 and end up with residual LUTS state. Some of them will undergo further de obstructive surgery if incontinence is not present, and some will be medically
 treated. The second surgery is always TURP, even in the HoLEP arm, as the
 experts in the GDG believe that HoLEP is unlikely to be performed twice. We


- varied the structure between the two arms in a structural sensitivity analysis
 where we assumed TURP was not possible after HoLEP either.
- 3 The list of the health states that are part of the model is reported in Table 1.

4 **Table 1 - Health states**

HEALTH STATES
(Moderate-to-Severe) LUTS
Remission
LUTS + Incontinence
LUTS + Incontinence AUS
Incontinence
Incontinence AUS

5

6 The experts of the GDG members have defined a significant remission of 7 symptoms after surgery as a change in IPSS greater than five. This was agreed 8 after considering that the minimally important difference is estimated as 3 points 9 (Barry 1998) but a more consistent improvement is expected after an invasive 10 intervention. It was agreed that a change by 5 points would constitute a 11 treatment success.



1

Figure 236 - Model structure. The health states are represented by the six blue circles on
 the top right corner. The arrows represent the possible transitions from a state to another
 or to the same state.

5

19

20

For each strategy the expected healthcare costs and expected QALYs were
calculated by estimating the costs and QALYs for each state and then multiplying
them by the proportion of patients who would be in that state as determined by
the strategy taken.

- We performed a probabilistic sensitivity analysis (SA) to test the robustness of
 the results against the imprecision of these estimates and the other model
 parameters, and to obtain more accurate estimates of expected costs and
 QALYs.
- We identified sensitive parameters with a threshold analysis and then conducted
 multi-way sensitivity analyses on those parameters at decision point.

16 10.3.2 Key assumptions

- The experts in the GDG were consulted in order to make the followingassumptions:
 - a) After a relapse in symptoms, only 5% of patients will undergo a second TURP. The remaining 95% are treated medically.
- b) The probability of success of the same intervention when performed a
 second time is 75% the probability of success when performed for the
 first time.

c) The proportion of men with incontinence after surgery/laser requiring an AUS is 5%. The remaining 95% are treated medically or with incontinence products (catheters, pads, etc).

4 10.3.3 Probability of success - TURP

We searched for an RCT which reported the probability of success of either
TURP or HoLEP as defined in our model (change in IPSS≥5). We found only one
large multicentre RCT⁸³ where 120 of the randomised patients received TURP
while the other 115 received TUVP. Data from this study⁸³ that were used in the
model are reported in Table 2.

10 Table 2 - Data on TURP used in the model (a)

· · · · · · · · · · · · · · · · · · ·		
	Data used in the model	
IPSS at baseline (IPSS pre)	20.7 (SD 6.9)	
IPSS at 6 months (IPSS post)	6.9 (SD 5.5)	
Probability of success of TURP at 6 months	85.4%	
Probability of success of TURP at 24 months	84.0%	

(a) From Fowler et al. (2005)⁸³

13 10.3.4 Probability of success - HoLEP

We could not find similar data for HoLEP so we adopted an alternative
 approach, linking the probability of success of the two interventions using the
 IPSS change data from our clinical review.

17

11

12

1

2

3

Table 3 - Effectiveness from meta-analysis

	HoLEP vs. TURP
Weighted Mean Difference (WMD) from baseline IPSS at 6 months	- 0.52
WMD from baseline IPSS at 24 months	- 0.80

18

19 10.3.4.1 Setting up the precondition

- 20 IPSSpost is the mean IPSS after the intervention and it is equal to:
- 21 I IPSSpost = Psuccess * IPSSsuccess + (1-Psuccess) * IPSSfail
- 22 Where IPSSfail and IPSSsuccess are respectively the mean IPSS in the group of 23 patients whose treatment has failed and the mean IPSS in the group of patients 24 whose treatment was successful.

1 By assuming that IPSSfail is the same for both TURP and HoLEP and also that 2 IPSSsucess is the same for both, we can estimate the success rate for HoLEP.

- 3 10.3.4.2 Deriving IPSS after a TURP failure
- 4 II IPSSfail = IPSSpre Δ IPSSfail

5 Where Δ IPSSfail is the change in IPSS in patients for whom the intervention has 6 failed. By definition this must be ≤ 4 . Assuming in some patients the symptoms 7 might have deteriorated, we can consider the range -1 to 4, and use the central 8 value 1.5, which is then varied in a sensitivity analysis. Substituting this value in II 9 and using the data from TURP we get IPSSfail = 20.7 - 1.5 = 19.2

10 10.3.4.3 Deriving IPSS after a successful TURP

- 11 We can rearrange equation I as
- 12 III IPSSsuccess = (IPSSpost- (1-Psuccess)xIPSSfail)/P(success)
- 13 Using data from Table 2 and our result for IPSSfail from 10.5.4.2 we get:

14 IV IPSSsuccess =
$$(6.9 - 14.6\%^{*}19.2)/85.4\% = 4.8$$

- 15 10.3.4.4 Deriving IPSS after HoLEP
- The mean difference in change in IPSS from baseline to 6 months was -0.52
 compared with TURP (Chapter 8.3.1). The IPSS 6 months after HoLEP is simply
 the IPSS at 6 months for TURP plus this difference:
- 19 V IPSSpost=6.9-0.52=6.4

20 10.3.4.5 Calculating the probability of HoLEP success at 6 months

- 21 We rearranged equation I to give us:
- 22 VI Psuccess= (IPSSpost-IPSSfail)/(IPSSsuccess-IPSSfail)
- 23 Substituting the values derived above (10.5.4.2, 10.5.4.3, 10.5.4.4) we get:
- 24 VII Psuccess = (6.4-19.2)/(4.8-19.2) = 88.9%

25 10.3.5 Probability of relapse

- According to the data reported in Fowler et al (2005)⁸³, TURP was more effective after 6 months than after 24 months, as only 84% of patients had an improvement in symptoms by at least 5 points at 24 months compared to 85.4% of patients at 6 months Table 2. To mimic what happens in real practice, where a relapse in symptoms sometimes follows an initial improvement, it was necessary to incorporate a time-dependent probability of relapse after an initial success.
- The probability of relapse between these two intervals (6 months and 24 months)is calculated as follows:
- 34 VIII (P success 6 months P success 24 months)/P success 6 months
- 35 Which in case of TURP is equal to (85.4% 84%)/85.4% = 1.6%

- 1 We converted the probability of relapse of TURP over 18 months into a 3-month 2 rate, which is the cycle length of the model, by using the formula:
- 3 **IX** 1 - exp((ln(1 - relapse 1 8 months))/6)
- 4 We used the same probability of relapse for HoLEP (a conservative assumption).

5 10.3.6 **Probability of complications**

6 Several complications of HoLEP and TURP were identified in the systematic 7 review (Appendix E). In our economic model we only included those that would 8 require additional treatment and generate additional costs.

9 To calculate the probability of complications following TURP (Table 4), we 10 aggregated data from the TURP arm in every study included in our review, 11 excluding the duplicates. We then compared the incidences of adverse events 12 after TURP with those reported in the AUA¹¹ and we found no considerable 13 difference.

14 The incidence of complications following HoLEP (Table 4) was estimated by 15 multiplying their probability after TURP by the risk ratio (RR) of HoLEP compared to TURP.

16

	TURP	HoLEP	
	Probability	RR vs. TURP	Probability
Incontinence	4.0%	1.19	4.8%
Blood transfusion	6.2%	0.27	1.8%
Acute urinary retention (AUR)	3.9%	0.71	2.8%
Urinary tract infections	6.9%	0.45	3.1%
Transurethral syndrome	2.0%	0.31	0.6%
Strictures	7.2%	0.69	5.0%

17 Table 4 - Probability of complications

18

19 All the adverse events were assumed to occur within three months after the 20 intervention, and so within the same cycle in the model. All of them have 21 associated one-off costs (see 10.5.11) and no detriment in quality of life with the 22 exception of incontinence which has a lifetime cost and disutility (10.5.8).

23 10.3.7 Life expectancy

24 The mean age of the men when entering the model was 71 as this was the mean 25 age of men in the diagnosis-related group 'Hyperplasia of prostate' in the 26 Hospital Episode Statistics 2006/07.

27 Life expectancy in patients with LUTS was assumed to be the same as the 28 general population in England and Wales. The remaining life expectancy for 29 men aged 71 is 12.99 years, as reported in the Life Tables for the general

- population of England and Wales in the year 2005-2007 from the Government
 Actuary Department
- 3 (http://www.gad.gov.uk/Documents/Demography/EOL/ILT%202005-
- 4 07/wltewm0507.xls).

5 10.3.8 Quality of life

6 The utility scores in Table 5 are a measure of the quality of life associated with 7 LUTS and incontinence. A systematic search for quality of life in men with LUTS 8 and with incontinence was performed (Appendix C). Studies were included if 9 they reported utility values for the states of LUTS or incontinence.

- 10 Studies reporting utilities specific to non-compared interventions were excluded.
- 11 Two studies^{18,173} were excluded because the values were obtained from 12 consensus rather than from patients or general public.
- Kok et al (2002)¹³⁰ reported utility values according to the obstructive and
 irritative dimension of IPSS. However, using this study to estimate an average
 utility score for LUTS would have required further assumptions on the nature of
 the symptoms.
- Ackerman et al (2000)⁶ assessed the preference of 13 patients to health states
 with the standard gamble technique. We excluded this study due to the small
 sample size but we used it as an alternative source of data in the sensitivity
 analysis.
- Trueman et al (1999)²⁵⁶ designed a survey to collect EQ-5D scores by symptoms severity in 1115 men in the UK. The results of this study²⁵⁶ were used in our model and are reported in Table 5. Although the population in the model is made of men with moderate-to-severe LUTS we used the utility value for severe LUTS as 20.7 was the average IPSS of this population.
- We found a UK study⁵⁰ reporting the deterioration in quality of life caused by incontinence. A multivariate analysis of EQ-5D scores, found that after controlling for age, gender and body mass index, incontinence was associated with a reduction in the EQ-5D score by 0.11 (SE 0.026). This value was subtracted from the remission and LUTS utility scores for the health states respectively characterised by symptoms remission and Incontinence and LUTS and Incontinence. The values thus obtained are reported in Table 5.
- Among patients with incontinence, 5% require an artificial urinary sphincter while
 the remaining 95% are treated pharmacologically or with incontinence products.
 The utility score does not differ for these two subgroups.
- 36 Other adverse events were assumed to be negligible in terms of quality of life 37 because they could be promptly treated.
- 38
- .
- 39
- 40

	Utility score
Remission (a)	0.91
LUTS (a)	0.71
Remission + Incontinence (a, b)	0.80
LUTS + Incontinence (a, b)	0.60

Table 5 - Utility values

(a) Source: Trueman at al (1999)²⁵⁶

(b) Source: Currie et al (2006)⁵⁰

- 6 10.3.9 Calculating QALYs gained
 - For each strategy, the expected QALYs in each cycle are calculated as follows:

8 X Expected QALYs =
$$\Sigma$$
 (U_i x P_i)

9 where

1

2 3 4

5

- 10 U_i = the utility score for health state i
- 11 P_i = the proportion of patients in health state i
- 12 and where health state i could be any of the health states reported in Table 1.
- 13 The proportion of patients in each health state depends on the effectiveness of 14 the treatment, in terms of symptoms improvement and incontinence, and on the 15 proportion of patients still alive, which falls as the number of cycles and 16 therefore age increases.
- 17 The overall lifetime expected QALYs are given by the sum of QALYs calculated 18 for each cycle. The incremental QALYs gained associated with a treatment 19 strategy are calculated as the difference between the expected QALYs with that 20 strategy and the expected QALYs with the comparator.
- 21 10.3.10 Cost of interventions
- 22 We adopted a bottom-up approach to calculate the intervention cost as 23 differentiating the total costs for the two intervention was not possible by using 24 national sources (NHS Reference Costs or Tariffs) or published evidence. In fact, 25 no UK study could be found which reported the cost of HoLEP as this is 26 performed only in a few UK centres only while TURP is a widespread technique. 27 For this reason we decided to include only the capital cost of the HoLEP 28 equipment as the TURP equipment is already present in every Urology centre. 29 Only disposables used in TURP were included in the calculation.
- We contacted the UK supplier of HoLEP equipment (SIGMACON) to obtain precise data on the cost of the machine and the cost and number of uses of disposables. We assumed the life span of the machine is 10 years. As we want to estimate the cost of the machine per patient, the GDG had to estimate the number of patients per centre undergoing surgery for LUTS in a year.

- 1 We found the cost of TURP disposables in a study⁸³ and the GDG estimated the
- 2 number of uses. The data thus collected are reported in Table 6.
- In addition to the cost of equipment, other factors influencing the total costs are
 the operating theatre cost, the length of stay after the intervention, and the
 complications. The costs of operating theatre and hospital stay are reported in
 Table 6 while the costs of complications are described in 10.5.11.

Table 6 – Resources used ar		
	HoLEP	Source
Cost of HoLEP machine	£150,000	UK supplier (SIGMACON)
Lifespan of HoLEP	10 years	Assumption
Number of patients per year per HoLEP machine	280	Expert opinion
Cost of morcellator blades (HoLEP)	£595 each	UK supplier (SIGMACON)
Number of uses per blade	10	UK supplier (SIGMACON)
Cost of fibres (HoLEP)	£550 each	UK supplier (SIGMACON)
Number of uses per fibre	20	UK supplier (SIGMACON)
Cost of loops (TURP)	£47	Expert opinion
Number of uses per loop	10	Expert opinion
Operating time TURP	60 minutes	Systematic review (Appendix E) (a)
Operating time HoLEP	75 minutes	Systematic review (Appendix E) (a)
Cost of urology operating theatre	£9 per minute	Local cost estimate
Median length of hospital stay after TURP (b)	3 days	Hospital Episode Statistics 2006/07
Median length of hospital stay after HoLEP (b)	2 days	Hospital Episode Statistics 2006/07
Mean cost per bed day	£204	National Schedule of Reference Costs 2006-07 for NHS Trust & PCT Combined – HRG LB25C

Table 6 – Resources used and costs

13

7

(a) Mean number of times reported in Gupta et al (2006)⁹⁷ and Montorsi et al (2004)¹⁷⁷.

(b) The median was used as an estimate of the mean to exclude outliers probably due to complications.

The annual cost of the HoLEP machine is a function of the capital cost of the machine, its life span and the discount rate according to the formula:

14 **XI**
$$E = K^*r/[1-(1+r)^{-n}]$$

1	where $E = annual cost of the machine$
2	K = capital outlay (cost of purchasing the machine)
3	r = discount rate / interest rate = 3.5%
4	n = lifespan
5	The total cost of a single intervention can be represented by the formula:
6	XII TCi = $E/np + cDisp_i + opT_i^*cTheatre + cComp * pComp_{A-i}$
7	Where $TC_i = total cost of the intervention i$
8	E = annual cost of machine (only HoLEP)
9	np = number of patients using the machine per year
10	$cDisp_i = cost of disposables of intervention i$
11	$opT_i = operating time of intervention i$
12	cTheatre = cost of theatre per minute
13	$cComp_A = cost of treating complication A (Table 7)$
14	$pComp_{A-i} = probability of complication A after intervention i (Table 4)$
15	where i is either TURP or HoLEP and A is any complication described in Table 7.
16	10.3.11 Cost of complications
17	The complications included in the model and their probabilities are reported in

17 Ine complications included in the model and their probabilities are reported in 18 10.5.6. The GDG estimated the resources used to treat each complication as 19 shown in Table 7 with the exception of acute urinary retention for which we used 20 a UK economic study¹⁴. When a procedure could be performed as a daycase or 21 inpatient, we checked this proportion in the Hospital Episode Statistics 2006/07 22 ².

	COST	SOURCE
Blood transfusion	£635 (a)	Varney et al (2003) ²⁶⁶
Stricture	£706 (b)	National Schedule of Reference Costs 2006- 07 – HRG code LB30B
Acute urinary retention	£2,029 (c)	Annemans et al (2005) ¹⁴
Trans-urethral syndrome	£1,710 (d)	National Schedule of Reference Costs 2006- 07: 1) High Dependency Unit – 0 organs supported XC07ZHDU; plus 2) Excess bed day - HRG LB25C
Urinary tract infections	£742 (e)	National Schedule of Reference Costs 2006

23 Table 7 - Cost of complications

0	07– HRG code LA04C

- (a) cost of a transfusion of red blood cells
- (b) weighted cost $\pounds 509 \times 54\%$ (daycase) + $\pounds 938 \times 46\%$ (inpatient)
- (c) cost of the most cost-effective intervention to treat AUR in the study
 - (d) cost of tow days in HDU and two days in normal ward
 - (e) weighted cost \pounds 376 x 10% (daycase) + \pounds 783 x 90% (inpatient)

7 Incontinence is a complication but it is also a health state in the model so its cost is 8 calculated separately in 10.5.12.

9 10.3.12Cost of health states

123456

10 The possible health states in which a patient could be in the model are listed in Table

11 1. By collecting information on the resources used while in these states from the GDG

12 experts, we calculated the costs reported in Table 8.

13 When the patient has a remission of symptoms, we assumed no further treatment would 14 be necessary and this state has no cost associated.

15 If after the intervention a patient still has LUTS, he would undergo urodynamic studies

16 to investigate the cause of the intervention failure. He would then be treated with

17 either anticholinergics or alpha-blockers and be recalled for a visit every six months.

18 We assumed that 50% would be treated with anticholinergics and 50% with alpha-

19 blockers. The details of the cost calculations are reported in Table 8.

Resources used	Proportion of patients using the resource	Unit cost of resource	Total cost per month per patient
Alpha-blockers	50%	£0.35 (a)	£5.32
5mg Oxybutynin twice daily	25%	£0.39 (b)	£5.93
Other Anticholinergics	25%	£1.05 (c)	£15.97
One visit every 6 months	100%	£75 (d)	12.50
TOTAL			£39.72
Urodynamic studies (one-off)	100%	£165 (e)	-

20 Table 8 - Cost of residual LUTS state

21 22 23 24 25 26 27 (a) Average cost per day of Alfuzosin, Tamsulosin, Doxazosin, and Prazosin (BNF 57)

(b) Cost of treatment per day (BNF 57)

- (c) Average cost per day of Darifenacin, Solifenacin, Tolterodine, Trospium, Propiverine and Fesoterodine (BNF 57)
- (d) From National Schedule of Reference Costs 2006-07– Consultant led follow-up attendance outpatient face-to-face - Urology
- (e) From National Schedule of Reference Costs 2006-07 Outpatient procedure LB42Z
- 28

29 To estimate the cost of incontinence in men treated with drugs or products we searched 30 for UK cost-of-illness studies excluding those studies conducted in women. We did not 31 find any so we estimated the resources and their costs with the help of experts from 32 the GDG (Table 9).

Resources used	Proportion of patients using the resource	Unit cost of resource	Total cost per month per patient (f)
3 ISC catheters per day	25%	£1.30	£29.66
1 indwelling catheter every 6 weeks	25%	£6.00	£1.08
5mg Oxybutynin twice daily	50%	£0.39 (a)	£5.93
Other anticholinergics	50%	£1.05 (b)	£15.97
1 pad a day	25%	£0.34	£2.58
1 leg bag per week	25%	£2.50	£2.71
1 overnight bag per night	25%	£0.10	£0.76
1 bag support, leg sleeve and Stalock Bard per week	25%	£6.00	£6.50
Sheath appliances	25%	£40.00 (c)	£10.00
1 district nurse visit per week	100%	£21.00 (d)	£91.00
1 specialist nurse visit every 6 months	100%	£66.00 (e)	£11.00
TOTAL			£177.19

1 Table 9 - Cost of incontinence in men treated with products or drugs

(a) Cost of treatment per day (BNF 57)

- (b) Average cost per day of Darifenacin, Solifenacin, Tolterodine, Trospium, Propiverine and Fesoterodine (BNF 57)
- (c) Estimate on cost per month rather than number of items.
- (d) From Curtis (2008)⁵¹ cost of district nurse per home visit including travel, excluding qualification
- (e) From Curtis (2008)⁵¹ cost of specialist nurse per hour of client contact, excluding qualification

(f) These figures account for the proportion of patients who use that resource

9

2345678

10 In the model, 5% of the men with incontinence have an AUS implanted. The costs associated with this intervention are the one-off cost of urodynamic studies, the cost of implanting the AUS and the recurrent visits. The AUS needs to be re-implanted on average every ten years and this is taken into account in the model with a recurrent

14 cost of the operation (Table 10).

15 Table 10 - Cost of artificial urinary sphincter (AUS)

Resources used	Frequency	Unit cost of resource	Source of cost
AUS implant	10 years	£4,137	National Schedule of Reference Costs 2006-07– HRG code LB21Z
Urology visit	6 months	£75	National Schedule of Reference Costs 2006-07– Consultant led follow-up attendance – outpatient face-to-face – Urology
Urodynamic studies	One-off	£165	National Schedule of Reference Costs 2006-07 - Outpatient procedure LB42Z

- 1
- The costs associated with the 'LUTS + Incontinence' state are similar to the costs of the Incontinence state, while the 'LUTS + Incontinence AUS' state generates the same costs as the 'LUTS+Incontinence AUS' state with the addition of the anticholinergics (in 50% of the men) and alpha-blockers (in the other 50%).
- 6 For each strategy, the expected cost per cohort of patients is calculated as follows:

7 XIII Expected cost =
$$C_s + \sum_{j=1}^{40} \sum_{i=1}^{6} C_i P_{ij}$$

- 9 where
- 10 $C_s = cost$ of the initial strategy (TURP or HoLEP)
- 11 $C_i = \text{cost of health state i}$
- 12 P_{ij} = proportion of patients in health state i in cycle j
- 13 and where health state i could be any stage in Table 1.
- 14 The proportion of patients in a health state depends on the magnitude of the
- 15 improvement in symptoms specific to each treatment, its probability of causing
- 16 incontinence, and on the proportion of patients still alive according to the mortality
- 17 rate for the general population of England and Wales.
- 18 The overall lifetime expected costs are given by the sum of costs calculated for each 19 cycle. The incremental cost associated with a treatment strategy is calculated as the 20 difference between the expected cost with that strategy and the expected cost with 21 the comparator.
- 22 10.3.13 Probabilistic sensitivity analysis
- A probabilistic sensitivity analysis was performed to assess the robustness of the model
 results to plausible variations in the model parameters.
- 25 Probability distributions were assigned to each model parameter, where there was
- 26 some measure of parameter variability (Table 11). We then re-calculated the main
- 27 results 10000 times, and each time all the model parameters were set simultaneously,
- 28 selecting from the respective parameter distribution at random.

29 Table 11 - Parameters and distributions used in the probabilistic sensitivity analysis

Description of variable	Mean value	Probability distribution	Parameters	Source
IPSS post treatment with TURP after 6 months	6.9	Normal	SD = 0.5102	Fowler et al (2005) ⁸³
IPSS post treatment with TURP after 2 years	7.5	Normal	SD = 0.6633	Fowler et al (2005) ⁸³
Initial IPSS	20.7	Normal	SD=0.6633	Fowler et al (2005) ⁸³

		I =		
IPSS change when treatment fails	1.5	Triangular	Min=0 Likeliest=1.5 Max=3	Assumption
Weighted mean difference of IPSS at 6 months	0.52	Normal	SD=0.4235	Systematic review of clinical effectiveness
Weighted mean difference of IPSS at 2 years	0.8	Normal	SD=0.9847	Systematic review of clinical effectiveness
Capital cost of HoLEP	£150,000	None		UK Supplier SIGMACON
Lifespan of HoLEP machine (years)	10	Gamma (a)	$\alpha = 61.46$ $\lambda = 6.146$	Assumption
Number of patients per year	280	Gamma (a)	$\alpha = 61.46$ $\lambda = 0.2195$	Assumption
Cost of each blade	£595	None		UK Supplier SIGMACON
Cost of each fibre	£550	None		UK Supplier SIGMACON
Cost of each loop	£47	None		Experts opinion
Number of uses of a blade	10	Triangular (b)	Min=5 Likeliest=10 Max=15	UK Supplier SIGMACON
Number of uses of a fibre	20	Triangular (b)	Min=15 Likeliest=20 Max=25	UK Supplier SIGMACON
Number of uses of a loop	10	Triangular	Min=5 Likeliest=10 Max=15	Experts opinion
Cost of operating theatre per minute	£9	Gamma (a)	$\alpha = 61.46$ $\lambda = 6.829$	Local cost estimate
Operating time – HoLEP (minutes)	75	Triangular	Min=55 Likeliest=75 Max=95	Gupta at al (2006) ⁹⁷ and Montorsi at el (2004) ¹⁷⁷
Operating time – TURP (minutes)	60	Triangular	Min=45 Likeliest=60 Max=75	Gupta at al (2006) ⁹⁷ and Montorsi at el (2004) ¹⁷⁷
Cost bed day	£204	Gamma (c)	$\alpha = 4.925$ $\lambda = 0.0241$	National Schedule of Reference Costs 2006- 07 Excess Bed Day HRG code LB25C
Hospital stay after HoLEP (days)	2	Triangular (d)	Min=1 Likeliest=2 Max=3	Hospital Episode Statistics 2006/07

Hospital stay after TURP (days)	3	Triangular (d)	Min=2 Likeliest=3 Max=4	Hospital Episode Statistics 2006/07
Cost of residual LUTS state	see 10.5.12	None		NCGC calculations
Cost of incontinence per three months (see 10.5.12)	£510	Gamma (a)	$\alpha = 61.46$ $\lambda = 0.1205$	NCGC calculation of cost of health states
Cost of AUS	£4,137	Gamma (c)	$\alpha = 7.089$ $\lambda = 0.0017$	National Schedule of Reference Costs 2006- 07 HRG code L25 – LB21Z
Cost of treating AUR	£2,029	Gamma (a)	$\begin{array}{l} \alpha = 61.46 \\ \lambda = 0.0303 \end{array}$	Annemans2005 ¹⁴
Cost of treating TUR	See Table 7			
Cost of HDU per day	£651	Gamma (c)	$\alpha = 5.096$ $\lambda = 0.0078$	National Schedule of Reference Costs 2006- 07 HDU – 0 organs supported XC07ZHDU
Cost of multichannel cystometry	£165	Gamma (c)	$\alpha = 4.094$ $\lambda = 0.0248$	National Schedule of Reference Costs 2006- 07 Outpatient procedure LB42Z
Cost of treating strictures – daycase	£509	Gamma (c)	$\begin{array}{l} \alpha = 4.055 \\ \lambda = 0.008 \end{array}$	National Schedule of Reference Costs 2006- 07 non elective LB30B
Cost of treating strictures – inpatient	£938	Gamma (c)	$\begin{array}{l} \alpha = 3.344 \\ \lambda = 0.0036 \end{array}$	National Schedule of Reference Costs 2006- 07 non elective LB30B
Cost of blood transfusion	£635	Gamma (a)	$\begin{array}{l} \alpha = 61.46 \\ \lambda = 0.0968 \end{array}$	Varney et al (2003) ²⁶⁶
Cost of treating UTI – daycase	£376	Gamma (c)	$\begin{array}{l} \alpha = 3.926 \\ \lambda = 0.0104 \end{array}$	National Schedule of Reference Costs 2006- 07 LA04C
Cost of treating UTI - inpatient	£783	Gamma (c)	$\alpha = 3.079$ $\lambda = 0.0039$	National Schedule of Reference Costs 2006- 07 LA04C
Cost of urology visit	£75	Gamma (c)	$\alpha = 7.898$ $\lambda = 0.1053$	National Schedule of Reference Costs 2006- 07 Consultant led follow-up attendance, face-to-face - Urology
Number of visits every 3 months	0.5	Triangular	Min=0.25 Likeliest=0.5 Max=1	Experts opinion
Probability of AUR after TURP (see 10.5.6)	3.9%	Beta	$\begin{array}{l} \alpha = 88\\ \beta = 2184 \end{array}$	Systematic review of clinical effectiveness

				-
Proportion of patients with incontinence requiring an AUS	5%	Triangular	Min=2.5% Likeliest=5% Max=7.5%	Experts opinion
Probability of incontinence after TURP (see 10.5.6)	4.0%	Beta	$\begin{array}{l} \alpha = 84 \\ \beta = 2036 \end{array}$	Systematic review of clinical effectiveness
Probability of strictures after TURP (see 10.5.6)	7.2%	Beta	$\begin{array}{l} \alpha = 180 \\ \beta = 2316 \end{array}$	Systematic review of clinical effectiveness
Proportion of treating strictures inpatient: daycase	0.46 : 0.54	None		Hospital Episodes Statistics 2006-07
Probability of success at 6 months after TURP	85%	Beta	$ \begin{array}{l} \alpha = 88 \\ \beta = 15 \end{array} $	Fowler et al (2005) ⁸³
Probability of success at 2 years after TURP	84%	Beta	$\begin{array}{l} \alpha = 63 \\ \beta = 12 \end{array}$	Fowler et al (2005) ⁸³
Probability of blood transfusion after TURP (see 10.5.6)	6.2%	Beta	$\alpha = 197$ $\beta = 2977$	Systematic review of clinical effectiveness
Probability of TUR after TURP (see 10.5.6)	2.0%	Beta	$\begin{array}{l} \alpha = 29 \\ \beta = 1454 \end{array}$	Systematic review of clinical effectiveness
Probability of UTI after TURP (see 10.5.6)	6.9%	Beta	$\alpha = 111$ $\beta = 1488$	Systematic review of clinical effectiveness
Proportion of treating UTI inpatient: daycase	0.9 : 0.1	None		Hospital Episodes Statistics 2006-07
Proportion of patients being re-operated after a first failure	5%	Triangular	Min=0% Likeliest=5% Max=10%	Experts opinion
Relative Risk of AUR – HoLEP vs. TURP	0.72	Log-normal	SD=0.157	Systematic review of clinical effectiveness
Relative Risk of incontinence – HoLEP vs. TURP	1.26	Log-normal	SD=0.106	Systematic review of clinical effectiveness
Relative Risk of strictures – HoLEP vs. TURP	0.69	Log-normal	SD=0.175	Systematic review of clinical effectiveness
Relative Risk of blood transfusion – HoLEP vs. TURP	0.27	Log-normal	SD=0.304	Systematic review of clinical effectiveness
Relative Risk of TUR – HoLEP vs. TURP	0.31	Log-normal	SD=0.809	Systematic review of clinical effectiveness
Relative Risk of UTI – HoLEP vs. TURP	0.45	Log-normal	SD=0.319	Systematic review of clinical effectiveness
Utility of severe LUTS	0.71	Beta	$\alpha = 80.23$ $\beta = 32.77$	Trueman et al (1999(²⁵⁶

Utility of Remission	0.91	Beta	$\begin{array}{l} \alpha = 33.67 \\ \beta = 3.33 \end{array}$	Trueman et al (1999(²⁵⁶
Disutility from incontinence	0.11	Normal	SD = 0.026	Currie et al (2006) ⁵⁰
Effectiveness when procedure is performed the second time compared to first time	75%	Triangular	Min=50% Likeliest=75% Max=100%	Experts opinion
Discount rate (cost and QALYs)	3.5%	None		

(a) We approximated the standard error (SE) of the mean by assuming the width of the 95% CI was 50%

of the mean using the following equation: SE=0.25 x mean / $Z_{0.0975}$

(b) Based on experts opinion

2 3 4 5 (c) We used the interquartile range (IQR) to approximately estimate the SE of the mean using the following

equation: SE=0.5 x IQR / Z_{0.75}

6 (d) Based on the range from HES 2006/07

7 10.3.14Results of the cost-effectiveness analysis

8 We analysed the data deterministically (Table 12) and probabilistically (Table 9 13 - Probabilistic SA results - HoLEP vs. TURP). We found that the results of the 10 model were sensitive to various parameters and this is reflected in the extreme 11 confidence intervals obtained with the probabilistic SA.

12 In the base case analysis HoLEP is more cost-effective than TURP but this result is

13 overthrown by minimal changes in variables (Table 12).

14 Table 12 - HoLEP vs. TURP - Results of base case analysis

	Mean cost (£)	QALYs	Incremental cost (£) per QALY gained (HOLEP vs. TURP)	Sensitivity analysis
TURP	2,479	6.2315	-	TURP is cost-effective if: - cost of treating AUR<£1,000;
HoLEP	2,480	6.2523	48	 cost of bed day <£190; cost of incontinence over three months £575; cost of operating theatre per minute £10; length of stay after HoLEP >2; length of stay after TURP<3; operating time of HoLEP >77minutes; operating time of TURP <58minutes; probability of incontinence TURP >4%; utility values; TURP is not possible after HoLEP.

15


16 The instability of this conclusion is even more evident from the results of the 17 probabilistic SA (Table 13).

	Mean	95% CI – lower	95% Cl – upper	Probabilit	y of			
	incremental	limit (£/QALY)	limit (£/QALY)	being cos	t-			
	cost/mean			effective	at			
	QALYs gained			£20,000/	QALY			
	HoLEP	HoLEP dominates	TURP dominates	HoLEP	55%			
	dominates (a)	HOLEF dominates	TORF dominates	TURP	45%			

Table 13 - Probabilistic SA results - HoLEP vs. TURP

(a) HoLEP dominates means that HoLEP is both more effective and less costly. Hence the ICER cannot be calculated.

The probability of HoLEP being cost-effective (55%) is very close to the probability of TURP being cost-effective (45%) at a willingness to pay of $\pm 20,000/\text{QALY}$ (the NICE threshold). The probabilities are very similar for other willingness to pay thresholds (Figure 238).



9

1

2 3

4 5

6

7


8

10 Figure 237 - Acceptability curve of HoLEP and TURP

11

12 The uncertainty can also be graphically represented by plotting the results of the 13 incremental analysis for all the 10,000 simulations into a cost-effectiveness plane 14 (Figure 239). Each point represents the ICER of TURP vs. HoLEP for each

- 15 simulation. The dotted line represents the $\pounds 20,000/QALY$ threshold while the
- 16 ellipse delimits the 95% confidence interval.



1

2 3

Figure 238 - Incremental cost-effectiveness scatterplot

4 **10.3.15Discussion**

5 HoLEP and TURP could be equally cost-effective.

TURP is the current standard of care in the UK while HoLEP is a relatively new
technique practiced in a small number of UK centres. Although our analysis shows
that HoLEP is at least as cost-effective as TURP, careful considerations should be
given to recommending its widespread use.

- 10 The cost-effectiveness of HoLEP seems to be associated with the skills of the 11 surgeons. For example the operating time was a parameter to which results were 12 sensitive. Also the probabilities of complications depend on the expertise of the 13 surgeon performing the operation. The probabilities as reported in the studies 14 included in our clinical review, where HoLEP was performed by specialised 15 surgeons, might be largely different from the actual events following an 16 operation performed by a trainee surgeon. Therefore we might have 17 overestimated the effectiveness of HoLEP.
- Another overestimation might be due to the blood transfusion rate after TURP as
 estimated from our review of clinical studies. Some of the included studies¹²⁷
 reported a blood transfusion rate after TURP higher than the average.
- The major limitation of our model is the arbitrary definition of success (IPSS change of at least 5 points). Although other authors⁸³ have adopted this definition, it is still debatable whether a change of 5 points could be considered a remission in symptoms. Other authors¹⁵⁰ have used an improvement by 10% in IPSS as a proxy for success but this was judged to be even more optimistic by

- 1 our experts, as this would equate to 2 points of improvement when the baseline 2 score is 20.
- The results of our study are based on trial data for men with moderate-to-severe
 symptoms with a mean baseline IPSS of 20.7. For men with less severe symptoms,
 TURP might be more cost-effective as it is less costly, while for men with more
 severe symptoms HoLEP might be more cost-effective as it is more effective than
 TURP at improving symptoms.

8 We compared the results of our study with the economic analysis from the 9 HTA¹⁵⁰ included in our review and we found similar results and conclusions. In this 10 study¹⁵⁰, HoLEP was more effective and less costly than TURP but the results were 11 highly sensitive to several parameters. Unlike this study¹⁵⁰ our model takes into 12 account the capital cost of HoLEP which might explain the higher cost of HoLEP 13 compared to TURP.

14 From an NHS perspective, the results of our study would suggest training new 15 surgeons in HoLEP could improve outcomes and save costs if performed correctly. 16 However, a shift from TURP to HoLEP would have to be gradual for it to be cost-17 effective since purchasing the new equipment might not warrant the improved 18 outcomes which were marginal. It is important to note that there is still 19 inadequate long-term data for HoLEP. However, if a centre has to replace old 20 equipment and surgeons trained in HoLEP are available, HoLEP could be an 21 efficient option.

- In conclusion, given the learning curve associated with the new technique and the
 cost of purchasing the new equipment, the GDG felt it was reasonable to
 recommend HoLEP only in centres specialised in the technique.
- 25 **10.3.16Conclusions**
- HoLEP and TURP are similarly cost-effective
- In settings where HoLEP is not currently performed, TURP is more cost effective because of the capital cost and the learning curve
- 29


30 10.4 NCGC Combination model

An economic model comparing Alpha-Blockers (AB) with a combination of AB and 5-Alpha-Reductase Inhibitors (Comb) was developed further to the exclusion of any economic evidence focusing on this comparison. The main outcomes considered were the change in IPSS from baseline and the treatment adverse events which were expressed in quality of life measures. Patients in this model are men who have moderate lower urinary tract symptoms and are selected for medical treatment.

We built a Markov model with a lifetime horizon (Figure 240) and we chose a cycle length of six months as it was the shortest follow up period in our clinical review of effectiveness (Chapter 6.10.1). All the probabilities, costs and health utilities were converted in order to reflect the six-month values. The time horizon was shortened to 5 years in a sensitivity analysis.

1 After a treatment period of six months, men can have either a meaningful 2 improvement in IPSS (treatment success) or a negligible/no improvement 3 (treatment failure). During this period they can also experience various adverse 4 events which are independent from the treatment success. However, a proportion 5 of those men experiencing adverse events will discontinue treatment, going back 6 to the LUTS state. Men who had a treatment failure to start with will go to the 7 LUTS state (with or without adverse events) but they can still have an 8 improvement in the following six month cycle. Some men in the LUTS state will undergo TURP and they will feed into the TURP model (10.5). 9

10



11

12 Figure 239 - Structure of the combination model. The squared boxes represent the chance

- 13 nodes in the model while the round boxes are the possible health states.
- 14

15 The list of the health states that are part of the combination model is reported in 16 Table 14.

17 Table 14 - Health states of combination model

HEALTH STATES	
(Moderate) LUTS	
Remission	
LUTS +adverse events	
Remission + adverse events	
TURP	

- While in the Surgery model a significant remission of symptoms was a change in
 IPSS greater than five, in the Combination model we used the 3 point estimate
 by Barry et al (1995)²¹.
- For each strategy the expected healthcare costs and expected QALYs were calculated by estimating the costs and QALYs for each state and then multiplying them by the proportion of patients who would be in that state as determined by the strategy taken.

8 We performed a probabilistic sensitivity analysis (PSA) to test the robustness of 9 the results against the imprecision of these estimates and the other model 10 parameters, and to obtain more accurate estimates of expected costs and 11 QALYs.

- 12 10.4.1 Key assumptions
- The experts in the GDG were consulted in order to make the followingassumptions:
- a) Patients are kept on treatment for all their life if the treatment iseffective and there are no adverse events.
- b) If the treatment does not work (i.e. IPSS improves by less than 3 points)
 the treatment is kept for one year then it is discontinued.
- c) 50% of the patients who discontinue the treatment after one yearundergo TURP.
- d) If adverse events have not occurred during the first two years, they will
 never occur.
- 23 The following assumption was based on the conclusions of our clinical review:
- a) After the first year the treatment effectiveness is stable (no improvement or deterioration in IPSS are possible).
- 26 10.4.2 Probability of success

We could not find any studies reporting the proportion of successful treatment where success was defined as an improvement of at least 3 points of IPSS. We assumed that the IPSS change was normally distributed and we used the standard deviation (SD) from the mean to obtain the proportion of cases within the 3-point cut-off (Table 15). This was calculated as:

- 32 Success rate=1- $\Phi_{\mu\sigma^2}$ (IPSS) where IPSS=3,
- 33 where μ =mean IPSS, σ^2 =IPSS variance= IPSS SD squared (Table 15), 3 is the 34 IPSS cut-off for success and where $\Phi_{\mu\sigma}2$ (IPSS) gives the cumulative distribution 35 function for a normal distribution with mean μ and variance σ^2 .

36

	Mean IPSS change (a)	SD of IPSS change (a)	Proportion of treatment success
AB – 6 months	6.3	5.8	72%
Comb – 6 months	6.1	7.4	66%
AB – 12 months	7.1	5.7	76%
Comb – 12 months	7.3	5.8	77%

Table 15 - Probability of treatment succes	s when the cut-off is 3 points
--	--------------------------------

a) Source: clinical review.

1

2 3

4

5

6

7

8

9

As the figures in Table 15 suggest, treatment success is more likely achieved at 12 months than 6 months. Therefore men in the model for whom treatment has failed in the first six months can still experience a remission in the following 6 months. The probability of remission is simply the difference between the probability of success at 12 months and the probability of success at 6 months (Table 16).

10 Table 16 - Probability of symptoms remission at 12 months

	P success 6 months	P success 12 months	P remission between 6 and 12 months (a)	
AB	72%	76%	14.3%	
Comb	66%	77%	16.6%	

11 a) (P success 12 months - P success 6 months)/(1 - P success 6 months)

We changed the definition of success in sensitivity analyses where we defined
 success as an improvement by at least 5 or at least 8 points.

15 10.4.3 Probability of adverse events and withdrawals

We looked for RCT data on adverse events and withdrawals due to adverse
events. We realised it was not feasible to estimate the incidence of specific
adverse events and their specific probability of causing withdrawals from
treatment. Consequently we adopted a three-step approach:

- estimate the overall probability of a man experiencing a drug-related adverse
 event with AB and with combinations
- 22 2. estimate the probability of an adverse event leading to treatment23 discontinuation with AB and with combination
- 3. once an adverse event occurs, estimate the probability of specific adverse
 events
- We found a large RCT²²⁵ reporting both drug related adverse events and drugrelated adverse events leading to study withdrawals. With these data (Table 17) we were able to perform step 1 and 2 (Table 17).


- 1
- 2

3 Table 17 - Probability of discontinuation in patients with adverse events*

	Number of drug- related adverse events x	Number of drug- related adverse events leading to withdrawal y	Probability of drug-related adverse events	Probability of discontinuation in patients with adverse events z=x/y		
АВ	258	48	16%	18.6%		
Comb	386	80	24%	20.7%		
* From Roehrborn et al (2008) ²²⁵						


6

Figure 241 and Figure 242 illustrate how these values were used in the model.



8 Figure 240 - Adverse events in the AB arm of the model


9



2 Figure 241 - Adverse events in the combination arm of the model

1

3 For step 3 we used the evidence from the review of clinical effectiveness 4 (Chapter 6.10.1). Various adverse events were reported in the included studies 5 and in order to avoid double-counting we grouped those adverse events that 6 could be similar in symptoms. The most common adverse event was used to 7 represent the group (Table 18). Therefore whilst in the clinical review postural 8 hypotension, headache, syncope and dizziness are all reported, it is likely to be 9 an overlap of those symptoms and just dizziness (the most frequent one) is 10 reported as part of that group. Similarly decreased libido was grouped 11 together with impotence or erectile dysfunction.



	Incidence		Proportion of a	adverse events
	AB	Comb	AB	Comb
	Xi	Yi	Xi/∑Xi	Yi/∑Yi
Dizziness	4.8%	4.3%	22%	16%
Fatigue	3.6%	4.2%	17%	16%
Rhinitis	6.6%	7.8%	31%	29%
Ejaculatory abnormality	0.6%	3.0%	3%	11%
Impotence/erectile dysfunction	3.0%	5.9%	14%	22%
Breast enlargement	1.8%	1.4%	8%	5%
Acute urinary	1.0%	0.4%	5%	1%

15 Table 18 - Incidence and proportion of adverse events

	retention (AUR)				
	TOTAL	21.4%	27.0%	100%	100%
1					

- The probability of each adverse event group was used in the model to estimate the detriment in quality of life and additional costs due to adverse events (see 10.6.5 and 10.6.7).
- 5 10.4.4 Life expectancy

3

4

6 Men in the Combination Model were assumed to be on average 60 years old.

Life expectancy in patients with LUTS was assumed to be the same as the
 general population in England and Wales. The remaining life expectancy for
 men aged 60 is 21.22 years, as reported in the Life Tables for the general
 population of England and Wales in the year 2005-2007 from the Government
 Actuary Department

- 12 (http://www.gad.gov.uk/Documents/Demography/EOL/ILT%202005-
- 13 07/wltewm0507.xls).

14 **10.4.5 Quality of life**

The same sources used in the Surgery Model for quality of life estimates of the
 residual LUTS and remission states were used in the Combination Model (10.5.8).
 However, while men in the Surgery Model had on average severe symptoms, in
 the Combination Model men have moderate symptoms.

- 19The health states 'Remission + Adverse events' and 'LUTS + Adverse events' are20made of the Remission or LUTS utility value and the disutility (decrease in utility)21due to adverse events.
- Being the spectrum of adverse events in the AB arm different from that in the
 combination arm (10.6.3), the adverse events health states will also have
 different utility values in the different arms.
- The utility value of the LUTS + adverse events state for intervention y will be calculated as:
- 27 **XIV** uLUTS-AEy = uLUTS + \sum (disutilityAEi * pAEiy)
- where uLUTS is the utility values of Moderate LUTS reported in Table 19,
- disutilityAEi is the disutility of the adverse event i where i is any of the adverse
 events reported in Table 18,
- and pAEi,y is the proportion of the adverse event i for the intervention y, wherey could be either AB or combination.
- From equation XIV it can be deduced that the utility of these health states
 depend on the intervention being the proportion of adverse events the variable
 parameter.

- We conducted a search in the CEA Registry (<u>https://research.tufts-</u>
 <u>nemc.org/cear/default.aspx</u>) to find quality of life values associated with the
 adverse events reported in Table 18.
- Two studies^{248,267} were found which reported the one-day disutilites deriving from dizziness, fatigue and rhinitis. We assumed that those symptoms were experienced half the time; therefore the original value was halved in our analysis (Table 19) but this assumption was varied in sensitivity analyses.
- 8 One study²⁰⁶ reported the disutility due to breast enlargement.

In a study by Dedhia et al (2008)⁶² patients with LUTS were interviewed and
their time-trade off scores for various adverse events collected. The utility values
reported in this study were 0.71 for ejaculatory abnormality and 0.73 for
erectile dysfunction in men with LUTS. If we assume that the utility decrements are
additive, we can calculate the disutility due to these adverse events as the
difference of the utility of LUTS and the utility of adverse event in presence of
LUTS:

16 XV disutilityAE = uLUTS – uLUTS+AE

By substituting the values from the study⁶² in formula XV we obtain the disutilities
 reported in Table 19.

	Utility score	Source
Remission	0.91	Trueman et al (1999) ²⁵⁶
Moderate LUTS	0.78	Trueman et al (1999) ²⁵⁶
Disutility breast enlargement	- 0.05	Penson et al (2005) ²⁰⁶
Disutility dizziness (a)	- 0.11	Vera-Llonch et al (2008) ²⁶⁷
Disutility ejaculatory abnormality	-0.07	Dedhia et al (2008) ⁶²
Disutility fatigue (a)	-0.125	Vera-Llonch et al (2008) ²⁶⁷
Disutility impotence	-0.05	Dedhia et al (2008) ⁶²
Disutility rhinitis (a)	-0.095	Sullivanet al (2004) ²⁴⁸
Disutility AB adverse events	- 0.088	Weighted average of above disutilities
Disutility Comb adverse events	- 0.086	Weighted average of above disutilities

19 Table 19 - Utility values used in the Combination Model

(a) Assuming symptoms are experienced half the time.

20 21

22 23 The disutility due to Acute Urinary Retention (AUR) was not included in the model as this complication was assumed to be treated and resolved within six months.

1 The cost associated with this adverse event is already explained in the Surgery 2 Model (see 10.5.11).

10.4.6 Calculating QALYs gained

4 See 10.5.9.

10.4.7 Cost of interventions and health states

6 The cost components of the health states in the model are made of the continuous 7 cost of drug therapy and the cost of visits (Table 20). During the first six-month 8 cycle men are treated with either AB or Combination and have a follow-up visit. 9 The cost of the initial treatment is kept for at least another cycle unless there is a 10 discontinuation due to adverse events. If the treatment is discontinued only the 11 cost of a visit is included in the cost of a cycle.

12

3

5

Table 20 - Resources used in the health states of the model

HEALTH STATE	RESOURCES USED
Moderate LUTS - initial	Drugs (AB or Comb) + 1 follow-up visit
Moderate LUTS - residual	1 follow-up visit
Remission	Drugs (AB or Comb)
LUTS +adverse events	1 follow-up visit
Remission + adverse events	Drugs (AB or Comb)

13

14 The cost details of the resources used in the health states are reported in Table 15 21.

16 Table 21 - Cost of resources used

Resource	Total cost per patient over six months	Source
Alpha-blockers	£65	BNF 57 (a)
Combination (5- ARI+AB)	£186	BNF 57 (b)
Follow-up visit	£75	National Schedule of Reference Costs 2006-07– Consultant led follow-up attendance – outpatient face-to- face – Urology

¹⁷ 18

a) Based on the average cost per day of Alfuzosin, Tamsulosin, Doxazosin, and Prazosin = \pounds 0.35 b) Based on the cost of AB and on the average cost per day of Dutasteride and Finasteride = $\pounds 0.66$

19

21

22

20 In addition, some costs are associated with particular events in the model: the cost of treating AUR when adverse events occur (adjusted by the proportion of AUR in the adverse events) and the cost of TURP if the therapy fails and the man 23 considers surgery. In this event the model feeds directly into the Surgery Model

described in 10.5 where the cost components are the same ones described in
 10.5.10 and 10.5.11 for the TURP strategy.

10.4.8 Probabilistic sensitivity analysis

4 A probabilistic sensitivity analysis was performed to assess the robustness of the 5 model results to plausible variations in the model parameters.

6 The same method described for the Surgery Model (10.5.13) was used for the 7 Combination Model. The same parameters used in the TURP arm of the Surgery 8 Model were used in the Combination Model when men undergo TURP after a 9 treatment failure. All the other parameters and their distributions are listed in

10 Table 22.

3

11 Table 22 - Parameters and distributions used in the probabilistic sensitivity analysis

Description of variable	Mean value	Probability distribution	Parameters	Source
Mean IPSS change at 6 months – AB	6.3	Normal	SD= 5.8	Systematic review of clinical effectiveness
Mean IPSS change at 6 months – Comb	6.1	Normal	SD=5.6	Systematic review of clinical effectiveness
Mean IPSS change at 12 months – AB	7.1	Normal	SD=5.7	Systematic review of clinical effectiveness
Mean IPSS change at 12 months – Comb	7.3	Normal	SD=5.8	Systematic review of clinical effectiveness
Probability of success at 6 months – AB	See Table 15			
Probability of success at 6 months - Comb	See Table 15			
Probability of success at 12 months – AB	See Table 15			
Probability of success at 12 months - Comb	See Table 15			
Probability of remission at 12 months – AB	See Table 16			
Probability of remission at 12 months - Comb	See Table 16			
Cost of Alpha-blockers treatment over 6 months	£65	None		BNF 57
Cost of combination treatment over 6 months	£186	None		BNF 57

	A--	-		
Cost of urology visit	£75	Gamma (a)	$\alpha = 7.898$ $\lambda = 0.1053$	National Schedule of Reference Costs 2006- 07 Consultant led follow-up attendance, face-to-face - Urology
Cost of treating AUR	£2,029	Gamma (b)	$\begin{array}{l} \alpha = 61.46 \\ \lambda = 0.0303 \end{array}$	Annemans et al (2005) ¹⁴
Probability of adverse events - AB	16%	Beta	$ \begin{array}{l} \alpha = 258 \\ \beta = 1353 \end{array} $	Roehrborn et al (2008) ²²⁵
Probability of adverse events - Comb	24%	Beta	$ \begin{array}{l} \alpha = 386 \\ \beta = 1224 \end{array} $	Roehrborn et al (2008) ²²⁵
Probability of discontinuing in men with adverse events - AB	18.6%	Beta	$ \begin{array}{l} \alpha = 48 \\ \beta = 210 \end{array} $	Roehrborn et al (2008) ²²⁵
Probability of discontinuing in men with adverse events - Comb	20.7%	Beta	$\begin{array}{l} \alpha = 80\\ \beta = 306 \end{array}$	Roehrborn et al (2008) ²²⁵
Proportion of breast enlargement/adverse events AB	8%	Dirichlet	0.08, 0.22,	Systematic review of clinical effectiveness
Proportion of dizziness/adverse events AB	22%	Dirichlet	0.17, 0.03,	Systematic review of clinical effectiveness
Proportion of fatigue/adverse events AB	17%	Dirichlet	0.14,	Systematic review of clinical effectiveness
Proportion of ejaculatory abnormality/adverse events AB	3%	Dirichlet	0.31, 0.05	Systematic review of clinical effectiveness
Proportion of impotence/adverse events AB	14%	Dirichlet	where each parameter refers to proportion of	Systematic review of clinical effectiveness
Proportion of rhinitis/adverse events AB	31%	Dirichlet	each type of adverse event	Systematic review of clinical effectiveness
Proportion of AUR/adverse events AB	5%	Dirichlet		Systematic review of clinical effectiveness
Proportion of breast enlargement/adverse events - Comb	5%	Dirichlet	0.05, 0.16,	Systematic review of clinical effectiveness
Proportion of dizziness/adverse events - Comb	16%	Dirichlet	0.16, 0.11,	Systematic review of clinical effectiveness
Proportion of fatigue/adverse events – Comb	16%	Dirichlet	0.22,	Systematic review of clinical effectiveness

Proportion of ejaculatory abnormality/adverse events AB	11%	Dirichlet	0.29, 0.01	Systematic review of clinical effectiveness
Proportion of impotence/adverse events – Comb	22%	Dirichlet	where each parameter refers to proportion of	Systematic review of clinical effectiveness
Proportion of rhinitis/adverse events – Comb	29%	Dirichlet	each type of adverse event	Systematic review of clinical effectiveness
Proportion of AUR/adverse events – Comb	1%	Dirichlet		Systematic review of clinical effectiveness
Proportion of men undergoing TURP after treatment failure	50%	Triangular	Min=0% Likeliest=50% Max=100%	Experts opinion
Utility of Moderate LUTS	0.78	Beta	$\alpha = 80.23$ $\beta = 32.77$	Trueman et al (1999(²⁵⁶
Utility of Remission	0.91	Beta	$\alpha = 33.67$ $\beta = 3.33$	Trueman et al (1999(²⁵⁶
Disutility from breast enlargement	0.05	Beta	$\alpha = 23.7$ $\beta = 450.3$	Penson et al (2005) ²⁰⁶
Disutility from dizziness	0.11	Beta	$\alpha = 6.22$ $\beta = 50.32$	Vera-Llonch et al (2008) ²⁶⁷
Disutility from fatigue	0.125	Beta	$\alpha = 6.097$ $\beta = 42.681$	Vera-Llonch et al (2008) ²⁶⁷
Disutility from ejaculatory abnormality	0.07	Beta	$\alpha = 14.81$ $\beta = 196.76$	Dedhia et al (2008) ⁶²
Disutility from impotence/erectile dysfunction	0.05	Beta	$\alpha = 6.706$ $\beta = 127.406$	Dedhia et al (2008) ⁶²
Disutility from rhinitis	0.19	Beta	$\alpha = 20.604$ $\beta = 87.836$	Dedhia et al (2008) ⁶²
Discount rate (cost and QALYs)	3.5%	None		NICE Reference Case

(a) We used the interquartile range (IQR) to approximately estimate the standard error (SE) of the mean

using the following equation: se=0.5 x IQR / $Z_{0.75}$

2 3 4 (b) We approximated the SE of the mean by assuming the width of the 95% CI was 50% of the mean

using the following equation: $se=0.25 \times mean / Z_{0.975}$

5 10.4.9 Results

6 Alpha-blockers generate less cost and more QALYs compared to combinations 7 (Table 23).

	Mean cost (£)	QALYs	Incremental cost (£) per QALY gained	Sensitivity analysis
Alpha-blockers	3,824	12.4347	-	One-way SA: Combination is cost- effective if probability of adverse
Combination	6,411	12.4276	Dominated	events with AB>29% (16% in base case). Results were not sensitive to other changes in parameters or structure.

1 Table 23 - Results of base case analysis - Combination vs. Alpha-blockers

2

3

4

5


6

7


8


9

In a set of one-way sensitivity analyses, where the low and high values were respectively half or double the base case value, we identified the parameters that might have changed the results. The only variable to which the model was sensitive was the probability of adverse events with AB. We explored this uncertainty further through a two-way SA where the probability of adverse events with AB was co-varied with the probability of adverse events with combination (Figure 243).



10






1 Table 24 - Results of probabilistic SA - Comb vs. AB

- Results of probabilistic SA - Collib Vs. Ab				
Mean ICER	95% Cl – lower	95% Cl – upper	Probability of	
(£/QALY)	limit (£/QALY)	limit (£/QALY)	being co	
			effective	-
			£20,000	/QALY
Comb	3,850	Comb dominated	AB	90%
dominated	3,030	Comb dominated	Comb	10%

However, at a willingness to pay of £20,000/QALY alpha-blockers have a 90%
 probability of being cost-effective (Figure 244).



5

6

7

Figure 243 - Acceptability curve of AB and Comb

8 10.4.10 Discussion

9 5-ARI and AB have a different mechanism of action and the combination of the 10 two could enhance the effectiveness on men with LUTS. Our review of clinical 11 evidence (Chapter 6.10.1) has shown that the long-term (one year) improvement 12 in IPSS is higher with combinations than with AB. However there are extra costs 13 associated with the improvement and more side effects. The results of our model 14 show that after weighting the advantages (improvement in IPSS) and 15 disadvantages (costs and side effects) combinations are not cost-effective in a 16 general population of men with LUTS.

We based our model on studies where men had a normal prostate size. We
have deliberately excluded those studies conducted on men with large prostates
as 5-ARI are believed to be more effective in this group of men. A specific
model for that population could be built once good data are available.

We encountered some challenges when building our model: defining success of
 treatment according to an IPSS improvement by 3 points might have been
 arbitrary even if based on a previous study²¹; however, when we changed this
 definition to up to 10 points the overall results did not change.

- 1 Other assumptions were made while building the model but those did not have 2 an impact on the conclusions.
- 3 Adverse events were a core component of the model and their incidence was the 4 only parameter to which the results were sensitive. When we changed the 5 probability of adverse events with AB and combinations simultaneously we noted 6 that if the probability was lower with combination than with AB the former would 7 have been more cost-effective than the latter. Nevertheless, as AB are part of 8 the combination it would be very unlikely that their adverse events while used in 9 combination would be less frequent than when they are used alone.
- 10 This is the only model which compares AB and combination using randomized 11 data. A cost-utility analysis by McDonald et at (2004)¹⁶⁷ concluded that 12 combinations were more cost-effective than Doxazosin but the clinical data were 13 obtained from men with large prostate for one arm and men with normal 14 prostate for the other arm. This explains the higher value-for-money of 15 combination in this study compared to ours. Conversely the cost-utility analysis by 16 DiSantostefano et al (2006)⁶³ reached our same conclusions, yet the 17 effectiveness data on combinations were not based on RCTs but on assumptions.
- 18 10.4.11 Conclusions

- Combination of alpha-blockers with 5-ARI was not cost-effective in a 20 general population of men with LUTS.
- 21 Clinical data on men with large prostate might be useful to assess the 22 cost-effectiveness in this group where combinations are presumed to be 23 more effective.

Appendix G - Recommendations for research

<u>PICO question</u> Each research recommendation should be formulated as an answerable question or a set of closely related questions. This should use the <u>PICO framework</u> (patient, intervention, comparison and outcome).	Question: What is the clinical and cost effectiveness of multichannel csytometry in improving patient related outcomes in men being considered for bladder outlet surgery? Patients: Bothersome LUTS not responding to conservative therapy (catheterised patients excluded). Intervention: Pressure flow studies. Comparison: Two groups, awaiting bladder outlet surgery, randomised either to pre-operative pressure flow studies, or not Outcome: Primary outcome-patient-related outcome (IPSS, EQ5D), secondary outcomes-adverse events, flow rate, residual urine, pdetQmax.
Importance to patients or the population. What would be the impact of any new or altered guidance on the population? (for example, acceptability to patients, quality of life, morbidity or disease prevalence, severity of disease or mortality).	This research would clarify whether this test could improve the outcome of surgery. If the result is positive, this could improve the chance of a good outcome from surgery.
Relevance to NICE guidance How would the answer to this question change future NICE guidance (that is, generate new knowledge and/or evidence)?	As above, it would add to knowledge about the utility of pressure flow studies and allow them to be recommended or not recommended in future revisions of guidance.
Relevance to the NHS What would be the impact on the NHS and (where relevant) the public sector of any new or altered guidance (for example, financial advantage, effect on staff, impact on strategic planning or service delivery)?	It would allow the NHS to know whether resources should be committed to the test or not.
National priorities Is the question relevant to a national priority area (such as a national service framework or white paper)? The relevant document should be specified.	NSF for older people, Integrated Continence Services.
<u>Current evidence base</u> What is the current evidence base? What are the problems with the current evidence	There are currently no randomised controlled trials comparing multichannel cystometry to no intervention in men

10.1 Multichannel cystometry

base? (that is, why is further research required?) Reference should be made to the section of the full guideline that describes the current evidence base, including details of trials and systematic reviews. The date on which the final literature search was undertaken should be specified.	before surgery.
Equality Does the research recommendation address equality issues? For example, does it focus on groups that need special consideration, or focus on an intervention that is not available for use by people with certain disabilities?	No specific consideration.
<u>Study design</u> It should also specify the most appropriate study design to address the proposed question(s). Primary research or secondary research (for example, systematic reviews) can be recommended.	Design: A randomised comparative trial of men awaiting bladder outlet surgery, to be randomised to either a pressure flow study or not, before their surgery. The results of the pressure flow study would be used in subsequent counselling of patients in a protocol-driven way, before the proposed surgery, and <i>might</i> result in surgery not being done. Outcome: As above.
<u>Feasibility</u> Can the proposed research be carried out in a realistic timescale and at an acceptable cost? As part of cost- effectiveness analysis, formal value-of- information methods may also sometimes be used to estimate the value for money of additional research. Are there any ethical or technical issues?	The research would be ethically and technically feasible.
Other comments Any other important issues should be mentioned, such as potential funders or outcomes of previous attempts to address this issue or methodological problems. However, this is not a research protocol.	The National Institute for Health Research (NIHR) would be an appropriate funding source. The normal service delivery cost to participants would be taken over by the research during the trial, thus relieving the service delivery budget. Since the NIHR is an NHS funded body the costs of care would simply be shifted from one NHS budget to another. Additional costs would be those associated with conducting the research itself.
Importance How important is the question to the overall guideline? The research	High. The research is essential to inform future updates of key recommendations in the guideline.

recommendation should be categorised into one of the following categories of importance:	
 High: the research is essential to inform future updates of key recommendations in the guideline Medium: the research is relevant to the recommendations in the guideline, but the research recommendations are not key to future updates Low: the research is of interest and will fill existing evidence gaps. 	

10.2 Catheterisation

<u>PICO question</u> Each research recommendation should be formulated as an answerable question or a set of closely related questions. This should use the <u>PICO framework</u> (patient, intervention, comparison and outcome)	What are the clinical and cost effectiveness and associated adverse events of intermittent catheterisation compared to indwelling suprapubic or urethral catheterisation for men with voiding difficulty and chronic retention of urine?
Importance to patients or the population. What would be the impact of any new or altered guidance on the population? (for example, acceptability to patients, quality of life, morbidity or disease prevalence, severity of disease or mortality).	The number of men judged unfit to undergo de-obstructing surgery is steadily increasing given the increasing proportion of older men in the population. Current practice varies widely across the UK with no established standard for long term management and no systematic review of practice. The research could establish the best approach to management in these men in the longer term and so bring more effective treatment, better focused on each patient's need, and consequent cost- efficiency gains.
Relevance to NICE guidance How would the answer to this question change future NICE guidance (that is, generate new knowledge and/or evidence)?	NICE currently cannot give clear guidance on this topic because of an inadequate evidence base.
Relevance to the NHS What would be the impact on the NHS and (where relevant) the public sector of any new or altered guidance (for example, financial advantage, effect on staff, impact on strategic planning or service delivery)?	Catheters are currently used variably across the UK with no systematic approach to management except for men with spinal cord injury. The aim of catheterisation, to drain the bladder so as to protect the upper renal tracts and maintain continence may not be achieved acceptably. Evidence-based guidance on the selection of the most suitable mode of catheterisation will benefit the quality of life of patients, ensure the efficient use of skilled staff and may reduce the costs of waste of unsuitable or sub-optimal product use.
National priorities Is the question relevant to a national priority area (such as a national service framework or white paper)? The relevant document should be specified.	None currently relevant.
<u>Current evidence base</u> What is the current evidence base? What	There is no currently no evidence for these interventions.

are the problems with the current evidence base? (that is, why is further research required?) Reference should be made to the section of the full guideline that describes the current evidence base, including details of trials and systematic reviews. The date on which the final literature search was undertaken should be specified.	
Equality Does the research recommendation address equality issues? For example, does it focus on groups that need special consideration, or focus on an intervention that is not available for use by people with certain disabilities?	This treatment predominantly affects older people.
Study design It should also specify the most appropriate study design to address the proposed question(s). Primary research or secondary research (for example, systematic reviews) can be recommended.	 A randomised controlled study of the interventions: a) intermittent catheterisation b) indwelling suprapubic catheterisation c) indwelling urethral catheterisation Outcomes of interest: quality of life, healthcare resource utilisation, adverse events (including leakage, skin breakdown, infection, erosion and death).
Feasibility Can the proposed research be carried out in a realistic timescale and at an acceptable cost? As part of cost- effectiveness analysis, formal value-of- information methods may also sometimes be used to estimate the value for money of additional research. Are there any ethical or technical issues?	The major issues with this trial would be the identification of cases and the studying of them in a primary care environment. An adequate population of men with this problem already exists precisely because of the absence of any consensus strategy for this group.
Other comments Any other important issues should be mentioned, such as potential funders or outcomes of previous attempts to address this issue or methodological problems. However, this is not a research protocol.	None.

Importance How important is the question to the overall guideline? The research recommendation should be categorised into one of the following categories of importance:	High. Surgery is indicated as therapy for retention – but may not be appropriate in the presence of impaired bladder function (underactive) or where comorbidity precludes it.
 High: the research is essential to inform future updates of key recommendations in the guideline Medium: the research is relevant to the recommendations in the guideline, but the research recommendations are not key to future updates Low: the research is of interest and will fill existing evidence gaps. 	

<u>PICO question</u> Each research recommendation should be formulated as an answerable question or a set of closely related questions. This should use the <u>PICO framework</u> (patient, intervention, comparison and outcome)	What is the clinical and cost effectiveness and associated adverse events of absorbent pads compared to sheath collectors for men with urinary incontinence?
Importance to patients or the population. What would be the impact of any new or altered guidance on the population? (for example, acceptability to patients, quality of life, morbidity or disease prevalence, severity of disease or mortality).	The number of patients in this group is steadily increasing with more radical prostatectomies and an ageing demographic. Current practise varies widely across the UK with no established standards of good practice. The research could establish the best approach to continence management in these men and so bring more effective treatment, better focussed on each patient's needs, and consequently cost-efficiency gains.
Relevance to NICE guidance How would the answer to this question change future NICE guidance (that is, generate new knowledge and/or evidence)?	NICE currently cannot give clear guidance on this topic because of an inadequate evidence base.
Relevance to the NHS What would be the impact on the NHS and (where relevant) the public sector of any new or altered guidance (for example, financial advantage, effect on staff, impact on strategic planning or service delivery)?	Containment products are currently used variably across the UK. It is rare that any element of bladder training or recognition and treatment of bladder dysfunction is recognised as part of the continence management problem. The aim, so often, is simply to keep the patient socially dry; and even that is not always achieved acceptably. Evidence-based guidance on the selection of the most suitable containment product and its subsequent management will benefit the quality of life of patients, use skilled nurse/career resources more efficiently and reduce the costs of waste of unsuitable or sub- optimal product use.
National priorities Is the question relevant to a national priority area (such as a national service framework or white paper)? The relevant document should be specified.	There is currently no national service framework for men with LUTS and incontinence or difficulty with bladder emptying.
<u>Current evidence base</u> What is the current evidence base? What are the problems with the current	There is no currently no level 1 evidence for pads and sheaths.

10.3 Products for men with urinary incontinence

	1
evidence base? (that is, why is further research required?) Reference should be made to the section of the full guideline that describes the current evidence base, including details of trials and systematic reviews. The date on which the final literature search was undertaken should be specified.	
Equality Does the research recommendation address equality issues? For example, does it focus on groups that need special consideration, or focus on an intervention that is not available for use by people with certain disabilities?	There are no equality issues.
<u>Study design</u> It should also specify the most appropriate study design to address the proposed question(s). Primary research or secondary research (for example, systematic reviews) can be recommended.	A randomised controlled trial to compare these interventions. Outcomes of interest would be symptom severity, quality of life, changes in measured leakage, and occurrence of adverse events.
Feasibility Can the proposed research be carried out in a realistic timescale and at an acceptable cost? As part of cost- effectiveness analysis, formal value-of- information methods may also sometimes be used to estimate the value for money of additional research. Are there any ethical or technical issues?	The major issues with this trial would be the identification of cases and the studying of them in a primary care environment. An adequate population of men with this problem already exists precisely because of the absence of any consensus strategy for this group.
Other comments Any other important issues should be mentioned, such as potential funders or outcomes of previous attempts to address this issue or methodological problems. However, this is not a research protocol.	In general, manufacturers have been reluctant to fund randomised controlled trials. Currently the D4D project is addressing unmet needs. Work with specialist and patient advocacy groups and manufacturers will be essential.
Importance How important is the question to the overall guideline? The research recommendation should be categorised into one of the following categories of importance:	High. This is a population of men who have been rendered incontinent by surgery. The impact on their quality of life is profound and there is currently only one realistic treatment option for more major incontinence namely surgery which many men find unacceptable. It is
 High: the research is essential to inform future updates of key recommendations in the guideline Medium: the research is relevant to the recommendations in the guideline, but the 	important that solutions are found for this growing number of men.

fill existing evidence gaps.

10.4 Green light laser prostatectomy

<u>PICO question</u> Each research recommendation should be formulated as an answerable question or a set of closely related questions. This should use the <u>PICO framework</u> (patient, intervention, comparison and outcome)	What is the clinical and cost effectiveness and associated adverse events of Green Light Laser prostatectomy compared to TURP in men with moderate to severe bothersome LUTS considering surgery for bladder outlet obstruction? Assessed by symptom severity, quality of life, and adverse events.
Importance to patients or the population. What would be the impact of any new or altered guidance on the population? (for example, acceptability to patients, quality of life, morbidity or disease prevalence, severity of disease or mortality).	The potential advantages of reduced blood loss, shorter hospital stay and earlier return to normal activities make Green Light Laser prostatectomy attractive to patients and healthcare providers although there is uncertainty around degree of symptom improvement and improvement in quality of life in the short and longer term.
Relevance to NICE guidance How would the answer to this question change future NICE guidance (that is, generate new knowledge and/or evidence)? Relevance to the NHS What would be the impact on the NHS and (where relevant) the public sector of any new or altered guidance (for example, financial advantage, effect on staff, impact on strategic planning or service delivery)?	NICE cannot give clear guidance on this intervention because the evidence base is inadequate. The proposed research will add new knowledge. Green Light laser use in the NHS is increasing at a rapid rate with approximately 70 units in the UK using it (~ 60% NHS and ~ 40% private sector) from personal communication with representatives of American Medical Systems Inc and clinical units. This is despite a lack of clinical and cost-effectiveness data to support this practice.
National priorities Is the question relevant to a national priority area (such as a national service framework or white paper)? The relevant document should be specified.	None
<u>Current evidence base</u> What is the current evidence base? What are the problems with the current evidence base? (that is, why is further research required?) Reference should be made to the section of the full guideline that describes the current evidence base, including details of trials and systematic reviews. The date on which the final literature search was undertaken should be specified.	A recent NCCHTA commissioned systematic review suggests that TURP should remain the standard of care and specifically that green Light Laser was unlikely to be cost-effective in the economic model and thereby arguing against its unrestricted use in the NHS until further evidence of effectiveness and cost- reduction is obtained ^{16,150-152} .
Equality Does the research recommendation address equality issues? For example, does it focus	Not applicable

on groups that need special consideration, or focus on an intervention that is not available for use by people with certain disabilities? <u>Study design</u> It should also specify the most appropriate study design to address the proposed question(s). Primary research or secondary research (for example, systematic reviews) can be recommended.	Primary research (RCT). Comparator is TURP. Careful consideration must be given to treatment strategies within the trial design such as incorporating early versus delayed intervention.
<u>Feasibility</u> Can the proposed research be carried out in a realistic timescale and at an acceptable cost? As part of cost-effectiveness analysis, formal value-of-information methods may also sometimes be used to estimate the value for money of additional research. Are there any ethical or technical issues?	Proposed research can be carried out in a realistic timescale and at an acceptable cost. There are no ethical issues. A potential risk is that Green Light Laser use may diminish without adequate assessment.
Other comments Any other important issues should be mentioned, such as potential funders or outcomes of previous attempts to address this issue or methodological problems. However, this is not a research protocol.	NCCHTA would be the obvious funder
 Importance How important is the question to the overall guideline? The research recommendation should be categorised into one of the following categories of importance: High: the research is essential to inform future updates of key recommendations in the guideline Medium: the research is relevant to the recommendations in the guideline, but the research recommendations are not key to future updates Low: the research is of interest and will fill existing evidence gaps. 	High

10.5 Male slings

PICO question Each research recommendation should be formulated as an answerable question or a set of closely related questions. This should use the <u>PICO framework</u> (patient, intervention, comparison and outcome)	In men with mild to moderate post prostatectomy urinary incontinence (P), what is the clinical or cost effectiveness of a male sling or an extraurethral non circumferential compression device (IC), when assessed by symptom severity, quality of life, changes in measured leakage, and occurrence of adverse events (O). Possible interventions include: Non compression retrobulbar sling, compressive bulbar slings, adjustable bulbar slings, extraurethral compressive support and extraurethral non circumferential compression devices. Paraurethral injections have been used but are not recommended by the recent WHO International Consultation on Incontinence.
Importance to patients or the population. What would be the impact of any new or altered guidance on the population? (for example, acceptability to patients, quality of life, morbidity or disease prevalence, severity of disease or mortality).	This increasingly prevalent group of men have, until recently, had no acceptable treatment option other than insertion of an artificial urinary sphincter but many men consider this treatment to be too invasive and too prone to complication or failure. A number of new interventions have been devised but there is no clarity on which of these offers the best outcomes. This research could lead to clear recommendations and effective treatment for the majority of these men.
Relevance to NICE guidance How would the answer to this question change future NICE guidance (that is, generate new knowledge and/or evidence)?	NICE currently cannot give clear guidance on this topic because of an inadequate evidence base.
Relevance to the NHS What would be the impact on the NHS and (where relevant) the public sector of any new or altered guidance (for example, financial advantage, effect on staff, impact on strategic planning or service delivery)?	This group of men currently depend on containment alone for control of their incontinence – there are likely to be cost savings from effective incontinence treatment Insertion of an artificial urinary sphincter, whilst of recognised efficacy, carries a significant cost. Guidance is needed on the most suitable surgical options for this group of men.
National priorities Is the question relevant to a national priority area (such as a national service framework or white paper)? The relevant document should be specified.	There is currently no national service framework for men with LUTS or incontinence.
<u>Current evidence base</u> What is the current evidence base? What are the problems with the current evidence base? (that is, why is further research required?) Reference should be made to the section of the	There is currently no level 1 evidence for these surgical interventions because they are relatively new and have not been subjected to randomised controlled trials.

full guideline that describes the current evidence base, including details of trials and systematic reviews. The date on which the final literature search was undertaken should be specified.	NICE Interventional Procedures Committee has reported on Male slings (mostly "Invance") and non circumferential extraurethral compression devices.
Equality Does the research recommendation address equality issues? For example, does it focus on groups that need special consideration, or focus on an intervention that is not available for use by people with certain disabilities?	There are no equality issues.
<u>Study design</u> It should also specify the most appropriate study design to address the proposed question(s). Primary research or secondary research (for example, systematic reviews) can be recommended.	A randomised controlled trial comparing up to three current interventions; retrobulbar "non compressive" male sling (Advance), adjustable compression sling (Argos), and extraurethral non circumferential compression device (Proact) is recommended. However other new devices are being introduced rapidly into the market place with little or no clinical data to underpin marketing.
Feasibility Can the proposed research be carried out in a realistic timescale and at an acceptable cost? As part of cost-effectiveness analysis, formal value- of-information methods may also sometimes be used to estimate the value for money of additional research. Are there any ethical or technical issues?	The major issues with this trial would be the centralisation of cases into centres able to offer the surgery and the training of participating surgeons since the procedures proposed are still relatively new. An adequate population of men with this problem already exists precisely because of the absence of any really effective treatment for this group.
Other comments Any other important issues should be mentioned, such as potential funders or outcomes of previous attempts to address this issue or methodological problems. However, this is not a research protocol.	In general, manufacturers have been reluctant to fund randomised controlled trials and prefer to sponsor the establishment of surgical registries. Whilst these facilitate the involvement of a greater number of surgeons and cases, the risk of bias is very high. It may be that independent registries are a better way to establish the associated risks of surgery because of the feasibility of including all patients, not just those eligible for inclusion in an RCT.
 Importance How important is the question to the overall guideline? The research recommendation should be categorised into one of the following categories of importance: High: the research is essential to inform future updates of key recommendations in the guideline Medium: the research is relevant to the recommendations in the guideline, but the research recommendations are not key to future updates Low: the research is of interest and will fill existing evidence gaps. 	High. This is a population of men who have been rendered incontinent by surgery which may or may not cure their cancer. The impact on their quality of life is profound and there is currently only one realistic treatment option which many men find unacceptable. It is important that solutions are found for this growing number of men.

Appendix H – IPSS score sheet

International prostate symptom score (IPSS)

	Not at	Less than 1	Less	About half the	More	Almost	Your score
Incomplete emptying Over the past month, how often have you had a sensation of not emptying your bladder completely after you finish urinating? Frequency	0	1	2	3	4	5	
Over the past month, how often have you had to urinate again less than two hours after you finished urinating?	0	1	2	3	4	5	
Intermittency Over the past month, how often have you found you stopped and started again several times when you urinated?	0	1	2	3	4	5	
Urgency Over the last month, how difficult have you found it to postpone urination?	0	1	2	3	4	5	
Weak stream Over the past month, how often have you had a weak urinary stream?	0	1	2	3	4	5	
Straining Over the past month, how often have you had to push or strain to begin urination?	0	1	2	3	4	5	

	None	1 time	2 times	3 times	4 times	5 times	Your score
Nocturia Over the past month, many times did you most typically get up to urinate from the time you went to bed until the time you got up in the morning?	0	1	2	3	4	5	

Total IPSS score	

Quality of life due to urinary symptoms	Delighted	Pleased	Mostly	Mixed – about equally	Mostly	Unhappy	Terrible
If you were to spend the rest of your life with your urinary condition the way it is now, how would you feel about that?	0	1	2	3	4	5	6

Total score: 0-7 Mildly symptomatic; 8-19 moderately symptomatic; 20-35 severely symptomatic.

Bibliography

- A comparison of quality of life with patient reported symptoms and objective findings in men with benign prostatic hyperplasia. The Department of Veterans Affairs Cooperative Study of transurethral resection for benign prostatic hyperplasia. *Journal of Urology* 1993, 150(5 Pt 2):1696-700. (*Guideline Ref ID: ANON1993*)
- 2. Hospital Episode Statistics 2006-07 <u>www.hesonline.nhs.uk</u> (Guideline Ref ID: ANON2007)
- Abbou CC, Payan C, Viens-Bitker C, Richard F, Boccon-Gibod L, Jardin A *et al.* Transrectal and transurethral hyperthermia versus sham treatment in benign prostatic hyperplasia: a double-blind randomized multicentre clinical trial. The French BPH Hyperthermia. *British Journal* of Urology 1995, **76**(5):619-24. (Guideline Ref ID: ABBOU1995)
- Abdel-Khalek M, El Hammady S, Ibrahiem E-H. A 4-year follow-up of a randomized prospective study comparing transurethral electrovaporization of the prostate with neodymium: YAG laser therapy for treating benign prostatic hyperplasia. *BJU International* 2003, 91(9):801-5. (*Guideline Ref ID: ABDELKHALEK2003*)
- Abrams P, Schafer W, Tammela TL, Barrett DM, Hedlund H, Rollema HJ et al. Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study Group. Journal of Urology 1999, 161(5):1513-7. (Guideline Ref ID: ABRAMS1999)
- Ackerman SJ, Rein AL, Blute ML, Beusterian K, Sullivan EM, Tanio CP et al. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia. Part I: methods. Urology 2000, 56(6):972-80. (Guideline Ref ID: ACKERMAN2000)
- 7. Ahmed M, Bell T, Lawrence WT, Ward JP, Watson GM. Transurethral microwave thermotherapy (Prostatron version 2.5) compared with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a randomized, controlled, parallel study. *British Journal of Urology* 1997, **79**(2):181-5. (*Guideline Ref ID: AHMED*1997)
- Aho TF, Gilling PJ, Kennett KM, Westenberg AM, Fraundorfer MR, Frampton CM. Holmium laser bladder neck incision versus holmium enucleation of the prostate as outpatient procedures for prostates less than 40 grams: a randomized trial. *Journal of Urology* 2005, **174**(1):210-4. (*Guideline Ref ID: AHO2005*)

- 9. Ahyai SA, Lehrich K, Kuntz RM. Holmium laser enucleation versus transurethral resection of the prostate: 3-year follow-up results of a randomized clinical trial. *European Urology* 2007, **52**(5):1456-63. *(Guideline Ref ID: AHYAI2007)*
- Albala DM, Fulmer BR, Turk TM, Koleski F, Andriole G, Davis BE *et al.* Office-based transurethral microwave thermotherapy using the TherMatrx TMx-2000. *Journal of Endourology* 2002, **16**(1):57-61. (*Guideline Ref ID: ALBALA2002*)
- 11. American Urological Association. (2006) Guideline on the management of benign prostatic hyperplasia (BPH). Americal Urological Association. *(Guideline Ref ID: AUA2006)*
- Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology 1995, 46(5):631-7. (Guideline Ref ID: ANDERSEN1995)
- 13. Andersen M, Dahlstrand C, Høye K. Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. *European Urology* 2000, **38**(4):400-9. *(Guideline Ref ID: ANDERSEN2000)*
- Annemans L, Cleemput I, Lamotte M, McNeill A, Hargreave T. The economic impact of using alfuzosin 10 mg once daily in the management of acute urinary retention in the UK: a 6-month analysis. BJU International 2005, 96(4):566-71. (Guideline Ref ID: ANNEMANS2005)
- Anson K, Nawrocki J, Buckley J, Fowler C, Kirby R, Lawrence W *et al.* A multicenter, randomized, prospective study of endoscopic laser ablation versus transurethral resection of the prostate. *Urology* 1995, 46(3):305-10. (*Guideline Ref ID: ANSON1995*)
- Armstrong N, Vale L, Deverill M, Nabi G, McClinton S, N'Dow J *et al.* Surgical treatments for men with benign prostatic enlargement: cost effectiveness study. *BMJ* 2009, **338**:b1288. (*Guideline Ref ID: ARMSTRONG2009*)
- 17. Autorino R, Damiano R, Di LG, Quarto G, Perdona S, D'Armiento M *et al*. Four-year outcome of a prospective randomised trial comparing bipolar plasmakinetic and monopolar transurethral resection of the prostate. *European Urology* 2009, **55**(4):922-31. *(Guideline Ref ID: AUTORINO2009)*
- Baladi JF, Menon D, Otten N. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. *Pharmacoeconomics* 1996, 9(5):443-54. (*Guideline Ref ID: BALADI1996*)

- Bales GT, Gerber GS, Minor TX, Mhoon DA, McFarland JM, Kim HL et al. Effect of preoperative biofeedback/pelvic floor training on continence in men undergoing radical prostatectomy. Urology 2000, 56(4):627-30. (Guideline Ref ID: BALES2000)
- Barry MJ, Cherkin DC, Chang Y, Fowler FJ, Jr., Skates S. A randomized trial of a multimedia shared decision-making program for men facing a treatment decision for benign prostatic hyperplasia. *Disease Management and Clinical Outcomes* 1997, 1(1):5-14. (*Guideline Ref ID: BARRY1997*)
- Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker-Corkery E et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? *Journal of Urology* 1995, 154(5):1770-4. (*Guideline Ref ID: BARRY1995B*)
- Bautista OM, Kusek JW, Nyberg LM, McConnell JD, Bain RP, Miller G et al. Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Controlled Clinical Trials 2003, 24(2):224-43. (Guideline Ref ID: BAUTISTA2003)
- 23. Bdesha AS, Bunce CJ, Snell ME, Witherow RO. A sham controlled trial of transurethral microwave therapy with subsequent treatment of the control group. *Journal of Urology* 1994, **152**(2 Pt 1):453-8. *(Guideline Ref ID: BDESHA1994)*
- 24. Bechara A, Romano S, Casabe A, Haime S, Dedola P, Hernandez C *et al.* Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. *Journal of Sexual Medicine* 2008, **5**(9):2170-8. (*Guideline Ref ID: BECHARA2008*)
- Beisland HO, Binkowitz B, Brekkan E, Ekman P, Kontturi M, Lehtonen T et al. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. *European Urology* 1992, **22**(4):271-7. (*Guideline Ref ID: BEISLAND1992*)
- 26. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H *et al.* Saw palmetto for benign prostatic hyperplasia. *New England Journal of Medicine* 2006, **354**(6):557-66. (*Guideline Ref ID: BENT2006*)
- Bhansali M, Patankar S, Dobhada S, Khaladkar S. Management of large (>60 g) prostate gland: PlasmaKinetic Superpulse (bipolar) versus conventional (monopolar) transurethral resection of the prostate. *Journal of Endourology* 2009, 23(1):141-5. (*Guideline Ref ID:* BHANSALI2009)
- 28. Blute ML, Patterson DE, Segura JW, Tomera KM, Hellerstein DK. Transurethral microwave thermotherapy v sham treatment: double-

blind randomized study. *Journal of Endourology* 1996, **10**(6):565-73. *(Guideline Ref ID: BLUTE1996)*

- Bouchier-Hayes DM, Anderson P, Van Appledorn S, Bugeja P, Costello AJ. KTP laser versus transurethral resection: early results of a randomized trial. *Journal of Endourology* 2006, **20**(8):580-5. *(Guideline Ref ID: BOUCHIERHAYES2006)*
- Brehmer M, Wiksell H, Kinn A. Sham treatment compared with 30 or 60 min of thermotherapy for benign prostatic hyperplasia: a randomized study. *BJU International* 1999, **84**(3):292-6. (*Guideline Ref ID: BREHMER1999*)
- Brown CT, Yap T, Cromwell DA, Rixon L, Steed L, Mulligan K *et al.* Self management for men with lower urinary tract symptoms: randomised controlled trial. *British Medical Journal* 2007, 334(7583):25-8. (*Guideline Ref ID: BROWN2007*)
- Bruskewitz R, Issa MM, Roehrborn CG, Naslund MJ, Perez-Marrero R, Shumaker BP *et al.* A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. *Journal of Urology* 1998, **159**(5):1588-93. *(Guideline Ref ID: BRUSKEWITZ1998)*
- Bryan NP, Hastie KJ, Chapple CR. Randomised prospective trial of contact laser prostatectomy (CLAP) versus visual laser coagulation of the prostate (VLAP) for the treatment of benign prostatic hyperplasia.
 2-year follow-up. *European Urology* 2000, **38**(3):265-71. (*Guideline Ref ID: BRYAN2000*)
- Burgio KL, Stutzman RE, Engel BT. Behavioral training for postprostatectomy urinary incontinence. *Journal of Urology* 1989, 141(2):303-6. (*Guideline Ref ID: BURGIO1989*)
- Byrnes CA, Morton AS, Liss CL, Lippert MC, Gillenwater JY. Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar. *Clinical Therapeutics* 1995, **17**(5):956-69. *(Guideline Ref ID: BYRNES1995)*
- Cannon A, Carter PG, McConnell AA, Abrams P. Desmopressin in the treatment of nocturnal polyuria in the male. *BJU International* 1999, 84(1):20-4. (*Guideline Ref ID: CANNON1999*)
- 37. Carbin BE, Bauer P, Friskand M, Moyse D. Efficacy of alfuzosine (an alpha 1-adrenoreceptor blocking drug) in benign hyperplasia of the prostate. *Scandinavian Journal of Urology and Nephrology Supplementum* 1991, **138**:73-5. (*Guideline Ref ID: CARBIN1991*)

- Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. *Prostate* 1996, **29**(4):231-40. (*Guideline Ref ID: CARRAR01996*)
- Carter A, Sells H, Speakman M, Ewings P, MacDonagh R, O'Boyle P. A prospective randomized controlled trial of hybrid laser treatment or transurethral resection of the prostate, with a 1-year follow-up. *BJU International* 1999, **83**(3):254-9. (*Guideline Ref ID: CARTER1999*)
- 40. Carter A, Sells H, Speakman M, Ewings P, O'Boyle P, MacDonagh R. Quality of life changes following KTP/Nd:YAG laser treatment of the prostate and TURP. *European Urology* 1999, **36**(2):92-8. *(Guideline Ref ID: CARTER1999A)*
- 41. Carter HB, Landis P, Wright EJ, Parsons JK, Metter EJ. Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life? *Journal of Urology* 2005, **173**(6):2040-3. *(Guideline Ref ID: CARTER2005)*
- Cetinkaya M, Ulusoy E, Adsan O, Saglam H, Ozturk B, Basay S. Comparative early results of transurethral electroresection and transurethral electrovaporization in benign prostatic hyperplasia. *British Journal of Urology* 1996, **78**(6):901-3. (*Guideline Ref ID: CETINKAYA1996*)
- 43. Chacko KN, Donovan JL, Abrams P, Peters TJ, Brookes ST, Thorpe AC *et al.* Transurethral prostatic resection or laser therapy for men with acute urinary retention: the ClasP randomized trial. *Journal of Urology* 2001, **166**(1):166-70. *(Guideline Ref ID: CHACKO2001)*
- Chapple CR, Al Shukri SH, Gattegno B, Holmes S, Martinez-Sagarra JM, Scarpa RM *et al.* Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): Efficacy and tolerability in a placebo and active comparator controlled phase 3a study. *European Urology, Supplements* 2005, 4(2):33-44. (Guideline Ref ID: CHAPPLE2005)
- 45. Chapple CR, Carter P, Christmas TJ, Kirby RS, Bryan J, Milroy EJ *et al.* A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. *British Journal of Urology* 1994, **74**(1):50-6. (*Guideline Ref ID: CHAPPLE1994*)
- Christensen MM, Aagaard J, Madsen PO. Transurethral resection versus transurethral incision of the prostate. A prospective randomized study. Urologic Clinics of North America 1990, **17**(3):621-30. (Guideline Ref ID: CHRISTENSEN1990)

- Christensen MM, Bendix HJ, Rasmussen PC, Jacobsen F, Nielsen J, Norgaard JP *et al.* Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study. *Scandinavian Journal of Urology and Nephrology* 1993, **27**(1):39-44. (Guideline Ref ID: CHRISTENSEN1993)
- Cimentepe E, Unsal A, Saglam R. Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months. *Journal of Endourology* 2003, **17**(2):103-7. *(Guideline Ref ID: CIMENTEPE2003)*
- Cowles RS, III, Kabalin JN, Childs S, Lepor H, Dixon C, Stein B *et al.* A prospective randomized comparison of transurethral resection to visual laser ablation of the prostate for the treatment of benign prostatic hyperplasia. *Urology* 1995, **46**(2):155-60. *(Guideline Ref ID: COWLES1995)*
- 50. Currie CJ, McEwan P, Poole CD, Odeyemi IA, Datta SN, Morgan CL. The impact of the overactive bladder on health-related utility and quality of life. *BJU International* 2006, **97**(6):1267-72. *(Guideline Ref ID: CURRIE2006)*
- 51. Curtis L. (2008) Unit costs of health and social care 2008. Personal Social Services Research Unit. *(Guideline Ref ID: CURTIS2008)*
- d'Ancona FC, Francisca EA, Witjes WP, Welling L, Debruyne FM, de la Rosette JJ. High energy thermotherapy versus transurethral resection in the treatment of benign prostatic hyperplasia: results of a prospective randomized study with 1 year of followup. *Journal of Urology* 1997, **158**(1):120-5. (*Guideline Ref ID: DANCONA1997*)
- d'Ancona FC, Francisca EA, Witjes WP, Welling L, Debruyne FM, de la Rosette JJ. Transurethral resection of the prostate vs. high-energy thermotherapy of the prostate in patients with benign prostatic hyperplasia: long-term results. *British Journal of Urology* 1998, 81(2):259-64. (*Guideline Ref ID: DANCONA1998*)
- Dahlstrand C, Geirsson G, Fall M, Pettersson S. Transurethral microwave thermotherapy versus transurethral resection for benign prostatic hyperplasia: preliminary results of a randomized study. *European Urology* 1993, 23(2):292-8. (*Guideline Ref ID:* DAHLSTRAND1993)
- Dahlstrand C, Walden M, Geirsson G, Pettersson S. Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up. *British Journal of Urology* 1995, **76**(5):614-8. (*Guideline Ref ID: DAHLSTRAND1995*)

- de la Rosette JJ, De Wildt MJ, Alivizatos G, Froeling FM, Debruyne FM. Transurethral microwave thermotherapy (TUMT) in benign prostatic hyperplasia: placebo versus TUMT. Urology 1994, 44(1):58-63. (Guideline Ref ID: DELAROSETTE1994)
- de la Rosette JJ, Floratos DL, Severens JL, Kiemeney LA, Debruyne FM, Pilar LM. Transurethral resection vs. microwave thermotherapy of the prostate: a cost-consequences analysis. *BJU International* 2003, 92(7):713-8. (*Guideline Ref ID: DELAROSETTE2003B*)
- de Sio M, Autorino R, Quarto G, Damiano R, Perdona S, di Lorenzo G et al. Gyrus bipolar versus standard monopolar transurethral resection of the prostate: a randomized prospective trial. Urology 2006, 67(1):69-72. (Guideline Ref ID: DESIO2006)
- De Wildt MJ, Hubregtse M, Ogden C, Carter SS, Debruyne FM, de la Rosette JJ. A 12-month study of the placebo effect in transurethral microwave thermotherapy. *British Journal of Urology* 1996, **77**(2):221-7. (*Guideline Ref ID: DEWILDT1996*)
- Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC et al. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. *European* Urology 2002, 41(5):497-506. (*Guideline Ref ID: DEBRUYNE2002*)
- Debruyne FM, Jardin A, Colloi D, Resel L, Witjes WP, Delauche-Cavallier MC *et al.* Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. *European Urology* 1998, **34**(3):169-75. (*Guideline Ref ID: DEBRUYNE1998*)
- 62. Dedhia RC, Calhoun E, McVary KT. Impact of phytotherapy on utility scores for 5 benign prostatic hyperplasia/lower urinary tract symptoms health states. *Journal of Urology* 2008, **179**(1):220-5. *(Guideline Ref ID: DEDHIA2008)*
- 63. Disantostefano RL, Biddle AK, Lavelle JP. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. *BJU International* 2006, **97**(5):1007-16. (*Guideline Ref ID: DISANTOSTEFANO2006*)
- Djavan B, Milani S, Davies J, Bolodeoku J. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: Preliminary results of a pilot study. *European Urology, Supplements* 2005, 4(2):61-8. (*Guideline Ref ID: DJAVAN2005D*)
- 65. Donovan JL, Peters TJ, Neal DE, Brookes ST, Gujral S, Chacko KN *et al.* A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study.

Journal of Urology 2000, **164**(1):65-70. (Guideline Ref ID: DONOVAN2000)

- Dorflinger T, Jensen FS, Krarup T, Walter S. Transurethral prostatectomy compared with incision of the prostate in the treatment of prostatism caused by small benign prostate glands. *Scandinavian Journal of Urology and Nephrology* 1992, **26**(4):333-8. (Guideline Ref ID: DORFLINGER1992)
- Dunsmuir WD, McFarlane JP, Tan A, Dowling C, Downie J, Kourambas J *et al.* Gyrus bipolar electrovaporization vs. transurethral resection of the prostate: a randomized prospective single-blind trial with 1 y follow-up. *Prostate Cancer & Prostatic Diseases* 2003, 6(2):182-6. (*Guideline Ref ID: DUNSMUIR2003*)
- Ekengren J, Haendler L, Hahn RG. Clinical outcome 1 year after transurethral vaporization and resection of the prostate. *Urology* 2000, 55(2):231-5. (*Guideline Ref ID: EKENGREN2000*)
- Ekman P. Maximum efficacy of finasteride is obtained within 6 months and maintained over 6 years. Follow-up of the Scandinavian Open-Extension Study. The Scandinavian Finasteride Study Group. *European Urology* 1998, **33**(3):312-7. (*Guideline Ref ID: EKMAN1998*)
- Elzayat EA, Al-Mandil MS, Khalaf I, Elhilali MM. Holmium laser ablation of the prostate versus photoselective vaporization of prostate 60 cc or less: short-term results of a prospective randomized trial. *Journal of Urology* 2009, **182**(1):133-8. (*Guideline Ref ID: ELZAYAT2009*)
- Engelmann U, Walther C, Bondarenko B, Funk P, Schlafke S. Efficacy and safety of a combination of sabal and urtica extract in lower urinary tract symptoms. A randomized, double-blind study versus tamsulosin. *Arzneimittel-Forschung* 2006, **56**(3):222-9. (*Guideline Ref ID:* ENGELMANN2006)
- 72. Erdagi U, Akman RY, Sargin SY, Yazicioglu A. Transurethral electrovaporization of the prostate versus transurethral resection of the prostate: a prospective randomized study. *Archivio Italiano di Urologia*, *Andrologia* 1999, **71**(3):125-30. *(Guideline Ref ID: ERDAGI1999)*
- 73. Erturhan S, Erbagci A, Seckiner I, Yagci F, Ustun A. Plasmakinetic resection of the prostate versus standard transurethral resection of the prostate: a prospective randomized trial with 1-year follow-up. *Prostate Cancer & Prostatic Diseases* 2007, **10**(1):97-100. *(Guideline Ref ID: ERTURHAN2007)*
- Ezz el Din K, Koch WF, De Wildt MJ, Debruyne FM, de la Rosette JJ. The predictive value of microscopic haematuria in patients with lower urinary tract symptoms and benign prostatic hyperplasia. *European* Urology 1996, **30**(4):409-13. (Guideline Ref ID: EZZ1996)

- Fader M, Cottenden A, Getliffe K, Gage H, Clarke-O'Neill S, Jamieson K et al. Absorbent products for urinary/faecal incontinence: a comparative evaluation of key product designs. *Health Technology Assessment* 2008, **12**(29):1-208. (Guideline Ref ID: FADER2008)
- Fader M, Macaulay M, Pettersson L, Brooks R, Cottenden A. A multicentre evaluation of absorbent products for men with light urinary incontinence. *Neurourology and Urodynamics* 2006, **25**(7):689-95. (*Guideline Ref ID: FADER2006*)
- 77. Falahatkar S, Mokhtari G, Pourreza F, Asgari SA, Kamran AN. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebocontrolled study. *Urology* 2008, **72**(4):813-6. *(Guideline Ref ID: FALAHATKAR2008)*
- Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. *Journal of Urology* 1995, **154**(1):105-9. *(Guideline Ref ID: FAWZY1995)*
- Fehrling M, Fall M, Peeker R. Maximal functional electrical stimulation as a single treatment: is it cost-effective? *Scandinavian Journal of Urology and Nephrology* 2007, **41**(2):132-7. (*Guideline Ref ID: FEHRLING2007*)
- Filocamo MT, Li M, V, Del Popolo G, Cecconi F, Marzocco M, Tosto A et al. Effectiveness of early pelvic floor rehabilitation treatment for postprostatectomy incontinence. *European Urology* 2005, **48**(5):734-8. (*Guideline Ref ID: FILOCAMO2005*)
- Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group. *Prostate* 1993, **22**(4):291-9. (*Guideline Ref ID: ANON1993A*)
- Floratos DL, Sonke GS, Rapidou CA, Alivizatos GJ, Deliveliotis C, Constantinides CA *et al.* Biofeedback vs. verbal feedback as learning tools for pelvic muscle exercises in the early management of urinary incontinence after radical prostatectomy. *BJU International* 2002, 89(7):714-9. (*Guideline Ref ID: FLORATOS2002*)
- 83. Fowler C, McAllister W, Plail R, Karim O, Yang Q. Randomised evaluation of alternative electrosurgical modalities to treat bladder outflow obstruction in men with benign prostatic hyperplasia. *Health Technology Assessment* 2005, **9**(4):iii-30. *(Guideline Ref ID: FOWLER2005)*
- 84. Francisca EA, d'Ancona FC, Hendriks JC, Kiemeney LA, Debruyne FM, de la Rosette JJ. Quality of life assessment in patients treated with lower energy thermotherapy (Prostasoft 2.0): results of a randomized

transurethral microwave thermotherapy versus sham study. *Journal of Urology* 1997, **158**(5):1839-44. *(Guideline Ref ID: FRANCISCA1997)*

- Franke JJ, Gilbert WB, Grier J, Koch MO, Shyr Y, Smith JA. Early postprostatectomy pelvic floor biofeedback. *Journal of Urology* 2000, 163(1):191-3. (*Guideline Ref ID: FRANKE2000*)
- 86. Fraundorfer MR, Gilling PJ, Kennett KM, Dunton NG. Holmium laser resection of the prostate is more cost effective than transurethral resection of the prostate: results of a randomized prospective study. *Urology* 2001, **57**(3):454-8. *(Guideline Ref ID: FRAUNDORFER2001)*
- Fung BT, Li SK, Yu CF, Lau BE, Hou SS. Prospective randomized controlled trial comparing plasmakinetic vaporesection and conventional transurethral resection of the prostate. *Asian Journal of Surgery* 2005, **28**(1):24-8. (*Guideline Ref ID: FUNG2005*)
- Gallucci M, Puppo P, Perachino M, Fortunato P, Muto G, Breda G *et al.* Transurethral electrovaporization of the prostate vs. transurethral resection. Results of a multicentric, randomized clinical study on 150 patients. *European Urology* 1998, **33**(4):359-64. *(Guideline Ref ID: GALLUCCI1998)*
- 89. Ghalayini IF, Al Ghazo MA, Pickard RS. A prospective randomized trial comparing transurethral prostatic resection and clean intermittent self-catheterization in men with chronic urinary retention. *BJU International* 2005, **96**(1):93-7. (*Guideline Ref ID: GHALAYINI2005*)
- Gillenwater JY, Conn RL, Chrysant SG, Roy J, Gaffney M, Ice K et al. Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebocontrolled, dose-response multicenter study. *Journal of Urology* 1995, 154(1):110-5. (*Guideline Ref ID: GILLENWATER1995*)
- Gilling PJ, Cass CB, Malcolm A, Cresswell M, Fraundorfer MR, Kabalin JN. Holmium laser resection of the prostate versus neodymium:yttriumaluminum-garnet visual laser ablation of the prostate: a randomized prospective comparison of two techniques for laser prostatectomy. Urology 1998, 51(4):573-7. (Guideline Ref ID: GILLING1998)
- 92. Gilling PJ, Kennett KM, Fraundorfer MR. Holmium laser resection v transurethral resection of the prostate: results of a randomized trial with 2 years of follow-up. *Journal of Endourology* 2000, **14**(9):757-60. *(Guideline Ref ID: GILLING2000)*
- Gilling PJ, Mackey M, Cresswell M, Kennett K, Kabalin JN, Fraundorfer MR. Holmium laser versus transurethral resection of the prostate: a randomized prospective trial with 1-year followup. *Journal of Urology* 1999, **162**(5):1640-4. (*Guideline Ref ID: GILLING1999*)

- Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD *et al.* The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. *New England Journal of Medicine* 1992, **327**(17):1185-91. (*Guideline Ref ID: GORMLEY1992*)
- Gotoh M, Okamura K, Hattori R, Nishiyama N, Kobayashi H, Tanaka K et al. A randomized comparative study of the Bandloop versus the standard loop for transurethral resection of the prostate. *Journal of Urology* 1999, **162**(5):1645-7. (*Guideline Ref ID: GOTOH1999*)
- 96. Gujral S, Abrams P, Donovan JL, Neal DE, Brookes ST, Chacko KN et al. A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention: The CLasP study. Journal of Urology 2000, 164(1):59-64. (Guideline Ref ID: GUJRAL2000)
- 97. Gupta N, Sivaramakrishna, Kumar R, Dogra PN, Seth A. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g. *BJU International* 2006, **97**(1):85-9. (*Guideline Ref ID: GUPTA2006*)
- Hammadeh MY, Fowlis GA, Singh M, Philp T. Transurethral electrovaporization of the prostate--a possible alternative to transurethral resection: a one-year follow-up of a prospective randomized trial. *British Journal of Urology* 1998, **81**(5):721-5. (*Guideline Ref ID: HAMMADEH1998B*)
- Hammadeh MY, Madaan S, Hines J, Philp T. 5-year outcome of a prospective randomized trial to compare transurethral electrovaporization of the prostate and standard transurethral resection. Urology 2003, 61(6):1166-71. (Guideline Ref ID: HAMMADEH2003)
- Hammadeh MY, Madaan S, Singh M, Philp T. A 3-year follow-up of a prospective randomized trial comparing transurethral electrovaporization of the prostate with standard transurethral prostatectomy. *BJU International* 2000, **86**(6):648-51. (*Guideline Ref ID: HAMMADEH2000*)
- 101. Hansen BJ, Nordling J, Mensink HJ, Walter S, Meyhoff HH. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, doubleblind, placebo-controlled trial. ALFECH Study Group. Scandinavian Journal of Urology and Nephrology Supplementum 1994, 157:169-76. (Guideline Ref ID: HANSEN1994)
- 102. Helke C, Manseck A, Hakenberg OW, Wirth MP. Is transurethral vaporesection of the prostate better than standard transurethral

resection? European Urology 2001, **39**(5):551-7. (Guideline Ref ID: HELKE2001)

- 103. Hill B, Belville W, Bruskewitz R, Issa M, Perez-Marrero R, Roehrborn C et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. Journal of Urology 2004, **171**(6 Pt 1):2336-40. (Guideline Ref ID: HILL2004)
- Hillman AL, Schwartz JS, Willian MK, Peskin E, Roehrborn CG, Oesterling JE *et al.* The cost-effectiveness of terazosin and placebo in the treatment of moderate to severe benign prostatic hyperplasia. *Urology* 1996, **47**(2):169-78. (*Guideline Ref ID: HILLMAN1996*)
- Hindley RG, Mostafid AH, Brierly RD, Harrison NW, Thomas PJ, Fletcher MS. The 2-year symptomatic and urodynamic results of a prospective randomized trial of interstitial radiofrequency therapy vs. transurethral resection of the prostate. *BJU International* 2001, 88(3):217-20. (*Guideline Ref ID: HINDLEY2001*)
- 106. Hizli F, Uygur MC. A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. *International Urology and Nephrology* 2007, **39**(3):879-86. (*Guideline Ref ID: HIZLI2007*)
- Ho HS, Yip SK, Lim KB, Fook S, Foo KT, Cheng CW. A prospective randomized study comparing monopolar and bipolar transurethral resection of prostate using transurethral resection in saline (TURIS) system. *European Urology* 2007, **52**(2):517-22. (*Guideline Ref ID:* HO2007)
- 108. Hon NH, Brathwaite D, Hussain Z, Ghiblawi S, Brace H, Hayne D et al. A prospective, randomized trial comparing conventional transurethral prostate resection with PlasmaKinetic vaporization of the prostate: physiological changes, early complications and long-term followup. *Journal of Urology* 2006, **176**(1):205-9. (*Guideline Ref ID: HON2006*)
- Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a short-term prospective randomized trial. *Urology* 2008, 71(2):247-51. (*Guideline Ref ID: HORASANLI2008*)
- Hunter KF, Moore KN, Cody DJ, Glazener CM. Conservative management for postprostatectomy urinary incontinence. *Cochrane Database of Systematic Reviews* 2007, Issue 2:CD001843. (Guideline *Ref ID: HUNTER2007*)

- 111. Iori F, Franco G, Leonardo C, Laurenti C, Tubaro A, Amico F *et al.* Bipolar transurethral resection of prostate: clinical and urodynamic evaluation. *Urology* 2008, **71**(2):252-5. (*Guideline Ref ID: IORI2008*)
- Jakobsson L. Indwelling catheter treatment and health-related quality of life in men with prostate cancer in comparison with men with benign prostatic hyperplasia. *Scandinavian Journal of Caring Sciences* 2002, 16(3):264-71. (*Guideline Ref ID: JAKOBSSON2002*)
- 113. Johansen TE, Istad JA. Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway. *Scandinavian Journal of Urology and Nephrology* 2007, **41**(2):124-31. *(Guideline Ref ID: JOHANSEN2007)*
- 114. Johnson N, Kirby R. Treatments for benign prostatic hyperplasia: an analysis of their clinical and economic impact in the United Kingdom and Italy. *Journal of drug assessment* 1999, **2**(3):371-86. *(Guideline Ref ID: JOHNSON1999)*
- 115. Johnson TMJ, Busby-Whitehead J, Ashford-Works C, Clarke MK, Fowler L, Williams ME. Promoting help-seeking behavior for urinary incontinence. *Journal of Applied Gerontology* 1998, **17**(4):419-41. *(Guideline Ref ID: JOHNSON1998)*
- 116. Kadow C, Feneley RC, Abrams PH. Prostatectomy or conservative management in the treatment of benign prostatic hypertrophy? *British Journal of Urology* 1988, **61**(5):432-4. (*Guideline Ref ID: KADOW1988*)
- Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. *European Urology* 2007, 51(6):1717-23. (*Guideline Ref ID: KAPLAN2007*)
- 118. Kaplan SA, Laor E, Fatal M, Te AE. Transurethral resection of the prostate versus transurethral electrovaporization of the prostate: a blinded, prospective comparative study with 1-year followup. *Journal of Urology* 1998, **159**(2):454-8. (*Guideline Ref ID: KAPLAN1998*)
- Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. *JAMA* 2006, **296**(19):2319-28. (*Guideline Ref ID: KAPLAN2006*)
- Karaman MI, Kaya C, Ozturk M, Gurdal M, Kirecci S, Pirincci N. Comparison of transurethral vaporization using PlasmaKinetic energy and transurethral resection of prostate: 1-year follow-up. *Journal of Endourology* 2005, **19**(6):734-7. (*Guideline Ref ID: KARAMAN2005*)
- 121. Kaya C, Ilktac A, Gokmen E, Ozturk M, Karaman IM. The long-term results of transurethral vaporization of the prostate using plasmakinetic

energy. BJU International 2007, **99**(4):845-8. (Guideline Ref ID: KAYA2007)

- 122. Keoghane SR, Cranston DW, Lawrence KC, Doll HA, Fellows GJ, Smith JC. The Oxford Laser Prostate Trial: a double-blind randomized controlled trial of contact vaporization of the prostate against transurethral resection; preliminary results. *British Journal of Urology* 1996, **77**(3):382-5. (*Guideline Ref ID: KEOGHANE1996A*)
- Keoghane SR, Doll HA, Lawrence KC, Jenkinson CP, Cranston DW. The Oxford Laser Prostate Trial: sexual function data from a randomized controlled clinical trial of contact laser prostatectomy. *European Urology* 1996, **30**(4):424-8. (*Guideline Ref ID: KEOGHANE1996*)
- 124. Keoghane SR, Lawrence KC, Gray AM, Doll HA, Hancock AM, Turner K et al. A double-blind randomized controlled trial and economic evaluation of transurethral resection vs. contact laser vaporization for benign prostatic enlargement: a 3-year follow-up. BJU International 2000, 85(1):74-8. (Guideline Ref ID: KEOGHANE2000)
- Keoghane SR, Lawrence KC, Jenkinson CP, Doll HA, Chappel DB, Cranston DW. The Oxford Laser Prostate Trial: sensitivity to change of three measures of outcome. Urology 1996, 47(1):43-7. (Guideline Ref ID: KEOGHANE1996B)
- 126. Keoghane SR, Sullivan ME, Doll HA, Kourambas J, Cranston DW. Five-year data from the Oxford Laser Prostatectomy Trial. *BJU International* 2000, **86**(3):227-8. *(Guideline Ref ID: KEOGHANE2000A)*
- 127. Kim JY, Moon KH, Yoon CJ, Park TC. Bipolar transurethral resection of the prostate: a comparative study with monopolar transurethral resection. *Korean Journal of Urology* 2006, **47**(5):493-7. *(Guideline Ref ID: KIM2006A)*
- 128. Kim TS, Choi S, Rhew HY, Ahn JH, Jang JH, Cho MH. Comparative study on the treatment outcome and safety of TURP, ILC, TUNA and TEAP for patients with benign prostatic hyperplasia. *Korean Journal of Urology* 2006, **47**(1):13-9. *(Guideline Ref ID: KIM2006)*
- 129. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003, 61(1):119-26. (Guideline Ref ID: KIRBY2003)
- Kok ET, McDonnell J, Stolk EA, Stoevelaar HJ, Busschbach JJ. The valuation of the International Prostate Symptom Score (IPSS) for use in economic evaluations. *European Urology* 2002, **42**(5):491-7. (*Guideline Ref ID: KOK2002*)

- Kuntz RM, Lehrich K. Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm.:: a randomized prospective trial of 120 patients. *Journal of Urology* 2002, **168**(4 Pt 1):1465-9. (*Guideline Ref ID: KUNTZ2002*)
- Kuntz RM, Lehrich K, Ahyai S. Transurethral holmium laser enucleation of the prostate compared with transvesical open prostatectomy: 18month follow-up of a randomized trial. *Journal of Endourology* 2004, 18(2):189-91. (*Guideline Ref ID: KUNTZ2004A*)
- Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. *European Urology* 2008, **53**(1):160-6. *(Guideline Ref ID: KUNTZ2008)*
- Kupeli B, Yalcinkaya F, Topaloglu H, Karabacak O, Gunlusoy B, Unal S. Efficacy of transurethral electrovaporization of the prostate with respect to standard transurethral resection. *Journal of Endourology* 1998, **12**(6):591-4. (*Guideline Ref ID: KUPELI1998A*)
- 135. Kupeli S, Baltaci S, Soygur T, Aytac S, Yilmaz E, Budak M. A prospective randomized study of transurethral resection of the prostate and transurethral vaporization of the prostate as a therapeutic alternative in the management of men with BPH. *European Urology* 1998, **34**(1):15-8. (*Guideline Ref ID: KUPELI1998*)
- Kupeli S, Yilmaz E, Soygur T, Budak M. Randomized study of transurethral resection of the prostate and combined transurethral resection and vaporization of the prostate as a therapeutic alternative in men with benign prostatic hyperplasia. *Journal of Endourology* 2001, 15(3):317-21. (*Guideline Ref ID: KUPELI2001*)
- Kursh ED, Concepcion R, Chan S, Hudson P, Ratner M, Eyre R. Interstitial laser coagulation versus transurethral prostate resection for treating benign prostatic obstruction: a randomized trial with 2-year follow-up. Urology 2003, 61(3):573-8. (Guideline Ref ID: KURSH2003)
- Laguna MP, Kiemeney LA, Debruyne FM, de la Rosette JJ. Baseline prostatic specific antigen does not predict the outcome of high energy transurethral microwave thermotherapy. *Journal of Urology* 2002, 167(4):1727-30. (*Guideline Ref ID: LAGUNA2002*)
- Larsen EH, Dørflinger T, Gasser TC, Graversen PH, Bruskewitz RC. Transurethral incision versus transurethral resection of the prostate for the treatment of benign prostatic hypertrophy. A preliminary report. *Scandinavian Journal of Urology and Nephrology Supplementum* 1987, 104:83-6. (Guideline Ref ID: LARSEN1987)
- 140. Larson TR, Blute ML, Bruskewitz RC, Mayer RD, Ugarte RR, Utz WJ. A high-efficiency microwave thermoablation system for the treatment of benign prostatic hyperplasia: results of a randomized, sham-controlled,

prospective, double-blind, multicenter clinical trial. *Urology* 1998, **51**(5):731-42. *(Guideline Ref ID: LARSON1998)*

- Lepor H, Jones K, Williford W. The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. *Journal of Urology* 2000, **163**(4):1134-7. (*Guideline Ref ID: LEPOR2000*)
- Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. New England Journal of Medicine 1996, 335(8):533-9. (Guideline Ref ID: LEPOR1996)
- 143. Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. *Journal of Urology* 1998, **160**(4):1358-67. (Guideline Ref ID: LEPOR1998)
- Li MK, Ng AS. Bladder neck resection and transurethral resection of the prostate: a randomized prospective trial. *Journal of Urology* 1987, 138(4):807-9. (*Guideline Ref ID: L11987*)
- 145. Liedberg F, Adell L, Hagberg G, Palmqvist IB. Interstitial laser coagulation versus transurethral resection of the prostate for benign prostatic enlargement--a prospective randomized study. *Scandinavian Journal of Urology and Nephrology* 2003, **37**(6):494-7. *(Guideline Ref ID: LIEDBERG2003)*
- 146. Liguori G, Trombetta C, De GG, Pomara G, Maio G, Vecchio D *et al.* Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: An integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. *Journal of Sexual Medicine* 2009, **6**(2):544-52. *(Guideline Ref ID: LIGUORI2009)*
- 147. Liu CK, Lee WK, Ko MC, Chiang HS, Wan KS. Transurethral electrovapor resection versus standard transurethral resection treatment for a large prostate: a 2-year follow-up study conducted in Taiwan. *Urology international* 2006, **76**(2):144-9. *(Guideline Ref ID: LIU2006)*
- Logan K, Shaw C, Webber I, Samuel S, Broome L. Patients' experiences of learning clean intermittent self-catheterization: a qualitative study. *Journal of Advanced Nursing* 2008, 62(1):32-41. (Guideline Ref ID: LOGAN2008)
- 149. Lopatkin N, Sivkov A, Walther C, Schlafke S, Medvedev A, Avdeichuk J *et al.* Long-term efficacy and safety of a combination of sabal and

urtica extract for lower urinary tract symptoms--a placebo-controlled, double-blind, multicenter trial. *World Journal of Urology* 2005, **23**(2):139-46. *(Guideline Ref ID: LOPATKIN2005)*

- 150. Lourenco T, Armstrong N, N'Dow J, Nabi G, Deverill M, Pickard R et al. Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. Health Technology Assessment 2008, **12**(35):iii-169. (Guideline Ref ID: LOURENCO2008B)
- 151. Lourenco T, Pickard R, Vale L, Grant A, Fraser C, MacLennan G *et al.* Minimally invasive treatments for benign prostatic enlargement: systematic review of randomised controlled trials. *British Medical Journal* 2008, **337**:a1662. (*Guideline Ref ID: LOURENCO2008A*)
- 152. Lourenco T, Pickard R, Vale L, Grant A, Fraser C, MacLennan G et al. Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trials. British Medical Journal 2008, 337:a449. (Guideline Ref ID: LOURENCO2008)
- Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU International 2005, 95(3):354-7. (Guideline Ref ID: LUCAS2005)
- 154. Macaulay M, Clarke-O'Neill S, Fader M, Pettersson L, Cottenden A. A pilot study to evaluate reusable absorbent body-worn products for adults with moderate/heavy urinary incontinence. *Journal of Wound, Ostomy and Continence Nursing* 2004, **31**(6):357-66. (Guideline Ref ID: MACAULAY2004A)
- 155. MacDiarmid SA, Peters KM, Chen A, Armstrong RB, Orman C, Aquilina JW *et al.* Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. *Mayo Clinic Proceedings* 2008, **83**(9):1002-10. *(Guideline Ref ID: MACDIARMID2008)*
- 156. Manassero F, Traversi C, Ales V, Pistolesi D, Panicucci E, Valent F et al. Contribution of early intensive prolonged pelvic floor exercises on urinary continence recovery after bladder neck-sparing radical prostatectomy: Results of a prospective controlled randomized trial. Neurourology and Urodynamics 2007, 26(7):985-9. (Guideline Ref ID: MANASSER02007)
- Marberger MJ. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group. Urology 1998, 51(5):677-86. (Guideline Ref ID: MARBERGER1998)

- Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003, 62(2):259-64. (Guideline Ref ID: MARIA2003)
- 159. Martenson AC, de la Rosette JJ. Interstitial laser coagulation in the treatment of benign prostatic hyperplasia using a diode laser system: results of an evolving technology. *Prostate Cancer & Prostatic Diseases* 1999, **2**(3):148-54. (*Guideline Ref ID: MARTENSON1999*)
- Martorana G, Giberti C, Di Silverio F, Von Heland M, Rigatti P, Colombo R *et al.* Effects of short-term treatment with the alpha 1blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. *European Urology* 1997, **32**(1):47-53. (*Guideline Ref ID: MARTORANA1997*)
- Mathewson-Chapman M. Pelvic muscle exercise/biofeedback for urinary incontinence after prostatectomy: an education program. *Journal of Cancer Education* 1997, **12**(4):218-23. (Guideline Ref ID: MATHEWSONCHAPMAN1997)
- 162. Mattiasson A, Wagrell L, Schelin S, Nordling J, Richthoff J, Magnusson B et al. Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study. Urology 2007, 69(1):91-6. (Guideline Ref ID: MATTIASSON2007)
- 163. Mavuduru RM. Comparison of HoLEP and TURP in terms of efficacy in the early postoperative period and perioperative morbidity. *Urologia Internationalis* 2009, **82**(2):130-5. *(Guideline Ref ID: MAVUDURU2009)*
- 164. McAllister WJ, Absalom MJ, Mir K, Shivde S, Anson K, Kirby RS et al. Does endoscopic laser ablation of the prostate stand the test of time? Five-year results from a multicentre randomized controlled trial of endoscopic laser ablation against transurethral resection of the prostate. BJU International 2000, 85(4):437-9. (Guideline Ref ID: MCALLISTER2000)
- 165. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL *et al.* The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. New England Journal of Medicine 1998, **338**(9):557-63. (Guideline Ref ID: MCCONNELL1998)
- 166. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Jr., Dixon CM, Kusek JW et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. New England Journal of Medicine 2003, 349(25):2387-98. (Guideline Ref ID: MCCONNELL2003)

- McDonald H, Hux M, Brisson M, Bernard L, Nickel JC. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. *Canadian Journal of Urology* 2004, **11**(4):2327-40. (*Guideline Ref ID: MCDONALD2004*)
- McNeill SA, Daruwala PD, Mitchell ID, Shearer MG, Hargreave TB. Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled. *BJU International* 1999, 84(6):622-7. (*Guideline Ref ID: MCNEILL1999*)
- McNeill SA, Hargreave TB, Members of the Alfaur Study Group. Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. *Journal of Urology* 2004, **171**(6 Pt 1):2316-20. (*Guideline Ref ID: MCNEILL2004A*)
- McNeill SA, Hargreave TB, Roehrborn CG, Alfaur study group. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology 2005, 65(1):83-9. (Guideline Ref ID: MCNEILL2005)
- 171. McVary KT, Monnig W, Camps JL, Jr., Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. *Journal of Urology* 2007, **177**(3):1071-7. *(Guideline Ref ID: MCVARY2007C)*
- McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM *et al.* Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Journal of Urology* 2007, **177**(4):1401-7. (*Guideline Ref ID: MCVARY2007B*)
- 173. Medicare Services Advisory Committee. Transurethral needle ablation (TUNA) for the treatment of benign prostatic hyperplasia Cochrane Database of Systematic Reviews (*Guideline Ref ID: MSAC2002*)
- Melo EA, Bertero EB, Rios LAS, Mattos J. Evaluating the efficiency of a combination of Pygeum africanum and stinging nettle (Urtica dioica) extracts in treating benign prostatic hyperplasia (BPH): Double-blind, randomized, placebo controlled trial. *International Braz J Urol* 2002, 28(5):418-25. (*Guideline Ref ID: MELO2002*)
- 175. Michielsen DP, Debacker T, De Boe V, Van Lersberghe C, Kaufman L, Braeckman JG *et al.* Bipolar transurethral resection in saline--an alternative surgical treatment for bladder outlet obstruction? *Journal of Urology* 2007, **178**(5):2035-9. *(Guideline Ref ID: MICHIELSEN2007)*
- 176. Mohanty NK, Nayak RL, Malhotra V, Arora RP. A double-blind placebo controlled study of tamsulosin in the management of benign prostatic hyperplasia in an Indian population. *Annals of the College of Surgeons* of Hong Kong 2003, **7**(3):88-93. (*Guideline Ref ID: MOHANTY2003*)

- 177. Montorsi F, Naspro R, Salonia A, Suardi N, Briganti A, Zanoni M et al. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. *Journal of Urology* 2004, **172**(5 Pt 1):1926-9. *(Guideline Ref ID: MONTORSI2004)*
- Moore KN, Griffiths D, Hughton A. Urinary incontinence after radical prostatectomy: a randomized controlled trial comparing pelvic muscle exercises with or without electrical stimulation. *BJU International* 1999, 83(1):57-65. (*Guideline Ref ID: MOORE1999A*)
- Moore KN, Schieman S, Ackerman T, Dzus HY, Metcalfe JB, Voaklander DC. Assessing comfort, safety, and patient satisfaction with three commonly used penile compression devices. *Urology* 2004, 63(1):150-4. (*Guideline Ref ID: MOORE2004*)
- Mostafid AH, Harrison NW, Thomas PJ, Fletcher MS. A prospective randomized trial of interstitial radiofrequency therapy versus transurethral resection for the treatment of benign prostatic hyperplasia. *British Journal of Urology* 1997, **80**(1):116-22. (Guideline Ref ID: MOSTAFID1997)
- Mottet N, Anidjar M, Bourdon O, Louis JF, Teillac P, Costa P et al. Randomized comparison of transurethral electroresection and holmium: YAG laser vaporization for symptomatic benign prostatic hyperplasia. *Journal of Endourology* 1999, **13**(2):127-30. (Guideline Ref ID: MOTTET1999)
- Murray E, Davis H, Tai SS, Coulter A, Gray A, Haines A. Randomised controlled trial of an interactive multimedia decision aid on benign prostatic hypertrophy in primary care. *British Medical Journal* 2001, 323(7311):493-6. (*Guideline Ref ID: MURRAY2001*)
- Narayan P, Tewari A, Aboseif S, Evans C. A randomized study comparing visual laser ablation and transurethral evaporation of prostate in the management of benign prostatic hyperplasia. *Journal of Urology* 1995, **154**(6):2083-8. (*Guideline Ref ID: NARAYAN1995*)
- 184. Naspro R, Suardi N, Salonia A, Scattoni V, Guazzoni G, Colombo R et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up. European Urology 2006, 50(3):563-8. (Guideline Ref ID: NASPRO2006)
- Nathan MS, Wickham JEA. TVP: a cheaper and effective alternative to TURP. *Minimally invasive therapy and allied technologies* 1996, 5(3):292-6. (Guideline Ref ID: NATHAN1996)
- 186. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisals <u>http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune20</u>

<u>08.pdf</u> [accessed 19-12-2008]. (Guideline Ref ID: NATIONALINSTITU2008)

- 187. Nawrocki JD, Bell TJ, Lawrence WT, Ward JP. A randomized controlled trial of transurethral microwave thermotherapy. *British Journal of Urology* 1997, **79**(3):389-93. (*Guideline Ref ID: NAWROCKI1997*)
- Netto NR, Jr., De Lima ML, Lucena R, Lavoura NS, Cortado PL, Netto MR. Is transurethral vaporization a remake of transurethral resection of the prostate? *Journal of Endourology* 1999, **13**(8):591-4. (*Guideline Ref ID: NETTO1999*)
- 189. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. Canadian Medical Association Journal 1996, 155(9):1251-9. (Guideline Ref ID: NICKEL1996)
- 190. Nielsen HO. Transurethral prostatotomy versus transurethral prostatectomy in benign prostatic hypertrophy. A prospective randomised study. *British Journal of Urology* 1988, **61**(5):435-8. *(Guideline Ref ID: NIELSEN1988)*
- Noble SM, Coast J, Brookes S, Neal DE, Abrams P, Peters TJ *et al.* Transurethral prostate resection, noncontact laser therapy or conservative management in men with symptoms of benign prostatic enlargement? An economic evaluation. *Journal of Urology* 2002, 168:2476-82. (*Guideline Ref ID: NOBLE2002*)
- 192. Norby B, Nielsen HV, Frimodt-Moller PC. Cost-effectiveness of new treatments for benign prostatic hyperplasia: results of a randomized trial comparing the short-term cost-effectiveness of transurethral interstitial laser coagulation of the prostate, transurethral microwave thermotherapy and standard transurethral resection or incision of the prostate. *Scandinavian Journal of Urology and Nephrology* 2002, **36**(4):286-95. (*Guideline Ref ID: NORBY2002*)
- 193. Nørby B, Nielsen HV, Frimodt-Møller PC. Transurethral interstitial laser coagulation of the prostate and transurethral microwave thermotherapy vs. transurethral resection or incision of the prostate: results of a randomized, controlled study in patients with symptomatic benign prostatic hyperplasia. *BJU International* 2002, **90**(9):853-62. *(Guideline Ref ID: NORBY2002A)*
- 194. Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. *BJU International* 2005, **95**(7):1006-12. *(Guideline Ref ID: NORDLING2005A)*

- 195. Nuhoglu B, Ayyildiz A, Fidan V, Ersoy E, Huri E, Germiyanogu C. Transurethral electrovaporization of the prostate: is it any better than standard transurethral prostatectomy? 5-year follow-up. *Journal of Endourology* 2005, **19**(1):79-82. *(Guideline Ref ID: NUHOGLU2005)*
- 196. Nuhoglu B, Ayyildiz A, Karaguzel E, Cebeci O, Germiyanoglu C. Plasmakinetic prostate resection in the treatment of benign prostate hyperplasia: results of 1-year follow up. *International Journal of Urology* 2006, **13**(1):21-4. *(Guideline Ref ID: NUHOGLU2006)*
- 197. O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Hofner K. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. *BJU International* 2003, **92**(3):262-6. *(Guideline Ref ID: OLEARY2003)*
- 198. O'Leary MP, Roehrborn CG, Black L. Dutasteride significantly improves quality of life measures in patients with enlarged prostate. *Prostate Cancer & Prostatic Diseases* 2008, **11**(2):129-33. *(Guideline Ref ID: OLEARY2008)*
- Oelke M, Hofner K, Jonas U, de la Rosette JJ, Ubbink DT, Wijkstra H. Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. *European Urology* 2007, 52(3):827-34. (*Guideline Ref ID: OELKE2007*)
- Ogden C, Reddy P, Johnson H, Carter S. Sham vs. TUMT: a randomized study with cross over. *Journal of Urology* 1993, **149**(4 Supp):250A. (*Guideline Ref ID: OGDEN1993*)
- Parekh AR, Feng MI, Kirages D, Bremner H, Kaswick J, Aboseif S. The role of pelvic floor exercises on post-prostatectomy incontinence. *Journal of Urology* 2003, **170**(1):130-3. (*Guideline Ref ID: PAREKH2003*)
- 202. Patankar S, Jamkar A, Dobhada S, Gorde V. PlasmaKinetic Superpulse transurethral resection versus conventional transurethral resection of prostate. *Journal of Endourology* 2006, **20**(3):215-9. (*Guideline Ref ID: PATANKAR2006*)
- Patel A, Fuchs GJ, Gutierrez-Aceves J, Ryan TP. Prostate heating patterns comparing electrosurgical transurethral resection and vaporization: a prospective randomized study. *Journal of Urology* 1997, 157(1):169-72. (*Guideline Ref ID: PATEL1997*)
- 204. Paterson J, Dunn S, Kowanko I, van Loon A, Stein I, Pretty L. Selection of continence products: Perspectives of people who have incontinence and their carers. *Disability and Rehabilitation: An International, Multidisciplinary Journal* 2003, **25**(17):955-63. (*Guideline Ref ID: PATERSON2003*)

- Paterson J, Pinnock CB, Marshall VR. Pelvic floor exercises as a treatment for post-micturition dribble. *British Journal of Urology* 1997, **79**(6):892-7. (*Guideline Ref ID: PATERSON1997*)
- 206. Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. *Journal of Urology* 2005, **174**(2):547-52. (*Guideline Ref ID: PENSON2005*)
- 207. Polat O, Ozbey I, Gul O, Demirel A, Bayraktar Y. Pharmacotherapy of benign prostatic hyperplasia: inhibitor of 5 alpha-reductase. International Urology and Nephrology 1997, 29(3):323-30. (Guideline Ref ID: POLAT1997)
- 208. Porru D, Campus G, Caria A, Madeddu G, Cucchi A, Rovereto B et al. Impact of early pelvic floor rehabilitation after transurethral resection of the prostate. *Neurourology and Urodynamics* 2001, **20**(1):53-9. (Guideline Ref ID: PORRU2001)
- 209. Poulsen AL, Schou J, Puggaard L, Torp-Pedersen S, Nordling J. Prostatic enlargement, symptomatology and pressure/flow evaluation: Interrelations in patients with symptomatic BPH. Scandinavian Journal of Urology and Nephrology Supplementum 1994, 157:67-73. (Guideline Ref ID: POULSEN1994)
- Preuss HG, Marcusen C, Regan J, Klimberg IW, Welebir TA, Jones WA. Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). *International Urology and Nephrology* 2001, 33(2):217-25. (*Guideline Ref ID: PREUSS2001*)
- Resnick MI, Roehrborn CG. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. *Prostate Cancer & Prostatic Diseases* 2007, 10(2):155-9. (*Guideline Ref ID: RESNICK2007*)
- 212. Reynard JM, Peters TJ, Lim C, Abrams P. The value of multiple freeflow studies in men with lower urinary tract symptoms. *British Journal* of Urology 1996, **77**(6):813-8. (*Guideline Ref ID: REYNARD1996*)
- Reynard JM, Yang Q, Donovan JL, Peters TJ, Schafer W, De la Rosette JJMC *et al.* The ICS-'BPH' Study: Uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. *British Journal of Urology* 1998, **82**(5):619-23. (*Guideline Ref ID: REYNARD1998*)
- Riehmann M, Knes JM, Heisey D, Madsen PO, Bruskewitz RC. Transurethral resection versus incision of the prostate: a randomized, prospective study. *Urology* 1995, 45(5):768-75. (*Guideline Ref ID: RIEHMANN1995*)

- 215. Rigatti L, Naspro R, Salonia A, Centemero A, Ghezzi M, Guazzoni G et al. Urodynamics after TURP and HoLEP in urodynamically obstructed patients: are there any differences at 1 year of follow-up? Urology 2006, 67(6):1193-8. (Guideline Ref ID: RIGATTI2006)
- 216. Rigatti P, Brausi M, Scarpa RM, Porru D, Schumacher H, Rizzi CA et al. A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Prostate Cancer & Prostatic Diseases 2003, 6(4):315-23. (Guideline Ref ID: RIGATTI2003)
- 217. Rodrigo Aliaga M, Valls Blasco F, Jimenez Cruz JF. Lasers as an alternative to the endoscopic surgery in BPH. *Actas Urologicas Espanolas* 1998, **22**(1):17-22. (*Guideline Ref ID: RODRIGO1998*)
- Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. *Urology* 2001, 58(6):953-9. (*Guideline Ref ID: ROEHRBORN2001A*)
- Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. *BJU International* 2006, **97**(4):734-41. *(Guideline Ref ID: ROEHRBORN2006)*
- 220. Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T *et al.* Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. *Urology* 1999, **54**(4):662-9. *(Guideline Ref ID: ROEHRBORN1999)*
- 221. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, A.R.I.A. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. *Urology* 2002, 60(3):434-41. (*Guideline Ref ID: ROEHRBORN2002A*)
- 222. Roehrborn CG, Burkhard FC, Bruskewitz RC, Issa MM, Perez-Marrero R, Naslund MJ *et al.* The effects of transurethral needle ablation and resection of the prostate on pressure flow urodynamic parameters: analysis of the United States randomized study. *Journal of Urology* 1999, **162**(1):92-7. (*Guideline Ref ID: ROEHRBORN1999B*)
- Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. *Journal of Urology* 2008, **180**(4):1228-34. (*Guideline Ref ID: ROEHRBORN2008B*)
- 224. Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DE *et al.* The Hytrin Community Assessment Trial study: a one-

year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. *Urology* 1996, **47**(2):159-68. *(Guideline Ref ID: ROEHRBORN1996A)*

- 225. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K, Morrill B *et al.* The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. *Journal of Urology* 2008, **179**(2):616-21. *(Guideline Ref ID: ROEHRBORN2008)*
- Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebocontrolled, crossover study. *Journal of Herbal Pharmacotherapy* 2005, 5(4):1-11. (*Guideline Ref ID: SAFARINEJAD2005*)
- 227. Saint S, Lipsky BA, Baker PD, McDonald LL, Ossenkop K. Urinary catheters: what type do men and their nurses prefer? *Journal of the American Geriatrics Society* 1999, **47**(12):1453-8. *(Guideline Ref ID: SAINT1999)*
- Salonia A, Suardi N, Naspro R, Mazzoccoli B, Zanni G, Gallina A *et al.* Holmium laser enucleation versus open prostatectomy for benign prostatic hyperplasia: an inpatient cost analysis. *Urology* 2006, 68(2):302-6. (*Guideline Ref ID: SALONIA2006*)
- 229. Saporta L, Aridogan IA, Erlich N, Yachia D. Objective and subjective comparison of transurethral resection, transurethral incision and balloon dilatation of the prostate. A prospective study. *European Urology* 1996, **29**(4):439-45. (*Guideline Ref ID: SAPORTA1996*)
- Schulman CC, De Sy W, Vandendris M, Tomas M, Santoni JP. Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group. Acta Urologica Belgica 1994, 62(4):15-21. (Guideline Ref ID: SCHULMAN1994)
- Seckiner.I., Yesilli C, Akduman B, Mungan NA. A prospective randomized study for comparing bipolar plasmakinetic resection of the prostate with standard TURP. *Urology international* 2006, **76**(2):139-43. (*Guideline Ref ID: SECKINER2006*)
- 232. Sengor F, Kose O, Yucebas E, Beysel M, Erdogan K, Narter F. A comparative study of laser ablation and transurethral electroresection for benign prostatic hyperplasia: results of a 6-month follow-up. *British Journal of Urology* 1996, **78**(3):398-400. *(Guideline Ref ID: SENGOR1996)*
- 233. Shah T, Palit V, Biyani S, Elmasry Y, Puri R, Flannigan GM. Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary

retention. *European Urology* 2002, **42**(4):329-32. (*Guideline Ref ID: SHAH2002*)

- 234. Shaw C, Logan K, Webber I, Broome L, Samuel S. Effect of clean intermittent self-catheterization on quality of life: a qualitative study. *Journal of Advanced Nursing* 2008, **61**(6):641-50. *(Guideline Ref ID: SHAW2008)*
- 235. Shi R, Xie Q, Gang X, Lun J, Cheng L, Pantuck A *et al.* Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. *Journal of Urology* 2008, **179**(2):610-5. *(Guideline Ref ID: SHI2008)*
- 236. Shingleton WB, Farabaugh P, May W. Three-year follow-up of laser prostatectomy versus transurethral resection of the prostate in men with benign prostatic hyperplasia. *Urology* 2002, **60**(2):305-8. *(Guideline Ref ID: SHINGLETON2002)*
- 237. Shingleton WB, Renfroe LD, Kolski JM, Fowler JE. A randomized prospective study of transurethral electrovaporization vs. laser ablation of the prostate in men with benign prostatic hypertrophy. *Scandinavian Journal of Urology and Nephrology* 1998, **32**(4):266-9. *(Guideline Ref ID: SHINGLETON1998)*
- 238. Shingleton WB, Terrell F, Renfroe DL, Kolski JM, Fowler JE, Jr. A randomized prospective study of laser ablation of the prostate versus transurethral resection of the prostate in men with benign prostatic hyperplasia. *Urology* 1999, **54**(6):1017-21. *(Guideline Ref ID: SHINGLETON1999)*
- 239. Shokeir AA, al Sisi H, Farage YM, el Maaboud MA, Saeed M, Mutabagani H. Transurethral prostatectomy: a prospective randomized study of conventional resection and electrovaporization in benign prostatic hyperplasia. *British Journal of Urology* 1997, **80**(4):570-4. (*Guideline Ref ID: SHOKEIR1997*)
- 240. Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A *et al.* Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. *Contemporary Clinical Trials* 2007, **28**(6):770-9. (*Guideline Ref ID: SIAMI2007*)
- Singh H, Desai MR, Shrivastav P, Vani K. Bipolar versus monopolar transurethral resection of prostate: randomized controlled study. *Journal of Endourology* 2005, **19**(3):333-8. (Guideline Ref ID: SINGH2005)
- 242. Skolarikos A, Papachristou C, Athanasiadis G, Chalikopoulos D, Deliveliotis C, Alivizatos G. Eighteen-month results of a randomized

prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. *Journal of Endourology* 2008, **22**(10):2333-40. *(Guideline Ref ID: SKOLARIKOS2008)*

- Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. *BJU International* 2000, 86(4):439-42. (*Guideline Ref ID: SOKELAND2000*)
- Sokeland J, Albrecht J. [Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study]. Urologe A 1997, 36(4):327-33. (Guideline Ref ID: SOKELAND1997)
- 245. Soonawalla PF, Pardanani DS. Transurethral incision versus transurethral resection of the prostate. A subjective and objective analysis. *British Journal of Urology* 1992, **70**(2):174-7. (*Guideline Ref ID: SOONAWALLA1992*)
- 246. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. *European Urology* 2008, **53**(6):1236-44. *(Guideline Ref ID: STIEF2008)*
- 247. Stovsky MD, Griffiths R, I, Duff SB. A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia. *Journal of Urology* 2006, **176**(4):1500-6. (*Guideline Ref ID: STOVSKY2006*)
- 248. Sullivan PW, Nichol MB. The economic impact of payer policies after the Rx-to-OTC switch of second-generation antihistamines. *Value in health* 2004, **7**(4):402-12. (*Guideline Ref ID: SULLIVAN2004*)
- 249. Suvakovic N, Hindmarsh JR. A step towards day case prostatectomy. British Journal of Urology 1996, **77**(2):212-4. (Guideline Ref ID: SUVAKOVIC1996)
- 250. Talic RF, El Tiraifi A, El Faqih SR, Hassan SH, Attassi RA, Abdel-Halim RE. Prospective randomized study of transurethral vaporization resection of the prostate using the thick loop and standard transurethral prostatectomy. *Urology* 2000, **55**(6):886-90. *(Guideline Ref ID: TALIC2000)*
- 251. Tan AH, Gilling PJ, Kennett KM, Frampton C, Westenberg AM, Fraundorfer MR. A randomized trial comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for the treatment of bladder outlet obstruction secondary to benign

prostatic hyperplasia in large glands (40 to 200 grams). *Journal of Urology* 2003, **170**(4 Pt 1):1270-4. *(Guideline Ref ID: TAN2003)*

- 252. Tenover JL, Pagano GA, Morton AS, Liss CL, Byrnes CA. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group. *Clinical Therapeutics* 1997, **19**(2):243-58. *(Guideline Ref ID: TENOVER1997)*
- 253. Tibaek S, Klarskov P, Hansen BL, Thomsen H, Andresen H, Jensen CS et al. Pelvic floor muscle training before transurethral resection of the prostate: A randomized, controlled, blinded study. Scandinavian Journal of Urology and Nephrology 2007, 41(4):329-34. (Guideline Ref ID: TIBAEK2007)
- 254. Tkocz M, Prajsner A. Comparison of long-term results of transurethral incision of the prostate with transurethral resection of the prostate, in patients with benign prostatic hypertrophy. *Neurourology and Urodynamics* 2002, **21**(2):112-6. *(Guideline Ref ID: TKOCZ2002)*
- 255. Trachtenberg J, Roehrborn CG. Updated results of a randomized, double-blind, multicenter sham-controlled trial of microwave thermotherapy with the Dornier Urowave in patients with symptomatic benign prostatic hyperplasia. Urowave Investigators Group. *World Journal of Urology* 1998, **16**(2):102-8. *(Guideline Ref ID: TRACHTENBERG1998)*
- 256. Trueman P, Hood SC, Nayak US, Mrazek MF. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK. *BJU International* 1999, **83**(4):410-5. *(Guideline Ref ID: TRUEMAN1999)*
- 257. Tubaro A, La Vecchia C. The relation of lower urinary tract symptoms with life-style factors and objective measures of benign prostatic enlargement and obstruction: An italian survey. *European Urology* 2004, **45**(6):767-72. (*Guideline Ref ID: TUBARO2004*)
- 258. Tuhkanen K, Heino A, Aaltomaa S, Ala-Opas M. Long-term results of contact laser versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia with small or moderately enlarged prostates. *Scandinavian Journal of Urology and Nephrology* 2003, **37**(6):487-93. (*Guideline Ref ID: TUHKANEN2003*)
- 259. Tuhkanen K, Heino A, Ala-Opas M. Two-year follow-up results of a prospective randomized trial comparing hybrid laser prostatectomy with TURP in the treatment of big benign prostates. *Scandinavian Journal of Urology and Nephrology* 2001, **35**(3):200-4. *(Guideline Ref ID: TUHKANEN2001)*
- 260. Tuhkanen K, Heino A, Alaopas M. Hybrid laser treatment compared with transurethral resection of the prostate for symptomatic bladder

outlet obstruction caused by a large benign prostate: a prospective, randomized trial with a 6-month follow-up. *BJU International* 1999, **84**(7):805-9. (*Guideline Ref ID: TUHKANEN1999A*)

- Van Kampen M, De Weerdt W, Van Poppel H, De Ridder D, Feys H, Baert L. Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: a randomised controlled trial. *Lancet* 2000, **355**(9198):98-102. (Guideline Ref ID: VANKAMPEN2000)
- 262. van Kerrebroeck P, Jardin A, Laval KU, Van Cangh P. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. *European Urology* 2000, **37**(3):306-13. *(Guideline Ref ID: VANKERREBROECK2000)*
- 263. van Melick HH, Van Venrooij GE, Eckhardt MD, Boon TA. A randomized controlled trial comparing transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia: urodynamic effects. *Journal of Urology* 2002, **168**(3):1058-62. *(Guideline Ref ID: VANMELICK2002)*
- 264. van Melick HH, Van Venrooij GE, Eckhardt MD, Boon TA. A randomized controlled trial comparing transurethral resection of the prostate, contact laser prostatectomy and electrovaporization in men with benign prostatic hyperplasia: analysis of subjective changes, morbidity and mortality. *Journal of Urology* 2003, **169**(4):1411-6. *(Guideline Ref ID: VANMELICK2003)*
- Van Melick HHE, Van Venrooij GEPM, Boon TA. Laser prostatectomy in patients on anticoagulant therapy or with bleeding disorders. *Journal* of Urology 2003, **170**(5):1851-5. (Guideline Ref ID: VANMELICK2003B)
- 266. Varney SJ, Guest JF. The annual cost of blood transfusions in the UK. *Transfusion Medicine* 2003, **13**(4):205-18. *(Guideline Ref ID: VARNEY2003)*
- 267. Vera-Llonch M, Brandenburg NA, Oster G. Cost-effectiveness of Addon Therapy with Pregabalin in Patients with Refractory Partial Epilepsy. *Epilepsia* 2008, **49**(3):431-7. (*Guideline Ref ID: VERALLONCH2008*)
- Wagrell L, Schelin S, Nordling J, Richthoff J, Magnusson B, Schain M et al. Feedback microwave thermotherapy versus TURP for clinical BPH--a randomized controlled multicenter study. Urology 2002, 60(2):292-9. (Guideline Ref ID: WAGRELL2002)
- 269. Wagrell L, Schelin S, Nordling J, Richthoff J, Magnusson B, Schain M *et al.* Three-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter

study. Urology 2004, **64**(4):698-702. (Guideline Ref ID: WAGRELL2004)

- 270. Wang ZL, Wang XF, Li B, Ji JT, Hou SC, Shao SX. Comparative study of transurethral electrovaporisation of prostate versus transurethral resection of prostate on benign prostatic hyperplasia. *Zhong hua nan ke xue* 2002, **8**(6):428-30. *(Guideline Ref ID: WANG2002)*
- 271. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. New England Journal of Medicine 1995, 332(2):75-9. (Guideline Ref ID: WASSON1995)
- 272. Westenberg A, Gilling P, Kennett K, Frampton C, Fraundorfer M. Holmium laser resection of the prostate versus transurethral resection of the prostate: results of a randomized trial with 4-year minimum longterm followup. *Journal of Urology* 2004, **172**(2):616-9. *(Guideline Ref ID: WESTENBERG2004)*
- Wille S, Sobottka A, Heidenreich A, Hofmann R. Pelvic floor exercises, electrical stimulation and biofeedback after radical prostatectomy: results of a prospective randomized trial. *Journal of Urology* 2003, **170**(2 Pt 1):490-3. (*Guideline Ref ID: WILLE2003*)
- Willetts KE, Clements MS, Champion S, Ehsman S, Eden JA. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. *BJU International* 2003, **92**(3):267-70. (*Guideline Ref ID: WILLETTS2003*)
- Wilson LC, Gilling PJ, Williams A, Kennett KM, Frampton CM, Westenberg AM *et al.* A randomised trial comparing holmium laser enucleation versus transurethral resection in the treatment of prostates larger than 40 grams: results at 2 years. *European Urology* 2006, 50(3):569-73. (*Guideline Ref ID: WILSON2006*)
- 276. Wilt TJ. Tamsulosin for benign prostatic hyperplasia. *Cochrane* Database of Systematic Reviews 2002, **Issue 4**:CD002081. (Guideline Ref ID: WILT2002)
- 277. Wilt TJ, Howe RW, Rukts I, MacDonald R. Terazosin for benign prostatic hyperplasia. *Cochrane Database of Systematic Reviews* 2000, **Issue 1**:CD003581. (*Guideline Ref ID: WILT2000A*)
- Wilt TJ, Ishani A, MacDonald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database of Systematic Reviews 2002, Issue 3:CD001423. (Guideline Ref ID: WILT2002A)
- 279. Wilt TJ, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J. Betasitosterols for benign prostatic hyperplasia. *Cochrane Database of*

Systematic Reviews 1999, **Issue 3**:CD001043. (Guideline Ref ID: WILT1999)

- 280. Xia SJ, Zhuo J, Sun XW, Han BM, Shao Y, Zhang YN. Thulium laser versus standard transurethral resection of the prostate: a randomized prospective trial. *European Urology* 2008, **53**(2):382-9. *(Guideline Ref ID: XIA2008)*
- 281. Zerbib M, Steg A, Conquy S, Debre B. Hyperthermia: a randomized prospective study applying hyperthermia or a sham procedure in obstructive benign hyperplasia of the prostate. *Progress in Clinical and Biological Research* 1994, **386**:439-48. (Guideline Ref ID: ZERBIB1994)
- 282. Zorn BH, Bauer JJ, Ruiz HE, Thrasher JB. Randomized trial of safety and efficacy of transurethral resection of the prostate using contact laser versus electrocautery. *Techniques in Urology* 1999, **5**(4):198-201. (*Guideline Ref ID: ZORN1999*)